

[Submitting Counsel on Signature Page]

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA**

IN RE: JUUL LABS, INC. MARKETING,  
SALES PRACTICES, AND PRODUCTS  
LIABILITY LITIGATION

Case No. 19-md-02913-WHO

THIS DOCUMENT RELATES TO:  
CLASS ACTIONS

**SECOND AMENDED CONSOLIDATED  
CLASS ACTION COMPLAINT**

**SECOND AMENDED CONSOLIDATED  
CLASS ACTION COMPLAINT  
CASE No. 19-MD-02913-WHO**

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
I. INTRODUCTION.....	1
II. PARTIES.....	5
A. Plaintiffs.....	5
B. Defendants .....	5
1. JUUL Labs, Inc.....	5
2. Altria Defendants .....	6
3. Management Defendants .....	8
III. JURISDICTION AND VENUE.....	10
IV. FACTUAL ALLEGATIONS.....	11
A. Each Defendant Was Instrumental in Seeking to Develop and Market the Blockbuster Sequel to Combustible Cigarettes, the “Most Successful Consumer Product of All Time.” .....	11
B. Defendants’ Strategy Was to Create a Nicotine Product That Would Maximize Profits Through Addiction. ....	19
1. Defendants Understood that the “Magic” Behind Cigarettes’ Stratospheric Commercial Success Was Nicotine Addiction. ....	19
2. Following the Cigarette Industry Playbook, Defendants Sought to Market a Product that would Create and Sustain Nicotine Addiction, but Without the Stigma Associated with Cigarettes .....	22
3. Defendants Sought to Position JLI for Acquisition by a Major Cigarette Company. ....	28
C. JLI and Bowen Designed a Nicotine Delivery Device Intended to Create and Sustain Addiction.....	35
1. JLI and Bowen Made Highly Addictive E-Cigarettes Easy for Young People and Non-Smokers to Inhale.....	36
2. JLI’s Initial Experiments Measured Non-Smokers’ “Buzz” Levels and Perceptions of Throat Harshness.....	37
3. JUULs Rapidly Deliver Substantially Higher Doses of Nicotine than Cigarettes. ....	39

1	4.	JLI and the Management Defendants Knew That JUUL was Unnecessarily Addictive Because It Delivered More Nicotine Than Smokers Needed or Wanted. ....	46
2			
3	5.	JUUL’s Design Did Not Look Like a Cigarette, Making it Attractive to Non-Smokers and Easy for Young People to Use Without Detection. ....	48
4			
5	6.	JLI Enticed Newcomers to Nicotine with Kid-Friendly Flavors Without Ensuring the Flavoring Additives Were Safe for Inhalation. ....	52
6			
7			
8	a.	JIL Develops Flavored JUUL Products That Would Appeal to Youth.....	52
9	b.	Defendants Developed and Promoted the Mint Flavor and Sought to Preserve its Market. ....	57
10			
11	D.	Defendants Developed and Implemented a Marketing Scheme to Mislead Consumers into Believing that JUUL Products Contained Less Nicotine Than They Actually Do and Were Healthy and Safe.....	62
12			
13	1.	The Defendants Knowingly Made False and Misleading Statements and Omissions Concerning JUUL’s Nicotine Content. ....	62
14			
15	2.	JLI, the Management Defendants, and Altria Transmitted, Promoted and Utilized Statements Concerning JUUL’s Nicotine Content that They Knew Was False and Misleading.....	67
16			
17	3.	Defendants Used Food and Coffee Themes to Give False Impression that JUUL Products Were Safe and Healthy.....	72
18			
19	4.	JLI’s “Make the Switch” Campaign Intentionally Misled and Deceived Users to Believe that JUUL Is a Cessation Device.....	76
20			
21	5.	JLI, Altria, and Others in the E-Cigarette Industry Coordinated with Third-Party Groups to Mislead the Public About the Harms and Benefits of E-Cigarettes. ....	89
22			
23	a.	The American Vaping Association.....	89
24	b.	Vaping360.....	91
25	c.	Foundation for a Smoke-Free World .....	93
26	d.	Vapor Technology Association.....	95
27	e.	Retailer Lobbying .....	95
28	6.	Altria Falsely Stated That It Intended to Use Its Expertise in “Underage Prevention” Issues to JLI.....	96

E.	Defendants Targeted the Youth Market.....	97
1.	JLI Emulated the Marketing of Cigarette Companies. ....	98
2.	The Management Defendants Intentionally Marketed JUUL to Young People.....	100
3.	JLI Advertising Exploited Young People’s Psychological Vulnerabilities.....	104
4.	JLI Pushed the Vaporized Campaign Into Youth Targeted Channels.....	109
a.	JLI Placed Its Vaporized Ads on Youth Oriented Websites and Media. ....	109
b.	JLI Used Influencers and Affiliates to Amplify Its Message to a Teenage Audience.....	111
c.	JLI Used Viral Marketing Techniques Known to Reach Young People.....	113
5.	JLI Targeted Youth Retail Locations.....	116
6.	JLI Hosted Parties to Create a Youthful Brand and Gave Away Free Products to Get New Consumers Hooked. ....	118
7.	The Management Defendants’ Direction of and Participation in JLI and in the Youth Marketing Schemes.....	122
a.	The Management Defendants, and in particular Pritzker, Valani, and Huh, controlled JLI’s Board at relevant times. ....	122
b.	Pritzker, Huh, and Valani were active, involved board members.....	124
c.	The Management Defendants, and in particular Bowen, Monsees, Pritzker, Valani, and Huh, oversaw and directed the youth marketing scheme. ....	125
d.	Pritzker, Huh, and Valani Were Able to Direct and Participate in the Youth Marketing Because They Seized Control of the JLI Board of Directors.....	132
8.	Pritzker, Valani, and Huh continued to exercise control over and direct the affairs of JLI even after a new CEO was appointed. ....	138
9.	Pritzker and Valani directed and controlled JLI’s negotiations with Altria .....	140
10.	JLI and the Management Defendants Knew Their Efforts Were Wildly Successful in Building a Youth Market and Took	

1	Coordinated Action to Ensure That Youth Could Purchase	
2	JUUL Products.....	142
3	a. JLI’s Strategy Worked.....	142
4	b. JLI Closely Tracked Its Progress in Reaching Young Customers	
5	through Social Media and Online Marketing.....	144
6	11. JLI Worked with Veratad Technologies To Expand Youth	
7	Access to JUUL Products. ....	148
8	12. JLI Engaged in a Sham “Youth Prevention” Campaign.....	157
9	13. The FDA Warned JUUL and Others That Their Conduct is	
10	Unlawful .....	160
11	14. In Response to Regulatory Scrutiny, Defendants Misled the	
12	Public, Regulators, and Congress that JLI Did Not Target Youth.....	162
13	F. Altria Knew JLI was Targeting Youth and, Together with the Management	
14	Defendants, Exercised Control Over JLI to Protect and Expand Youth Sales	
15	and Defraud The Public About Their Actions. ....	168
16	1. Before Altria’s Investment in JLI, Altria Knew JLI Was	
17	Targeting Youth.....	168
18	2. Altria Worked with Pritzker and Valani to Secure Control of	
19	JLI and to Exploit JLI for Their Mutual Benefit.....	170
20	3. Altria Participated in and Directed the Fraudulent Acts of JLI	
21	Designed to Protect the Youth Market for JUUL .....	181
22	a. Altria Participated in and Directed JLI’s Make the Switch	
23	Campaign.....	181
24	b. Altria Participated in and Directed JLI’s Fraudulent Scheme to	
25	Keep Mint on the Market.....	182
26	4. JLI, the Management Defendants and Altria Coordinated to	
27	Market JUUL in Highly-Visible Retail Locations.....	183
28	a. Altria Installs Its Own Executives into Leadership Positions to	
	Direct the Affairs of JLI.....	186
	b. Altria Furthered the JLI Enterprise by Participating in and	
	Directing the Marketing and Distribution of JUUL Products....	192
	G. JLI, Altria, and Others Have Successfully Caused More Young People to Start	
	Using E-Cigarettes, Creating a Youth E-Cigarette Epidemic and Public Health	
	Crisis. ....	200

1	1.	Defendants’ Scheme Caused Consumers to be Misled into	
2		Believing that JUUL was Safe and Healthy. ....	201
3	2.	Use of JUUL by Minors Has Skyrocketed .....	202
4	H.	JLI Thrived Due to Extensive Efforts to Delay Meaningful Regulation of its	
5		Products.....	207
6	1.	E-Cigarette Manufacturers Successfully Blocked the Types of	
7		Regulations that Reduced Cigarette Sales, Creating the Perfect	
8		Opportunity for JLI. ....	207
9	2.	JLI, the Management Defendants, and Altria Defendants	
10		Successfully Shielded the Popular Mint Flavor from Regulation. ....	210
11	3.	In Response to the Public Health Crisis Created by JUUL, the	
12		FDA Belatedly Tried to Slow the Epidemic. ....	220
13	4.	The Government’s Efforts to Address the JUUL Crisis Were	
14		Too Late and the Damage Has Already Been Done .....	221
15	I.	JUUL Usage Increases the Risk of Cardiovascular, Pulmonary, Neurological,	
16		and Other Bodily Injuries.....	222
17	1.	JUUL Products Cause Acute and Chronic Lung (Pulmonary)	
18		Injuries .....	222
19	2.	JUUL Products Cause Cardiovascular Injuries.....	228
20	3.	JUUL Products Cause and Contribute to Seizure(s).....	230
21	4.	Animal Studies Demonstrate Carcinogenic Potential of JUUL.....	231
22	V.	INTERSTATE AND INTRASTATE COMMERCE.....	232
23	VI.	CLASS ACTION ALLEGATIONS.....	233
24	A.	Nationwide Class .....	233
25	B.	State Classes and Subclasses .....	233
26	C.	Class Exclusions .....	240
27	D.	Rule 23 Prerequisites .....	240
28	VII.	CAUSES OF ACTION .....	242
	A.	Violations of California Law Brought on Behalf of the Nationwide Class and	
		the California Subclass .....	242

1	1.	Violation of the California Unfair Competition Law (Cal. Bus. & Prof. Code § 17200, <i>et seq.</i> ) (Sales and Marketing Practices).....	242
2			
3	2.	Violation of the California Consumer Legal Remedies Act (Cal. Civ. Code § 1750, <i>et seq.</i> ).....	245
4			
5	3.	Violation of the California False Advertising Law (Cal. Bus. & Prof. Code § 17500, <i>et seq.</i> ).....	248
6	4.	Common Law Fraud .....	249
7	5.	Breach of the Implied Warranty of Merchantability.....	251
8	6.	Unjust Enrichment .....	253
9	B.	Violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”).....	254
10			
11	1.	Violation of 18 U.S.C. § 1962(c).....	254
12	a.	JLI is an Enterprise Engaged in, or its Activities Affect, Interstate or Foreign Commerce .....	255
13	b.	“Conduct or Participate, Directly or Indirectly, in the Conduct of Such Enterprise’s Affairs” .....	255
14	c.	“Pattern of Racketeering Activity” .....	271
15	d.	Harm to Plaintiffs.....	279
16	2.	Violations of 18 U.S.C. § 1962(d) .....	281
17			
18	3.	Violation of the Magnuson-Moss Warranty Act (15 U.S.C. §§ 2301, <i>et seq.</i> ).....	283
19	C.	Causes of Action Brought on Behalf of the State Classes .....	285
20	1.	Alabama .....	285
21	a.	Violation of the Alabama Deceptive Trade Practices Act (Ala. Code § 8-19-1, <i>et seq.</i> ).....	285
22	b.	Common Law Fraud .....	288
23	c.	Breach of the Implied Warranty of Merchantability.....	291
24	d.	Unjust Enrichment .....	292
25	2.	Alaska .....	293
26	a.	Violation of the Alaska Unfair Trade Practices and Consumer Protection Act (Alaska Stat. § 45.50.471, <i>et seq.</i> ) .....	293
27	b.	Common Law Fraud .....	297
28			

1	c.	Breach of the Implied Warranty of Merchantability.....	299
2	d.	Unjust Enrichment .....	300
3	3.	Arizona.....	302
4	a.	Violation of the Arizona Consumer Fraud Act (Ariz. Rev. Stat. § 44-1521, <i>et seq.</i> ).....	302
5	b.	Common Law Fraud .....	305
6	c.	Breach of the Implied Warranty of Merchantability.....	307
7	d.	Unjust Enrichment .....	308
8	4.	Arkansas.....	310
9	a.	Violation of the Arkansas Deceptive Trade Practices Act (Ark. Code § 4-88-101, <i>et seq.</i> ).....	310
10	b.	Common Law Fraud .....	313
11	c.	Breach of the Implied Warranty of Merchantability.....	315
12	d.	Unjust Enrichment .....	317
13	5.	Colorado.....	318
14	a.	Violation of the Colorado Consumer Protection Act (Colo. Rev. Stat. § 6-1-101, <i>et seq.</i> ).....	318
15	b.	Common Law Fraud .....	321
16	c.	Breach of the Implied Warranty of Merchantability.....	323
17	d.	Unjust Enrichment .....	325
18	6.	Connecticut .....	326
19	a.	Violation of the Connecticut Unfair Trade Practices Act (Conn. Gen. Stat. § 42-110a, <i>et seq.</i> ).....	326
20	b.	Common Law Fraud .....	329
21	c.	Breach of the Implied Warranty of Merchantability.....	331
22	d.	Unjust Enrichment .....	333
23	7.	Delaware .....	334
24	a.	Violation of the Delaware Consumer Fraud Act (Del. Code tit. 6 § 2511, <i>et seq.</i> ).....	334
25	b.	Common Law Fraud .....	336
26	c.	Breach of the Implied Warranty of Merchantability.....	339
27	d.	Unjust Enrichment .....	340
28	8.	District of Columbia .....	341



a.	Violation of the D.C. Consumer Protection Procedures Act (D.C. Code § 28-3901, <i>et seq.</i> ) .....	341
b.	Common Law Fraud .....	344
c.	Breach of the Implied Warranty of Merchantability.....	347
d.	Unjust Enrichment .....	348
9.	Florida .....	349
a.	Violation of the Florida Deceptive and Unfair Trade Practices Act (Fla. Stat. § 501.201, <i>et seq.</i> ) .....	349
b.	Violation of the Florida False Advertising Law (Fla. Stat. §§ 817.06 and 817.41, <i>et seq.</i> ) .....	352
c.	Common Law Fraud .....	355
d.	Breach of the Implied Warranty of Merchantability.....	357
e.	Unjust Enrichment .....	359
10.	Georgia.....	360
a.	Violation of the Georgia Uniform Deceptive Trade Practices Act (Ga. Code § 10-1-370, <i>et seq.</i> ).....	360
b.	Violation of the Georgia Fair Business Practices Act (Ga. Code § 10-1-390, <i>et seq.</i> ) .....	362
c.	Common Law Fraud .....	366
d.	Breach of the Implied Warranty of Merchantability.....	368
e.	Unjust Enrichment .....	370
11.	Hawaii.....	371
a.	Violation of the Hawaii Unfair and Deceptive Trade Practices Act (Haw. Rev. Stat. § 480-1, <i>et seq.</i> ) .....	371
b.	Violation of the Hawaii Uniform Deceptive Trade Practice Act (Haw. Rev. Stat. § 481A-1, <i>et seq.</i> ) .....	374
c.	Common Law Fraud .....	376
d.	Breach of the Implied Warranty of Merchantability.....	378
e.	Unjust Enrichment .....	380
12.	Idaho .....	381
a.	Violation of the Idaho Consumer Protection Act (Idaho Code § 48-601, <i>et seq.</i> ).....	381
b.	Common Law Fraud .....	385
c.	Breach of the Implied Warranty of Merchantability.....	387

1	d.	Unjust Enrichment .....	388
2	13.	Illinois .....	389
3	a.	Violation of the Illinois Consumer Fraud and Deceptive Business Practices Act (815 Ill. Comp. Stat. § 505/1, <i>et seq.</i> ).....	389
4	b.	Common Law Fraud .....	393
5	c.	Breach of the Implied Warranty of Merchantability.....	395
6	d.	Unjust Enrichment .....	396
7	14.	Indiana.....	398
8	a.	Violation of Indiana’s Deceptive Consumer Sales Act (Ind. Code §§ 24-5-0.5-1, <i>et seq.</i> ).....	398
9	b.	Common Law Fraud .....	401
10	c.	Breach of the Implied Warranty of Merchantability.....	404
11	d.	Unjust Enrichment .....	405
12	15.	Iowa.....	406
13	a.	Violation of the Iowa Consumer Fraud Act (Iowa Code § 714H.1, <i>et seq.</i> ).....	406
14	b.	Common Law Fraud .....	409
15	c.	Breach of the Implied Warranty of Merchantability.....	411
16	d.	Unjust Enrichment .....	413
17	16.	Kansas.....	414
18	a.	Violation of Kansas Consumer Protection Act (Kan. Stat. Ann. § 50-623, <i>et seq.</i> ).....	414
19	b.	Common Law Fraud .....	418
20	c.	Breach of the Implied Warranty of Merchantability.....	420
21	d.	Unjust Enrichment .....	421
22	17.	Kentucky .....	422
23	a.	Violation of Kentucky Consumer Protection Act (Ky. Rev. Stat. Ann. § 367.110, <i>et seq.</i> ).....	422
24	b.	Common Law Fraud .....	426
25	c.	Breach of the Implied Warranty of Merchantability.....	428
26	d.	Unjust Enrichment .....	429
27	18.	Louisiana.....	431

a.	Violation of Louisiana Unfair Trade Practices and Consumer Protection Law (La. Rev. Stat. Ann. § 51:1401, <i>et seq.</i> ) .....	431
b.	Common Law Fraud .....	434
c.	Breach of the Implied Warranty of Merchantability.....	436
d.	Unjust Enrichment .....	437
19.	Maine .....	438
a.	Violation of Maine Unfair Trade Practices Act (5 M.R.S.A. § 205-A, <i>et seq.</i> ).....	439
b.	Violation of Maine Uniform Deceptive Trade Practices Act (10 M.R.S.A. § 1211, <i>et seq.</i> ).....	442
c.	Common Law Fraud .....	444
d.	Breach of the Implied Warranty of Merchantability.....	446
e.	Unjust Enrichment .....	448
20.	Maryland.....	449
a.	Violation of Maryland Consumer Protection Act (Md. Code Ann. Com. Law § 13-101, <i>et seq.</i> ).....	449
b.	Common Law Fraud .....	452
c.	Breach of the Implied Warranty of Merchantability.....	455
d.	Unjust Enrichment .....	456
21.	Massachusetts .....	457
a.	Violation of Massachusetts Regulation of Business Practice and Consumer Protection Act (M.G.L.A. 93A, § 1, <i>et seq.</i> ) .....	457
b.	Common Law Fraud .....	460
c.	Breach of the Implied Warranty of Merchantability.....	463
d.	Unjust Enrichment .....	464
22.	Michigan .....	465
a.	Violation of Michigan Consumer Protection Act (M.C.L.A. § 445.901, <i>et seq.</i> ).....	465
b.	Common Law Fraud .....	468
c.	Breach of the Implied Warranty of Merchantability.....	470
d.	Unjust Enrichment .....	472
23.	Minnesota.....	473
a.	Violation of Minnesota Prevention of Consumer Fraud Act (Minn. Stat. § 325F.69).....	473

b.	Violation of Minnesota False Statement in Advertising Law (Minn. Stat. § 325F.67).....	476
c.	Violation of Minnesota Deceptive Trade Practices Act (Minn. Stat. § 325D.43, <i>et seq.</i> ).....	478
d.	Common Law Fraud .....	480
e.	Breach of the Implied Warranty of Merchantability.....	483
f.	Unjust Enrichment .....	484
24.	Mississippi .....	485
a.	Violation of Mississippi Consumer Protection Act (Miss. Code Ann. § 75-24-1, <i>et seq.</i> ) .....	485
b.	Common Law Fraud .....	488
c.	Breach of the Implied Warranty of Merchantability.....	490
d.	Unjust Enrichment .....	491
25.	Missouri .....	492
a.	Violation of the Missouri Merchandising Practices Act (Mo. Rev. Stat. § 407.010, <i>et seq.</i> ).....	493
b.	Common Law Fraud .....	495
c.	Breach of the Implied Warranty of Merchantability.....	498
d.	Unjust Enrichment .....	499
26.	Montana .....	500
a.	Violation of the Montana Unfair Trade Practices and Consumer Protection Act (Mont. Code Ann. § 30-14-101, <i>et seq.</i> ).....	500
b.	Common Law Fraud .....	503
c.	Breach of the Implied Warranty of Merchantability.....	505
d.	Unjust Enrichment .....	507
27.	Nebraska .....	508
a.	Violation of the Nebraska Consumer Protection Act (Neb. Rev. Stat. §§ 59-1601, <i>et seq.</i> ) .....	508
b.	Violation of the Nebraska Uniform Deceptive Trade Practices Act (Neb. Rev. Stat. §§ 87-301, <i>et seq.</i> ).....	511
c.	Common Law Fraud .....	514
d.	Breach of the Implied Warranty of Merchantability.....	516
e.	Unjust Enrichment .....	517
28.	Nevada .....	519

1	a.	Violation of the Nevada Deceptive Trade Practices Act (Nev. Rev. Stat. §§ 598.0903, <i>et seq.</i> ) .....	519
2	b.	Common Law Fraud .....	522
3	c.	Breach of the Implied Warranty of Merchantability.....	524
4	d.	Unjust Enrichment .....	525
5	29.	New Hampshire .....	526
6	a.	Violation of the New Hampshire Regulation of Business Practices for Consumer Protection (N.H. Rev. Stat. §§ 358-A:1, <i>et seq.</i> )	527
7	b.	Common Law Fraud .....	530
8	c.	Breach of the Implied Warranty of Merchantability.....	532
9	d.	Unjust Enrichment .....	534
10	30.	New Jersey .....	535
11	a.	Common Law Fraud .....	535
12	b.	Breach of the Implied Warranty of Merchantability.....	537
13	c.	Unjust Enrichment .....	538
14	31.	New Mexico.....	540
15	a.	Violation of the New Mexico Unfair Trade Practices Act (N.M. Stat. § 57-12-1) .....	540
16	b.	Common Law Fraud .....	543
17	c.	Breach of the Implied Warranty of Merchantability.....	545
18	d.	Unjust Enrichment .....	547
19	32.	New York.....	548
20	a.	Violation of New York General Business Law § 349 .....	548
21	b.	Violation of New York General Business Law § 350 .....	550
22	c.	Common Law Fraud .....	553
23	d.	Breach of the Implied Warranty of Merchantability.....	555
24	e.	Unjust Enrichment .....	556
25	33.	North Carolina .....	558
26	a.	Violation of the North Carolina Unfair & Deceptive Trade Practices Act (N.C. Gen. Stat. §§ 75-1.1, <i>et seq.</i> ).....	558
27	b.	Common Law Fraud .....	561
28	c.	Breach of the Implied Warranty of Merchantability.....	563
	d.	Unjust Enrichment .....	564

34.	North Dakota.....	566
a.	Violation of North Dakota Consumer Fraud Act (N.D. Cent. Code § 51-15-01, <i>et seq.</i> ) .....	566
b.	Violation of North Dakota False Advertising Law (N.D. Cent. Code § 51-12-08) .....	569
c.	Common Law Fraud .....	571
d.	Breach of the Implied Warranty of Merchantability.....	573
e.	Unjust Enrichment .....	575
35.	Ohio.....	576
a.	Violation of the Ohio Consumer Sales Practices Act (Ohio Rev. Code Ann. §§ 1345.01, <i>et seq.</i> ).....	576
b.	Violation of the Ohio Deceptive Trade Practices Act (Ohio Rev. Code §§ 4165.01 - .04) .....	579
c.	Common Law Fraud .....	581
d.	Breach of the Implied Warranty of Merchantability.....	584
e.	Unjust Enrichment .....	585
36.	Oklahoma.....	586
a.	Violation of the Oklahoma Consumer Protection Act (Okla. Stat. tit. 15, §§ 751, <i>et seq.</i> ).....	586
b.	Violation of the Oklahoma Deceptive Trade Practices Act (Okla. Stat. tit. 78, §§ 51, <i>et seq.</i> ) .....	589
c.	Common Law Fraud .....	592
d.	Breach of the Implied Warranty of Merchantability.....	594
e.	Unjust Enrichment .....	595
37.	Oregon.....	596
a.	Violation of the Oregon Unfair Trade Practices Act (Or. Rev. Stat. §§ 646.605, <i>et seq.</i> ).....	597
b.	Common Law Fraud .....	600
c.	Breach of the Implied Warranty of Merchantability.....	602
d.	Unjust Enrichment .....	603
38.	Pennsylvania .....	604
a.	Violation of the Pennsylvania Unfair Trade Practices and Consumer Protection Law (73 Pa. Stat. Ann. §§ 201-1, <i>et seq.</i> ).....	605
b.	Common Law Fraud .....	607

1	c.	Breach of the Implied Warranty of Merchantability.....	609
2	d.	Unjust Enrichment .....	611
3	39.	Rhode Island .....	612
4	a.	Violation of the Rhode Island Unfair Trade Practice and Consumer Protection Act (6 R.I. Gen. Laws §§ 13.1-1, <i>et seq.</i> )	612
5	b.	Common Law Fraud .....	615
6	c.	Breach of the Implied Warranty of Merchantability.....	618
7	d.	Unjust Enrichment .....	619
8	40.	South Carolina .....	620
9	a.	Violation of the South Carolina Unfair Trade Practices Act (S.C. Code Ann. §§ 39-5-10, <i>et seq.</i> ) .....	620
10	b.	Common Law Fraud .....	623
11	c.	Breach of the Implied Warranty of Merchantability.....	625
12	d.	Unjust Enrichment .....	627
13	41.	South Dakota.....	628
14	a.	Violation of the South Dakota Deceptive Trade Practices and Consumer Protection Act (S.D. Codified Laws §§ 37-24-1, <i>et</i> <i>seq.</i> ).....	628
15	b.	Common Law Fraud .....	631
16	c.	Breach of the Implied Warranty of Merchantability.....	633
17	d.	Unjust Enrichment .....	634
18	42.	Tennessee.....	636
19	a.	Violation of the Tennessee Consumer Protection Act (Tenn. Code Ann. §§ 47-18-101, <i>et seq.</i> ) .....	636
20	b.	Common Law Intentional Misrepresentation .....	639
21	c.	Breach of the Implied Warranty of Merchantability.....	641
22	d.	Unjust Enrichment .....	643
23	43.	Texas.....	644
24	a.	Violation of the Texas Deceptive Trade Practices-Consumer Protection Act (Tex. Bus. & Com. Code §§ 17.41, <i>et seq.</i> ).....	644
25	b.	Common Law Fraud .....	647
26	c.	Breach of the Implied Warranty of Merchantability.....	649
27	d.	Unjust Enrichment .....	651

44.	Utah.....	652
a.	Violation of the Utah Consumer Sales Practices Act (Utah Code Ann. §§ 13-11-1, <i>et seq.</i> ) .....	652
b.	Violation of the Utah Truth in Advertising Law (Utah Code Ann. §§ 13-11a-1, <i>et seq.</i> ).....	655
c.	Common Law Fraud .....	657
d.	Breach of the Implied Warranty of Merchantability.....	659
e.	Unjust Enrichment .....	661
45.	Vermont .....	662
a.	Violation of the Vermont Consumer Protection Act (Vt. Stat. Ann. tit. 9 §§ 2451, <i>et seq.</i> ).....	662
b.	Common Law Fraud .....	665
c.	Breach of the Implied Warranty of Merchantability.....	667
d.	Unjust Enrichment .....	669
46.	Virginia .....	670
a.	Violation of the Virginia Consumer Protection Act (Va. Code Ann. § 59.1-196, <i>et seq.</i> ).....	670
b.	Common Law Fraud .....	673
c.	Breach of the Implied Warranty of Merchantability.....	675
d.	Unjust Enrichment .....	676
47.	Washington .....	678
a.	Violation of the Washington Consumer Protection Act (Wash. Rev. Code §§ 19.86.010, <i>et seq.</i> ) .....	678
b.	Common Law Fraud .....	681
c.	Breach of the Implied Warranty of Merchantability.....	683
d.	Unjust Enrichment .....	685
48.	West Virginia.....	686
a.	Violation of the West Virginia Consumer Credit and Protection Act (W. Va. Code §§ 46A-6-101, <i>et seq.</i> ) .....	686
b.	Common Law Fraud .....	688
c.	Breach of the Implied Warranty of Merchantability.....	691
d.	Unjust Enrichment .....	692
49.	Wisconsin.....	693



1	a.	Violation of the Wisconsin Deceptive Trade Practices Act (Wis. Stat. § 100.18).....	693
2	b.	Common Law Fraud .....	696
3	c.	Breach of the Implied Warranty of Merchantability.....	698
4	d.	Unjust Enrichment .....	699
5	50.	Wyoming.....	700
6	a.	Violation of the Wyoming Consumer Protection Act (Wyo. Stat. Ann. §§ 40-12-101, <i>et seq.</i> ) .....	701
7	b.	Common Law Fraud .....	704
8	c.	Breach of the Implied Warranty of Merchantability.....	706
9	d.	Unjust Enrichment .....	708
10	VIII.	PRAYER FOR RELIEF .....	709
11	IX.	LACK OF ADEQUATE REMEDIES AT LAW .....	709
12	X.	RELIEF NOT REQUESTED AND RESERVATION OF RIGHTS .....	710
13	XI.	DEMAND FOR JURY TRIAL.....	710

**I. INTRODUCTION**

1. The battle to end nicotine addiction and its associated diseases and death has consumed our nation's public health resources for more than half a century. After five decades of tireless efforts by public health advocates, litigators, and regulators, the war on tobacco was on the path to victory. By 2014, rates of smoking and nicotine addiction in this country were finally at an all-time low, particularly among teenagers. Until now. The United States, closer than ever to consigning the nicotine industry to the dustbin of history, now faces a youth nicotine epidemic of historic proportions. The swift rise in a new generation of nicotine addicts has overwhelmed parents, schools, and the medical community, drawing governmental intervention at nearly every level—but it's too little, too late.

2. This public health crisis is no accident. What had been lauded as progress in curbing cigarette use, JUUL Labs Inc.'s (JLI) co-founders Adam Bowen and James Monsees viewed as opportunity. Seizing on the decline in cigarette consumption and the lax regulatory environment for e-cigarettes, Bowen, Monsees, and investors in their company sought to introduce nicotine to a whole new generation, with JLI as the dominant supplier. To achieve that common purpose, they knew they would need to create and market a product that would make nicotine cool again, without any of the stigma associated with cigarettes. With help from their early investors and board members, who include Nicholas Pritzker, Riaz Valani, and Huyoung Huh (together, the "Management Defendants"), they succeeded in hooking millions of youth, intercepting millions of adults trying to overcome their nicotine addictions, and, of course, earning billions of dollars in profits.

3. Every step of the way, JLI, by calculated intention, adopted the cigarette industry's playbook, in coordination with one of that industry's innovators, cigarette giant Altria. JLI was created in the image of the iconic American cigarette companies, which JLI founders praised for creating "the most successful consumer product of all time. . . . an amazing product." The secret to that "amazing product"? Nicotine, a chemical that has deleterious effects on the developing brains of youths, and is the fundamental reason that people persist in using tobacco products posing the risk of pulmonary injuries, cardiovascular disease and other

1 serious, often fatal, conditions. Through careful study of decades of cigarette industry  
2 documents, JLI knew that the key to developing and sustaining addiction was the amount and  
3 the efficiency of the nicotine delivery.

4 4. Three tactics were central to decades of cigarette industry market dominance:  
5 product design to maximize addiction; mass deception; and targeting of youth. JLI and its co-  
6 conspirators adopted and mastered them all. *First*, JLI and Bowen designed JUUL products to  
7 create and sustain addiction, not break it. JLI and Bowen were the first to design an e-cigarette  
8 that could compete with combustible cigarettes on the speed and strength of nicotine delivery.  
9 Indeed, JUUL products use nicotine formulas and delivery methods much stronger than  
10 combustible cigarettes, confirming that what JLI and Bowen designed was a starter product, not  
11 a cessation or cigarette replacement product. JLI and Bowen also innovated by making an e-  
12 cigarette that was smooth and easy to inhale, practically eliminating the harsh “throat hit,”  
13 which otherwise deters nicotine consumption, especially among nicotine “learners,” as R.J.  
14 Reynolds’ chemist Claude Teague called new addicts, primarily young people.

15 5. *Second*, JLI, the Management Defendants and Altria engaged in a campaign of  
16 deceit, through sophisticated mass media and social media communications, advertisements and  
17 otherwise, about the purpose and dangers of JUUL products. JUUL products’ packaging and  
18 advertising grossly understates the nicotine content in its products. Advertising campaigns  
19 featured JUUL paired with food and coffee, positioning JUUL as part of a healthy meal, a  
20 normal part of a daily routine, and as safe as caffeine. In partnership with Altria, JLI adopted a  
21 “Make the Switch” campaign to mislead consumers into thinking that JLI products were benign  
22 smoking cessation devices, even though JUUL was never designed to break addictions. JLI, the  
23 Management Defendants, and Altria also concealed the results of studies that revealed that  
24 JUUL products were far more powerfully addictive than was disclosed. JLI’s deceptive  
25 marketing scheme was carried out across the country through broad distribution channels:  
26 veteran cigarette industry wholesalers, distributors and retailers ensured that JUUL products  
27 would become widely available to a new market of nicotine-newcomers, especially youth. JLI  
28 and the Management Defendants joined with these veteran cigarette industry marketers to

1 secure premium shelf space for vivid displays at convenience stores, like 7-11, and gas stations,  
2 including Chevron, that would lure e-cigarette users, young and old, who would become long-  
3 term customers. These marketing efforts have been resounding successes—when JUUL  
4 products were climbing in sales, most adults and youth believed that e-cigarettes did not contain  
5 nicotine at all.

6         6.       *Third*, JLI and the Management Defendants, just like cigarette companies before  
7 them, targeted kids as their customer base. One of JLI’s “key needs” was the need to “own the  
8 ‘cool kid’ equity.” JUUL products were designed to appear slick and high-tech like a cool  
9 gadget, including video-game-like features like “party mode.” JLI offered kid-friendly flavors  
10 like mango and cool mint, and partnered with Altria to create and preserve the market for mint-  
11 flavored products—all because Defendants knew that flavors get young people hooked. Under  
12 the guise of youth smoking prevention, JLI sent representatives directly to schools to study  
13 teenager e-cigarette preferences.

14         7.       JLI and the Management Defendants reached their intended demographic  
15 through a diabolical pairing of notorious cigarette company advertising techniques (long banned  
16 for cigarettes because they cause young people to start smoking) with cutting-edge viral  
17 marketing campaigns and social media. They hired young models and advertised using bright,  
18 “fun” themes, including on media long barred to the cigarette industry, such as billboards, on  
19 children’s websites such as “Nick Junior” and Cartoon Network, and on websites providing  
20 games and educational tools to students in middle school and high school. JLI and the  
21 Management Defendants also employed young social-media “influencers” and celebrities  
22 popular with teenagers. When the public, regulators, and Congress caught onto JLI’s relentless  
23 focus on children, JLI and the Management Defendants simply lied, even though they knew  
24 well that they had purposefully targeted youth in their marketing and those efforts had been  
25 breathtakingly successful. JUUL products are rampant in the nation’s schools, with the  
26 percentage of 12th graders who reported consuming nicotine almost doubling between 2017 and  
27 2018. The Surgeon General has warned that this new “epidemic of youth e-cigarette use” could  
28 condemn a generation to “a lifetime of nicotine addiction and associated health risks.”

1           8.       It should come as little surprise that JLI and the Management Defendants’  
2 misconduct, expressly patterned after decades of cigarette company practices, could not have  
3 been carried out without the involvement and expertise of an actual cigarette company. In  
4 December 2018, Altria paid \$12.8 billion to acquire a 35% stake in JLI. Nicholas Pritzker and  
5 Riaz Valani led the negotiations for JLI and worked closely with Altria’s executives to secure  
6 Altria’s agreement to pull its own competing e-cigarette product off the market and instead  
7 throw its vast resources and cigarette industry knowledge behind JUUL. Altria thus supported  
8 and ultimately directed JLI, working to ensure its continued success despite Altria’s knowledge  
9 that JLI and the Management Defendants’ had mislead the public and targeted youth. JUUL’s  
10 market dominance was established, positioning Altria and the Management Defendants to share  
11 in JLI’s profits. Defendants’ conduct prompted the Federal Trade Commission to sue JLI and  
12 Altria on April 1, 2020 alleging violations of the antitrust laws and seeking to unwind the  
13 JLI/Altria transaction. But even well before Altria announced its investment in JLI, the  
14 connections between the two companies ran deep. With the assistance and direction of the  
15 Management Defendants, Altria collaborated with JLI to maintain and grow JUUL sales,  
16 despite its knowledge that JUUL was being marketed fraudulently to all consumers and targeted  
17 to youth, including by sharing data and information and coordinating marketing activities,  
18 including acquisition of key shelf space next to top-selling Marlboro cigarettes. Altria’s  
19 investment in JLI is not merely a financial proposition, but a key element of Defendants’ plan to  
20 stave off regulation and public outcry and keep their most potent and popular products on the  
21 market. JLI (and the Management Defendants) have benefitted from Altria’s expertise in  
22 designing and marketing addictive products, and in thwarting regulation.

23           9.       There is no doubt about it—JLI, the Management Defendants, Altria, and their  
24 co-Defendants have created this public health crisis. At the heart of this disastrous epidemic are  
25 the concerted efforts of JLI, its co-conspirators, and all those in JUUL’s supply and distribution  
26 chain to continuously expand their market share and profits by preying upon a vulnerable young  
27 population and deceiving the public about the true nature of the products they were selling.  
28 Nicotine is not benign like coffee, contrary to what many JUUL users believe. Nor is the aerosol

as harmless as puffing room air. Worse, the flavors in JUUL products are themselves toxic and dangerous, and have never been adequately tested to ensure they are safe for inhalation. According to the most recent scientific literature, JUUL products cause acute and chronic pulmonary injuries, cardiovascular conditions, and seizures. Yet JUUL products and advertising contain no health risk warnings at all. Many smokers, believing that JUUL would help them “make the switch,” ended up only further trapped in their nicotine addiction. Older adults who switch to JUUL are more susceptible to cardiovascular and pulmonary problems, and CDC data shows that older patients hospitalized due to vaping lung related conditions had much longer hospital stays than younger patients. And a generation of kids is now hooked, ensuring long-term survival of the nicotine industry because, today just as in the 1950s, 90% of smokers start as children.

10. Hundreds of individual and class actions have been filed in state and federal courts on behalf of the countless victims of JUUL’s e-cigarettes. On August 10, 2019, the Judicial Panel on Multidistrict Litigation consolidated all such actions then pending for pretrial purposes in this Court. *See In re Juul Labs, Inc., Marketing, Sales Practices, and Products Liability Litigation*, 396 F. Supp. 3d 1366 (J.P.M.L. 2019). On January 13, 2020, this Court directed the filing of Master Complaints on behalf of the Plaintiffs. ECF No. 351. Plaintiffs submit this Consolidated Class Action Complaint seeking compensatory and punitive damages, restitution, disgorgement, and other relief arising from the conduct alleged in this complaint.

## **II. PARTIES**

### **A. Plaintiffs**

11. Allegations specific to each plaintiff are included in Appendix A.

### **B. Defendants**

#### **1. JUUL Labs, Inc.**

12. Defendant JUUL Labs, Inc. (“JLI”) is a Delaware corporation, having its principal place of business in San Francisco, California. Ploom, Inc., a predecessor company to JLI, was incorporated in Delaware on March 12, 2007. In 2015, Ploom, Inc. changed its name to PAX Labs, Inc. In April 2017, PAX Labs, Inc. changed its name to JUUL Labs, Inc., and

1 formed a new subsidiary corporation with its old name, PAX Labs, Inc. That new subsidiary,  
2 PAX Labs, Inc. (“PAX”), was incorporated in Delaware on April 21, 2017 and has its principal  
3 place of business in San Francisco, California.

4 13. JLI designs, manufactures, sells, markets, advertises, promotes and distributes  
5 JUUL e-cigarettes devices, JUUL pods and accessories (collectively “JUUL” or “JUUL  
6 products”). Prior to the formation of separate entities PAX Labs, Inc. and JLI in or around April  
7 2017, JUUL designed, manufactured, sold, marketed, advertised, promoted, and distributed  
8 JUUL under the name PAX Labs, Inc.

9 14. Together with its predecessors, JUUL Labs, Inc is referred to herein as “JLI.”

## 10 **2. Altria Defendants**

11 15. Defendant Altria Group, Inc., (“Altria” or “Altria Group” or together with its  
12 wholly owned subsidiaries and their predecessors, “Altria” or together with Defendants Philip  
13 Morris USA, Inc., Altria Client Services LLC, and Altria Group Distribution Company, the  
14 “Altria Defendants”) is a Virginia corporation, having its principal place of business in  
15 Richmond, Virginia. Altria is one of the world’s largest producers and marketers of tobacco  
16 products, manufacturing and selling combustible cigarettes for more than a century.

17 16. Defendant Philip Morris USA, Inc. (“Philip Morris”), is a wholly-owned  
18 subsidiary of Altria. Philip Morris is also a Virginia corporation that has its principal place of  
19 business in Richmond, Virginia. Philip Morris is engaged in the manufacture and sale of  
20 cigarettes in the United States. Philip Morris is the largest cigarette company in the United  
21 States. Marlboro, the principal cigarette brand of Philip Morris, has been the largest selling  
22 cigarette brand in the United States for over 40 years.

23 17. On December 20, 2018, Altria Group and Altria Enterprises LLC purchased a  
24 35% stake in JLI. Altria and JLI executed a Services Agreement that provides that Altria,  
25 through its subsidiaries, Philip Morris, Altria Client Services LLC, and Altria Group  
26 Distribution Company, would assist JLI in the selling, marketing, promoting, and distributing of  
27 JUUL, among other things.

28 18. Defendant Altria Client Services LLC (“Altria Client Services” or “ACS”) is a

Virginia limited liability company with its principal place of business in Richmond, Virginia. Altria Client Services provides Altria Group, Inc. and its companies with services in many areas including digital marketing, packaging design & innovation, product development, and safety, health, and environmental affairs. Pursuant to Altria's Relationship Agreement with JLI, Altria Client Services assists JLI in the sale, marketing, promotion and distribution of JUUL products.<sup>1</sup> Such services include database support, direct marketing support, and premarket product application support.<sup>2</sup> On September 25, 2019, the former senior vice president and chief growth officer of Altria Client Services, K.C. Crosthwaite, became the new chief executive officer of JLI.

19. Defendant Altria Group Distribution Company ("AGDC") is a Virginia corporation and wholly owned subsidiary of Altria Group, Inc. with its principal place of business in Richmond, Virginia. Altria Group Distribution Company provides sales, distribution and consumer engagement services to Altria's tobacco companies. Altria Group Distribution Company performs services under the Relationship Agreement to assist JLI in the sale, marketing, promotion and distribution of JLI. Such services include JUUL-distribution support, the removal by Altria Group Distribution Company of Nu Mark products (such as Green Smoke or MarkTen) and fixtures in retail stores and replacing them with JUUL products and fixtures, and sales support services.

20. While Plaintiffs have attempted to identify the specific Altria defendant which undertook certain acts alleged in this Complaint, they were not always able to do so due to ambiguities in Altria's and JLI's own documents. References in these internal documents to "Altria" without further detail are common. In other words, Defendants do not always specify which entity is involved in particular activities in their own internal documentation. Moreover, key employees moved freely between Altria Group, Inc. and its various operating subsidiaries,

---

<sup>1</sup> Altria Group, Inc., *Relationship Agreement by and among JUUL Labs, Inc., Altria Group, Inc., and Altria Enterprises LLC* ("Relationship Agreement") (Form 8-K), Ex. 2.2 (Dec. 20, 2018), <https://www.sec.gov/Archives/edgar/data/764180/000119312518353970/d660871dex22.htm>.

<sup>2</sup> *Id.*



1 including defendants Altria Client Services, Altria Group Distribution Company, and Philip  
2 Morris USA Inc – each of which is a wholly owned subsidiary of Altria Group, Inc. For  
3 example, K.C. Crosthwaite (who would later become CEO of JLI) was at various points from  
4 2017 through 2019 employed by Altria Client Services, Philip Morris, and Altria Group. And in  
5 its own annual reports to Shareholders, when identifying the “Executive Officers” of Altria  
6 Group, Altria states that the “officers have been employed by Altria *or its subsidiaries* in  
7 various capacities during the past five years.”<sup>3</sup>

8 21. Notably, Altria Group directs the activities of its varying operating companies,  
9 including defendants Altria Client Services, AGDC, and Philip Morris. For this reason, and  
10 unless otherwise specified, the term “Altria” refers to Altria Group Inc. as the responsible entity,  
11 by virtue of its control over its various operating subsidiaries. To the extent such an assumption  
12 is incorrect, the knowledge of which Altria Group Inc. subsidiary is responsible for specific  
13 conduct is knowledge solely within the possession of the Altria Defendants.

### 14 3. Management Defendants

15 22. Defendant James Monsees is a resident of the San Francisco Bay area,  
16 California. In 2007, he co-founded Ploom with Adam Bowen. He served as Chief Executive  
17 Officer of JLI until October 2015. Since October 2015, he has been Chief Product Officer of  
18 JLI. At all relevant times, he has been a member of the Board of Directors of JLI until he  
19 stepped down in March 2020.

20 23. Defendant Adam Bowen is a resident of the San Francisco Bay area, California.  
21 In 2007, he co-founded Ploom with Defendant Monsees. At all relevant times, he has been  
22 Chief Technology Officer and a member of the Board of Directors of JLI.

23 24. Defendant Nicholas Pritzker is a resident of San Francisco, California, and a  
24 member of the Pritzker family, which owned the chewing-tobacco giant Conwood before selling  
25 it to Reynolds American, Inc., a subsidiary of British American Tobacco. Pritzker received a  
26 J.D. from the University of Chicago. He served as president of the Hyatt Hotels Corporation and  
27

---

28 <sup>3</sup> Altria Group, Inc., *2018 Altria Group, Inc. Annual Report* at 98, available at  
<http://investor.altria.com/file/4087349/Index?KeyFile=1001250956> (emphasis added).

1 was a member of its Board of Directors from 1980 to 2007. More recently, he co-founded Tao  
 2 Capital, an early investor in, among other companies, Tesla Motors and Uber. In 2011, he  
 3 invested in JLI.<sup>4</sup> He has been on the Board of Directors of JLI since at least August 2013.<sup>5</sup> At  
 4 least from October 2015 to August 2016, he was on the Executive Committee in the Board of  
 5 Directors and served as Co-Chairman. He controlled two of JLI's seven maximum Board seats  
 6 (the second of which was occupied at relevant times by Alexander Asseily and Zachary  
 7 Frankel).<sup>6</sup>

8 25. Defendant Hoyoung Huh currently lives in Florida. During most of the relevant  
 9 time period, he lived and worked in the Silicon Valley area, California. He holds an M.D. from  
 10 Cornell and a Ph.D. in Genetics/Cell Biology from Cornell/Sloan-Kettering. He has been CEO  
 11 or a Board member of numerous biotechnology businesses, including Geron Corporation. Huh  
 12 has been on the Board of Directors of JLI since at least June 2015. At least from October 2015  
 13 to August 2016, he was on the Executive Committee in the Board of Directors. Huh occupied  
 14 the Board seat appointed by a majority of the JLI Board.<sup>7</sup> Huh resigned from JLI's board in  
 15 May 2018.<sup>8</sup>

16 26. Defendant Riaz Valani lives near San Jose, California and is a general partner at  
 17 Global Asset Capital, a San Francisco-based private equity investment firm. He first invested in  
 18 JLI in 2007, and has been on the Board of Directors of JLI since at least 2007.<sup>9</sup> At least from  
 19 October 2015 to August 2016, he was on the Executive Committee in the Board of Directors.  
 20 He controlled two JLI's maximum seven Board seats.<sup>10</sup> Beginning around March 2015,

---

22 <sup>4</sup> Ainsley Harris, *How JUUL went from a Stanford thesis to \$16 billion startup*, Fast Co. (Mar.  
 23 8, 2020), <https://www.fastcompany.com/90263212/how-JUUL-went-from-a-stanford-thesis-to-16-billion-startup>.

24 <sup>5</sup> JLI01426164.

25 <sup>6</sup> JLI01356230; JLI01356237; JLI00417815 (same in February 2018); JLI01362388;  
 JLI01439393; JLI01440776.

26 <sup>7</sup> *Id.*

27 <sup>8</sup> JLI01425022.

28 <sup>9</sup> JLI01437838; Ploom, Inc., Notice of Exempt Offering of Securities (Form D) (May 5, 2011),  
[https://www.sec.gov/Archives/edgar/data/1520049/000152004911000001/xslFormDX01/primary\\_doc.xml](https://www.sec.gov/Archives/edgar/data/1520049/000152004911000001/xslFormDX01/primary_doc.xml).

<sup>10</sup> JLI01426710; JLI01365707; INREJUUL\_00327603; JLI00417815.

Valani's second seat was occupied by Hank Handelsman; Zach Frankel may have occupied Valani's second seat starting in 2017, though Handelsman remained on the board.<sup>11</sup>

27. Defendants Monsees, Bowen, Pritzker, Huh, and Valani are referred to collectively as the "Management Defendants."

28. The Altria Defendants, Monsees, Bowen, Pritzker, Huh, and Valani are referred to collectively as the "RICO Defendants."

### **III. JURISDICTION AND VENUE**

29. This Court has subject matter jurisdiction pursuant to the Class Action Fairness Act of 2005, 28 U.S.C. § 1332(d), because at least one class member is of diverse citizenship from one Defendant, there are more than 100 class members nationwide; and the aggregate amount in controversy exceeds \$5,000,000 and minimal diversity exists.

30. Defendants JUUL and the Altria Defendants have significant contacts in each States and Territories of the United States, such that personal jurisdiction would be proper in any of them. Defendants Monsees, Bowen, Pritzker, and Valani reside within the Northern District of California and are subject to the general jurisdiction of this Court. Defendant Huh resided in the Northern District of California when he engaged in the conduct alleged herein. All Defendants have materially participated in conduct that had intended and foreseeable effects on plaintiffs and class members in each state such that the courts in each state could exercise personal jurisdiction over defendants. Defendants' conduct was purposefully directed at Plaintiffs and class members throughout the United States and in each individual state.

31. A substantial part of the events and omissions giving rise to Plaintiffs' causes of action occurred in and/or emanated from this District. Pursuant to 28 U.S.C. § 1391(a), venue is proper in said District.

---

<sup>11</sup> JLI01356230; JLI01356237; JLI00417815; JLI01365706; JLI01362388; JLI01439393; JLI01440776.

1 **IV. FACTUAL ALLEGATIONS**

2 **A. Each Defendant Was Instrumental in Seeking to Develop and Market the**  
 3 **Blockbuster Sequel to Combustible Cigarettes, the “Most Successful**  
 4 **Consumer Product of All Time.”**

5 32. JLI’s co-founder James Monsees has described the cigarette as “the most  
 6 successful consumer product of all time . . . an amazing product.”<sup>12</sup> This statement, which  
 7 ignores the fact that cigarettes have caused more deaths than any other human invention,  
 8 contained a kernel of truth. When U.S. smoking rates peaked in the mid-1960s, 42% of adults  
 9 smoked cigarettes. Cigarettes were everywhere; people smoked on airplanes, in movie theatres,  
 10 at the office, and at sports games. Movie stars and sports heroes smoked. Cigarette advertising  
 11 wallpapered American life, glamorizing smoking as sophisticated, cool, and the thing to do.

12 33. But in reality, of course, this “successful” product has long been the world’s  
 13 leading cause of preventable death.

14 34. Years of anti-smoking campaigns, including work by local government public  
 15 health departments and school-based anti-tobacco programs, have made great strides towards  
 16 denormalizing cigarette smoking. But where public health officials and schools saw progress,  
 17 others saw an opportunity.

18 35. Citing “some problems” inherent in the cigarette, Monsees and JLI co-founder  
 19 Adam Bowen set out to “deliver[] solutions that refresh the magic and luxury of the tobacco  
 20 category.”<sup>13</sup> Monsees saw “a huge opportunity for products that speak directly to those  
 21 consumers who aren’t perfectly aligned with traditional tobacco products.”<sup>14</sup> Successfully  
 22 capitalizing on this opportunity would mean not only billions of dollars in short-term revenue  
 23 but lucrative acquisition by a cigarette industry power player.

24 36. Bowen and Monsees took the first major step toward realizing their vision by

25 <sup>12</sup> Kathleen Chaykowski, *Billionaires-to-be: Cigarette Breakers—James Monsees and Adam*  
 26 *Bowen Have Cornered the US E-Cigarette Market with Juul. Up Next: The World*, FORBES  
 INDIA (Sept. 27, 2018), [www.forbesindia.com/article/leaderboard/billionairestobe-cigarette-breakers/51425/1](http://www.forbesindia.com/article/leaderboard/billionairestobe-cigarette-breakers/51425/1).

27 <sup>13</sup> Josh Mings, *Ploom Model Two Slays Smoking With Slick Design and Heated Tobacco Pods*,  
 28 SOLID SMACK (Apr. 23, 2014), [www.solidsmack.com/design/ploom-modeltwo-slick-design-tobacco-pods](http://www.solidsmack.com/design/ploom-modeltwo-slick-design-tobacco-pods).

<sup>14</sup> *Id.*

1 deliberately creating an extremely potent nicotine product that looked nothing like a cigarette.  
2 But achieving widespread adoption of their highly addictive product required resources and  
3 expertise beyond those possessed by Bowen, Monsees or others at JLI.

4 37. When it became clear that Bowen and Monsees could not achieve vision of  
5 growing the number of nicotine-addicted e-cigarette users to ensure a base of customers for life  
6 through JLI by themselves, the Management Defendants planned a fundamental shift in roles to  
7 allow Pritzker, Huh, and Valani to direct and take control of JLI and use it to commit the  
8 Defendants' unlawful acts.

9 38. Specifically, in October 2015, Monsees stepped down from his role as Chief  
10 Executive Officer of JLI (to become Chief Product Officer) and, in his stead, Pritzker, Valani,  
11 and Huh formed an Executive Committee of the JLI Board of Directors that would take charge  
12 of fraudulently marketing JUUL products, including to youth.

13 39. Prior to the installation of Tyler Goldman as JLI's new CEO in August 2016,  
14 Defendants Pritzker, Valani, and Huh used their newly formed Executive Committee to expand  
15 the number of addicted e-cigarette users through fraudulent advertising and representations to  
16 the public. They overrode other board members' arguments that JLI's youth oriented marketing  
17 campaign should be abandoned or scaled back, directed the continuation of the marketing  
18 campaign that they knew was actively targeting youth, and cleaned house at JLI by  
19 "dismiss[ing] other senior leaders and effectively tak[ing] over the company."<sup>15</sup> Once their  
20 leadership was secure, defendants Pritzker, Valani, and Huh pressed for even "more aggressive  
21 rollout and [marketing]."<sup>16</sup>

22 40. Defendants Bowen, Monsees, Pritzker, Valani, and Huh thus, and as further set  
23 forth in this complaint, controlled JLI and used it to make fraudulent misrepresentations or  
24 omissions regarding Juul's intentional addictiveness and method of nicotine delivery, combined  
25 with the intent, contrary to public statements, to grow the market for nicotine-addicted  
26

27  
28 <sup>15</sup> Julie Creswell & Sheila Kaplan, *How Juul Hooked a Generation on Nicotine*, N.Y. TIMES  
(Nov. 23, 2019), <https://www.nytimes.com/2019/11/23/health/juul-vaping-crisis.html>.

<sup>16</sup> INREJUUL\_00278359.

1 individuals for their own financial gain.

2 41. And, as set forth in this complaint, Defendants Bowen, Monsees, Pritzker, Huh,  
3 and Valani sought to personally profit from their unlawful acts, using their control of JLI to  
4 position the company for acquisition. By no later than August 2015, and likely earlier,  
5 Defendant Monsees was in talks with Japan Tobacco International (an early investor in Ploom,  
6 JLI's predecessor), British American Tobacco, and Phillip Morris International regarding a  
7 potential acquisition of the JUUL business. Monsees had already received "a couple good faith  
8 lowball offers" from British American Tobacco and was awaiting a proposal from PMI that  
9 month. At the same time, Monsees was looking for "banking support to give an internal tobacco  
10 champion the tools to argue for a sizeable deal."<sup>17</sup>

11 42. By no later than August 2015, Defendants Bowen, Pritzker, Valani, and Huh  
12 joined in the discussions of a potential acquisition by a major cigarette company,<sup>18</sup> as they  
13 knew, in the words of Defendant Bowen, "big tobacco is used to paying high multiples for  
14 brands and market share."

15 43. Unable to secure an early acquisition, the Management Defendants knew that  
16 their desire to monetize a massive new market for JUUL would be aided if they could convert  
17 Altria, a competitor through its e-cigarette subsidiary Nu Mark LLC and an experienced  
18 cigarette company with a history of marketing to youth and covering it up, into an ally and  
19 eventual purchaser. They began that effort as late as the Spring of 2017. While Defendants JLI,  
20 Bowen, Monsees, Valani, and Huh are relative newcomers to the tobacco industry, Altria has  
21 been manufacturing and selling "combustible" cigarettes for more than a century.

22 44. Altria, for its part, desperately sought a replenishing customer base. Cigarette  
23 companies have long known that profitable growth requires a pipeline of "replacement"  
24 customers. After decades of tobacco litigation and regulation, Altria (including through its  
25 subsidiary Philip Morris) had little ability to recruit new smokers in the ways that had driven  
26 Philip Morris's success through most of the 1900s. In 2017, Altria's combustible cigarette  
27

---

28 <sup>17</sup> JLI01369437.

<sup>18</sup> INREJUUL\_00016386 (Stifel Presentation, Aug. 2015).

products (sold through Philip Morris) were facing increasing regulatory pressures. In late July 2017, Altria's stock value plummeted shortly after the FDA announced that it would reduce the amount of nicotine allowed in cigarettes with an eye toward reaching non-addictive levels.<sup>19</sup> In late 2017, Altria, and other major cigarette companies, also finally complied with a consent decree from the 1990s tobacco litigation that required them to issue corrective advertising statements that highlighted the addictiveness and health impacts of smoking cigarettes.<sup>20</sup>

45. Due in large part to this litigation and regulation, cigarette use has been declining in the United States in the last decade, especially among youth.<sup>21</sup> Altria estimates that the cigarette industry declined by 4% in 2017 and by 4.5% in 2018, and it predicted a continued 4% to 5% decline in the average annual U.S. cigarette industry volume for 2019 through 2023.<sup>22</sup> Altria later adjusted the estimated rate of decline to 4% to 6%, to reflect efforts to increase the legal age for cigarette smoking to 21.<sup>23</sup>

46. In the face of this continued downward trend in the traditional cigarette market, Altria had undertaken its own efforts at marketing an e-cigarette product through its subsidiary Nu Mark LLC. Altria, through Nu Mark, had launched the MarkTen product nationwide in 2014 with an aggressive marketing campaign, eclipsing the advertising expenditures for the market leader at that time, blu e-cigarettes.<sup>24</sup> Of the \$88.1 million spent on e-cigarette advertising in

<sup>19</sup> See Dan Caplinger, *Altria Group in 2017: The Year in Review*, The Motley Fool (Dec. 18, 2017), <https://www.fool.com/investing/2017/12/18/altria-group-in-2017-the-year-in-review.aspx>.

<sup>20</sup> <https://www.law360.com/articles/1037281/tobacco-cos-settle-long-running-health-warning-dispute>.

<sup>21</sup> *Current Cigarette Smoking Among Adults In the United States*, CDC, [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/adult\\_data/cig\\_smoking/index.htm](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm) (last visited February 10, 2020); *Youth and Tobacco Use*, CDC, [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/youth\\_data/tobacco\\_use/index.htm](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/youth_data/tobacco_use/index.htm) (last visited February 10, 2020).

<sup>22</sup> *Altria's Fourth-Quarter 2018 Earnings Conference Call*, Altria (Jan. 31, 2019), <http://investor.altria.com/Cache/1001247877.PDF?O=PDF&T=&Y=&D=&FID=1001247877&iid=4087349>.

<sup>23</sup> *Altria Shares Slide As Cigarette Sales Continue to Decline*, Tobacco Bus. (July 31, 2019), <https://tobaccobusiness.com/altria-shares-slide-as-cigarette-sales-continue-to-decline/>.

<sup>24</sup> Jennifer Cantrell et al., *Rapid increase in e-cigarette advertising spending as Altria's MarkTen enters the marketplace*, Tobacco Control 25 (10) (2015), <http://dx.doi.org/10.1136/tobaccocontrol-2015-052532>.



2014, nearly 40% of that was Altria's MarkTen campaign, at \$35 million.<sup>25</sup> Altria was clear in its intent to dominate the e-cigarette market as it has the combustible cigarette market: "We are the market leader today and we will continue to be," then-CEO Marty Barrington told investors at the time of MarkTen's launch.<sup>26</sup> The original MarkTen was a "cigalike," designed to mimic the look and feel of a combustible cigarette.

47. Altria had also been acquiring small companies in the e-cigarette industry, starting in 2014 with Green Smoke, Inc., whose e-cigarettes were also the "cigalike" style, and were sold in flavors including "Vanilla Dreams" and "Smooth Chocolate."<sup>27</sup> In 2016, Altria acquired an e-cigarette product called Cync, from Vape Forward.<sup>28</sup> Cync is a small e-cigarette device that uses prefilled pods in a variety of flavors, similar to the JUUL.

48. At the same time Altria was struggling to market a successful e-cigarette product through Nu Mark, it was carefully studying JUUL. A May 13, 2016 presentation by Altria Client Services titled "JUUL Market Summary" included detailed information on the sale of JUUL, including market share, the number of chain stores selling JUUL, the price of JUUL and JUUL pods, updates to the design of JUUL and JUUL pods, new flavor names, the purported nicotine strength of JUUL pods, the "Target consumer" for JUUL, and the "Business Model/Sources of Funding" of JLI (then PaxLabs).<sup>29</sup>

49. In February 2017, Altria told investors at the 2017 Consumer Analyst Group of New York (CAGNY) Conference that over the past year, "Nu Mark LLC (Nu Mark) made

---

<sup>25</sup> *Id.*

<sup>26</sup> Melissa Kress, *MarkTen National Rollout Hits 60,000 Stores*, Convenience Store News (July 22, 2014), <https://csnews.com/markten-national-rollout-hits-60000-stores>.

<sup>27</sup> Mike Esterl, *Altria To Launch MarkTen E-Cigarette Nationally*, Wall St. J. (Feb. 19, 2014), <https://www.wsj.com/articles/altria-to-launch-markten-e-cigarette-nationally-1392832378>; Senator Richard J. Durbin et al., *Gateway to Addiction? A Survey of Popular Electronic Cigarette Manufacturers and Targeted Marketing to Youth* at 12 (Apr. 14, 2014), <https://www.durbin.senate.gov/imo/media/doc/Report%20-%20E-Cigarettes%20with%20Cover.pdf>.

<sup>28</sup> Remarks by Jody Begley, 2017 Altria Investor Day (Nov. 2, 2017), [http://media.corporate-ir.net/media\\_files/IROL/80/80855/2017InvestorDay/Remarks\\_and\\_Reconciliations.pdf](http://media.corporate-ir.net/media_files/IROL/80/80855/2017InvestorDay/Remarks_and_Reconciliations.pdf).

<sup>29</sup> ALGAT0002577924.



1 excellent progress toward its long-term aspiration of becoming a leader in e-vapor.”<sup>30</sup> In his  
 2 remarks, Altria Group’s current then-CEO, Howard A. Willard III, said, “Nu Mark, our e-vapor  
 3 company, had a very strong year. It made excellent progress toward establishing MarkTen as a  
 4 leading brand in the category, continued to improve its supply chain, and took the necessary  
 5 steps to comply with the deeming regulations.” He noted, however, that the estimated “total  
 6 2016 e-vapor consumer spending was roughly flat compared to the prior year at approximately  
 7 \$2.5 billion.”<sup>31</sup> In 2017, Altria’s MarkTen e-cigarettes had a market share of only 13.7%, well  
 8 behind JLI’s growing market share of 40%.<sup>32</sup> Thus, despite its public statements to the contrary,  
 9 Altria knew the popularity of JUUL stood in the way of Altria becoming the dominant force in  
 10 the e-cigarette market.

11 50. With smoking on the decline, litigation and regulatory controls were ramping up  
 12 and threatening Altria’s ability to attract new smokers, and JUUL outperforming Altria’s  
 13 products in the market, Altria saw a solution in JLI, with its exponential growth and large youth  
 14 market. That youth market would be key to replacing Altria’s lost profits for years to come. So  
 15 Altria Group and Altria Client Services set out to court the leaders of JLI in an eighteen-month  
 16 dance, all the while signaling that a massive payout would await those leaders if they  
 17 maintained JLI’s large youth market.

18 51. Essential to maintaing JLI’s large youth market, of course, was delaying or  
 19 preventing regulation or public outcry that could interfere with Altria’s and the Management  
 20 Defendants’ efforts. Altria, with its decades of experience doing just that, aided JLI and the  
 21 Management Defendants in these efforts along the way, ultimately attempting to deceive the  
 22 public and the FDA itself in order to defraud consumers when the specter of regulation  
 23

---

24 <sup>30</sup> Remarks by Marty Barrington, Altria Group, Inc.’s (Altria) Chairman, CEO and President,  
 25 and other members of Altria’s senior management team 2017 Consumer Analyst Group of New  
 26 York (CAGNY), (2017), <http://investor.altria.com/Cache/IRCache/1ac8e46a-7eb4-5df2-843d-06673f29b6b0.PDF?O=PDF&T=&Y=&D=&FID=1ac8e46a-7eb4-5df2-843d-06673f29b6b0&iid=4087349>.

27 <sup>31</sup> *Id.*

28 <sup>32</sup> Richard Craver, *Vuse falls further behind Juul on e-cig sales*, Winston-Salem Journal (Dec. 14, 2017), [https://www.journalnow.com/business/vuse-falls-further-behind-juul-on-e-cig-sales/article\\_ed14c6bc-5421-5806-9d32-bba0e8f86571.html](https://www.journalnow.com/business/vuse-falls-further-behind-juul-on-e-cig-sales/article_ed14c6bc-5421-5806-9d32-bba0e8f86571.html).

1 threatened the value of its impending investment in late 2018. Altria's best bet for maintaining  
2 its sales by increasing the number of users, addicted to nicotine was to partner with JLI's  
3 leadership (1) to maintain or increase the number of users, hooked on JUUL; and (2) to delay  
4 and prevent regulation that could interfere with this first scheme.

5 52. For those reasons and others, Altria began coordinating with the Management  
6 Defendants in the Spring of 2017. And so, with Defendants Bowen, Monsees, Pritzker, Valani,  
7 and Huh looking for a big payout, and Altria and Altria Client Services looking for new  
8 customers, this group of Defendants began to work together, using JLI to further their unlawful  
9 ends, in the Spring of 2017. Of course, these Defendants were not strangers to one another.  
10 Before the Spring of 2017, Altria (through Altria Client Services) and JLI were members of at  
11 least one industry group that shared information and coordinated public statements regarding  
12 vaping,<sup>33</sup> and Ploom's advisory committee included Altria's former growth officer. Howard  
13 Howard Willard, Altria's CEO said, the company followed "JUUL's journey rather closely"  
14 from its early beginnings.<sup>34</sup>

15 53. As discussed further below, Altria first contacted JLI's leadership, including  
16 Defendants Pritzker and Valani, about a partnership by early 2017, with "confidential  
17 discussions" beginning in the Spring of 2017.<sup>35</sup> JLI's pitch deck to investors at the time boasted  
18 that "Viral Marketing Wins," and that JUUL's super potent nicotine formulation was  
19 "cornering" the consumables market with the highest customer retention rate of any e-cigarette.<sup>36</sup>

20 54. By the Fall of 2017, JLI, through its leadership including the Management  
21 Defendants, and Altria had agreed to and had taken coordinated actions to maintain and expand  
22 JUUL's market share, knowing that it was based on sales to youth and fraudulent and  
23 misleading advertising to consumers of all ages.

---

25 <sup>33</sup> INREJUUL\_00278740.

26 <sup>34</sup> Olivia Zaleski & Ellen Huet, *Juul Expects Skyrocketing Sales of \$3.4 Billion, Despite*  
27 *Flavored Vape Restrictions*, Bloomberg (Feb. 22, 2019),  
[https://www.bloomberg.com/news/articles/2019-02-22/juul-expects-skyrocketing-sales-of-3-4-](https://www.bloomberg.com/news/articles/2019-02-22/juul-expects-skyrocketing-sales-of-3-4-billion-despite-flavored-vape-ban)  
28 [billion-despite-flavored-vape-ban](https://www.bloomberg.com/news/articles/2019-02-22/juul-expects-skyrocketing-sales-of-3-4-billion-despite-flavored-vape-ban).

<sup>35</sup> Altria's October 14, 2019 letter to Senator Durbin, et. al., by Howard Willard III (2019).

<sup>36</sup> INREJUUL\_00349529.

55. The “confidential discussions” continued, with Altria’s leadership meeting regularly with Pritzker and Valani for “a period of approximately 18 months.”<sup>37</sup> Defendants Pritzker and Valani took the lead on these discussions (together with JLI CEO Kevin Burns), working to establish the formal JLI-Altria partnership. On August 1, 2018, Pritzker, Valani, and JLI’s CEO Kevin Burns met Willard and William Gifford, Altria’s CFO, at the Park Hyatt Hotel in Washington, D.C., to discuss their partnership and Altria’s support of JUUL’s mission.

56. During the roughly 18-month negotiating period, Pritzker, Valani, and JLI’s leadership communicated regularly with Altria as they all worked together to fraudulently grow and maintain JUUL’s market share. Through their control of JLI, Bowen, Monsees and also Huh remained critical to the success of these efforts. Without their control of the JLI Board of Directors and prior fraudulent conduct, the close coordination between JLI’s leadership and Altria and Altria’s investment in JLI to support JUUL’s mission, would not have been possible.

57. In December 2018, Altria decided to take the next step in its coordination with the Management Defendants and JLI’s leadership by making a \$12.8 billion equity investment in JLI, the largest equity investment in United States history. This arrangement was profitable for Altria, as well as enormously lucrative for Defendants Monsees, Bowen, Pritzker, Valani, and Huh, as detailed below.

58. Both before and after Altria’s investment, JLI, through its employees and officers, provided Altria with critical information regarding the design and nicotine content of the JUUL product, the labeling of the JUUL product, and related topics including advertising, retail distribution, online sales, age verification procedures, information on underage user’s flavor preferences, and regulatory strategies. Altria, for its part, increasingly guided and directed JLI and the Management Defendants in these areas and helped them devise and execute schemes to preserve JLI’s youth appeal and market, including by deceiving consumers of all ages and regulators.

59. JLI, the Management Defendants, and Altria worked together to implement their

---

<sup>37</sup> *Id.*

shared goal of growing a youth market in the image of the combustible cigarette market through a multi-pronged strategy to: (1) create an highly addictive product that consumers would not associate with cigarettes and that would appeal to the lucrative youth market, (2) deceive the public into thinking the product was a fun and safe alternative to cigarettes that would also help smokers quit, (3) actively attract young users through targeted marketing, and (4) use a variety of tools, including false and deceptive statements to the public and regulators, to delay regulation of e-cigarettes. As detailed more fully throughout this Complaint, each of the Defendants played a critical role—at times overlapping and varying over time—in each of these strategies.

**B. Defendants’ Strategy Was to Create a Nicotine Product That Would Maximize Profits Through Addiction.**

**1. Defendants Understood that the “Magic” Behind Cigarettes’ Stratospheric Commercial Success Was Nicotine Addiction.**

60. The first step in replicating the success of combustible cigarettes was to create a product that, like combustible cigarettes, was based on getting users addicted to the nicotine in the product. Nicotine is an alkaloid, a class of plant-derived nitrogenous compounds that is highly addictive and the key ingredient that drives addiction to cigarettes. Nicotine’s addictive properties are similar to heroin and cocaine.<sup>38</sup>

61. Route of administration and speed of delivery are key to understanding nicotine’s addictive potential. Dr. Neal Benowitz, Scientific Editor of the 1988 Surgeon General’s Report on nicotine addiction, wrote: “After a puff, high levels of nicotine reach the brain in 10–20 s[econds], faster than with intravenous administration, producing rapid behavioral reinforcement. The rapidity of rise in nicotine levels permits the smoker to titrate the level of nicotine and related effects during smoking, and makes smoking the most reinforcing and dependence-producing form of nicotine administration.”<sup>39</sup>

<sup>38</sup> See e.g., U.S. Dep’t of Health and Human Servs., *Nicotine Addiction: A Report of the Surgeon General*, DHHS Publication Number (CDC) 88-8406, (1988).

<sup>39</sup> Neal L. Benowitz et al., *Nicotine Chemistry, Metabolism, Kinetics and Biomarkers*, 192 HANDB. EXP. PHARMACOL. 29 (2010), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953858/>.

62. Again, according to Dr. Benowitz, “The rapid rate of delivery of nicotine by smoking ... results in high levels of nicotine in the central nervous system with little time for development of tolerance. The result is a more intense pharmacologic action. The short time interval between puffing and nicotine entering the brain also allows the smoker to titrate the dose of nicotine to a desired pharmacologic effect [often subconsciously], further reinforcing drug self-administration and facilitating the development of addiction.”<sup>40</sup>

63. Nicotine fosters addiction through the brain’s “reward” pathway. Both a stimulant and a relaxant, nicotine affects the central nervous system; increases blood pressure, pulse, and metabolic rate; constricts blood vessels of the heart and skin; and causes muscle relaxation. Long-term exposure to nicotine causes upregulation—an increase in the number of these high-affinity nicotinic receptors in the brain. When nicotine binds to these receptors it triggers a series of physiological effects in the user that are perceived as a “buzz” that includes pleasure, happiness, arousal, and relaxation of stress and anxiety. With regular nicotine use, however, these feelings diminish, and the user must consume increasing amounts of nicotine to achieve the same effects.

64. Kids are particularly vulnerable to nicotine addiction, as Defendants know well. As described by the United States Surgeon General, “Tobacco use is a pediatric epidemic.” Nine out of ten smokers begin by age 18 and 80% who begin as teens will smoke into adulthood.<sup>41</sup>

65. The above statements apply equally, if not more so, to e-cigarettes. Further, the Surgeon General has explained how the nicotine in e-cigarettes affects the developing brain and can addict kids more easily than adults: “Until about age 25, the brain is still growing. Each time a new memory is created, or a new skill is learned, stronger connections—or synapses—are built between brain cells. Young people’s brains build synapses faster than adult brains.

---

<sup>40</sup> *Id.*

<sup>41</sup> *Preventing Tobacco Use Among Youth and Adults, A Report of the Surgeon General* at 1 (2012), <https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/index.html>.

Because addiction is a form of learning, adolescents can get addicted more easily than adults.”<sup>42</sup>

The effects of nicotine exposure on the brain of youth and young adults include not only addiction, priming for use of other addictive substances, but also reduced impulse control, deficits in attention and cognition, and mood disorders.<sup>43</sup> A highly addictive, psychoactive substance that targets brain areas involved in emotional and cognitive processing, nicotine poses a particularly potent threat to the adolescent brain, as it can “derange the normal course of brain maturation and have lasting consequences for cognitive ability, mental health, and even personality.”<sup>44</sup>

66. In 2014, the United States Surgeon General reported that nicotine addiction is the “fundamental reason” that individuals persist in using tobacco products, and this persistent tobacco use contributes to millions of needless deaths and many diseases, including diseases that affect the heart and blood vessels (cardiovascular disease), lung diseases (chronic obstructive pulmonary disease (COPD) and lung cancer), cancer almost anywhere in the body, and birth defects.<sup>45</sup>

67. It took five decades of public health initiatives, government intervention, impact litigation, consumer education and tobacco regulation to finally see a significant drop in cigarette smoking and nicotine addiction.

68. By 2014, the number of adults that reported using cigarettes had dropped to 18%, and the number of adult smokers who reported quitting smoking increased from 50.8% in 2005

---

<sup>42</sup> *Know The Risks: E-Cigarettes & Young People* (2019), <https://e-cigarettes.surgeongeneral.gov/knowtherisks.html>.

<sup>43</sup> Menglu Yuan et al., *Nicotine and the Adolescent Brain*, 593 J. OF PHYSIOLOGY 3397 (2015), [www.ncbi.nlm.nih.gov/pmc/articles/PMC4560573/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560573/); U.S. Surgeon General and U.S. Centers for Disease Control & Prevention, Office on Smoking and Health, *Know the Risks: E-Cigarettes and Young People* (2019), <https://e-cigarettes.surgeongeneral.gov/>.

<sup>44</sup> Natalia A. Goriounova & Huibert D. Mansvelder, *Short- and Long-Term Consequences of Nicotine Exposure During Adolescence for Prefrontal Cortex Neuronal Network Function*, 2 COLD SPRING HARBOR PERSP. MED. 12 (2012), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543069/>.

<sup>45</sup> U.S. Dep’t of Health and Human Servs. *2014 Surgeon General's Report: The Health Consequences of Smoking—50 Years of Progress* (2014), [https://www.cdc.gov/tobacco/data\\_statistics/sgr/50th-anniversary/index.htm#report](https://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm#report).

to 59% by 2016.<sup>46</sup> By 2014, teen smoking also hit a record low.<sup>47</sup> In June 2014, the Centers for Disease Control and Prevention (“CDC”) reported that “in achieving a teen smoking rate of 15.7 percent, the United States has met its national Healthy People 2020 objective of reducing adolescent cigarette use to 16 percent or less.”

69. The United States Surgeon General reported in 2014 that: “We are at a historic moment in our fight to end the epidemic of tobacco use that continues to kill more of our citizens than any other preventable cause. The good news is that we know which strategies work best. By applying these strategies more fully and more aggressively, we can move closer to our goal of making the next generation tobacco-free.”<sup>48</sup>

70. Where the public health community saw progress in curbing the use of cigarettes and nicotine addiction, Defendants saw an opportunity.

## 2. Following the Cigarette Industry Playbook, Defendants Sought to Market a Product that would Create and Sustain Nicotine Addiction, but Without the Stigma Associated with Cigarettes

71. Seeking to build and dominate a new market for nicotine products without the baggage of combustible cigarettes (i.e. well-established link to death and disease), JLI engineered a cool-looking e-cigarette device capable of delivering more nicotine and fueling higher levels of consumer addiction than ever before. JLI marketed that highly-addictive device as healthy, safe, cool and available in kid-friendly flavors.

72. In doing so, JLI followed the cigarette industry’s playbook. Monsees admitted

<sup>46</sup> Centers for Disease Control and Prevention, U.S. Dep’t of Health and Human Services, *Trends in Cigarette Smoking Among High School Students—United States, 1991-2001*, 51 MORBIDITY & MORTALITY WKLY. REP. 409 (May 17, 2002), <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5119a1.htm>; Teresa W. Wang et al., *Tobacco Product Use Among Adults—United States, 2017*, 67 MORBIDITY & MORTALITY WKLY. REP. 1225 (Nov. 9, 2018), <https://www.cdc.gov/mmwr/volumes/67/wr/pdfs/mm6744a2-H.pdf>; U.S. Dep’t of Health and Human Servs. *2014 Surgeon General’s Report: The Health Consequences of Smoking—50 Years of Progress* (2014), [https://www.cdc.gov/tobacco/data\\_statistics/sgr/50th-anniversary/index.htm#report](https://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm#report).

<sup>47</sup> Press Release, Centers for Disease Control and Prevention, *Cigarette smoking among U.S. high school students at lowest level in 22 years* (June 12, 2014), <https://www.cdc.gov/media/releases/2014/p0612-YRBS.html>.

<sup>48</sup> U.S. Dep’t of Health and Human Servs. *Let’s Make the Next Generation Tobacco-Free: Your Guide to the 50th Anniversary Surgeon General’s Report on Smoking and Health* (2014), <https://www.hhs.gov/sites/default/files/consequences-smoking-consumer-guide.pdf>.



1 that when creating JLI, he and Bowen carefully studied the marketing strategies,  
 2 advertisements, and product design revealed in cigarette industry documents that were  
 3 uncovered through litigation and made public under the November 1998 Master Settlement  
 4 Agreement between the state Attorneys General of forty-six states, five U.S. territories, the  
 5 District of Columbia and the four largest cigarette manufacturers in the United States.  
 6 “[Cigarette industry documents] became a very intriguing space for us to investigate because we  
 7 had so much information that you wouldn’t normally be able to get in most industries. And we  
 8 were able to catch up, right, to a huge, huge industry in no time. And then we started building  
 9 prototypes.”<sup>49</sup>

10 73. In a thesis presentation Bowen and Monsees gave in 2004, Monsees candidly  
 11 admitted, “The cigarette is actually a carefully engineered product for nicotine delivery and  
 12 addiction.”<sup>50</sup> JLI researched how cigarette companies engineered their products and chemically  
 13 manipulated nicotine to maximize delivery: “We started looking at patent literature. We are  
 14 pretty fluent in ‘Patentese.’ And we were able to deduce what had happened historically in the  
 15 tobacco industry.”<sup>51</sup> With access to the trove of documents made public to curb youth smoking  
 16 and aid research to support tobacco control efforts, JLI was able to review literature on  
 17 manipulating nicotine pH to maximize its delivery in a youth-friendly vapor with minimal  
 18 “throat hit.”

19 74. Through studying industry documents, JLI learned that the cigarette industry had  
 20 tried for years to figure out ways to create and sustain addiction by delivering more nicotine in  
 21 way that would be easy to ingest—without the nausea, cough, or other aversive side effects that  
 22 many new smokers experienced. In the 1970s, R.J. Reynolds scientists eventually found a  
 23 solution: Combine the high-pH nicotine with a low-pH acid. The result was a neutralized  
 24 compound referred to as nicotine salt. In a 1973 RJR memorandum titled “Cigarette concept to  
 25

26 <sup>49</sup> Gabriel Montoya, *Pax Labs: Origins with James Monsees*, SOCIAL UNDERGROUND,  
<https://socialunderground.com/2015/01/pax-ploom-origins-future-james-monsees/>.

27 <sup>50</sup> Jordan Crook, *This is the Stanford Thesis Presentation That Launched Juul*, TECH CRUNCH  
 28 (Feb. 27, 2019), <https://techcrunch.com/2019/02/27/this-is-the-stanford-thesis-presentation-that-launched-juul/>.

<sup>51</sup> *Id.*



1 assure RJR a larger segment of the youth market,” RJR highlighted that this chemical  
 2 manipulation of the nicotine content was expected to give its cigarettes an “additional nicotine  
 3 ‘kick’” that would be more appealing and addictive. A young RJ Reynolds chemist, Thomas  
 4 Perfetti, synthesized 30 different nicotine salt combinations, tested the salts’ ability to dissolve  
 5 into a liquid, and heated them in pursuit of the “maximum release of nicotine.”<sup>52</sup> Perfetti  
 6 published his results in a 1979 memo stamped “CONFIDENTIAL,” which was found among  
 7 the documents that the FDA obtained from JLI in 2018. Relying on cigarette industry research  
 8 like this, and assistance from Perfetti himself, JLI developed a cartridge-based e-cigarette using  
 9 nicotine salts. As described in herein, JLI’s use of nicotine salts, pioneered by major  
 10 combustible tobacco companies, was a critical tool for addicting non-smokers, including youth.

11 75. JLI also engaged former cigarette industry researchers to consult on the design of  
 12 their product. As Monsees noted in an interview with WIRED magazine: “The people who  
 13 understood the science and were listed on previous patents from tobacco companies aren’t at  
 14 those companies anymore. If you go to Altria’s R&D facility, it’s empty.”<sup>53</sup> The WIRED article  
 15 stated that “[s]ome of those people are now on [PAX Lab, Inc.’s] team of advisers, helping  
 16 develop JUUL.”<sup>54</sup>

17 76. One of the keys to JLI’s success was its ability to fuse addiction and technology.  
 18 The JUUL e-cigarette system is comprised of three parts: (1) the JUUL e-cigarette device (2)  
 19 the JUUL pod (with e-liquid), and (3) the Universal Serial Bus [USB] charger (collectively  
 20 referred to herein as “JUUL”). The JUUL e-cigarette device is a thin, sleek rectangular e-  
 21 cigarette device consisting of an aluminum shell, a battery, a magnet (for the USB-charger), a  
 22 circuit board, an LED light, and a pressure sensor. JLI manufactures and distributes JUUL pods  
 23 that contain liquid that includes nicotine, flavoring and other additives. Each JUUL pod is a  
 24 plastic enclosure containing 0.7 milliliters of JLI’s patented nicotine liquid and a coil heater.

25  
 26 <sup>52</sup> Thomas A. Perfetti, *Smoking Satisfaction and Tar/Nicotine Control* (Dec. 7, 1978), <https://ca-times.brightspotcdn.com/3a/12/a5ec27874843a56e26b4ecd221/nicotine-salts-investigation.pdf>.

27 <sup>53</sup> David Pierce, *This Might Just Be the First Great E-Cig*, WIRED (Apr. 21, 2015),  
 28 [www.wired.com/2015/04/pax-juul-ecig/](http://www.wired.com/2015/04/pax-juul-ecig/).

<sup>54</sup> *Id.*





**Figure 1**

78. JLI attempted to distinguish JUUL products from the death and disease associated with cigarettes by deliberately providing a false assurance of safety. For example, on May 8, 2018, a document titled “Letter from the CEO” appeared on JUUL’s website. The document stated: “[JUUL]’s simple and convenient system incorporates temperature regulation to heat nicotine liquid and deliver smokers the satisfaction that they want without the combustion and the harm associated with it.”<sup>56</sup>

79. JLI even took this message to ninth graders: in 2018, a representative from JLI spoke at a high school during a presentation for ninth graders, stating that JUUL “was much safer than cigarettes,” that the JUUL was “totally safe,” that the JUUL was a “safer alternative than smoking cigarettes,” and that the “FDA was about to come out and say it [JUUL] was 99% safer than cigarettes . . . and that. . . would happen very soon.”<sup>57</sup>

<sup>56</sup> Letter from U.S. Food & Drug Admin. to Kevin Burns, CEO of Juul Labs, Inc. (Sept. 9, 2019), <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/juul-labs-inc-590950-09092019>.

<sup>57</sup> *Id.*

80. This was not just a rogue employee. Internal messaging around JUUL, crafted by the executives, emphasized that JUUL was safer than smoking. In a “Marketing Update” presentation dated March 26, 2015, a message from then-Chief Marketing Officer Scott Dunlap stated that “[v]aporization technology is fundamentally disruptive, because it is *safer*, faster, more effective and less intrusive than alternatives.”<sup>58</sup> More than a year later, on April 28, 2016, Tim Danaher sent Tyler Goldman a slide deck aimed at investors which he said that “James [Monsees] owns” and “will pull / update the relevant slides.”<sup>59</sup> The deck claimed that “PAX Labs’ new delivery system is faster, *safer*, more effective and less intrusive than[,]” among other options, “[s]moking[.]”<sup>60</sup> The consistency of the wording in these presentations more than a year apart shows that this was standard company language.

81. JLI’s mission was not to improve public health. Rather, JLI sought to introduce a new generation of consumers to nicotine. JLI’s business model was never about reducing addiction. As one JLI engineer put it: “We don’t think a lot about addiction here because we’re not trying to design a cessation product at all . . . anything about health is not on our mind.”<sup>61</sup>

82. JLI, Bowen, and Monsees achieved their vision. Pioneering a nicotine delivery technology that eliminated the harshness of traditional free-base nicotine, JLI’s e-cigarette system provided consumers with palatable access to high-concentrations of nicotine like never before. Since the JUUL’s launch in 2015, JLI has become the dominant e-cigarette manufacturer in the United States. Its revenues grew by 700 percent in 2017 alone. By 2019, JLI owned three-quarters of the e-cigarette market.<sup>62</sup>

<sup>58</sup> INREJUUL\_00441986 (emphasis added).

<sup>59</sup> JLI00373324.

<sup>60</sup> JLI00373328 (emphasis added).

<sup>61</sup> Kevin Roose, *Juul’s Convenient Smoke Screen*, N.Y. TIMES (Jan. 11, 2019), <https://www.nytimes.com/2019/01/11/technology/juul-cigarettes-marketing.html>.

<sup>62</sup> Dick Durbin et al., *Durbin & Senators to JUUL: You are More Interested in Profits Than Public Health*, Durbin Newsroom (Apr. 8, 2019), <https://www.durbin.senate.gov/newsroom/press-releases/durbin-and-senators-to-juul-you-are-more-interested-in-profits-than-public-health>.

1                   **3. Defendants Sought to Position JLI for Acquisition by a Major**  
 2                   **Cigarette Company.**

3           83. JLI, along with the Management Defendants, worked together to maintain and  
 4 expand the number of nicotine-addicted e-cigarette users in order to ensure a steady and  
 5 growing customer base.

6           84. That growing customer base was crucial to JLI's and the Management  
 7 Defendants' long term objective—lucrative acquisition by another company. They recognized  
 8 that JLI's product, with its potential to dominate the nicotine products market by hooking new  
 9 users, would appeal to one segment of the economy in particular: the cigarette industry.

10          85. JLI and the Management Defendants also recognized that their business goal—  
 11 becoming part of the cigarette industry—was unlikely to endear them to the consumers that they  
 12 needed to purchase their products. Years of anti-smoking campaigns have successfully  
 13 stigmatized cigarette smoking. When Monsees and Bowen presented their thesis and product  
 14 design to their classmates, they included a clip from a South Park episode showing the  
 15 characters assembled at the Museum of Tolerance and shaming a smoker.<sup>63</sup>

16          86. Monsees and Bowen needed to shape social norms such that the public attitude  
 17 towards e-cigarettes would allow consumers to use their product without the stigma and self-  
 18 consciousness smokers experienced. Monsees and Bowen saw a market opportunity in a  
 19 generation of non-smoking consumers brought up on anti-smoking norms. In Monsees' words,  
 20 they wanted to redesign the cigarette “to meet the needs of people who want to enjoy tobacco  
 21 but don't self-identify with—or don't necessarily want to be associated with—cigarettes.”<sup>64</sup>

22          87. Part of this approach was consistently portraying JUUL as an enemy of the  
 23 cigarette industry, with a publicly announced goal of eliminating the cigarette. In an interview,  
 24 Bowen asserted that he and Monsees spent a lot of time talking about “the kind of typical  
 25

26 <sup>63</sup> Gabriel Montoya, *Pax Labs: Origins with James Monsees*, SOCIAL UNDERGROUND,  
 27 <https://socialunderground.com/2015/01/pax-ploom-origins-future-james-monsees/>.

28 <sup>64</sup> *Id.*; see also, INREJUUL\_00064696 (May 28, 2015) (Slides describing JUUL's market  
 overview and positioning as a “tech lifestyle product with a nicotine experience that satisfies,  
 JUUL will appeal to regular ecig users and wealthy, tech savvy smokers – a significant portion  
 of the market.”).

thoughts of evil Big Tobacco companies like coming down and squashing you.”<sup>65</sup> The “Mission Statement” on JLI’s homepage proclaims:

Our mission is to transition the world’s billion adult smokers away from combustible cigarettes, eliminate their use, and combat underage usage of our products.

We envision a world where fewer adults use cigarettes, and where adults who smoke cigarettes have the tools to reduce or eliminate their consumption entirely, should they so desire.<sup>66</sup>

In fact, JLI’s Chief Administrative Officer has publicly stated that the goal behind JLI is “eliminating cigarettes.”<sup>67</sup>

88. This public message of eliminating cigarettes and challenging tobacco companies stands in direct contrast with JLI’s actual business and investment strategy, which involved replicating in JUUL’s new market the tobacco companies’ historical success in the market for cigarettes. From the beginning, Bowen and Monsees actively sought the investment and assistance of major cigarette companies. Bowen and Monsees’ initial foray into the e-cigarette business, Ploom, launched its e-cigarette as the ModelOne in 2010, using pods of loose-leaf tobacco heated by butane. It did not catch on. Ploom only sold a few thousand devices. By then a company with a dozen employees, Ploom was faltering, in need of money, technological expertise, and marketing savvy.<sup>68</sup>

89. Help came from Japan Tobacco International (“Japan Tobacco”), a division of Japan Tobacco Inc., the fourth-largest tobacco company in the world. In December 2011, Japan Tobacco and Ploom entered into a strategic agreement, which gave Japan Tobacco a minority stake in Ploom and made it a strategic partner. In a statement regarding the agreement, Monsees said, “We are very pleased to partner with [Japan Tobacco] as their deep expertise, global distribution networks and capital resources will enable us to enter our next phase of growth and

<sup>65</sup> Alison Keeley, *Vice Made Nice? A High-tech Alternative to Cigarettes*, STANFORD MAGAZINE (2012), <https://stanfordmag.org/contents/vice-made-nice>.

<sup>66</sup> JUUL Labs, *Our Mission* (2019), <https://www.juul.com/mission-values>.

<sup>67</sup> Ashley Gould, *JUUL Labs is Committed to Eliminating Cigarettes*, CAL MATTERS (March 18, 2019), <https://calmatters.org/commentary/e-cigarette/>.

<sup>68</sup> David H. Freedman, *How do you Sell a Product When You Really Can’t Say What it Does?*, Inc., <https://www.inc.com/magazine/201405/david-freedman/james-monsees-ploom-ecigarette-company-marketing-dilemma.html>.



1 capitalize on global expansion opportunities.”<sup>69</sup> As Bowen explained in an interview, “We were  
2 still doing a lot of our own internal product development, but now we had access to floors of  
3 scientists at [Japan Tobacco].”<sup>70</sup>

4 90. According to internal documents, JLI (then known as Pax) entered into a  
5 “strategic partnership” with Japan Tobacco after it “evaluated all major tobacco industry  
6 companies.”<sup>71</sup> When JLI was getting ready to launch JUUL, its business plan called for a  
7 “massive distribution for JUUL,” to “be distributed by the four largest US tobacco  
8 distributors.”<sup>72</sup> In addition, in 2015, JLI counted among its advisors Charles Blixt, the former  
9 general counsel of Reynold American, Chris Skillin, former director of corporate business  
10 development at Altria Group, Bryan Stockdale, the former SVP/President & CEO of R.J.  
11 Reynolds / American Snuff Company, and Chris Coggins, a toxicologist at Reynolds for 20  
12 years.<sup>73</sup>

13 91. JLI and the Management Defendants even retained the Investment Bank Stifel to  
14 help JLI “establish strong international partnerships with leading tobacco companies (“LT”) to  
15 accelerate JUUL.”<sup>74</sup> According to Stifel, “JUUL could be a multi-billion opportunity to LT  
16 [leading tobacco companies] over time,” and Stifel offered to manage a process that: “Identified  
17 the best Partner(s) for JUUL”; “Best positions JUUL to each Partner”; “Creates a catalyst for  
18 [leading tobacco company] decision making”; and “drives strong economic value and terms  
19 through competition.”<sup>75</sup> The end result of the process would be an exclusive agreement with the  
20 cigarette industry that would “maximize JUUL Growth Trajectory”.<sup>76</sup>

---

21  
22 <sup>69</sup> *Innovative P’ship for Ploom and Japan Tobacco Int’l JTI to Take Minority Share in Ploom*,  
23 JAPAN TOBACCO INT’L (Dec. 8, 2011), <https://www.jti.com/sites/default/files/press-releases/documents/2011/innovative-partnership-for-ploom-and-japan-tobacco-international.pdf>.

24 <sup>70</sup> David H. Freedman, *How do you Sell a Product When You Really Can’t Say What it Does?*,  
25 INC. MAGAZINE (2014), <https://www.inc.com/magazine/201405/david-freedman/james-monsees-ploom-ecigarette-company-marketing-dilemma.html>.

26 <sup>71</sup> INREJUUL\_00371423 (Pax Labs company overview, Feb. 2015).

27 <sup>72</sup> INREJUUL\_00371447.


28 <sup>73</sup> INREJUUL\_00371458-INREJUUL\_00371459.

<sup>74</sup> INREJUUL\_00016386 (Stifel Presentation, Aug. 2015).

<sup>75</sup> *Id.*

<sup>76</sup> *Id.*

92. Stifel's presentation to the JLI Board of Directors, which included each of the Management Defendants, also emphasized both the stagnant and declining cigarette market, and the sharply growing e-cigarette market.<sup>77</sup>



<sup>77</sup> INREJUUL\_0016399.



93. According to Stifel, “[s]ince 2013 [leading tobacco companies] have aggressively but unprofitably entered the vape category . . . with products that are not compelling.”<sup>78</sup> Stifel’s conclusion was that in light of the leading cigarette companies’ failures to develop an appealing e-cigarette product: “JUUL Presents a Prime Opportunity for [leading tobacco companies] to Compete with [vaporizers, tanks and mods] in Form Factor and Dominate the E-cig Experience Through Retail Channels that Leverage its Distribution Strengths.”<sup>79</sup>

94. Consistent with Stifel’s presentation, and the profits it was forecasting, a draft December 7, 2015 presentation to the board of directors included as a “management committee recommendation” that JLI position itself for “strategic alternatives (including licensing or sale)”:<sup>80</sup>

## **JUUL**

### **Position JUUL for strategic alternatives (including licensing or sale) by EOY by strengthening the core proposition**

- Improve IRI report traction through dollar contributions and ACV
- Continue to improve repeat rates by adding more pre-qualified consumer doors
- Significantly strengthen IP portfolio
- Continue to support pillar accounts as required to preserve a strong brand reputation

### **Demonstrate a path towards positive JUUL margin contribution**

- Ensure COGS improvements are realized and future improvements are clearly attainable
- Increase same store sales by focusing on high ROI doors
- Improve BDF requirements, particularly at pillar accounts, by reducing POP costs and negotiating improved sell-in cost repayment schedules.
- Reduce brand awareness and identity building programs until positive ROI is proven

95. The presentation also made clear that the “strategic alternative” for JLI


<sup>78</sup> INREJUUL\_0016400-INREJUUL\_0016401.

<sup>79</sup> INREJUUL\_0016404.

<sup>80</sup> INREJUUL\_00061757 (board meeting presentation, Dec. 7, 2015).

envisioned by management was its acquisition by a large cigarette company:<sup>81</sup>

## JUUL sale considerations



96. This goal—acquisition by a major cigarette company—was a motive that the JLI and the Management Defendants would return to in making decisions about the manufacture and marketing of JUUL products. As an example, in a 2016 email exchange with JLI employees regarding potential partnerships with e-cigarette juice manufacturers, Defendant Bowen reminded the employees that “big tobacco is used to paying high multiples for brands and market share.”<sup>82</sup> Bowen knew that to achieve the ultimate goal of acquisition, JLI and the Management Defendants would have to grow the market share of nicotine-addicted e-cigarette users, regardless of the human cost.

97. JLI and the Management Defendants sought to grow the market share of nicotine-addicted e-cigarette users beginning by at least early 2015 through two related schemes: first, by designing an unsafe product with a high nicotine content that was intended to addict, or exacerbate the addiction of, its users; and, second, by marketing and misbranding that potent product to the broadest possible audience of potential customers, including young people whose addiction would last the longest and be the most profitable for the Defendants.

<sup>81</sup> INREJUUL\_00061833.

<sup>82</sup> INREJUUL\_00294198.

98. These schemes were an overwhelming success. In December 2016, Monsees observed in an email to Valani that “Soon enough [JUUL’s success] will catch the eyes of big tobacco and they’ll either swing a new product more directly towards us, get aggressive about acquisition or do both in parallel.”<sup>83</sup> By the close of 2017, according to Nielsen data, JLI had surpassed its competitors in capturing 32.9% of the e-cigarette market, with British American Tobacco at 27.4% and Altria at 15.2%.<sup>84</sup> The total e-cigarette market expanded 40% to \$1.16 billion.<sup>85</sup>

99. By 2018, JLI represented 76.1% of the national e-cigarette market,<sup>86</sup> and JLI’s gross profit margins were 70%.<sup>87</sup> In a complaint it filed in November 2018 against 24 vape companies for alleged patent infringement, JLI asserted that it was “now responsible for over 95% of the growth in the ENDS cartridge refill market in the United States” and included the following chart:<sup>88</sup>

---

<sup>83</sup> JLI00380274.

<sup>84</sup> Ari Levy, *E-cigarette maker Juul is raising \$150 million after spinning out of vaping company*, CNBC (Dec. 20, 2017), <https://www.cnbc.com/2017/12/19/juul-labs-raising-150-million-in-debt-after-spinning-out-of-pax.html>.

<sup>85</sup> *Id.*

<sup>86</sup> Robert K. Jackler et al., *JUUL Advertising Over Its First Three Years on the Market*, Stan. Rsch. into the Impact of Tobacco Advert. (2019), [http://tobacco.stanford.edu/tobacco\\_main/publications/JUUL\\_Marketing\\_Stanford.pdf](http://tobacco.stanford.edu/tobacco_main/publications/JUUL_Marketing_Stanford.pdf).

<sup>87</sup> Dan Primack, *Scoop: The Numbers Behind Juul’s Investor Appeal*, Axios (July 2, 2018), <https://www.axios.com/numbers-juul-investor-appeal-vaping-22c0a2f9-beb1-4a48-acee-5da64e3e2f82.html>.

<sup>88</sup> Verified Complaint Under Section 337 of the Tariff Act of 1930 at 6, *In the Matter of Certain Cartridges for Elec. Nicotine Delivery Sys. & Components Thereof*, Investigation No. 337-TA-1141 (USITC Nov. 19, 2018).

**Appendix 5: U.S. ENDS Pod Market Retail Unit Sales Growth 2018**

4-Week Unit Sales by End Date

	Nielsen			IRI		
	Apr 21	Sep 8	Share of Growth	Apr 22	Sep 9	Share of Growth
Total Market	36,002,645	55,773,039	100%	29,546,883	50,793,955	100%
Juul	22,618,886	41,501,172	95.5%	14,964,158	35,166,120	95.1%
Vuse	6,385,922	6,172,595	-1.1%	7,204,900	7,409,312	1.0%
MarkTen	3,677,300	4,240,285	2.8%	2,904,168	3,230,237	1.5%
Logic	1,785,167	2,018,023	1.2%	1,928,841	1,876,006	-0.2%
Blu	1,062,360	1,461,127	2.0%	1,305,209	1,937,225	3.0%
Other	473,010	379,837	-0.5%	1,239,607	1,175,055	-0.3%

100. JLI shattered previous records for reaching decacorn status, reaching valuation of over \$10 billion in a matter of months—four times faster than Facebook.<sup>89</sup> This all came just three years after its product launch.

**C. JLI and Bowen Designed a Nicotine Delivery Device Intended to Create and Sustain Addiction.**

101. JLI was well-aware from the historical cigarette industry documents that the future of any nicotine-delivery business depends on snaring kids before they age beyond the window of opportunity. One memo from a Lorillard marketing manager to the company's president put it most succinctly, "[t]he base of our business is the high school student."<sup>90</sup> It is no surprise, then, that the industry designed products specifically to attract and addict teen smokers. Claude Teague of R.J. Reynolds titled one internal memo "Research Planning Memorandum on Some Thoughts About New Brands of Cigarettes for the Youth Market." In it he frankly observed, "Realistically, if our Company is to survive and prosper, over the long

<sup>89</sup> Zack Guzman, *Juul Surpasses Facebook As Fastest Startup to Reach Decacorn Status*, YAHOO! FIN. (Oct. 9, 2018), <https://finance.yahoo.com/news/juul-surpasses-facebook-fastest-startup-reach-decacorn-status-153728892.html>.

<sup>90</sup> Internal Memo from T.L. Achey, Lorillard Tobacco Company, to Curtis Judge, Product Information (August 1978).

term, we must get our share of the youth market. In my opinion this will require new brands tailored to the youth market.”<sup>91</sup> Dr. Teague noted that “learning smokers” have a low tolerance for throat irritation so the smoke should be “as bland as possible,” i.e., not harsh; and he specifically recommended an acidic smoke “by holding pH down, probably below 6.” As seen below, JLI heeded Dr. Teague’s advice.

**1. JLI and Bowen Made Highly Addictive E-Cigarettes Easy for Young People and Non-Smokers to Inhale.**

102. As combustible cigarettes were on the decline, e-cigarettes were introduced to the U.S. market beginning in 2007. Over time, e-cigarettes developed a small group of regular users, who were primarily current or former smokers. By 2014, the e-cigarette market in the U.S. was in decline.

103. E-cigarettes struggled to compete with combustible cigarettes, because of the technical challenge of delivering enough aerosolized nicotine to satisfy a smoker’s addiction in a palatable form.<sup>92</sup> Before JUUL, most e-cigarettes used an alkaline form of nicotine called free-base nicotine.<sup>93</sup> When aerosolized and inhaled, free-base nicotine is relatively bitter, irritates the throat, and is perceived as harsh by the user.<sup>94</sup> This experience is often referred to as a “throat hit.” The higher the concentration of free-base nicotine, the more intense the “throat hit.”<sup>95</sup> While some “harshness” would not have much impact on seasoned cigarette smokers, it would deter newcomers, or nicotine “learners,” as Claude Teague at R.J. Reynolds called young non-smokers decades ago.

104. Before 2015, most e-liquids on the market were between 1% and 2% concentration; 3% concentrations were marketed as appropriate for consumers who were

---

<sup>91</sup> Internal Memo from Claude Teague, R.J. Reynolds, *Research Planning Memorandum on Some Thoughts About New Brands of Cigarettes for the Youth Market* (Feb. 2, 1973).

<sup>92</sup> Robert K. Jackler & Divya Ramamurthi, *Nicotine Arms Race: JUUL and the High-nicotine Product Market*, 28 TOBACCO CONTROL 623 (2019).

<sup>93</sup> *Id.*

<sup>94</sup> *Id.*

<sup>95</sup> *Id.*

1 accustomed to smoking approximately forty cigarettes a day.<sup>96</sup> None of these e-liquids delivered  
2 as much nicotine as quickly as a combustible cigarette.

3 105. Around 2013, JLI scientists developed new e-liquids and new devices to increase  
4 the amount of nicotine that e-cigarettes could deliver to users and to reduce the throat hit. JLI  
5 scientists focused on nicotine salts rather than free-base nicotine, and they tested their  
6 formulations in a variety of ways.

7 **2. JLI's Initial Experiments Measured Non-Smokers' "Buzz" Levels**  
8 **and Perceptions of Throat Harshness.**

9 106. JLI intentionally designed its product to minimize "throat hit" and maximize  
10 "buzz." JLI's first known testing of JUUL-related products occurred in 2013, when it conducted  
11 "buzz" experiments that included non-smoker participants, and measured "buzz" and throat  
12 harshness. JLI officers and directors Adam Bowen, Ari Atkins, and Gal Cohen served as the  
13 initial subjects in the "buzz" experiments. These early tests were performed with the assistance  
14 of Thomas Perfetti, the same RJR chemist who had studied nicotine salt decades ago to help  
15 RJR palatably deliver more nicotine.

16 107. In these early tests, JLI's goal was to develop a "buzz-effective e-cig  
17 formulation," which would principally turn on "effectiveness (buzz, harshness)," followed by  
18 shelf life and patentability.<sup>97</sup> The aim was to develop a nicotine salt formulation that maximized  
19 buzz, minimized harshness. "Employees tested new liquid-nicotine formulations on themselves  
20 or on strangers taking smoke breaks on the street. Sometimes, the mix packed too much punch –  
21 enough nicotine to make some testers' hands shake or send them to the bathroom to  
22 vomit . . . ."<sup>98</sup>

23 108. The "buzz" experiments, which used heart rate as a qualitative measurement for  
24 buzz, showed that Bowen tested a 4% benzoate (nicotine salt) solution, which caused his resting  
25 heart rate to increase by about 70% in under 2 minutes, far exceeding all other formulations JLI  
26


27 <sup>96</sup> *Id.*

28 <sup>97</sup> INREJUUL\_00002903.

<sup>98</sup> Chris Kirkham, *Juul Disregarded Early Evidence it was Hooking Teens*, REUTERS (Nov. 5, 2019), <https://www.reuters.com/investigates/special-report/juul-ecigarette/>.



was considering:<sup>99</sup>



109. Because they personally consumed these formulations, Bowen, Cohen, and Atkins knew that the 4% benzoate solution delivered a strong buzz that matched or exceeded a cigarette but had minimal throat hit.

110. A later study by Anna K. Duell et al., which examined 4% benzoate solutions—the basis for JUUL’s subsequent commercial formulations—explains why there was so little throat hit. The Duell study determined that the fraction of free-base nicotine in JUUL’s “Fruit Medley” flavor was 0.05 and in “Crème Brulee” was 0.07.<sup>100</sup> Given total nicotine content of 58 mg/ml and 56 mg/ml in each flavor, respectively, these flavors have roughly 3-4 mg/ml free-base nicotine. For comparison, “Zen” brand e-liquid contains 17 mg/ml of nicotine—less than one-third of the total nicotine content of JUUL’s flavors—but has a free-base fraction of 0.84,<sup>101</sup> resulting in over 14 mg/ml of free-base nicotine. The Duell Study’s authors found that the low free-base fraction in JUUL aerosols suggested a “decrease in the perceived harshness of the aerosol to the user and thus a greater abuse liability.”<sup>102</sup>

<sup>99</sup> INREJUUL\_00002903.

<sup>100</sup> U.S. Patent No. 9,215, 895; Anna K. Duell et al., *Free-Base Nicotine Determination in Electronic Cigarette Liquids by H NMR Spectroscopy*, 31 CHEM. RES. TOXICOL. 431, 432 (Fig. 3).

<sup>101</sup> Anna K. Duell et al., *Free-Base Nicotine Determination in Electronic Cigarette Liquids by H NMR Spectroscopy*, 31 CHEM. RES. TOXICOL. 431 (hereinafter “Duell Study”).

<sup>102</sup> *Id.* at 431–34.

111. Dramatically reducing the throat hit is not necessary for a product that is aimed at smokers, who are accustomed to the harshness of cigarette smoke, but it very effectively appeals to nonsmokers, especially youths. The cigarette industry has long recognized this; a published study of industry documents concluded that “product design changes which make cigarettes more palatable, easier to smoke, or more addictive are also likely to encourage greater uptake of smoking.”<sup>103</sup> The Duell study concluded that JLI’s use of nicotine salts “may well contribute to the current use prevalence of JUUL products among youth.”<sup>104</sup>

112. Reducing the harshness of nicotine also allows more frequent use of e-cigarettes, for longer periods of time, and masks the amount of nicotine being delivered. By removing the physiological drawbacks of inhaling traditional free-base nicotine, JLI’s technology removes the principal barrier to nicotine consumption and addiction. The Duell study further concluded that JLI’s creation of a non-irritating vapor that delivers unprecedented amounts of nicotine is “particularly problematic for public health.”<sup>105</sup>

### 3. JUULs Rapidly Deliver Substantially Higher Doses of Nicotine than Cigarettes.

113. In 2014, after the “buzz” experiments, JLI engineers ran a pilot pharmacokinetic study in New Zealand, called the Phase 0 Clinical Study.<sup>106</sup> The participants in the study—Adam Bowen, Gal Cohen, and Ari Atkins<sup>107</sup>—had their blood drawn while vaping prototype JUUL aerosols. From these measurements, the scientists calculated key pharmacokinetic parameters, including maximum concentration of nicotine in the blood (Cmax) and total nicotine exposure (Area Under the Curve or AUC). JLI reported the results in U.S. Patent No. 9,215,895 (the ’895 patent), for which JLI applied on October 10, 2014,<sup>108</sup> and which was

<sup>103</sup> David A. Kessler, *Juul Says It Doesn’t Target Kids. But Its E-Cigarettes Pull Them In*, N.Y. TIMES (July 31, 2019), <https://www.nytimes.com/2019/07/31/opinion/juul-kids.html>.

<sup>104</sup> Duell Study at 433 (citing J.G. Willett, et al., *Recognition, Use and Perceptions of JUUL Among Youth and Young Adults*, TOBACCO CONTROL 054273 (2018)).

<sup>105</sup> *Id.* at 431.

<sup>106</sup> INREJUUL\_00350930.


<sup>107</sup> *Id.*

<sup>108</sup> This application was a continuation of U.S. Patent Application No. 14/271,071 (filed May 6, 2014), which claimed the benefit of U.S. Provisional Patent Application Serial No.



granted in December 2015. The named inventors on the patent were Adam Bowen and Chenyue Xing.

114. Among the formulations was a 4% benzoate formulation, which was made with 3.8% benzoic acid and 5% nicotine, as well as propylene glycol and vegetable glycerin.<sup>109</sup> As a comparator, JLI also measured nicotine blood levels after smoking Pall Mall cigarettes. The Phase 0 study also tested a 2% benzoate formulation, which had a similar Cmax as a Pall Mall cigarette, and a variety of other formulations.<sup>110</sup> The following graph shows the pharmacokinetic results of the Phase 0 study:



115. According to Table 1 in the patent, the Cmax (the maximum nicotine concentration in blood) for Pall Mall cigarettes was 11.65 ng/mL, and for 4% benzoate it was 15.06 ng/mL, which is nearly 30% higher. The total nicotine exposure (as measured by Area Under the Curve or AUC) was 367.5 ng \* min/mL for Pall Mall cigarettes and 400.2 ng \* min/mL for 4% benzoate, which is almost 9% higher. The 4% benzoate formulation had the highest Cmax and AUC of any of the formulations measured.

116. Describing these results, JLI's '895 patent all but brags that it surpassed a

61/820,128, (filed May 6, 2014), and U.S. Provisional Patent Application Serial No. 61/912,507 (filed December 5, 2013).

<sup>109</sup> U.S. Patent No. 9,215,895, at 19:63-20:4 (filed Dec. 22, 2015).

<sup>110</sup> INREJUUL\_00024437.

commercially available combustible cigarette (Pall Mall) in maximum delivery and nearly rivaled it in how soon it could deliver peak nicotine. According to the ‘895 patent, “certain nicotine salt formulations [i.e., JLI’s] provide satisfaction in an individual superior to that of free base nicotine, and more comparable to the satisfaction in an individual smoking a traditional cigarette.”<sup>111</sup> The patent further explains that the “rate of nicotine uptake in the blood” is higher for some claimed nicotine salt formulations “than for other nicotine salt formulations aerosolized by an electronic cigarette . . . and likewise higher than nicotine free-base formulations, while the peak nicotine concentration in the blood and total amount of nicotine delivered appears comparable to a traditional cigarette.”<sup>112</sup>

117. In other words, JLI distinguishes itself, and established the patentability of its e-liquids, by reference to their superlative ability to deliver nicotine, both in terms of peak blood concentration and total nicotine delivery. The rate of nicotine absorption is key to providing users with the nicotine “kick”<sup>113</sup> that drives addiction and abuse.<sup>114</sup> Because “nicotine yield is strongly correlated with tobacco consumption,”<sup>115</sup> a JUUL pod with more nicotine will strongly correlate with higher rates of consumption of JUUL pods, generating more revenue for JUUL. For example, a historic cigarette industry study that looked at smoker employees found that “the number of cigarettes the employees smoked per day was directly correlated to the nicotine levels.”<sup>116</sup> In essence, JLI distinguished itself based on its e-liquids’ extraordinary potential to addict.

<sup>111</sup> U.S. Patent No. 9,215, 895, at 7:51-55 (filed Dec. 22, 2015) (emphasis added).

<sup>112</sup> *Id.* at 7:63-8:4.

<sup>113</sup> Internal Memo from Frank G. Colby, R.J. Reynolds, *Cigarette Concept to Assure RJR a Larger Segment of the Youth Market* (Dec. 4, 1973).

<sup>114</sup> As the National Institutes of Health has noted, the “amount and speed of nicotine delivery . . . plays a critical role in the potential for abuse of tobacco products.” U.S. Dep’t of Health & Human Servs., *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease, A Report of the Surgeon General* at 181 (2010), [https://www.ncbi.nlm.nih.gov/books/NBK53017/pdf/Bookshelf\\_NBK53017.pdf](https://www.ncbi.nlm.nih.gov/books/NBK53017/pdf/Bookshelf_NBK53017.pdf).

<sup>115</sup> Martin J. Jarvis et al., *Nicotine Yield From Machine Smoked Cigarettes and Nicotine Intakes in Smokers: Evidence From a Representative Population Survey*, 93 NT’L CANCER INST. 134 (Jan. 17, 2001), <https://academic.oup.com/jnci/article/93/2/134/2906355>.

<sup>116</sup> Letter from Peggy Martin to Study Participants, *Resume of Results from Eight-Week Smoking Study*, UCSF Library, 1003285443-5443 (Sept. 10, 1971).

118. Another study corroborates the key result of the Phase 0 study that the 4% benzoate solution delivers more nicotine than a combustible cigarette.<sup>117</sup> The Reilly study tested JUUL's tobacco, crème brûlée, fruit medley, and mint flavors and found that a puff of JUUL delivered  $164 \pm 41$  micrograms of nicotine per 75 mL puff. By comparison, a 2014 study using larger 100 mL puffs found that a Marlboro cigarette delivered 152-193  $\mu\text{g/puff}$ .<sup>118</sup> Correcting to account for the different puff sizes between these two studies, this suggests that, at 75 mL/puff, a Marlboro would deliver about 114-145  $\mu\text{g/puff}$ . In other words, the Reilly study suggests that JUUL delivers more nicotine per puff than a Marlboro cigarette.

119. Additionally, depending on how the product is used, an e-cigarette with the 4% benzoate solution is capable of delivering doses that are materially higher than those seen in the Phase 0 study. As a paper published by the European Union notes: "[A]n e-cigarette with a concentration of 20 mg/ml delivers approximately 1 milligram of nicotine in five minutes (the time needed to smoke a traditional cigarette, for which the maximum allowable delivery is 1 mg of nicotine)."<sup>119</sup> With at least 59 mg/ml of nicotine in a salt form that increases the rate and efficiency of uptake (and even with a lower mg/ml amount), a JUUL pod easily exceeds the nicotine dose of a combustible cigarette. Not surprisingly, the European Union has banned all e-cigarette products with a nicotine concentration of more than 20 mg/ml nicotine, and other countries have considered similar regulations.<sup>120</sup>

120. Around 2014, JLI engineers designed the JUUL vaping device, which also was designed for addictiveness. On average, the JUUL was engineered to deliver between four to


<sup>117</sup> Samantha M. Reilly et al., *Free Radical, Carbonyl, and Nicotine Levels Produced by JUUL Electronic Cigarettes*, 21 NICOTINE TOBACCO RESEARCH 1274 (Aug. 19, 2019), <https://www.ncbi.nlm.nih.gov/pubmed/30346584>.

<sup>118</sup> Megan J. Schroeder & Allison C. Hoffman, *Electronic Cigarettes and Nicotine Clinical Pharmacology*, 23 TOBACCO CONTROL ii30 (May 23, 2014), [www.ncbi.nlm.nih.gov/pmc/articles/PMC3995273/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995273/).

<sup>119</sup> E-Cigarettes, European Comm'n, [https://ec.europa.eu/health/sites/health/files/tobacco/docs/fs\\_ecigarettes\\_en.pdf](https://ec.europa.eu/health/sites/health/files/tobacco/docs/fs_ecigarettes_en.pdf) (citing United Kingdom Medicines and Healthcare Products Regulatory Agency and industry reports).

<sup>120</sup> Charis Girvalaki et al., *Discrepancies in Reported Versus Measured Nicotine Content of E-cigarette Refill Liquids Across Nine European Countries Before and After the Implementation of the EU Tobacco Products Directive*, 55 EUR. RESPIR. J. 1900941 (2020), <https://doi.org/10.1183/13993003.00941-2019>.

five milligrams of aerosol per puff, which is an unusually massive puff<sup>121</sup>:



121. Given the concentration of nicotine in a JUUL pod, four to five milligrams of JUUL e-liquid contains about 200-250 micrograms ( $\mu\text{g}$ ) of nicotine. As noted by Dan Myers, a JLI scientist, in an internal 2018 email to Adam Bowen and Ziad Rouag, a regulatory employee at JLI at the time, “much more nicotine than 150 per puff could be problematic” because, according to Myers, cigarettes deliver between around 100-150  $\mu\text{g}$  of nicotine per puff.<sup>122</sup> In other words, JUUL’s precisely calibrated nicotine delivery system was specifically engineered to aerosolize up to 2.5 times as much nicotine per puff as a cigarette. Myers also noted that “Adam put in his recommendation of ~4mg/puff as the target” for a pharmacokinetic study.<sup>123</sup>

122. JLI scientists realized in 2014 that the amount of nicotine that JUUL e-cigarettes delivered could be problematic. Chenyue Xing stated that “[y]ou hope that they get what they

<sup>121</sup> INREJUUL\_00442040-INREJUUL\_00442080; INREJUUL\_00442064.

<sup>122</sup> INREJUUL\_00347306.

<sup>123</sup> *Id.*

want, and they stop,” but JLI scientists were concerned that “a Juul—unlike a cigarette—never burns out,” so the device gives no signal to the user to stop. According to Xing, JLI scientists “didn’t want to introduce a new product with stronger addictive power.”<sup>124</sup> For this reason, “the company’s engineers explored features to stop users from ingesting too much of the drug, too quickly. JLI’s founders applied for a patent in 2014 that described methods for alerting the user or disabling the device when the dose of a drug such as nicotine exceeds a certain threshold.”<sup>125</sup> For example, “[o]ne idea was to shut down the device for a half-hour or more after a certain number of puffs[.]”<sup>126</sup> But upper management rejected the concerns that the scientists raised, and “[t]he company never produced an e-cigarette that limited nicotine intake.”<sup>127</sup>

123. As another option, JLI could have limited the duration of each puff to prevent the JUUL from delivering doses of nicotine exceeding those of a cigarette on a per-puff basis. Instead, it programmed the device to emit puffs for up to six seconds.<sup>128</sup> JUUL knew from the Phase 0 pharmacokinetic study in 2014 and the CH-1702 pharmacokinetic study in 2017 that puffs of three seconds generate pharmacokinetic profiles matching that of a cigarette.<sup>129</sup>

124. Further warnings about the addictive power of the JUUL e-cigarette—and its appeal to youths—came from consumer research that Ploom commissioned in 2014. Ploom hired the consumer research firm Tragon to do research with prototypes of the JUUL e-cigarette. On September 30, 2014, Lauren Collinsworth, a consumer researcher at Tragon, emailed Chelsea Kania, a marketing employee at Ploom, with some of the preliminary results from the studies. She stated that the testing showed that “the younger group is open to trying something new and liked J1 [the JUUL prototype] for being smart, new, techy, etc.”<sup>130</sup> Ms. Collinsworth added that “the qualitative information suggests J1 could fit into the e-cig or vapor

<sup>124</sup> Chris Kirkham, *Juul Disregarded Early Evidence it was Hooking Teens*, REUTERS (Nov. 5, 2019), <https://www.reuters.com/investigates/special-report/juul-ecigarette/>.

<sup>125</sup> *Id.*

<sup>126</sup> *Id.*

<sup>127</sup> *Id.*

<sup>128</sup> INREJUUL\_00431693.

<sup>129</sup> INREJUUL\_00351218; INREJUUL\_00351239.

<sup>130</sup> JLI00365905.

category for the younger group. The qualitative findings suggested *this product isn't going to fit as well with consumers who are looking to cut back on the cigarette intake.*"<sup>131</sup>

125. On October 1, 2014, Ms. Collinsworth followed up with additional comments. She stated that "[t]he delivery was almost too much for some smokers, especially those used to regular e-cigarettes. When they approached the product like they would a Blu or other inexpensive e-cig, they were floored by the delivery and didn't really know how to control it."<sup>132</sup>

126. Survey responses showed that the least important product attribute for the adult smokers and non-smokers in that group was "buzz."<sup>133</sup> Comments from the study's subjects included "overwhelming when I first inhaled," "too much for me," "it was too strong," and "it caught me off-guard."<sup>134</sup> Comments on the device's style said JUUL "might manage to make smoking cool again"; others "thought it was a data storage device."<sup>135</sup>

127. The final results from this consumer research were distributed to upper management, including to then-CEO James Monsees<sup>136</sup> and then-Chief Marketing Officer Richard Mumby.<sup>137</sup>

128. In late 2014, knowing the results of the buzz tests, the Phase 0 study and the consumer research, JLI executives, including Bowen, selected the 4% benzoate formulation to serve as the model for all formulations to be used in the JUUL product to be released in 2015. All JUUL formulations at launch used the same amount of nicotine and benzoic acid as did the formulation that resulted in the highest nicotine blood levels in the Phase 0 study. JUUL pods were foreseeably exceptionally addictive, particularly when used by persons without prior exposure to nicotine.

---

<sup>131</sup> *Id.* (emphasis added).

<sup>132</sup> JLI00365709.

<sup>133</sup> JLI00365176.

<sup>134</sup> INREJUUL\_00058345.

<sup>135</sup> *Id.*

<sup>136</sup> JLI00364678.

<sup>137</sup> JLI00364487.

4. **JLI and the Management Defendants Knew That JUUL was Unnecessarily Addictive Because It Delivered More Nicotine Than Smokers Needed or Wanted.**

129. The JUUL e-cigarette launched in 2015. After the launch, JLI and the Management Defendants continued to collect information about the addictiveness of JUUL. This information confirmed what they already knew: JUUL was exceptionally dangerous because of its addictiveness.

130. For example, on April 22, 2017, an e-cigarette retailer emailed Gal Cohen expressing concern about the addictiveness of JLI's products. He wrote:

I am very concerned about the JLI products. People's addiction behavior is SEVERE with this JLI device. I don't think I can justify carrying this anymore.

The Brooklyn store is run by someone else and he still wants to carry it. I am not really happy about this. It was a simple product for users who do not want to fill tanks and change atomizers and it was easy to sell, but I really don't feel good about selling it. I know we talked about this back a few years ago before we were carrying the product, but I am curious to know what is in the liquid. I know the nicotine salts are added but I would like to know what else is in it. Do you guys have a GCMS or ingredient listing for the liquid? Are there other additives? I want to feel more comfortable so I can keep carrying these, but **I have seen what it is doing to people and I am very uncomfortable with it.** Last year when the news came to me and wanted me to help them with the story that teens were using JLI I shut that story down by telling them it wasn't true. **It is true. kids are getting hooked on this thing and they don't even understand half the time that it has nicotine in it! Little kids.. like 14 and 15 year olds.** They try to come in my shop and we tell them it is 21 and over and get them out... but it is REALLY bad!

I have kids calling and trying to order using delivery services as well. We will only allow pickup and delivery for regular customers whose ID we have already checked... but they TRY and that worries me.. because the smoke shops and bodegas are NOT checking that the person they are picking up for is old enough to buy the product.

I agree that it is certainly less hazardous than smoking... **but to intentionally increase the addictiveness of nicotine seems really irresponsible and makes me feel like Big Tobacco pushing people onto a really addictive product.** I just don't think that it is necessary and I don't feel good about it.

Anyway... if there is any info you have that might make me feel better about selling it let me know... or if you could send me ingredient listing (I know Pax applied for the patent on the liquid with the nicotine salts so it should be ok to share now?) I would appreciate it.<sup>138</sup>

<sup>138</sup> INREJUUL\_00264888-INREJUUL\_00264890.



131. Another example came just days later. On April 28, 2017, JLI held a science meeting discussing the scientific information in JLI's possession with outside scientists. Notes from the meeting state that "concern was raised that because the nicotine update [sic] is slightly faster the data could be interpreted as feeding an addiction faster. Given the current climate with addictions to OxyContin how the data is presented needs to be considered carefully."<sup>139</sup>

132. Additionally, Dan Myers wrote to Adam Bowen in October 2017 that "single puff data from Juul suggests that a small number of puffs, at the beginning of the pod's lifetime, may contain 2-3X" the levels of nicotine in the puffs from the rest of the pod, "i.e., 200-300 [μ]g/puff."<sup>140</sup> This is consistent with a central goal of the product's design: capturing "users with the first hit."<sup>141</sup>

133. None of this information was a surprise, nor did it cause JLI or the Management Defendants to change JLI's products or marketing. In fact, they embraced it. On November 3, 2017, Steven Hong, JLI's Director of Consumer Insights, described JUUL's "design and chemical formulation (fast acting nic salts)" as JLI's "ace in the hole" over the competition.<sup>142</sup>

134. The following year, JLI and the Management Defendants obtained even more evidence that the amount of nicotine in JUULpods was needlessly high. By no later than May of 2018, JLI had completed Phase I of "Project Bears," a JLI study of smoker and vaper nicotine strength preferences. The results showed that "[a]cross the smoker segments, product liking is very similar[,] and the "heaviest smokers (21+ cigs) like 1.7% more than higher strengths" such as 3% and 5%.<sup>143</sup> Similarly, "for those who evaluated the 5% pod, when given the choice of lower level pod strengths, at least half would choose a lower strength pods."<sup>144</sup>

135. The same tests also showed that, contrary to JLI's expectations, smokers did not increase their use of the 1.7% formulation relative to the 5% formulation in order to achieve

---

<sup>139</sup> INREJUUL\_00230416.

<sup>140</sup> INREJUUL\_00434580-INREJUUL\_00434590.

<sup>141</sup> Chris Kirkham, *Juul Disregarded Early Evidence it was Hooking Teens*, REUTERS (Nov. 5, 2019), <https://www.reuters.com/investigates/special-report/juul-ecigarette>.

<sup>142</sup> INREJUUL\_00228928-INREJUUL\_00228930.

<sup>143</sup> INREJUUL\_00260068.

<sup>144</sup> INREJUUL\_00260065.



1 nicotine satisfaction. “Smoking volume does seem to be a driver of vaping volume, but this does  
2 not vary much by strength within a given smoker type.”<sup>145</sup>

3 136. Thus, Project Bears revealed that 5% JUULpods delivered more nicotine than  
4 necessary to satisfy cigarette smokers, even those characterized as “heavy” smokers.<sup>146</sup>

5 137. At some point during the coordination between JLI, the Management  
6 Defendants, and Altria, but no later than the due-diligence period for Altria’s investment in JLI,  
7 either JLI (through its employees) or one or more of Defendants Bowen, Monsees, Pritzker,  
8 Huh, and Valani provided Altria with a copy of the Project Bears findings.<sup>147</sup>

9 138. Nonetheless, JLI, the Management Defendants, and Altria have maintained and  
10 promoted the 5% JUULpods as JLI’s flagship offering of JUULpods although they knew that  
11 even current smokers prefer a *lower* nicotine content. They pushed the 5% JUULpod because it  
12 hooked users faster and kept them addicted to nicotine.<sup>148</sup>

13 139. In addition to Project Bears, JLI and the Management Defendants (and  
14 potentially Altria) were aware of other internal studies that established that its 5% JUUL pod  
15 product would not be a successful cessation tool, as it was not attractive to an audience looking  
16 to reduce cigarette consumption.<sup>149</sup>

17 **5. JUUL’s Design Did Not Look Like a Cigarette, Making it Attractive**  
18 **to Non-Smokers and Easy for Young People to Use Without**  
**Detection.**

19 140. Not only did JUUL contain high levels of nicotine that delivered a strong “buzz”  
20 from the first puff, JLI designed its product to look appealing to youth and non-smokers. In  
21 January 2015, six months before JUUL’s launch, JLI’s Marketing Director, Sarah Richardson,  
22 identified “key needs” for JUUL’s PR strategy, including “Establish premium positioning to  
23 entice the “masses” to follow the trend setters; own the “early adopter” / “cool kid” equity as we  
24 build out volume”, and highlighted that “JUUL deliberately doesn’t resemble e-cigs or  
25

---

26 <sup>145</sup> INREJUUL\_00244200.

27 <sup>146</sup> *Id.*

28 <sup>147</sup> *Id.*

<sup>148</sup> *Id.*

<sup>149</sup> *Id.*

1 cigitalikes” that are “awkward” and “douche-y”.<sup>150</sup> Instead, JUUL is “elegant” and “cool”.

2 141. JLI’s strategy to position a nicotine-delivery device as the cool thing to do is not  
3 new. Decades before, Dr. Teague from R.J. Reynolds observed: “pre-smokers” face  
4 “psychological pressure” to smoke if their peers are doing so, “a new brand aimed at a young  
5 smoker must somehow be the ‘in’ brand and its promotion should emphasize togetherness,  
6 belonging and group acceptance, while at the same time emphasizing ‘doing one’s own  
7 thing.’”<sup>151</sup> Again, JUUL followed the cigarette playbook verbatim.

8 142. JLI knew that among its target audience, young people, cigarette smoking had  
9 become increasingly stigmatized. JLI wanted to create a product that would create “buzz” and  
10 excitement, totally different from the image of addicted cigarette smokers huddling outside their  
11 workplaces in the cold to get their nicotine fix.

12 143. Unlike the distinct smell and odor emitted from combustible cigarettes, JUUL  
13 emits a reduced aerosol with a nearly undetectable scent. And unlike other e-cigarettes, the  
14 JUUL device does not produce large plumes of smoke. Instead, the vapor cloud is very small  
15 and dissipates very quickly, allowing for concealed use. As a result, young users can, and do, use  
16 JUUL—in class or at home—without detection.

17 144. The JUUL device is also designed to be small and discrete. Fully assembled, the  
18 device is just over 9.5 cm in length and 1.5 cm wide. The JUUL device resembles a memory  
19 stick and can be charged in a computer’s USB drive. This design allows the device to be  
20 concealed in plain sight, camouflaged as a thumb-drive, for use in public spaces, like schools  
21 and even charged in school computers. JLI has been so successful in emulating harmless  
22 technology that its small, rectangular devices are often mistaken for—or passed off as—flash  
23 drives. According to one high school senior, “that’s what people tell the teachers a lot, too, if  
24 you charge it in class, they’ll just say it’s my flash drive.”<sup>152</sup>

25  
26  
27 <sup>150</sup> INREJUUL\_00057291 *et seq.*

28 <sup>151</sup> Internal RJR Memo, Claude Teague, *Research Planning Memorandum on Some Thoughts About New Brands of Cigarettes for the Youth Market*, (Feb. 2, 1973).




145. Referred to as “the iPhone of e-cigarettes,” JLI’s design was also slick and high-tech, which made it appealing to youth. JLI co-founder Bowen drew on his experience as a design engineer at Apple Inc. to make JUUL resonate with Apple’s popular aesthetics. This high-tech style made JUULs look “more like a cool gadget and less like a drug delivery device. This wasn’t smoking or vaping, this was JUULing.”<sup>153</sup> The evocation of technology makes JUUL familiar and desirable to the younger tech-savvy generation, particularly teenagers. According to a 19-year-old interviewed for the Vox series By Design, “our grandmas have iPhones now, normal kids have JUULs now. Because it looks so modern, we kind of trust modern stuff a little bit more so we’re like, we can use it, we’re not going to have any trouble

<sup>153</sup> *How JUUL Made Nicotine Go Viral*, VOX (Aug. 10, 2018), <https://www.youtube.com/watch?v=AFOpoKBUyok>.

with it because you can trust it.”<sup>154</sup> A 16-year-old agreed, explaining that “the tech aspect definitely helps people get introduced to it and then once they’re introduced to it, they’re staying, because they are conditioned to like all these different products. And then this is another product. And it’s just another product. Until you’re addicted to nicotine.”<sup>155</sup>

146. JUUL’s design also included an LED light, which allowed users to active “party mode,” whereby the LED light would flash a rainbow of colors. “Party mode” is activated by the user by waving the JUUL device back and forth until the white LED light starts flashing multiple colors, so that the rainbow colors are visible while the person inhales from the JUUL device. “Party mode” can also be permanently activated on the JUUL by the user quickly and firmly slapping the JUUL against the palm of the hand, until the LED light starts flashing multiple colors permanently. Party mode on the JUUL is described by users to be “like an Easter egg in a video game” and allows for “some cool tricks that are going to drive [] friends crazy.”<sup>156</sup> This feature was another characteristic that set JUUL apart from other e-cigarettes on the market, and made it even more appealing and “cool” to young users.



147. According to Dr. David Kessler, a former Commissioner of the FDA and current Professor of Pediatrics at the University of California, San Francisco, JUUL’s “fundamental

<sup>154</sup> *Id.*

<sup>155</sup> *Id.*

<sup>156</sup> Jon Hos, *Getting Your Juul Into Party Mode*, (Jul. 12, 2018), <https://vapedrive.com/getting-your-juul-into-party-mode>.

design appears to ease young people into using these e-cigarettes and ultimately, addiction.”<sup>157</sup> Dr. Kessler emphasized the reduced harshness of JUUL’s nicotine salt formulation, the high nicotine content, discreet vapor cloud, and use of flavors as design features that appeal to youth.<sup>158</sup> On April 24, 2018, the FDA sent JLI a letter, based on the FDA’s concern “about the popularity of JUUL products among youth” and stated that this popularity may be related to “the product design.”<sup>159</sup> As a result, the FDA requested documents related to product design, including its “shape or form,” “nicotine salt formulation” and “nicotine concentration/content,” “flavors,” and “features such as: appearance, or lack thereof, or plume . . . [and] USB port rechargeability.”

**6. JLI Enticed Newcomers to Nicotine with Kid-Friendly Flavors Without Ensuring the Flavoring Additives Were Safe for Inhalation.**

**a. JIL Develops Flavored JUUL Products That Would Appeal to Youth.**

148. Cigarette companies have known for decades that flavored products are key to getting young people to acclimate to nicotine. A 1972 Brown & Williamson memorandum: Youth Cigarette – New Concepts, specifically noted the “well known fact that teenagers like sweet products.”<sup>160</sup> A 1979 Lorillard memorandum concluded that younger customers would be “attracted to products with ‘less tobacco taste,’” and even proposed borrowing data from the “Life Savers” candy company to determine which flavors enjoyed the widest appeal among youth.<sup>161</sup>

149. Altria’s subsidiary U.S. Smokeless Tobacco Company (formerly called United

<sup>157</sup> David A. Kessler, *Juul Says It Doesn’t Target Kids. But Its E-Cigarettes Pull Them In*, N.Y. TIMES (July 31, 2019), <https://www.nytimes.com/2019/07/31/opinion/juul-kids.html>.

<sup>158</sup> *Id.*

<sup>159</sup> Letter from Matthew R. Holman, Dir. of the Off. of Sci. at the Ctr. for Tobacco Prods., to Ziad Rouag, V.P. of Regul. & Clinical Affairs, JUUL Labs, Inc. (Apr. 24, 2018), <https://www.fda.gov/media/112339/download>.

<sup>160</sup> Marketing Innovations, Inc., *Brown & Williamson Tobacco Corp. Project Report: Youth Cigarette—New Concepts*, U.C.S.F. Truth Tobacco Indus. Documents (Sept. 1972), <https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=hazpd0040>.

<sup>161</sup> *Flavored Tobacco FAQs*, Students Working Against Tobacco, <http://swatflorida.com/uploads/fightresource/Flavored%20Tobacco%20Industry%20Quotes%20and%20Facts.pdf> (citing Sedgfield Idea Sessions 790606-790607 (June 8, 1979), Bates No. 81513681/3691) (last visited Nov. 12, 2020).


States Tobacco Company) described the initiation of new customers through flavored products as “the graduation theory”:

New users of smokeless tobacco—attracted to the product for a variety of reasons—are most likely to begin with products that are milder tasting, more flavored, and/or easier to control in the mouth. After a period of time, there is a natural progression of product switching to brands that are more full-bodied, less flavored, have more concentrated “tobacco taste” than the entry brand.<sup>162</sup>

150. A sales manager who worked at U.S. Tobacco in the 1980s told the Wall Street Journal that “They talked about graduation all the time—in sales meetings, memos and manuals for the college program. It was a mantra.”<sup>163</sup>

151. A 2004 study found that seventeen-year-old smokers were more than three times as likely as those over the age of twenty-five to smoke flavored cigarettes, and they viewed flavored cigarettes as safer.<sup>164</sup>

152. In June 2015, JUUL came to market in four flavors including tabaac (later renamed tobacco), fruit (later renamed fruit medley), bruulé (later renamed crème brulee), and miint (later renamed mint).




153. JUUL later offered other kid-friendly flavors, including cool mint, cucumber, and mango.

<sup>162</sup> G.N. Connolly, *The marketing of nicotine addiction by one oral snuff manufacturer*, 4 Tobacco Control 73-79 (1995), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1759392/pdf/v004p00073.pdf>.

<sup>163</sup> Alix Freedman, *Juiced Up: How a Tobacco Giant Doctors Snuff Brands to Boost Their 'Kick,'* Wall St. J. (Oct. 26, 1994), <https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=mlch0185>.

<sup>164</sup> Gardiner Harris, *Flavors Banned From Cigarettes to Deter Youth*, N.Y. TIMES (Sept. 22, 2009), <https://www.nytimes.com/2009/09/23/health/policy/23fda.html>.





154. In 2009, the FDA banned flavored cigarettes (other than menthol) as its first major anti-tobacco action pursuant to its authority under the Family Smoking Prevention and Tobacco Control Act of 2009. “Flavored cigarettes attract and allure kids into addiction,” Health and Human Services Assistant Secretary Howard Koh, MD, MPH, said at a news conference held to announce the ban.<sup>165</sup> In January 2020, the FDA banned flavored e-cigarette pods, other than “Tobacco” and “Menthol” flavors, in response to “epidemic levels of youth use of e-cigarettes” because these products are “so appealing” to children.”<sup>166</sup>

155. The availability of e-liquids in flavors that appeal to youth increases rates of e-cigarette adoption by minors. A national survey found that that 81% of youth aged twelve to seventeen who had ever used e-cigarettes had used a flavored e-cigarette the first time they tried the product, and that 85.3% of current youth e-cigarette users had used a flavored e-cigarette in the past month. Moreover, 81.5% of current youth e-cigarette users said they used e-cigarettes “because they come in flavors I like.”<sup>167</sup>

<sup>165</sup> Daniel J. DeNoon, *FDA Bans Flavored Cigarettes: Ban Includes Cigarettes With Clove, Candy, and Fruit Flavors*, WebMD (Sept. 22, 2009), <https://www.webmd.com/smoking-cessation/news/20090922/fda-bans-flavored-cigarettes#2>.

<sup>166</sup> U.S. Food & Drug Admin., *FDA Finalizes Enforcement Policy on Unauthorized Flavored Cartridge-Based E-cigarettes that Appeal to Children, Including Mint* (Jan. 22, 2020), <https://www.fda.gov/news-events/press-announcements/fda-finalizes-enforcement-policy-unauthorized-flavored-cartridge-based-e-cigarettes-appeal-children>.

<sup>167</sup> See Bridget K. Ambrose et al., *Flavored Tobacco Product Use Among US Youth Aged 12-17 Years, 2013-2014*, 314 JAMA 1871 (2015). Another peer-reviewed study concluded that young adults who use electronic cigarettes are more than four times as likely to begin using regular cigarettes as their peers who have not used e-cigarettes. See Brian A. Primack, et al. *Initiation of Traditional Cigarette Smoking after Electronic Cigarette Use Among Tobacco-Naïve US Young Adults*, 131 AM. J. MED. 443.e1 (2018).

156. Adding flavors to e-liquids foreseeably increases the risk of nicotine addiction by making it easier and more pleasant to ingest nicotine.<sup>168</sup> Research has shown that adolescents whose first tobacco product was flavored are more likely to continue using tobacco products than those whose first product was not flavored.

157. In a recent study, 74% of youth surveyed indicated that their first use of a JUUL was of a flavored JUUL pod.<sup>169</sup>

158. Research shows that when youth see advertisements for flavored e-cigarettes, they believe the advertisements and products are intended for them.<sup>170</sup>

159. Flavors like mint and menthol are attractive to youth. According to Robin Koval, CEO and president of Truth Initiative, mint and menthol are among the most popular flavors for youth and that “[w]e also know, as does the tobacco industry, that menthol has been and continues to be the starter flavor of choice for young cigarette users.” According to the FDA, “younger populations have the highest rate of smoking menthol cigarettes” and “menthol in cigarettes is likely associated with increased initiation and progression to regular [] cigarette smoking.”<sup>171</sup>

160. A significant majority of under-age users chose flavored e-cigarette products.<sup>172</sup> By at least early 2017, JLI knew that its flavors had attracted young people and non-smokers in

---

<sup>168</sup> See U.S. Dep’t of Health & Human Servs., *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General*, Chapter 4 (Centers for Disease Control and Prevention ed. 2010), <https://www.ncbi.nlm.nih.gov/books/NBK53018/#ch4.s92>.

<sup>169</sup> Karma McKelvey et al., *Adolescents and Young Adults Use in Perceptions of Pod-based Electronic Cigarettes*, 1 JAMA NETWORK OPEN e183535 (2018), <https://doi:10.1001/jamanetworkopen.2018.3535>.

<sup>170</sup> D.C. Petrescu, et al., *What is the Impact of E-Cigarette Adverts on Children’s Perceptions of Tobacco Smoking? An Experimental Study*, 26 TOBACCO CONTROL 421 (2016); Julia C. Chen-Sankey et al., *Perceived Ease of Flavored E-Cigarette Use and E-Cigarette Use Progression Among Youth Never Tobacco Users*, 14 PLOS ONE 1 (2019).

<sup>171</sup> *Preliminary Scientific Evaluation of the Possible Public Health Effects of Menthol Versus Nonmenthol Cigarettes*, FDA 5, <https://www.fda.gov/media/86497/download> (last visited Nov. 12, 2020).

<sup>172</sup> Karen A. Cullen et al., *E-cigarette Use Among Youth in the United States*, 322 JAMA 2095 (2019), <https://tinyurl.com/y3g75gmg> (“Among current exclusive e-cigarette users, an estimated 72.2% . . . of high school students and 59.2% . . . of middle school students used flavored e-cigarettes. . .”).



droves.<sup>173</sup> Instead of taking corrective action or withdrawing the kid friendly flavors, JLI capitalized on their popularity with kids continued to promote JUUL's flavors. In a social media post from August 2017, for example, JLI tweeted "Beat The August Heat with Cool Mint" and "Crisp peppermint flavor with a pleasant aftertaste."<sup>174</sup> In another August 2017 tweet, JLI compared JUUL to dessert: "Do you brulée? RT [re-tweet] if you enjoy dessert without the spoon with our Creme Brulee #JUULpods."<sup>175</sup>

161. JLI asserts that it did not intend its flavors to appeal to underage consumers. After eleven Senators sent a letter to JLI questioning its marketing approach and kid-friendly e-cigarette flavors, JLI visited Capitol Hill and told Senators that it never intended its products to appeal to kids and did not realize they were using the products, according to a staffer for Senator Richard Durbin<sup>176</sup>. JLI's statements to Congress—which parallel similar protests of innocence by cigarette company executives—were false.

162. A former JUUL manager, who spoke to The New York Times on the condition that his name not be used, said that within months of JUUL's 2015 introduction, it became evident that teenagers were either buying JUULs online or finding others who made the purchases for them. Some people bought more JUUL kits on the company's website than they could individually use—sometimes ten or more devices at a time. "First, they just knew it was being bought for resale," said the former senior manager, who was briefed on the company's business strategy. "Then, when they saw the social media, in fall and winter of 2015, they

<sup>173</sup> See INREJLI\_00265068 (Feb. 13, 2017 internal JLI email string: ". . . [f]lavors are important for retention – especially when you consider the switching effectiveness of JLI. Would we still have these people as customers if we didn't offer fruit or dessert flavors? Hard to say on this alone, but if we removed our highest quality flavors (mint or mango), we would surely risk churn.").

<sup>174</sup> JUUL Labs, Inc. (@JUULvapor), Twitter (Aug. 4, 2017), [http://tobacco.stanford.edu/tobacco\\_web/images/pod/juul/twitter/large/twitter\\_39.jpg](http://tobacco.stanford.edu/tobacco_web/images/pod/juul/twitter/large/twitter_39.jpg).

<sup>175</sup> Kathleen Chaykowski, *The Disturbing Focus of Juul's Early Marketing Campaigns*, Forbes (Nov. 16, 2018), <https://www.forbes.com/sites/kathleenchaykowski/2018/11/16/the-disturbing-focus-of-juuls-early-marketing-campaigns/#3da1e11b14f9>.

<sup>176</sup> Lorraine Woellert & Sarah Oweremohle, *Juul Tries to Make Friends in Washington as Regulators Circle*, POLITICO (Dec. 28, 2018), <https://www.politico.com/story/2018/12/08/juul-lobbying-washington-1052219>.

1 suspected it was teens.”<sup>177</sup>

2 163. JLI’s use of flavors unfairly targeted not only youth, but unsuspecting adults as  
3 well. By positioning JUUL pods as a flavor-oriented product rather than a system for delivering  
4 a highly addictive drug, JLI deceptively led consumers to believe that JUUL pods were not only  
5 healthy (or at least essentially harmless), but also a pleasure to be enjoyed regularly, without  
6 guilt or adverse effect.

7 **b. Defendants Developed and Promoted the Mint Flavor and**  
8 **Sought to Preserve its Market.**

9 164. While JLI and the Management Defendants were developing and marketing their  
10 flavored products to appeal to and recruit youth, Altria, recognizing the value of those young  
11 “replacement smokers” committed itself to the cause. With the shared goal to grow the number  
12 of nicotine-addicted users, and as detailed further herein, JLI’s leadership, the Management  
13 Defendants, and Altria set out to do whatever was necessary to create and preserve the lucrative  
14 market for flavors. In order to maximize the value of its mint line of JUULpods, JLI, with the  
15 support of the Management Defendants, chemically and socially engineered its mint pods to  
16 become the most popular “flavor” among youth, including through extensive surveillance of  
17 youth behavior and preferences, all while seeking to conceal mint’s appeal to youth.

18 165. In July 2013, Reynolds American Inc.<sup>178</sup> released the Vuse, the first-known  
19 cartridge-based nicotine salt e-cigarette to reach the domestic market.<sup>179</sup> Altria entered the  
20 nicotine salt market one month later, with the MarkTen cig-a-like.<sup>180</sup> JLI would enter the market  
21 in June 2015.

22 166. Though mint was one of the least popular e-cigarette flavor categories with youth  
23

---

24 <sup>177</sup> Matt Richtel & Sheila Kaplan, *Did Juul Lure Teenagers and Get ‘Customers for Life’?*,  
25 N.Y. TIMES (Aug. 27, 2018), <https://www.nytimes.com/2018/08/27/science/juul-vaping-teen-marketing.html>.

26 <sup>178</sup> Reynolds is now a wholly owned subsidiary of British American Tobacco.

27 <sup>179</sup> See FAQs, RJR Vapor Co., LLC, <http://www.vusevapor.com/faqs/product/> (“Since Vuse’s  
28 launch in 2013, all of our closed systems available for sale nationally (i.e., Vuse Solo, Vuse  
Ciro, Vuse Vibe, and Vuse Alto) include nicotine salts.”).

<sup>180</sup> Additional Info, Nu Mark LLC, <https://markten.com> (“certain varieties” of MarkTen  
Original “contain ... acetic acid, benzoic acid, and lactic acid.”).

in 2015, trailing the fruit and dessert categories,<sup>181</sup> Reynolds, Altria and JLI had all introduced mint-flavored products within a year of each company's initial release. By mid-2014, Reynolds had added "Mint, Rich Mint, Spearmint, [and] Wintergreen" to its Vuse lineup.<sup>182</sup> By February 2015, Altria's Nu Mark LLC, under the leadership of Joe Murillo (JLI's current regulatory head), released a Winter Mint flavor for MarkTen.

167. Unlike Reynolds and Altria, which released mint products after first releasing a menthol variant, JLI skipped menthol and went straight to mint, adding Menthol in late 2017 around the same time it released its mango JUULpods.

168. JLI's flavored JUULpods were particularly popular with its underage users and, when mango was introduced, it was the underage user's flavor of choice.

169. JLI, the Management Defendants, and Altria recognized both the potential of using flavors to hook kids and the inevitability that the government would seek to regulate said flavors. So, they sought to solidify the market presence of a "substitute" youth-friendly flavor—mint—which might escape regulation and preserve JLI's astronomical sales figures.

#### **i. JLI Manipulates Chemistry of Mint JUUL Pods.**

170. One recent study found that JLI's mango had the lowest free-base content, making it the least harsh formula; and that mint had the highest free-base content (30% more free-base than mango), making mint the formula with the strongest nicotine impact:<sup>183</sup>

<sup>181</sup> See M.B. Harrell et al., *Flavored E-cigarette Use: Characterizing Youth, Young Adult, and Adult Users*, 5 PREVENTIVE MEDICINE REPS. 33-40, § 3.3 (Mar. 2017), <https://www.sciencedirect.com/science/article/pii/S2211335516301346>.

<sup>182</sup> See Sen. Richard Durbin, et al., *Gateway to Addiction?* (April 14, 2014), <https://www.durbin.senate.gov/imo/media/doc/Report%20-%20E-Cigarettes%20with%20Cover.pdf>.

<sup>183</sup> See Duell AK, et al. *Nicotine in Tobacco Product Aerosols: "It's Déjà vu All Over Again,"* 5 TOBACCO CONTROL (Dec. 17, 2019), <https://tobaccocontrol.bmj.com/content/tobaccocontrol/early/2019/12/16/tobaccocontrol-2019-055275.full.pdf>.

	$C_{HA}/C_{Nic}$	$\alpha_{Bb}$
Benzoic acid		
JUUL 'Cool Mint' (5% nicotine)	0.97*	0.13
JUUL 'Classic Menthol' (5% nicotine)	0.98*	0.13
JUUL 'Crème Brûlée' (5% nicotine)	0.97*	0.12
JUUL 'Fruit Medley' (5% nicotine)	0.99*	0.12
JUUL 'Cool Cucumber' (5% nicotine)	1.00*	0.11
JUUL 'Classic Tobacco' (5% nicotine)	1.00*	0.11
JUUL 'Virginia Tobacco' (5% nicotine)	1.00*	0.11
JUUL "Mango" (5% nicotine)	0.99*	0.09
JUUL "Virginia Tobacco" (3% nicotine)	0.94*	0.14
JUUL 'Mint' (3% nicotine)	1.04*	0.11
Averages for JUUL	0.99±0.03 SD	0.12±0.01

Anna K. Duell et al., Nicotine in tobacco product aerosols: 'It's déjà vu all over again'

171. These findings evidence JLI, the Management Defendants, and the Altria Defendants' plan to make the flavor whose lifespan they were working hard to preserve the most potent when it got into the hands of nonsmokers, including youth.

**ii. JLI's Youth Surveillance Programs Confirmed that Mint JUUL Pods are Preferred by Teens.**

172. In January 2018, Kevin Burns, JLI's new CEO, deployed his experience as the former CEO of a yogurt company to begin developing JUUL's flavor portfolio.

173. One part of this initiative included studying consumer reactions to flavor names. By February 2018, McKinsey & Company had provided a roadmap to JLI's Consumer Insights department, which included multiple flavor studies including a flavor "likability" tests, which was carried out under JUUL's marketing and commercial department.<sup>184</sup>

174. In April 2018, JLI received a document request from the FDA on April 24, 2018, seeking information about the design and marketing of JLI's products, among other things.<sup>185</sup>

175. In response, JLI announced a commitment of \$30 million to youth prevention efforts and began sending JLI representatives to schools to present what were essentially advertising campaigns for JUUL products. This conduct resulted in a Warning Letter from the

<sup>184</sup> INREJUUL\_00053172.

<sup>185</sup> Matthew Holman, U.S. Food & Drug Admin., to Ziad Rouag, Juul Labs, Inc., *Letter from Director of Office of Science, Center for Tobacco Products* (Apr. 24, 2018), <https://www.fda.gov/media/112339/download>.

1 FDA's Center for Tobacco Products to JLI in September 2019.<sup>186</sup>

2 176. Under the guise of this youth prevention program, *JLI directly studied 13- to 17-*  
 3 *year-old teens' e-cigarette flavor preferences.*<sup>187</sup> These studies, undertaken at a time when JLI  
 4 and Altria were coordinating their activities, asked teens to rank a variety of e-cigarette flavors  
 5 in terms of appeal, and included the names of current JUUL flavors, JUUL flavors under  
 6 development, and flavors offered by JLI's competitors. Though they were not made public,  
 7 through document requests, two such studies have been identified from April 2018.

8 177. The first study, carried out by McKinsey & Company, generated over 1,000  
 9 responses from teens aged 13 to 17 years old.<sup>188</sup> The second study, conducted by DB Research,  
 10 appears to have gathered data from a focus group of 16 kids in Bethesda, Maryland, and  
 11 Baltimore, Maryland.<sup>189</sup>

12 178. Both studies found that teens' co-favorite JUUL flavors were mango and mint,  
 13 and that teens found only one third-party flavor more desirable than mango and mint: "Cotton  
 14 Candy" (McKinsey)<sup>190</sup> and "Fruit Loops" (DB Research).<sup>191</sup>

15 179. Though the McKinsey study did not survey teens' preference for menthol, the  
 16 DB Research study did and found that while 28% of teens found menthol appealing, 72% of  
 17 teens liked mint.<sup>192</sup>

18 180. In other words, these surveys showed that teens respond to mint the way they  
 19 respond to their favorite candy flavors and respond to Menthol the way they respond to  
 20 traditional tobacco flavors typically disfavored by youth. This is unsurprising, as the "Mint"  
 21 flavor was designed not to taste like a Menthol cigarette. Users have described JLI's Menthol  
 22 flavor as "tast[ing] like a [N]ewport" cigarette that "doesn't have that good peppermint taste  
 23

24 <sup>186</sup> Letter from U.S. Food & Drug Admin. to Kevin Burns, CEO of Juul Labs, Inc. (Sept. 9,  
 25 2019), [https://www.fda.gov/inspections-compliance-enforcement-and-criminal-](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/juul-labs-inc-590950-09092019)  
[investigations/warning-letters/juul-labs-inc-590950-09092019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/juul-labs-inc-590950-09092019).

26 <sup>187</sup> INREJUUL\_00121627 (preliminary slides); INREJUUL\_00124965 (data).

27 <sup>188</sup> *Id.*

28 <sup>189</sup> INREJUUL\_00035325.

<sup>190</sup> INREJUUL\_00124965.

<sup>191</sup> *Id.*

<sup>192</sup> INREJUUL\_00035325.

1 like [C]ool [M]int.”<sup>193</sup>

2 181. Because of these and other studies, JLI, the Management Defendants, and the  
3 Altria Defendants knew that mint is an attractive flavor for kids. According to Siddharth Breja,  
4 who was senior vice president for global finance at JLI, after JLI pulled most flavored pods,  
5 including mango, from the market in a purported attempt to reduce youth usage of JUUL, then-  
6 CEO Kevin Burns said that “[y]ou need to have an IQ of 5 to know that when customers don’t  
7 find mango they buy mint.”<sup>194</sup> And it was public knowledge that mint and menthol have a well-  
8 documented history of facilitating youth tobacco use, as Dr. Jonathan Winickoff testified before  
9 Congress:

10 [it is] completely false to suggest that mint is not an attractive flavor to children.  
11 From candy canes to toothpaste, children are introduced to mint flavor from a  
12 young age. Not only do children enjoy mint, but it has special properties that  
13 make it an especially dangerous flavor for tobacco. Menthol’s anesthetic  
properties cool the throat, mask the harshness of nicotine, and make it easier for  
children to start using and continue using tobacco products. The impact of mint  
and menthol flavors on increasing youth tobacco addiction is well documented.<sup>195</sup>

14 182. If the purpose of these youth prevention studies was to “better understand how  
15 different flavor profiles appeal to different age groups to inform youth prevention,” as the  
16 McKinsey slides presenting that study’s findings indicate, the lesson for JLI, the Management  
17 Defendants, and the Altria Defendants was that teens like mint as much or more than any other  
18 JUUL flavor, including mango, fruit medley, crème brulee, cucumber, and more than a dozen  
19 other candy-like flavors produced by third-parties for use with the JUUL device.

20 183. With that knowledge and with no genuine interest in youth prevention, and as  
21 detailed below, JLI, the Management Defendants, and Altria committed to work to preserve  
22

23 <sup>193</sup> Reddit, *How does Classic Menthol Compare to Cool Mint*,  
24 [https://www.reddit.com/r/juul/comments/7wo39m/how\\_does\\_classic\\_menthol\\_compare\\_to\\_cool\\_mint/](https://www.reddit.com/r/juul/comments/7wo39m/how_does_classic_menthol_compare_to_cool_mint/).

25 <sup>194</sup> Sheila Kaplan and Jan Hoffman, *Juul Knowingly Sold Tainted Nicotine Pods, Former*  
26 *Executive Say*, N.Y. TIMES (Nov. 20, 2019), <https://www.nytimes.com/2019/10/30/health/juul-pods-contaminated.html>.

27 <sup>195</sup> *Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on*  
28 *Oversight and Reform, Subcomm. on Econ. and Consumer Policy*, 116th Cong. 3 (2019)  
(statement of Jonathan P. Winickoff, American Academy of Pediatrics),  
<https://oversight.house.gov/sites/democrats.oversight.house.gov/files/2019.07.24%20Winickoff%20AAP%20Testimony.pdf>.



1 mint as a flavor for as long as possible. Indeed, to further this goal, Defendants Pritzker and  
 2 Valani poured additional money into JLI a mere two months later as part of a \$600 million  
 3 funding round.<sup>196</sup>

4 184. By keeping mint on the market long after other flavors were pulled, these  
 5 Defendants continued to expand the number of addicted e-cigarette users.

6 **D. Defendants Developed and Implemented a Marketing Scheme to Mislead**  
 7 **Consumers into Believing that JUUL Products Contained Less Nicotine**  
 8 **Than They Actually Do and Were Healthy and Safe.**

9 185. Having created a product designed to hook users to its nicotine, JLI had to  
 10 mislead consumers into believing JUUL was something other than what it actually was. So, the  
 11 company engaged in a years' long campaign to downplay JUUL's nicotine content, nicotine  
 12 delivery, and the unprecedented risks of abuse and addiction JUUL poses. Defendants devised  
 13 and knowingly carried out a material scheme to defraud and addict consumers by  
 14 (a) misrepresenting the nicotine content, nicotine delivery profile, and risks of JUUL products,  
 15 (b) representing to the public that JUUL was a smoking cessation tool, and (c) using third-party  
 groups to spread false and misleading narratives about e-cigarettes, and JUUL in particular.

16 **1. The Defendants Knowingly Made False and Misleading Statements**  
 17 **and Omissions Concerning JUUL's Nicotine Content.**

18 186. As part of their strategy to market to youth and nonsmokers, JLI and the  
 19 Management Defendants also did not effectively inform users that JUUL products contain  
 20 nicotine. Despite making numerous revisions to JUUL products' packaging since 2015, JLI did  
 21 not include nicotine warnings until forced to do so in August 2018.<sup>197</sup>

22 187. Even after Defendants added a nicotine warning to JUUL products, they  
 23 continued to mislead youth and the public about the amount of nicotine in a JUULpod. Every  
 24

25 <sup>196</sup> Alex Wilhelm & Jason D. Rowley, *JUUL Raises \$650M Of Its \$1.25B Mega-Round*,  
 26 CRUNCHBASE (Jul. 10, 2018), <https://news.crunchbase.com/news/juul-raises-650m-of-its-1-25b-mega-round/>.

27 <sup>197</sup> See INREJUUL\_00444332 (2015 image of JLI packaging). The JLI packaging originally  
 28 included such warnings about nicotine, but were removed during various rounds of revisions,  
 see e.g., INREJUUL\_00021583-586 at 583 (2014 image of JLI packaging containing  
 handwritten revisions of the original language).



5% strength JUUL pod package represents that one pod is equivalent to one pack of cigarettes. This statement is deceptive, false and misleading. As JLI's regulatory head explained internally to former CEO Kevin Burns in 2018, each JUUL pod contains "roughly *twice the nicotine content* of a pack of cigarettes."<sup>198</sup>

188. In addition, and as JLI and the Management Defendants know, it is not just the amount of nicotine, but the efficiency with which the product delivers nicotine into the bloodstream, that determines the product's narcotic effect, risk of addiction, and therapeutic use. Most domestic cigarettes contain 10–15 mg of nicotine per cigarette<sup>199</sup> and each cigarette yields between 1.0 to 1.4 mg of nicotine,<sup>200</sup> meaning that around 10% of the nicotine in a cigarette is typically delivered to the user. JUUL e-cigarettes, on the other hand, have been found to deliver at least 82% of the nicotine contained in a JUUL pod to the user.<sup>201</sup> JLI's own internal studies suggest a nicotine transfer efficiency rate of closer to 100%.<sup>202</sup>

189. Defendants also knew that the use of benzoic acid and nicotine salts in JUUL pods affects pH and facilitates "absorption of nicotine across biological membranes."<sup>203</sup> JUUL's e-liquid formulation is highly addictive not only because it contains a high concentration of nicotine, but because it contains a particularly potent form of nicotine, i.e., nicotine salts. Defendants knew this, as Adam Bowen advised the Board of Directors at an October 2015 Board meeting on JLI's "nicotine salts patent application."<sup>204</sup> And the Altria Defendants were aware of the research showing the potency of nicotine salts from their many years in the tobacco

<sup>198</sup> INREJUUL\_00279931.

<sup>199</sup> Neal L Benowitz & Jack E Henningfield, *Reducing the Nicotine Content to Make Cigarettes less addictive*, 22 TOBACCO CONTROL Supp. 1, i14-17 (2013), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632983/>.

<sup>200</sup> Lynn T. Kozlowski & Janine L. Pilliteri, *Compensation for Nicotine by Smokers of Lower Yield Cigarettes*, 7 SMOKING AND TOBACCO CONTROL MONOGRAPH 161, 164 (1983), [https://cancercontrol.cancer.gov/brp/tcrb/monographs/7/m7\\_12.pdf](https://cancercontrol.cancer.gov/brp/tcrb/monographs/7/m7_12.pdf).

<sup>201</sup> Samantha M. Reilly et al., *Free Radical, Carbonyl, and Nicotine Levels Produced by JUUL Electronic Cigarettes*, 21 NICOTINE TOBACCO RESEARCH 1274 (2019), <https://www.ncbi.nlm.nih.gov/pubmed/30346584> (about 82%, for averages of 164 µg per puff).

<sup>202</sup> See, e.g., INREJUUL\_00023597 (finding 94% nicotine transfer efficiency with 4% benzoate formula).

<sup>203</sup> Neal L. Benowitz et al., *Nicotine Chemistry, Metabolism, Kinetics and Biomarkers*, 192 HANDB.EXP.PHARMACOL. 29(2010), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953858/>

<sup>204</sup> INREJUUL\_00278408.

business.

190. JLI and Defendant Bowen, knowing that the Phase 0 results illustrated that the nicotine content was greater than they wanted to represent, sought to engineer test results that differed from those results and were more consistent with JLI's deceptive messaging. In May 2014, within weeks of the Phase 0 study, JLI and Defendant Bowen carried out a second pharmacokinetics study in New Zealand. This study was called the CH-1401, or the "Phase 1" study. This study again examined the effects of inhaling aerosol from various 2% nicotine solutions: nicotine benzoate (blend A), nicotine malate (blend B), and free-base nicotine (blend C).<sup>205</sup> In a further departure from the Phase 0 study, which used experienced e-cigarette users, the Phase 1 study used subjects that had not previously ingested aerosolized nicotine vapor, and who had certainly never ingested aerosolized nicotine vapor from nicotine salts. As Defendants JLI and Bowen knew, this difference is critical. Just as first-time smokers would not inhale as much cigarette smoke as regular smokers, inexperienced (or "learning") e-cigarette users will not inhale vapor at a rate that maximizes nicotine delivery.<sup>206</sup> JLI's decision to omit participants with previous e-cigarette experience from the criteria for inclusion in CH-1401 resulted in artificially deflated Cmax results.<sup>207</sup>

191. The Cmax recorded in the Phase 1 study was approximately a third of that achieved by smoking a cigarette. Specifically, e-cigarette users recorded a Cmax of approximately 12.87 ng/ml, compared with the 31.47 ng/ml Cmax resulting from smoking a Pall Mall.<sup>208</sup>

192. In possession of the results from both the Phase 0 and Phase 1 studies, JLI nevertheless decided to launch a 5% nicotine salt solution as its commercial product. An internal memo explained JLI's reasoning as follows: "[s]ince the Cmax of the [2%] nicotine salt was about 1/3 that of cigarettes, we chose a concentration of 5% for our commercial product

---

<sup>205</sup> INREJUUL\_00014159-INREJUUL\_00014226.

<sup>206</sup> INREJUUL\_00002526-INREJUUL\_00002625.

<sup>207</sup> *Id.*

<sup>208</sup> *Id.*

(JUUL), which should provide a Tmax and Cmax consistent with a cigarette.”<sup>209</sup>

193. Instead of testing a 5% solution, JLI *estimated* the Cmax result of a 5% nicotine solution using a model.<sup>210</sup> But the Phase 0 data showed that a 4% benzoic acid / 5% nicotine solution would have a higher Cmax and AUC than those of a cigarette, not one that was equal.

194. JLI and the Management Defendants knew that JLI’s studies indicated that their 5% solution product was more potent and more addictive than a typical cigarette. But JLI and the Management Defendants then used their unsupported extrapolation of their flawed studies to market JUUL as providing a nicotine experience on par with a cigarette, even though they designed JUUL to ensure that was not true. In reality, there were never any measured test results in accord with JLI’s marketing to distributors, retailers, and the public at large.


195. In the United States, the unsupported extrapolations from what appears to be the Phase 1 study were used to create charts, which JLI posted on its website, shared with journalists, sent to retailers, and distributed to third party promoters, showing that JUUL’s 5% solution achieved a pk profile just below that of a cigarette. For example, the following chart appeared on the online publication TechCrunch:<sup>211</sup>

---


<sup>209</sup> INREJUUL\_00351717-INREJUUL\_00351719.

<sup>210</sup> *Id.*

<sup>211</sup> Ryan Lawler, *Vaporization Startup Pax Labs Introduces Juul, Its Next-Gen-E-Cigarette*, TECH CRUNCH (Apr. 21, 2015), <https://techcrunch.com/2015/04/21/pax-juul/>.



196. Simultaneously, while providing extrapolated data to the public, Phase 1 was used as the basis for representations to retailers that a 2% solution achieved a pk profile equalling that of a cigarette. In a pitch deck dated March 25, 2015, and labeled as being intended for the convenience store distributor Core-Mark, JLI presented interim<sup>212</sup> Phase 1 data showing this equivalence:<sup>213</sup>



<sup>212</sup> See JLI00363360.

<sup>213</sup> INREJUUL\_00448896.

197. These misrepresentations to the public were not accidental, nor were they the work of a rogue employee. In a June 2014 Ploom Board meeting in London, the Ploom executives' presentation to the Board, which at that time included Defendants Bowen, Monsees, Pritzker, and Valani, explained the differences between the Phase 0 and Phase 1 results as "due to averaging across more subjects with variability in puffing behavior."<sup>214</sup> Their explanation did not note that "variability in puffing behaviour" was partly a result of the fact that participants in the Phase 0 study were experienced e-cigarette users whereas the participants in the Phase 1 study were not. Thus, Defendants Bowen, Monsees, Pritzker, and Valani were privy to both the Phase 0 and Phase 1 results. And they *knew* that the data JLI (then Ploom) was pushing on the public was false and misleading, but none made any efforts to correct or withdraw those false and misleading statements. Aside from submitting the testing protocol and results of the Phase 0 study with the '895 patent, JLI, Bowen, Monsees, Pritzker, and Valani otherwise ignored the Phase 0 study and omitted it from public discussion of JUUL's nicotine delivery.

**2. JLI, the Management Defendants, and Altria Transmitted, Promoted and Utilized Statements Concerning JUUL's Nicotine Content that They Knew Was False and Misleading.**

198. As set forth above, the statements in JLI advertisements and on JUUL pod packaging that each JUUL pod contains about as much nicotine as a pack of cigarettes are deceptive, false and misleading. Defendants knew this.

199. JLI and the Management Defendants caused deceptive, false and misleading statements that a JUUL pod had an equivalent amount of nicotine as one pack of cigarettes to be distributed via the wires and mails. These Defendants have thus materially misrepresented the nicotine content of JUUL products to the consuming public including Plaintiffs, through acts of mail and wire fraud.

200. By no later than October 30, 2016 (and likely earlier), the JLI Website—which, as discussed above, the Management Defendants on JLI's Board of Directors reviewed and approved—advertised that "[e]ach JUULpod contains 0.7mL with 5% nicotine by weight,

---

<sup>214</sup> INREJUUL\_00016443-INREJUUL\_00016507.

1 approximately equivalent to 1 pack of cigarettes or 200 puffs.”<sup>215</sup> The language on the website  
 2 would later change, but still maintained the same fraudulent misrepresentation—i.e., that  
 3 “[e]ach 5% JUULpod is roughly equivalent to one pack of cigarettes in nicotine delivery.”<sup>216</sup>

4 201. As noted above, JLI and the Management Defendants directed and approved the  
 5 content of the JUUL website, and they also directed and approved the distribution channels for  
 6 JUUL pods and deceptive, misleading and fraudulent statements regarding JUUL’s nicotine  
 7 content. And although they knew that these statements, which they caused to be transmitted  
 8 over the wires and mails, were untrue, JLI and the Management Defendants have made no effort  
 9 to retract such statements or correct their lies. Moreover, by no later than July 2018, James  
 10 Monsees required JLI employees to personally seek his approval for the artwork on all JUUL  
 11 and JUUL pod packaging.<sup>217</sup>

12 202. In addition to approving the JLI website, knowing that it contained deceptive,  
 13 misleading and false statements, JLI (through its employees) and the Management Defendants  
 14 also were directly responsible for the interstate transport, *via* U.S. mail, of JUULpod packaging  
 15 contained misrepresentations and omissions. At the same Board Meeting where Defendants  
 16 Pritzker, Huh, and Valani were installed as the Executive Committee, the Board directed JLI’s  
 17 management on, among other things, “the need to rely on distributors and the challenges in  
 18 reaching customers otherwise.”<sup>218</sup>

19 203. JUUL pod packages that were sent *via* U.S. mail stated that a single Juul pod is  
 20 “approximately equivalent to about 1 pack of cigarettes.”<sup>219</sup> These statements, as well as the  
 21 statements on the JLI website, are false and misleading.

22 204. The statement on the JLI website, and in its advertisements and packaging, that  
 23

---

24  
 25 <sup>215</sup> JUULpod, JUUL Labs, Inc. (Oct. 30, 2016),  
<https://web.archive.org/web/20161030085646/https://www.juulvapor.com/shop-pods/>.

26 <sup>216</sup> What is Vaping?, JUUL Labs, Inc. (July 2, 2019), <https://www.JUUL.com/resources/What-is-Vaping-How-to-Vape>.

27 <sup>217</sup> JLI10045538.

28 <sup>218</sup> INREJUUL\_00278408.

<sup>219</sup> Juul Labs, Inc., Twitter, (Feb. 14, 2018),  
<https://twitter.com/JUULvapor/status/963844069519773698>.

1 each JUUL pod contains 5% nicotine and is approximately equivalent to a pack of cigarettes is  
2 false and likely to deceive and mislead, because the actual amount of nicotine contained in a  
3 JUUL pod is as much as twice as high as that in a pack of cigarettes.

4 205. AGDC and Altria Client Services greatly expanded the reach of this fraud by  
5 providing their retail and distribution might for JLI products, causing millions of JUUL pods to  
6 be sent via U.S. mail with packaging stating that JUUL pods contain only 5% nicotine by  
7 weight and are “approximately equivalent to about 1 pack of cigarettes.”<sup>220</sup> JLI, the  
8 Management Defendants, and the Altria Defendants knew that these statements were false and  
9 misleading, but nevertheless utilized JUUL product packing, marketing and advertising to  
10 maintain their fraud.

11 206. The Altria Defendants knew in 2017 that a JUUL pod delivered more nicotine  
12 than one pack of cigarettes. In 2017, Altria, through its wholly owned subsidiary Nu Mark,  
13 launched its MarkTen Bold e-cigarette, a relatively high-strength 4% formulation compared to  
14 the 2.5% and 3.5% strength MarkTen products initially offered. Even though JUUL was already  
15 on store shelves and was rapidly gaining market share with its 5% nicotine formulation, Altria  
16 (through Nu Mark) chose to bring a less potent 4% formulation to market.

17 207. According to Altria’s own pharmacokinetic testing (likely conducted by Altria  
18 Client Services) as reflected in the chart below, this 4% less potent formulation was  
19 nevertheless sufficient to raise plasma nicotine to levels approaching those generated by  
20 combustible cigarettes. In other words, the Altria Defendants’ own pharmacokinetic testing  
21 suggested the highly addictive nature of a 5% formulation, as such a formulation would readily  
22 equal or exceed the nicotine delivery profile of a combustible cigarette.

23  
24  
25  
26  
27  
28  

---

<sup>220</sup> *Id.*






Figure 1: Presented at Altria Group Inc.'s November 1, 2017 Investor Day Presentation.  
MarkTen Bold 4%

208. Based on its own internal knowledge, the Altria Defendants knew that a 5% nicotine formulation would carry more nicotine than one pack of cigarettes. In addition to data it Altria and Altria Client Services received from JLI, their due diligence undoubtedly included a careful examination of JLI's intellectual property, including the '895 patent, which provides a detailed overview of nicotine benzoate's pharmacokinetic profile.

209. Thus, JLI, the Management Defendants, and the Altria Defendants knew that the statement on JUUL pod packaging that each JUUL pod contains 5% nicotine and about as much nicotine as a pack of cigarettes is literally false and they intended such statements to mislead. Neither the Altria Defendants nor JLI or the Management Defendants have made any effort to correct or retract the false and misleading statements as to the true nicotine content in JUUL pods. Instead, they have continued to misrepresent the product's nicotine content and design, with the goal of misleading and deceiving consumers.

210. From JUUL's pre-release announcements to this day, JLI has continuously represented that each pod is approximately equivalent to a pack of cigarettes. These claims, which JLI repeats widely in advertisements, press releases, and its web site, have been distributed *via* the wires and mails and disseminated by reputable and widely reliable sources that accepted those representations as true.<sup>221</sup>

<sup>221</sup> See Truth Initiative, *6 Important Facts about Juul*, <https://truthinitiative.org/research-resources/emerging-tobacco-products/6-important-facts-about-juul>; Erin Brodwin, *An E-*

211. Not only have JLI and the Management Defendants misrepresented or concealed the actual amount of nicotine consumed *via* JUUL pods, but they also did not effectively or fully inform users about the risks associated with the potent dose of nicotine delivered by JLI's products. Despite going through numerous revisions since 2015, the JUUL packaging did not include nicotine addiction warnings until JLI was forced to add them in August 2018. The original JUUL product labels had a California Proposition 65 warning indicating that the product contains a substance known to cause cancer, and a warning to keep JUUL pods away from children and pets, but contained no warnings specifically about the known effects, or unknown long-term effects, of nicotine or consuming e-cigarettes/inhaling nicotine salts.<sup>222</sup>

212. Moreover, the form of nicotine JUUL pods contain is particularly potent. JUUL's use of "strength" to indicate concentration by weight is also at odds with the industry standard of reporting concentration by volume,<sup>223</sup> leading consumers to believe it contains less nicotine than other formulations advertised as 6% nicotine, when JUUL pods in fact contain approximately the same nicotine as a solution that is 6% nicotine by volume.

213. The "5% strength" statement in Defendants' advertisements misrepresents the most material feature of the JUUL product—the nicotine content—and has misled consumers to their detriment. Resellers, apparently assuming that "5% strength" means "50mg/ml" nicotine

*cigarette with Twice the Nicotine of Comparable Devices is Taking over High Schools – and Scientists are Sounding the Alarm*, BUSINESS INSIDER (Apr. 30, 2018), <https://www.businessinsider.com/juul-e-cig-vaping-health-effects-2018-3>; Caroline Kee, *Everything you Need to Know About the JUUL, Including the Health Effects*, BUZZFEED NEWS (Feb. 5, 2018), <https://www.buzzfeednews.com/article/carolinekee/juul-ecigarette-vape-health-effects>; Jan Hoffman, *The Price of Cool: A Teenager, a Juul and Nicotine Addiction*, NEW YORK TIMES, (November 16, 2018), <https://www.nytimes.com/2018/11/16/health/vaping-juul-teens-addiction-nicotine.html>; Sarah Milov, *Like the Tobacco Industry, E-cigarette Manufacturers are Targeting Children*, THE WASHINGTON POST, (Sept. 23, 2018) <https://www.washingtonpost.com/outlook/2018/09/23/like-tobacco-industry-e-cigarette-manufacturers-are-targeting-children/>; Washington State Dep't of Health, *What are Vapor Products?*, <https://www.doh.wa.gov/YouandYourFamily/Tobacco/VaporProducts>.

<sup>222</sup> See INREJUUL\_00444332 (2015 image of JLI packaging). Note that JLI packaging originally included such warnings about nicotine, but were apparently removed during various rounds of revisions, see e.g. INREJUUL\_00021583 (2014 image of JLI packaging containing handwritten revisions of the original language.).

<sup>223</sup> See, e.g., American E-Liquids Manufacturing Standards Association, *E-Liquids Manufacturing Standards*, § 1.05 (2017), <https://www.aemsa.org/wp-content/uploads/2017/03/AEMSA-Standards-v2.3.3.pdf>, (quantifying e-liquid nicotine content in terms of volume).

by volume, compound confusion among consumers by stating that JUUL pods contain “50 mg/ml,” which they do not.<sup>224</sup>

214. If JLI and the Management Defendants did not know when JLI released JUUL pods that the “5% strength” representation in Defendants’ advertisements was misleading, they learned that there was widespread confusion about the JUUL pods’ nicotine content. By 2017, studies revealed that smokers did not understand “5% strength,” and some understood that phrase to mean 5% of a cigarette. Though this was identified as a “pain point” for new users,<sup>225</sup> JLI and the Management Defendants (and later the Altria Defendants) did nothing to stop or correct this confusion about the nicotine content.

215. The “5% strength” statement in Defendants’ advertisements is also misleading. At least two independent studies testing multiple varieties of JUUL pods have likewise found significantly higher concentrations of nicotine than the 59 mg/mL JUUL’s website represents, suggesting that the difference in the total nicotine content of a JUUL pod vs. a pack of combustible cigarettes could be even greater.<sup>226</sup>

### 3. Defendants Used Food and Coffee Themes to Give False Impression that JUUL Products Were Safe and Healthy.


216. In late 2015, JLI and the Management Defendants employed a deceptive marketing scheme to downplay the harms of e-cigarettes with a food-based advertising campaign called “Save Room for JUUL.” The campaign framed JUUL’s addictive pods as

<sup>224</sup> See, e.g., Tracy Vapors, Starter Kit, <http://web.archive.org/web/20190422143424/https://www.tracyvapors.com/collections/starter-kit>; Lindsey Fox, *JUUL Vapor Review, E-cigarette Reviewed*, (Mar. 20, 2017), <https://ecigaretterevuewed.com/juul-review> (“The nicotine content of the JUUL pods is always the same: 5% or 50 mg/ml”); Jason Artman, *JUUL E-Cigarette Review*, eCig One (Oct. 26, 2016) <https://ecigone.com/e-cigarette-reviews/juul-e-cigarette-review/> (“the e-liquid contains 50 mg of nicotine per ml of e-liquid”); West Coast Vape Supply, Juul Starter Kit (July 18, 2019), <http://web.archive.org/web/20190718190102/https://westcoastvapesupply.com/products/juul-starter-kit> (“5% . . . 50 mg”); Vapor4Life, *How Much Nicotine is In a JUUL?* (Aug. 24, 2018), <https://www.vapor4life.com/blog/how-much-nicotine-is-in-a-JUUL/>. “Each official JUUL pod contains a whopping 50mg of nicotine per milliliter of liquid (most other devices range from 3 to 30mg per milliliter.”

<sup>225</sup> INREJUUL\_00123540.

<sup>226</sup> See J.F. Pankow et al., *Benzene Formation in Electronic Cigarettes*, 12 PLoS ONE 1 (2017); See also Anna K. Duell, et al., *Free-Base Nicotine Determination in Electronic Cigarette Liquids by 1H NMR Spectroscopy*, 31 CHEM. RES. TOXICOL. 431, 431-34 (2018).

“flavors” to be paired with foods.<sup>227</sup> JLI described its Crème Brûlée nicotine pods as “the perfect evening treat” that would allow users to “indulge in dessert without the spoon.”<sup>228</sup> In one 2016 email, JLI bluntly suggested that users satisfy their sugar cravings with JUUL’s highly-addictive nicotine vapor: “Have a sweet tooth? Try Brulee.”<sup>229</sup> JLI similarly promoted the fruit medley pods using images of ripe berries.<sup>230</sup> JLI described its “Cool” Mint pods as having a “crisp peppermint taste with a pleasant aftertaste” and encouraged consumers to “Beat The August Heat With Cool Mint.”<sup>231</sup>



<sup>227</sup> Erin Brodwin, *\$15 Billion Startup JUUL Used ‘Relaxation, Freedom, and Sex Appeal’ to Market its Crème-brulee-flavored E-cigs on Twitter and Instagram—but its Success has Come at a Big Cost*, BUSINESS INSIDER (Oct. 26, 2018), <https://www.businessinsider.com/juul-e-cig-marketing-youtube-twitter-instagram-social-media-advertising-study-2018-10>.

<sup>228</sup> Stanford University, *Research into the Impact of Tobacco Advertising*, [http://tobacco.stanford.edu/tobacco\\_main/images\\_pods.php?token2=fm\\_pods\\_st658.php&token1=fm\\_pods\\_img36019.php&theme\\_file=fm\\_pods\\_mt068.php&theme\\_name=JUUL&subtheme\\_name=Flavors](http://tobacco.stanford.edu/tobacco_main/images_pods.php?token2=fm_pods_st658.php&token1=fm_pods_img36019.php&theme_file=fm_pods_mt068.php&theme_name=JUUL&subtheme_name=Flavors).

<sup>229</sup> Stanford University, *Research into the Impact of Tobacco Advertising*, [http://tobacco.stanford.edu/tobacco\\_main/images\\_pods.php?token2=fm\\_pods\\_st658.php&token1=fm\\_pods\\_img36019.php&theme\\_file=fm\\_pods\\_mt068.php&theme\\_name=JUUL&subtheme\\_name=Flavors](http://tobacco.stanford.edu/tobacco_main/images_pods.php?token2=fm_pods_st658.php&token1=fm_pods_img36019.php&theme_file=fm_pods_mt068.php&theme_name=JUUL&subtheme_name=Flavors).

<sup>230</sup> Stanford University, *Research into the Impact of Tobacco Advertising*, [http://tobacco.stanford.edu/tobacco\\_web/images/pod/juul/flavors/large/flavor\\_6.jpg](http://tobacco.stanford.edu/tobacco_web/images/pod/juul/flavors/large/flavor_6.jpg).

<sup>231</sup> Stanford University, *Research into the Impact of Tobacco Advertising*, [http://tobacco.stanford.edu/tobacco\\_main/images\\_pods.php?token2=fm\\_pods\\_st658.php&token1=fm\\_pods\\_img36019.php&theme\\_file=fm\\_pods\\_mt068.php&theme\\_name=JUUL&subtheme\\_name=Flavors](http://tobacco.stanford.edu/tobacco_main/images_pods.php?token2=fm_pods_st658.php&token1=fm_pods_img36019.php&theme_file=fm_pods_mt068.php&theme_name=JUUL&subtheme_name=Flavors).



217. Again, none of these advertisements disclosed that JUUL was addictive and unsafe.


218. In several caffeine-pairing advertisements, JUUL devices or pods sit next to coffee and other caffeinated drinks, sometimes with what appear to be textbooks in the picture.<sup>232</sup> JLI's coffee-based advertisements suggest that JUUL should be part of a comfortable routine, like a cup of coffee.

219. JLI's reference to coffee is no mere marketing gimmick, it reflects the larger effort to mislead customers into believing that JUUL is no more harmful than coffee, reinforcing the false and dangerous concept that if a substance is "not harmful," then addiction to that substance cannot be harmful.

---

<sup>232</sup> *Id.*





220. Defendants knew that tying JUUL to caffeine and food would mislead their target audience—youth and non-smokers—into believing that JUUL was a healthy, safe treat.

4. **JLI's "Make the Switch" Campaign Intentionally Misled and Deceived Users to Believe that JUUL Is a Cessation Device.**

221. JLI, the Altria Defendants, and the Management Defendants recognized that one of the keys to growing and preserving the number of nicotine-addicted e-cigarette users (and thus JLI's staggering market share), was to mislead potential customers about the true nature of JUUL products. Defendants knew that if it became public that JUUL was designed as a way to introduce nicotine to youth and otherwise hook new users with its potent nicotine content and delivery, it would not survive the public and regulatory backlash. Therefore, JLI (with the knowledge and support of the Management Defendants) and the Altria Defendants repeatedly made false and misleading statements to the public that JUUL was created and designed as a smoking cessation device, and falsely and misleadingly used the mails and wires to spread the subterfuge. JLI, the Management Defendants, and the Altria Defendants committed these deceptive, misleading and fraudulent acts intentionally and knowingly. In making these representations, JLI, the Management Defendants, and the Altria Defendants intended that consumers, the public, and regulators rely on misrepresentations that JUUL products were designed to assist smoking cessation.

222. The most blatant evidence of the cover-up scheme was the January 2019, \$10 million "*Make the Switch*" television advertising campaign. This campaign, which was a continuation of JLI's web-based Switch campaign, was announced less than a month after the Altria Defendants announced Altria's investment in JLI.

223. The "*Make the Switch*" television ads featured former smokers aged 37 to 54 discussing "how JUUL helped them quit smoking."<sup>233</sup> According to JLI's Vice President of Marketing, the "*Make the Switch*" campaign was "an honest, straight down the middle of the fairway, very clear communication about what we're trying to do as a company."<sup>234</sup> These

---

<sup>233</sup> Angelica LaVito, *JLI Combats Criticism with New TV Ad Campaign Featuring Adult Smokers Who Quit after Switching to E-cigarettes*, CNBC (Jan. 8, 2019), <https://www.cnbc.com/2019/01/07/juul-highlights-smokers-switching-to-e-cigarettes-in-ad-campaign.html>.

<sup>234</sup> *Id.*



statements were false as JUUL was not intended to be a smoking cessation device. JLI and the Management Defendants committed acts of wire fraud when they caused the “Make the Switch” campaign to air on television with the fraudulent intent of deceiving and misleading the public, the United States Congress, and government regulators into believing that JLI is and had been focused solely on targeting adult smokers. The Altria Defendants also committed acts of mail fraud when they caused tens of thousands, if not millions, of written versions of the *Make the Switch* campaign to be distributed with packages of Altria’s combustible cigarettes.

224. The “*Make the Switch*” campaign was fraudulent and was made to protect, maintain, and expand the tremendous market share gained by lying to consumers and hooking youth on nicotine by convincing regulators and the public that JUUL was actually as cessation device and JLI’s marketing was never aimed at youth.

225. Defendants continually and intentionally sought to frame JUUL products as smoking cessation devices in their public statements and on their website as part of their scheme to mislead and defraud the public. Defendant Monsees explained during his testimony before Congress:

***The history of cessation products have extremely low efficacy. That is the problem we are trying to solve here.*** So, if we can give consumers an alternative and market it right next to other cigarettes, then we can actually make something work.

[T]raditional nicotine replacement therapies, which are generally regarded as the gold standard for tools, right, for quitting, those are nicotine in a patch or a gum form, typically, and the efficacy rates on those hover just below about a 10 percent or so. JUUL—we ran a very large study of JUUL consumers, ex-smokers who had picked up JUUL, and looked at them, looked at their usage on a longitudinal basis, which is usually the way that we want to look at this, in a sophisticated fashion ... what we found was that after 90 days, 54 percent of those smokers had stopped smoking completely, for a minimum of 30 days already. And the most interesting part of this study is that if you follow it out further, to 180 days, that number continues to go up dramatically, and that is quite the opposite of what happens with traditional nicotine replacement therapies.<sup>235</sup>

---

<sup>235</sup> *Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on Oversight and Reform, Subcomm. on Econ. and Consumer Policy*, 116th Cong. (2019) (statement of James Monsees, Co-Founder, JUUL Labs, Inc.), <https://oversight.house.gov/legislation/hearings/examining-juul-s-role-in-the-youth-nicotine-epidemic-part-ii>.

226. In response to a direct question about whether people buy JUUL to stop smoking, Defendant Monsees responded: “Yes. I would say nearly everyone uses our product as an alternative to traditional tobacco products.”<sup>236</sup>

227. Following Defendants Monsees’ and Altria’s lead, Defendants caused a number of other misleading public statements—suggesting that Juul would help existing adult smokers even though it delivered more nicotine than cigarettes and was designed to appeal to kids—to be made, including the following:

- “JUUL Labs was founded by former smokers, James and Adam, with the goal of improving the lives of the world’s one billion adult smokers by **eliminating cigarettes**. We envision a world where fewer adults use cigarettes, and **where adults who smoke cigarettes have the tools to reduce or eliminate their consumption entirely**, should they so desire.” (JLI Website, April 2018 (or earlier)),<sup>237</sup>
- “JUUL Labs, which exists to **help adult smokers switch** off of combustible cigarettes.” (JLI Website, September 19, 2019); and,<sup>238</sup>
- “To paraphrase Commissioner Gottlieb, **we want to be the offramp for adult smokers** to switch from cigarettes, not an on-ramp for America’s youth to initiate on nicotine.” (JLI Website, November 13, 2018),<sup>239</sup>
- “We are taking significant action to prepare for a future where adult smokers overwhelmingly choose non-combustible products over cigarettes by investing \$12.8 billion in JUUL, **a world leader in switching adult smokers** . . . . We have long said that providing adult smokers with superior, satisfying products with the potential to reduce harm is the best way to achieve tobacco harm reduction.” (Altria Website, December 20, 2018),<sup>240</sup>

<sup>236</sup> *Id.*

<sup>237</sup> *Our Mission*, JUUL Labs, Inc. (2019), <https://www.juul.com/mission-values>.

<sup>238</sup> CONSUMER UPDATE: 9/19, JUUL Labs, Inc. (Sept. 19, 2019), <https://newsroom.juul.com/consumer-update-9-19/>.

<sup>239</sup> JLI Labs Action Plan, JUUL Labs, Inc. (Nov. 13, 2018), <https://newsroom.juul.com/juul-labs-action-plan/> (statement of then-CEO Kevin Burns).

<sup>240</sup> *Altria Makes \$12.8 Billion Minority Investment in JUUL to Accelerate Harm Reduction and Drive Growth*, BUSINESSWIRE (Dec. 20, 2018), <https://www.businesswire.com/news/home/20181220005318/en/Altria-12.8-Billion-Minority-Investment-JUUL-Accelerate>.

- 1 • “We believe e-vapor products present an **important opportunity to**  
2 **adult smokers to switch from combustible cigarettes.**” (Letter to  
3 FDA Commissioner Gottlieb, 10/25/18).<sup>241</sup>
- 4 • “We have long said that **providing adult smokers with superior,**  
5 **satisfying products with the potential to reduce harm** is the best  
6 way to achieve tobacco harm reduction. **Through Juul,** we are making  
7 the biggest investment in our history toward that goal.” (Altria Press  
8 Release, Dec. 20, 2018).<sup>242</sup>
- 9 • “Through JUUL, we have found a unique opportunity to not only  
10 participate meaningfully in the e-vapor category but to also **support**  
11 **and even accelerate transition to noncombustible alternative**  
12 **products by adult smokers.**” (Altria Earning Call, January 31,  
13 2019).<sup>243</sup> and
- 14 • We expect the **JUUL product features that have driven JUUL’s**  
15 **success in switching adult smokers in the U.S.** to strongly appeal to  
16 international adult cigarette smokers. (Altria Earning Call, January 31,  
17 2019).<sup>244</sup>

18 228. Defendants knew that the “switch” messaging they initiated for JUUL was false,  
19 deceptive and misleading. JUUL does not have FDA approval as a cessation product. The  
20 *Switch* advertisements reinforced the impression left by the testimony of JLI’s co-founder,  
21 clearly linking JUUL to cessation and quitting. For example:

22  
23  
24 <sup>241</sup> Letter from Howard A. Willard III, Altria, to Dr. Scott Gottlieb, FDA, at 1-2 (Oct. 25,  
25 2018).

26 <sup>242</sup> *Altria Makes \$12.8 Billion Minority Investment in JUUL to Accelerate Harm Reduction and*  
27 *Drive Growth*, (Dec. 20, 2018), BUSINESS WIRE,  
28 <https://www.businesswire.com/news/home/20181220005318/en/Altria-12.8-Billion-Minority-Investment-JUUL-Accelerate>.

<sup>243</sup> Altria Group (MO) Q4 2018 Earnings Conference Call Transcript: MO earnings call for the  
period ending December 31, 2018, (Jan. 31, 2019), <https://www.fool.com/earnings/call-transcripts/2019/02/01/altria-group-mo-q4-2018-earnings-conference-call-t.aspx>.

<sup>244</sup> *Id.*



229. Representative Rashida Tlaib, upon presenting this ad to Monsees, had the following exchange:

**Rep. Tlaib:** After 30 lines, starting with “quit,” the ad says “switch,” followed by no further mentions of start smoking again. You were a smoker. Does this ad give a smoker hope that there might be a way to quit cigarettes for good?

**Mr. Monsees:** I think the intention of this ad is to make it very clear to consumers that there is an alternative, finally, to combustible cigarettes. I am one of those

1 people.<sup>245</sup>

2 230. Defendants' tacit message in their *Switch* advertisements is: switch because,  
3 unlike cigarettes, JUUL is harmless to your health.

4 231. Defendants' false, deceptive and misleading *Switch* campaign suggests that  
5 purchasing a JUUL will "switch" a smoker to a non-smoker and that it was designed to switch  
6 adult smokers off cigarettes rather than addict youth to nicotine.

7 232. Defendants know that a large number of smokers who use JUUL products do not  
8 end up switching but instead end up consuming both cigarettes and JUUL.

9 233. Moreover, Defendants know that, by design, a large number of their customers  
10 are first-time youth users and that JUUL was never designed to be a cessation device.

11 234. JLI has advertised cost-savings calculators as part of its *Switch* campaign. Those  
12 calculators assume that a smoker who switches will continue consuming the same amount of  
13 nicotine that he or she did as a smoker (*i.e.*, a pack a day smoker is presumed to consume one  
14 JUUL pod a day). Defendants know that the calculator is misleading because smokers who  
15 switch to JUUL frequently increase their nicotine intake.

16 235. JUUL labels and advertisements also marketed the product as an "alternative" to  
17 cigarettes:

---

18  
19  
20  
21  
22  
23  
24  
25  
26  
27 <sup>245</sup> *Examining Juul's Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on*  
28 *Oversight and Reform, Subcomm. on Econ. and Consumer Policy, 116th Cong. (2019)*  
(statement of James Monsees, Co-Founder, JUUL Labs, Inc.), <https://www.c-span.org/video/?c4811191/user-clip-wasserman-grothman-tlaib-question-monsees> at 12:33-13:04.



236. Other advertisements similarly marketed the product as smoking “evolved”:



237. The goal of these advertisements was to convey the deceptive, misleading and false impression that JUUL products could help consumers quit smoking and break nicotine addiction in a way that was healthy and safe. But, as noted above, that was simply not the case. Defendants never disclosed to consumers that JUUL e-cigarettes and JUUL pods are at least as, if not more, addictive than combustible cigarettes. And each of JLI, the Management Defendants, and the Altria Defendants received data to this effect, as discussed above, and were aware of this fact.

238. In addition, the notions that JUUL products are designed only for existing cigarette smokers, and safer than combustible cigarettes are belied by JLI’s own knowledge, marketing plan and intentions on several fronts. *First*, Defendants sought to grow a new group



of consumers of nicotine products (e.g., “vapers”), not just to market to the shrinking number of existing cigarette smokers. *Second*, JLI and Bowen designed the JUUL device to be easy to use for youth and others who have never smoked and to create and exacerbate nicotine addiction by encouraging ingestion of excessive amounts of nicotine. *Third*, as noted above, JLI’s own internal testing revealed that JUUL products were often more potent than combustible cigarette smokers prefer. Each of the Management Defendants knew this from his position on JLI’s Board of Directors, and the Altria Defendants knew the same when they began to actively coordinate with JLI and the Management Defendants. Despite this knowledge, these Defendants made numerous deceptive, false and misleading public statements that JUUL was intended to be a cessation device.

239. JUUL is not a product adults typically use to quit smoking. Researchers have found that as of 2018, only 7.9% of American adults had ever used USB shaped e-cigarette devices, like JUUL, and only 2% of adults currently used them.<sup>246</sup> By contrast, a recent study found that 15- to 17-year-olds are *sixteen times* more likely to use JUUL products than 25 to 34-year-olds.<sup>247</sup>

240. JLI’s own marketing research indicated that JUUL was not appropriate as a cessation device for adults. In 2014, JLI when it was called Ploom hired the consumer research firm Tragon to do research with prototypes of the JUUL e-cigarette. On September 30, 2014, Lauren Collinsworth, a consumer researcher at Tragon, e-mailed Chelsea Kania, a marketing employee at Ploom, with some of the preliminary results from the studies. She stated that the testing showed that “the younger group is open to trying something new and liked J1 [the JUUL prototype] for being smart, new, techy, etc.”<sup>248</sup> Ms. Collinsworth added that “The qualitative findings suggested *this product isn’t going to fit as well with consumers who are looking to cut*

<sup>246</sup> Kristy L. Marynak et al., *Use and Reasons for Use of Electronic Vapour Products Shaped like USB Flash Drivers Among a National Sample of Adults*, 28 TOBACCO CONTROL 685 (Nov. 2019), <https://tobaccocontrol.bmj.com/content/28/6/685>.


<sup>247</sup> D.M. Vallone et al., *Prevalence and Correlates of JLI Use Among a National Sample of Youth and Young Adults*, TOBACCO CONTROL (Oct. 29, 2018), <http://dx.doi.org/10.1136/tobaccocontrol-2018-054693>.

<sup>248</sup> JLI00365905.



back on the cigarette intake.”<sup>249</sup> On October 1, 2014, Ms. Collinsworth followed up with additional comments. She stated that “[t]he delivery was almost too much for some smokers, especially those used to regular e-cigarettes.”<sup>250</sup> The final results from this consumer research were distributed to upper management, including to then-CEO James Monsees<sup>251</sup> and then-Chief Marketing Officer Richard Mumby.<sup>252</sup>

241. The deceptive, misleading and fraudulent nature of the “*Make the Switch*” campaign is evident when comparing the campaign’s advertisements to JUUL’s initial advertising, as demonstrated below. The fact that these advertisements are for the same product confirms that, notwithstanding the advice JLI and the Altria Defendants received from their media consultants, the Defendants never intended to target only adult smokers.



<sup>249</sup> *Id.* (emphasis added).


<sup>250</sup> JLI00365709.

<sup>251</sup> JLI00364678.

<sup>252</sup> JLI00364487.



And



242. Defendants ensured that JUUL was the *opposite* of a “tool[] to reduce or eliminate” nicotine consumption. According to the National Institutes of Health, the “amount and speed of nicotine delivery . . . plays a critical role in the potential for abuse of tobacco products.”<sup>253</sup> As described above, JLI and Bowen designed the JUUL product to deliver nicotine in larger amounts and at a faster rate than even cigarettes, and then knowingly misled the public about those facts.

243. The *Switch* campaign also does not disclose or warn about the risks of using

<sup>253</sup> U.S. Dep’t of Health & Human Servs., *Nicotine Addiction: Past and Present, How Tobacco Smoke Causes Disease* (2010), <https://www.ncbi.nlm.nih.gov/books/NBK53018/#ch4.s92>.

multiple tobacco products, “dual use” or that the JUUL is not a smoking cessation product. In addition to the heightened risks of addiction that multiple tobacco product use poses, one recent study found that persons who use e-cigarettes and smoke have blood toxin levels far higher than one would expect given the blood toxin levels that e-cigarettes and cigarettes generate individually.<sup>254</sup>

244. The FDA and other government regulators, enforcing existing laws addressing e-cigarettes,<sup>255</sup> publicly criticized the “*Make the Switch*” campaign and other efforts by Defendants to depict JUUL as a smoking cessation device. Section 911(b)(2)(A)(i) of the Federal Food, Drug, and Cosmetics Act (FDCA) (21 U.S.C. § 387k(b)(2)(A)(i)) states that when advertising or labeling of a cigarette product directly or indirectly suggests that the product has a lower risk of cigarette-related disease, is less harmful than traditional cigarettes, or is otherwise ‘safer’ than traditional cigarettes, then the product becomes a “modified risk tobacco product.”<sup>256</sup>

245. In late 2019, and in response to the House of Representatives hearings in which JLI executives testified, the FDA issued two warning letters to JLI detailing its concern that JLI was unlawfully marketing its e-cigarette products as cessation tools or as “modified risk tobacco products” within the meaning of the FDCA.<sup>257</sup>

246. Then, in its September 9, 2019 letter to JLI, the FDA notified JLI that its advertising slogans such as “99% safer,” “much safer,” and “a safer alternative” than cigarettes was “particularly concerning because [those] statements were made directly to children in

---

<sup>254</sup> Julie B. Wang et al., *Cigarette and E-Cigarette Dual use and Risk of Cardiopulmonary Symptoms in the Health eHeart Study*, 13 PLoS ONE 1 (2018).

<sup>255</sup> Section 911(b)(2)(A)(i) of the FDCA (21 U.S.C. § 387k(b)(2)(A)(i)) states that when advertising or labeling of a cigarette product directly or indirectly suggests that the product has a lower risk of cigarette-related disease, is less harmful than traditional cigarettes, or is otherwise ‘safer’ than traditional cigarettes, then the product becomes a “modified risk tobacco product.”

<sup>256</sup> *Id.*

<sup>257</sup> Letter from U.S. Food and Drug Admin. to Kevin Burns, CEO of JUUL Labs, Inc., (Sept. 9, 2019), <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/juul-labs-inc-590950-09092019>.

1 school.”<sup>258</sup> The FDA concluded that in using advertising language that e-cigarettes were safer  
 2 than cigarettes, JLI had violated Sections 902(8) and 911 by marketing JUUL products as  
 3 “modified risk tobacco products” without prior approval.<sup>259</sup>

4 247. The September 9, 2019 letter also detailed the FDA’s concerns with JLI’s  
 5 “Switch” marketing campaign. “[T]roubled by recent testimony” that JLI had given to the  
 6 House Subcommittee on Economic and Consumer Policy of the Committee on Oversight and  
 7 Reform, the FDA noted that JLI’s *Switch* advertising campaign “may also convey that switching  
 8 to JUUL is a safer alternative to cigarettes.”<sup>260</sup>

9 248. The FDA specifically highlighted the *Switch* campaign slogans which referenced  
 10 smoking cigarettes, or attempts to quit smoking, followed by “*Make the Switch.*” The FDA  
 11 stated that JLI’s campaign was in violation of multiple FDA regulations and the FDCA  
 12 subsections, and that JLI’s *Switch* campaign purported to tell the public that using e-cigarettes  
 13 was an alternative to smoking, or a possible cessation tool.<sup>261</sup>

14 249. On the same day, the FDA requested that JLI provide all documents related to its  
 15 decision to market the Switch campaign to the Cheyenne River Sioux Tribe, in light of the  
 16 testimony by JLI that it had taken a “public health” approach to Native American tribes, and had  
 17 sought healthcare professionals to refer Native American smokers to JLI’s Switching  
 18 Program.<sup>262</sup>

19 250. Perhaps unsurprisingly, the *Make the Switch* campaign was spearheaded by a  
 20 marketing firm with long-standing ties to the cigarette industry. In particular, it was led by a  
 21 subsidiary of Omnicom Group, Inc., one of the “Big Four” advertising holding companies  
 22 dominating marketing and communications worldwide since the 1990s, second only to WPP.  
 23 Omnicom is the parent company of Mercury Public Affairs which, by at least April 2018,

---

25 <sup>258</sup> *Id.*

26 <sup>259</sup> *Id.*

27 <sup>260</sup> Letter from U.S. Food and Drug Admin. Ctr. for Tobacco Prods. to JUUL Labs, Inc. (Sept.  
 28 9, 2019), <https://www.fda.gov/media/130859/download>.

<sup>261</sup> *Id.*

<sup>262</sup> *Id.*

counted both Altria and JLI as its clients. Mercury lobbied for Altria on tobacco regulations,<sup>263</sup> and helped JLI push back against negative press coverage of youth usage of its products.<sup>264</sup>

251. For example, on April 2, 2018, a managing director from Mercury, Erick Mullen, emailed Defendant Valani and Daniel Cruise, Chief Public Affairs Officer at JLI, with a numbered list of actions in response to *The New York Times* article published that day, “‘I Can’t Stop’: Schools Struggle With Vaping Explosion.”<sup>265</sup> Mercury’s list includes the recommendation to push the idea that JLI’s nicotine formulation is no more harmful than water, sugar, and caffeine: “Engage the press on all the definitions in every fucking story: it’s not a ‘cigarette’ of any kind; there’s no smoke and nothing medical science has on the books says water and nicotine is more harmful than water, sugar and caffeine.”<sup>266</sup>

252. Defendant Valani and Cruise each separately forwarded the email to JLI CEO Kevin Burns, with Cruise commenting, “Kevin, recent email from friend Erick—a possible ‘campaign manager’” for us. His argument is in line with yours. We need to be systematic, aggressive and relentless. Btw we are not tobacco—have [you] corrected today’s NYT story?”<sup>267</sup>

253. In August 2018, Omnicom agency DDB Chicago<sup>268</sup> sent JLI a proposal for an estimated \$11 million campaign “to more firmly establish the true intent of the company,” noting that JLI was “moving *very* fast.”<sup>269</sup> This campaign was “*Make the Switch.*”

<sup>263</sup> Kevin McCauley, *Altria Taps Mercury For Tobacco Regulation Work*, O’DWYER’S (Jun. 4, 2018), <https://www.odwyerpr.com/story/public/10754/2018-06-04/altria-taps-mercury-for-tobacco-regulation-work.html>.

<sup>264</sup> See, e.g., INREJUUL\_00262168; INREJUUL\_00262226-INREJUUL\_00262227.

<sup>265</sup> See INREJUUL\_00262168; see also Kate Zernike, *‘I Can’t Stop’: Schools Struggle With Vaping Explosion*, N.Y. Times (Apr. 2, 2018), <https://www.nytimes.com/2018/04/02/health/vaping-ecigarettes-addiction-teen.html>.

<sup>266</sup> INREJUUL\_00262168.

<sup>267</sup> INREJUUL\_00262226-227.

<sup>268</sup> See INREJUUL\_00066530-539 (Other Omnicom entities were involved in this campaign. For example, OMD, “sister company to DDB and part of the Omnicom Group,” sent JLI detailed Statements of Work for a U.S. Brand Campaign covering September 16, 2018 through February 28, 2019).

<sup>269</sup> See INREJUUL\_00074841; see also INREJUUL\_00074842-844 at 842.



**5. JLI, Altria, and Others in the E-Cigarette Industry Coordinated with Third-Party Groups to Mislead the Public About the Harms and Benefits of E-Cigarettes.**

254. Through a collective and parallel effort of funding, leadership, and board membership, JLI, the Altria Defendants and others in the e-cigarette industry leveraged third-parties, ranging from industry-funded non-governmental organizations to online blogs more accessible to youth, to mislead the public about the impacts of consuming e-cigarettes.

255. An assortment of lobbyists, trade associations, and online publications have coordinated with the e-cigarette industry, including JLI and the Altria Defendants, to promote a consistent message that consuming e-cigarettes is not harmful, that nicotine is not harmful, and that the impacts of e-cigarettes are greatly exaggerated. These organizations receive funding from the e-cigarette industry, feature executives on those companies's boards of directors, and in return, promote industry products, industry views, or fund "independent" studies of their own that reach the same conclusions as e-cigarette industry-funded research.

**a. The American Vaping Association**

256. The American Vaping Association ("AVA") is a pro-e-cigarette lobby group founded by Greg Conley, who notably publishes articles criticizing the CDC for its stance on restricting e-cigarette use.<sup>270</sup> Other executive members of the AVA possess business interests in e-cigarettes; for example, Treasurer David J. Danzak Jr. is associated with an e-cigarette business called Vapornine LLC.<sup>271</sup> Vice-President Antoinette Lanza is an owner of an exclusively e-cigarette shop in Hoboken, New Jersey called Smokeless Image.<sup>272</sup> Half of the AVA's functional expenses are for lobbying efforts.<sup>273</sup> It lists several sponsors, all of which are

<sup>270</sup> Jeff Stier & George Conley, *The War on E-Cigarettes*, NATIONAL REVIEW (Sept. 19, 2011), <https://www.nationalreview.com/2011/09/war-e-cigarettes-jeff-stier-gregory-conley/>.

<sup>271</sup> Vapornine LLC, BUZZFILE, <http://www.buzzfile.com/business/Vapornine-LLC-904-372-3244> (business information page).

<sup>272</sup> Stacy Jones, *Tobacco Regulators Mull More Oversight as E-cigarettes See Increased Popularity*, NJ.com (Mar. 30, 2019), [https://www.nj.com/business/2013/07/tobacco\\_regulators\\_mull\\_more\\_o.html](https://www.nj.com/business/2013/07/tobacco_regulators_mull_more_o.html).

<sup>273</sup> Form 990, American Vaping Association Inc.'s Return of Organization Exempt from Income Tax (2018), [https://apps.irs.gov/pub/epostcard/cor/464203951\\_201812\\_990O\\_2019122716980021.pdf](https://apps.irs.gov/pub/epostcard/cor/464203951_201812_990O_2019122716980021.pdf).

1 e-cigarette, e-liquid, or cigarette companies.<sup>274</sup>

2 257. Conley has a prolific social media presence and frequently appears on television  
3 and radio to tout the benefits of consuming e-cigarettes and dispute negative news. The AVA  
4 website lists “studies” which are uniformly authored by noted industry-funded or industry-  
5 friendly authors, such as Polosa and Shahab.<sup>275</sup> AVA lists CASAA, Not Blowing Smoke, and  
6 the VTA, all established fronts for the e-cigarette industry, as “Resources.”

7 258. The AVA receives its funding from sponsors, who are organized into tiers such  
8 as Platinum, Gold, Silver, Bronze, and Green.<sup>276</sup> Current advertised sponsors include e-cigarette  
9 distributors and retailers such as E-Cigarette Empire, and VaporBeast.<sup>277</sup> Prior sponsors are a  
10 who’s who of e-cigarette retailers. In 2016, Platinum sponsors included AltSmoke and Vapor  
11 Kings, while Gold sponsors included the now defunct Smokeless Image.<sup>278</sup>

12 259. On social media, the AVA regularly downplays the risks of consuming e-  
13 cigarettes, criticizes negative coverage as myths or exaggerations, and lauds efforts to curb any  
14 regulation of the e-cigarette industry.<sup>279</sup>

15 260. JLI actively sought out the AVA to promote JUUL. In January 2016, e-mails  
16 between employees at JLI (then known as PAX) discussed a “list of thought leaders [JLI] can  
17 tap for stories for JUUL” which included Conley at the AVA and Satel.<sup>280</sup>

18 261. In 2018, JLI took advantage of its coordinated efforts with the AVA to downplay  
19 the risks associated with JUUL. In an e-mail exchange between Christine Castro of JLI and a  
20 “Stratcomms” internal mailing list, Castro lamented a “testy conversation” with a USA Today  
21 reporter who pointed out that JLI’s marketing and advertising appeared to feature and target  
22  
23

24 <sup>274</sup> AVA Sponsors, American Vaping Association, <https://vaping.org/about-us/ava-sponsors/>.

25 <sup>275</sup> Research Reports, American Vaping Association, <https://vaping.org/research-report/>.

26 <sup>276</sup> AVA Sponsors, American Vaping Association, <https://vaping.org/about-us/ava-sponsors/>.

27 <sup>277</sup> *Id.*

28 <sup>278</sup> AVA Sponsors, American Vaping Association, Wayback Machine – Internet Archive (Aug. 14, 2017), <https://web.archive.org/web/20170814221226/http://vaping.org/about-us/ava-sponsors/>.

<sup>279</sup> American Vaping Association (@AVABoard), Twitter, <https://twitter.com/AVABoard>.

<sup>280</sup> INREJUUL\_00278889.



minors and teenagers.<sup>281</sup> Castro noted that “I hit back at [the reporter] very aggressively but we can expect the usual B.S. Greg Conley is being allowed to write a 300-word rebuttal. I will email him and copy you Ashley [JLI employee] just so we can stay coordinated.”<sup>282</sup>

262. The AVA also coordinated with JLI on pro-e-cigarette research. In March 2018, Conley facilitated a conversation between Dr. Konstantinos Farsalinos, a researcher at the University of Patras, Greece, who regularly publishes e-cigarette industry-friendly articles, and Gal Cohen, then Director of Scientific Affairs at JLI.<sup>283</sup> In the e-mail, Conley asks Farsalinos to send Cohen “some info on your flavor study” to which Farsalinos responds by sending Conley and Cohen an attachment: “USA FLAVORS SURVEY.pptx” and the note: “[A]ttached is a powerpoint presentation about the study we proposed.”<sup>284</sup>

263. The proposed study was a survey aimed at determining what flavors different demographic groups preferred as e-cigarette flavors, which flavors they use frequently, and which flavors they used when they first started consuming e-cigarettes. While the study was purportedly to determine the impact of e-cigarette flavors on e-cigarette and smoking behavior, the data obtained from such a study would have allowed JLI to understand which flavors were not only the most popular, but which flavors were most popular by demographic.<sup>285</sup>

#### **b. Vaping360**

264. Vaping360 is a website dedicated to news regarding the e-cigarette industry. The website boasts “40 million smokers and vaping enthusiasts reached since 2015.” This entity has a big social media presence and huge publication strategy.

265. Vaping360’s main message misleads the public about the health impacts of consuming e-cigarettes. Vaping360 has published various articles, including “10 Lies and

---

<sup>281</sup> See INREJUUL\_00173252 (Apr. 4, 2018 email).

<sup>282</sup> *Id.*

<sup>283</sup> Juul Labs, Inc., *JUUL Labs Presents Findings at the Global Forum on Nicotine 2018*, Cision PR Newswire (June 15, 2018), <https://www.prnewswire.com/news-releases/juul-labs-presents-findings-at-the-global-forum-on-nicotine-2018-300666743.html>.

<sup>284</sup> INREJUUL\_0034128.

<sup>285</sup> *Id.*

1 Myths About Juuling Exposed.”<sup>286</sup> This article, published in May 9, 2018, claimed, among other  
 2 things, that JUUL was not as dangerous as smoking; JUUL did not cause cancer or “popcorn  
 3 lung”; JUUL was not popular among teenagers, nor did JLI sell kid-friendly flavors or flavors  
 4 aimed to entice young people; and the nicotine in JUUL is “a relatively mild drug, [and] may  
 5 cause dependence.”<sup>287</sup>

6 266. Vaping360 regularly published articles praising, promoting, or downplaying the  
 7 risks of JUUL, including, among others: “These Scientists Want to Kill Smokers’ Hope (For  
 8 Vaping)”; “UK Scientists to WHO: Your Vape Report Is Junk”; “One Free Pack JUUL Coupon  
 9 Codes 2019”; and an article disparaging anti-smoking advocacy group Truth Initiative by  
 10 claiming that “Truth Initiative Promo Encourages Risky Teen Behavior.”<sup>288</sup>

11 267. One of the main writers at Vaping360 is Jim McDonald who aggressively attacks  
 12 any negative science as fake news. For example, McDonald frequently posts on social media  
 13 platforms, including on Facebook and Twitter, but also comments on others posts extensively  
 14 disputing negative news about consuming e-cigarettes.<sup>289</sup>

15 268. Vaping360 has taken funding from e-cigarette manufacturers, and in return  
 16 coordinates with e-cigarette manufacturers to promote their products, while publishing  
 17 favorable content. Vaping360 was paid by JLI for advertising, and was given kickbacks  
 18 (referred to as commission) for every coupon used for JUUL that originated from Vaping 360’s  
 19 website.

20 269. In March 2017, JLI (then PAX) communicated with Chris Kendell and others at  
 21 Vaping360 to discuss promoting JLI’s products with a 15% discount coupon on Vaping360’s  
 22

---

23 <sup>286</sup> Jim McDonald, *10 Lies and Myths About Juuling Exposed*, Vaping 360 (May 9, 2018),  
 24 <https://vaping360.com/lifestyle/juuling/>.

<sup>287</sup> *Id.*

25 <sup>288</sup> Jim McDonald, *Truth Initiative Promo Encourages Risky Teen Behavior*, Vaping 360 (Jan.  
 26 9, 2020), <https://vaping360.com/vape-news/87705/truth-initiative-promo-encourages-risky-teen-behavior/>.

27 <sup>289</sup> Jim McDonald, *Mass. Senate Passes Worst Vaping Law in the Countr*, Vaping 360 (Nov.  
 28 21, 2019), <https://vaping360.com/vape-news/86852/mass-senate-passes-worst-vaping-law-in-the-country/>; Jim McDonald, *Meet the Rich Moms Who Want to Ban Vaping*, Vaping 360 (Oct. 8, 2018), <https://vaping360.com/vape-news/71696/meet-the-rich-moms-who-want-to-ban-vaping/>.

website.<sup>290</sup> JLI representative Andy Martin also noted that JLI “figured out the commission issue,” and expressed excitement at JLI’s new mango flavor JUUL pod.<sup>291</sup> They also discussed a Facebook advertising link whereby Vaping360 could offer similar discounts for JLI products on social media.<sup>292</sup>

270. In November 2017, Martin of JLI and Rawad Nassif of Vaping360 discussed a meeting agenda, with topics such as “new affiliate commission terms,” “JLI funnelling [sic] project,” and “exploring further opportunities.”<sup>293</sup>

271. In 2018, McDonald continued to write articles specifically praising JLI, such as “Coming Soon: A JUUL to Help You Quit JUULing” and “10 Lies and Myths About JUULing Exposed.”<sup>294</sup> As of 2020, Vaping360 continues to offer discounts for JUUL products.<sup>295</sup>

### c. Foundation for a Smoke-Free World

272. The Foundation was founded in 2017, and presents itself as a public health organization, purportedly “advancing global progress in smoking cessation and harm reduction.”<sup>296</sup> It is funded entirely by Philip Morris International, which in 2017 announced a \$1 billion commitment to fund the Foundation.<sup>297</sup> The Foundation’s 2018 Form 990 lists only one donor: PMI Global Services, Inc., or Philip Morris International, with a contribution of \$80 million.<sup>298</sup>

273. The Foundation is headed by Derek Yach, a noted advocate and promoter of e-

---

<sup>290</sup> INREJUUL\_00143870.

<sup>291</sup> *Id.*

<sup>292</sup> *Id.*

<sup>293</sup> INREJUUL\_00139196.

<sup>294</sup> Jim McDonald, *Coming Soon: A JUUL to Help You Quit Juuling*, Vaping 360 (Sept. 7, 2018), <https://vaping360.com/vape-news/70262/coming-soon-a-juul-to-help-you-quit-juuling/>.

<sup>295</sup> [One FREE Pack] JUUL Coupon Codes 2019, Vaping 360 (Aug. 24, 2018), <https://vaping360.com/vape-coupons/juul-coupon-promo-code/>.

<sup>296</sup> Foundation for a Smoke-Free World (2020), <https://www.smokefreeworld.org/>.

<sup>297</sup> David Meyer, *Philip Morris Pledges Almost \$1 Billion to Anti-Smoking Fight*, FORTUNE (Sept. 13, 2017), <https://www.webcitation.org/6tjyBv4dA>.

<sup>298</sup> Return of Private Foundation, Foundation for a Smoke-Free World (2018), [https://web.archive.org/web/20190828104138/https://www.smokefreeworld.org/sites/default/files/uploads/documents/fsfw\\_2018\\_form\\_990-pf\\_public\\_inspection.pdf](https://web.archive.org/web/20190828104138/https://www.smokefreeworld.org/sites/default/files/uploads/documents/fsfw_2018_form_990-pf_public_inspection.pdf).

cigarettes and consuming e-cigarettes.<sup>299</sup>

274. In 2018, the Foundation announced that it would support Centers of Excellence to conduct tobacco control research.<sup>300</sup> This tactic is a well-known tool of the cigarette industry, which has a history of funding “research” centers to promote industry-friendly views, such as the Center for Indoor Air Research, which promulgated industry-funded studies that sowed doubt about the addictiveness of nicotine, claimed that indoor air quality was unaffected by cigarette smoke and downplayed the harms of cigarettes broadly. Institutes such as the Center for Indoor Air Research were forced to dissolve as part of the Master Settlement Agreement in 1998.

275. A 2017 report in The Verge detailed the e-cigarette industry’s apparently coordinated efforts to use biased research to downplay the risks of consuming e-cigarettes.<sup>301</sup> For example, e-cigarette manufacturers routinely conduct studies focusing on the “good news” about e-cigarettes, *i.e.* they release less harmful aerosolized chemicals than combustible cigarettes, or that their aerosol lingers for less time indoors than combustible cigarettes.<sup>302</sup> Industry-funded authors then regularly cite to each other’s studies in their own research.<sup>303</sup> On

---

<sup>299</sup> Derek Yach: *Anti-smoking Advocates Should Embrace E-cigarettes*, NATIONAL POST (Aug. 26, 2015), <https://nationalpost.com/opinion/derek-yach-anti-smoking-advocates-should-embrace-e-cigarettes>.

<sup>300</sup> Support Global Research, Foundation for a Smoke-Free World (May 31, 2018), <https://web.archive.org/web/20180531105105/https://www.smokefreeworld.org/our-areas-focus/support-global-research>.

<sup>301</sup> Liza Gross, *Vaping Companies are Using the Same Old Tricks as Big Tobacco*, THE VERGE (Nov. 16, 2017), <https://www.theverge.com/2017/11/16/16658358/vape-lobby-vaping-health-risks-nicotine-big-tobacco-marketing>.

<sup>302</sup> See, e.g., J. Margham, et al., *Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke*, 29 CHEM. RES. TOXICOL. 1662 (2016); Tanvir Walele et al., *Evaluation of the Safety Profile of an Electronic Vapour Product Used for Two Years by Smokers in a Real-life Setting*, 92 REG. TOXICOL. PHARMACOL. 226 (2018); D. Martuzevicius, et al., *Characterization of the Spatial and Temporal Dispersion Differences Between Exhaled E-Cigarette Mist and Cigarette Smoke*, 21 NICOTINE & TOBACCO RES. 1371 (2019).

<sup>303</sup> See, e.g., Gene Gillman et al., *Determining the Impact of Flavored E-liquids on Aldehyde Production During Vaping*, 112 REG. TOXICOL. PHARMACOL. 1 (2020); Colin Mendelsohn & Alex Wodak, *Legalising Vaping in Australia*, The McKell Institute (March 2019), <https://pdfs.semanticscholar.org/3e13/8e46419913a29f8fc9ddad52ec771f73fa76.pdf>; Violeta Kaunelienė et al., *Impact of Using a Tobacco Heating System (THS) on Indoor Air Quality in a Nightclub*, 19 AEROSOL AND AIR QUAL. RES. 1961 (2019); Maya Mitova et al., *Human*

information and belief, JLI and Altria, among others in the e-cigarette industry, funnel their industry-funded studies to friendly pro-industry groups knowing that those entities will misrepresent the results as evidence that e-cigarettes are safe, or not harmful.

**d. Vapor Technology Association**

276. The Vapor Technology Association (VTA) bills itself as a trade association and advocates for the e-cigarette industry. It was founded in January 2016, with the banner tagline on its website reading “VAPE IS HOPE.”<sup>304</sup>

277. In 2018, JLI, SMOK, VMR, Turning Point Brands, and Joyetech were all featured as “Platinum Members,” a level of membership that required a \$100,000 annual contribution. Thus, JLI paid VTA \$100,000 in 2018 to become a Platinum Member, and in return, VTA offered JLI a board seat; invitations to lobbying strategy meetings; access to the FDA, other federal agencies, and members of Congress; and conference participation.<sup>305</sup>

278. The VTA, like other lobbying and trade association groups in the industry, advocates for less regulation of e-cigarettes, and testifies in opposition to flavor bans.<sup>306</sup>

**e. Retailer Lobbying**

279. Retailers have also taken to creating subsidiaries or wholly owned companies whose purpose is to produce quasi-journalistic content to promote consuming e-cigarettes, discredit health initiatives, and suggest that consuming e-cigarettes has no harmful health impacts. The best example of this is the website SoupWire, which publishes articles and editorials that promote consuming e-cigarettes and criticizes studies that look at the negative impacts of consuming e-cigarettes.<sup>307</sup> For example, when JLI donated \$7.5 million towards a study on the impacts of consuming e-cigarettes on teens, a SoupWire report concluded that the

---

*Chemical Signature: Investigation on the Influence of Human Presence and Selected Activities on Concentrations of Airborne Constituents*, 257 ENV'TL POLLUTION 1 (2020).

<sup>304</sup> Vape is Hope, Vapor Technology Association (Feb. 25, 2016), <https://web.archive.org/web/20160225154600/http://www.vaportechnology.org:80/>.

<sup>305</sup> Some of Our Members, Vapor Technology Association (Nov. 28, 2018), <https://web.archive.org/web/20181128162940/https://vaportechnology.org/membership/>.

<sup>306</sup> Vapor Technology Association, <https://vaportechnology.org/>.

<sup>307</sup> Soupwire – The Truth About Vaping, <https://soupwire.com/>.

study will likely find “nothing Earth-shattering.”<sup>308</sup>

**6. Altria Falsely Stated That It Intended to Use Its Expertise in “Underage Prevention” Issues to JLI**

280. Altria’s announcement that it intended to invest in JLI came less than two months after it told the FDA that Altria “believe[s] that pod-based products significantly contribute to the rise in youth use of e-vapor products” and that it accordingly would be removing its own pod-based products from the market.<sup>309</sup> Altria made the same representations to its investors.<sup>310</sup>

281. Although Altria claimed its investment in JLI had an altruistic motive—“ When you add to JUUL’s already substantial capabilities, our underage tobacco prevention expertise and ability to directly connect with adult smokers, we see a compelling future with long-term benefits for both adult tobacco consumers and our shareholders,” Altria recently confirmed that JLI has not even availed itself of that experience.<sup>311</sup> In Altria’s October 2019 letter to Senator Richard Durbin, Altria CEO Howard Willard acknowledged that while Altria “offered to JUUL services relating to underage prevention efforts,” to date “JUUL has not accepted Altria’s offers of assistance in addressing underage vaping relating issues.”<sup>312</sup> Willard has stated that the deal would allow Altria to “work[] with JUUL to accelerate its mission.”<sup>313</sup> but as Altria knew, as reflected in its letter to the FDA just two months prior, that mission involved had resulted in

<sup>308</sup> Jeff Hawkins, *JUUL Donates \$7.5 Million to Teen Vaping Study*, Soupwire – The Truth About Vaping (July 2, 2019), <https://soupwire.com/juul-donates-7-5-million-to-teen-vaping-study/>.

<sup>309</sup> Letter from Howard A. Willard III, Altria, to Dr. Scott Gottlieb, FDA, 2 (October 25, 2018)

<sup>310</sup> Altria Group Inc (MO) Q3 2018 Earnings Conference Call Transcript, (October 25, 2018) <https://www.fool.com/earnings/call-transcripts/2018/10/25/altria-group-inc-mo-q3-2018-earnings-conference-ca.aspx>.

<sup>311</sup> Altria Group (MO) Q4 2018 Earnings Conference Call Transcript: MO earnings call for the period ending December 31, 2018. (Jan. 31, 2019), <https://www.fool.com/earnings/call-transcripts/2019/02/01/altria-group-mo-q4-2018-earnings-conference-call-t.aspx>.

<sup>312</sup> Letter from Howard A. Willard III to Senator Richard J. Durbin (October 14, 2019) (emphasis added).

<sup>313</sup> Altria Makes \$12.8 Billion Minority Investment in JUUL to Accelerate Harm Reduction and Drive Growth, Business Wire (Dec. 20, 2018, 7:00 AM EST), <https://www.businesswire.com/news/home/20181220005318/en/Altria-12.8-Billion-Minority-Investment-JUUL-Accelerate>.



usage throughout the youth market. Altria's admission that pod-based products contributed to underage use show that Altria knew its investment in JLI would "strengthen[] its financial profile and enhance[] future growth prospects" specifically because JLI dominated the youth market for e-cigarettes.<sup>314</sup>

282. Altria recognized that JLI's market share dominance in the e-cigarette market, a share that it knew was gained via youth targeting and false and misleading advertising, was the path to Altria's continued viability and profitability. In a January 31, 2019 earnings call, Altria explained that "[w]hen you add to JUUL's already substantial capabilities, our underage tobacco prevention expertise and ability to directly connect with adult smokers, we see a compelling future with long-term benefits for both adult tobacco consumers and our shareholders. We are excited about JUUL's domestic growth and international prospects and their potential impact on our investment."<sup>315</sup> JUUL's growth was, as Altria well knew, due to the product's viral popularity among teens. Willard briefly acknowledged the youth vaping crisis, stating, "Briefly touching on the regulatory environment, the FDA and many others are concerned about an epidemic of youth e-vapor usage. We share those concerns. This is an issue that we and others in the industry must continue to address aggressively and promptly."<sup>316</sup>

283. Altria's representations that it intended to help JUUL curb the prevalence of underage use was false and misleading. As discussed below, Altria coordinated with JUUL to capture and maintain the youth market.

#### **E. Defendants Targeted the Youth Market**

284. Having created a product, like combustible cigarettes, that sought to get users addicted to nicotine, and while taking steps to ensure that consumers and regulators did not appreciate the true nicotine content or potential harm from using JUULs, to successfully sink

<sup>314</sup> Press Release, *Altria Makes \$12.8 Billion Minority Investment In Juul To Accelerate Harm Reduction And Drive Growth*, Altria (Dec. 20, 2018), <https://www.sec.gov/Archives/edgar/data/764180/000119312518353970/d660871dex991.htm>.

<sup>315</sup> Altria Group (MO) Q4 2018 Earnings Conference Call Transcript: MO earnings call for the period ending December 31, 2018 (Jan. 31, 2019), <https://www.fool.com/earnings/call-transcripts/2019/02/01/altria-group-mo-q4-2018-earnings-conference-call-t.aspx>.

<sup>316</sup> *Id.*



1 their high-tech nicotine hook into American consumers, JLI, Bowen, and Monsees needed  
 2 investors willing to adopt the tactics of the cigarette industry as their own. They found those  
 3 investors in Pritzker, Huh, and Valani.

4 285. Under the leadership of the Management Defendants, JLI marketed nicotine to  
 5 kids. JLI and the Management Defendants deployed a sophisticated viral marketing campaign  
 6 that strategically laced social media with false and misleading messages to ensure their uptake  
 7 and distribution among young consumers. JLI and the Management Defendants' campaign was  
 8 wildly successful—burying their hook into kids and initiating a public health crisis.

9 **1. JLI Emulated the Marketing of Cigarette Companies.**

10 286. As Defendants know, nearly 9 out of 10 smokers start smoking by age 18, and  
 11 more than 80% of underage smokers choose brands from among the top three most heavily  
 12 advertised.<sup>317</sup> The overwhelming consensus from public health authorities, independent studies,  
 13 and credible expert witnesses is that “marketing is a substantial contributing factor to youth  
 14 smoking initiation.”<sup>318</sup>

15 287. Struggling to define their own identities, teenagers are particularly vulnerable to  
 16 image-heavy advertisements that psychologically cue them on the “right” way to look and  
 17 behave amongst peers.<sup>319</sup> Advertisements that map onto adolescent aspirations and  
 18 vulnerabilities drive adolescent tobacco product initiation.<sup>320</sup>

19 288. For decades, cigarette companies spun smoking as signifier of adulthood. This  
 20 turned smoking into a way for teenagers to project independence and enhance their image  
 21 among their peers.<sup>321</sup>

22 289. Youth marketing was critical to the success of cigarette companies. In the 1950s,  
 23 Philip Morris—now JUUL's corporate affiliate—intentionally marketed cigarettes to young  
 24

---

25 <sup>317</sup> U.S. Dep't Health & Human Servs., *Preventing Tobacco Use Among Youths*, Surgeon  
 26 General Fact Sheet, [https://www.hhs.gov/surgeongeneral/reports-and-](https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/preventing-youth-tobacco-use-factsheet/index.html)  
 27 [publications/tobacco/preventing-youth-tobacco-use-factsheet/index.html](https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/preventing-youth-tobacco-use-factsheet/index.html).

28 <sup>318</sup> *United States v. Philip Morris*, 449 F. Supp. 2d 1, 570 (D.D.C. 2006) (J. Kessler).

<sup>319</sup> *Id.* at 578.

<sup>320</sup> *Id.* at 570, 590.

<sup>321</sup> *Id.* at 1072.

1 people as a pool from which to “replace smokers” to ensure the economic future of the cigarette  
2 industry.<sup>322</sup>

3 290. Philip Morris’s documents set out their youth strategy, explaining: “Today’s  
4 teenager is tomorrow’s potential regular customer, and the overwhelming majority of smokers  
5 first begin to smoke while still in their teens”.<sup>323</sup>

6 291. It wasn’t just Philip Morris. The strategy of hooking kids was an open secret in  
7 the cigarette industry.<sup>324</sup>

8 292. As detailed below, JLI and the Management Defendants sought to emulate this  
9 approach. Indeed, Monsees admitted to using historical cigarette ads to inform JLI’s own  
10 advertising campaign.<sup>325</sup>

11 293. The emulation is obvious. A side-by-side comparison of JUUL advertisements  
12 with historical cigarette advertisements reveals the appropriated pattern of focusing on imagery  
13 related to attractiveness, stylishness, sex appeal, fun, “belonging,” relaxation, and sensory  
14 pleasure, including taste.<sup>326</sup>

---




21 <sup>322</sup> *United States. v. Philip Morris*, No. 99- 2496 (D.D.C. Aug. 17, 2006), ECF No. 5750 at 972  
(Amended Final Opinion).

22 <sup>323</sup> *Tobacco Company Quotes on Marketing to Kids*, Campaign for Tobacco-Free Kids (May  
14, 2001), <https://www.tobaccofreekids.org/assets/factsheets/0114.pdf>.

23 <sup>324</sup> C.A. Tucker, *Marketing Plans Presentation to RJRI B of D* at 2, U.C.S.F. Truth Tobacco  
24 Industry Documents (Sept. 30, 1974),  
<https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=ympmw0091> (RJ Reynolds  
25 executive explaining that the “young adult . . . market . . . represent[s] tomorrow’s cigarette  
business. As this 14-24 age group matures, they will account for a key share of the total  
cigarette volume—for at least the next 25 years.”).

26 <sup>325</sup> Matthew Perone & Richard Lardner, *Juul exec: Never intended electronic cigarette for*  
27 *teens*, AP News (July 26, 2019), <https://apnews.com/4b615e5fc9a042498c619d674ed0dc33>;  
28 Gabriel Montoya, *Pax Labs: Origins with James Monsees*, Social Underground,  
<https://socialunderground.com/2015/01/pax-ploom-origins-future-james-monsees> (last visited  
Apr. 3, 2020).

<sup>326</sup> See Appendix B, Ads 9-50.



294. JLI and the Management Defendants deployed this same strategy, but adapted it to modern advertising tactics.

## 2. The Management Defendants Intentionally Marketed JUUL to Young People.

295. The risk that children would use a new e-cigarette product was well known and well publicized in the months leading up to the launch of the JUUL e-cigarette. For example, in

1 April 2015, the CDC published the results from its 2014 National Youth Tobacco Survey.<sup>327</sup>  
 2 The CDC found that “[i]n 2014, e-cigarettes were the most commonly used tobacco product  
 3 among middle (3.9%) and high (13.4%) school students.”<sup>328</sup> Moreover, “[b]etween 2011 and  
 4 2014, statistically significant increases were observed among these students for current use of  
 5 both e-cigarettes and hookahs ( $p < 0.05$ ), while decreases were observed for current use of more  
 6 traditional products, such as cigarettes and cigars, resulting in no change in overall tobacco  
 7 use.”<sup>329</sup> The CDC blamed e-cigarette marketing, the use of “a mixture of ‘sex, free samples,  
 8 [and] flavors’—the same things that were originally found to be problematic with cigarette  
 9 ads.”<sup>330</sup>

10 296. Seeking to enter this nascent youth market for e-cigarettes, JLI intentionally  
 11 targeted youth from its inception. In March 2015, Management Defendants supervised the  
 12 advertising campaigns that would accompany the launch of JUUL.

13 297. JLI knew that its initial customer base would be the key to its growth. On June  
 14 15, 2015, JLI’s COO Scott Dunlap wrote an article on Entrepreneur.com called “6 Ways to Get  
 15 a Fanatical Customer Base,” #1 of which was “Seed your initial customer base.”

16 298. Your first group of customers is the foundation of all future growth, so know  
 17 who they’ll be, why they’ll rave and help them tell your story. They’ll first act as role models  
 18 and then as advocates to help spread your mission, so make locating and engaging those core  
 19 customers a priority. This is especially important if you’re introducing something completely  
 20 new to a traditional industry.<sup>331</sup> Despite this professed knowledge that JLI’s “first group of  
 21 customers is the foundation of all future growth” and consistent with Monsees’ position that he  
 22

---

23 <sup>327</sup> Centers for Disease Control and Prevention, *Tobacco Use Among Middle and High School*  
 24 *Students — United States, 2011–2014*, Morbidity and Mortality Weekly Report (MMWR)  
 25 64(14):381–385 (Apr. 17, 2015), <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6414a3.htm>.

26 <sup>328</sup> *Id.*

27 <sup>329</sup> *Id.*

28 <sup>330</sup> Jacob Kastrenakes, *More teens are vaping instead of smoking*, The Verge (Apr. 16, 2015),  
<https://www.theverge.com/2015/4/16/8429639/teen-ecigarette-use-triples-vaping-beats-smoking>.

<sup>331</sup> Scott Dunlap, *6 Ways to Get a Fanatical Customer Base*, Entrepreneur (June 17, 2015)  
<https://www.entrepreneur.com/article/247424>.

has no “qualms” with marketing to people that were not yet addicted to nicotine,<sup>332</sup> JLI’s marketing strategy targeted people that were “flavor-seeking, social ‘vapers,’” and those who “have very limited experience with traditional tobacco cigarettes.”<sup>333</sup>

299. JLI’s first major marketing hire, Cult Collective Ltd. (“Cult Collective”), presented a pitch deck to JLI in late 2014, which defined the “target consumer” as a person “within a life stage or mindset where they are defining their own identity.”<sup>334</sup> The study described the “modern vaper” as “trendy, sophisticated image managers seeking to balance their desire for originality against acceptance.”<sup>335</sup> Put differently, their target consumer was an adolescent.

300. JLI professedly wanted kids to think JUUL was cool. In an email dated January 29, 2015, Sarah Richardson—then Director of Communications—sent a document dated December 31, 2014, to Dima Martirosyan, Director of Digital Marketing, who forwarded it to Rafael Burde, Director of Ecommerce.<sup>336</sup> The document stated that “[m]ost e-cigarettes to date are unsatisfying and seem ‘douche-y’. The JUUL product delivers nicotine far more effectively, and the product design is elegant and cool. We need to tell this story in a credible fashion through press, influencers and social media.”<sup>337</sup> The document repeatedly referred to Pax Labs’s plan to target the “cool kids[.]”<sup>338</sup> For example, it described as one of the “Key needs” to “Establish premium positioning to entice the ‘masses’ to follow the trend setters; own the ‘early adopter’ / ‘cool kid’ equity as we build out volume[.]”<sup>339</sup> The document noted that “the voices of influencers can build strong demand.”<sup>340</sup> Messaging to media similarly focused on “coolness”

---

<sup>332</sup> David H. Freedman, *How do you Sell a Product When You Really Can’t Say What it Does?*, Inc., <https://www.inc.com/magazine/201405/david-freedman/james-monsees-ploom-ecigarette-company-marketing-dilemma.html> (last visited Apr. 4, 2020).

<sup>333</sup> INREJUUL\_00441209.

<sup>334</sup> INREJUUL\_00057298-INREJUUL\_00057487.

<sup>335</sup> INREJUUL\_00057298-INREJUUL\_00057487.

<sup>336</sup> INREJUUL\_00057289.

<sup>337</sup> INREJUUL\_00057293.

<sup>338</sup> *Id.*

<sup>339</sup> *Id.*

<sup>340</sup> *Id.*



and the message that “JUUL singlehandedly made e-cigarettes cool.”<sup>341</sup>

301. This focus on “cool kids” continued up to and after launch. On May 18, 2015, Kate Morgan, field marketing manager, emailed Richard Mumby, Chief Marketing Officer, and a variety of other marketing employees about “Some Music Options for JUUL Party” and noted that one of the options was a pair who were both “cool kids.”<sup>342</sup> On June 7, 2015, Rafael Burde emailed Scott Dunlap, then Chief Operating Officer, stating that the JUUL launch party “was a resounding success (at least in my mind) in terms of winning over the cool kids . . . .”<sup>343</sup> Pax Labs employees used similar wording regarding interest in targeting “cool kids” in an email from Sarah Richardson on August 12, 2015,<sup>344</sup> and emails from Ashley Marand on September 15, 2015,<sup>345</sup> and October 21, 2015.<sup>346</sup> The consistency of the language around this target demographic confirms that marketing to “cool kids” was a company policy set by the executives and the Board, particularly because, before selling the Ploom assets to JTI, James Monsees said similar things about Ploom.<sup>347</sup>

302. JLI identified its competitor in this space as cigarette companies, complaining that “cigarettes continue to own the ‘cool’ equity,” and identifying a “key pillar to go-to-market” as “win[ning] with the ‘cool crowd’” away from cigarettes.<sup>348</sup>

303. With this goal in mind, JLI hired the Grit Creative Group (“Grit”), which billed itself as an agency whose marketing appealed to “cool kids.”<sup>349</sup> Grit helped JLI to “use external audiences to communicate nuanced messages around early adoption ‘coolness’ and product performance.”<sup>350</sup>

---

<sup>341</sup> INREJUUL\_00441325-INREJUUL\_00441326.

<sup>342</sup> JLI00218598.

<sup>343</sup> JLI00206206.

<sup>344</sup> JLI00222528.

<sup>345</sup> JLI00461564.

<sup>346</sup> JLI00235965.

<sup>347</sup> JLI00514343 (describing Ploom as “providing optionality for distribution growth and consumer outreach to a younger, opinion leading audience”).

<sup>348</sup> INREJUUL\_00161703-INREJUUL\_00161715.

<sup>349</sup> *Id.*

<sup>350</sup> INREJUUL\_00277080-INREJUUL\_00277104.

304. In short order, the phrase “it’s cool to JUUL” became an anthem among kids while youth e-cigarette use skyrocketed.

### 3. JLI Advertising Exploited Young People’s Psychological Vulnerabilities.

305. Informed by decades of tobacco marketing, JLI ran a consistent, simple message: JUUL is used by young, popular, attractive, and stylish people.

306. This was not the only marketing scheme JLI could have adopted. JLI had other options. In 2014, JLI engaged a Calgary-based advertising agency, Cult Collective, to complete a “diagnostic” evaluation of the JUUL brand and to make recommendations regarding the best advertising strategy to market the JUUL e-cigarette.

307. In keeping with typical e-cigarette marketing, which messaged to existing smokers looking to quit, Cult Collective recommended that JUUL position its e-cigarette technology as the focus of its advertisements. Cult Collective presented JUUL with exemplar advertisements that used images of a boom box and a joy stick, juxtaposed against the JUUL e-cigarette, with the tag line: “Everything changes. JUUL the evolution of smoking.”



308. This campaign expressly invokes combustible cigarettes and positions the JUUL as a technological upgrade for the modern smoker.

309. JLI rejected this approach.



310. Instead, in June of 2015, JLI launched the “Vaporized” advertising campaign.<sup>351</sup>  
 The express mission of the Vaporized campaign was to “own the ‘early adopter’/‘cool kid’  
 equity.”<sup>352</sup>

311. Applying the template for preying on teens established by the cigarette industry,  
 the Vaporized campaign used stylish models, bold colors, and highlighted themes of sexual  
 attractiveness, thinness, independence, rebelliousness and being “cool.”<sup>353</sup>

312. The targeting of young consumers was evident in the design and implementation  
 of the Vaporized campaign, which featured models in their 20s whose “poses were often  
 evocative of behaviors more characteristic of underage teen than mature adults.”<sup>354</sup>



<sup>351</sup> Declan Harty, *JUUL Hopes to Reinvent E-Cigarette Ads with ‘Vaporized Campaign’*, AdAge (June 23, 2015), <http://adage.com/article/cmo-strategy/juul-hopes-reinvent-e-cigarette-ads-campaign/299142/>.

<sup>352</sup> INREJUUL\_00057291-INREJUUL\_00057295.

<sup>353</sup> See Appendix B, Advertisement 1 (example of targeting of young people).

<sup>354</sup> *Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on Oversight and Reform, Subcomm. on Econ. and Consumer Policy*, 116th Cong. (2019) (statement of Robert K. Jackler, Professor, Stanford University).  
<https://docs.house.gov/meetings/GO/GO05/20190724/109844/HHRG-116-GO05-Wstate-JacklerR-20190724.pdf>.



313. In the months leading up to the launch of JUUL e-cigarettes, Pax Labs executives and directors discussed how to market the new product and the Board approved specific marketing materials used in JUUL's launch. On March 23, 2015,<sup>355</sup> there was a meeting of the Board of Directors where the upcoming advertising campaign was discussed.<sup>356</sup> The Board at that time had five members: Pritzker, Valani, Monsees, Bowen, and Handelsman (occupying Valani's second seat). According to Chelsea Kania, then Brand Manager at Pax Labs, prior to this meeting, she had met with the Board to discuss the models who would be used in the marketing collateral accompanying the JUUL launch. At that meeting, "there was some commentary at the youthfulness of the models[,] but "nobody disliked them" and

<sup>355</sup> INREJUUL\_00371285.

<sup>356</sup> INREJUUL\_00371314.

“everybody agreed they are pretty ‘effective[.]’”<sup>357</sup> Ms. Kania also noted that she told the Board that “we have quite the arsenal of model images to work with, and that they should let us know if the ones we selected are going to be problematic. So just waiting on any further feedback if they do a pass with the board.”<sup>358</sup> The Management Defendants knew that the ads targeted youth and had the authority to determine which models to use, but “Juul’s board of directors signed off on the company’s launch plans[.]”<sup>359</sup> In addition, “Monsees, who was CEO at the time, personally reviewed images from the billboard photo shoot while it was in session.”<sup>360</sup> A senior manager later told the New York Times that “he and others in the company were well aware” that the marketing campaign “could appeal to” teenagers.<sup>361</sup>

314. As part of the Vaporized campaign, JLI advertised on a 12-panel display over Times Square.<sup>362</sup> Billboard advertising of cigarettes has for years been unlawful under the Master Settlement Agreement.

---

<sup>357</sup> INREJUUL\_00174387.

<sup>358</sup> *Id.*

<sup>359</sup> Ainsley Harris, *How Juul, founded on a life-saving mission, became the most embattled startup of 2018: E-cigarette startup Juul Labs is valued at more than \$16 billion. It’s also hooking teens on nicotine and drawing scrutiny from the FDA. Can the company innovate its way out of a crisis it helped create?*, Fast Company (Nov. 19, 2018), <https://www.fastcompany.com/90262821/how-juul-founded-on-a-life-saving-mission-became-the-most-embattled-startup-of-2018>.

<sup>360</sup> *Id.*

<sup>361</sup> Matt Richtel & Sheila Kaplan, *Did Juul Lure Teenagers and Get ‘Customers for Life’?*, N.Y. Times (Aug. 27, 2018), <https://www.nytimes.com/2018/08/27/science/juul-vaping-teen-marketing.html>.

<sup>362</sup> See Appendix B, image 14; see also <https://inrejuul.myportfolio.com> (also available at [http://tobacco.stanford.edu/tobacco\\_main/subtheme\\_pods.php?token=fm\\_pods\\_mt068.php](http://tobacco.stanford.edu/tobacco_main/subtheme_pods.php?token=fm_pods_mt068.php)) (last visited April 3, 2020) (additional images and videos).



315. These ads, which ran for nearly a month, generated an estimated 1.5 million impressions per day.<sup>363</sup>

316. In fact, JLI's Vaporized campaign was so effective that it gained national attention on an October 15th, 2015 episode of Late Night with Stephen Colbert, who ridiculed the notion that the young, dancing models were consistent with a target market of adult smokers. As Colbert joked after viewing the close-up video of young models dancing in place, "[y]eah! There is something about vaping that just makes me want to dance in a way that doesn't require much lung strength. . . . And it's not just ads featuring hip young triangles that appeal to the youths. . . . There is no reason to worry about the long-term effects of vaping, because e-cigarettes are so new that their long-term effects are still unknown."<sup>364</sup>

317. The Vaporized campaign was not limited to the Times Square billboards however. The ads were also placed in nationally-distributed magazines, and the videos were displayed on screens at the top of point-of-sale JUUL kiosks provided by JUUL to retailers

<sup>363</sup> INREJUUL\_00093933-INREJUUL\_00093934.

<sup>364</sup> *The Late Show With Stephen Colbert: Vaping is So Hot Right Now*, YouTube (Oct. 7, 2015), [https://www.youtube.com/watch?v=PMtGca\\_7leM](https://www.youtube.com/watch?v=PMtGca_7leM).

1 across the country.

2 318. To the extent that the Vaporized advertisements disclosed that JUUL contained  
3 nicotine, the warnings were in small print against low-contrast backgrounds, making them easy  
4 to overlook. By way of comparison, cigarette advertisements, are required to display a health  
5 warning in high contrast black and white, covering 20% of the image.

6 319. Likewise, JLI's social media ads did not disclose any health risks of using JUUL  
7 until May of 2018, when they were required to warn of addiction. But even then, JUUL placed  
8 these warnings in areas that were only viewable if the social media user clicked on the "full  
9 version" of the JLI post, which is not how teens typically engage with social media  
10 advertising.<sup>365</sup> Notably, on Twitter, a social media platform that is geared towards reading text,  
11 and on Facebook, where some users do read text, JLI typically did not include the disclaimer in  
12 its advertisements at all.<sup>366</sup>

#### 13 4. JLI Pushed the Vaporized Campaign Into Youth Targeted Channels.

##### 14 a. JLI Placed Its Vaporized Ads on Youth Oriented Websites 15 and Media.

16 320. JLI engaged programmatic media buyers to place advertisements on websites  
17 attractive to children, adolescents in middle school and high school, and underage college  
18 students. These advertisements, which included the images of models from the Vaporized  
19 campaign, began appearing on websites as early as June 2015. The chosen websites included:  
20 nickjr.com (the website for a children's television network run by Nickelodeon Group); the  
21 Cartoon Network's website at cartoonnetwork.com; allfreekidscrafts.com; hellokids.com; and  
22 kidsgameheroes.com.

23 321. A picture of the homepage of nickjr.com is below:  
24  
25  
26

---

27 <sup>365</sup> See Appendix B, Advertisement 3.

28 <sup>366</sup> See Appendix B, Advertisement 65; see also Juul Image Galleries (2015-2018) SRITA Collection, <https://inrejuul.myportfolio.com/twitter-1> (last visited Apr. 3, 2020).





322. JLI also purchased banner advertisements on websites providing games targeted to younger girls,<sup>367</sup> educational websites for middle school and high school students,<sup>368</sup> and other teen-targeted websites.<sup>369</sup>

323. JLI knew what it was doing. In May 2015, Chelsea Kania contacted Cult Collective to raise concerns about advertising on *younghollywood.com*. Kania explained that the website's demographics are "age 12-34 . . . and weighing the % who could actually afford *JUUL* against the risk we'd run being flagged for advertising on that site – I don't think we should do it."<sup>370</sup> Nevertheless, JLI continued to push its campaign on websites with young demographics.

324. JLI promoted the Vaporized campaign on Facebook, Instagram, and Twitter.

325. JLI could have employed age-gating on its social media accounts to prevent underage consumers from viewing its Vaporized advertisements, but chose not to do so.

326. The Vaporized campaign included the largest e-cigarette smartphone campaign

<sup>367</sup> The sites included *dailydressupgames.com*, *didigames.com*, *forhergames.com*, *games2girls.com*, *girlgames.com*, and *girlsgogames.com*.

<sup>368</sup> E.g., *coolmath-games.com*. JUUL also purchased advertisements on *basic-mathematics.com*, *coolmath.com*, *math-aids.com*, *mathplayground.com*, *mathway.com*, *onlinemathlearning.com*, and *purplemath.com*.

<sup>369</sup> E.g., *teen.com*, *seventeen.com*, *justjaredjr.com*, and *hireteen.com*. JUUL purchased advertisements on websites for high school students hoping to attend college such as *collegeconfidential.com* and *collegeview.com*.

<sup>370</sup> INREJUUL\_00082179-INREJUUL\_00082185.



of 2015, which accounted for 74% of all such smartphone advertising that year.

327. JLI promoted Vaporized through Vice Magazine, which bills itself as the “#1 youth media brand” in the world.<sup>371</sup>



328. By 2016, an estimated 20.5 million U.S. middle and high school students were exposed to advertisements for e-cigarettes, including JUUL.<sup>372</sup>

**b. JLI Used Influencers and Affiliates to Amplify Its Message to a Teenage Audience.**

329. JLI used “influencers” to push their product to young people. Influencers are “high-social net worth” individuals who have developed large social media followings—*i.e.*, the “cool kids” of the social media world.<sup>373</sup> Influencers are prized sources of brand promotion on social media networks.

330. Like its Vaporized campaign, JLI’s influencer strategy was youth-focused, with the stated aim of “show[ing] that the tastemakers, cool kids and early adopters who consume

<sup>371</sup> Kathleen Chaykowski, *The Disturbing Focus of Juul’s Early Marketing Campaigns*, Forbes (Nov. 16, 2018), <https://www.forbes.com/sites/kathleenchaykowski/2018/11/16/the-disturbing-focus-of-juuls-early-marketing-campaigns/#3da1e11b14f9>.

<sup>372</sup> Kristy Marynak et al., *Exposure to Electronic Cigarette Advertising Among Middle and High School Students – United States, 2014-2016*, CDC: Morbidity and Mortality Weekly Report (Mar. 16, 2018), <https://www.cdc.gov/mmwr/volumes/67/wr/mm6710a3.htm>.

<sup>373</sup> See INREJUUL\_00091138 (Aug. 26, 2015 “JLI Influencer Program” defining an influencer as “individuals who have strong influence over their audience. We are aiming for influencers in popular culture with large audiences in various sectors such as music, movies, social, pop media, etc.”).

1 tobacco use JUUL.”<sup>374</sup> In keeping with this strategy, JLI targeted influencers that were young  
 2 and popular with adolescents. One influencer JLI targeted was Tavi Gevinson, who was  
 3 nineteen years old in the summer of 2015. The year before, Rolling Stone magazine described  
 4 Gevinson as “possibly the most influential 18-year-old in America.”<sup>375</sup>

5 331. JLI contracted with Grit to enlist influencers by sending them free JUUL e-  
 6 cigarettes.

7 332. Grit also provided free JUULs to Luka Sabbat, known as the “the Internet’s  
 8 Coolest Teenager,”<sup>376</sup> who was 17 years old during the summer of 2015.

9 333. Grit targeted celebrities with large numbers of underage fans, including Miley  
 10 Cyrus, former star of “Hannah Montana,” a series that aired for four seasons on the Disney  
 11 Channel and won eight Teen Choice Awards.<sup>377</sup>

12 334. JLI encouraged its distributors, wholesalers, and other resellers—either explicitly  
 13 or implicitly— to hire affiliates and influencers to promote JLI’s brand and products. Even if  
 14 not paid directly by JLI, these influencers profited from the promotion of JUUL products either  
 15 because they were paid by JUUL resellers, JUUL accessory sellers, or sellers of JUUL-  
 16 compatible products.

17 335. For example, one YouTube user Donnysmokes (Donny Karle, age twenty-one)  
 18 created a JUUL promotional video in 2017 that garnered roughly 52,000 views, many of which  
 19 were from users under the age of eighteen.<sup>378</sup> Since that time, Karle has made a series of videos,  
 20

---

21 <sup>374</sup> INREJUUL\_00057293.

22 <sup>375</sup> Alex Morris, *Tavi Gevinson: A Power Teen’s New Direction*, Rolling Stone (Aug. 14,  
 23 2014), <https://www.rollingstone.com/culture/culture-features/tavi-gevinson-a-power-teens-new-direction-232286/>.

24 <sup>376</sup> Alexis Barnett, *Who Is Luka Sabbat? Meet the Internet’s Coolest Teenager*, Complex (Aug.  
 25 17, 2015), <https://www.complex.com/style/luka-sabbat-interview-on-youth-kanye-west-and-fashion>.

26 <sup>377</sup> See, INREJUUL\_00091141 (Aug. 26, 2015 “JLI Influencer Seeding Chart” provided by Grit  
 listing various celebrities and influencers, including Miley Cyrus.).

27 <sup>378</sup> *Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on*  
 28 *Oversight and Reform, Subcomm. on Econ. and Consumer Policy*, 116th Cong. (2019)  
 (statement of Robert K. Jackler, Professor, Stanford University).  
<https://docs.house.gov/meetings/GO/GO05/20190724/109844/HHRG-116-GO05-Wstate-JacklerR-20190724.pdf>.

including videos titled “How to hide your JUUL from your parents” and “How to HIDE & HIT Your JUUL at SCHOOL WITHOUT Getting CAUGHT.”<sup>379</sup> Karle has admitted to earning approximately \$1200 a month from unspecified sources simply from posting videos of himself consuming e-cigarettes, especially of JUUL products online.<sup>380</sup>

336. In or around 2017, JLI began using a company called Impact Radius for the management of JLI’s affiliate program. Impact Radius’s affiliate application stated that JLI “auto-approve[d]” applications and did not ask for or confirm the affiliate’s age.<sup>381</sup> JLI’s affiliates promoted JUUL on social media platforms including YouTube, Instagram, Facebook, Snapchat, and Twitter and routinely failed to disclose that they were being paid to promote JUUL products.

337. As with much of the marketing strategy for JUUL, the practices described above are prohibited by the Master Settlement Agreement.

**c. JLI Used Viral Marketing Techniques Known to Reach Young People.**

338. JLI deployed “viral marketing” techniques to great success. Viral marketing is defined as “marketing techniques that seek to exploit pre-existing social networks to produce exponential increases in brand awareness, through processes similar to the spread of an epidemic.”<sup>382</sup> Viral marketing effectively converts customers into salespeople, who, by sharing their use of a product (on social media or otherwise), repeat a company’s representations and endorse the product within their network. The success of viral marketing depends on peer-to-peer transmission. Hence, a successful viral marketing campaign looks like a series of unrelated, grassroots communications, when in fact they are the result of carefully orchestrated corporate

---

<sup>379</sup> *Id.*


<sup>380</sup> Allie Conti, *This 21-year-old is Making Thousands a Month Vaping on YouTube*, Vice (Feb. 5, 2018), [https://www.vice.com/en\\_us/article/8xvjm/this-21-year-old-is-making-thousands-a-month-vaping-on-youtube](https://www.vice.com/en_us/article/8xvjm/this-21-year-old-is-making-thousands-a-month-vaping-on-youtube).

<sup>381</sup> INREJUUL\_00113437-INREJUUL\_00113441.

<sup>382</sup> N. Deepa et al., *Viral Marketing as an On-Line Marketing Medium*, IOSR J. of Bus. & Mgmt. 18, <http://www.iosrjournals.org/iosr-jbm/papers/ncibppte-volume-2/1115.pdf> (last visited Apr. 3, 2020); P. R. Datta et al., *Viral Marketing: New Form of Word-of-Mouth Through Internet*, 3 The Bus. Rev. 69 (2005).

advertising campaigns.

339. As JLI boasted in a pitch deck to potential investors dated December 2016, “Viral Marketing Wins.”<sup>383</sup>



340. Social media platforms are the most effective way to launch viral marketing campaigns among young people. As of May 2018, among teenagers, 95% reported use of a smart phone, 85% use YouTube, 72% use Instagram, and 45% reported being online “constantly.”<sup>384</sup>

341. A key feature of JLI’s viral marketing campaign was inviting user-generated content. This strategy revolves around prompting social media followers to provide their own JUUL-related content—e.g., post a selfie in your favorite place to use JUUL. The response provided by a user is then typically distributed—by the social media platform employed—into the user’s personal network. In this way, brands can infiltrate online communities with personalized content that promotes their product (e.g. a picture of a friend using a JUUL e-cigarette ).<sup>385</sup>

<sup>383</sup> INREJUUL\_00349529-560 at 541.

<sup>384</sup> Monica Anderson & Jingjing Jiang, *Teens, Social Media & Technology 2018: Appendix A: Detailed Tables*, Pew Research Center (May 31, 2018), <https://www.pewresearch.org/internet/2018/05/31/teens-technology-appendix-a-detailed-tables/>.

<sup>385</sup> *The Rise in the Use of Juul Among Young People: The Power of Design and Social Media Marketing*, Campaign for Tobacco Free Kids, [https://www.tobaccofreekids.org/assets/images/content/JUUL\\_Presentation.pdf](https://www.tobaccofreekids.org/assets/images/content/JUUL_Presentation.pdf). (last visited Nov. 12, 2020).




342. Within a few months of the JLI's commercial release in June 2015, a former JLI executive reportedly told the New York Times that JLI "quickly realized that teenagers were, in fact, using [JUULs] because they posted images of themselves vaping JUULs on social media."<sup>386</sup>

343. To drive consumer participation in its ad campaign, JLI peppered its advertising and social media posts with hashtags, including those referencing JLI and consuming e-cigarettes (e.g., #juul, #juulvapor, #switchtojuul, #vaporized, #juulnation, #juullife, #juulmoment); and trending topics unrelated to JUUL, as well as topics #mothersday, #goldenglobes, #nyc, etc. JLI's hashtag marketing went beyond passive posts to being "very proactive to find and reach out to people who are (or might be) interested in JUUL. This means searching hashtags to engage, using widely used hashtags, paying close attention to our followers, being responsive to posts, etc."<sup>387</sup>

<sup>386</sup> Matt Richtel & Sheila Kaplan, *Did Juul Lure Teenagers and Get 'Customers for Life'?*, N.Y. Times (Aug. 27, 2018), <https://www.nytimes.com/2018/08/27/science/juul-vaping-teen-marketing.html>.

<sup>387</sup> INREJUUL\_00093294.





344. JLI's hashtags attracted an enormous community of youthful posts on a wide array of subjects. According to Dr. Jackler, #Juul contains literally thousands of juvenile postings, and numerous Instagram hashtags contain the JUUL brand name.<sup>388</sup>

345. Just as JLI intended, JUUL users began taking photos of themselves using JUUL devices and putting them on social media with the hashtag #juul. They were creating JUUL content that looked and felt like real JUUL ads: featuring young people having fun and using JUUL. The flavor-based hashtag campaigns #MangoMonday and #coolmint generated hundreds of thousands of user-generated posts.

346. JLI could have stepped in and attempted to stop the use of its trademark in posts directed to underage audiences, including the use of all the hashtags that contain the word "JUUL." It could have sought to shut down infringing accounts such as @doit4juul and @JUULgirls. It did not do so.

## 5. JLI Targeted Youth Retail Locations.

347. Studies show that tobacco use is associated with exposure to retail advertising and relative ease of in-store access to tobacco products. Some studies have shown that youth who were frequently exposed to point of sale tobacco marketing were twice as likely to try or

<sup>388</sup> Robert K. Jackler et al., *JUUL Advertising Over Its First Three Years on the Market at 2, STAN. RES. INTO THE IMPACT OF TOBACCO ADVERT.* (2019), [http://tobacco.stanford.edu/tobacco\\_main/publications/JUUL\\_Marketing\\_Stanford.pdf](http://tobacco.stanford.edu/tobacco_main/publications/JUUL_Marketing_Stanford.pdf).



1 initiate smoking than those who were not as frequently exposed.

2 348. For years, JLI made it difficult for smoke shops and other age-restricted stores to  
3 carry its products, instead directing its product to gas stations and convenience stores, which  
4 historically make the most underage sales. JLI knows that nicotine-naïve young people frequent  
5 gas stations and convenience stores rather than smoke shops. By distributing in those kinds of  
6 stores, JUUL increased the likelihood that these people would purchase its product.

7 349. JLI marketed its products extensively in convenience stores, employing video  
8 and product displays with bright colors and young adults using and displaying the JUUL device.  
9 The retail marketing worked and, by late 2017, JUUL became the most popular e-cigarette sold  
10 in convenience stores according to Nielsen data.<sup>389</sup>

11 350. Like all in-store cigarette advertising, JLI's point-of-sale materials played a  
12 major role in driving youth addiction. JLI actively encouraged youth to seek out these laxly  
13 regulated retail locations, sending marketing e-mails to hundreds of thousands of customers,  
14 referring them to the JUUL store locator and offering discounts. And JLI actively encouraged its  
15 retailers to leniently regulate sales to youth by providing profit margins that far exceeded any  
16 other tobacco product being sold.


17 351. Before JUUL's launch in 2015, JLI and Cult Collective developed packaging and  
18 in-store displays that looked similar to iPhone packaging, which JLI knew would resonate with  
19 young people and further JLI's campaign to be the "the iPhone of e-cigarettes."

20 352. As a 2015 marketing plan shows, JLI's in-store promotional content "stands out"  
21 from competing tobacco products by conveying that the "JUUL brand is colorful, approachable,  
22 and fun—core elements of trade support assets."<sup>390</sup>

23  
24  
25  
26  
27 <sup>389</sup> Laura Bach, *JUUL and Youth: Rising E-Cigarette Popularity*, Campaign for Tobacco-Free  
28 Kids (July 6, 2018), [http://www.kdheks.gov/tobacco/download/Campaign\\_for\\_tobacco-free\\_kids\\_rising\\_popularity\\_of\\_e-cigarettes.pdf](http://www.kdheks.gov/tobacco/download/Campaign_for_tobacco-free_kids_rising_popularity_of_e-cigarettes.pdf).

<sup>390</sup> INREJUUL\_00370796-INREJUUL\_00370806, 805.

POS Poster



Merchandising Unit



Retail Video Stills

POS Video Link: <https://vimeo.com/121325103>

Password: ploom

## 6. JLI Hosted Parties to Create a Youthful Brand and Gave Away Free Products to Get New Consumers Hooked.

353. JLI also sponsored at least twenty-five live social events for its products in California, Florida, New York, and Nevada. The invitations to JUUL's events did not indicate that the JUUL was intended for cigarette smokers, contained nicotine, or was addictive.<sup>391</sup> Instead, the invitations traded on PAX Lab, Inc.'s (PAX) reputation as a manufacturer of marijuana vaporizers and promised attendees "free #JUUL starter kit[s]," live music, or slumber parties.<sup>392</sup> Photographs from these events indicate that they drew a youthful crowd. Product promotion through sponsored events was a long-standing practice for cigarette companies, but is now prohibited.

<sup>391</sup> See Appendix B, Advertisements 78-81.

<sup>392</sup> *Id.*



CONFIDENTIAL

BelleAGCIC0003146



354. At these live social events, JLI gave attendees free JUUL “Starter Kits,” which contain a JUUL device and 4 JUUL pods of various flavors. JLI gave away samples at music events without age restrictions, including Outside Lands in San Francisco’s Golden Gate Park.

355. Giving away free samples is prohibited conduct for a cigarette company under the Master Settlement Agreement.



Juul's container bar

393

356. JLI also held sampling events in stores. By September 2015, JLI was on schedule to host sampling events in more than 5,000 stores in twenty cities in twelve states.<sup>394</sup> Documents obtained by the New York Attorney General show that JLI recruited young “brand ambassadors” to staff these events and required a dress code that included skinny jeans, high-top sneakers or booties, and an iPhone in a JUUL-branded case.<sup>395</sup>

<sup>393</sup> Declan Harty, *JUUL Hopes to Reinvent E-Cigarette Ads with ‘Vaporized Campaign’*, AdAge (June 23, 2015), <http://adage.com/article/cmo-strategy/juul-hopes-reinvent-e-cigarette-ads-campaign/299142/>.

<sup>394</sup> INREJUUL\_00160394.

<sup>395</sup> Jake Offenhartz, *Juul Hooked Teens Through Sick Parties and Hip Ambassadors, NY AG Says*, Gothamist (Nov. 19, 2019), <https://gothamist.com/news/juul-hooked-teens-through-sick-parties-and-hip-ambassadors-ny-ag-says>; Kathleen Chaykowski, *The Disturbing Focus of Juul’s Early Marketing Campaigns*, Forbes (Nov. 16, 2018), <https://www.forbes.com/sites/kathleenchaykowski/2018/11/16/the-disturbing-focus-of-juuls-early-marketing-campaigns/#3da1e11b14f9>.



# TOOLKIT


## PROVIDED BY JUUL:

1. Juul T-Shirt (2)
2. Juul sampling bag (2)
3. Phone Case (2)
4. Sampling Device (2)
5. Starter Kit for "101 answer" (2) (Sampling)
6. Sampling Notebook (2) (Sampling)
7. \$10 off Cigarette (2) (Sampling)
8. Mail to 558 Charger (2)
9. Take Away Card (2) (Sampling)
10. Clear bag (2) (Sampling)

## PROVIDED BY MODEL:

1. Black men or black fitted jeans with Converse high-top sneakers (black sneakers) or sneakers (white)
2. Iphone

→ The Juul-branded "tool kit" encouraged ambassadors to dress in skinny jeans and Converse  
DOCUMENT OBTAINED PURSUANT TO OAG INVESTIGATION.



357. Though JLI publicly acknowledged in October 2017 that it is unlawful to distribute free samples of its products at live events,<sup>396</sup> it continued to reach out to new users by offering samples, sometimes at \$1 “demo events.” Like so many of JLI’s initiatives, promotions of this kind are prohibited for cigarette companies by the Master Settlement Agreement.

358. The effect—and purpose—of JLI’s Vaporized giveaways was to flood major cities with products that would hook thousands of new users, and to generate buzz for the brand among urban trendsetters who would then spread JLI’s message to their friends via word of mouth and social media.

359. According to BeCore, one of the firms responsible for designing and implementing JLI’s live events, JLI distributed the nicotine-equivalent of approximately 500,000 packs of cigarettes at all twenty-five events.<sup>397</sup> And this was just to get people started.

<sup>396</sup> See Nik Davis (@bigbabynik), Twitter (Nov. 17, 2017 1:11 PM), <https://twitter.com/JLIVapor/status/931630885887266816>; *The Role of the Company in the Juul Teen Epidemic, Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on Oversight and Reform, Subcomm. on Econ. and Consumer Policy*, 116th Cong. (2019) (statement of Robert K Jackler, Professor, Stanford University). <https://docs.house.gov/meetings/GO/GO05/20190724/109844/HHRG-116-GO05-Wstate-JacklerR-20190724.pdf>.

<sup>397</sup> Robert K. Jackler et al., *JUUL Advertising Over Its First Three Years on the Market*, Stan Rsch. into the Impact of Tobacco Advert. 9 (Jan. 31, 2019), [http://tobacco.stanford.edu/tobacco\\_main/publications/JUUL\\_Marketing\\_Stanford.pdf](http://tobacco.stanford.edu/tobacco_main/publications/JUUL_Marketing_Stanford.pdf).

**7. The Management Defendants' Direction of and Participation in JLI and in the Youth Marketing Schemes.**

**a. The Management Defendants, and in particular Pritzker, Valani, and Huh, controlled JLI's Board at relevant times.**

360. During the relevant time frame, JLI's operative Voting Agreements provided for a maximum of seven board seats.<sup>398</sup> By March 2013, Valani, through Ploom Investments LLC, controlled two of JLI's maximum seven board seats.<sup>399</sup> Valani continued to control two JLI board seats at all relevant times. Pritzker joined Monsees, Bowen, and Valani on JLI's board in August 2013.<sup>400</sup>

361. In March 2015, after JTI's board appointees resigned, Hank Handelsman—a lawyer who serves as general counsel for the Pritzker Organization, and was a senior executive officer and general counsel for the Hyatt Corporation for several decades—joined Monsees, Bowen, Pritzker, and Valani on JLI's board.<sup>401</sup> JLI documents indicate that Handelsman occupied Valani's second seat on the board.<sup>402</sup> Thus, by March 2015, Pritzker and Valani controlled three board seats, which comprised a majority of the board at the time since only five of seven possible seats were filled then. And Defendants Monsees and Bowen held the other two board seats.

362. JLI's Fourth Amended and Restated Voting Agreement, dated March 2015, provided for a maximum of seven board seats. Monsees and Bowen each occupied one seat; Valani had two seats; Pritzker had one seat at that time; another investor would obtain one board seat if enough shares were raised (but ultimately, they were not), and one seat was to be filled by vote of a majority of the board.<sup>403</sup> Sometime after that, Pritzker assumed control of a

---

<sup>398</sup> JLI01362389 (Fifth Amended and Restated Voting Agreement, March 2015); JLI01362388 (Fifth Amended and Restated Voting Agreement, Dec 2016); JLI01439393 (Sixth Amended and Restated Voting Agreement, March 2017); JLI01440777 (Seventh Amended and Restated Voting Agreement, Jun 2018).

<sup>399</sup> JLI01426710 (March 25, 2013 board minutes note V has seats, discuss a potential designee by Ploom Investments/aka V); JLI0268480 ("Ploom Investments is controlled by Riaz Valani").

<sup>400</sup> JLI01426164.

<sup>401</sup> JLI00216307; JLI01365707/.

<sup>402</sup> JLI01362388.

<sup>403</sup> JLI01365707.



second board seat.

363. By the summer of 2015, Hoyoung Huh and Alexander Asseily joined the Board. At that time, the Board had seven members: Monsees, Bowen, Valani, Pritzker, Handelsman, Huh, and Asseily.<sup>404</sup> Handelsman continued to occupy Valani's second seat.

364. Valani, Pritzker, and Huh continued to control JLI's board through at least 2018. In June 2017, Altria was already contemplating a deal with Juul and asked its financial advisor, Perella Weinberg Partners, to conduct diligence on JLI. Altria reported Perella Weinberg's findings while preparing for a meeting with JLI, noting that "Valani and Pritzker control majority of voting power and 44% economic interests."<sup>405</sup>

365. JLI's December 2016 Fifth Amended and Restated Voting Agreement provided that Monsees and Bowen controlled the two seats they occupied; Valani controlled the two seats occupied at that time by himself and Handelsman; Pritzker controlled the two seats occupied at that time by himself and Asseily; and Huh occupied the seat appointed by a majority of board members.<sup>406</sup> JLI's March 2017 Sixth Amended and Restated Voting Agreement provided the same board seat composition as the Fifth.<sup>407</sup>

366. Even after Huh resigned from JLI's board in May 2018,<sup>408</sup> Pritzker and Valani continued to control the board, as they still controlled four of seven board seats. JLI's June 2018 Seventh Amended and Restated Voting Agreement provided that Monsees and Bowen controlled the two seats they occupied; Valani controlled the two seats occupied at that time by himself and Handelsman; Pritzker controlled the two seats occupied at that time by himself and Zach Frankel; and Kevin Burns occupied the seat appointed by a majority of board members.<sup>409</sup> Consistent with this distribution of board seats, an internal Altria presentation from October 2017 reported on Altria's "continued dialogue with key [JLI] investors," noting that Valani and

---

<sup>404</sup> JLI00220992.

<sup>405</sup> ALGAT0002834151.

<sup>406</sup> JLI01362388.

<sup>407</sup> JLI01439394.

<sup>408</sup> JLI01425021.

<sup>409</sup> JLI01440776.

Pritzker “indicate that they control majority of voting power.”<sup>410</sup> JLI also noted in 2017 and 2018 that Pritzker and Valani “have two board seats” each, and they “are active on the board as well as providing strategic advice to the company on a weekly basis.”<sup>411</sup>

367. The Bylaws of the JLI Board of Directors provide that “all questions and business shall be determined by the vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these bylaws.”<sup>412</sup> So, by virtue of their control of four of the seven seats on the JLI Board of Directors, Defendants Pritzker and Valani had the ability to approve or reject any matter considered by the Board of Directors. This power included, among other things, the decision to remove any officer of JLI (which only required an “affirmative vote of a a majority of the directors” – which, as stated above, rested with Pritzker and Valani during all relevant times).<sup>413</sup> In this way, Pritzker and Valani ensured JLI would be run as they saw fit.

**b. Pritzker, Huh, and Valani were active, involved board members.**

368. JLI’s board members, and especially Pritzker, Valani, and Huh, were “more involved than most.”<sup>414</sup> In June 2015, then-COO Scott Dunlap observed that “[o]ur board members are more involved than most, and likely crazier than most, given the depth of experience they have in this industry,” specifically referencing comments made by Pritzker and Valani about JLI’s Vaporized marketing campaign.<sup>415</sup> They were so involved, in fact, that Dunlap worried that “the board [will] try and write copy” for future branding changes, and he encouraged Richard Mumby to prepare branding materials in advance so that “we could lead that discussion, should it happen.”<sup>416</sup> (Dunlap’s efforts to wrestle control over marketing from Pritzker, Valani, and Huh failed—he was the first person fired when their Executive Committee

---

<sup>410</sup> ALGAT0000280623.

<sup>411</sup> JLI01356230; JLI01356237 (Nov. 2017); JLI00417815 (Feb. 2018).

<sup>412</sup> JLI01385478.

<sup>413</sup> *Id.*

<sup>414</sup> JLI00206239.

<sup>415</sup> *Id.*

<sup>416</sup> *Id.*

1 began to clean house, as discussed below.<sup>417</sup>)

2 369. JLI's board met far more frequently than is typical: they had *weekly* board calls  
3 in addition to monthly meetings.<sup>418</sup> Hoyoung Huh began joining these weekly board calls  
4 starting in May 2015, before he formally took a seat on the board.<sup>419</sup> In the months following  
5 JUUL's June 2015 launch, the youth appeal of JUUL's marketing became a "common  
6 conversation" at weekly board calls.<sup>420</sup> Weekly meetings continued into at least 2018. JLI told  
7 investors in 2017 and 2018 that Pritzker and Valani "are active on the board as well as  
8 providing strategic advice to the company on a weekly basis."<sup>421</sup> Then-CEO Tyler Goldman told  
9 an investor in June 2017 that "Nick [Pritzker] has been a driving force in the building the [JLI]  
10 business."<sup>422</sup>

11 **c. The Management Defendants, and in particular Bowen,**  
12 **Monsees, Pritzker, Valani, and Huh, oversaw and directed the**  
**youth marketing scheme.**

13 370. The Management Defendants were well aware that JUUL branding was oriented  
14 toward teens and duplicated earlier efforts by the cigarette industry to hook children on nicotine.  
15 The Management Defendants directed and approved JUUL branding to be oriented toward  
16 teenagers. The Management Defendants directed and participated in every marketing campaign  
17 pushing the JUUL e-cigarette, as they had "final say" over all marketing campaigns (including  
18 the Vaporized campaign and the other formal and informal marketing efforts described  
19 above),<sup>423</sup> and Monsees provided specific direction on the content of the website to JLI  
20 employees.

21 371. James Monsees testified to Congress in 2019 that the Board of Directors had  
22 "final say" over marketing campaigns, and he was not speaking to only the current state of  
23

---

24 <sup>417</sup> JLI01369470.

25 <sup>418</sup> *See, e.g.*, JLI00210436; JLI00380098.

26 <sup>419</sup> JLI00206172.

27 <sup>420</sup> INREJUUL\_00174498.

28 <sup>421</sup> JLI01356230; JLI01356237 (Nov. 2017); JLI00417815 (Feb. 2018).

<sup>422</sup> JLI02272904.

<sup>423</sup> *Examining JLI's Role in the Youth Nicotine Epidemic: Part II: Hearing Before the Subcomm. on Econ. & Consumer Policy of the Comm. on Oversight & Reform, H.R.*, 116<sup>th</sup> Cong. 70 (2019) (statement of James Monsees, Co-Founder, JUUL Labs, Inc.).

1 affairs at the time. As noted above, from 2015 on, JLI's own documents establish that the Board  
 2 of Directors closely reviewed and approved marketing plans and specific marketing materials,  
 3 and set the marketing strategy for the company.

4 372. As early as November 2014, Monsees, Pritzker, and Valani discussed "the  
 5 addiction issue" with JUUL, working on "defining our strategy" for how to frame and market  
 6 their nicotine product.<sup>424</sup>

7 373. In January 2015, JLI's Board of Directors, including Monsees, Bowen, Valani,  
 8 Pritzker, met and discussed JLI's marketing.<sup>425</sup> At this meeting, the "key pillars" identified  
 9 included "win[ing] with the 'cool crowd' in critical markets," "build[ing] demand among the  
 10 masses," "lead[ing] with digital and ecommerce foundation," and "us[ing] external audiences to  
 11 communicate nuanced messages around early adoption 'coolness.'" The presentation for this  
 12 meeting also included "how" to market JUUL, including "PR & influencer coverage with  
 13 regarded national media in targeted markets, including LA & NYC at launch," and "build[ing]  
 14 loyal consumer community via social media." The Board recognized that JLI had to act quickly  
 15 because "[o]nline regulatory restrictions may affect [its] future e-commerce strategy." In short,  
 16 the entire marketing strategy, including the planned partnership with the #1 youth media  
 17 magazine, Vice, was presented to the Board for approval before its launch.

18 374. The Board, including Pritzker and Valani, also controlled JLI's messaging on  
 19 nicotine even before JUUL launched. In January 2015, the Board directed the marketing team  
 20 on several key topics related to JLI's marketing approach regarding nicotine. Sarah Richardson  
 21 noted that "[a]fter yesterday's board meeting conversation," she and Gal Cohen sought to  
 22 clarify in a follow-up meeting with Adam Bowen "direction from the board on their comfort  
 23 level with" aspects of the marketing approach. She noted that sales materials reference JUUL's  
 24 "cigarette-level nicotine satisfaction," "nicotine delivery akin to a cigarette," and "nicotine  
 25 absorption rates." The marketing team planned to ask the Board to clarify its "comfort level  
 26 with 'satisfying' messaging," and "Is our goal still that we are champions of transparency,  
 27

28 <sup>424</sup> JLI01259728.

<sup>425</sup> JLI00212009.

1 public health, and consumer interests? If so – at what level are we comfortable being proactive  
2 in achieving this?”<sup>426</sup>

3 375. On March 23, 2015, JLI’s Board of Directors—at that time composed of  
4 Monsees, Bowen, Valani, Pritzker, and Handelsman (occupying Valani’s second seat)—met  
5 and discussed, among other things, their plan for JUUL, including summaries for the launch,  
6 what was next, and “ROI opportunities.”<sup>427</sup> The presentation for the meeting noted that “to build  
7 a company worth \$500B+ you need INNOVATION that fundamentally disrupts MANY  
8 \$100B+ industries . . . and creates entirely new \$B industries along the way.” The meeting  
9 included a “JUUL launch update,” which noted that “Influencer Marketing has begun.”

10 376. The Board also approved specific marketing materials used in JUUL’s launch. In  
11 March 2015, the Board approved of the Vaporized marketing campaign despite its obvious  
12 youth appeal. The Board reviewed Vaporized marketing images and made “some commentary  
13 at the youthfulness of the models[,]” but “nobody disliked them” and “everybody agreed they  
14 are pretty ‘effective[.]’”<sup>428</sup> The Board knew that the ads targeted youth, but “Juul’s board of  
15 directors signed off on the company’s launch plans[.]”<sup>429</sup>

16 377. Because the Board of Directors—which in March 2015 included only Bowen,  
17 Monsees, Pritzker, Valani, and Handelsman (in Valani’s second seat)—reviewed and approved  
18 these marketing campaigns, Defendants Bowen, Monsees, Pritzker, and Valani caused the  
19 Vaporized campaign, including its omission of any reference to nicotine content, to be  
20 distributed via the mails and wires. Notably, Pritzker and Valani, who controlled three of the  
21 five Board seats filled at that time, had veto power over the launch plans which included this  
22 youthful advertising with no representations of nicotine content, yet they approved the  
23

---

24 <sup>426</sup> JLI01121750.

25 <sup>427</sup> JLI00216307.

26 <sup>428</sup> INREJUUL\_00174387.

27 <sup>429</sup> Ainsley Harris, *How Juul, founded on a life-saving mission, became the most embattled*  
28 *startup of 2018: E-cigarette startup Juul Labs is valued at more than \$16 billion. It’s also*  
*hooking teens on nicotine and drawing scrutiny from the FDA. Can the company innovate its*  
*way out of a crisis it helped create?*, Fast Company (Nov. 19, 2018),  
<https://www.fastcompany.com/90262821/how-juul-founded-on-a-life-saving-mission-became-the-most-embattled-startup-of-2018>.

1 marketing to go forward.

2 378. After launch, executives and directors discussed whether to rein in the  
3 advertising to teenagers. According to Scott Dunlap, then Chief Operating Officer, in June  
4 2015, Nicholas Pritzker commented that the branding “feels too young[.]”<sup>430</sup> At the June 17,  
5 2015 Board meeting, the Board heard “an update on the rollout of JUUL. . . . Mr. Mumby then  
6 provided the board with his perspective on the JUUL launch and customer feedback. The Board  
7 discussed the Company’s approach to advertising and marketing and portrayal of the product,  
8 which led to a discussion of the Company’s longer term strategy led by Mr. Monsees.”<sup>431</sup>

9 379. According to an anonymous former company manager: “Inside the company, the  
10 first signs that Juul had a strong appeal to young people came almost immediately after the  
11 sleek device went on sale in 2015.”<sup>432</sup> “[E]arly signs of teenage use kicked off an internal debate  
12 . . . Some company leaders . . . argued for immediate action to curb youth sales. . . . The  
13 counter-argument came from other company directors, including healthcare entrepreneur  
14 Hoyoung Huh and other early investors”—that is, Pritzker and Valani—who “argued the  
15 company couldn’t be blamed for youth nicotine addiction.”<sup>433</sup>

16 380. In early July 2015, Alexander Asseily “spoke to James [Monsees] at length” on  
17 the “JUUL approach.”<sup>434</sup> Asseily also spoke “at length” with Valani and Pritzker, following up  
18 with a lengthy email advocating against continued youth marketing. He began by noting that  
19 “our fears around tobacco / nicotine are not going away. We will continue to have plenty of  
20 agitation if we don’t come to terms with the fact that these substances are almost irretrievably  
21 connected to the shittiest companies and practices in the history of business.”<sup>435</sup> He stated that  
22 “an approach needs to be taken that actively, if implicitly, distances us from [Big Tobacco]:  
23 what we say, the way we sell, the way we run the company, what we emphasi[z]e, who we hire,  
24

---

25 <sup>430</sup> JLI00206239.

26 <sup>431</sup> JLI01426553.

27 <sup>432</sup> Chris Kirkham, *Juul Disregarded Early Evidence it was Hooking Teens*, REUTERS (Nov. 5,  
2019), <https://www.reuters.com/investigates/special-report/juul-ecigarette/>.

28 <sup>433</sup> *Id.*

<sup>434</sup> JLI00214617.

<sup>435</sup> *Id.*



etc.”<sup>436</sup> Referring to JLI’s strategy to use the same marketing techniques as major tobacco companies used to market to youths, Asseily added that “[t]he trouble with just doing ‘what the others do’ is that we’ll end up as Nick [Pritzker] rightly points out in the same ethical barrel as them, something none of us want no matter the payoff (I think).”<sup>437</sup> He continued that “the world is transparent and increasingly intolerant of bullshit. It’s not about faking it - it’s about doing it correctly....which could mean **not doing a lot of things we thought we would do like putting young people in our poster ads or drafting in the wake of big players in the market.**”<sup>438</sup> He pushed for an alternative marketing plan targeting only “existing smokers” and laid out a vision for the company “making products based in science and with a state goal of doing right by our customer.”<sup>439</sup>

381. Pritzker, Valani, and Huh rejected this approach, opposing any actions to curb youth sales. Youth sales were a large potential source of revenue.<sup>440</sup> As one manager explained, perhaps “people internally had an issue” with sales of JUULs to teenagers, “[b]ut a lot of people had no problem with 500 percent year-over-year growth.”<sup>441</sup> And company leaders understood that teenagers who were hooked on nicotine were the most likely segment to become lifelong addicts and thus were the most profitable customers to target.<sup>442</sup>

382. In October 2015, the debate was resolved in favor of selling to teens. Although JLI’s highly sanitized Board minutes do not reflect whether this debate was put to a vote, Huh, Pritzker, and Valani were the driving force behind this decision. They were aligned in favor of continuing youth marketing, and Valani’s second board seat (occupied by Handelsman) would have given them a majority if a vote was necessary (regardless of Bowen’s vote). Pritzker, Valani and Huh’s position ultimately prevailed—JLI continued marketing JUUL to youths,

---

<sup>436</sup> *Id.*

<sup>437</sup> *Id.*

<sup>438</sup> *Id.* (emphasis added).

<sup>439</sup> *Id.*

<sup>440</sup> Chris Kirkham, *Juul Disregarded Early Evidence it was Hooking Teens*, Reuters (Nov. 5, 2019), <https://www.reuters.com/investigates/special-report/juul-ecigarette/>.

<sup>441</sup> *Id.*

<sup>442</sup> *Id.*

Monsees was removed as CEO, and Pritzker, Valani, and Huh appointed themselves the newly formed Executive Committee. Even though the directors and executives of JLI knew—and explicitly stated—that what they were doing was wrong, they pressed ahead with JUUL’s youth-oriented Vaporized ad campaign through early 2016.<sup>443</sup>

383. The company also implemented the Board’s decision to target and sell to minors in many other ways. For example, in early October 2015, sales and marketing employees of Pax Labs noted that only 74% of users were able to pass the age gate on the website, “which is a steep decline in sales for us.”<sup>444</sup> In mid-January 2016, a similar group of employees estimated that about 11% of those reaching the JUUL Purchase Confirmation Page on Pax Labs’s own website were under 18 years old.<sup>445</sup> But, rather than strengthen JUUL’s age verification system, Pax Labs worked to weaken it. In February 2016,<sup>446</sup> Pax Labs modified the age verification system so that 92% of users were able to pass the age gate.<sup>447</sup> By changing the age verification process so that users were more likely to pass—while knowing that some minors had already been able to pass before the change—Pax Labs deliberately chose to continue selling to underage purchasers.

384. In July 2015, Asseily suggested “a cheeky campaign that asks existing smokers to return their unused cigarette packets (or other vaping products) to us in return for a discount on JUUL” because that would “send the only message that’s needed: JUUL is a superior alternative to conventional smoking and mediocre vaping products.”<sup>448</sup> But JLI did not run this campaign then and in fact did not begin focusing its advertising on switching from combustible

---

<sup>443</sup> The Vaporized advertising campaign continued at least into early 2016. Robert K. Jackler et al., *JUUL Advertising Over Its First Three Years on the Market*, Stan Rsch. into the Impact of Tobacco Advert.7 (Jan. 31, 2019), [http://tobacco.stanford.edu/tobacco\\_main/publications/JUUL\\_Marketing\\_Stanford.pdf](http://tobacco.stanford.edu/tobacco_main/publications/JUUL_Marketing_Stanford.pdf).

<sup>444</sup> INREJUUL\_00276445.

<sup>445</sup> Native attachment to INREJUUL\_00078494.

<sup>446</sup> JLI00068428.

<sup>447</sup> Kate Horowitz’s LinkedIn profile, <https://www.linkedin.com/in/k8horowitz> (last visited Mar. 9, 2020).

<sup>448</sup> JLI00214617.

1 cigarettes until 2018.<sup>449</sup>

2 385. By March 2016, however, JLI employees internally recognized that JLI's efforts  
3 to market to children were too obvious. On March 2, 2016, Richard Mumby, the Chief  
4 Marketing Officer, sent a document related to JLI's branding to Hoyoung Huh and a number of  
5 other marketing employees of JLI.<sup>450</sup> According to Mumby, he was sending the document  
6 because Hoyoung Huh "indicated that [he] would review [JLI's] brand and collateral  
7 positioning on behalf of the board."<sup>451</sup> The attached document noted that "[t]he models that we  
8 used for the #Vaporized campaign appeared to be too youthful for many consumers (and the  
9 media)[.]"<sup>452</sup> Under a header that listed as one of JLI's "Objectives" to "Be Different & Have  
10 Integrity[.]" the document stated that "[w]e need to be sensitive to the subjectivity of  
11 youthfulness by positioning the brand to be mature and relatable."<sup>453</sup> On March 11, 2016,  
12 Mumby sent another version of this document to Hoyoung Huh and Zach Frankel (who was  
13 then an observer on the Board and would later become a director), and Mumby thanked them  
14 "for the support on this."<sup>454</sup> Around this time, Pax Labs reoriented its JUUL advertising from the  
15 explicitly youth-oriented Vaporized campaign to a more subtle approach to appeal to the young.  
16 The advertising's key themes continued to include pleasure/relaxation, socialization/romance,  
17 and flavors<sup>455</sup>—all of which still appealed to teenagers, as was made clear in the previous  
18 litigation against the cigarette industry and Altria and Philip Morris in particular.

19 386. Pritzker, Valani, and Huh, along with Bowen and Monsees continued to direct  
20 and approve misleading marketing campaigns long after launch. For example, JLI deceptively  
21 marketed mint to youth, through flavor-driven advertising, hashtag campaigns, and ads cross-  
22

23 <sup>449</sup> Robert K. Jackler et al., *JUUL Advertising Over Its First Three Years on the Market*, Stan  
24 Rsch. into the Impact of Tobacco Advert. 16 (Jan. 31, 2019),  
[http://tobacco.stanford.edu/tobacco\\_main/publications/JUUL\\_Marketing\\_Stanford.pdf](http://tobacco.stanford.edu/tobacco_main/publications/JUUL_Marketing_Stanford.pdf).

25 <sup>450</sup> INREJUUL\_00178377.

26 <sup>451</sup> INREJUUL\_00061469.

27 <sup>452</sup> INREJUUL\_00178379.

28 <sup>453</sup> INREJUUL\_00178384.

<sup>454</sup> INREJUUL\_00061274.

<sup>455</sup> Robert K. Jackler et al., *JUUL Advertising Over Its First Three Years on the Market*, Stan  
Rsch. into the Impact of Tobacco Advert. 9 (Jan. 31, 2019),  
[http://tobacco.stanford.edu/tobacco\\_main/publications/JUUL\\_Marketing\\_Stanford.pdf](http://tobacco.stanford.edu/tobacco_main/publications/JUUL_Marketing_Stanford.pdf).

1 promoting mango and mint.

2 387. Notably, none of JLI's early advertisements, including those of the "Vaporized"  
3 campaign and others targeted to youths, disclosed that JUUL contains high amounts of nicotine;  
4 indeed, many of those advertisements did not advertise JUUL's nicotine content whatsoever.

5 388. Likewise, none of JLI's advertisements, including those of the "Vaporized"  
6 campaign and others targeted to youths, disclosed the health risks from consuming JUUL  
7 products.

8 389. JLI and the Management Defendants knew of course that JUUL contained an  
9 ultra-high concentration of nicotine, and that ultra-high concentration of nicotine was designed  
10 to addict. They also knew that e-cigarette products, including JUUL, would expose users to  
11 increased health risks, including risks to their lungs and cardiovascular system. Despite that  
12 knowledge, JLI and the Management Defendants took affirmative actions, the natural  
13 consequence of which was the approval and transmission of these false and misleading  
14 advertisements that did not include a disclosure of JUUL's high nicotine content and  
15 concentration, nor any health risks at all.

16 **d. Pritzker, Huh, and Valani Were Able to Direct and**  
17 **Participate in the Youth Marketing Because They Seized**  
**Control of the JLI Board of Directors.**

18 390. Although Defendants Bowen and Monsees were the visionaries behind JLI and  
19 the most hands-on in its early stages, by the time JLI was pushing its marketing campaigns in  
20 early-to mid-2015, JLI (through the individuals running the company), Bowen, Monsees,  
21 Pritzker, Valani, and Huh were each intimately involved in the planning and execution of  
22 activities.

23 391. For example, JLI stopped interacting with the press in the summer of 2015 while  
24 its Board of Directors, controlled by Bowen, Monsees, Pritzker, Huh, and Valani, was finalizing  
25 a "messaging framework."<sup>456</sup> A legitimate business enterprise would typically ramp up, rather  
26 than shut down, press outreach at the very time the company is supposed to be building  
27

28 \_\_\_\_\_  
<sup>456</sup> INREJUUL\_00056077 [Confidential].

1 awareness for its recently launched product.

2 392. But the Management Defendants at this point were taking actions that went  
3 beyond the regular and legitimate business operations of JLI. At the same time JLI stopped  
4 traditional press engagement, the Board of Directors was directing and monitoring the launch  
5 plans that they had set in motion – including the launch of sponsored content on social media in  
6 July 2015 (which content did not include any warnings about JUUL’s nicotine content or health  
7 risks).<sup>457</sup>

8 393. And at the same time the Management Defendants had approved the early JLI  
9 marketing campaigns that were intentionally targeting youth, there was a fundamental shift in  
10 roles when Defendants Pritzker, Valani, and Huh took charge of the instrumentalities of JLI,  
11 including its employees and resources.

12 394. Specifically, in October 2015, Monsees stepped down from his role as Chief  
13 Executive Officer of JLI (to become Chief Product Officer) and, in his stead, Pritzker, Valani,  
14 and Huh formed an Executive Committee of the JLI Board of Directors that would take charge  
15 of fraudulently marketing JUUL products, including to youth. The Management Defendants,  
16 and in particular Huh, wanted to continue their fraudulent marketing, knowing that these ads  
17 were also targeted to youth, “argu[ing] that the company couldn’t be blamed for youth nicotine  
18 addiction[.]”<sup>458</sup>

19 395. Keeping the company’s youth marketing on track was critical to and consistent  
20 with Pritzker, Valani, and Huh’s objective of accelerating JUUL’s growth and expanding its  
21 customer base—and increasing profitability. Monsees reported to investors that the Executive  
22 Committee was “formed to provide more consistent and focused direction to the company,” and  
23 Monsees stepped down as CEO so that the Executive Committee could “usher in the next phase  
24 of growth for the business.”<sup>459</sup> Hoyoung Huh served as the Executive Chairman and Pritzker as  
25 Co-Chairman.

---

26  
27 <sup>457</sup> *Id.*


28 <sup>458</sup> Chris Kirkham, *Juul Disregarded Early Evidence it was Hooking Teens*, Reuters (Nov. 5, 2019), <https://www.reuters.com/investigates/special-report/juul-ecigarette/>.

<sup>459</sup> JLI01369470.

396. On October 6, 2015, the day after Pritzker, Valani, and Huh ousted Monsees as CEO and rejected suggestions to abandon the current youth-oriented marketing, Richard Mumby acknowledged in an email to Huh, Pritzker, and Valani that their seizing power would facilitate JUUL's growth: "Many thanks for the candid conversation yesterday. Not an easy moment for PAX Labs, but I'm excited about the future that these changes will afford. . . . Clearly, improving our sales strategy and integrating sales/marketing better is crucial to our growth."<sup>460</sup>

397. JLI's organizational charts later reflected the executive committee in the place of a CEO. Before late 2015, the company's organizational charts showed the CEO at the head of the company, reporting to the Board.<sup>461</sup>

#### org chart - October 2015




398. After Monsees was removed as CEO, the Executive Committee appeared in the place of the CEO.<sup>462</sup>

<sup>460</sup> JLI00214159.

<sup>461</sup> See INREJUUL\_00016456 (July 9, 2014).

<sup>462</sup> INREJUUL\_00278332 (Dec. 7, 2015); INREJUUL\_00061420 (Apr.21, 2016).





399. Board minutes also illustrate how the Executive Committee of Pritzker, Valani and Huh, acted as CEO of JLI during this time period, taking direct control of the company and making critical decisions about how to market JUUL. Until late October 2015, Monsees (then the CEO) ran Board meetings.<sup>463</sup> In late October 2015 and thereafter, however, Huh (then Executive Chairman and member of the Executive Board) began running Board meetings.<sup>464</sup> Also, the late October minutes report that the “Board discussed . . . the additional responsibilities that would be assigned to Bryan White” (who was a Vice President of Engineering and Product Design at the time), and furthermore that “[a] discussion followed regarding who Bryan should report to, and it was agreed that the executive committee that had been formed since the last Board meeting, consisting of Messrs. Huh, Pritzker and Valani, would address this issue.”<sup>465</sup> Additionally, the Board “discussed how these new roles and

<sup>463</sup> See INREJUUL\_00278406 *et seq.* (Oct. 5, 2015); INREJUUL\_00278410 *et seq.* (Sept. 24, 2015).

<sup>464</sup> See INREJUUL\_00278404 *et seq.* (October 26, 2015); INREJUUL\_00278402 *et seq.* (Nov. 10, 2015).

<sup>465</sup> INREJUUL\_00278405 (Oct. 26, 2015).

responsibilities would be communicated internally.”<sup>466</sup> Over time, the list of direct reports to the board grew. By early 2018, every senior JUUL executive officer was reporting to the board directly.<sup>467</sup>

400. By December 2015, it was confirmed that “Hoyoung [Huh] will make decisions on behalf of the BOD [Board of Directors] Exec[utive] Comm[ittee]” and “3-4 days/week Nick [Pritzker] and/or Hoyoung [Huh] will be in the office” to “help us manage our people[.]”<sup>468</sup>

401. Consistent with his role as Executive Chairman, Huh delivered the “Vision for the company” agenda item at the December 2015 Board meeting.<sup>469</sup> Huh laid out JLI’s action plans going forward, and the explicit goal was to grow JUUL for sale to or joint venture with “Big Tobacco.”<sup>470</sup> To this end and as part of the discussion about how to “grow and sell Juul,” Defendants Huh, Pritzker, and Valani wanted even “more aggressive rollout and [marketing].”<sup>471</sup>

402. Huh served as the Executive Chairman of the Board from October 2015 until at least May 2016, and others, particularly Monsees, deferred heavily to Huh as the decision-maker during that period. For example, a JLI executive emailed Huh, Valani, Pritzker, and Handelsman to organize a Board call with Fidelity on December 16, 2015, and added “let me know if you think we should invite James [Monsees].”<sup>472</sup> Pritzker deferred that decision to Huh, who decided that Monsees was allowed, responding, “Am fine w[ith] James joining.”<sup>473</sup>

---

<sup>466</sup> *Id.*

<sup>467</sup> JLI01115999. Direct reports attending board meetings included Piotr Breziznski, VP International; Christine Castro, VP, Public Relations; Gal Cohen, Senior Director Scientific and Regulatory Affairs; Tim Danaher, CFO; Joanna Engelke, CQO; Ashley Gould, Chief Administrative Officer; Jacob Honig, Head of E-commerce; Mark Jones, Associate General Counsel; Vittal Kadapakkam, Senior Director Strategic Finance; Sonia Kastner, VP Global Supply; Vincent Lim, VP, Human Resources; Danna McKay, General Manager; Isaac Pritzer, Advisor to Executive Team; Bob Robbins, Chief Sales Officer; Wayne Sobon, VP, Intellectual Property; Tevi Troy, VP, Public Policy; Jacob Turner, Director of Finance; William Ward, Senior IP Counsel; Bryan White, VP Product Design; Rasmus Wissmann, VP Data.

<sup>468</sup> INREJUUL\_00061856.

<sup>469</sup> JLI01346296.

<sup>470</sup> INREJUUL\_00278352 – 00278359.

<sup>471</sup> *Id.*

<sup>472</sup> JLI01363643.

<sup>473</sup> JLI01363649.

403. In December 2015, Monsees expressed concerns about JLI's marketing budget to Huh in an extremely deferential way, concluding, "As I've said, I'm highly sensitive right now to not overstepping my mandate and risk deteriorating the management committee dynamic. I request your assistance in helping me find the right time and place (if any) to present and discuss these concerns. I'm at your service."<sup>474</sup>

404. Again expressing concerns about JLI's leadership and management, Monsees sent Huh an email in December 2015, discussing what he perceived as needed changes, including Board restructuring, the appointment of an interim CEO, and restructuring of Executive Committee. Monsees communicated these concerns in the form of a draft letter written on Huh's behalf to Pritzker, Valani, and Hank Handelsman.<sup>475</sup> These suggestions ultimately were not implemented.

405. In May 2016, Monsees responded to an inquiry from potential investors, saying that "Hoyoung Huh (our Executive Chairman)" should be involved in any discussions.<sup>476</sup> Monsees separately sought Huh's advice and guidance on how to respond to unsolicited investor inquiries like this, adding "if there's something else you'd like me to do (pass along to you or someone else?) I'll be happy to do so."<sup>477</sup>

406. Over the next year, until the installation of a new CEO in August 2016, Defendants Pritzker, Valani, and Huh used their newly formed Executive Committee to expand the number of e-cigarette users through fraudulent advertising and representations to the public. They cleaned house at JLI by "dismiss[ing] other senior leaders and effectively tak[ing] over the company."<sup>478</sup> Despite any potential internal misgivings about their fraudulent conduct, notably, none of Management Defendants terminated their relationship with JLI during this time period.

---

<sup>474</sup> JLI01363612.

<sup>475</sup> JLI01363610.

<sup>476</sup> JLI01369376.

<sup>477</sup> JLI01369407.

<sup>478</sup> Julie Creswell & Sheila Kaplan, *How Juul Hooked a Generation on Nicotine*, N.Y. Times (Nov. 24, 2019), <https://www.nytimes.com/2019/11/23/health/juul-vaping-crisis.html>.

**8. Pritzker, Valani, and Huh continued to exercise control over and direct the affairs of JLI even after a new CEO was appointed.**

407. Although JLI hired a new CEO in August 2016, Pritzker, Valani, and Huh’s Executive Committee does not appear to have been dissolved, and these three Defendants continued to exercise control over and direct the affairs of JLI.

408. In 2017, the Board—controlled at that time by Pritzker, Valani, and Huh—continued to make decisions on the details of the media plans for marketing. For example, a JLI marketing employee reported to JLI’s media vendor, Mediasmith, that JLI’s chief marketing officer “presented the entire media plan to the board,” but “we need to put the plan on hold” because the Board did not approve. She also acknowledged that JUUL’s board was aware their message was reaching a youth audience, noting that “What we need to do now is educate the board” on “the ways we can ensure [the] message is NOT reaching an unintended, young audience.”<sup>479</sup>

409. In December 2017, Valani directed aspects of JLI’s distribution and dissemination. For example, he initiated a conversation checking the progress on plans to sell JUUL devices in vending machines, asking for early design images and constructs.<sup>480</sup>

410. Pritzker also controlled several aspects of JLI’s branding. He was directly involved in creating JUUL’s corporate website in May 2017. Pritzker dictated specific changes to the content on the site in a conversation with Ashley Gould (Chief Administrative Officer).<sup>481</sup>

411. Also in May 2017, Ashley Gould asked the Board for their feedback on a proposed name for JUUL’s parent company, and Pritzker weighed in by saying “I’d like to discuss,” and also evaluated potential names, and sought to ensure that if the new name were to appear on any packaging, the JUUL brand name would still be the most prominent.<sup>482</sup>

412. In October 2017, the Board reviewed sample marketing campaign materials, and Pritzker rejected a specific proposal, noting that he “didn’t like ‘smokers deserve better

---

<sup>479</sup> INREJUUL\_00100719.

<sup>480</sup> JLI00308379.

<sup>481</sup> JLI01345258.

<sup>482</sup> JLI01345255.

alternatives.”<sup>483</sup>

413. Pritzker even got involved in customer service issues. In July 2017, Dave Schools, a JUUL customer, member of a famous band, and influencer, complained about bad customer service and defective devices. Schools’ email to JLI begins, “Please note I have copied Nick Pritzker on this email only because he asked me to do so.”<sup>484</sup>

414. Pritzker and Valani were also in close control of JLI’s public relations and media strategies. For example, Pritzker received an email from a teacher addressing youth use of Juul in schools, forwarded it to the team and directed a specific and personal response to the teacher.<sup>485</sup> In January 2018, Ashley Gould reported directly to Valani, Monsees, and Kevin Burns about a study linking teen e-cigarette use to an increased likelihood of trying cigarettes. Valani responded with a detailed messaging strategy and action items to respond to this negative press, including running “strategic media analysis [to] see where these articles are coming from,” “debunk[ing] the studies, . . . ideally in coordination with independent researchers,” financially supporting efforts to raise the tobacco minimum legal sales age to twenty-one years old, hiring a “credible head” of youth policy, and estimating “the number of adult smokers that have switched.” Valani directed Gould to give a “week-by-week progress” report on these tasks.<sup>486</sup>

415. Valani sent Gould another unfavorable news article about e-cigarettes in April 2018, and she responded that her teams were already working on “next steps” in response. Valani asked Gould for an update later the same day.<sup>487</sup>

416. After Kevin Burns replaced Tyler Goldman as JLI’s CEO, Burns worked closely with Pritzker and Valani in particular, seeking their approval regularly. For example, in April 2018, Kevin Burns suggested making several key hires to Valani and Pritzker, seeking their input; he also noted that he would seek Pritzker and Valani’s approval on a draft response to an

---

<sup>483</sup> JLI00322485.

<sup>484</sup> JLI11015358.

<sup>485</sup> JLI00024566.

<sup>486</sup> JLI00147328.

<sup>487</sup> JLI1053533.

inquiry by U.S. Senators and a press release regarding youth prevention efforts.<sup>488</sup> Also in April 2018, Valani edited a press release about JUUL's "Comprehensive Strategy to Prevent Underage Use" and sent his redline to the CEO.<sup>489</sup> In December 2018, CEO Kevin Burns sought approval from Valani and Pritzker on a specific advertising campaign, saying, "I suggest we proceed" with specified television, print, and radio spots.<sup>490</sup> Valani, copying Pritzker, approved only certain videos, deciding "[w]e shouldn't air the short form ones."<sup>491</sup>

417. Also in December 2018, JLI's marketing team prepared slides for Burns to give a marketing overview presentation to the board,<sup>492</sup> and Burns sent the slides to Pritzker and Valani in advance, inviting their feedback.<sup>493</sup> Likewise, in January 2019 Burns sent Valani and Pritzker a news article characterizing the *Make the Switch* campaign as aimed at adult smokers, noting that the article said "this campaign and positioning is starkly different from 2015." Valani responded, copying Pritzker, "Really good. Happy to see this reaction."<sup>494</sup>

418. In March 2019, Burns sent a copy of his op-ed in the Washington Post, called "Vape Makers Must Do More to Stop Kids from Using E-Cigarettes," to Pritzker and Valani, saying, "We just got word that our youth survey has been accepted for peer review and will be published in 2-3 weeks by a well regarded journal." Pritzker responded "Awesome. And I like the timing and wording of the op ed."<sup>495</sup> Valani also responded, saying "This is really great. Nicely written." Pritzker and Burns then discussed making a "strategic decision" about the availability of flavors in retail stores.<sup>496</sup>

## **9. Pritzker and Valani directed and controlled JLI's negotiations with Altria**

419. Pritzker and Valani, along with Kevin Burns, were the lead negotiators for JLI on

---

<sup>488</sup> JLI10529705.

<sup>489</sup> JLI00151297; JLI00151298.

<sup>490</sup> JLI10071280.

<sup>491</sup> JLI10071228.

<sup>492</sup> JLI1007754.

<sup>493</sup> JLI10071922.

<sup>494</sup> JLI0070326.

<sup>495</sup> JLI10064121.

<sup>496</sup> JLI01144202.



1 the Altria deal.

2 420. Altria knew that when it was negotiating with JLI, Pritzker and Valani were the  
3 company. In June 2017, Altria, preparing for a meeting with JLI, noted that “Per Perella  
4 Weinberg Partners, Valani and Pritzker control majority of voting power and 44% economic  
5 interests.”<sup>497</sup> A later internal Altria presentation reported on Altria’s “continued dialogue with  
6 key [JLI] investors,” noting that Valani and Pritzker “indicate that they control majority of  
7 voting power.”<sup>498</sup>

8 421. On paper, negotiations were between Howard Willard (Altria’s then-CEO), and  
9 Pritzker, Valani, and Kevin Burns for JLI. In April 2018, Willard sent confidential “Exchange  
10 of Volume Information” to Pritzker, copying Valani and Burns.<sup>499</sup> Willard also sent a detailed  
11 email to Pritzker and Valani, along with Burns, regarding Altria’s proposed “collaboration ...  
12 [that] creates a plan to manage that [antitrust] risk,” and “productive partnership that can create  
13 substantial value above what is achievable under a standalone scenario in a dynamic tobacco  
14 category environment.”<sup>500</sup> Many other email exchanges related to the deal are between Altria’s  
15 team, Pritzker, Valani, and Kevin Burns.<sup>501</sup>

16 422. But some key discussions involved only Pritzker and Valani as the real power  
17 brokers for JLI. For example, an April 2018 email string discussing how to resolve a standstill  
18 and restart the Altria deal negotiation included only Willard, Pritzker, and Valani.<sup>502</sup> Pritzker  
19 told Willard what he and Altria’s lawyers needed to work out to have “the continuing right to  
20 talk to Riaz [Valani] and me.”<sup>503</sup>

---

21 <sup>497</sup> ALGAT0002834151.

22 <sup>498</sup> ALGAT0000280623.

23 <sup>499</sup> JLI10530188.

24 <sup>500</sup> JLI10530232.

25 <sup>501</sup> *See, e.g.*, JLI01389789; JLI10523767; JLI01389792; JLI10518886.

26 <sup>502</sup> ALGAT0000113109.

27 <sup>503</sup> *Id.*

423. Pritzker and Valani worked to build a partnership with Altria. After attending a closing dinner, Hank Handelsman, JLI Board member and proxy for Pritzker and Valani, emailed Willard and stated, “More importantly to me was the camaraderie shown after a bruising negotiation! In 45 years of doing deals, some in the tobacco industry, I have not seen the ‘we are at peace, let’s move on’ attitude that I witnessed that lovely evening!” In response, Pritzker added KC Crosthwaite to the email chain and thanked Willard and the Altria personnel for the dinner, and stated, “We truly appreciate our partnership, and look forward to an even deeper collaboration in the future.”<sup>504</sup>

424. Pritzker and Valani continued to communicate with Altria’s CEO on behalf of JLI after the negotiations ended. May 26, 2019, Pritzker asked Willard whether he was planning to attend “the youth/PMTA meeting in DC,” and “if so, do you think we can find time for you, Riaz [Valani] and I to get together separately?”<sup>505</sup>

425. Pritzker, Valani, Willard, and Crosthwaite coordinated a response to the Youth Vaping Prevention Plan in July 2019. Willard offered his “reaction to the [Youth Vaping Prevention] Plan” and advised JLI, based on his experience as a cigarette company CEO, not to publicly commit to using the plan or otherwise make an announcement addressing it.<sup>506</sup>

**10. JLI and the Management Defendants Knew Their Efforts Were Wildly Successful in Building a Youth Market and Took Coordinated Action to Ensure That Youth Could Purchase JUUL Products.**

**a. JLI’s Strategy Worked.**

426. The Management Defendants knew that the JUUL marketing campaigns they directed and approved were successful in targeting youth. As Reuters has reported, “the first signs that JUUL had a strong appeal to young people came almost immediately after the sleek

---

<sup>504</sup> ALGAT0003889812.

<sup>505</sup> ALGAT0003285214.

<sup>506</sup> ALGAT0003279064.

device went on sale in 2015 . . . . Employees started fielding calls from teenagers asking where they could buy more JUULs, along with the cartridge-like disposable ‘pods’ that contain the liquid nicotine.”<sup>507</sup> A former senior manager told the New York Times that “[s]ome people bought more JLI kits on the company’s website than they could individually use—sometimes 10 or more devices.” He added that “[f]irst, they just knew it was being bought for resale,” but later “when they saw the social media, in fall and winter of 2015, they suspected it was teens.”<sup>508</sup> Adam Bowen admitted that “he was aware early on of the risks e-cigarettes posed to teenagers[.]”<sup>509</sup> On January 5, 2016, Gal Cohen forwarded a presentation dated December 16, 2015, which asked the question: “If *large numbers of youth are initiating tobacco use with flavored e-cigarettes*, but adults [*sic*] smokers may benefit from completely switching to an e-cigarette, what should the market look like?”<sup>510</sup> It was common knowledge within JLI that JUULs were being sold to children.

427. After the Vaporized campaign, retail stores began selling out of JUUL products, and JLI had a difficult time trying to meet demand coming from its online ordering platform.

428. Furthermore, it was obvious to those outside the company that JLI was selling JUUL products to children. In June 2015, reporting on the “Vaporized” campaign that accompanied the JUUL launch, AdAge reported that John Schachter, director of state communications for Campaign for Tobacco-Free Kids, “expressed concern about the JUUL campaign because of the youth of the men and women depicted in the campaign, especially when adjoined with the design” and added that there had been “obvious trends that appeal to adolescents in e-cigarette campaigns[.]”<sup>511</sup> Robert Jackler, a Stanford physician who investigated

<sup>507</sup> Chris Kirkham, *Juul Disregarded Early Evidence it was Hooking Teens*, Reuters (Nov. 5, 2019), <https://www.reuters.com/investigates/special-report/juul-ecigarette/>.

<sup>508</sup> Matt Richtel & Sheila Kaplan, *Did Juul Lure Teenagers and Get ‘Customers for Life’?: The e-cigarette company says it never sought teenage users, but the F.D.A. is investigating whether Juul intentionally marketed its devices to youth*, NY Times (Aug. 27, 2018), <https://www.nytimes.com/2018/08/27/science/juul-vaping-teen-marketing.html>.

<sup>509</sup> *Id.*

<sup>510</sup> INREJUUL\_00339938 (emphasis added).

<sup>511</sup> Declan Harty, *JUUL Hopes to Reinvent E-Cigarette Ads with ‘Vaporized Campaign’*, AdAge (June 23, 2015), <http://adage.com/article/cmo-strategy/juul-hopes-reinvent-e-cigarette-ads-campaign/299142/>.

JLI's launch campaign, concluded that "JLI's launch campaign was patently youth-oriented."<sup>512</sup> JLI's commercials' attempts to appeal to teenagers were so obvious that, by October 2015, Stephen Colbert ran a satirical segment on it that noted, among other things: "And it's not just ads featuring hip young triangles that appeal to the youths; so do vape flavors like cotton candy, gummi bear, and skittles."<sup>513</sup>

429. Moreover, the Management Defendants knew that kids were marketing JLI products on social media, and some even sought to take advantage of that to build the JLI brand. For example, on July 16, 2016, Adam Bowen emailed Tyler Goldman about social media posts by children about JUUL e-cigarettes, stating, "I'm astounded by this 'ad campaign' that apparently some rich east coast boarding school kids are putting on."<sup>514</sup> Bowen added that "Riaz [Valani] was thinking maybe we can leverage user generated content."<sup>515</sup>

**b. JLI Closely Tracked Its Progress in Reaching Young Customers through Social Media and Online Marketing**

430. Tracking the behaviors and preferences of youth that are under twenty-one, and especially those under eighteen, has long been essential to the successful marketing of tobacco products. Whether the activity is called "tracking" or "targeting," the purpose has always been the same: getting young people to start smoking and keeping them as customers.

431. As early as 1953, Philip Morris was gathering survey data on the smoking habits of "a cross section of men and women 15 years of age and over."<sup>516</sup> Commenting on these data, George Weissman, then-Vice President of Philip Morris, observed that "we have our greatest strength in the 15-24 age group."<sup>517</sup>

<sup>512</sup> Erin Brodwin, *See how Juul turned teens into influencers and threw buzzy parties to fuel its rise as Silicon Valley's favorite e-cig company*, Bus. Insider (Nov 26, 2018).

<https://www.businessinsider.com/stanford-juul-ads-photos-teens-e-cig-vaping-2018-11>.

<sup>513</sup> *The Late Show with Stephen Colbert: Vaping is So Hot Right Now*, YouTube (Oct. 7, 2015), [https://www.youtube.com/watch?v=PMtGca\\_7leM](https://www.youtube.com/watch?v=PMtGca_7leM). The "triangles" ad was a JUUL ad; the listed flavors were not, but JUUL also had flavors that appealed to children.

<sup>514</sup> JLI00382271.

<sup>515</sup> *Id.*

<sup>516</sup> Philip Morris Vice President for Research and Development, *Why One Smokes, First Draft*, 1969, Autumn (Minnesota Trial).

<sup>517</sup> *United States v. Philip Morris*, 449 F. Supp. 2d 1, 581 (D.D.C. 2006).

432. Traditional approaches to youth tracking (e.g., interviews conducted face-to-face or over the telephone) were limited, however, in that they often failed to capture data from certain subsets of the target market. As a Philip Morris employee noted in a June 12, 1970 memorandum, Marlboro smokers were “among the types of young people our survey misses of necessity (on campus college students, those in the military and those under 18 years of age).”<sup>518</sup>

433. However, modern technology has removed many of the hurdles that made youth tracking difficult in decades past. With industry connections, e-mail, social media and online forums, JLI can track, and has consistently tracked and monitored its target youth market, including those below the minimum legal age to purchase or use JUUL products.

434. First, JLI knew from its sales data that the large majority of its customers were under the age of 21. In December 2017, JLI employees discussed potentially supporting raising the legal age to purchase e-cigarettes to 21 and started that based on the data collected by Avail Vapor, “this would be a devastating mistake” because “70% + of sales would be eliminated.”<sup>519</sup> According to Avail’s data, 70% of purchasers of JUUL were between 18 and 21 years old, 15% of customers were 22 to 29 years old, 7% of customers were 30 to 44 years old, 6% of customers were 45 to 64 years old, and just 1% of customers were 65 years old or older. JLI employees only noted that “Retailers know well that younger adults buy in greater quantities than mature adults” and supporting a raise of the legal age to 21 “would show we simply do not understand our product success” and “would alienate a large portion of our existing consumers and advocates.”<sup>520</sup> The JLI employee also noted that “we need to understand (at least at the senior decision maker level) that our current success is fuel primarily by younger adult users” and not by “mass market adult combustion smokers.”<sup>521</sup>

435. Second, using the tools available to it, JLI would have known that its viral marketing program was a resounding success, and in particular with young people.

---

<sup>518</sup> *Id.*

<sup>519</sup> JLI10344468.

<sup>520</sup> *Id.*

<sup>521</sup> *Id.*

436. Between 2015 and 2017, JUUL-related posts on Twitter increased quadratically, which is the exact result to be expected from an effective viral marketing campaign.<sup>522</sup> Its growth on Instagram was likely even more rapid.

437. A 2018 study of JLI's sales and presence on social media platforms found that JLI grew nearly 700%, yet spent "no recorded money" in the first half of 2017 on major advertising channels, and spent only \$20,000 on business-to-business advertising.<sup>523</sup> Despite JLI's apparently minimal advertising spend in 2017, the study found a significant increase in JUUL-related tweets in 2017.<sup>524</sup>

438. On Instagram, the study found seven JUUL-related accounts, including DoIt4JUUL and JUUL.girls, which accounted for 4,230 total JUUL-related posts and had more than 270,000 followers.<sup>525</sup>

439. In addition to JUUL's explosive growth on individual social media platforms, the study found JUUL products being marketed across platforms in an apparently coordinated fashion, including smaller targeted campaigns and affiliate marketing, all of which caused the authors to question whether JLI was paying for positive reviews and JUUL-related social media content.

440. The lead author of the study concluded that JLI was "taking advantage" of the reach and accessibility of multiple social media platforms to "target the youth and young adults . . . because there are no restrictions," on social media advertising.<sup>526</sup>

441. A separate study of e-cigarette advertising on mobile devices, where young people spend most of their day consuming media, found that 74% of total advertising

<sup>522</sup> See Brittany Emelle, et al., *Mobile Marketing of Electronic Cigarettes in the U.S.*, (May 2017), <https://www.slideshare.net/YTHorg/mobile-marketing-of-electronic-cigarettes>.

<sup>523</sup> Jidong Huang et al., *Vaping versus JUULing: how the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market*, Tobacco Control (May 31, 2018), <https://tobaccocontrol.bmj.com/content/28/2/146.full>.

<sup>524</sup> *Id.*

<sup>525</sup> *Id.*

<sup>526</sup> Laura Kelly, *JUUL Sales Among Young People Fueled by Social Media, Says Study*, The Wash. Times (June 4, 2018), <https://www.washingtontimes.com/news/2018/jun/4/juul-sales-among-young-people-fueled-by-social-med/>.



1 impressions were for JUUL products.<sup>527</sup>

2 442. A 2019 study found that as much as half of JUUL's Twitter followers were aged  
3 thirteen to seventeen.<sup>528</sup>

4 443. A 2019 study characterizing JUUL-related Instagram posts between March and  
5 May 2018 found that among nearly 15,000 relevant posts from over 5,000 unique Instagram  
6 accounts, more than half were related to youth or youth lifestyle.<sup>529</sup>

7 444. Some Twitter users have reported what appear to be JUUL bots.<sup>530</sup> Other Twitter  
8 users appear to either be bot accounts or native advertisers, in that they have a small number of  
9 followers, follow few other users, and post exclusively about JUUL content.<sup>531</sup>

10 445. By April 2018, searching "JUUL" on YouTube yielded 137,000 videos with  
11 forty-three videos having over 100,000 views.<sup>532</sup> Of these, a huge number were plainly related to  
12 underage use, including: 1,730 videos on "hiding JUUL in school," 789 on "JUUL in school  
13 bathroom," 992 on "hiding JUUL at home," and 241 on "hiding JUUL in Sharpie."<sup>533</sup>

14 446. In 2018, JLI was internally collecting hundreds of social media posts—directed  
15 at JLI—informing it of JUUL's wild popularity with young people and in many cases  
16 requesting that JLI do something to stop it.<sup>534</sup>

---

17  
18  
19 <sup>527</sup> See Brittany Emelle et al., *Mobile Marketing of Electronic Cigarettes in the U.S.*, Truth  
20 Initiative (May 2017), [https://www.slideshare.net/YTHorg/mobile-marketing-of-electronic-](https://www.slideshare.net/YTHorg/mobile-marketing-of-electronic-cigarettes)  
21 [cigarettes](https://www.slideshare.net/YTHorg/mobile-marketing-of-electronic-cigarettes).

22 <sup>528</sup> Steven Reinberg, *Study: Half of Juul's Twitter followers are teens, young adults*, HealthDay  
23 News, (May 20, 2019) [https://www.upi.com/Health\\_News/2019/05/20/Study-Half-of-Juuls-](https://www.upi.com/Health_News/2019/05/20/Study-Half-of-Juuls-Twitter-followers-are-teens-young-adults/1981558384957/)  
24 [Twitter-followers-are-teens-young-adults/1981558384957/](https://www.upi.com/Health_News/2019/05/20/Study-Half-of-Juuls-Twitter-followers-are-teens-young-adults/1981558384957/).

25 <sup>529</sup> Lauren Czaplicki et al., *Characterising JUUL-related posts on Instagram*, Truth Initiative  
26 (Aug. 1, 2019), [https://tobaccocontrol.bmj.com/content/early/2019/07/30/tobaccocontrol-2018-](https://tobaccocontrol.bmj.com/content/early/2019/07/30/tobaccocontrol-2018-054824)  
27 [054824](https://tobaccocontrol.bmj.com/content/early/2019/07/30/tobaccocontrol-2018-054824).

28 <sup>530</sup> One example of what appear to be JUUL bots in action on Twitter is available at:  
29 <https://twitter.com/search?q=juul%20bot&src=typd> (last visited Apr. 4, 2020).

30 <sup>531</sup> Hennrythejuul (@hennrythejuul), Twitter (Mar. 4, 2020, 9:35 am)  
31 <https://twitter.com/hennrythejuul>.

32 <sup>532</sup> Divya Ramamurthi et al., *JUUL and Other Stealth Vaporizers: Hiding the Habit from*  
33 *Parents and Teachers*, *Tobacco Control* 2019, Stanford Univ. (Sept. 15, 2018),  
34 <https://tobaccocontrol.bmj.com/content/tobaccocontrol/28/6/610.full.pdf>.

35 <sup>533</sup> *Id.*

36 <sup>534</sup> Complaint at 60, *People v. JUUL Labs, Inc.*, No. RG19043543 (Super. Ct. of Cal. Nov. 18,  
37 2019), <https://oag.ca.gov/system/files/attachments/press-docs/91186258.pdf>.

**11. JLI Worked with Veratad Technologies To Expand Youth Access to JUUL Products.**

447. At the same time JLI and the Management Defendants were taking coordinated actions to maintain and expand the number of nicotine-addicted e-cigarette users in order to ensure a steady and growing customer base through unlawful marketing and distribution activities, they worked with an outside entity—Veratad Technologies LLC—to get JUULs into the hands of the largest number of consumers possible.

448. In furtherance of JLI and the Management Defendants’ efforts to secure youth sales so crucial to expanding JUUL’s market share (and JLI’s profits), and as detailed below, from approximately 2015 to 2018, JLI and Veratad worked together to try to pass as many people as possible through an on-line “age verification” system that users had to pass to be able to order JUUL products.

449. JLI’s website, including its online store, was pivotal to these efforts. Early marketing documents show that JLI planned a “consumer journey” that started with a consumer being exposed to misleading JUUL marketing in stores, where JUUL’s “fun” and “approachable” in-store marketing would lead consumers to JLI’s website for additional misrepresentations and omissions about JUUL products, an email subscription sign-up, and purchases through JLI’s ecommerce platform.<sup>535</sup>

---

<sup>535</sup> INREJUUL\_00329660

**CUSTOMER JOURNEY**

450. JLI worked with Veratad to provide age verification services for its website from 2015 to 2018. Veratad has also provided age verification services to other e-cigarette sellers, including Lorillard<sup>536</sup> and Altria.<sup>537</sup> Consistent with the claim on Veratad's website that "*You can create your own verification rules,*" the company encouraged sellers like JLI to set the desired compliance level for age verification. As a member of a major e-cigarette trade organization, Veratad also offered insight into what competitors were doing, and offered to "guide your setup to follow industry best practices for age verification."

451. Though it is illegal to sell and ship e-cigarettes to minors under both state and federal law, JLI and Veratad designed and implemented an age verification system designed to maximize the number of prospective purchasers who "pass" the process, rather than to minimize the number of underage sales.<sup>538</sup> As a result of these intentionally permissive age verification practices, JLI and Veratad used online payment systems and the US mails to ship tens of

<sup>536</sup> Staff of Sen. Richard Durbin et al., 113th Cong., *Gateway to Addiction?* (Apr. 14, 2014), <https://www.durbin.senate.gov/imo/media/doc/Report%20-%20E-Cigarettes%20with%20Cover.pdf>.

<sup>537</sup> INREJUUL\_00174362.

<sup>538</sup> Complaint at 165, *People v. JUUL Labs, Inc.*, No. RG19043543 (Super. Ct. of Cal. Nov. 18, 2019), <https://oag.ca.gov/system/files/attachments/press-docs/91186258.pdf>.

1 millions of dollars of JUULpods to unverified customers, many of whom were minors.

2 452. From June 2015 through the end of 2018, the age verification process on JLI's  
3 website typically prompted prospective purchasers to submit their name, address, and date of  
4 birth, which JLI forwarded to Veratad. Veratad then attempted to match all or some limited part  
5 of the consumer's information to a person of the minimum legal sales age in its database. If  
6 Veratad was able to locate a sufficient match of the prospective purchaser to a person of the  
7 minimum legal sales age in its database, then it would return a "pass" result to JLI. If Veratad  
8 was unable to make such a match, Veratad returned a "fail" result to JLI.

9 453. If Veratad returned a "fail" result to JLI, rather than decline the prospective  
10 purchaser, JLI would prompt the person to enter an "alternate" address. If Veratad still could not  
11 find a match based on this alternate address, JLI would prompt the consumer to enter the last  
12 four digits of his or her social security number.

13 454. If Veratad, supplied with the last four digits of a consumer's social security  
14 number, still could not match the consumer to a person of the minimum legal sales age in its  
15 database, JLI would prompt the consumer to upload an image or photograph of his or her  
16 driver's license or another governmental identification document. A JLI employee would then  
17 conduct a personal review of the image and decide whether the consumer was of the minimum  
18 legal sales age.

19 455. Crucially, Veratad's age verification system was purposefully flexible, so JLI  
20 and Veratad could work together to decide just how closely a prospective purchaser's personal  
21 information had to match records in Veratad's database in order to "pass" the age verification  
22 process. JLI and Veratad could also set, or modify, the applicable minimum legal sales age to be  
23 used for verification.

24 456. By the fall of 2015, JLI and Veratad knew that bulk purchases were being made  
25 for resale on JLI's website by minors and for resale to minors.<sup>539</sup> For example, on May 25, 2016,  
26

---

27 <sup>539</sup> Matt Richtel & Sheila Kaplan, *Did Juul Lure Teenagers and Get 'Customers for Life'? The*  
28 *e-cigarette company says it never sought teenage users, but the F.D.A. is investigating whether*  
*Juul intentionally marketed its devices to youth*, NY Times (Aug. 27, 2018),  
<https://www.nytimes.com/2018/08/27/science/juul-vaping-teen-marketing.html>.

JLI employees discussed an online purchase of JUUL products made by a fifteen-year-old boy. A JLI employee wrote that “[t]his order had failed age verification a few times with the person’s information as below. The person even uploaded an ID, which was obviously fake and rejected by us. Then, the user entered a different email address and passed from Veratad, and the order was sent.” The employee discussed a communication with Veratad that confirmed that Veratad did not review the date of birth entered by the user when determining whether a person passed age verification for JUUL. JLI recognized that “[t]his situation can potentially happen again.”<sup>540</sup>

457. Internal JLI documents confirm that JLI discussed underage purchases with Veratad. For example, on May 27, 2016, JLI’s Head of Compliance & Brand Protection wrote that an “underage purchaser changed his email address; which, allowed the order to be passed by Veratad. . . . I believe that Nick and his team are still looking into the matter with Veratad to see if they can get a better understanding of what happened.” A JLI employee replied “hmmm. Probably impossible to put up an age gate that thwarts a committed teenager from penetrating it :)”<sup>541</sup>

458. Nevertheless, the two companies worked together to find ways to “bump up [JLI’s] rate of people who get through age verification.”<sup>542</sup> JLI repeatedly sought, and Veratad repeatedly recommended and directed, changes to the age verification process so that more prospective JUUL purchasers would “pass.” Both did so in an effort to increase direct sales of JLI’s e-cigarettes without regard to whether its less stringent age verification process would permit more underage consumers to purchase them.

459. Between June 2015 and August 2017 (and perhaps even through early 2018), JLI and Veratad tailored the age verification system to “pass” prospective purchasers even if certain portions of the purchaser’s personal information—e.g., the purchaser’s street address or date of birth—did not match the information corresponding to a person of the minimum legal sales age

---

<sup>540</sup> INREJUUL\_00300253-258.

<sup>541</sup> INREJUUL\_00209176-180.

<sup>542</sup> INREJUUL\_00276489-INREJUUL\_00276490.

1 in Veratad's database.<sup>543</sup>

2 460. Similarly, between June 2015 and August 2017, JLI and Veratad tailored the  
3 system to "pass" a prospective purchaser under certain circumstances even when the  
4 prospective purchaser's year of birth did not match the information corresponding to a person of  
5 the minimum legal sales age in Veratad's database.

6 461. JLI and Veratad sought to increase "pass" rates by modifying the age verification  
7 system to allow users multiple opportunities to change their personal information if a match was  
8 not initially found in an appropriate government database. A Veratad Performance Report from  
9 August 5, 2017 shows that, for 1,963 consumers Veratad recorded 3,794 transactions—an  
10 average of 1.93 attempts per consumer.<sup>544</sup> Only 966 consumers—less than half—passed age  
11 verification on the first attempt.<sup>545</sup> By allowing consumers to alter their personal information  
12 and attempt age verification up to three times, JLI was able to increase its database match pass  
13 rate from 49.2% to 61.2%.<sup>546</sup>

14 462. By design, these lax requirements ensured underage consumers could "pass"  
15 JLI's age verification process and purchase JUUL e-cigarettes directly from JLI's website by  
16 using their parent's name, home address, and an approximate date of birth. JLI was aware of  
17 this fact, as evidenced by the multiple complaints it received from parents who alleged their  
18 children did just that.<sup>547</sup>

19 463. JLI directed and approved the system it had implemented with Veratad that  
20

---

21  
22 <sup>543</sup> Complaint at 43, *People v. JUUL Labs, Inc.*, No. RG19043543 (Super. Ct. of Cal. Nov. 18,  
23 2019), <https://oag.ca.gov/system/files/attachments/press-docs/91186258.pdf>. A January 29,  
24 2018 email exchange between Tom Canfarotta, Director of Strategic Accounts & Client  
25 Quality Services at Veratad, and Annie Kennedy, JUUL's Compliance Manager, reveals this to  
26 have been the case. Kennedy asked Canfarotta why a particular customer had "passed via the  
27 address step (public record check)...but we've since learned that is not a correct address—so  
28 we're curious as to how it passed." In response, Canfarotta wrote, "Your current rule set does  
not require a full address match." He went on to explain that approval of the customer was not  
an anomaly or a mistake; instead, Veratad's age verification system was working exactly the  
way it was designed.

<sup>544</sup> *Id.*

<sup>545</sup> *Id.*

<sup>546</sup> *Id.*

<sup>547</sup> INREJUUL\_00184119.



caused accounts with “bad info” to be “AV approved” but, as a Senior Business Systems Manager at JLI commented, “if [v]eratad passed it [then] it’s not on us.”

464. JLI customer service representatives even encouraged those who failed age verification to “make multiple accounts in order to pass AV [age verification].”<sup>548</sup> Customer service representatives would go so far as to alter identifying information for them; a Slack chat among customer service representatives confirmed that representatives were authorized to “adjust the street address, apartment number, or zip code” associated with shipment.<sup>549</sup>

465. The age verification procedures designed by JLI and Veratad have allowed hundreds of thousands of e-cigarette products to be sold and/or delivered to fictitious individuals at fictitious addresses.<sup>550</sup> Many of these improper sales may have been made to underage purchasers or to resellers who sold the products to underage consumers on the grey market.<sup>551</sup>

466. By divorcing the address from the other customer data in the age verification process, JLI and Veratad allowed consumers to request that tobacco products be sent to locations other than their permanent legal residences.<sup>552</sup> For example, JLI sent thousands of orders to commercial high rises and office parks.<sup>553</sup> It is unlikely these orders would have been approved had JUUL and Veratad required that addresses provided by users match information in an appropriate government database and followed the requirement that the shipping address and billing address be the same.<sup>554</sup>

467. The failure of the JLI/Veratad age verification procedure was intentional.<sup>555</sup> And despite JLI’s concerted effort to enable the sale of federally regulated tobacco products to minors, JLI nevertheless publicly touted Veratad as the “gold standard” of age verification

---

<sup>548</sup> INREJUUL\_00215324-INREJUUL\_00215325.

<sup>549</sup> Complaint at 168, *People v. JUUL Labs, Inc.*, No. RG19043543 (Super. Ct. of Cal. Nov. 18, 2019), <https://oag.ca.gov/system/files/attachments/press-docs/91186258.pdf>.=..

<sup>550</sup> *Id.* at 138.

<sup>551</sup> *Id.*

<sup>552</sup> *Id.* at 146.

<sup>553</sup> *Id.* at 147.

<sup>554</sup> *Id.*

<sup>555</sup> *Id.* at 173.

services. For example, JLI told a reporter with CBS, Pam Tighe, that “[t]here is an extensive age verification process in place to purchase JUUL online” and that JLI “work[s] with Veratad Technologies, the state-of-the-art, gold-standard for age verification. . . . Veratad uses billions of records from multiple trusted data sources to verify the information customers provide and to ensure customers qualify to access and purchase products from JUULvapor.com.”<sup>556</sup> JLI later planned on sending this same, canned false language to a student journalist at Georgetown University.<sup>557</sup> Similarly, a JLI spokesperson told a reporter at a New York newspaper, *AMNY*, that JLI uses “industry-leading ID match and age verification technology to ensure that customers” are over twenty-one years of age and that the “information is verified against multiple databases.”<sup>558</sup>

468. In August 2017, JLI responded to public scrutiny by publicly stating that it would increase the purchase age on its website to 21+ by August 23, 2017. In the weeks leading up to that date, it emailed the approximately 500,000 or more potential customers to report that customers who signed up for JLI’s “auto-ship” subscription service before August 23, 2017 would not have to prove that they were 21+ for as long as they maintained the subscription to receive JUULpods. As discussed herein, JLI knew that these marketing emails were being sent to underage individuals, including those who failed age verification. And at the same time, JLI advertised that the most popular flavor among youth, Mango, was now available on its “auto-ship” subscription service. As a result of this scheme, JLI’s subscription gains more than offset any losses from the site’s heightened age verification requirements.

---

<sup>556</sup> INREJUUL00178123-24.

<sup>557</sup> INREJUUL\_00264882-84.

<sup>558</sup> Alison Fox, *‘Juil’ e-cigarettes require stronger FDA regulation, Schmuier Says*, *AMNY*, (Oct. 15, 2017), <https://www.amny.com/news/juul-e-cigarettes-fda-regulation-1-14485385/>.

**Sunday Savings**  
1 message

JUUL <hello@juulvapor.com>  
Reply To: JUUL <hello@juulvapor.com>  
To:

Sun, Aug 20, 2017 at 7:48 PM

Experience the easiest way to enjoy JUUL and save 15% on each and every purchase.

**JUUL**

**Save 15%  
Today**

**SAVE NOW**

Try Auto-Ship for free shipping and 15% savings  
on each and every JUUL order.



**Save Money**

Enjoy 15% savings  
on JUULpods.



**Free Delivery**

JUULpods delivered to  
your door every month.



**Cancel Anytime**

No contracts.  
No stress.



mango



cool mint



virginia tobacco



fruit medley



creamy vanilla

**5 Great  
Flavors To  
Choose From**

**SHOP JUULPODS >**

**Changes to JUUL Minimum Age Policy**

Starting this Wednesday 8/23/17, the minimum age to purchase  
products on JUULvapor.com will be 21+.

Existing age-verified Auto-Ship subscribers will not be impacted by this change.

**Need Help?**

Contact [JUL Support](#)

Live support is available everyday, 9am-10pm PT.

JUULVAPOR

JUUL

1471 4th Avenue St. #17

JUULVAPOR.COM

**JUUL** @JUULvapor · 28 Jul 2017  
#ICYM! Mango is now in Auto-ship! Get the #JUULpod flavor you love delivered  
& save 15%. Sign up today: [bit.ly/2su3cXJ](https://bit.ly/2su3cXJ)



5

19

469. Further underscoring JLI's purpose of growing the e-cigarette market, even if that meant selling to youth, JLI and Veratad did not require that the year of birth and last four digits of the social security number match exactly the information corresponding to a person of the minimum legal sales age in Veratad's database until August 2018.

470. Tellingly, after JLI and Veratad implemented industry-standard age verification practices, JLI boasted to the FDA that approval rate for sales on its website had dropped to 27%.

471. While on one hand JLI continued working with Veratad to ensure minors could purchase JUUL products online, on the other JLI continued to make false and fraudulent statements about the strength of its age verification system. For example, on June 5, 2018, JLI tweeted about its relationship with Veratad, claiming that "We've partnered with Veratad Technologies to complete a public records search, only reporting back whether or not you are 21 years of age or older."<sup>559</sup> In addition, on November 13, 2018, JLI and the Management Defendants caused a post to appear on JLI's website stating that JLI was "Restricting Flavors to Adults 21+ On Our Secure Website" and that JLI's age-verification system was "an already industry-leading online sales system that is restricted to 21+ and utilizes third party verification."<sup>560</sup> A video accompanying this message stated "At JUUL labs we're committed to leading the industry in online age verification security to ensure that our products don't end up in the hands of underage users" and included an image of a computer with a chain wrapped around it and locked in place.<sup>561</sup> These statements were fraudulent because JLI and the Management Defendants were and had been coordinating with Veratad to ensure that their age verification system did not actually prevent youth from purchasing JUUL products.

472. Not only did JLI's efforts result in more sales to minors, JLI was also able to build a marketing email list that included minors—a data set that would prove highly valuable to Altria.

---

<sup>559</sup> JUUL Labs, Inc. (@JUULvapor), Twitter (June 5, 2018), <https://twitter.com/juulvapor/status/1004055352692752386>.

<sup>560</sup> *JUUL Labs Action Plan* ("November 2018 Action Plan"), JUUL Labs, Inc. (Nov. 12, 2018), <https://newsroom.juul.com/juul-labs-action-plan/> (last visited Apr. 30, 2020).

<sup>561</sup> *Id.*

473. In the summer of 2017, JLI engaged a company called Tower Data to determine the ages of the persons associated with email addresses on its email marketing list. According to this analysis, approximately 269,000 email addresses on JLI's email marketing list were not associated with a record of an individual who had "passed" JLI's age verification process.<sup>562</sup> Additionally, approximately 40,000 email addresses on JLI's email marketing list were associated with records of individuals who had "failed" JLI's own age verification process.<sup>563</sup> Tower Data informed JLI that 83% of the approximately 420,000 email addresses on JLI's marketing list could not be matched with the record of an individual at least eighteen years of age.<sup>564</sup>

474. Despite knowing that their marketing list included minors, JLI continued to use that marketing list to sell JUUL products, and then shared that list with Altria to use for its marketing purposes.

475. JLI and the Management Defendants knew, however, that it was not enough to disseminate advertisements and marketing materials that promote JLI to youth or to open online sales to youth, while omitting mention of JUUL's nicotine content and manipulated potency. To truly expand the nicotine market, they needed to deceive those purchasing a JUUL device and JUULpods as to how much nicotine they were actually consuming. And, through Pritzker, Huh, and Valani's control of JLI's Board of Directors, they did just that.

## 12. JLI Engaged in a Sham "Youth Prevention" Campaign

476. By April 2017, JLI had determined that the publicity around its marketing to children was a problem. Ashley Gould, the company's General Counsel and Chief Regulatory and Communications Officer, thus sought to "hire a crisis communication firm to help manage

---

<sup>562</sup> Complaint at 121, *Commonwealth of Massachusetts v. JUUL*, et al., No. 20-00402 (Super. Ct. of Mass. Feb. 12, 2020) <https://www.mass.gov/doc/juul-complaint/download>; Janice Tan, *E-cigarette firm JUUL sued for using programmatic buying to target adolescents*, Marketing (Feb. 14, 2020), <https://www.marketing-interactive.com/e-cigarette-firm-juul-sued-for-using-programmatic-buying-to-target-adolescents>.

<sup>563</sup> *Id.*

<sup>564</sup> *Id.*

the youth interest JUUL has received[.]”<sup>565</sup> By June 2017, JLI began developing a “youth prevention program[.]”<sup>566</sup> While ostensibly aimed at reducing youth sales, JLI’s youth prevention program actually served to increase, not reduce, sales to children.

477. By December 2017, JLI’s youth prevention program included extensive work with schools.<sup>567</sup> JLI paid schools for access to their students during school time, in summer school, and during a Saturday School Program that was billed as “an alternative to ‘traditional discipline’ for children caught using e-cigarettes in school.”<sup>568</sup> JLI created the curriculum for these programs, and, like the “Think Don’t Smoke” campaign by Philip Morris, which “insidiously encourage[d] kids to use tobacco and become addicted Philip Morris customers[.]”<sup>569</sup> JLI’s programs were shams intended to encourage youth ee-cigarette use, not curb it. According to testimony before Congress, during at least one presentation, “[n]o parents or teachers were in the room, and JUUL’s messaging was that the product was ‘totally safe.’ The presenter even demonstrated to the kids how to use a JUUL.”<sup>570</sup> Furthermore, JLI “provided the children snacks” and “collect[ed] student information from the sessions.”<sup>571</sup>

478. The problems with JLI’s youth prevention programs were widespread. According to outside analyses, “the JUUL Curriculum is not portraying the harmful details of their product, similar to how past tobacco industry curricula left out details of the health risks of cigarette use.”<sup>572</sup> Although it is well-known that teaching children to deconstruct ads is one of

<sup>565</sup> INREJUUL\_00264878; *see also* INREJUUL\_00265042 (retaining Sard Verbinnen, a strategic communications firm).

<sup>566</sup> *See, e.g.*, INREJUUL\_00211242.

<sup>567</sup> INREJUUL\_00173409.

<sup>568</sup> Subcommittee on Economic and Consumer Policy Memo (July 25, 2019), <https://oversight.house.gov/sites/democrats.oversight.house.gov/files/Supplemental%20Memo.pdf>.

<sup>569</sup> William V. Corr, *American Legacy Foundation Study Shows Philip Morris 'Think Don't Smoke' Youth Anti-Smoking Campaign is a Sham*, Campaign for Tobacco Free Kids (May 29, 2002), [https://www.tobaccofreekids.org/press-releases/id\\_0499](https://www.tobaccofreekids.org/press-releases/id_0499).

<sup>570</sup> Subcommittee on Economic and Consumer Policy Memo (July 25, 2019), <https://oversight.house.gov/sites/democrats.oversight.house.gov/files/Supplemental%20Memo.pdf>.

<sup>571</sup> *Id.*

<sup>572</sup> Victoria Albert, *Juul Prevention Program Didn't School Kids on Dangers, Expert Says*, The Daily Beast (Oct. 19, 2018), <https://www.thedailybeast.com/juul-prevention-program-didnt-school-kids-on-dangers-expert-says>.



the most effective prevention techniques, JLI programs entirely omitted this skill, and JLI’s curriculum barely mentioned JUUL products as among the potentially harmful products to avoid.<sup>573</sup> As one expert pointed out, “we know, more from anecdotal research, that [teens] may consider [JUULs] to be a vaping device, but they don’t call it that. So when you say to a young person, ‘Vapes or e-cigarettes are harmful,’ they say, ‘Oh I know, but I’m using a JUUL.’”<sup>574</sup>

479. Internal emails confirm both that JLI employees knew about the similarities of JLI’s “youth prevention program” to the earlier pretextual antismoking campaigns by the cigarette industry and that JLI management at the highest levels was personally involved in these efforts. In April 2018, Julie Henderson, the Youth Prevention Director, emailed school officials about “the optics of us attending a student health fair” because of “how much our efforts seem to duplicate those of big tobacco (Philip Morris attended fairs and carnivals where they distributed various branded items under the guise of ‘youth prevention’).”<sup>575</sup> She later wrote that she would “confirm our participation w[ith] Ashley & Kevin”<sup>576</sup>—an apparent reference to Kevin Burns, at the time the CEO of JLI, who would later personally approve JLI’s involvement in school programs. In May 2018, Julie Henderson spoke with former members of Philip Morris’s “youth education” team,<sup>577</sup> and Ashley Gould received and forwarded what was described as “the paper that ended the Think Don’t Smoke campaign undertaken by Philip Morris.”<sup>578</sup> The paper concluded that “the Philip Morris campaign had a counterproductive influence.”<sup>579</sup>

480. JLI also bought access to teenagers at programs outside of school. For example, JLI paid \$89,000 to the Police Activities League of Richmond, California, so that all youth in the Richmond Diversion Program—which targeted “youth, aged 12-17, who face suspension

---

<sup>573</sup> *Id.*

<sup>574</sup> *Id.*

<sup>575</sup> INREJUUL\_00197608.

<sup>576</sup> INREJUUL\_00197607.

<sup>577</sup> INREJUUL\_00196624.

<sup>578</sup> INREJUUL\_00265202.

<sup>579</sup> Matthew C. Farrelly et al., *Getting to the Truth: Evaluating National Tobacco Countermarketing Campaigns*, 92 Am. J. Public Health 901 (2002).

from school for using e-cigarettes and/or marijuana” and “juveniles who have committed misdemeanor (lesser category) offenses”—would “participate in the JUUL labs developed program, Moving Beyond” for as long as ten weeks.<sup>580</sup> Similarly, JLI paid \$134,000 to set up a summer program for 80 students from a charter school in Baltimore, Maryland.<sup>581</sup> Participants were “recruited from grades 3 through 12”<sup>582</sup> and worked closely with teachers to develop personal health plans. JLI paid nearly 70% of the cost of hiring eight teachers, eight instructional aides, and three other support personnel for the program.<sup>583</sup>

481. JLI was aware that these out-of-school programs were, in the words of Julie Henderson, “eerily similar” to the tactics of the tobacco industry.<sup>584</sup> In June 2018, Ms. Henderson described “current executive concerns & discussion re: discontinuing our work w[ith] schools[.]”<sup>585</sup> Eventually, JLI ended this version of the youth prevention program, but the damage had been done: following the playbook of the tobacco industry, JLI had hooked more kids on nicotine.

482. The Board was intimately involved in these “youth prevention” activities. For example, in April 2018, Riaz Valani and Nicholas Pritzker edited a youth prevention press release, noting that they “don’t want to get these small items wrong” and “think it’s critical to get this right.”<sup>586</sup>

### 13. The FDA Warned JUUL and Others That Their Conduct is Unlawful

483. Throughout 2018, the FDA put JLI and others in the e-cigarette industry on notice that their practices of marketing to minors needed to stop. It issued a series of warnings

<sup>580</sup> JLI-HOR-00002181 – 00002182.

<sup>581</sup> INREJUUL\_00194247; Invoice to JUUL Labs from The Freedom & Democracy Schools, Inc. for \$134,000, dated June 21, 2018, <https://oversight.house.gov/sites/democrats.oversight.house.gov/files/JLI-HOR-00003711.pdf>.

<sup>582</sup> INREJUUL\_0019428.

<sup>583</sup> The Freedom & Democracy Schools, Inc., *Proposal to JUUL Labs for Funding the Healthy Life Adventures Summer Pilot* (June 9, 2018), [https://oversight.house.gov/sites/democrats.oversight.house.gov/files/JLI-HOR-00002789\\_Redacted.pdf](https://oversight.house.gov/sites/democrats.oversight.house.gov/files/JLI-HOR-00002789_Redacted.pdf).

<sup>584</sup> INREJUUL\_00194646.

<sup>585</sup> INREJUUL\_00194646.

<sup>586</sup> JLI00151300.

1 letters and enforcement actions:

2 484. On February 24, 2018, the FDA sent a letter to JLI expressing concern about the  
3 popularity of its products among youth and demanding that JLI produce documents regarding its  
4 marketing practices.<sup>587</sup>

5 485. In April 2018, the FDA conducted an undercover enforcement effort, which  
6 resulted in fifty-six warning letters issued to online retailers, and six civil money complaints to  
7 retail establishments, all of which were related to the illegal sale of e-cigarettes to minors.<sup>588</sup>  
8 Manufacturers such as JLI were also sent letters requesting documents regarding their  
9 marketing and sales methods.<sup>589</sup>

10 486. In May 2018, the FDA again issued more warning letters to manufacturers,  
11 distributors, and retailers of e-liquids for labeling and advertising violations; these labels and  
12 advertisements targeted children and resembled children's food items such as candy or  
13 cookies.<sup>590</sup>

- 14 • In September 2018, the FDA engaged in several other regulatory enforcement  
15 actions, issuing over 1300 warning letters and civil money complaints to e-  
cigarette and e-liquid retailers and distributors.<sup>591</sup>
- 16 • On September 12, 2018, the FDA sent letters to JLI and other e-cigarette  
17 manufacturers putting them on notice that their products were being used by  
18 youth at disturbing rates.<sup>592</sup> The FDA additionally requested manufacturers to  
19 enhance their compliance monitoring mechanisms, implement stricter age  
verification methods, and limit quantities and volume of e-cigarette products that  
could be purchased at a time.<sup>593</sup>

21 <sup>587</sup> Matthew Holman, *Letter from Director of Office of Science, Center for Tobacco Products,*  
22 *to Zaid Rouag, at JUUL Labs, Inc.*, U.S. FDA (Apr. 24, 2018),  
<https://www.fda.gov/media/112339/download>.

23 <sup>588</sup> *Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed*  
24 *Products on the Market Without Premarket Authorization*, U.S. FDA (Jan. 2020),  
<https://www.fda.gov/media/133880/download>.

25 <sup>589</sup> *Id.*

26 <sup>590</sup> *Id.*

27 <sup>591</sup> *Id.*

28 <sup>592</sup> *Letter from US FDA to Kevin Burns*, U.S. FDA (Sept. 12, 2018),  
<https://www.fda.gov/media/119669/download>.

<sup>593</sup> Press Release, *FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access*, US FDA (Sept. 11, 2018), <https://www.fda.gov/news-events/press->

487. Finally, in October 2018, the FDA raided JLI's headquarters and seized more than a thousand documents relating to JLI's sales and marketing practices.<sup>594</sup> Since then, the FDA, the Federal Trade Commission, multiple state attorneys general and the U.S. House of Representatives Committee on Oversight and Reform have all commenced investigations into JLI's role in the youth e-cigarette epidemic and whether JLI's marketing practices purposefully targeted youth.

488. Siddharth Breja, who was senior vice president for global finance at JLI, "claims that after the F.D.A. raided Juul headquarters in October 2018, seeking internal documents, Mr. Burns instructed Mr. Breja and other executives not to put anything relating to regulatory or safety issues in writing, so that the F.D.A. could not get them in the future."<sup>595</sup>

**14. In Response to Regulatory Scrutiny, Defendants Misled the Public, Regulators, and Congress that JLI Did Not Target Youth**

489. To shield their youth-driven success from scrutiny, Altria, JLI, and the Management Defendants' had a long-running strategy to feign ignorance over JLI and the Management Defendants' youth marketing efforts and youth access to JLI's products. They were well aware that JLI's conduct in targeting underage users was reprehensible and unlawful, and that if it became widely known that this was how JLI obtained its massive market share, there would be a public outcry and calls for stricter regulation or a ban on JLI's products. Given the increasing public and regulatory scrutiny of JLI's market share and marketing tactics, a disinformation campaign was urgently needed to protect the Defendants' bottom line. For this reason, JLI, the Management Defendants, and Altria all hid JLI's conduct by vociferously denying that JLI had marketed to and targeted youth and instead falsely claimed that JLI

[announcements/fda-takes-new-steps-address-epidemic-youth-e-cigarette-use-including-historic-action-against-more.](#)

<sup>594</sup> Laurie McGinley, *FDA Seizes Juul E-Cigarette Documents in Surprise Inspection of Headquarters*, Wash. Post (Oct. 2, 2018), <https://www.washingtonpost.com/health/2018/10/02/fda-seizes-juul-e-cigarette-documents-surprise-inspection-headquarters/>.

<sup>595</sup> Sheila Kaplan & Jan Hoffman, *Juul Knowingly Sold Tainted Nicotine Pods, Former Executive Say*, N.Y. Times (Nov. 20, 2019), <https://www.nytimes.com/2019/10/30/health/juul-pods-contaminated.html>.

engaged in youth prevention. Defendants continued to make these statements while and after actively and successfully trying to market to and recruit youth non-smokers. These false statements were designed to protect JLI's market share, and Altria's investment, by concealing JLI's misconduct.

490. For example, after 11 senators sent a letter to JLI questioning its marketing approach and kid-friendly e-cigarette flavors like Fruit Medley, Creme Brulee and mango, JLI visited Capitol Hill and told senators that it never intended its products to appeal to kids and did not realize youth were using its products, according to a staffer for Sen. Dick Durbin (D-Ill.). JLI's statements to Congress—which parallel similar protests of innocence by tobacco company executives—were false.

491. Defendants also caused JLI to make public statements seeking to disavow the notion that it had targeted and sought to addict teens:

- “It’s a really, really important issue. **We don’t want kids using our products.**” (CNBC Interview of JLI’s Chief Administrative Officer, December 14, 2017)<sup>596</sup>
- “We market our products responsibly, following strict guidelines to have material directly **exclusively toward adult smokers and never to youth audiences.**” (JLI Social Media Post, March 14, 2018)<sup>597</sup>
- “Our company’s mission is to eliminate cigarettes and **help the more than one billion smokers worldwide switch to a better alternative,**” said JUUL Labs Chief Executive Officer Kevin Burns. “We are already seeing success in our efforts to enable adult smokers to transition away from cigarettes and believe our products have the potential over the long-term to contribute meaningfully to public health in the U.S. and around the world. At the same time, we are committed to deterring young people, as well as adults who do not currently smoke, from using our products. **We cannot be more emphatic on this point: No young person or non-nicotine user should ever try JUUL.**” (JLI Press Release, April 25, 2018);<sup>598</sup>
- “Our objective is to provide the 38 million American adult smokers with **meaningful alternatives to cigarettes while also ensuring that individuals who**

<sup>596</sup> Angelica LaVito, *Nearly one-quarter of teens are using pot*, CNBC (Dec. 14, 2017), <https://www.cnbc.com/2017/12/13/marijuana-and-nicotine-vaping-popular-among-teens-according-to-study.html> (Interview with Ashely Gould, JUUL Chief Administrative Officer) (emphasis added).

<sup>597</sup> Robert K. Jackler et al., *JUUL Advertising Over Its First Three Years on the Market*, Stan Rsch. into the Impact of Tobacco Advert. 15 (Jan. 31, 2019), [http://tobacco.stanford.edu/tobacco\\_main/publications/JUUL\\_Marketing\\_Stanford.pdf](http://tobacco.stanford.edu/tobacco_main/publications/JUUL_Marketing_Stanford.pdf) (citing a JUUL social media post from March 14, 2018) (emphasis added).

<sup>598</sup> JUUL Labs, Inc., *JUUL Labs Announces Comprehensive Strategy to Combat Underage Use*, MarketWatch (Apr. 25, 2018), <https://www.marketwatch.com/press-release/juul-labs-announces-comprehensive-strategy-to-combat-underage-use-2018-04-25> (emphasis added).

are not already smokers, particularly young people, are not attracted to nicotine products such as JUUL,” said JUUL Labs Chief Administrative Officer Ashley Gould, who heads the company's regulatory, scientific and youth education and prevention programs. “We want to be a leader in seeking solutions, and are actively engaged with, and listening to, community leaders, educators and lawmakers on how best to effectively keep young people away from JUUL.” (JLI Press Release, April 25, 2018);<sup>599</sup>

- “Of course, we understand that **parents and lawmakers are concerned about underage use of JUUL. As are we.** We can’t restate this enough. As an independent company that is not big tobacco, we are driven by our mission and commitment to adult smokers.” (JLI CEO Kevin Burns Letter to JUUL Community on Reddit, July 18, 2018)<sup>600</sup>
- “We welcome the opportunity to work with the Massachusetts Attorney General because, **we too, are committed to preventing underage use of JUUL.** We utilize stringent online tools to block attempts by those under the age of 21 from purchasing our products, including unique ID match and age verification technology. Furthermore, we have never marketed to anyone underage. Like many Silicon Valley technology startups, our growth is not the result of marketing but rather a superior product disrupting an archaic industry. When adult smokers find an effective alternative to cigarettes, they tell other adult smokers. That’s how we’ve gained 70% of the market share. . . . Our ecommerce platform utilizes unique ID match and age verification technology to make sure minors are not able to access and purchase our products online.” (Statement from Matt David, JLI Chief Communications Officer, July 24, 2018);<sup>601</sup>
- “**We did not create JUUL to undermine years of effective tobacco control, and we do not want to see a new generation of smokers.** . . . We want to be part of the solution to end combustible smoking, not part of a problem to attract youth, never smokers, or former smokers to nicotine products. . . . We adhere to strict guidelines to ensure that our marketing is directed towards existing adult smokers.” (JLI’s website as of July 26, 2018);<sup>602</sup>
- “We don’t want anyone who doesn’t smoke, or already use nicotine, to use JUUL products. We certainly don’t want youth using the product. It is bad for public health, and it is bad for our mission. JUUL Labs and FDA share a common goal – preventing youth from initiating on nicotine. . . . **Our intent was never to have youth use JUUL products.**” (JLI Website, November 12, 2018)<sup>603</sup>

<sup>599</sup> *Id* (emphasis added).

<sup>600</sup> *A Letter to the JUUL Community from CEO Kevin Burns*, Reddit (July 18, 2018), [https://www.reddit.com/r/juul/comments/8zvlbh/a\\_letter\\_to\\_the\\_juul\\_community\\_from\\_ceo\\_kevin/](https://www.reddit.com/r/juul/comments/8zvlbh/a_letter_to_the_juul_community_from_ceo_kevin/) (emphasis added).

<sup>601</sup> *Statement Regarding The Press Conference Held By The Massachusetts Attorney General*, JUUL Labs, Inc. (July 24, 2018), <https://newsroom.juul.com/statement-regarding-the-press-conference-held-by-the-massachusetts-attorney-general/> (emphasis added).

<sup>602</sup> *Our Responsibility*, JUUL Labs, Inc. (July 26, 2018), <https://web.archive.org/web/20180726021743/https://www.juul.com/our-responsibility> (last visited Mar. 29, 2020) (emphasis added).

<sup>603</sup> *JUUL Labs Action Plan*, JUUL Labs, Inc. (Nov. 13, 2018), <https://newsroom.juul.com/juul-labs-action-plan/> (statement of Ken Burns, former CEO of JUUL) (emphasis added).



- 1 • “To paraphrase Commissioner Gottlieb, **we want to be the offramp for adult**
- 2 **smokers** to switch from cigarettes, not an on-ramp for America’s youth to initiate
- 3 on nicotine.” (JLI Website, November 13, 2018)<sup>604</sup>
- 4 • “Any underage consumers using this product are absolutely a negative for our
- 5 business. We don’t want them. **We will never market to them. We never have.**”
- 6 (James Monsees, quoted in *Forbes*, November 16, 2018);<sup>605</sup>
- 7 • “First of all, I’d tell them that I’m sorry that their child’s using the product. **It’s**
- 8 **not intended for them.** I hope there was nothing that we did that made it
- 9 appealing to them. As a parent of a 16-year-old, I’m sorry for them, and I have
- 10 empathy for them, in terms of what the challenges they’re going through.”
- 11 (CNBC Interview of JLI CEO, July 13, 2019)<sup>606</sup>
- 12 • “We have **no higher priority than to prevent youth usage of our products**
- 13 which is why we have taken aggressive, industry leading actions to combat youth
- 14 usage.” (JLI Website, August 29, 2019)<sup>607</sup>
- 15 • James Monsees, one of the company’s co-founders, said **selling JUUL products**
- 16 **to youth was “antithetical to the company’s mission.”**(James Monsees’
- 17 Statement to New York Times, August 27, 2019)<sup>608</sup>
- 18 • Adam Bowen, one of the company’s co-founders, said he was aware early on of
- 19 the risks e-cigarettes posed to teenagers, and the **company had tried to make**
- 20 **JUUL “as adult-oriented as possible.”**(Adam Bowen’s Statement to the New
- 21 York Times, August 27, 2019);<sup>609</sup>
- 22 • “**We have never marketed to youth and we never will.**”(JLI Statement to Los
- 23 Angeles Times, September 24, 2019);<sup>610</sup>
- 24 • “I have long believed in a future where adult smokers overwhelmingly choose
- 25 alternative products like JUUL. **That has been this company’s mission since it**
- 26 **was founded,** and it has taken great strides in that direction.” (JLI’s CEO K.C.
- 27 Crosthwaite, September 25, 2019);<sup>611</sup>
- 28

---

<sup>604</sup> *Id.* (emphasis added).

<sup>605</sup> Kathleen Chaykowski, *The Disturbing Focus of Juul’s Early Marketing Campaigns*, *Forbes* (Nov. 16, 2018 2:38 PM), <https://www.forbes.com/sites/kathleenchaykowski/2018/11/16/the-disturbing-focus-of-juuls-early-marketing-campaigns/#3da1e11b14f9> (emphasis added) (statement of James Monsees).

<sup>606</sup> Angelica LaVito, *As JLI grapples with teen vaping ‘epidemic,’ CEO tells parent ‘I’m sorry’*, *CNBC* (July 13, 2019), <https://www.cnn.com/2019/07/13/as-juul-deals-with-teen-vaping-epidemic-ceo-tells-parents-im-sorry.html> (emphasis added).

<sup>607</sup> *Our Actions to Combat Underage Use*, JUUL Labs, Inc. (Aug. 29, 2019), <https://newsroom.juul.com/our-actions-to-combat-underage-use/> (JUUL statement in response to lawsuits) (emphasis added).

<sup>608</sup> Matt Richtel & Sheila Kaplan, *Did Juul Lure Teenagers and Get ‘Customers for Life’?*, *N.Y. Times* (Aug. 27, 2018), <https://www.nytimes.com/2018/08/27/science/juul-vaping-teen-marketing.html> (emphasis added).

<sup>609</sup> *Id.* (emphasis added).

<sup>610</sup> Michael Hiltzik, *Column: Studies show how JLI exploited social media to get teens to start vaping*, *L.A. Times* (Sept. 24, 2019), <https://www.latimes.com/business/story/2019-09-24/hiltzik-juul-target-teens> (statement made on behalf of JUUL) (emphasis added).

<sup>611</sup> Juul Labs Names New Leadership, Outlines Changes to Policy and Marketing Efforts, JUUL Labs, Inc. (Sept. 25, 2019), <https://newsroom.juul.com/juul-labs-names-new-leadership-outlines-changes-to-policy-and-marketing-efforts/> (emphasis added) (statement by K.C. Crosthwaite).

- “As scientists, product designers and engineers, we believe that vaping can have a positive impact when used by adult smokers, and can have a negative impact when used by nonsmokers. **Our goal is to maximize the positive and reduce the negative.**” (JLI Website, March 6, 2020).<sup>612</sup>
- **“JUUL was designed with adult smokers in mind.”** (JLI Website, last visited March 29, 2020).<sup>613</sup>

492. Defendants either made these statements directly or caused them to be transmitted as a part of their schemes to defraud the public about what they were selling and to whom.

493. Altria also engaged in wire fraud when it made public statements seeking to disavow the notion that JLI had targeted and sought to addict teens:

- “Altria and JUUL are committed to preventing kids from using any tobacco products. As recent studies have made clear, youth vaping is a serious problem, which both Altria and JUUL are committed to solve. **As JUUL previously said, ‘Our intent was never to have youth use JUUL products.’**” (Altria News Release, December 20, 2018).<sup>614</sup>

494. However, JLI, the Management Defendants, and Altria realized that attempting to shift public opinion through fraudulent statements was not enough to achieve their goal of staving off regulation. To accomplish this goal, they would also need to deceive the FDA and Congress. And so they set out to do just that through statements and testimony by JLI representatives. These include, but are not limited to, the following:

***Statements by JLI to the FDA:***

- “JUUL was not designed for youth, **nor has any marketing or research effort since the product’s inception been targeted to youth.**” (Letter to FDA, June 15, 2018).<sup>615</sup>
- “With this response, the Company hopes FDA comes to appreciate why the product was developed and **how JUUL has been marketed — to provide a**

<sup>612</sup> *Our Mission*, JUUL LABS (2019), <https://www.juul.com/mission-values> (last visited Apr. 4, 2020) (emphasis added).

<sup>613</sup> JUUL Labs, Inc., <https://www.juul.com/> (last visited Mar. 29, 2020) (emphasis added).

<sup>614</sup> Altria Group, Inc., *Altria Makes \$12.8 Billion Minority Investment to Accelerate Harm Reduction and Drive Growth* (“Altria Minority Investment”) (Form 8-K), Ex. 99.1 (Dec. 20, 2018), <https://www.sec.gov/Archives/edgar/data/764180/000119312518353970/d660871dex991.htm> (emphasis added).

<sup>615</sup> Letter from JUUL's Counsel at Sidley Austin to Dr. Matthew Holman, FDA at 2 (June 15, 2018) (emphasis added).

viable alternative to cigarettes for adult smokers.” (Letter to FDA, June 15, 2018).<sup>616</sup>

*Statements by Altria to the FDA:*

- “[W]e do not believe we have a current issue with youth access to or use of our pod-based products, we do not want to risk contributing to the issue.” (Letter from Altria CEO to FDA Commissioner Scott Gottlieb, October 25, 2018).<sup>617</sup>
- “We believe e-vapor products present an important opportunity to **adult smokers to switch from combustible cigarettes.**” (Letter to FDA Commissioner Gottlieb, 10/25/18)

*Statements by JLI to Congress:*

- “We never wanted any non-nicotine user, and certainly nobody under the legal age of purchase, to ever use JLI products. . . . That is a serious problem. Our company has no higher priority than combatting underage use.” (Testimony of James Monsees, July 25, 2019).<sup>618</sup>
- “Our product is **intended to help smokers stop smoking combustible cigarettes.**” (Ashley Gould, JLI Chief Administrative Officer, Testimony before House Committee on Oversight and Reform, July 25, 2019).<sup>619</sup>

*Statements by Altria to Congress:*

- “In late 2017 and into early 2018, we saw that the previously flat e-vapor category had begun to grow rapidly. JUUL was responsible for much of the category growth and **had quickly become a very compelling product among adult vapers.** We decided to pursue an economic interest in JUUL, believing that an investment would **significantly improve our ability to bring adult smokers a leading portfolio of non-combustible products** and strengthen our competitive position with regards to potentially reduced risk products.” (Letter from Altria CEO to Senator Durbin, October 14, 2019).<sup>620</sup>

495. Each of the foregoing statements constitutes an act of wire fraud. JLI, Monsees, and Altria made these statements, knowing they would be transmitted via wire, with the intent

<sup>616</sup> *Id.* at 3 (emphasis added).

<sup>617</sup> Letter from Altria CEO Howard Willard to Dr. Scott Gottlieb, FDA at 2 (October 25, 2018) (emphasis added).

<sup>618</sup> *Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on Oversight and Reform, Subcomm. on Econ. and Consumer Policy*, 116th Cong. 1 (2019) (statement of James Monsees, Co-Founder, JUUL Labs, Inc.), <https://docs.house.gov/meetings/GO/GO05/20190725/109846/HHRG-116-GO05-Wstate-MONSEESJ-20190725.pdf>.

<sup>619</sup> *Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on Oversight and Reform, Subcomm. on Econ. and Consumer Policy*, 116th Cong. (2019) (statement of Ashley Gould, Chief Administrative Officer, JUUL Labs, Inc.), <https://www.c-span.org/video/?462992-1/hearing-cigarettes-teen-usage-day-2&start=6431> at 01:53:25 (emphasis added).

<sup>620</sup> Letter from Howard A. Willard III, Altria to Senator Richard J. Durbin, 6 (October 14, 2019) (emphasis added).

1 to deceive the public, the FDA, and Congress as to the Defendants’ true intentions of hooking  
2 underage users.

3 496. Their disinformation scheme was successful. While certain groups such as the  
4 American Medical Association were calling for a “sweeping ban on vaping products,”<sup>621</sup> no  
5 such ban has been implemented to date. Accordingly, JLI’s highly addictive products remain on  
6 the market and available to underage users.

7 **F. Altria Knew JLI was Targeting Youth and, Together with the Management**  
8 **Defendants, Exercised Control Over JLI to Protect and Expand Youth Sales**  
9 **and Defraud The Public About Their Actions.**

10 **1. Before Altria’s Investment in JLI, Altria Knew JLI Was Targeting**  
11 **Youth.**

12 497. As stated above, according to Howard Willard, Altria first contacted JLI about a  
13 commercial relationship in early 2017, with “confidential discussions” spearheaded by Pritzker  
14 and Valani, on the one hand, and senior executives of Altria and Altria Client Services on the  
15 other, beginning in the Spring of 2017.<sup>622</sup> These continued for eighteen months, culminating in  
16 Altria’s December 2018 equity investment in JLI.

17 498. While at first blush, these meetings between Altria and Altria Client Services and  
18 Pritzker and Valani about potential investment—described in detail below—might seem like  
19 ordinary business activity, they were anything but. For nearly 18 months, Altria and Altria  
20 Client Services dangled the carrot of a multi-billion dollar payout in front of Pritzker and  
21 Valani—months in which Pritzker, Valani, and the other Management Defendants committed  
22 numerous acts of fraud to grow the business of JLI in order to satisfy Altria’s expectations. And  
23 at the same time, Altria and Altria Client Services were actively courting Pritzker and Valani  
24 with that promised payout, they were gathering information on JLI that confirmed Altria would  
25 be purchasing a company with a proven track-record of sales to youths.

26 499. Even before 2017, Altria and Altria Client Services—as with anyone paying

27 <sup>621</sup> Karen Zraick, *A.M.A. Urges Ban on Vaping Products as JLI is Sued by More States*, N.Y.  
28 Times (Nov. 19, 2019), <https://www.nytimes.com/2019/11/19/health/juul-lawsuit-ny-california.html>.

<sup>622</sup> Altria’s October 14, 2019 letter to Senator Durbin, et. al., by Howard Willard III (2019).

1 attention to the e-vapor industry at the time—were well aware that JLI had been targeting kids  
2 with its youthful marketing. As noted above, JLI’s “Vaporized” campaign had made its way  
3 into the national zeitgeist, with Stephen Colbert noting that the advertising appealed “to the  
4 youths.” So, not only did Altria and Altria Client Services know JLI was targeting kids at the  
5 time it reached out to begin negotiations, it also knew that such targeting was highly successful.  
6 A May 23, 2017 presentation by Altria Client Services observed that “[l]ines outside of vape  
7 shops and/or calls to vape shops regarding stock [of JUUL] are common” and that JLI’s sales  
8 revenue was growing at an exponential rate.<sup>623</sup>

9         500. And beginning no later than January 2018, Altria received explicit warnings  
10 about the youth appeal of the JUUL product. During a January 3, 2018 meeting between David  
11 Wise, Steven Schroeder, and Zane Underwood of Altria (Underwood was in communication  
12 with KC Crosthwaite at the time) and Avail Vapor<sup>624</sup> CEO James Xu and Avail Vapor scientists  
13 at Altria’s Headquarters—specifically, in the “Library” conference room—the Altria  
14 representatives requested granular data that Avail had on the sale of JUUL and JUUL pods. The  
15 Altria representatives asked for, and Avail’s representatives provided, data on the number of  
16 sales of certain flavor pods, purchasing patterns, and the demographics of JUUL users. With  
17 regard to the demographics of JUUL users, the Avail representatives showed the Altria  
18 representatives a ski slope diagram indicating that the vast majority of JUUL purchasers at  
19 Avail stores were 18 or 19 years old.

20         501. James Xu of Avail Vapor, who was intimately familiar with JUUL sales and  
21 tracked data related to such sales closely, repeatedly warned Altria executives of the youth  
22 appeal of JUUL. And in November 2018, Xu presented the demographics data on JUUL  
23 directly to KC Crosthwaite (and David Wise), thus providing further evidence that Altria and  
24 Altria Client Services knew of JLI’s role in the youth vaping epidemic prior to Altria’s  
25 investment in JLI.

---

26  
27 <sup>623</sup> ALGAT0002412177.

28 <sup>624</sup> As discussed below, JLI had a partnership with Avail Vapor in which Avail gathered detailed data on the sale of JUUL products. Also discussed below, Altria was a minority owner of Avail at the time.

502. Notwithstanding their own observations about JUUL's success with a young demographic, the data Altria received from Avail which concerned the same, and Xu's repeated warnings, Altria and Altria Client Services aggressively pursued a deal with Pritzker and Valani throughout 2018. Thus, for Altria and Altria Client Services, the large youth make-up of JLI's marketshare was a feature—not a flaw—of the company that it sought to acquire. It is no surprise then that, even in the face of these warnings and knowledge, Altria continued to aggressively pursue an investment or potential acquisition of JLI.

**2. Altria Worked with Pritzker and Valani to Secure Control of JLI and to Exploit JLI for Their Mutual Benefit.**

503. The initial discussions between Altria (and Altria Client Services) and JLI's leadership began no later than the week of April 16, 2017 when JLI's then-CEO Tyler Goldman and Defendant James Monsees met with Steven Schroder, David Wise, and K.C. Crosthwaite of Altria Client Services in San Francisco. Crosthwaite, who would later become CEO of JLI, was at the time the Vice President of Strategy and Business Development for Altria Client Services. Goldman spoke again with Schroeder, Crosthwaite and Wise on April 27, 2017 to discuss "preliminary thoughts on potential ways to work together."<sup>625</sup>

504. Internal documents from the time show that Altria was eyeing JLI as an acquisition target. A May 23, 2017 presentation prepared by Altria Client Services for Altria Group, Inc. titled "Project Mule: Review of E-vapor Closed-System Opportunities" identified JLI (then PAXLabs) as one of two "Potentially Attractive Options."<sup>626</sup> Among the attractive features of JLI was that JUUL had "early market success," had "projected sales to reach ~\$300 million at year-end 2017." But Altria knew that aggressive growth would be necessary, writing that "[g]enerating an attractive return would require consistently strong EBITDA growth." The presentation also viewed as attractive features that JLI offered "mint, berry, tobacco, and cream varieties" with "[i]ndications of additional flavor pods in potential pipeline," and that there "[l]ines outside of vape shops and/or calls to vape shops regarding stock are common." The

<sup>625</sup> JLI01369848.

<sup>626</sup> ALGAT0002412177.



1 presentation also revealed that Altria (through an unidentified subsidiary, though likely Altria  
2 Client Services) had tested “all five flavors” of JUUL pods and was aware of the amount of  
3 “[n]icotine per puff” in a JUUL pod. Altria Client Services’s conclusions about the popularity of  
4 JUUL were consistent with the narrative JLI was presenting to potential investors. JLI’s pitch  
5 deck to investors at the time boasted that “Viral Marketing Wins,” and that JUUL’s super potent  
6 nicotine formulation was “cornering” the consumables market with the highest customer  
7 retention rate of any e-cigarette.<sup>627</sup>

8 505. In a May 31, 2017 presentation prepared by Altria Client Services titled “Closed  
9 Tank for AS Analysis,” Altria Client Services stated that “Nu Mark [a subsidiary of Altria  
10 Group, Inc.] and S&BD [a division of Altria Client Services] have engaged in discussions with  
11 Pax Labs (Juul) . . . regarding a potential transaction.”<sup>628</sup> Altria Client Services noted that it was  
12 seeking “a meeting of senior management of both firms in the next few weeks to explore  
13 potential interest in a transaction.” Notably, to Altria Client Services, the “senior management”  
14 of JLI was interchangeable with Defendants Pritzker and Valani, as later in the same  
15 presentation Altria Client Services stated that it was “[s]eeking a meeting between Altria  
16 management and Pax lead investors to discuss deal interest.”

17 506. From the very beginning of their negotiations, it was clear to Altria and Altria  
18 Client Services that they were operating within a closing window in which JLI’s sales to youths  
19 could continue unabated. In this same May 23, 2017 presentation, Altria Client Services focused  
20 on the “significant risk” of unfavorable regulations to “this rapidly growing product segment”  
21 given that no PMTAs had been granted for closed-pod products.<sup>629</sup> And as set forth below,  
22 Altria and Altria Client Services were well aware of the public scrutiny of JLI’s youth  
23 marketing efforts, which could only lead to unfavorable regulatory action. Altria and Altria  
24 Client Services had to convince Pritzker and Valani to let Altria acquire or buy into JLI before it  
25 was too late.

---

27 <sup>627</sup> INREJUUL\_00349529.

28 <sup>628</sup> ALGAT0002412181.

<sup>629</sup> *Id.*

507. In a June 2017 internal presentation prepared by Altria Client Services in anticipation of the meeting with Pritzker and Valani on a potential deal involving a minority stake in JLI with a call option (i.e., the ability to acquire JLI at a later date), which Altria had codenamed “Project Tree,” Altria Client Services identified Valani and Pritzker as “control[ling] majority of voting power [of JLI] and 44% of economic interests.” Altria Client Services’s stated goal was to “build relationship/rapport” with Valani and Pritzker at their first meeting and to convey “Altria’s strengths and potential strategic contributions,” which included “[e]xpertise building premium and iconic brands,” a “[b]est in class distribution and sales force,” “[e]xperience and resources to navigate a complex [regulatory] environment,” “[r]esources to navigate and respond to evolving [government affairs] landscape,” and a “[s]trategic relationship with Philip Morris international.”<sup>630</sup> More important, though, is that the presentation made clear that Altria and Altria Client Services sought to appeal to Pritzker and Valani’s personal interest as investors, and not just the contributions that Altria and its subsidiaries could make for the business of JLI, noting that its potential deal would “[p]rovide return on percentage of equity invested to date; provide opportunity for upside on equity retained.”<sup>631</sup>

508. From the very beginning of their relationship, Altria and Altria Client Services communicated to Pritzker and Valani—who, in turn, communicated to Defendants Bowen, Monsees, and Huh—that they would profit handsomely by accepting Altria’s investment and following its lead in growing the business of JLI. Of course, and as set forth herein, this growth would be pursued through fraud and deceit to both the public and regulators.

509. Beyond controlling the “majority of voting power” of JLI, Pritzker and Valani were the perfect choice to liaise with Altria and Altria Client Services on behalf of the Management Defendants. Pritzker has been long familiar with the tobacco industry from his family’s ownership of chewing-tobacco giant Conwood before selling it to Reynolds American, Inc., a subsidiary of British American Tobacco. And Valani, for his part, was intimately familiar

---

<sup>630</sup> ALGAT0002834151.

<sup>631</sup> *Id.*

with the business of JLI. He was the company's first "angel investor" and was a regular presence within the halls of JLI (then Pax Labs) well before the company even had a working product.<sup>632</sup> Notably, Pritzker and Valani are the only Defendants who have admitted to using non-discoverable messaging services to communicate regarding JLI business. Pritzker and Valani both used the "Confide" messaging application, which allows users to send encrypted, ephemeral and screenshot proof messages.<sup>633</sup> And Pritzker and Valani both used Signal, which provides state-of-the-art end-to-end encryption for phone calls and messages.<sup>634</sup>

510. Altria was an ideal model for growing JLI. Altria, including through its subsidiaries, has decades of experience targeting kids through youth-appealing marketing images and themes.<sup>635</sup> It also had decades of experience using flavors to hook kids, and still does so in many international markets.<sup>636</sup> And Altria has decades of experience misleading and lying to the public about their efforts to target kids through marketing and flavors, and making similar fraudulent representations to regulators in order to delay or deter regulations.<sup>637</sup> Yet, because it was a party to the Master Settlement Agreement, many of the tactics used by JLI to target kids were unavailable to Altria. So Altria and Altria Client Services found a new way, drawing on Altria's storied history of unlawful activity to partner to the Management Defendants in JLI's fraud at every turn. The result was bundles of cash for the Management Defendants, a new generation of youth customers for Altria and its subsidiaries, and a public left reeling from a rapidly growing youth vaping epidemic.

511. Following their early discussions with Nu Mark and Altria Client Services,

---

<sup>632</sup> Alex Norcia, JUUL Founders' First Marketing Boos Told Us the Vape Giant's Strange, Messy Origins, VICE (Nov. 5, 2019), <https://www.vice.com/en/article/43kmwm/juul-founders-first-marketing-boss-told-us-the-vape-giants-strange-messy-origins>.

<sup>633</sup> Riaz Valani's Responses and Objections to Plaintiffs' First Set of Interrogatories; Nicholas Pritzker's Responses and Objections to Plaintiffs' First Set of Interrogatories.

<sup>634</sup> *Id.*

<sup>635</sup> Hafez, N., & Ling, P. M. (2005). How Philip Morris built Marlboro into a global brand for young adults: implications for international tobacco control. *Tobacco Control*, 14(4), 262-271. Retrieved from <https://escholarship.org/uc/item/5tp828kn>.

<sup>636</sup> Campaign for Tobacco Free Kids, *The Facts about Philip Morris International: Company Is Cause of the Tobacco Problem, Not the Solution* (November 15, 2017), available at [https://www.tobaccofreekids.org/assets/images/content/PMI\\_bad\\_acts.pdf](https://www.tobaccofreekids.org/assets/images/content/PMI_bad_acts.pdf).

<sup>637</sup> See, e.g., *United States v. Philip Morris USA, Inc.*, 449 F. Supp. 2d 1 (D.D.C. 2006).

1 Defendant Valani met with Howard Willard (then-CEO of Altria Group, Inc.) and William  
 2 Gifford (then-CFO and now CEO of Altria Group, Inc.) on July 28, 2017. They discussed  
 3 Altria’s “perspective on the industry, the future of reduced risk products, and your thoughts on  
 4 possible collaboration between ourselves.”<sup>638</sup> Valani followed up on this meeting with an email  
 5 on July 31, 2017 connecting Gifford with Defendant Pritzker, “convey[ing] our warm regards to  
 6 Howard,” and offering to “come to Richmond” in order “to continue our discussion.”<sup>639</sup>

7 512. Defendants Pritzker and Valani traveled to Richmond less than a month later for  
 8 an August 25, 2017 meeting with Howard Willard and William Gifford.<sup>640</sup> Altria Client  
 9 Services, in an internal presentation dated September 2017, would report that either at this  
 10 meeting or the July 2017 meeting, Pritzker and Valani “asked Altria to consider three questions  
 11 to be addressed at the next meeting being scheduled for mid-late September.” Those questions  
 12 focused on the transaction structure and how Altria would assign a value JLI, including its  
 13 international prospects.<sup>641</sup>

14 513. This presentation also reveals that Pritzker and Valani were open to a deal, and  
 15 that they had “high value expectations,” even though the presentation later notes that Pritzker  
 16 and Valani conveyed that JLI “does not need capital.”<sup>642</sup> Taken together, these observations  
 17 make clear that Pritzker and Valani sought a massive payday for themselves and were not  
 18 looking out for the strategic interests of JLI as a corporation. JLI did “not need” the massive  
 19 capital infusion that Altria’s investment would ultimately provide. It was the investors—i.e.,  
 20 Pritzker, Huh, Valani, Bowen, and Monsees—who stood to benefit. It was that promise of an  
 21 impending personal payout that incentivized and motivated the Management Defendants to  
 22 accept Altria’s and Altria Client Services’s influence and control. If their fraudulent schemes  
 23 were successful, they would reap billions of dollars for themselves, regardless of what ended up  
 24 happening to JLI itself. In this way, Altria and Altria Client Services were able to influence JLI  
 25

---

26 <sup>638</sup> ALGAT0000082947.

27 <sup>639</sup> *Id.*

28 <sup>640</sup> *Id.*

<sup>641</sup> ALGAT0000112523.

<sup>642</sup> *Id.*

1 well before Altria formalized its investment in December 2018.

2 514. Communications between Altria, Altria Client Services, Pritzker, and Valani  
3 were frequent and their meetings continued at a regular pace over the next year and a half. For  
4 example, on December 15, 2017, Howard Willard, William Gifford, and Jay Moore (Senior  
5 Vice President of Business Development, Altria Client Services) met with the Project Tree  
6 investors (Defendants Pritzker and Valani) again, this time in White Plains, New York at the  
7 Andaz 5<sup>th</sup> Avenue Hotel.<sup>643</sup>

8 515. By no later than January 25, 2018, Howard Willard directly involved K.C.  
9 Crosthwaite, who had transitioned from Altria Client Services to become President and CEO of  
10 Defendant Philip Morris USA, in the negotiations with JLI. For example, on January 25, 2018,  
11 Howard Willard sent a presentation about “Project Tree” (Altria’s investment in JLI) to K.C.  
12 Crosthwaite and the two men agreed to discuss the matter the next morning.<sup>644</sup> By June 2018,  
13 Crosthwaite would be rewarded through a promotion to Senior Vice President, Chief Strategy &  
14 Growth Officer for both Altria Client Services and Altria Group, Inc. and would assist Willard  
15 in quarterbacking the JLI deal.

16 516. Altria and Altria Client Services and Pritzker and Valani continued their  
17 correspondence between December 2017 and July 2018. An internal Altria Client Services  
18 presentation references a letter Altria received regarding the proposed deal in April 2018.<sup>645</sup> On  
19 April 13, 2018, Howard Willard sent an email to Nicholas Pritzker, Riaz Valani, and JLI’s then-  
20 CEO Kevin Burns, “getting back to you” and requesting a call “early next week” in which  
21 Altria would share its plans for a “win/win partnership that enables us to fully collaborate” and  
22 to “deliver maximum value in the long run.” Altria also wanted to discuss the “critical item[]”  
23 of “strategy alignment and chemistry between our respective operating teams in supportive [sic]  
24 of a productive partnership that can create substantial value.”<sup>646</sup> Prior to this call, Pritzker,  
25 Valani, and Burns on the one hand and Altria (and/or Altria Client Services) on the other shared

26  
27 <sup>643</sup> ALGAT0000025589; ALGAT0000041165.

<sup>644</sup> ALGAT0000036407; ALGAT0000111921.

28 <sup>645</sup> ALGAT0002817348.

<sup>646</sup> JLIFTC00639178.

“volume forecast for [JLI’s] business.”<sup>647</sup> The call between Willard, Pritzker, Valani, and Burns took place on April 16, 2018, prior to which Willard sent the JLI parties a “Payment Structure Proposal” and noted that legal counsel need to “connect to assess antitrust risk.”<sup>648</sup> The Payment Structure Proposal provided various scenarios for a potential 50.1% investment by Altria in JLI, each of which contemplated billions of dollars in “Investor Value” for JLI’s investors (i.e., the Management Defendants).<sup>649</sup> Valani forwarded this document to attorney Jorge A. del Calvo at Pillsbury Winthrop Shaw Pittman LLP who then forwarded the document to Defendants Adam Bowen and James Monsees.<sup>650</sup>

517. Willard followed up on this call with a May 3, 2018 Proposal Letter to Pritzker, Valani, and Burns.<sup>651</sup> The Proposal Letter also contemplated a 50.1% investment that contemplated majority of payment to be made after antitrust approval and a separate “earn-out payment” of “up to \$3.5 billion” to the “selling JUUL shareholders”; Willard described the valuation as “compelling to your investors, particularly taking into account the substantial regulatory and legal contingencies relating to eVapor generally and JUUL products specifically.”<sup>652</sup> Notably, Willard wrote that Altria was “open to discussing the exact terms of [the earn-out] payment **but prefer to discuss it in person.**”<sup>653</sup> The letter goes on to further state that Altria was “prepared to discuss offering a series of liquidity events for the current JUUL investors with respect to their residual 49.9% ownership interest.”<sup>654</sup> This letter is yet another example of the ways in which Altria sought to influence Pritzker and Valani and indirectly control JLI, with the promise of a multi-billion dollar payment if they were to get JLI to go along with an Altria investment. Willard emphasized that they were aligned on a “strategic vision as to how to grow the JUUL business rapidly.” Altria sought to control the JLI business,

---

<sup>647</sup> JLIFTC00638936; ALGAT0005452943.

<sup>648</sup> ALGAT0004031391.

<sup>649</sup> JLIFTC01082372.

<sup>650</sup> JLIFTC01082370.

<sup>651</sup> ALGAT0004030132.

<sup>652</sup> ALGAT0004031645-46.

<sup>653</sup> *Id.* (emphasis added).

<sup>654</sup> *Id.*



1 with Willard writing that “we would require that, following the first two payments outlined  
 2 above, Altria (a) owns a majority of the JUUL equity and voting rights and (b) **has the right to**  
 3 **control generally the JUUL business.**”<sup>655</sup>

4 518. Altria and Altria Client Services viewed these meetings, and Valani in particular,  
 5 as a “back-channel” to communicate with the decision-makers behind JLI—i.e., the  
 6 Management Defendants. In a presentation by Altria Client Services in June 2018 to Altria  
 7 Management regarding preparations for a July 13, 2018 meeting with Pritzker and Valani, Altria  
 8 Client Services considered a “[b]ack-channel with Riaz and / or [Goldman Sachs] in advance of  
 9 meeting.”<sup>656</sup>

10 519. Altria and Altria Client Services were pursuing this “back-channel” even though  
 11 the lawyers for JLI and Altria had grown concerned over Pritzker and Valani’s roles in the  
 12 negotiations. On April 26, 2018, Pritzker sent an email to Howard Willard, copying Valani,  
 13 regarding a “standstill” in the negotiations. Pritzker wrote: “[O]ur lawyers are apparently at a  
 14 standstill over the standstill (in the NDA). I understand that you want the continuing right to talk  
 15 to Riaz and me. That’s just fine, and we are both happy to talk to y’all any time, but it needs to  
 16 be limited to in our capacity as directors: we need to avoid any appearance of conflict. I can’t  
 17 imagine this makes a difference. If not, can you intercede so we can get this going, and if so  
 18 perhaps you could give us a call to explain.” This email makes clear that Willard wanted  
 19 unfettered access to his back-channel of Pritzker and Valani, and that Altria and Altria Client  
 20 Services had not been communicating with Pritzker and Valani “in [their] capacity as  
 21 directors.”<sup>657</sup> Again, Altria and Altria Client Services were appealing to Pritzker and Valani’s  
 22 personal financial interest, which inevitably affected the actions they took as directors of JLI.

23 520. Howard Willard responded that he conveyed “our joint view” to Altria’s counsel  
 24 and then suggested a meeting on May 6, 2018 involving lawyers for both sides. Willard also set  
 25 up a separate dinner or breakfast for himself and Pritzker.<sup>658</sup> Valani was not available on this  
 26

---

27 <sup>655</sup> *Id.* (emphasis added).

28 <sup>656</sup> ALGAT0002817356.

<sup>657</sup> ALGAT0000113109.

<sup>658</sup> *Id.*

1 date, so the meeting was rescheduled, and the back-channeling continued.<sup>659</sup>

2 521. The parties met again in July 2018. According to the June 2018 presentation by  
3 Altria Client Services, at the July 13, 2018 meeting with Pritzker and Valani, Altria and Altria  
4 Client Services planned to push for a deal in which Altria would be able to “appoint[] majority  
5 of board” of JLI and have control of “board decisions by majority vote (including  
6 hiring/removal of CEO).” Altria was planning on structuring part of its payment for its  
7 ownership in JLI to include a separate “PMTA payment” of “\$1 - \$3 Billion” which Altria  
8 Client Services conceded was, in part “to compensate Tree [JLI] investors for potential upside  
9 in the business.”<sup>660</sup>

10 522. The same presentation revealed that Altria or Altria Client Services was planning  
11 on engaging with JLI regarding its “Youth vaping prevention plan” by August 10, 2018, with  
12 Altria or Altria Client Services preparing its own plan for JLI.<sup>661</sup>

13 523. The July 13, 2018 meeting was attended by Howard Willard, Billy Gifford, and  
14 K.C. Crosthwaite.<sup>662</sup>

15 524. At some point after negotiations had been ongoing between Altria, Altria Client  
16 Services, Pritzker, and Valani, Kevin Burns, then-CEO of JLI, joined the negotiations. By this  
17 point, Pritzker and Valani had already pushed Altria and Altria Client Services to offer terms  
18 highly favorable to the individual investors in JLI, regardless of the true benefit to the company.  
19 And by virtue of their control of JLI, the Management Defendants ensured that Kevin Burns  
20 went along with the deal.

21 525. On August 1, 2018, Pritzker, Valani and Burns met with Howard Willard and  
22 William Gifford at the Park Hyatt Hotel in Washington, D.C., to further discuss the terms of an  
23 impending deal.<sup>663</sup> Following this meeting, Valani and Pritzker were working the machinery of  
24 JLI to obtain the information that Altria needed to consummate their deal. On August 7, 2018,

---

26 <sup>659</sup> ALGAT0000113121.

27 <sup>660</sup> *Id.*

28 <sup>661</sup> *Id.*

<sup>662</sup> *Id.*

<sup>663</sup> ALGAT0003443977.

1 Tim Danaher (CFO of JLI) sent Burns, Valani, and Pritzker a “Summary Cap Table,” which  
2 Burns forwarded to Howard Willard with a comment that he would “call you tomorrow.”  
3 Howard Willard forwarded this email to K.C. Crosthwaite, who at this point was intimately  
4 involved at the negotiations between Altria, Pritzker and Valani.<sup>664</sup>

5 526. Around this time, K.C. Crosthwaite also made explicit Altria’s goal to influence  
6 and control JLI. In a presentation by Crosthwaite to Altria Group, Inc. at the Board of Directors’  
7 Strategy Session on August 22, 2018, Crosthwaite indicated that Altria should keep pursuing  
8 their “strategic investment in JUUL” because it would give Altria “[s]ignificant ownership and  
9 influence in U.S. e-vapor leader.”<sup>665</sup> This presentation reveals that Altria sought to require JLI to  
10 seek “Altria approval” of its “Youth vaping prevention plan.”

11 527. The negotiations between JLI, Altria, and Altria Client Services continued full  
12 steam from August 2018 through the announcement of the investment in December 2018. In an  
13 August 14, 2018 email from Nicholas Pritzker to Howard Willard and Billy Gifford, copying  
14 Kevin Burns and Valani, Pritzker wrote that “Riaz [Valani] met with Dinny [Devitre, Altria  
15 Group Board of Directors, Chair of Finance Committee] and that the two of you and maybe  
16 Dinny as well may be interested in meeting with us in San Francisco this Saturday.”<sup>666</sup> Willard  
17 responded that he, Billy Gifford, K.C. Crosthwaite and Dinny Devitre would attend the meeting.  
18 Pritzker responded that lawyers should attend, though Kevin Burns emailed him separately that  
19 he “wouldn’t add lawyers to the meeting but would put them in back rooms for support,” and  
20 that it “[l]ooks like we are a go pending Riaz’s meeting today.” In advance of the Saturday  
21 meeting, Willard set up a separate call with Nicholas Pritzker to discuss the remaining  
22 negotiating points. Burns and Valani were aware of, and possibly included in, this call.<sup>667</sup> So, in  
23 August 2018, information was being exchanged between Altria and Altria Client Services and  
24 JLI at a rapid pace, and numerous meetings between Valani, Pritzker, and Altria and/or Altria  
25 Client Services were taking place.

26  
27 <sup>664</sup> ALGAT0003352121; ALGAT0003352122.

28 <sup>665</sup> ALGAT0003327931.

<sup>666</sup> JLI01389789.

<sup>667</sup> JLI01389792.

528. On October 25, 2018, Howard Willard, Billy Gifford, KC Crosthwaite, and Murray Garnick participated in a call with Pritzker, and possibly Valani and Kevin Burns, to discuss the ongoing negotiations.<sup>668</sup> Pritzker, Valani, and Burns also met privately with Howard Willard and other Altria (and Altria Client Services) executives on October 28, 2018 for a dinner at Dinny Devitre's home to discuss the deal, while sending their lawyers to a separate meeting that same night.<sup>669</sup>

529. Also on October 25, 2018, the day Altria and Pritzker, Valani and Burns held a call to discuss the deal, Howard Willard shared with Pritzker and Valani the letter that Altria had sent to the FDA, which was a key part of the Management Defendant's and Altria's scheme to deceive regulators and keep youth-appealing Mint Juul pods on the market long after other flavors were removed, as set forth below.<sup>670</sup>

530. Over the following six weeks prior to the announcement of Altria's investment in JLI, K.C. Crosthwaite became even more hands on, leading the aggressive diligence efforts on behalf of Altria and Altria Client Services. October 30, 2018, K.C. Crosthwaite sent JLI a preliminary diligence list which requested a list of all material intellectual property, including all patents (which, notably, would have included the '895 patent revealing that JLI's nicotine content was misrepresented to the public; of course, Altria already knew this because it had undertaken its own testing of the nicotine strength of JUUL pods, as set forth above). It also included requests for "materials related to underage use prevention, underage product appeal, and underage use." JLI agreed to produce this information by November 9, 2018.<sup>671</sup> Crosthwaite and Kevin Burns, as well as others from Altria, Altria Client Services, and JLI, held a call to discuss these diligence requests on November 2, 2018.<sup>672</sup>

531. By this point, Pritzker and Valani had brought in other senior leadership of JLI to get the deal across the finish line. Kevin Burns, Tim Danaher, Bob Robbins (President, JUUL

---

<sup>668</sup> JLI10518738.

<sup>669</sup> *Id.*

<sup>670</sup> JLIFTC00653389.

<sup>671</sup> JLI01374739; JLI01374736.

<sup>672</sup> JLI01374736.

Americas), Jerry Masoudi (Chief Legal Officer), Mark Jones (Associate General Counsel), Ashley Gould, and Defendants Bowen and Monsees attended meetings with Altria and Altria Client Services from November 15, 2018 through November 17, 2018.<sup>673</sup> As set forth below, the deal was finally consummated—and Pritzker, Valani, Huh, Bowen and Monsees handsomely rewarded—in December 2018.

**3. Altria Participated in and Directed the Fraudulent Acts of JLI Designed to Protect the Youth Market for JUUL**

**a. Altria Participated in and Directed JLI's Make the Switch Campaign.**

532. Altria did not simply take in information regarding JLI's youth sales passively while it pursued ownership of JLI. It also worked to ensure that the Management Defendants would take steps to continue JUUL's exponential sales growth and to stave off any regulation that might hinder that growth.

533. Specifically, Altria worked behind the scenes to bolster JLI's public narrative claiming that JUUL was a cessation device intended for adult smokers. Well before JLI launched the "Make the Switch" campaign in January 2019, Altria was pushing the narrative that e-vapor products could help adult smokers "switch" off of combustible cigarettes. In an October 25, 2018 letter from Howard Willard to the FDA—sent while Altria was finalizing the terms of its deal with Pritzker, Valani, and Burns—Willard touted that "We believe e-vapor products present an **important opportunity to adult smokers to switch from combustible cigarettes.**"<sup>674</sup> As noted below, Howard Willard shared this letter with Pritzker and Valani the same day he sent it to the FDA.

534. Moreover, Altria's partners within JLI—Valani and Pritzker—were involved in reviewing and approving the Make the Switch Campaign, allowing Altria to influence the marketing efforts of JLI. For example, on December 27, 2018, Kevin Burns forwarded an email from Chelsea Kania to Pritzker and Valani with "assets for the [Make the Switch] campaign

<sup>673</sup> ALGAT0003776795.

<sup>674</sup> Letter from Howard A. Willard III, Altria, to Dr. Scott Gottlieb, FDA, at 1 (Oct. 25, 2018) (emphasis added).

including 20/60 radio spots and 30/60 tv spots,” and the next day Valani directed which videos should be aired as part of the campaign.<sup>675</sup>

**b. Altria Participated in and Directed JLI’s Fraudulent Scheme to Keep Mint on the Market.**

535. Altria and Altria Client Services also came to the bargaining table with Pritzker and Valani armed with important knowledge – that flavors would be crucial to JLI’s continued ability to target and sell to youth users and wanting to ensure JLI proactively and fraudulently protect those flavors.

536. Within weeks of the FDA’s July 2017 notice of proposed rulemaking (“ANPR”) regarding ENDS flavor regulations, Gal Cohen proposed that JLI and others “build a coalition and common agenda to influence or challenge FDA’s approach” to regulating flavors.<sup>676</sup> Foreshadowing their joint effort to portray Mint as a traditional tobacco or menthol flavor (as opposed to a flavor that appealed to kids), Cohen asked whether Altria and JLI might respond to the FDA with “a common approach and understanding,” and asked if the companies might find “a damage limitation option” concerning the regulation of ENDS flavors.<sup>677</sup>

537. Ashley Gould, copying Adam Bowen, responded that the “Consensus seems to be there is a value in participating in a discussion. *Less sure that participating in a joint effort to influence FDA makes sense, so please don't commit to that at the meeting.*” In the same email, Gould seemingly reversed course and gave Cohen the go-ahead to meet with Altria (or Altria Client Services) in pursuit of a damage limitation option “(but maybe best if the group is smaller).”<sup>678</sup>

538. Cohen attended a September 15, 2017 Global Tobacco Networking Forum (“GTNF”) industry event with James Xu, CEO of Avail Vapor, and Altria Client Services’s Phil Park. The small group Gould recommended seems to have materialized, as a September 27, 2017 email from Cohen notes that “Clive Bates organized a group that met on Friday with reps

<sup>675</sup> JLI10071280; JLI10071228.

<sup>676</sup> JLI10678579.

<sup>677</sup> *Id.*

<sup>678</sup> *Id.*



1 from Altria etc. . . they want to help drive standards definitions.”<sup>679</sup>

2 539. Through this meeting, Altria knew that JLI would be a good partner because it  
3 shared a similar vision of preserving flavors. Indeed, Altria (or Altria Client Services) went into  
4 this meeting with Cohen expecting to find a willing partner on flavors. As noted above, a May  
5 2017 presentation from Altria Client Services touted that JLI offered “mint, berry, tobacco, and  
6 cream varieties” with “[i]ndications of additional flavor pods in potential pipeline.”<sup>680</sup>

7 540. The following year, 2018, when it became clear that the FDA was increasing  
8 scrutiny of the e-vapor industry, JLI, the Management Defendants, and Altria publicly defended  
9 mint flavoring as a substitute for menthol cigarette smokers, when in fact JLI’s studies—which  
10 had been made available to Altria and Altria Client Services as part of due diligence for its  
11 ultimate investment in JLI—indicated that mint users are not former menthol smokers and that  
12 mint pods were as popular with teens as Mango pods. By fighting to keep mint as the last flavor  
13 on the market, the cigarette industry could continue to appeal to non-smokers, including youth.  
14 JLI and the Management Defendants coordinated with Altria to pursue a fraudulent scheme to  
15 persuade the FDA into leaving the mint flavor on the market, willingly sacrificing other flavors  
16 in the process as a purported show of commitment to youth prevention.

17 541. Altria’s specific fraudulent acts with regard to this fraudulent scheme are detailed  
18 further below.

19 **4. JLI, the Management Defendants and Altria Coordinated to Market**  
20 **JUUL in Highly-Visible Retail Locations**

21 542. JLI, the Management Defendants, and Altria’s coordination continued in other  
22 ways throughout 2018 as they prepared for Altria’s equity investment in JLI.

23 543. A key aspect of this early coordination was Altria’s acquisition of shelf-space  
24 that it would later provide to JLI to sustain the exponential growth of underage users of JUUL  
25 products. By acquiring shelf space, Altria took steps to ensure that JUUL products would be  
26 placed in premium shelf space next to Marlboro brand cigarettes, the best-selling cigarette  
27

28 <sup>679</sup> JLI10679070.

<sup>680</sup> ALGAT0002412177.

overall and by far the most popular brand among youth.<sup>681</sup>

544. Altria's investment was not for its own e-cigarette products. Altria spent approximately \$100 million in 2018 to secure shelf-space at retailers for e-cigarette products—purportedly for the MarkTen e-cigarette that Altria stopped manufacturing in 2018, and its pod-based MarkTen Elite, which it launched on a small scale in only 25,000 stores.<sup>682</sup> By comparison, the 2014 launch of the original MarkTen resulted in product placement in 60,000 stores in the first month in the western United States alone.<sup>683</sup> Yet Altria's payments for shelf space were a mixture of "cash and display fixtures in exchange for a commitment that its e-cigarettes would occupy prime shelf space for at least two years."<sup>684</sup>

545. In reality, Altria spent approximately \$100 million on shelf-space in furtherance of expanding the e-cigarette market, including JLI's massive, ill-gotten market share.<sup>685</sup>

546. When Altria later announced its \$12.8 billion investment in JLI, part of the agreement between the two companies was that Altria would provide JLI with this premium shelf space.<sup>686</sup>

547. Altria's purchase of shelf space in 2018 and its subsequent provision of that space to JLI shows how Altria, JLI, and the Management Defendants were coordinating even before Altria announced its investment in JLI. Altria's actions ensured that, even after public and regulatory scrutiny forced JLI to stop its youth-oriented advertising, JUUL products would still be placed where kids are most likely to see them—next to Marlboros, the most iconic, popular brand of cigarettes among underage users—in a location they are most likely to buy

<sup>681</sup> *Preventing Tobacco Use Among Youth and Adults, A Report of the Surgeon General*, Centers for Disease Control & Prevention 161, 164 (2012), <https://www.ncbi.nlm.nih.gov/books/NBK99237/>.

<sup>682</sup> Sheila Kaplan, *Altria to Stop Selling Some E-Cigarette Brands That Appeal to Youths*, N.Y. Times (Oct. 25, 2018), <https://www.nytimes.com/2018/10/25/health/altria-vaping-ecigarettes.html>.

<sup>683</sup> Melissa Kress, *MarkTen National Rollout Hits 60,000 Stores*, Convenience Store News (July 22, 2014), <https://csnews.com/markten-national-rollout-hits-60000-stores>.

<sup>684</sup> Jennifer Maloney & John McKinnon, *Altria-JLI Deal Is Stuck in Antitrust Review*, Wall St. J. (Jan. 17, 2020), <https://www.wsj.com/articles/altria-juul-deal-is-stuck-in-antitrust-review-11579257002>.

<sup>685</sup> *Id.*

<sup>686</sup> *Id.*

1 them—retail establishments.<sup>687</sup> Altria Works with the Management Defendants to Direct JLI's  
2 Affairs and Commit Fraud.

3 548. In December 2018, Altria formalized its relationship with JLI's leadership by  
4 making a \$12.8 billion equity investment in JLI through Altria Group and is wholly-owned  
5 subsidiary, Altria Enterprises,<sup>688</sup> the largest equity investment in United States history. [REDACTED]

6 [REDACTED]  
7 [REDACTED]  
8 [REDACTED]  
9 [REDACTED]  
10 [REDACTED]  
11 [REDACTED]<sup>689</sup> In turn, Altria and its  
12 subsidiaries received millions of loyal teen customers, customers Altria was no longer able to  
13 get through the sale of its own cigarette products. The Management Defendants' payout reflects  
14 their active role in JLI's growth, not just a return on their investment.

15 549. In July 2018, JLI's valuation was approximately \$15 billion.<sup>690</sup> But, in December  
16 2018, Altria's investment of \$12.8 billion for a 35% stake in the company reflected a valuation  
17 of approximately \$38 billion—more than two and a half times the valuation just five months  
18 earlier. Defendants Monsees, Bowen, Pritzker, Huh, and Valani thus saw the value of their  
19 investments in JLI skyrocket as a result of the Altria agreement, allowing them to cash out via a  
20 special dividend and bonus, as well as through stock sales that were not available to other of  
21 JLI's minority shareholders.<sup>691</sup> This investment further intertwined JLI and the Altria.

22 550. While Pritzker, Valani, and Altria carefully structured the deal to avoid the  
23

---

24 <sup>687</sup> Laura Bach, *Where Do Youth Get Their E-Cigarettes?*, Campaign for Tobacco Free Kids  
25 (Dec. 3, 2019), <https://www.tobaccofreekids.org/assets/factsheets/0403.pdf>.

26 <sup>688</sup> Archive00760162.

27 <sup>689</sup> JLI11387060.

28 <sup>690</sup> <https://www.theverge.com/2018/7/3/17529442/juul-vapes-nicotine-electronic-cigarettes-addiction-funding>.

<sup>691</sup> Tiffany Kary, *JUUL Founders Sued for Self-Dealing Over Altria's \$12.8 Billion*, Bloomberg (Jan. 13, 2020), <https://www.bloomberg.com/news/articles/2020-01-13/juul-founders-sued-for-self-dealing-over-altria-s-12-8-billion>.

appearance of Altria's control of JLI, for fear of drawing regulatory and public scrutiny, the structure does not tell the whole story. Altria and Altria Client Services had been involved in directing the affairs of JLI indirectly long before its investment, and the Altria Defendants' involvement was even more direct following the investment. And although Altria took only a 35% share initially, it retained the option to buy JLI outright in 2022. This promise of a future purchase gave it significant influence over the actions of JLI's leadership—i.e., the Management Defendants who stood to profit even more handsomely from an ultimate acquisition by Altria.

551. While JLI and Altria remain separate corporate entities in name, following its equity investment in JLI, the Altria Defendants worked with the Management Defendants, and Pritzker and Valani in particular, to forge Altria and JLI forged even greater significant, systemic links, *i.e.*, shared leadership, contractual relationships, financial ties, and continuing coordination of activities with JLI's leadership. Because Altria and its subsidiaries could no longer market Altria's products to children or lie to adults about the safety, addictiveness, or health effects of its own cigarettes as result of prior tobacco litigation and regulation, Altria took even greater control of JLI in order to accomplish both of these goals through that company.

**a. Altria Installs Its Own Executives into Leadership Positions to Direct the Affairs of JLI.**

552. To exercise its influence and control of JLI, Altria worked with Pritzker and Valani to install two key Altria executives into leadership positions at JLI: K.C. Crosthwaite and Joe Murillo:

- a. K.C. Crosthwaite, who was Vice President of Altria Client Services when the company carried out a study that would later be used by Altria to shield JUUL's Mint pods from federal regulation, is now JLI's CEO. Before joining JLI, Crosthwaite was Altria's and Altria Client Services's Chief Growth Officer and played a major role in Altria's investment in JLI, and had experience in the marketing of tobacco products from his time as president of Philip Morris USA.
- b. Joe Murillo, who launched the MarkTen e-cigarette line at Altria (as President and General Manager of Nu Mark LLC) and more recently headed regulatory affairs for Altria (as Senior Vice President of Regulatory Affairs of Altria Client Services) , is now

JLI's chief regulatory officer.<sup>692</sup> A 24-year career Altria executive, Murillo previously ran Altria's e-cigarette business, Nu Mark, "before Altria pulled its e-cigarettes off the market as part of its deal with J[UUL]."<sup>693</sup>

553. As mentioned above, K.C. Crosthwaite played a major role in Altria's investment in JLI. Crosthwaite frequently communicated with Altria Group's senior management about Altria's investment. For example, on January 25, 2018, Altria Group's CEO, Howard Willard sent a presentation about "Project Tree" (Altria's investment in JLI) to K.C. Crosthwaite (who was, at the time, President of Defendant Philip Morris USA) and the two men agreed to discuss the matter the next morning.<sup>694</sup> Then in July 2018, Crosthwaite (who, at the time, had transitioned to his role as Senior Vice President and Chief Growth Officer of Altria Client Services and Altria Group) was also listed as one of three "meeting participants," along with Willard and Altria Group's CFO, Gifford, for a July 13, 2018 meeting with JLI's leadership about the deal between Altria and JLI.<sup>695</sup> In addition, Crosthwaite led Altria Group's due diligence efforts,<sup>696</sup> signed the investment exclusivity agreement on behalf of Altria Group shortly before the deal was publicly announced,<sup>697</sup> and was listed as the Altria point of contact for any "notices, requests and other communications" regarding the Services Agreement between Altria Group and JLI.<sup>698</sup>

554. While working on this investment, Altria, and Crosthwaite himself, discussed their goal to influence and control JLI. For example, in a presentation by Crosthwaite to Altria Group, Inc. at the Board of Directors' Strategy Session on August 22, 2018, Crosthwaite indicated that Altria should keep pursuing their "strategic investment in JUUL" because it would give Altria "[s]ignificant ownership and influence in U.S. e-vapor leader."<sup>699</sup>

<sup>692</sup> Jennifer Maloney, *JLI Hires Another Top Altria Executive*, Wall St. J. (Oct. 1, 2019), <https://www.wsj.com/articles/juul-hires-another-top-altria-executive-11569971306>. /

<sup>693</sup> *Id.*

<sup>694</sup> ALGAT0000036407; ALGAT0000111921.

<sup>695</sup> ALGAT0002817348.

<sup>696</sup> JLI01374736; JLI01416851.

<sup>697</sup> JLI01392046.

<sup>698</sup> Archive00760280.

<sup>699</sup> ALGAT0003327931-33.

555. After the deal was official, in January 2019, Altria appointed Crosthwaite to the JLI Board of Directors.<sup>700</sup> Crosthwaite was required to be a non-voting observer until the FTC gave the Altria investment in JLI clearance, which has yet to occur. Altria planned to use this role to help guide JLI. According to Crosthwaite, Altria was focusing on “ensur[ing] JUUL maintains long-term leadership in global E-vapor by leveraging Altria’s best-in-class infrastructure and providing guidance through board participation.”<sup>701</sup>

556. However, despite his now official role, Crosthwaite continued to meet privately with Pritzker and Valani. For example, on January 16, 2019, Pritzker asked Crosthwaite if he would meet with Valani and Pritzker after the JUUL Board meeting later that month. Crosthwaite promptly reported back to Willard that he “agreed to have dinner with Nick and Riaz on the 31st after the JUUL BOD meeting.”<sup>702</sup>

557. Crosthwaite continue to be involved in meetings between Altria and the Management Defendants as his time as an “observer” on the JLI Board went on. On March 26, 2019, Willard, Gifford, and Crosthwaite and a few other Altria employees flew to San Francisco to attend a dinner with the JLI leadership, including Bowen, Monsees, Pritzker, Valani, and others.<sup>703</sup> After the dinner, Pritzker emailed Willard, Gifford, and Crosthwaite, telling them that “[w]e truly appreciate our partnership, and look forward to an even deeper collaboration in the future.”<sup>704</sup>

558. To facilitate that “deeper collaboration” and its control of JLI, Altria decided to install one of its own career executives, Crosthwaite, as the head of JLI. In furtherance of that goal, in April 2019, Howard Willard told Pritzker that he believed JLI would benefit from “a new direction.”<sup>705</sup> That same month, Pritzker invited Crosthwaite to Pritzker’s house in San Francisco for a weekend visit.<sup>706</sup> During this visit, according to JLI, Crosthwaite expressed

---

<sup>700</sup> JLI01416851.

<sup>701</sup> ALGAT0002856951.

<sup>702</sup> ALGAT0000114034.

<sup>703</sup> ALGAT0000080766.

<sup>704</sup> ALGAT0003889812.

<sup>705</sup> JLI01416851.

<sup>706</sup> JLI01416851.



concerns about JLI's leadership's ability to guide JLI, and Pritzker and Crosthwaite discussed Crosthwaite potentially joining JLI in some capacity.

559. As the summer approached, JLI admits that "various Board members" continued to communicate with Crosthwaite and that "the Board valued his perspective on JLI's business," in other words, Altria's perspective on JLI's business.<sup>707</sup> In his discussions with the Board, Crosthwaite continued to express a view that JLI would benefit from a change in leadership.<sup>708</sup>

560. While Altria had not yet officially installed Crosthwaite as JLI's CEO, that did not prevent them from giving JLI's leadership, and specifically Pritzker and Valani, advice and direction about how to run the company. On May 26, 2019, Pritzker emailed Willard asked whether he was "coming to the youth/PMTA meeting in DC June 14" and "[i]f so, do you think we can find a time for you, Riaz, and I to get together separately?" Willard responded "Yes and yes. We can arrange the plan next week."<sup>709</sup>

561. Similarly, on July 9, 2019, Willard emailed Valani, Pritzker, JLI's then-CEO Kevin Burns and cc'd Crosthwaite giving JLI advice and feedback on their "Youth Vaping Prevention Plan." Willard stated that the "plan represents a modest improvement rather than an impressive 'new day.'" Willard also gave them advice and direction, telling them to "[k]eep working on it, but do not make a big announcement at this time" but that their proposed "internal changes sound reasonable and appropriate."<sup>710</sup>

562. In June 2019, Howard Willard spoke to Pritzker and Valani again, along with Frankel (who "[s]erves as Mr. Valani's second board seat"<sup>711</sup>). Willard reiterated that he believed JLI would be benefit from a new direction.<sup>712</sup> Willard conveyed explicitly that "JLI could benefit from Mr. Crosthwaite's leadership."<sup>713</sup> Willard "expressed his view that Mr.

---

<sup>707</sup> JLI01416851.

<sup>708</sup> JLI01416851.

<sup>709</sup> ALGAT0003285214.

<sup>710</sup> ALGAT0003279064.

<sup>711</sup> JLI00417815.

<sup>712</sup> JLI01416851.

<sup>713</sup> JLI01416851.

Crosthwaite's unique experience would make him a strong leader for JLI.”<sup>714</sup>

563. After this conversation, on July 22, 2019, a draft press release was created and sent to Crosthwaite announcing Crosthwaite as JLI's new CEO.<sup>715</sup> The draft press release states that Crosthwaite was “most recently a JUUL Board Advisor” and includes a quote from Defendant Monsees, explaining that “Adam [Bowen] and [Monsees] . . . have had the pleasure of getting to know K.C. through our partnership with Altria and have already benefitted tremendously from his strategic insights as a Board observer.”<sup>716</sup> This document was sent to Crosthwaite by Carina Davidson, the President of communications firm Abernathy MacGregor, with whom Altria works regularly.<sup>717</sup> Crosthwaite reviewed the documents and discussed it with Davidson, including asking her to “tone down the language re: Kevin” Burns, JLI's then-CEO, who Crosthwaite would be replacing.<sup>718</sup>

564. On August 23, 2019, Valani met with Crosthwaite again to discuss “business and non-business topics.”<sup>719</sup>

565. Throughout the month of September, Defendant Valani and Defendant Pritzker continued to meet with Altria about Crosthwaite taking over leadership of JLI. For example, on September 11, 2019, Valani and Pritzker spoke with Willard, about “the challenges facing JLI” and Willard “expressed concern about Mr. Burns' [JLI's then-CEO] leadership” and “expressed his opinion that JLI would benefit from a new direction.”<sup>720</sup> As mentioned above, Willard had previously suggested Crosthwaite be installed in a leadership role. Four days later, on September 15, 2019, Crosthwaite met with Valani and Frankel “to further discuss the possibility of Mr. Crosthwaite joining JLI.”<sup>721</sup> During this meeting Crosthwaite told Valani and Frankel that he also wanted them to consider hiring Joe Murillo, then the head of regulatory affairs for

---

<sup>714</sup> JLI01416851.

<sup>715</sup> ALGAT0005389689.

<sup>716</sup> ALGAT0005389689.

<sup>717</sup> ALGAT0005389689; ALGAT0005389687; *see also, e.g.*, ALGAT0003360382, ALGAT0003778898.

<sup>718</sup> ALGAT0005410667.

<sup>719</sup> JLI01416851.

<sup>720</sup> JLI01416851.

<sup>721</sup> JLI01416851.

Altria, as Chief Regulatory Officer for JLI.<sup>722</sup>

566. On September 17, 2019, Valani met with Crosthwaite in New York to further discuss Crosthwaite taking over as the formal leader of JLI.<sup>723</sup> Valani and Frankel met with Crosthwaite again on September 18, 2019, in New York.<sup>724</sup> On September 19, 2019, Bowen, Monsees, Pritzker, and Valani met with Crosthwaite for dinner in San Francisco.<sup>725</sup> On September 20, 2019, Pritzker and Valani met with Crosthwaite again in San Francisco to discuss the details of Crosthwaite's leadership role.<sup>726</sup>

567. On September 22, 2019, Pritzker, Valani, and Frankel spoke to Crosthwaite over the phone about taking over leadership at JLI.<sup>727</sup> Crosthwaite continued to express the view that JLI would benefit from leadership changes and reiterated his view that JLI should hire Murillo, should Crosthwaite join JLI. While Crosthwaite expressed some doubts about his position, the parties agreed to continue to discuss the matter.<sup>728</sup> Ultimately, the Board met that day and resolved to offer Crosthwaite a leadership position at JLI.<sup>729</sup>

568. On September 24, 2019, JLI's Board of Directors voted to accept the resignation of current JLI CEO Kevin Burns, approve Crosthwaite's appointment as CEO of JLI and appoint him to the Board.<sup>730</sup> That same day, Crosthwaite told "JLI to begin preparations on an offer of employment for Murillo."<sup>731</sup>

569. Crosthwaite formally took over as CEO of JLI on September 25, 2019.<sup>732</sup> Murillo accepted a position as JLI's Chief Regulatory Officer on September 29, 2019 and began

---

<sup>722</sup> JLI01416851.

<sup>723</sup> JLI01416851.

<sup>724</sup> JLI01416851.

<sup>725</sup> JLI01416851.

<sup>726</sup> JLI01416851.

<sup>727</sup> JLI01416851.

<sup>728</sup> JLI01416851.

<sup>729</sup> JLI01416851.

<sup>730</sup> JLI01416851. Pursuant to JLI's by-laws, the Company's CEO is automatically appointed to the Board.

<sup>731</sup> JLI01416851.

<sup>732</sup> JLI01416851.

1 work on October 7, 2019.<sup>733</sup> Altria's plan was a success.

2 **b. Altria Furthered the JLI Enterprise by Participating in and**  
 3 **Directing the Marketing and Distribution of JUUL Products.**

4 570. In addition to installing its own executives as senior leadership at JLI, after its  
 5 investment, the Altria Defendants worked with JLI's leadership to assist JUUL's growth  
 6 through marketing and distribution, despite its knowledge that JUUL's growth was based on  
 7 selling to minors and lying to adults about JUUL products. The Altria Defendants helped JUUL  
 8 thrive in the areas of "direct marketing; sales, distribution and fixture services; and regulatory  
 9 affairs."<sup>734</sup> This included, among other things:

- 10 a. "Piloting a distribution program to provide long haul freight,  
 11 warehouse storage and last mile freight services."
- 12 b. "Making available [Altria's] previously contracted shelf space with  
 13 certain retailers," thus allowing JUUL products to receive  
 14 prominent placement alongside a top-rated brand of combustible  
 15 cigarettes, Marlboro, favored by youth.
- 16 c. "Executing direct mail and email campaigns and related activities.  
 17 . . ."
- 18 d. "Leveraging Altria's field sales force to . . . provide services such  
 19 as limited initiative selling, hanging signs, light product  
 20 merchandising, and surveys of a subset of the retail stores that  
 21 Altria calls upon."
- 22 e. "Providing regulatory affairs consulting and related services to  
 23 [JUUL] as it prepares its PMTA application."<sup>735</sup>

24 571. In an attempt to legitimize its support of JUUL's growth and despite public and  
 25 regulatory concern, the Altria Defendants entered into a number of formal agreements with JLI.  
 26 These agreements included collaboration with Defendants Altria Group Distribution Company,  
 27 Altria Client Services, and Philip Morris USA, each known in the agreement as "the Altria  
 28 Company." Each agreement listed Altria Group, Inc. as the "Provider" and was managed by  
 Theodore J. Edlich IV of Altria Client Services as the "Provider Manager."<sup>736</sup>

<sup>733</sup> JLI01416851.

<sup>734</sup> Letter from Howard Willard III, Altria Senator Durbin, et. al., at 11 (Oct. 14, 2019).

<sup>735</sup> *Id.* at 13.

<sup>736</sup> *See, e.g.*, JLI10490204.

572. In each agreement, JLI agreed to “cooperate fully with the Altria Company in its performance of the Services, including without limitation, by timely providing all information, materials, resources, decisions, and access to personnel and facilities necessary for the proper performance of the Services by the Altria Company.”<sup>737</sup>

573. In exchange, Altria Group Distribution Company agreed to distribute and sell JUUL products across the country greatly expanding JUUL’s retail footprint. While JUUL products have typically been sold in 90,000 U.S. retail outlets, Altria’s products reach 230,000 U.S. outlets. Altria Group Distribution Company also brings its logistics and distribution experience (although, after increasing public scrutiny, Altria announced on January 30, 2020 that it would limit its support to regulatory efforts beginning in March 2020<sup>738</sup>).

574. Specifically, AGDC agreed to:

- a. Market JUUL products in 1,073 Speedway stores initially, followed by a second wave of 1,937 stores, provide key account assistance and field sales force management, and install Point of Sale materials for JUUL products;<sup>739</sup>
- b. Sell and execute pre-books/pre-orders for JUUL products for 83 Chain accounts and up to 51 distributors;<sup>740</sup>
- c. Provide territory sales managements, key retail account assistance, and field sales force management to perform a “full reset” (including merchandising JUUL products to replace Nu Mark products and installing JUUL graphics and other marketing materials) in up to 40,399 stores, including Circle K, 7-Eleven, Chevron, Sheetz, Speedway, Wawa, Giant Eagle, Walmart, and many more;<sup>741</sup>
- d. Provide sales support at 77,806 stores by improving out of stock and distribution gaps, providing labor and Field Sales Force services to handle merchandising, account management, tracking insights, and conduct inventory management;<sup>742</sup>

<sup>737</sup> See, e.g., JLI10490204.

<sup>738</sup> Nathan Bomey, *Marlboro maker Altria distances itself from vaping giant JLI amid legal scrutiny*, USA Today (Jan. 31, 2020), <https://www.usatoday.com/story/money/2020/01/31/juul-altria-distances-itself-e-cigarette-maker-amid-scrutiny/4618993002/>.

<sup>739</sup> JLI10490204.

<sup>740</sup> JLI01339886.

<sup>741</sup> JLI01339886.

<sup>742</sup> JLI01339878.

- e. Conduct supply chain management for distribution of JUUL products, as well as line haul freight, public warehouse storage in San Bernardino, CA, last mile freight to customers, and shipping to distributions (including Circle K, Core Mark, and McLane) in Nevada, Arizona, and California;<sup>743</sup>
- f. Provide distribution assistance, including freight from DCL to Richmond, Virginia and warehouse storage and handling of JUUL products;<sup>744</sup>
- g. Provide sales support for JUUL products including working in tens of thousands of stores number of stores to provide insights and conduct surveys, update and install point of sale marketing, address “inventory opportunities,” including out of stock issues and distribution gaps, check prices and advertising the price in the store, and selling in new initiatives at the headquarters or store level, including new product launches, fixture merchandising, and training store personnel, and store and ship JUUL point-of-sale materials to support JUUL sales;<sup>745</sup>
- h. Bring JLI into Altria Group Distribution Company’s Retail Council in June 2019, including giving opening remarks, three breakout group sessions, and a trade show booth;<sup>746</sup> and
- i. Distribute JUUL products and provide supply chain management for distribution to Arizona, California, Hawaii, Nevada, Texas, Louisiana, and Oklahoma (including line haul freight, public warehouse storage and handling in San Bernardino, California and Fort Worth, Texas, and last mile freight to customers);<sup>747</sup>

575. Through these distribution services, Altria Group Distribution Services, and Altria Client Services (as the “Provider Manager”) used the mail and wires to transmit JUUL collateral and packaging that contained the false representation that a single JUUL pod was equivalent to a pack of cigarettes. A representation which, as discussed above, Altria and Altria Client Services knew was false.

576. Altria Group Distribution Company also worked to sell Mint JUUL products in particular. For example, Altria Group Distribution Company led a “market blitz” for JUUL

---

<sup>743</sup> JLI01339918.

<sup>744</sup> JLI01339903.

<sup>745</sup> JLI01339937; JLI01339930; JLI01339980. The November to December 2019 agreement also included AGDC’s assistance in removing the companies’ “Make the Switch” campaign materials, which were the subject of a warning letter by the FDA.

<sup>746</sup> JLI01339973.

<sup>747</sup> JLI01339955.



1 products starting in February 2019.<sup>748</sup> As part of this blitz effort, JLI employees recognized that  
 2 “Mint growth is huge – may need double space for certain SKUs to avoid out of stock  
 3 situations,” but that “sales are low” for Classic Tobacco.<sup>749</sup>

4 577. Similarly, a March 18, 2019 AGDC presentation of its work to sell JUUL  
 5 showed that it was pushing Mint more than Menthol and Virginia Tobacco combined. The re-  
 6 order form for 7-Eleven included seven choices, four of which were for Mint JUUL pods.<sup>750</sup> In  
 7 the presentation, AGDC also indicated that Mint was flying off the shelves and that the Mint 5%  
 8 4-pack in particular was out of stock 25% of the time.<sup>751</sup>

9 578. Crosthwaite, when he was still formally working for Altria and Altria Client  
 10 Services, was directly involved in supervising the distribution of JUUL products, including  
 11 Mint. For example, a senior director at Altria Group Distribution Company notified Crosthwaite  
 12 that certain JUUL products, including Mint 5% JUULpods, were experiencing “inventory  
 13 constraints” which “may be relevant to [Crosthwaite’s] conversation with Kevin Burns,” JLI’s  
 14 then-CEO.<sup>752</sup> Crosthwaite forwarded the email to Burns, asking him “Assume your guys are all  
 15 over this?”<sup>753</sup>

16 579. AGDC’s work was effective. When listing JUUL Performance Results in March  
 17 2019, AGDC included a quote from “Alex Cantwel, VP JUUL Strategy” reporting “We just had  
 18 our largest refill kit order in history. Thank you and your team for all the work.”<sup>754</sup>

19 580. Altria Client Services, for its part, not only served as the “provider manager” for  
 20 each of the formal agreements between JLI and various “Altria Compan[ies]”, but also agreed to  
 21 work with JLI’s regulatory affairs employees on the PMTA application for JUUL and directly  
 22 market JUUL to millions of customers.

23 581. For example, to assist with PMTA, ACS agreed to:

---

24  
 25 <sup>748</sup> JLI01010641.

26 <sup>749</sup> JLI01010641.

27 <sup>750</sup> ALGAT0000772561.

28 <sup>751</sup> ALGAT0000772561.

<sup>752</sup> JLI01392499.

<sup>753</sup> JLI01392499.

<sup>754</sup> ALGAT0002940950.

- a. Study JUUL products, including conducting pre-clinical (chemistry, toxicology and biological sciences), clinical, aerosol, modeling and simulation, sensory and population research (perception, behavior, population modeling, consumer research and post-market surveillance) and assist with JLI's regulatory affairs problems by providing with strategy and engagement, regulatory intelligence and insight, advocacy and regulatory narrative writing and submissions;<sup>755</sup>
- b. Study and consult with JLI for examination of consumer perception, behavior, and intentions relating to JUUL products, such as whether consumers comprehend JUUL's e-vapor communications (instructions for use, labeling and safety warning) and the impact of exposure to JUUL promotional materials among users and on users on, the likelihood of switching, dual use, initiation, and cessation of tobacco products, appeal of JUUL, absolute risk perceptions associated with use of JUUL, risk perceptions relative to other tobacco products, NRTs and quitting, and general harm perceptions associated with the use of JUUL;<sup>756</sup>
- c. Study and consult with JLI on preclinical in vivo inhalation exposure of JLI's 1.7% Glacial Mint flavor product and its effect on rats;<sup>757</sup>
- d. Study and consult with JLI on chemical profiling analysis of Golden Tobacco, Virginia Tobacco, Mango, Mint, and Menthol JUUL products in 1.7, 3, and 5 nicotine strength;<sup>758</sup> and
- e. Study and consult with JLI on population modeling, including on assessing the population health impact to the U.S. population with the introduction of JUUL products, focusing on tobacco use prevalence and all-cause mortality;<sup>759</sup>
- f. Conduct JUUL topical literature reviews relating to e-vapor products, including collecting and summarizing these articles into a literature review summaries and create evidence tables on information about initiation, cessation, relapse, patterns of use, abuse liability, gateway, perceptions, chemistry, and health effects topics;<sup>760</sup>
- g. Develop, execute, and document exposure characterization for JUUL's classic tobacco product;<sup>761</sup>
- h. Study and consult with JLI on passive vaping modeling, including modeling of second and third hand exposures to e-vapor and cigarette smoke aerosols;<sup>762</sup> and

---

<sup>755</sup> JLI01339882; JLI013398976.

<sup>756</sup> JLI01426119

<sup>757</sup> JLI01426125

<sup>758</sup> JLI01426135.

<sup>759</sup> JLI01426141.

<sup>760</sup> JLI01339943.

<sup>761</sup> JLI01426146.

<sup>762</sup> JLI01426130.

- i. Provide access to and use of Altria's product testing services, including its Smoking Machine Vitrocell 1/7, Vitrocell 24/28 system, and Vitrocell Ames 48 System.<sup>763</sup>

582. Altria Client Services also market JUUL products by sending out mailers, emails, and coupons to millions of people across the United States. For example, ACS agreed to:

- a. Work with JLI to develop the final creative design for direct mail campaigns, execute the plans, and mail the JUUL advertisements and coupons to 1.5 million people in March 2019, 1 million people in May 2019, 2.5 million people in September 2019, and 3.8 million people in December 2019;<sup>764</sup>
- b. Work with JLI to develop the final creative design for an email campaign and send out direct marketing via email, including three email campaigns with a combined total audience of 515,000, including coupons of JUUL;<sup>765</sup>

583. Altria also worked with JLI to cross-market JUUL and Marlboro cigarettes. As memorialized in an agreement between Philip Morris USA, Inc. and JLI, "the Altria Company" worked with JLI to design inserts to put in Altria's cigarettes and eventually distributed coupons for JUUL starter kits in 20 million packs of L&M and Parliament brand cigarettes and 30 million packs of Marlboro cigarettes.<sup>766</sup>



<sup>763</sup> JLI01339988.

<sup>764</sup> JLI01339912; JLI01339915; JLI01339967; JLI01339970. In the December 2019 agreement, but not the March, May, or September agreement, ACS claimed to "reserve the right not to send any mailing of portion thereof where all [JUUL] vapor products cannot be legally sold." JLI01339970.

<sup>765</sup> JLI01339927.

<sup>766</sup> *Points for us!*, Reddit (Sept. 16, 2019), [https://www.reddit.com/r/juul/comments/d50jku/points\\_for\\_us/](https://www.reddit.com/r/juul/comments/d50jku/points_for_us/) (depicting an image of a Marlboro carton with a JUUL starter kit coupon inside); JLI01339874.

584. Both the inserts distributed by Philip Morris and the mail and email advertisements sent by Altria Client Services were advertisements for JLI's fraudulent "Make the Switch" campaign described above.

585. In order to help JUUL expand and be able to keep selling to kids and lying to adults, Altria and Altria Client Services also directed JLI in combatting legal and regulatory challenges, helping with patent infringement battles and consumer health claims and helping to navigate the regulatory waters and FDA pressure. For example, in 2019, internal documents from Altria Client Services confirm that the Altria Defendants were engaged in ongoing efforts to provide "services and insight to accelerate JUUL's U.S. performance" and "actively engage FDA and other stakeholders to address youth vaping."<sup>767</sup>

586. Altria also brings lobbying muscle to the table, which worked to prevent new federal or state legislation targeting JUUL or the e-cigarette category more broadly. Altria "has a potent lobbying network in Washington [D.C.] and around the country."<sup>768</sup> Vince Willmore, a spokesman for the Campaign for Tobacco-Free Kids, which has been involved in many state lobbying battles, said, "It's hard to say where Altria ends and JLI begins."<sup>769</sup> While an Altria spokesman has denied that there was any contractual services agreement for lobbying between JLI and Altria, he admitted that he did not know what informal advice and conversations Altria has had with JLI about lobbying efforts. Crosthwaite admitted internally that Altria would be "collaborat[ing] on regulatory matters" with JLI (likely through Altria Client Services).<sup>770</sup> And Altria installed Joe Murillo, then the head of regulatory affairs for Altria and a 24-year Altria veteran with extensive experience in e-cigarette regulations, as Chief Regulatory Officer for JLI. Indeed, since Altria worked with the Management Defendants to assume some control over JLI, JLI's spending on lobbying has risen significantly. JLI spent \$4.28 million on lobbying in

---

<sup>767</sup> ALGAT0002856956.

<sup>768</sup> Shelia Kaplan, *In Washington, JLI Vows to Curb Youth Vaping. Its Lobbying in States Runs Counter to That Pledge.*, N.Y. Times (Apr. 28, 2019), <https://www.nytimes.com/2019/04/28/health/juul-lobbying-states-ecigarettes.html>.

<sup>769</sup> *Id.*

<sup>770</sup> ALGAT0002856953.

2019, compared to \$1.64 million in 2018.<sup>771</sup>

587. Contrary to public statements, Altria's investment in JLI was not only a financial contribution nor were these agreements about just "services"; rather, they were manifestations of Altria's and the Management Defendants' plan to continue selling JUUL to kids and lying to adults about JUUL products, all while staving off regulation and public outcry. Internal documents show that Altria did not consider itself a mere non-voting minority investor or service provider. Instead, it viewed itself as JLI's "valued partner" and wanted to ensure it could "completely unlock partnership benefits," "guide [JLI's] strategic direction through board engagement," including "providing strategic advice and expertise," and "collaborate on youth vaping."<sup>772</sup> According to an Altria Group Distribution Company presentation, AGDC should be "viewed as more than a vendor but as a strategic partner in supporting JUUL's mission."<sup>773</sup>

588. The Altria Defendants' services agreements with JLI obscured Altria's takeover of large portions of JUUL's distribution and marketing. Altria's goal was always to expand the reach and sales of JUUL products, despite the knowledge of their lies and youth targeting. According to the Altria Client Services employees working with KC Crosthwaite on summarizing Altria Group's 2019 "Strategic Initiatives", Altria Group's CEO Howard Willard "investment thesis from the beginning" was that Altria could accelerate JUUL growth "as it gains more prominent shelf space" and "category management."<sup>774</sup> And importantly, as noted above, Altria gives JLI access to shelf space that it had obtained under fraudulent pretenses. This is not just any shelf space; it is space near Altria's (Philip Morris USA's) blockbuster Marlboro cigarettes, and other premium products and retail displays. The arrangement allows JLI's tobacco and menthol-based products to receive prominent placement alongside a top-rated brand of combustible cigarettes.

589. Altria's investment and the Altria Defendants' collaboration with the

---

<sup>771</sup> *Client Profile: JUUL Labs*, Center for Responsive Politics, <https://www.opensecrets.org/federal-lobbying/clients/summary?cycle=2019&id=D000070920> (last visited Apr. 4, 2020).

<sup>772</sup> ALGAT0002856956.

<sup>773</sup> ALGAT0000772561.

<sup>774</sup> ALGAT0002856953.

Management Defendants was not just about investing in a legitimate business or selling to adult smokers. Instead, Altria used its relationship with the Management Defendant and with JLI to continue selling to youth and lying to the public, just as it had done in the past. Despite its knowledge of JUUL's youth targeting, when announcing its investment, Altria explained that its investment in JLI "enhances future growth prospects" and committed to applying "its logistics and distribution experience to help JLI expand its reach and efficiency."<sup>775</sup> Altria sought to achieve this goal through "strategic guidance," "board influence," and marketing and distribution assistance.<sup>776</sup> And with the help of the Management Defendants, and Pritzker and Valani in particular, the Altria Defendants have successfully ensured that JUUL would maintain and expand its market share—a market share that, based on Altria's own October 25, 2018 letter to the FDA, it believes was gained by employing marketing and advertising practices that contributed to youth e-cigarette use.

**G. JLI, Altria, and Others Have Successfully Caused More Young People to Start Using E-Cigarettes, Creating a Youth E-Cigarette Epidemic and Public Health Crisis.**

590. Defendants' tactics have misled the public regarding the addictiveness and safety of e-cigarettes generally, and JUUL products specifically, resulting in an epidemic of e-cigarette use among youth in particular.

591. Defendants' advertising and third-party strategy, as discussed above, ensured that everyone from adults to young children, would believe JUULing was a cool, fun, and safe activity.

592. To this day, JLI has not fully disclosed the health risks associated with its products, has not recalled or modified its products despite the known risks, and continues to foster a public health crisis, placing millions of people in harm's way.

---

<sup>775</sup> *Altria Makes \$12.8 Billion Minority Investment in JUUL to Accelerate Harm Reduction and Drive Growth*, BusinessWire (Dec. 20, 2018), <https://www.businesswire.com/news/home/20181220005318/en/Altria-12.8-Billion-Minority-Investment-JUUL-Accelerate>.

<sup>776</sup> ALGAT0004641801.



**1. Defendants' Scheme Caused Consumers to be Misled into Believing that JUUL was Safe and Healthy.**

593. In 2016, the National Institute on Drug Abuse issued findings regarding “Teens and Cigarettes,” reporting that 66% of teens believed that e-cigarettes contained only flavoring, rather than nicotine.<sup>777</sup>

594. Two years later, despite the ongoing efforts of public health advocates, a 2018 study of JUUL users between the ages of fifteen and twenty-four revealed that 63% remained unaware that JUUL products contain nicotine.<sup>778</sup> Further, the study found that respondents using e-cigarettes were less likely to report that e-cigarettes were harmful to their health, that people can get addicted to e-cigarettes, or that smoke from others' e-cigarettes was harmful.<sup>779</sup>

595. Similarly, in 2018, a literature review of seventy-two articles published in the International Journal of Environmental Research and Public Health found that e-cigarettes were perceived by adults and youth as being healthier, safer, less addictive, safer for one's social environment, and safer to use during pregnancy than combustible cigarettes.<sup>780</sup> Further, researchers found that specific flavors (including dessert and fruit flavors) were perceived to be less harmful than tobacco flavors among adult and youth e-cigarette users.<sup>781</sup> In addition, researchers found that youth e-cigarette users perceived e-cigarettes as safe to use and fashionable.<sup>782</sup>

596. In 2019, a study published in Pediatrics found that 40% of participants reported using nicotine-free e-cigarette products, when in fact the products they were using contained

<sup>777</sup> *Teens and E-cigarettes*, Nat'l Inst. on Drug Abuse, <https://www.drugabuse.gov/related-topics/trends-statistics/infographics/teens-e-cigarettes> (last visited Apr. 4, 2020).

<sup>778</sup> Jeffrey G. Willett et al. *Recognition, Use and Perceptions of Juul Among Youth and Young Adults*, 28 Tobacco Control 054273 (2019).

<sup>779</sup> *Id.*

<sup>780</sup> *Id.*

<sup>781</sup> Kim A. G. J. Romijnders et al., *Perceptions and Reasons Regarding E-Cigarette Use Among Users and Non-Users: A Narrative Literature Review*, 15 Int'l J. of Env'tl. Research & Public Health 1190 (2018), <https://doi.org/10.3390/ijerph15061190>.

<sup>782</sup> *Id.*

significant levels of nicotine.<sup>783</sup>

597. In 2019, a study published in the British Medical Journal Open systematically reviewed all peer-reviewed scientific literature published on e-cigarette perceptions through March 2018 which included fifty-one articles.<sup>784</sup> Researchers found consistent evidence showing that flavors attract both youth and young adults to use e-cigarettes.<sup>785</sup> In addition, among this same group, fruit and dessert flavors decrease the perception that e-cigarettes are harmful, while increasing the willingness to try e-cigarettes.<sup>786</sup>

## 2. Use of JUUL by Minors Has Skyrocketed

598. On December 28, 2018, the University of Michigan's National Adolescent Drug Trends for 2018 reported that increases in adolescent e-cigarette use from 2017 to 2018 were the "largest ever recorded in the past 43 years for any adolescent substance use outcome in the U.S."<sup>787</sup>

599. The percentage of 12th grade students who reported consuming nicotine almost doubled between 2017 and 2018, rising from 11% to 20.9%.<sup>788</sup> This increase was "twice as large as the previous record for largest-ever increase among past 30-day outcomes in 12th grade."

600. By 2018 approximately 3.6 million middle and high school students were consuming e-cigarettes regularly,<sup>789</sup> and one in five 12th graders reported used an e-cigarette containing nicotine in the last 30 days.<sup>790</sup> As of late 2019, 5 million students reported active use

<sup>783</sup> Rachel Boykan et al., *Self-Reported Use of Tobacco, E-Cigarettes, and Marijuana versus Urinary Biomarkers*, 143 *Pediatrics* (2019), <https://doi.org/10.1542/peds.2018-3531>.

<sup>784</sup> Meernik, et al., *Impact of Non-Menthol Flavours in E-Cigarettes on Perceptions and Use: An Updated Systematic Review*, *BMJ Open*, 9:e031598 (2019), <https://bmjopen.bmj.com/content/9/10/e031598>.

<sup>785</sup> *Id.*

<sup>786</sup> *Id.*


<sup>787</sup> *National Adolescent Drug Trends in 2018*, Univ. of Mich. Inst. for Social Research (Dec. 17, 2018), <http://monitoringthefuture.org/pressreleases/18drugpr.pdf>.

<sup>788</sup> News Release, *Teens Using Vaping Devices in Record Numbers*, Nat'l Insts. of Health (Dec. 17, 2018) <https://www.nih.gov/news-events/news-releases/teens-using-vaping-devices-record-numbers>.

<sup>789</sup> See Jan Hoffman, *Addicted to Vaped Nicotine, Teenagers Have no Clear Path to Quitting*, N.Y. Times (Dec. 18, 2018), <https://www.nytimes.com/2018/12/18/health/vaping-nicotine-teenagers.html>.

<sup>790</sup> *Id.*

of e-cigarettes, with 27.5% of high school students and 10.5% of middle school students using them within the last thirty days and with most youth reporting JUUL as their usual brand.<sup>791</sup>



601. The Secretary of the U.S. Department of Health and Human Services declared that “[w]e have never seen use of any substance by America’s young people rise as rapidly as e-cigarette use [is rising].”<sup>792</sup> Then FDA Commissioner Dr. Gottlieb described the increase in e-cigarette consumption as an “almost ubiquitous—and dangerous—trend” that is responsible for an “epidemic” of nicotine use among teenagers.<sup>793</sup> The rapid—indeed infectious—adoption of e-cigarettes “reverse[s] years of favorable trends in our nation’s fight to prevent youth addiction to tobacco products.”<sup>794</sup> CDC Director Robert Redfield agreed, “The skyrocketing growth of young people’s e-cigarette use over the past year threatens to erase progress made in reducing tobacco use. It’s putting a new generation at risk for nicotine addiction.”<sup>795</sup> Then-Commissioner

<sup>791</sup> National Youth Tobacco Survey, U.S. FDA (2019), <https://www.fda.gov/tobacco-products/youth-and-tobacco/youth-tobacco-use-results-national-youth-tobacco-survey>; Karen Cullen et al., *e-Cigarette Use Among Youth in the United States*, 322 JAMA 2095 (2019).

<sup>792</sup> Jan Hoffman, *Study Shows Big Rise in Teen Vaping This Year*, N.Y. Times (Dec. 17, 2018), <https://www.nytimes.com/2018/12/17/health/ecigarettes-teens-nicotine-.html>; Rajiv Bahl, *Teen Use of Flavored Tobacco was Down, But E-Cigarettes Are Bringing It Back Up*, Healthline (Jan. 9, 2019), <https://www.healthline.com/health-news/flavored-tobacco-use-rising-again-among-teens#An-unhealthy-habit>.

<sup>793</sup> News Release, *FDA Launches New, Comprehensive Campaign to Warn Kids About the Dangers of E-Cigarette Use as Part of Agency’s Youth Tobacco Prevention Plan, Amid Evidence of Sharply Rising Use Among Kids*, U.S. FDA (Sept. 18, 2018), <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620788.htm>.

<sup>794</sup> *Id.*

<sup>795</sup> Amir Vera, *Texas Governor Signs Law Increasing the Age to Buy Tobacco Products to 21*, CNN (June 8, 2019), <https://www-m.cnn.com/2019/06/08/health/texas-new-tobacco-law/index.html>.

1 Gottlieb identified the two primary forces driving the epidemic as “youth appeal and youth  
2 access to flavored tobacco products.”<sup>796</sup>

3 602. Within days of the FDA’s declaration of an epidemic, Surgeon General Dr.  
4 Jerome Adams also warned that the “epidemic of youth e-cigarette use” could condemn a  
5 generation to “a lifetime of nicotine addiction and associated health risks.”<sup>797</sup> The Surgeon  
6 General’s 2018 Advisory states that JUUL, with its combination of non-irritating vapor and  
7 potent nicotine hit, “is of particular concern for young people, because it could make it easier  
8 for them to initiate the use of nicotine . . . and also could make it easier to progress to regular e-  
9 cigarette use and nicotine dependence.”<sup>798</sup>

10 603. The JUUL youth addiction epidemic spread rapidly across high schools in the  
11 United States. JUUL surged in popularity, largely through social media networks, and created  
12 patterns of youth usage, illegal youth transactions, and addiction, that are consistent with this  
13 account from Reddit in 2017:

14 Between classes the big bathroom in my school averages 20-25 kids, and 5-10  
15 JUULs. Kids usually will give you a dollar for a JUUL rip if you don’t know  
16 them, if you want to buy a pod for 5\$ you just head into the bathroom after lunch.  
17 We call the kids in there between every class begging for rips ‘JUUL fiends.’ Pod  
18 boys are the freshman that say ‘can I put my pod in ur juul?’ and are in there  
19 every block. I myself spent about 180\$ on mango pods and bought out a store,  
20 and sold these pods for 10\$ a pod, making myself an absolutely massive profit in  
21 literally 9 days. Given because I’m 18 with a car and that’s the tobacco age  
22 around here, I always get offers to get pod runs or juuls for kids. people even  
23 understand the best system to get a head rush in your 2 minutes between classes,  
24 is all the juuls at once. So someone yells “GIVE ME ALL THE JUULS” and 3-7  
25 are passed around, two hits each. This saves us all juice, and gives you a massive  
26 head rush. Kids also scratch logos and words onto their juuls to make i[t] their  
27 own, every day you can find the pod covers in my student parking lot. I know this  
28 sounds exaggerated, but with a school with 1400 kids near the city and JUULs  
being perceived as popular, it’s truly fascinating what can happen.<sup>799</sup>

---

<sup>796</sup> *Id.*

<sup>797</sup> Surgeon General’s Advisory on E-cigarette Use Among Youth (2018), <https://e-cigarettes.surgeongeneral.gov/documents/surgeon-generals-advisory-on-e-cigarette-use-among-youth-2018.pdf>.

<sup>798</sup> *Id.* a 2.

<sup>799</sup> *What’s Juul in School*, [https://www.reddit.com/r/juul/comments/61is7i/whats\\_juul\\_in\\_school/](https://www.reddit.com/r/juul/comments/61is7i/whats_juul_in_school/) (last visited Apr. 4, 2020).

604. In response to the post above, several others reported similar experiences:

- a. “[T]his is the exact same thing that happens at my school, we call [JUUL fiends] the same thing, kind of scary how similar it is.”<sup>800</sup>
- b. “Same thing at my school. JUUL fiend is a term too.”<sup>801</sup>
- c. “Yeah nicotine addiction has become a huge problem in my high school because of juuls even the teachers know what they are.”<sup>802</sup>
- d. “[S]ame [expletive] at my school except more secretive because it’s a private school. It’s crazy. Kids hit in class, we hit 3-5 at once, and everyone calls each other a juul fiend or just a fiend. Funny how similar it all is.”<sup>803</sup>
- e. “[T]he same [expletive] is happening in my school. kids that vaped were called [expletive] for the longest time, that all changed now.”<sup>804</sup>
- f. “Made an account to say that it’s exactly the same way in my school! LOL. I’m from California and I think I know over 40 kids that have it here just in my school. We do it in the bathrooms, at lunch etc. LMAO. ‘Do you have a pod man?’”<sup>805</sup>
- g. “It’s the same at my school and just about every other school in Colorado.”<sup>806</sup>
- h. “2 months into this school year, my high school made a newspaper article about the ‘JUUL epidemic.’”<sup>807</sup>
- i. “Wow do you go to high school in Kansas because this sounds EXACTLY like my school. I’ll go into a different bathroom 4 times a day and there will be kids in there ripping JUUL’s in every single one.”<sup>808</sup>
- j. “At my high school towards the end of lunch everyone goes to the bathroom for what we call a ‘juul party.’ People bring juuls, phixes, etc. It’s actually a great bonding experience because freshman can actually relate to some upperclassmen and talk about vaping.”<sup>809</sup>

---

<sup>800</sup> *Id.*

<sup>801</sup> *Id.*

<sup>802</sup> *Id.*

<sup>803</sup> *Id.*

<sup>804</sup> *Id.*

<sup>805</sup> *Id.*

<sup>806</sup> *Id.*


<sup>807</sup> *Id.* (citing *Juuls Now Rule the School as Students Frenzy Over E-cig* (Oct. 5, 2016), <https://imgur.com/a/BKewp>).

<sup>808</sup> *Id.*

<sup>809</sup> *Id.*

k. “To everyone thinking that this is just in certain states, it’s not. This is a nationwide trend right now. I’ve seen it myself. If you have one you’re instantly insanely popular. Everyone from the high-achievers to the kids who use to say ‘e-cigs are for [expletives]’ are using the juul. It’s a craze. I love it, I’ve made an insane amount of money. It’s something that has swept through our age group and has truly taken over. And it happened almost overnight.”<sup>810</sup>

605. The following graph illustrates JLI’s responsibility for the nationwide youth e-cigarette epidemic. While the rest of the e-cigarette industry stagnated from 2017 through 2018, JLI experienced meteoric growth. Through that same timeframe, youth e-cigarette rates nearly doubled from more than 11% in 2017 to more than 20% in 2018. Through October 5, 2019 (the last date for which data was available), rates of youth e-cigarette use continued to increase, tracking the growth of JUUL.



606. The unique features of the JUUL e-cigarette—high nicotine delivery, low

<sup>810</sup> *Id.* (emphasis added).

<sup>811</sup> The area graph depicts e-cigarette unit sale volumes in retail outlets tracked by Nielsen by manufacturer and month from 2013 through October 5, 2019; the line graph depicts national high school and middle school e-cigarette past-30-day usage rates as percentages from 2013 through 2019, with each data point representing a year. See Nielsen: Tobacco All Channel Data; National Youth Tobacco Survey (2019), <https://www.fda.gov/tobacco-products/youth-and-tobacco/youth-tobacco-use-results-national-youth-tobacco-survey>; see also Compl. at 2 (Figure 1), *Commonwealth of Penn. v. Juul Labs, Inc.*, (Ct. Common Pleas, Feb. 10, 2020).



harshness, and easy-to-conceal design—have caused patterns of addiction with no historical precedent. It is not uncommon for fifteen-year-old students, even those who live at home with their parents, to consume two or more JUUL pods a day.

607. The downwards trend in youth smoking that public health departments and school anti-tobacco programs worked so hard to create has completely reversed. In 2018, more than one in four high school students in the United States reported using a tobacco product in the past thirty days, a dramatic increase from just one year before.<sup>812</sup> But there was no increase in the use of cigarettes, cigars, or hookahs during that same time period.<sup>813</sup> There was only increased use in a single tobacco product: e-cigarettes. While use of all other tobacco products continued to decrease as it had been for decades, e-cigarette use increased 78% in just one year.<sup>814</sup> This drastic reversal caused the CDC to describe youth e-cigarette use as an “epidemic.”<sup>815</sup>

#### **H. JLI Thrived Due to Extensive Efforts to Delay Meaningful Regulation of its Products**

##### **1. E-Cigarette Manufacturers Successfully Blocked the Types of Regulations that Reduced Cigarette Sales, Creating the Perfect Opportunity for JLI.**

608. One of the main reasons e-cigarettes like JUUL were so appealing from an investment and business development perspective is that, unlike combustible cigarettes, e-cigarettes were relatively unregulated. This regulatory void was not an accident; the cigarette industry, and then the e-cigarette industry, spent significant resources blocking, frustrating, and delaying government action. A 1996 article in the *Yale Law & Policy Review* detailed how

<sup>812</sup> *Progress Erased: Youth Tobacco Use Increased During 2017-2018*, CDC (Feb. 11, 2019), <https://www.cdc.gov/media/releases/2019/p0211-youth-tobacco-use-increased.html>.

<sup>813</sup> *Tobacco Use By Youth Is Rising: E-Cigarettes are the Main Reason*, CDC (Feb. 2019), <https://www.cdc.gov/vitalsigns/youth-tobacco-use/index.html>.

<sup>814</sup> Scott Gottlieb, Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes, FDA (Nov. 15, 2018), <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-proposed-new-steps-protect-youth-preventing-access>.

<sup>815</sup> Jerome Adams, *Surgeon General’s Advisory on E-cigarette Use Among Youth*, CDC (Dec. 2018), <https://e-cigarettes.surgeongeneral.gov/documents/surgeon-generals-advisory-on-e-cigarette-use-among-youth-2018.pdf>.

cigarette companies vehemently opposed the FDA mid-1990s rules on tobacco products, using lawsuits, notice-and-comment, and arguments related to the FDA’s jurisdiction to delay or undo any regulatory efforts.<sup>816</sup>

609. In 2009, Congress enacted the Family Smoking Prevention and Tobacco Control Act (“TCA”). The TCA amended the Federal Food, Drug, and Cosmetic Act to allow the FDA to regulate tobacco products.

610. Although the TCA granted the FDA immediate authority to regulate combustible cigarettes, it did not give the FDA explicit authority over all types of tobacco products—including those that had not yet been invented or were not yet popular. To “deem” a product for regulation, the FDA must issue a “deeming rule” that specifically designates a tobacco product, such as e-cigarettes, as falling within the purview of the FDA’s authority under the TCA.

611. The TCA also mandated that all “new” tobacco products (i.e., any product not on the market as of February 15, 2007) undergo a premarket authorization process before they could be sold in the United States.

612. Four years later, on April 25, 2014, the FDA finally issued a proposed rule deeming e-cigarettes for regulation under the Tobacco Act (“2014 Proposed Rule”).

613. Once issued, the e-cigarette industry, together with its newfound allies, parent companies, and investors—the cigarette industry and pro-e-cigarette lobbyists—set to work to dilute the rule’s effectiveness. For example, in comments to the 2014 Proposed Rule, companies such as Johnson Creek Enterprises (one of the first e-liquid manufacturers) stated that the “FDA [] blatantly ignored evidence that our products improve people’s lives.”<sup>817</sup>

614. The New York Times reported that Altria was leading the effort to dilute, diminish, or remove e-cigarette regulations. Notwithstanding Altria’s professed concern about flavors attracting youth customers, Altria submitted comments in August 2014 in response to

---

<sup>816</sup> Melvin Davis, *Developments in Policy: The FDA’s Tobacco Regulations*, 15 Yale L. & Policy Rev. 399 (1996).

<sup>817</sup> Eric Lipton, *A Lobbyist Wrote the Bill. Will the Tobacco Industry Win Its E-Cigarette Fight?*, N.Y. Times (Sept. 2, 2016), <https://www.nytimes.com/2016/09/03/us/politics/e-cigarettes-vaping-cigars-fda-altria.html>.

the proposed rule opposing the regulation of flavors. Altria asserted that restrictions could result in more illicit sales, and that adults also liked fruity and sweet e-cigarette flavors.<sup>818</sup>

615. In 2015, Altria lobbied Capitol Hill with its own draft legislation to eliminate the new requirement that most e-cigarettes already on sale in the United States be evaluated retroactively to determine if they are “appropriate for the protection of public health.” In effect, Altria lobbied to “grandfather” all existing e-cigarette brands, including JUUL, into a lax regulatory regime. That proposed legislation was endorsed by R.J. Reynolds. Altria delivered its proposal, entitled “F.D.A. Deeming Clarification Act of 2015,” to Representative Tom Cole of Oklahoma, who introduced the bill two weeks later using Altria’s draft verbatim.<sup>819</sup> Seventy other representatives signed on to Altria’s legislation.<sup>820</sup>

616. The e-cigarette industry, along with the intertwined cigarette industry, was able to leverage support among Members of Congress such as Representative Cole and Representative Sanford Bishop of Georgia, who advocated for cigarette industry interests and opposed retroactive evaluation of e-cigarette products. Both Cole and Bishop echoed a common cigarette and e-cigarette industry refrain, that any regulations proposed by the FDA would bankrupt small businesses, even though the overwhelming majority of e-cigarettes were manufactured and distributed by large cigarette companies.

617. Representatives Cole and Bishop received some of the largest cigarette industry contributions of any member of the U.S. House of Representatives, with Representative Bishop receiving \$13,000 from Altria, and Representative Cole \$10,000 from Altria in the 2015-2016 cycle.<sup>821</sup>

618. By thwarting and delaying regulation, or by ensuring what regulation did pass

---

<sup>818</sup> Altria Client Services Inc., Comment Letter on Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act 47-48 (Aug. 8, 2014), <https://www.altria.com/-/media/Project/Altria/Altria/about-altria/federal-regulation-of-tobacco/regulatory-filings/documents/ALCS-NuMark-Comments-FDA-2014-N-0189.pdf>.

<sup>819</sup> Eric Lipton, *A Lobbyist Wrote the Bill. Will the Tobacco Industry Win Its E-Cigarette Fight?*, N.Y. Times (Sept. 2, 2016), <https://www.nytimes.com/2016/09/03/us/politics/e-cigarettes-vaping-cigars-fda-altria.html>.

<sup>820</sup> *Id.*

<sup>821</sup> *Id.*; Rep. Tom Cole - Oklahoma District 04, *Contributors 2015-16*, OpenSecrets (2017), <https://www.opensecrets.org/members-of-congress/contributors?cid=N00025726&cycle=2016>.

was laced with industry-friendly components, the e-cigarette industry, including Defendants, hobbled the FDA—and by extension—Congress’s efforts to regulate e-cigarettes. Simultaneously, the e-cigarette industry continued to market their products to youth, and it coordinated to sow doubt and confusion about the addictiveness and health impacts of e-cigarettes.

619. Even after the FDA issued its final deeming rule in 2016, e-cigarette industry lobbying continued to pay dividends to companies like JLI. In 2017, when Dr. Scott Gottlieb took over as the FDA Commissioner, one of his first major acts was to grant e-cigarette companies a four-year extension to comply with the deeming rule, even as data indicated sharp increases in teen e-cigarette use.<sup>822</sup> Gottlieb had previously served on the board of Kure, a chain of e-cigarette lounges in the United States, though he fully divested before taking the helm at the FDA.<sup>823</sup>

620. The four-year extension was celebrated by e-cigarette lobbyists. Greg Conley, president of the American Vaping Association (“AVA”), stated that but for the extension, “over 99 percent of vapor products available on the market today would be banned next year.”<sup>824</sup> Despite the minimal research publicly available on the health effect of e-cigarettes, Ray Story, who had since become commissioner of the Tobacco Vapor Electronic Cigarette Association, lauded the decision: “Absolutely, it’s a good thing . . . [w]hen you look at harm reduction, it’s a no brainer.”<sup>825</sup>

## 2. JLI, the Management Defendants, and Altria Defendants Successfully Shielded the Popular Mint Flavor from Regulation.

621. JLI, the Management Defendants, and Altria Defendants had a two-fold plan for

<sup>822</sup> Katie Thomas & Sheila Kaplan, *E-Cigarettes Went Unchecked in 10 Years of Federal Inaction*, N.Y. Times (Oct. 14, 2019), <https://www.nytimes.com/2019/10/14/health/vaping-e-cigarettes-fda.html>.

<sup>823</sup> Zeke Faux et al., *Vaping Venture Poses Potential Conflict for Trump’s FDA Nominee*, Bloomberg, (Apr. 19, 2017), <https://www.bloomberg.com/news/articles/2017-04-19/vaping-venture-poses-potential-conflict-for-trump-s-fda-nominee>.

<sup>824</sup> Sheila Kaplan, *F.D.A. Delays Rules That Would Have Limited E-Cigarettes on Market*, N.Y. Times (July 28, 2017), <https://www.nytimes.com/2017/07/28/health/electronic-cigarette-tobacco-nicotine-fda.html>.

<sup>825</sup> *Id.*

1 staving off regulation: (1) ensure the FDA allowed certain flavors, namely mint, to remain on  
2 the market; and (2) stave off a total prohibition on JUUL that was being contemplated in light of  
3 JLI's role in the youth e-cigarette epidemic. These schemes involved acts of mail and wire  
4 fraud, with the intent to deceive the FDA, Congress, and the public at large.

5 622. First, JLI, the Management Defendants, and Altria publicly defended mint  
6 flavoring as a substitute for menthol cigarette smokers, when in fact JLI's studies indicated that  
7 mint users are not former menthol smokers. Second, by fighting to keep mint as the last flavor  
8 on the market, the cigarette industry could continue to appeal to non-smokers, including youth.  
9 JLI and the Management Defendants coordinated with Altria to pursue a fraudulent scheme to  
10 convince the FDA into leaving the mint flavor on the market, sacrificing other flavors in the  
11 process.

12 623. On August 2, 2018, JLI met with the FDA to discuss a proposed youth-  
13 behavioral study regarding the prevalence of use, perceptions of use, and intentions to use  
14 JUUL and other tobacco products among adolescents aged 13-17 years (the "Youth Prevalence  
15 Study").<sup>826</sup>

16 624. On November 5, 2018, JLI transmitted the results of the Youth Prevalence Study  
17 to the FDA and reported that a study of over 1,000 youth had found that only 1.5% of youth had  
18 ever used a JUUL, and that only 0.8% of youth had used a JUUL in the last 30 days. And in  
19 stark contrast to the McKinsey and DB Research studies discussed above, the Youth Prevalence  
20 Study suggested that mango was four times as popular as mint.<sup>827</sup> Specifically, the study found  
21 that 47% of youth who reported use of a JUUL device in the last 30-days professed to using  
22 mango most often, with only about 12% reporting the same for mint.

23 625. JLI's study was a sham. JLI, the Management Defendants, and Altria knew their  
24 reported data was inconsistent with the McKinsey and DB Research studies conducted just a  
25 few months earlier. JLI's report featured responses to a carefully selected survey question—  
26

27 <sup>826</sup> Letter from Joanna Engelke, JUUL Labs, Inc., to David Portnoy, Ph.D., M.P.H., FDA  
28 Center for Tobacco Products (Nov. 5, 2018).

<sup>827</sup> *Id.* at 3.

1 which *single* flavor youth used most often?—that obscured the widespread use of mint JUUL  
2 pods among youth.

3 626. Ironically, just a few days after JLI submitted the misleading Youth Prevalence  
4 Study to the FDA, the National Youth Tobacco Survey was released. Revealing the depths of  
5 the deception of JLI’s Youth Prevalence Study, which found that only 1.5% of youth were  
6 current users of e-cigarettes, the National Youth Tobacco Survey found that 20.8% of high  
7 school student were current users (*i.e.*, consumed e-cigarettes within the last 30 days).

8 627. The Youth Prevalence Study that JLI submitted to the FDA, either via U.S. mail  
9 or by electronic transmission, was false and misleading. JLI, the Management Defendants, and  
10 Altria knew as much. Indeed, they counted on it.

11 628. As the e-cigarette crisis grew, on September 25, 2018, then-FDA Commissioner  
12 Scott Gottlieb sent letters to Altria, JLI and other e-cigarette manufacturers, requesting a  
13 “detailed plan, including specific timeframes, to address and mitigate widespread use by  
14 minors.”<sup>828</sup>

15 629. As evidenced by Altria’s recent admission that negotiations with JLI were  
16 ongoing in late 2017,<sup>829</sup> Altria and JLI’s responses to the FDA reflect a coordinated effort to  
17 mislead the FDA with the intention that regulators, in reliance on their statements, allow JLI to  
18 continue marketing mint JUUL pods.<sup>830</sup>

19 630. Defendants’ plan centered on efforts to deceive the FDA that (1) mint was more  
20 akin to Tobacco and Menthol than other flavors; and (2) kids did not prefer mint.

21 631. JLI took the first step in this coordinated effort to deceive the FDA. In response  
22 to then-Commissioner Gottlieb’s September 12, 2018 letter, JLI prepared an “Action Plan,”  
23 which it presented to the FDA at an October 16, 2018 meeting, and presented to the public on  
24 November 12, 2018. The substance of JLI’s presentation to the FDA and its public-facing  
25

26 <sup>828</sup> Letter from Scott Gottlieb, M.D. to JUUL Labs, Inc. (Sept. 12, 2018); Letter from Scott  
Gottlieb, M.D. to Altria Group Inc. (Sept. 12, 2018).

27 <sup>829</sup> Letter from Howard Willard III, Altria to Senator Durbin, et. al. ( Oct. 14, 2019).

28 <sup>830</sup> See *United States v. Jones*, 712 F.2d 1316, 1320-21 (9th Cir. 1983) (“It is enough that the  
mails be used as part of a ‘lulling’ scheme by reassuring the victim that all is well and  
discouraging him from investigating and uncovering the fraud.”).



Action Plan were largely identical.<sup>831</sup> JLI purported to “share a common goal- preventing youth from initiating on nicotine.”<sup>832</sup> As part of this plan, JLI stated that it would be “stopping flavored JUUL pod sales to all 90,000+ retail stores.”

632. But this statement was not true. JLI was continuing retail sales of its mint JUUL pods, which JLI categorized as a non-flavored “tobacco and menthol product.”<sup>833</sup> In JLI’s Action Plan, then-CEO Burns stated that only products that “mirror what is currently available for combustible cigarettes—tobacco and menthol-based products (menthol and mint pods)—will be sold to retail stores.”<sup>834</sup>

633. In both JLI’s October 2018 presentation to the FDA and JLI’s Action Plan that was shared with the public, JLI and its CEO fraudulently characterized mint as a non-flavored cigarette product, akin to tobacco and menthol cigarettes, suggesting that it was a product for adult smokers. The image below was included in both the public-facing Action Plan and JLI’s presentation to the FDA.



<sup>831</sup> JUUL did not include in its Action Plan a proposal for Bluetooth or Wi-Fi equipped devices that was included in JLI’s October presentation.

<sup>832</sup> JUUL Labs, Inc. *FDA Presentation*, 2 (Oct. 16, 2018); INREJUUL\_00182989.

<sup>833</sup> *Id.*

<sup>834</sup> *JUUL Labs Action Plan*, JUUL Labs, Inc. (Nov. 13, 2018), <https://newsroom.juul.com/juul-labs-action-plan/>.

634. JLI knew that non-smoking youth liked mint as much as any flavor.

635. Numerous internal studies had informed JLI that mint's success was "not because it's a menthol/a familiar tobacco flavor but because it is the best JUUL flavor profile on multiple levels."<sup>835</sup> Indeed, despite JLI's attempts to explicitly link mint to menthol, JLI knew there was "No Implied Relationship Between Mint & Menthol,"<sup>836</sup> and "menthol smokers are not the only driver behind the popularity of mint flavored JUUL pods."<sup>837</sup>

636. Most importantly, JLI knew that mint was the most popular JUUL pod. Though other flavors might draw new customers, JLI's most addictive "flavor" predictably became its most popular.

637. The characterization of mint as an adult tobacco product was also fraudulent because JLI *knew first hand* from the McKinsey and DB Research studies that teens viewed mint as favorably as mango, which implies that mango and mint were fungible goods for JLI's underage users. The McKinsey and DB Research studies also showed that youth preferred mint over the more stereotypically youth-oriented flavors like fruit medley, crème brule, and cucumber. As alleged in a Whistlerblower Complaint, JLI's then-CEO told his employees: "You need to have an IQ of 5 to know that when customers don't find mango they buy mint."<sup>838</sup>

638. On October 25, 2018, less than ten days after JLI presented its fraudulent, misleading Action Plan to the FDA, Altria's CEO Howard Willard submitted a letter in response to the FDA's call to combat the youth epidemic. Willard's letter was a clear indication of Altria's willingness to continue the fraudulent scheme and deception of the FDA. While Willard's letter confirmed that Altria understood that JLI's conduct and product was addicting many children to nicotine, this letter repeated the misleading statement that mint was a "traditional tobacco flavor" despite Altria and JLI knowing it was no such thing. Willard then claimed that the youth epidemic was caused, in part, by "flavors that go beyond traditional

---

<sup>835</sup> INREJUUL\_00265069.

<sup>836</sup> INREJUUL\_00079307-INREJUUL\_00079409, at 395.

<sup>837</sup> *Id.*

<sup>838</sup> Angelica LaVito, *Former JLI executive sues over retaliation, claims company knowingly sold tainted nicotine pods*, CNBC (Oct. 30, 2019), <https://www.cnbc.com/2019/10/30/former-juul-executive-sues-over-retaliation-claims-company-knowingly-sold-tainted-pods.html>.

1 tobacco flavors”—which, according to JLI and Altria, did not include mint—and announced  
 2 that Altria would discontinue all MarkTen flavors except for “traditional tobacco, menthol and  
 3 mint flavors.” Willard asserted that these three flavors were essential for transitioning smokers.  
 4 But Willard, and Altria, knew this was not true.<sup>839</sup>

5 639. That same day—October 25, 2018—Altria continued its deception on an  
 6 earnings call with investors. Altria fraudulently described its decision to remove its pod-based  
 7 products from the market as one intended to address the dramatic increase in youth e-cigarette  
 8 use, while it was only weeks away from publicly announcing its 35% stake in JLI:

9 We recently met with Commissioner Gottlieb to discuss steps that could be taken  
 10 to address underage access and use. Consistent with our discussion with the FDA  
 11 and because we believe in the long-term promise of e-vapor products and harm  
 12 reduction, we’re taking immediate action to address this complex situation.

13 First, Nu Mark will remove from the market MarkTen Elite and Apex by  
 14 MarkTen pod-based products until these products receive a market order from the  
 15 FDA or the youth issue is otherwise addressed. Second, for our remaining  
 16 MarkTen and Green Smoke cig-a-like products, Nu Mark will sell only tobacco,  
 17 menthol and mint varieties. Nu Mark will discontinue the sale of all other flavor  
 18 variants of our cig-a-like products until these products receive a market order  
 19 from the FDA or the youth issue is otherwise addressed. Although we don't  
 20 believe we have a current issue with youth access or use of our e-vapor products,  
 21 we are taking this action, because we don't want to risk contributing to the issue.

22 After removing Nu Mark’s pod-based products and cig-a-like flavor variants,  
 23 approximately 80% of Nu Mark's e-vapor volume in the third quarter of 2018 will  
 24 remain on the market.<sup>840</sup>

25 640. Willard reiterated that “pod-based products and flavored products” were behind  
 26 the increase in youth use of e-cigarettes:

27 I mean, I think the way we thought about this was that we believe e-vapor has a  
 28 lot of opportunity to convert adult cigarette smokers in the short, medium and  
 long-term, but clearly, this significant increase in youth usage of the products puts  
 that at risk and we think rapid and significant action is necessary. And I think as  
 we looked at the data that is available in some of the remarks from the FDA, I  
 think we concluded that the driver of the recent increase we think is pod-based  
 products and flavored products and so we thought that the two actions that we

<sup>839</sup> Letter from Howard Willard III, Altria to Senator Durbin, et. al. (Oct. 14, 2019).

<sup>840</sup> Altria Group Inc (MO) Q3 2018 Earnings Conference Call Transcript MO earnings call for the period ending September 30, 2018 (Oct. 25, 2018), <https://www.fool.com/earnings/call-transcripts/2018/10/25/altria-group-inc-mo-q3-2018-earnings-conference-ca.aspx>.

took addressed the drivers of the increased youth usage here in the short run.<sup>841</sup>

641. Willard emphasized that Altria’s withdrawal of its own pod-based products was intended to address youth use: “[W]e really feel like in light of this dramatic increase in youth usage, withdrawing those products until the PMTA is filed is one path forward.” He later said: “And frankly, the actions we took were the actions that we thought we could take that would have the biggest impact on addressing the increased use of e-vapor products by youth . . . we wanted to make a significant contribution to addressing the issue.”<sup>842</sup> As noted above, however, it has since been reported that Altria “pulled its e-cigarettes off the market” not out of concern for the epidemic of youth nicotine addiction that JLI created, but because a non-compete clause was a “part of its deal with J[LI].”<sup>843</sup>

642. Thus, while Altria publicly announced that it would pull its pod-based products to combat youth usage, and publicly seemed to support removal of youth-friendly flavors, its defense of mint as a tobacco-analog was actually part of the scheme to protect the profits associated with JLI’s mint JUUL pods, one of JLI’s strongest products with the highest nicotine content and highest popularity among non-smokers and youth.

643. In support of his arguments to the FDA that mint was a flavor for adult smokers, Willard cited to a study that Altria Client Services had conducted and presented at a conference that JLI attended.<sup>844</sup> But Willard did *not* disclose that Altria Client Services’s “study” was merely a “quasi-experimental online survey” and not a true scientific study.<sup>845</sup> Notably, JLI’s current CEO, K.C. Crosthwaite, was the Vice President of Strategy and Business Development of Altria Client Services when it conducted Altria’s mint “study” in Spring 2017, the same time

---

<sup>841</sup> *Id.*

<sup>842</sup> *Id.*

<sup>843</sup> *Id.*

<sup>844</sup> Jessica Parker Zdinak, Ph.D., *E-vapor Product Appeal Among Tobacco Users and Non-users and the Role of Flavor in Tobacco Harm Reduction*, 72nd Tobacco Science Research Conference (Sept. 18, 2018), <https://sciences.altria.com/library/-/media/Project/Altria/Sciences/library/conferences/2018%20TSRC%20J%20Zdniak%20Presentation.pdf>.

<sup>845</sup> *Id.*

that the Management Defendants and Altria and Altria Client Services began their “confidential negotiations.”<sup>846</sup> Willard did not disclose that this study was contradicted by the “youth prevention” data provided by JLI during its acquisition due-diligence showing that mint was popular among teens.

644. Through these letters, Altria sought to prevent the FDA—which was actively considering regulating flavors<sup>847</sup>—from banning JLI’s mint JUULpods.

645. Acting in concert, JLI and Altria committed acts of mail or wire fraud when (1) JLI transmitted its Action Plan to the FDA and the public; and (2) Altria transmitted Willard’s letter to the FDA.

646. On October 25, 2018, the same day Howard Willard sent the FDA his letter fraudulently misrepresenting the Mint flavor and Altria’s view on pod-based products, Willard provided Pritzker and Valani with a copy of the very same letter.<sup>848</sup>

647. It is no surprise that Altria was coordinating with Pritzker and Valani on the scheme to protect flavors. It knew a potential ban on flavors would have a material impact on the ability of JLI to continue its youth sales, and on the value of those sales. For example, in November 2018, Crosthwaite asked Brian Blaylock at Altria Client Services to model a scenario for Altria’s investment in JLI where the FDA enacts a flavor ban.<sup>849</sup>

648. At the heart of these acts of fraud was Defendants’ characterization of mint as a tobacco product that was targeted to adult smokers. This characterization was fraudulent because Defendants knew kids prefer mint flavor and that JLI designed mint to be one of JLI’s most potent products. Altria supported this plan and helped execute it. Together, these actions by JLI and Altria ensured that mint would remain available to youths for many months, furthering their efforts to maintain and expand the number of nicotine-addicted e-cigarette users

---

<sup>846</sup> Letter from Howard Willard III, Altria to Senator Durbin, et. al. (Oct. 14, 2019).

<sup>847</sup> Alex Lardieri, *FDA Considers Ban on E-Cigarette Flavors Amid 'Epidemic' Use By Teens*, U.S. News & World Report (Sept. 12, 2018), <https://www.usnews.com/news/health-care-news/articles/2018-09-12/fda-considers-ban-on-e-cigarette-flavors-amid-epidemic-use-by-teens>.

<sup>848</sup> JLIFTC00653389.

<sup>849</sup> ALGAT0000389729.

1 in order to ensure a steady and growing customer base.

2 649. The deceptive scheme worked—the FDA did not protest JLI and Altria’s plan.  
3 And on December 20, 2018, one month after JLI announced its Action Plan to keep selling  
4 mint, Altria made a \$12.8 billion equity investment in JLI.

5 650. By February of 2019, the FDA became aware that it had been deceived by JLI  
6 and Altria. On February 6, 2019, then-FDA commissioner Gottlieb wrote JLI and Altria  
7 demanding in-person meetings, excoriating Altria for its “newly announced plans with JUUL  
8 [that] *contradict the commitments you made to the FDA*” in a prior meeting and Willard’s  
9 October 25, 2018 letter to the FDA.<sup>850</sup> Gottlieb’s letter to JLI alleged that JLI’s conduct was  
10 “inconsistent with its previous representations to the FDA.”<sup>851</sup>

11 651. The FDA demanded Altria be prepared to explain itself regarding its “plans to  
12 stop marketing e-cigarettes and to address the crisis of youth use of e-cigarettes.” Then-  
13 Commissioner Gottlieb told Altria that “deeply concerning data” shows that “youth use of  
14 JUUL represents a significant proportion of overall use of e-cigarette products by children” and  
15 despite any alleged steps the companies had taken to address the issue he “ha[d] no reason to  
16 believe these youth patterns of use are abating in the near term, and they certainly do not appear  
17 to be reversing.”

18 652. JLI and Altria met with Gottlieb in March 2019 in a meeting the then-  
19 Commissioner described as “difficult.”<sup>852</sup> Gottlieb “did not come away with any evidence that  
20 public health concerns drove Altria’s decision to invest in JLI, and instead said it looked like a  
21 business decision. According to reporting by the New York Times, Gottlieb angrily criticized  
22 JLI’s lobbying of Congress and the White House, stating:

23 We have taken your meetings, returned your calls and I had personally met with  
24 you more times than I met with any other regulated company, and yet you still  
25 tried to go around us to the Hill and White House and undermine our public  
26 health efforts. I was trying to curb the illegal use by kids of your product and you

26 <sup>850</sup> Letter from Scott Gottlieb, FDA to Howard Willard, Altria (Feb. 9, 2019).

27 <sup>851</sup> Letter from Scott Gottlieb, FDA to Kevin Burns, JUUL Labs, Inc. (Feb. 9, 2019).

28 <sup>852</sup> Kate Rooney & Angelica LaVito, *Altria Shares Fall After FDA’s Gottlieb Describes ‘Difficult’ Meeting on Juul*, CNBC (Mar. 19, 2019), <https://www.cnbc.com/2019/03/19/altria-shares-fall-after-fdas-gottlieb-describes-difficult-meeting-on-juul.html>.



are fighting me on it.<sup>853</sup>

653. But just a week after the “difficult” meeting with JLI and Altria, Gottlieb posted a statement about the FDA’s new e-cigarette policy, proposing to ban all flavors *except* “tobacco-, mint- and menthol-flavored products.”<sup>854</sup> He cited the strong support of President Trump (whose administration JLI had aggressively lobbied<sup>855</sup>), and also cited “recent evidence indicat[ing] that mint- and menthol-flavored ENDS products are preferred more by adults than minors.”<sup>856</sup> Just a few weeks later, Gottlieb resigned from his position as commissioner of the FDA.

654. The scheme had succeeded in saving mint JUUL pods, as well as each Defendant’s bottom line. JLI’s sale of mint JUUL pods rose from one third of its sales in September 2018 to approximately two thirds in February 2019. JLI’s 2019 revenues were estimated to be between \$2.36 billion and \$3.4 billion, and mint JUUL pods accounted for approximately 75% of JLI’s total 2019 sales. And because mint remained on the market until JLI withdrew it in November 2019 in the face of growing scrutiny,<sup>857</sup> thousands, if not millions, of underage JUUL users suffered the consequences.

655. As former New York City Mayor Mike Bloomberg stated: “JUUL’s decision to keep mint- and menthol-flavored e-cigarettes on the shelves is a page right out of the tobacco industry’s playbook.”<sup>858</sup>

---

<sup>853</sup> Julie Creswell & Sheila Kaplan, *How Juul Hooked a Generation on Nicotine*, N.Y. Times (Nov. 24, 2019), <https://www.nytimes.com/2019/11/23/health/juul-vaping-crisis.html>.

<sup>854</sup> News Release, *Statement from FDA Commissioner Scott Gottlieb, M.D., on advancing new policies aimed at preventing youth access to, and appeal of, flavored tobacco products, including e-cigarettes and cigars*, U.S. FDA (Mar. 13, 2019), <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-advancing-new-policies-aimed-preventing-youth-access>.

<sup>855</sup> Evan Sully & Ben Brody, *JLI Spent Record \$1.2 Million Lobbying as Regulators Stepped Up*, Wash. Post (Oct. 22, 2019), [https://www.washingtonpost.com/business/on-small-business/juul-spent-record-12-million-lobbying-as-regulators-stepped-up/2019/10/22/2a0dbc52-f4de-11e9-b2d2-1f37c9d82dbb\\_story.html](https://www.washingtonpost.com/business/on-small-business/juul-spent-record-12-million-lobbying-as-regulators-stepped-up/2019/10/22/2a0dbc52-f4de-11e9-b2d2-1f37c9d82dbb_story.html).

<sup>856</sup> *Id.*

<sup>857</sup> Ellen Huet, *JLI Pulls Mint-Flavor Vaping Products, but Menthol Remains*, Bloomberg (Nov. 7, 2019), <https://www.bloomberg.com/news/articles/2019-11-07/juul-stops-selling-mint-flavored-vaping-products>.

<sup>858</sup> *Id.*

656. JLI continues to sell menthol-flavored products.<sup>859</sup>

**3. In Response to the Public Health Crisis Created by JUUL, the FDA Belatedly Tried to Slow the Epidemic.**

657. In 2017, the FDA announced that it would be taking steps to regulate e-cigarette devices such as JUUL. In late 2017, the FDA initiated its investigation of e-cigarette companies' advertising and sales practices. But, as noted above, the FDA's 2017 Compliance Policy issued a four-year extension for compliance with the 2016 deeming rule, apparently to "balance between regulation and encouraging development of innovative tobacco products that may be less harmful than cigarettes."<sup>860</sup> In March 2018, the 2017 Compliance Policy was challenged by the American Academy of Pediatrics, along with other public health organizations concerned that a compliance extension for the e-cigarette industry would allow more e-cigarette products into the market and continue to addict thousands of youth.<sup>861</sup>

658. In March 2019, the FDA drafted guidance that modified the 2017 Compliance Policy, but it did not go into full effect. However, on May 15, 2019, the lawsuit filed by the American Academy of Pediatrics was successful—the U.S. District Court for the District of Maryland vacated the 2017 Compliance Policy, and directed the FDA to "require that premarket authorization applications for all new deemed products" ("new" referred to any product launched after February 15, 2007 and thus would include JUUL) be submitted within ten months, by May 2020.<sup>862</sup>

659. In January 2020, the FDA issued: Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization: Guidance for Industry (2020 FDA Guidance), directed at the e-cigarette industry, which detailed the FDA's plan to prioritize enforcement of regulations prohibiting the sale of

---

<sup>859</sup> Sheila Kaplan, *Juul Halts Sales of Mint, Its Top-Selling e-Cigarette Flavor*, N.Y. Times (Nov. 7, 2019), <https://www.nytimes.com/2019/11/07/health/vaping-juul-mint-flavors.html>.

<sup>860</sup> *Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization*, U.S. FDA (Jan. 2020), <https://www.fda.gov/media/133880/download>.

<sup>861</sup> *Id.*

<sup>862</sup> *Id.*; *Am. Academy of Pediatrics v. FDA*, 379 F. Supp. 3d 461, 496 (D. Md. 2019).

flavored e-cigarette products and prohibiting the targeting of youth and minors.<sup>863</sup> The 2020 FDA Guidance focused on flavored e-cigarettes that appeal to children, including fruit and mint: “[C]ompanies that do not cease manufacture, distribution and sale of unauthorized flavored cartridge-based e-cigarettes . . . within 30 days risk FDA enforcement actions.”<sup>864</sup>

#### 4. The Government’s Efforts to Address the JUUL Crisis Were Too Late and the Damage Has Already Been Done

660. By the time the FDA acted, youth consumption of e-cigarettes had already reached an all-time high, and the e-cigarette industry’s presence on social media became an unstoppable force. The 2020 FDA Guidance acknowledges that two of the largest 2019 surveys of youth cigarette use found that e-cigarette use had reached the highest levels ever recorded.<sup>865</sup> By December 2019, there were over 2,500 reported cases of e-cigarette related hospitalization for lung injury, including over fifty confirmed deaths.<sup>866</sup> Despite the FDA’s efforts between 2017 and 2019, youth consumption of e-cigarettes doubled among middle and high school students over the same period.<sup>867</sup> In 2019, the total number of middle and high school students reporting current use of e-cigarettes surpassed five million for the first time in history.<sup>868</sup>

661. JLI’s presence on social media has also persisted, even without further initiation by JLI—the hallmark of a successful viral marketing campaign. When the “#juul” hashtag was first used on social media, it was a series of thirteen tweets on Twitter. By the time JLI announced it would shut down its Instagram account, “#juul” had been featured in over 250,000 posts on Instagram. A study by Stanford University found that in the eight months after JLI

---

<sup>863</sup> *Id.*

<sup>864</sup> News Release, *FDA Finalizes Enforcement Policy on Unauthorized Flavored Cartridge-Based E-Cigarettes That Appeal to Children, Including Fruit and Mint*, U.S. FDA (Jan. 2, 2020), <https://www.fda.gov/news-events/press-announcements/fda-finalizes-enforcement-policy-unauthorized-flavored-cartridge-based-e-cigarettes-appeal-children>.

<sup>865</sup> *Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization*, U.S. FDA (Jan. 2020), <https://www.fda.gov/media/133880/download>.

<sup>866</sup> Karen A. Cullen et al., *E-cigarette Use Among Youth in the United States, 2019*, 322 JAMA 2095 (2019).

<sup>867</sup> *Id.*

<sup>868</sup> *Id.*

1 ceased all promotional postings, community posting accelerated, to nearly half a million posts.  
 2 Whereas before JLI exited Instagram, “#juul” appeared on average in 315 posts per day, that  
 3 number tripled to 1084 posts per day after JLI shut down its Instagram account.<sup>869</sup>

4 662. The FDA’s anti-e-cigarette campaign on social media was aimed at youth and  
 5 middle and high school students. The campaign used the slogan “The Real Cost” to educate  
 6 youth on social media platforms about the health impacts of e-cigarette consumption—the real  
 7 cost of using e-cigarettes. A recent study from the University of California Berkeley found that  
 8 since September 2018, when the FDA’s social media campaign began, the hashtag  
 9 “#TheRealCost” was used about fifty times per month on Instagram. By comparison, e-cigarette  
 10 related hashtags were used as many as 10,000 times more often. Despite the FDA’s social media  
 11 intervention, the number of e-cigarette related posts, and the median number of likes (a strong  
 12 metric of viewer engagement) the posts received, increased three-fold and six-fold,  
 13 respectively.<sup>870</sup>

14 663. In short, by the time the FDA reacted to the epidemic created by Defendants,  
 15 millions of youth were addicted to e-cigarettes and nicotine, and were sharing e-cigarette related  
 16 posts on social media on their own.

17 **I. JUUL Usage Increases the Risk of Cardiovascular, Pulmonary,**  
 18 **Neurological, and Other Bodily Injuries**

19 **1. JUUL Products Cause Acute and Chronic Lung (Pulmonary)**  
 20 **Injuries**

21 664. The use of e-cigarettes, including JUUL, cause significant lung toxicity<sup>871</sup> and  
 22 have been implicated in multiple severe pathological lung injuries.

23 665. Recent studies have demonstrated that exposure to JUUL aerosol induces  
 24

25 <sup>869</sup> Robert K. Jackler et al., *Rapid Growth of JUUL Hashtags After the Company Ceased Social*  
 26 *Media Promotion*, Stanford Research Into the Impact of Tobacco Advertising (July 22, 2019),  
 27 [http://tobacco.stanford.edu/tobacco\\_main/publications/Hashtag\\_JUUL\\_Project\\_7-22-19F.pdf](http://tobacco.stanford.edu/tobacco_main/publications/Hashtag_JUUL_Project_7-22-19F.pdf).

28 <sup>870</sup> Julia Vassey, *#Vape: Measuring E-cigarette Influence on Instagram With Deep Learning*  
 and Text Analysis, 4 *Frontiers in Commc’n* 75  
 (2020), <https://www.frontiersin.org/articles/10.3389/fcomm.2019.00075/full>.

<sup>871</sup> Lauren F. Chun et al., *Pulmonary Toxicity of E-cigarettes*, 313 *Am. J. Physiol. Lung Cell*  
*Mol. Physiol.* L193 (2017), <https://www.ncbi.nlm.nih.gov/pubmed/28522559>.

oxidative stress, inflammation, epithelial barrier dysfunction, and DNA damage in lung cells.<sup>872</sup>

An impaired epithelial barrier function allows greater passage of inhaled chemicals into the body, increasing inflammation both locally in the lungs and systemically. This can lead to acute and chronic lung injury as well as exposure to, and increased susceptibility to, respiratory infections in users of e-cigarettes, including JUUL.<sup>873</sup>

666. Research has also demonstrated that ultrafine metal particles from heating devices have been found in e-cigarette aerosol, and in e-cigarette user's lungs.<sup>874</sup>

667. In addition, exposure to JUUL aerosol has been shown to significantly impair endothelial function comparable to impairment of endothelial function caused by use of combustible cigarettes.<sup>875</sup>

668. It is well-established that endothelial dysfunction and injury from direct toxic effects of inhalants such as cigarette smoke, can cause lung injuries such as chronic obstructive pulmonary disease (COPD), emphysema, asthma and chronic bronchitis.<sup>876</sup>

669. Recent epidemiological and toxicological studies detected links between asthma frequency and e-cigarette use in adolescents and reported that vaporized e-liquids containing the

<sup>872</sup> Thivanka Muthumalage et al., *E-cigarette Flavored Pods Induce Inflammation, Epithelial Barrier Dysfunction, and DNA Damage in Lung Epithelial Cells and Monocytes*, 9 Scientific Reports 19035 (2019), <https://www.nature.com/articles/s41598-019-51643-6>.

<sup>873</sup> Laura E. Crotty Alexander et al., *Chronic Inhalation of E-cigarette Vapor Containing Nicotine Disrupts Airway Barrier Function and Induces Systemic Inflammation and Multiorgan Fibrosis in Mice*, 314 Am. J. Physiol. Regul. Comp. Physiol. R834 (2018), <https://journals.physiology.org/doi/full/10.1152/ajpregu.00270.2017>; Pieter S. Hiemstra et al., *The Innate Immune Function of Airway Epithelial Cells in Inflammatory Lung Disease*, 45 Eur. Respir. J. 1150 (2015), <https://erj.ersjournals.com/content/45/4/1150>.

<sup>874</sup> Alessandra Caporale et al., *Acute Effects of Electronic Cigarette Aerosol Inhalation on Vascular Function Detected at Quantitative MRI*, 293 Radiology 97 (2019), <https://www.ncbi.nlm.nih.gov/pubmed/31429679>.

<sup>875</sup> Poonam Rao et al., *Juul and Combusted Cigarettes Comparably Impair Endothelial Function*, 6 Tob. Regul. Sci. 30 (2020), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953758/>.

<sup>876</sup> Francesca Polverino et al. *COPD as an Endothelial Disorder: Endothelial Injury Linking Lesions in the Lungs and Other Organs?*, 8 Pulm. Circ. 1 (2018), <https://www.ncbi.nlm.nih.gov/pubmed/29468936>.

1 same flavor aldehydes found in JUUL induce inflammation in human respiratory epithelia.<sup>877</sup>

2 670. A study published in December 2019, found that among individuals who never  
3 smoked combustible cigarettes, current e-cigarette use was associated with 75% higher odds of  
4 chronic bronchitis, emphysema, and COPD compared to those who never used e-cigarettes.<sup>878</sup>

5 671. In addition, the flavoring compounds used in e-cigarettes such as JUUL, include  
6 numerous chemicals known to be toxins if inhaled, such as diacetyl, acetyl propionyl, and  
7 benzaldehyde. These chemicals are linked to serious lung disease.<sup>879</sup>

8 672. A multitude of published case reports have linked e-cigarette use, including  
9 JUUL, to a variety of acute inhalational lung injuries such as lipoid pneumonia, bronchiolitis  
10 obliterans (popcorn lung), alveolar hemorrhage, eosinophilic pneumonia, hypersensitivity  
11 pneumonitis, chemical pneumonitis and collapsed lungs, among others.

12 673. In 2012, one article reported on the case of a 42-year-old woman admitted with a  
13 seven-month history of dyspnea, cough, and fevers that began when the patient had begun using  
14 e-cigarettes. The authors hypothesized the source of lipoid pneumonia was e-cigarette use, due  
15 to “glycerin-based oils found in e-cigarette nicotine vapor” added to “make the visual smoke  
16 when the solution is vaporized.”<sup>880</sup>

17 674. A 2014 report described a 20-year-old previously healthy U.S. active-duty male  
18 sailor who presented with a three-day history of “persistent cough, shortness of breath, and  
19

20  
21 <sup>877</sup> Phillip W. Clapp and Ilona Jaspers, *Electronic Cigarettes: Their Constituents and Potential*  
22 *Links to Asthma*, 79 Curr Allergy Asthma Rep. 17 (2017),  
<https://www.ncbi.nlm.nih.gov/pubmed/28983782>.

23 <sup>878</sup> Albert D. Osei et al., *Association Between E-Cigarette Use and Chronic Obstructive*  
24 *Pulmonary Disease by Smoking Status: Behavioral Risk Factor Surveillance System 2016 and*  
25 *2017*, 132 Am. J. Prev. Med. 949 (2019), <https://www.ncbi.nlm.nih.gov/pubmed/30853474>.

26 <sup>879</sup> Centers for Disease Control & Prevention, *Flavorings-Related Lung Disease* (Oct. 3,  
27 2017), <https://www.cdc.gov/niosh/topics/flavorings/default.html>; Won Hee Lee et al.,  
28 *Modeling Cardiovascular Risks of E-Cigarettes with Human-Induced Pluripotent Stem Cell-*  
*Derived Endothelial Cells*. 73 J. Am. College of Cardiology 2722 (2019),  
<https://www.ncbi.nlm.nih.gov/pubmed/31146818>; Sheila Kaplan & Matt Richtel, *Mysterious*  
*Vaping Illness That's 'Becoming an Epidemic,'* N.Y. Times (Aug. 31, 2019),  
<https://www.nytimes.com/2019/08/31/health/vaping-marijuana-ecigarettes-sickness.html>.

<sup>880</sup> Lindsay McCauley et al., *An Unexpected Consequence of Electronic Cigarette Use*, 141  
Chest 1110 (2012).



facial flushing” which began an hour after using an e-cigarette device. The patient was diagnosed with acute eosinophilic pneumonia. The patient was given prednisone and discharged after five days in the hospital, with improvement of his symptoms and significant resolution of lung opacity.<sup>881</sup>

675. In 2015, Atkins and Drescher reported the case of a 60-year-old man admitted repeatedly with weakness, chills, cough, a fever, and hypoxemia, with “bilateral upper lung zone crackles.” The patient revealed before each emergency room admittance he had used e-cigarettes and was diagnosed with “suspected acute hypersensitivity pneumonitis, related to ENDS” and had no further episodes with cessation of e-cigarette use.

676. In another case in 2015, a 31-year-old woman was admitted to the hospital for dyspnea and cough. The patient “became increasingly hypoxic and was intubated due to concerns of acute respiratory distress syndrome.” The patient was started on IV steroids and diagnosed with lipoid pneumonia, given the close temporality of her recent initiation of e-cigarettes three months prior to her onset of symptoms. The patient rapidly improved with steroids and cessation of use of e-cigarettes.<sup>882</sup> A different published a case report in 2015 describes bilateral pneumonia and pleural effusions associated with e-cigarette use.<sup>883</sup>

677. In 2016, another case report described the case of a 27-year-old otherwise healthy man who was admitted to the hospital with dyspnea, cough, fever, and hemoptysis after increasing use of e-cigarettes for seven months prior to presentation, initiated in an effort to decrease his combustible tobacco dependence. The patient worsened and required intubation and mechanical ventilator support. There were no notable findings on microorganism workup, “making infectious etiology for his pneumonia very unlikely.”<sup>884</sup>

---

<sup>881</sup> Darshan Thota & Emi Latham, *Case Report of Electronic Cigarettes Possibly Associated with Eosinophilic Pneumonitis in a Previously Healthy Active-duty Sailor*, 47 J. Emerg. Med. 15 (2014).

<sup>882</sup> Sujal Modi et al., *Acute Lipiod Pneumonia Secondary to E-Cigarettes Use: An Unlikely Replacement for Cigarettes*, 148 Chest 382 (2015).

<sup>883</sup> Kendall Moore et al., *Bilateral Pneumonia and Pleural Effusions Subsequent to Electronic Cigarette Use*, 3 Open J. of Emergency Med. 18 (2015).

<sup>884</sup> Ronnie D. Mantilla et al., *Vapor Lung: Bronchiolitis Obliterans Organizing Pneumonia (BOOP) in Patient with E-Cigarette Use*, 193 Am. J. of Respiratory & Critical Care Med. A6513 (2016).

678. Also in January 2020, another article reported on a teenager who developed acute fibrinous organizing pneumonia (AFOP) after using JUUL as well as other vaping products. AFOP presents with diffuse ground glass infiltrates and intra-alveolar fibrin balls. Subpleural sparing and pneumomediastinum described elsewhere in vaping associated lung injury were also seen. The authors noted that this patient's presentation fit with existing literature, but his young age, choice of e-cigarette, and lung pathology were considered unique. The images characterized AFOP, a newly evolving rare lung pathology, which is now associated with vaping.<sup>885</sup>

679. Additional published case reports and case series were published since 2016 noting serious and significant acute lung injuries associated with vaping or e-cigarette use. Despite the increasing reports in the published medical literature and the widespread use of JUUL among teenagers, JLI did not take any steps to warn the public and consumers of the risks of JUUL products.

680. Over the summer of 2019, healthcare providers started to note an influx of acute respiratory failure and a myriad of lung injuries in patients who were using e-cigarettes. This prompted a Center for Disease Control ("CDC") investigation of an outbreak of vaping associated lung injuries. The reported injuries mirrored the injuries that had been reported in the medical literature since 2012. In October 2019, the CDC issued treatment guidelines to assist doctors in clinical practice. The CDC defined a new recognized medical condition referred to as E-cigarette, or Vaping, Product Use Associated Lung Injury illnesses (EVALI).

681. Researchers noted that the recent proliferation of vaping-related cases, known as EVALI, demonstrated a heterogeneous collection of pneumonitis patterns that include acute eosinophilic pneumonia, organizing pneumonia, lipoid pneumonia, diffuse alveolar damage and acute respiratory distress syndrome (ARDS), diffuse alveolar hemorrhage, hypersensitivity pneumonitis, and the rare giant-cell interstitial pneumonitis. Active infection (which would include live bacterial contamination of e-cigarette fluids) did not appear to explain the clinical

---

<sup>885</sup> Monica A. Lu et al., *Vaping-related Lung Injury in an Adolescent*, 201 Am. J. of Respiratory & Critical Care Med. 481(2020).

1 presentation, but acute toxic lung injury did seem to fit.<sup>886</sup>

2 682. Further, a recent publication in 2020 noted that there were almost 2000 cases of  
3 EVALI at the time it was written. The authors further noted that Vitamin E acetate was one  
4 possible cause of the recent outbreak but there may be more than one cause and therefore,  
5 everyone should refrain from using any e-cigarette or vaping products.<sup>887</sup>

6 683. Another publication in January 2020 noted that there were a number of patients  
7 who were diagnosed with EVALI who reported the use of nicotine only e-cigarettes. The  
8 authors concluded that EVALI was also associated with nicotine only products.<sup>888</sup>

9 684. In addition, multiple reports have been published in the medical literature of  
10 acute alveolar hemorrhage caused by e-cigarette use.<sup>889</sup> Diffuse alveolar hemorrhage (DAH) is a  
11 life-threatening disorder which refers to bleeding that originates in the pulmonary  
12 microvasculature. It often results in acute respiratory failure.<sup>890</sup> Hypersensitivity pneumonitis  
13 has been linked to the use of e-cigarettes, such as JUUL, since 2015.<sup>891</sup> In 2018, researchers  
14 published the first reported case of hypersensitivity pneumonitis and acute respiratory distress  
15 syndrome (ARDS) as a risk of e-cigarette use in an adolescent.<sup>892</sup> Recent case reports have also  
16  
17  
18

---

19 <sup>886</sup> David C. Christiani, *Vaping-Induced Injury*, 68 New England J. Med. 787 (2019).

20 <sup>887</sup> Sascha Ellington et al., *Update: Product, Substance-Use, and Demographic Characteristics*  
21 *of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-*  
22 *Associated Lung Injury—United States, August 2019–January 2020*, 69 Morbidity & Mortality  
23 Weekly Rep. 44 (2020).

24 <sup>888</sup> Isaac Ghinai et al., *Characteristics of Persons Who Report Using Only Nicotine-Containing*  
25 *Products Among Interviewed Patients with E-cigarette, or Vaping, Product Use-Associated*  
26 *Lung Injury - Illinois, August-December 2019*, 69 Morbidity & Mortality Weekly Rep. 84  
27 (2020).

28 <sup>889</sup> Michael Agustin et al., *Diffuse Alveolar Hemorrhage Induced by Vaping*, 2018 Case Rep.  
Pulmonol. 1 (2018); Peter J. Edmonds et al., *Vaping-induced Diffuse Alveolar Hemorrhage*, 29  
Respiratory Med. Case Reports 1 (2020).

<sup>890</sup> Brandi R. Newsome & Juan E. Morales, *Diffuse Alveolar Hemorrhage*, 104 Southern Med.  
J. 269 (2011).

<sup>891</sup> Graham Atkins et al., *Acute Inhalational Lung Injury Related to the Use of Electronic*  
*Nicotine Delivery Systems (ENDS)*, 148 Chest 83A (2015).

<sup>892</sup> Casey G. Sommerfield et al., *Hypersensitivity Pneumonitis and Acute Respiratory Distress*  
*Syndrome From E-Cigarette Use*, 141 Pediatrics 1 (2018).

linked spontaneous pneumothorax (lung collapse) to vaping and use of e-cigarettes.<sup>893, 894</sup>

685. The multiple pathological lung injuries and toxicity associated with e-cigarette use, including JUUL, can lead to acute respiratory failure, intubation with mechanic ventilation and death.

686. It has been established that the use of e-cigarettes, including JUUL, can lead to acute and chronic lung injuries such as EVALI, lipoid pneumonia, organizing pneumonia, chemical pneumonitis, alveolar hemorrhage, bronchiolitis obliterans (popcorn lung), pneumothorax, acute respiratory failure, acute respiratory distress syndrome (ARDS), asthma, emphysema and COPD. Defendants never warned the public of the risk of serious acute and chronic lung injuries that were associated with the use of e-cigarettes, including JUUL.

687. The failure to properly and adequately test the safety of JUUL prior to marketing it to the public, including teenagers and young adults, and continuing in the face of the onslaught of publications in the medical literature demonstrating an association with e-cigarette use and significant lung injuries, amounts to a reckless disregard for public safety.

## 2. JUUL Products Cause Cardiovascular Injuries

688. In addition to severe lung injuries and addiction, JUUL products cause significant and severe risks of cardiovascular injuries. Studies have shown that use of e-cigarettes such as JUUL increase the risk of strokes and heart attacks.<sup>895</sup>

---

<sup>893</sup> Alex Bonilla et al., *Recurrent Spontaneous Pneumothoraces and Vaping in an 18-year-old Man: A Case Report and Review of the Literature*, 13 J. of Med. Case Reports 283 (2019), <https://doi.org/10.1186/s13256-019-2215-4>.

<sup>894</sup> Munish Sharma et al., *A Case Report of Secondary Spontaneous Pneumothorax Induced by Vape*, 11 Cureus e6067 (2019), <https://www.cureus.com/articles/24542-a-case-report-of-secondary-spontaneous-pneumothorax-induced-by-vape>.

<sup>895</sup> News Release, *E-cigarettes linked to higher risk of stroke, heart attack, diseased arteries*, Am. Stroke Ass'n, Abstract 9, Session A2 (Jan. 30, 2019), <https://newsroom.heart.org/news/e-cigarettes-linked-to-higher-risk-of-stroke-heart-attack-diseased-arteries>; Mohindar R. Vindhya et al., *Impact on Cardiovascular Outcomes Among E-cigarette Users: A Review From National Health Interview Surveys*, 73 J. of the Am. College of Cardiology Suppl. 2 (2019), [www.onlinejacc.org/content/73/9\\_Supplement\\_2/11](http://www.onlinejacc.org/content/73/9_Supplement_2/11); Paul M. Ndunda & Tabitha M. Muutu, *Electronic Cigarette Use is Associated with a Higher Risk of Stroke*, 50 Int'l Stroke Conference 2019 Oral Abstracts: Community/Risk Factors, Suppl. 1, Abst. 9, [www.ahajournals.org/doi/10.1161/str.50.suppl\\_1.9](http://www.ahajournals.org/doi/10.1161/str.50.suppl_1.9).

689. Research has demonstrated that e-cigarettes significantly increase blood pressure and arterial stiffness, which also increases the risk of strokes and heart attacks.<sup>896</sup> Further, scientists have found that e-cigarettes cause oxidative stress, which leads to vascular disease and damage, known risk factors for cardiovascular injuries.<sup>897</sup>

690. Biological and epidemiologic studies have found that significant associations exist between e-cigarette use and myocardial infarctions (heart attacks), which appear to be dose-dependent. Biological investigations support this association, whereby a prothrombotic phenotype may develop after exposure to nicotine-containing e-cigarette vapors.<sup>898</sup>

691. Researcher Florian Rader and others found that chronic e-cigarette users demonstrated substantially impaired coronary microvascular endothelial function, even more pronounced than that seen in chronic tobacco cigarette users. These findings also suggested that chronic e-cigarette use leads to measurable and persistent adverse vascular effects that are not directly related to nicotine.<sup>899</sup>

692. Talal Alzahrani found that daily e-cigarette use was associated with an increased risk of myocardial infarction.<sup>900</sup>

693. A systematic review of the literature found that acute mainstream exposure to aerosol from JUUL, or from previous generations of e-cigarettes using free-base nicotine, impaired vascular function comparably to combusted cigarette smoke and delivered

<sup>896</sup> Charalambos Vlachopoulos et al., *Electronic Cigarette Smoking Increases Aortic Stiffness and Blood Pressure in Young Smokers*, 67 J. Am. Coll. Cardiol. (2016).

<sup>897</sup> Dennis Thompson, *Vaping May Hurt the Lining of Your Blood Vessels*, WebMD HealthDay Reporter (May 28, 2019), [www.webmd.com/mental-health/addiction/news/20190528/vaping-may-hurt-the-lining-of-your-blood-vessels#1](http://www.webmd.com/mental-health/addiction/news/20190528/vaping-may-hurt-the-lining-of-your-blood-vessels#1); JUUL e-cigarettes and JUUL pods deliver dangerous toxins and carcinogens to users. The ingredients in JUUL pods include glycerol, propylene glycol, nicotine, benzoic acid, and flavoring chemicals. *See What Are JUULpods?*, [www.juul.com/learn/pods](http://www.juul.com/learn/pods) (last visited Apr. 4, 2020).

<sup>898</sup> Giuseppe Lippi & Emmanuel J. Falavero, *An Update on Biological and Clinical Associations Between E-Cigarettes and Myocardial Infarction*, Semin. Thromb. Hemost. (2019), <https://doi.org/10.1055/s-0039-3402451>.

<sup>899</sup> Florian Rader et al., *E-Cigarette Use and Subclinical Cardiac Effects*, medRxiv (preprint) (2020), <https://www.medrxiv.org/content/10.1101/2020.01.16.20017780v1>.

<sup>900</sup> Talal Alzahrani et al., *Association Between Electronic Cigarette Use and Myocardial Infarction*, 55 Am. J. Preventive Med. 455 (2018).

considerably more nicotine to the blood on a per puff basis.<sup>901</sup>

694. The overarching conclusion from dozens of studies published in the past 8 years is that use of e-cigarettes, including JUUL, increases the risk of cardiovascular injury which can lead to strokes, heart attacks and death. JLI never warned the public or consumers of the serious and significant risk of cardiovascular injuries associated with its products.

### 3. JUUL Products Cause and Contribute to Seizure(s)

695. On April 3, 2019 the FDA Center for Tobacco Products issued a Special Announcement notifying the public of an increase in reports of tobacco-related seizures, specifically relating to an increase in e-cigarette use, particularly among youth.<sup>902</sup>

696. Additionally, FDA Commissioner Gottlieb and the Principal Deputy Commissioner Amy Abernethy issued a joint statement addressing the FDA's ongoing scientific investigation of seizures following e-cigarette use as a potential safety issue in youth and young adults. The statement identifies seizures following e-cigarette use as a source of concern for the FDA, adding that in addition to the 35 reported cases from 2010 to early 2019, the FDA "recognize[s] that not all of the cases may be reported" due to their voluntary nature.<sup>903</sup>

697. Symptomatic nicotine toxicity is a consequence of excessive vaping.<sup>904</sup> As the FDA acknowledges in their statement, "seizures or convulsions are known potential side effects of nicotine toxicity."<sup>905</sup> It is well-documented that nicotine poisoning can cause seizures,

<sup>901</sup> Nicholas Buchanan et al. *Cardiovascular Risk of Electronic Cigarettes: A Review of Preclinical and Clinical Studies*, 116 *Cardiovascular Research* 40 (2019).

<sup>902</sup> News Release, *Some E-cigarette Users Are Having Seizures, Most Reports Involving Youth and Young Adults*, U.S. FDA (Apr. 10, 2019), <https://www.fda.gov/tobacco-products/ctp-newsroom/some-e-cigarette-users-are-having-seizures-most-reports-involving-youth-and-young-adults>.

<sup>903</sup> News Release, *Statement from FDA Commissioner Scott Gottlieb, M.D., and Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., on FDA's Ongoing Scientific Investigation of Potential Safety Issue Related to Seizures Reported Following E-cigarette Use, Particularly in Youth and Young Adults*, U.S. FDA (Apr. 3, 2019), <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-principal-deputy-commissioner-amy-abernethy-md-phd>.

<sup>904</sup> Adrienne Hughes et al., *An Epidemiologic and Clinical Description of E-cigarette Toxicity*, 57 *Clin. Toxicol.* 287 (2018), <https://doi.org/10.1080/15563650.2018.1510503>.

<sup>905</sup> News Release, *Some E-cigarette Users Are Having Seizures, Most Reports Involving Youth and Young Adults*, U.S. FDA (Apr. 10, 2019), <https://www.fda.gov/tobacco-products/ctp->



including ingestion of e-cigarette fluid.<sup>906</sup> Nicotine-induced seizure has long been considered a possible side effect of long-term nicotine exposure.<sup>907</sup> JUUL's high nicotine content and addictive nature cause JUUL users to be highly susceptible to seizures. Moreover, it has been suggested that the use of e-cigarettes has been associated with an exacerbation of seizures in individuals who are predisposed.<sup>908</sup>

698. Seizures following e-cigarette use are a significant cause for concern due to the unnecessarily high levels of nicotine delivered, by design, via JUUL. As described herein, JLI intentionally designed its products to deliver a higher amount of nicotine, particularly targeting young people, and then failed to warn of the subsequent risks. JUUL devices were deliberately designed to deliver higher concentrations of nicotine per puff as compared to cigarettes, creating the risk for addiction as well as the risk of seizure due to potentially toxic levels of nicotine exposure.

699. JLI never warned the public or consumers of the risk of seizures associated with the use of e-cigarettes including JUUL.

#### 4. Animal Studies Demonstrate Carcinogenic Potential of JUUL

700. Several studies conducted on animals show a significant likelihood that JUUL could cause cancer for users.

701. In 2017, a report by Donatella Canistro and others found that e-cigarettes induce toxicological effects that can raise the risk of cancer.<sup>909</sup> Similarly, a 2018 study measured the DNA damage induced by nitrosamines in the organs (lung, bladder, and heart) of mice subjected to e-cigarette vapor and concluded that e-cigarette vapor induces DNA damage in all

newsroom/some-e-cigarette-users-are-having-seizures-most-reports-involving-youth-and-young-adults.

<sup>906</sup> Gerdinique C. Maessen et al., *Nicotine Intoxication by E-cigarette Liquids: A Study of Case Reports, Pathophysiology*, 58 *Clinical Toxicology* 1 (2020), <https://www.tandfonline.com/doi/full/10.1080/15563650.2019.1636994>.

<sup>907</sup> Lucinda L. Miner et al., *The Effect of Chronic Nicotine Treatment on Nicotine-induced Seizures*, 95 *Psychopharmacology* 52 (1988), <https://doi.org/10.1007/BF00212766>.

<sup>908</sup> Jessica D. Wharton et al., *Increased Seizure Frequency Temporally Related to Vaping: Where There's Vapor, There's Seizures?*, 104 *Pediatric Neurology* 66 (2020).

<sup>909</sup> Donatella Canistro et al., *E-cigarettes Induce Toxicological Effects That Can Raise the Cancer Risk*, 7 *Sci. Reports* 1 (2017).

three organs and reduces DNA-repair functions and proteins in mouse lungs. They further found that nicotine-derived nitrosamine ketone can induce the same effects and enhance mutational susceptibility and tumorigenic transformation of cultured human bronchial epithelial and urothelial cells (leading them to believe that vaping could contribute to heart disease and lung and bladder cancer in humans).<sup>910</sup> And in 2019, a report by Moon-shong Tang and others found that exposure to e-cigarette vapor, induced lung adenocarcinoma and bladder urothelial hyperplasia in mice.<sup>911</sup>

702. There is a likely association between e-cigarettes, including JUUL, and cancer. Long term epidemiological studies will likely reveal an increased risk of cancer among this generation of youth who were unwitting targets of JLI in complete and utter reckless disregard for their safety.

## **V. INTERSTATE AND INTRASTATE COMMERCE**

703. Defendants' conduct as alleged herein has had a substantial effect on interstate and intrastate commerce.

704. At all material times, Defendants participated in the manufacture, marketing, promotion, distribution, and sale substantial amounts of JUUL products in a continuous and uninterrupted flow of commerce across state and national lines and throughout the United States.

705. Defendants' conduct also had substantial intrastate effects in that, among other things, JUUL products were advertised and sold in each state and the District of Columbia. At least thousands of individuals in each state and the District of Columbia were impacted by Defendants' fraudulent, deceptive, and unfair conduct. As alleged below, absent Defendants' unlawful conduct, Plaintiffs and class members within each state and the District of Columbia would not have purchased JUUL products or would have paid less for them.

---

<sup>910</sup> Hyun-Wook Lee et al., *E-cigarette Smoke Damages DNA and Reduces Repair Activity in Mouse Heart, Lung, and Bladder as well as in Human Lung and Bladder Cells*, 115 PNAS E1560 (2017).

<sup>911</sup> Moon-shong Tang, et al., *Electronic-cigarette Smoke Induces Lung Adenocarcinoma and Bladder Urothelial Hyperplasia in Mice*, 116 PNAS 21727 (2019).

**VI. CLASS ACTION ALLEGATIONS**

706. Plaintiffs bring this action on behalf of themselves and, under Federal Rules of Civil Procedure 23(a), (b)(2), (b)(3) and/or (c)(4), as representatives of classes defined as follows:

**A. Nationwide Class**

707. The Nationwide Class is defined as:

All persons who purchased, in the United States, a JUUL e-cigarette and/or JUUL pods.

**B. State Classes and Subclasses**

708. As an alternative or in addition to the Nationwide Class, Plaintiffs allege a separate class for each State and the District of Columbia based upon the applicable laws set forth in the alternate state law counts. Each class is defined as follows for the claims asserted under a particular jurisdiction's law:

709. The Alabama Subclass is defined as:

All persons who purchased, in Alabama, a JUUL e-cigarette and/or JUUL pods.

710. The Alabama Direct Purchaser Subclass is defined as:

All persons who purchased, in Alabama, a JUUL e-cigarette and/or JUUL pods directly from JUUL.

711. The Alaska Subclass is defined as:

All persons who purchased, in Alaska, a JUUL e-cigarette and/or JUUL pods.

712. The Arizona Subclass is defined as:

All persons who purchased, in Arizona, a JUUL e-cigarette and/or JUUL pods.

713. The Arkansas Subclass is defined as:

All persons who purchased, in Arkansas, a JUUL e-cigarette and/or JUUL pods.

1           714.    The California Subclass is defined as:

2                   All persons who purchased, in California, a JUUL e-cigarette and/or  
3                   JUUL pods.

4           715.    The Colorado Subclass is defined as:

5                   All persons who purchased, in Colorado, a JUUL e-cigarette and/or JUUL  
6                   pods.

7           716.    The Connecticut Subclass is defined as:

8                   All persons who purchased, in Connecticut, a JUUL e-cigarette and/or  
9                   JUUL pods.

10          717.    The Delaware Subclass is defined as:

11                   All persons who purchased, in Delaware, a JUUL e-cigarette and/or JUUL  
12                   pods.

13          718.    The District of Columbia Subclass is defined as:

14                   All persons who purchased, in District of Columbia, a JUUL e-cigarette  
15                   and/or JUUL pods.

16          719.    The Florida Subclass is defined as:

17                   All persons who purchased, in Florida, a JUUL e-cigarette and/or JUUL  
18                   pods.

19          720.    The Georgia Subclass is defined as:

20                   All persons who purchased, in Georgia, a JUUL e-cigarette and/or JUUL  
21                   pods.

22          721.    The Georgia Direct Purchaser Subclass is defined as:

23                   All persons who purchased, in Georgia, a JUUL e-cigarette and/or JUUL  
24                   pods directly from JUUL.

25          722.    The Hawaii Subclass is defined as:

26                   All persons who purchased, in Hawaii, a JUUL e-cigarette and/or JUUL  
27                   pods.

28          723.    The Idaho Subclass is defined as:

All persons who purchased, in Idaho, a JUUL e-cigarette and/or JUUL pods.

724. The Illinois Subclass is defined as:

All persons who purchased, in Illinois, a JUUL e-cigarette and/or JUUL pods.

725. The Illinois Direct Purchaser Subclass is defined as:

All persons who purchased, in Illinois, a JUUL e-cigarette and/or JUUL pods directly from JUUL.

726. The Indiana Subclass is defined as:

All persons who purchased, in Indiana, a JUUL e-cigarette and/or JUUL pods.

727. The Iowa Subclass is defined as:

All persons who purchased, in Iowa, a JUUL e-cigarette and/or JUUL pods.

728. The Kansas Subclass is defined as:

All persons who purchased, in Kansas, a JUUL e-cigarette and/or JUUL pods.

729. The Kentucky Subclass is defined as:

All persons who purchased, in Kentucky, a JUUL e-cigarette and/or JUUL pods.

730. The Kentucky Direct Purchaser Subclass is defined as:

All persons who purchased, in Kentucky, a JUUL e-cigarette and/or JUUL pods directly from JUUL.

731. The Louisiana Subclass is defined as:

All persons who purchased, in Louisiana, a JUUL e-cigarette and/or JUUL pods.

732. The Maine Subclass is defined as:

All persons who purchased, in Maine, a JUUL e-cigarette and/or JUUL pods.

733. The Maryland Subclass is defined as:

All persons who purchased, in Maryland, a JUUL e-cigarette and/or JUUL pods.

734. The Massachusetts Subclass is defined as:

All persons who purchased, in Massachusetts, a JUUL e-cigarette and/or JUUL pods.

735. The Michigan Subclass is defined as:

All persons who purchased, in Michigan, a JUUL e-cigarette and/or JUUL pods.

736. The Minnesota Subclass is defined as:

All persons who purchased, in Minnesota, a JUUL e-cigarette and/or JUUL pods.

737. The Mississippi Subclass is defined as:

All persons who purchased, in Mississippi, a JUUL e-cigarette and/or JUUL pods

738. The Missouri Subclass is defined as:

All persons who purchased, in Missouri, a JUUL e-cigarette and/or JUUL pods.

739. The Montana Subclass is defined as:

All persons who purchased, in Montana, a JUUL e-cigarette and/or JUUL pods.

740. The Nebraska Subclass is defined as:

All persons who purchased, in Nebraska, a JUUL e-cigarette and/or JUUL pods.

741. The Nevada Subclass is defined as:

All persons who purchased, in Nevada, a JUUL e-cigarette and/or JUUL pods.

742. The New Hampshire Subclass is defined as:



1 All persons who purchased, in New Hampshire, a JUUL e-cigarette and/or  
2 JUUL pods.

3 743. The New Jersey Subclass is defined as:

4 All persons who purchased, in New Jersey, a JUUL e-cigarette and/or  
5 JUUL pods.

6 744. The New Mexico Subclass is defined as:

7 All persons who purchased, in New Mexico, a JUUL e-cigarette and/or  
8 JUUL pods.

9 745. The New York Subclass is defined as:

10 All persons who purchased, in New York, a JUUL e-cigarette and/or  
11 JUUL pods.

12 746. The New York Direct Purchaser Subclass is defined as:

13 All persons who purchased, in New York, a JUUL e-cigarette and/or  
14 JUUL pods directly from JUUL.

15 747. The North Carolina Subclass is defined as:

16 All persons who purchased, in North Carolina, a JUUL e-cigarette and/or  
17 JUUL pods.

18 748. The North Dakota Subclass is defined as:

19 All persons who purchased, in North Dakota, a JUUL e-cigarette and/or  
20 JUUL pods.

21 749. The Ohio Subclass is defined as:

22 All persons who purchased, in Ohio, a JUUL e-cigarette and/or JUUL  
23 pods.

24 750. The Ohio Direct Purchaser Subclass is defined as:

25 All persons who purchased, in Ohio, a JUUL e-cigarette and/or JUUL  
26 pods directly from JUUL.

27 751. The Oklahoma Subclass is defined as:

28 All persons who purchased, in Oklahoma, a JUUL e-cigarette and/or  
JUUL pods.

752. The Oregon Subclass is defined as:

All persons who purchased, in Oregon, a JUUL e-cigarette and/or JUUL pods.

753. The Oregon Direct Purchaser Subclass is defined as:

All persons who purchased, in Oregon, a JUUL e-cigarette and/or JUUL pods directly from JUUL.

754. The Pennsylvania Subclass is defined as:

All persons who purchased, in Pennsylvania, a JUUL e-cigarette and/or JUUL pods.

755. The Rhode Island Subclass is defined as:

All persons who purchased, in Rhode Island, a JUUL e-cigarette and/or JUUL pods.

756. The South Carolina Subclass is defined as:

All persons who purchased, in South Carolina, a JUUL e-cigarette and/or JUUL pods.

757. The South Dakota Subclass is defined as:

All persons who purchased, in South Dakota, a JUUL e-cigarette and/or JUUL pods.

758. The Tennessee Subclass is defined as:

All persons who purchased, in Tennessee, a JUUL e-cigarette and/or JUUL pods.

759. The Tennessee Direct Purchaser Subclass is defined as:

All persons who purchased, in Tennessee, a JUUL e-cigarette and/or JUUL pods directly from JUUL.

760. The Texas Subclass is defined as:

All persons who purchased, in Texas, a JUUL e-cigarette and/or JUUL pods.

761. The Utah Subclass is defined as:

1 All persons who purchased, in Utah, a JUUL e-cigarette and/or JUUL  
2 pods.

3 762. The Vermont Subclass is defined as:

4 All persons who purchased, in Vermont, a JUUL e-cigarette and/or JUUL  
5 pods.

6 763. The Vermont Direct Purchaser Subclass is defined as:

7 All persons who purchased, in Vermont, a JUUL e-cigarette and/or JUUL  
8 pods directly from JUUL.

9 764. The Virginia Subclass is defined as:

10 All persons who purchased, in Virginia, a JUUL e-cigarette and/or JUUL  
11 pods.

12 765. The Washington Subclass is defined as:

13 All persons who purchased, in Washington, a JUUL e-cigarette and/or  
14 JUUL pods.

15 766. The Washington Direct Purchaser Subclass is defined as:

16 All persons who purchased, in Washington, a JUUL e-cigarette and/or  
17 JUUL pods directly from JUUL.

18 767. The West Virginia Subclass is defined as:

19 All persons who purchased, in West Virginia, a JUUL e-cigarette and/or  
20 JUUL pods.

21 768. The Wisconsin Subclass is defined as:

22 All persons who purchased, in Wisconsin, a JUUL e-cigarette and/or  
23 JUUL pods.

24 769. The Wisconsin Direct Purchaser Subclass is defined as:

25 All persons who purchased, in Wisconsin, a JUUL e-cigarette and/or  
26 JUUL pods directly from JUUL.

27 770. The Wyoming Subclass is defined as:

28 All persons who purchased, in Wyoming, a JUUL e-cigarette and/or JUUL  
pods.

**C. Class Exclusions**

771. The following persons and entities are excluded from the proposed classes: Defendants, their employees, co-conspirators, officers, directors, legal representatives, heirs, successors and wholly or partly owned subsidiaries or affiliated companies; class counsel and their employees; and the judicial officers and their immediate family members and associated court staff assigned to this case.

**D. Rule 23 Prerequisites**

772. Each of the proposed classes meets the requirements of Federal Rules of Civil Procedure 23(a), (b)(2), (b)(3) and/or (c)(4).

773. The members of each class are so numerous that joinder is impracticable. Each class includes at least thousands of members. Members of the classes are widely dispersed throughout the country and/or each respective state.

774. Plaintiffs' claims are typical of the claims of all class members. Plaintiffs' claims arise out of the same common course of conduct that gives rise to the claims of the other class members. Plaintiffs and all class members were and will continue to be damaged by the same wrongful conduct—*i.e.*, Defendants' scheme to engage in fraudulent and unfair business practices regarding the marketing and sale of JUUL products, including the marketing of such products to minors.

775. Plaintiffs will fairly and adequately protect and represent the interests of the classes. Plaintiffs' interests are coincident with, and not antagonistic to, those of the classes.

776. Plaintiffs are represented by counsel who are experienced and competent in the prosecution of class action litigation and have particular expertise with consumer class actions and cases in the tobacco industry.

777. Questions of law and fact common to the classes include:

- a. Whether the advertising for JUUL products was misleading, fraudulent, deceptive, unfair and/or unconscionable;
- b. Whether the targeting of minors in the marketing and sale of JUUL products was unfair and/or unconscionable;

- c. Whether Defendants have been unjustly enriched through the false, misleading and deceptive advertising of JUUL products and the marketing and sale of JUUL products to minors;
- d. Whether JUUL products were merchantable condition when sold, were defective when sold, and possessed the most basic degree of fitness for ordinary use;
- e. Whether Defendants' conduct violated the Magnuson-Moss Warranty Act, 15 U.S.C. §§ 2301, *et seq.*;
- f. Whether Defendants' conducted an enterprise in violation of the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1961, *et seq.*;
- g. The amount of damages owed the classes;
- h. The appropriate measure of disgorgement; and
- i. The type and format of injunctive relief.

778. Questions of law and fact common to members of each class will predominate over any questions that may affect only individual class members because Defendants have acted on grounds generally applicable to members of the classes.

779. Class treatment is a superior method for the fair and efficient adjudication of the controversy because, among other things, class treatment will permit a large number of similarly situated persons to prosecute their common claims in a similar forum simultaneously, efficiently, and without the unnecessary duplication of evidence, effort, and expense that numerous individual actions would engender. The benefits of proceeding through the class mechanism, including providing injured persons and entities with a means of obtaining redress on claims that might not be practicable to pursue individually, substantially outweigh any difficulties that may arise in the management of this class action.

780. Class treatment is also manageable, and Plaintiffs know of no management difficulties that would preclude class certification in this.

781. Plaintiffs reserve the right to seek to certify common questions related to Defendants' knowledge, conduct, products, and duties.

**VII. CAUSES OF ACTION**

**A. Violations of California Law Brought on Behalf of the Nationwide Class and the California Subclass**

782. Except as otherwise noted, Plaintiffs bring each of the claims in this Section on behalf of the Nationwide Class and, in the alternative, on behalf of the California Class.

**1. Violation of the California Unfair Competition Law (Cal. Bus. & Prof. Code § 17200, *et seq.*) (Sales and Marketing Practices)**

783. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

784. This claim is brought against JLI and, for certain claims as noted below, all Defendants.

785. JLI is a “person” under Cal. Bus. & Prof. Code § 17201.

786. Plaintiffs and class members purchased JUUL products for personal purposes.

787. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

788. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

789. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully



1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 790. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 791. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes, and other representations.

10 792. JLI's conduct was unfair and unconscionable in that it included (i) the  
11 manufacture and sale of products with a heightened propensity to cause addiction and physical  
12 injuries and (ii) misrepresentations and omissions of material facts concerning the  
13 characteristics and safety of JUUL products that offended public policy; were immoral,  
14 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
15 substantial harm that greatly outweighs any possible utility from the conduct.

16 793. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
17 omissions at issue were likely to, and in fact did, deceive reasonable consumers, including the  
18 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
19 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
20 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
21 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
22 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
23 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes, and (vi)  
24 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
25 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
26 in Plaintiffs' and class members' decisions to purchase JUUL products.

27 794. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
28 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties

other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

795. As set forth in the allegations concerning each Plaintiff in Appendix A, in purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions. Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

796. JLI's conduct was also unlawful in that it violated the following statutes: Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1961, *et seq.*; the Magnuson-Moss Warranty Act, 15 U.S.C. §§ 2301, *et seq.*; Cal. Bus. & Prof. Code § 22963(a); and Cal. Penal Code § 308(a)(1)(A).

797. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL products were appropriate for minors, when in fact the products never should have been marketed to minors and are especially harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health risks.

798. All Defendants engaged in conduct that is unfair and unconscionable because the targeting of minors offends public policy (in particular Cal. Bus. & Prof. Code § 22963(a) and Cal. Penal Code § 308(a)(1)(A)) is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has caused substantial harm that greatly outweighs any possible utility from the conduct.

799. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI and others have continued the deceptive, misleading, unfair, and unconscionable practices that Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by minors continues to rise.

800. Defendants’ conduct actually and proximately caused Plaintiffs and class members to lose money or property. Absent Defendants’ unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants’ misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—restitution, injunctive relief (except as to the Management Defendants), and reasonable attorneys’ fees, as well as any other relief the Court may deem just or proper.

**2. Violation of the California Consumer Legal Remedies Act (Cal. Civ. Code § 1750, *et seq.*)**

801. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

802. This claim is brought against JLI.

803. JLI is a “person” under Cal. Civ. Code § 1761.

804. Plaintiffs and class members are “consumers” under Cal. Civ. Code § 1761 and purchased JUUL products for personal purposes.

805. JUUL products are “goods” under Cal. Civ. Code § 1761.

806. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

807. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or

1 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
2 decades, JLI used third parties and word of mouth to spread false and misleading information  
3 about JUUL products and word of mouth to spread false and misleading information about  
4 JUUL products.

5 808. Advertisements and representations for JUUL products concealed and failed to  
6 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed significant risks of substantial physical injury resulting from the use of the  
9 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
10 consumed through a pack of combustible cigarettes, and that the nicotine consumed through one  
11 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

12 809. The labels on JUUL products failed to disclose that the products posed  
13 significant risks of substantial physical injury resulting from the use of the products. The labels  
14 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

15 810. The omissions were misleading and deceptive standing alone and were  
16 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
17 cigarettes and other representations.

18 811. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
19 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
20 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
21 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
22 model, when they are not; (c) advertising goods or services with intent not to sell them as  
23 advertised; and (d) misrepresenting that the subject of a transaction has been supplied in  
24 accordance with a previous representation when it has not.

25 812. JLI's conduct was likely to, and in fact did, deceive reasonable consumers,  
26 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
27 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
28 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely

1 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
2 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
3 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
4 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
5 Plaintiffs' and class members' decisions to purchase JUUL products.

6 813. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
7 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
8 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
9 facts; because the facts would be material to reasonable consumers; because JLI actively  
10 concealed them; because JLI intended for consumers to rely on the omissions in question;  
11 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
12 made partial representations concerning the same subject matter as the omitted facts.

13 814. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
14 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
15 Reasonable consumers would have been expected to have relied on the misrepresentations and  
16 omissions.

17 815. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
18 class members. Absent JLI's unfair and fraudulent conduct, Plaintiffs and class members would  
19 have behaved differently and would not have purchased JUUL products or would have paid less  
20 for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to  
21 purchase JUUL products they would not otherwise have purchased and enter into purchase  
22 contracts they would not otherwise have entered into. In addition, class members who are  
23 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
24 seek—on behalf of themselves and each member of the class—actual damages, punitive  
25 damages, injunctive relief, reasonable attorneys' fees, and restitution, as well as any other relief  
26 the Court may deem just or proper.

27 816. Plaintiffs have complied or substantially complied with all applicable notice  
28 requirements.

1 817. Concurrently with the filing of this complaint, plaintiff are filing an affidavit  
2 pursuant to Cal. Civ. Code § 1780(d).

3 **3. Violation of the California False Advertising Law (Cal. Bus. & Prof.**  
4 **Code § 17500, *et seq.*)**

5 818. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

6 819. This claim is brought against JLI.

7 820. JUUL intended to directly and indirectly sell JUUL products. JUUL induced  
8 consumers to buy JUUL products and made and disseminated, and caused to be made and  
9 disseminated, from California misrepresentations and omissions that were untrue and  
10 misleading.

11 821. Defendants knew or should have known that their misrepresentations and/or  
12 omissions were false and misleading, and intended for consumers to rely on such  
13 misrepresentations and omissions.

14 822. The misrepresentations and omissions were likely to, and in fact did, deceive  
15 reasonable consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
16 would have found it material to their purchasing decisions that JUUL's products (i) were not  
17 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
18 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
19 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
20 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
21 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
22 in Plaintiffs' and class members' decisions to purchase JUUL products.

23 823. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
24 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
25 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
26 facts; because the facts would be material to reasonable consumers; because JLI actively  
27 concealed them; because JLI intended for consumers to rely on the omissions in question;  
28 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI



made partial representations concerning the same subject matter as the omitted facts.

824. As set forth in the allegations concerning each Plaintiff in Appendix A, in purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions. Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

825. JLI's conduct actually and proximately caused loss of money or property by Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—restitution and injunctive relief, as well as any other relief the Court may deem just or proper.

#### **4. Common Law Fraud**

826. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

827. This claim is brought against JLI.

828. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

829. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous

1 decades, JLI used third parties and word of mouth to spread false and misleading information  
2 about JUUL products.

3 830. Advertisements and representations for JUUL products concealed and failed to  
4 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
5 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
6 addictive, posed significant risks of substantial physical injury resulting from the use of the  
7 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
8 consumed through a pack of combustible cigarettes.

9 831. The labels on JUUL products failed to disclose that the products posed  
10 significant risks of substantial physical injury resulting from the use of the products. The labels  
11 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

12 832. The omissions were misleading and deceptive standing alone and were  
13 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
14 cigarettes and other representations.

15 833. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
16 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
17 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
18 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
19 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
20 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
21 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
22 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
23 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
24 Plaintiffs' and class members' decisions to purchase JUUL products.

25 834. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
26 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
27 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
28 facts; because the facts would be material to reasonable consumers; because JUUL products

pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

835. As set forth in the allegations concerning each Plaintiff in Appendix A, in purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations and/or omissions. Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

836. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

837. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

##### **5. Breach of the Implied Warranty of Merchantability**

838. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

839. This claim is brought against JLI.

840. JLI has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

841. Each JUUL product sold comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. Cal Comm. Code § 2314. JLI has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1           842. The ordinary intended purpose of JUUL products—and the purpose for which  
2 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
3 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
4 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
5 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
6 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
7 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
8 recreation smoking devices.

9           843. Plaintiffs and each member of the class have had sufficient direct dealings with  
10 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
11 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
12 each member of the class, on the other hand.

13           844. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
14 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
15 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
16 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
17 the express purpose an intent of being sold to consumers.

18           845. Plaintiffs and the members of the class were injured as a direct and proximate  
19 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
20 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
21 because, had they been aware of the unmerchantable condition of JUUL products, they would  
22 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
23 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

24           846. JUUL was provided notice of these issues by numerous complaints filed against  
25 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
26 individual letters and communications sent by consumers before or within a reasonable amount  
27 of time after they discovered or should have discovered that’s JUUL product were defective and  
28 unmerchantable.

**6. Unjust Enrichment**

847. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

848. This claim is brought against JLI and the Management Defendants.

849. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

850. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Cal. Bus. & Prof. Code § 22963(a) prohibits the marketing and sale of JUUL products to minors, and Cal. Penal Code § 308(a)(1)(A) makes doing so a criminal violation.

851. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

852. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

853. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

854. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

855. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

**B. Violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”)<sup>912</sup>**

**1. Violation of 18 U.S.C. § 1962(c)**

856. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

857. This claim is brought by Plaintiffs against Defendants Monsees, Bowen, Pritzker, Huh, Valani, and Altria (the “RICO Defendants”) for actual damages, treble damages, and equitable relief under 18 U.S.C. § 1964, for violations of 18 U.S.C. § 1961, et seq.

858. Section 1962(c) makes it “unlawful for any person employed by or associated with any enterprise engaged in, or the activities of which affect, interstate or foreign commerce, to conduct or participate, directly or indirectly, in the conduct of such enterprise’s affairs through a pattern of racketeering activity . . .” 18 U.S.C. § 1962(c).

859. At all relevant times, each RICO Defendant is and has been a “person” within the meaning of 18 U.S.C. § 1961(3), because they are capable of holding, and do hold, “a legal or beneficial interest in property.”

860. Each RICO Defendant conducted the affairs of an enterprise through a pattern of racketeering activity, in violation of 18 U.S.C. § 1962(c), as described herein.

861. Plaintiffs are each a “person,” as that term is defined in 18 U.S.C. § 1961(3), and have standing to sue under 18 U.S.C. § 1964(c) as they were and are injured in their business and/or property “by reason of” the RICO Act violations described herein.

862. Plaintiffs demand the applicable relief set forth in the Prayer for Relief below.

---

<sup>912</sup> Plaintiffs bring both of the claims in this Section on behalf of the Nationwide Class.



**a. JLI is an Enterprise Engaged in, or its Activities Affect, Interstate or Foreign Commerce**

863. Section 1961(4) defines an enterprise as “any individual, partnership, corporation, association, or other legal entity, and any union or group of individuals associated in fact although not a legal entity.” 18 U.S.C. § 1961(4).

864. JUUL Labs, Inc. (“JLI”) is a corporation and therefore meets the definition of “enterprise” under the RICO Act. Specifically, JLI is registered as a corporate entity in the State of Delaware.

865. Each of Defendants Pritzker, Huh, Valani, Bowen, and Monsees controlled the JLI Enterprise—that is, they used JLI as the vehicle through which an unlawful pattern of racketeering activity was committed—through their roles as officers and directors of JLI. As set forth below, their roles allowed them to control the resources and instrumentalities of JLI and use that control to perpetrate a number of fraudulent schemes involving the use of mail and wires, including sales to youth and fraudulently misrepresenting or omitting the truth about JUUL products to adult consumers and the public at large. For its part, Altria and Altria Client Services began conspiring with Defendants Pritzker and Valani to direct the affairs of JLI as early as Spring 2017, messaging that if JLI continued its massive growth—which they knew was achieved through youth marketing and fraudulent misrepresentations and omissions—they would receive a massive personal pay-off. The Altria Defendants started personally transmitting statements over the mail and wires in furtherance of the fraudulent schemes even before Altria’s December 2018 investment in JLI. After that point, Altria gained even further influence over the JLI Board of Directors and installed its own personnel in key roles at JLI, cementing its direction of the Enterprise.

866. JLI is an enterprise that is engaged in and affects interstate commerce because the company has sold and continues to sell products across the United States, as alleged herein.

**b. “Conduct or Participate, Directly or Indirectly, in the Conduct of Such Enterprise’s Affairs”**

867. “[T]o conduct or participate, directly or indirectly, in the conduct” of an

enterprise, “one must participate in the operation or management of the enterprise itself.” *Reves v. Ernst & Young*, 507 U.S. 170, 185 (1993).

868. As described herein, each RICO Defendant participated in the operation or management of the JLI Enterprise, and directed the affairs of the JLI Enterprise through a pattern of racketeering activity, including masterminding schemes to defraud that were carried out by and through JLI using the mail and wires in furtherance of plans that were designed with specific intent to defraud.

**Bowen and Monsees founded the JLI Enterprise and started its mission of hooking kids and lying to the public and regulators**

869. Plaintiffs incorporate by reference, as if fully set forth herein, the factual allegations stated against Defendants Bowen and Monsees above.

870. As described above in more detail, Defendants Bowen and Monsees were the visionaries behind JUUL, led JLI in its infancy to develop a highly addictive product, and formed JLI with the aim of creating a growing base of loyal users, including an illicit youth market of nicotine users, by following the same tactics that the cigarette industry has used for decades: selling to kids and lying to adults about their products. Together, Bowen and Monsees set out to “deliver solutions that refresh the magic and luxury of the tobacco category.”<sup>913</sup>

871. Monsees admitted that when creating JLI, he and Bowen carefully studied the marketing strategies, advertisements, and product design revealed in cigarette industry documents that were uncovered through litigation and made public under the November 1998 Master Settlement Agreement between the state Attorneys General of forty-six states, five U.S. territories, the District of Columbia, and the four largest cigarette manufacturers in the United States. “[Cigarette industry documents] became a very intriguing space for us to investigate because we had so much information that you wouldn’t normally be able to get in most industries. And we were able to catch up, right, to a huge, huge industry in no time. And then

---

<sup>913</sup> Josh Mings, *Ploom Model Two Slays Smoking With Slick Design and Heated Tobacco Pods*, SOLID SMACK (Apr. 23, 2014), [www.solidsmack.com/design/ploom-modeltwo-slick-design-tobacco-pods](http://www.solidsmack.com/design/ploom-modeltwo-slick-design-tobacco-pods).

1 we started building prototypes.”<sup>914</sup>

2 872. Seizing on the decline in cigarette consumption and the lax regulatory  
3 environment for e-cigarettes, Bowen, Monsees, and investors in their company sought to  
4 introduce nicotine to a whole new generation of youth users, with JLI as the dominant supplier,  
5 by concealing the nicotine content and addictiveness of the products, and promoting these  
6 products to youth users. To achieve that goal, they knew they would need to create and market  
7 a product that would make nicotine cool to kids again, without the stigma associated with  
8 cigarettes, deceive the public about what they were doing, and prevent and delay regulation that  
9 would hinder their efforts to expand JUUL sales.

10 873. Bowen led the design of the JUUL product, including by participating as a  
11 subject in many of the company’s human studies. Bowen was instrumental in making the JUUL  
12 product appealing to youth, even though “he was aware early on of the risks e-cigarettes posed  
13 to teenagers.” He drew on his experience as a design engineer at Apple to make JUUL resonate  
14 with Apple’s popular aesthetics. This high-tech style made JUULs look “more like a cool  
15 gadget and less like a drug delivery device. This wasn’t smoking or vaping, this was  
16 JUULing.”<sup>915</sup> The evocation of technology makes JUUL familiar and desirable to the younger  
17 tech-savvy generation, particularly teenagers. According to a 19-year-old interviewed for the  
18 Vox series By Design, “our grandmas have iPhones now, normal kids have JUULs now.  
19 Because it looks so modern, we kind of trust modern stuff a little bit more so we’re like, we can  
20 use it, we’re not going to have any trouble with it because you can trust it.”<sup>916</sup>

21 874. Bowen designed JUUL products to foster and sustain addiction, not break it. JLI  
22 and Bowen were the first to design an e-cigarette that could compete with combustible  
23 cigarettes on the speed and strength of nicotine delivery. Indeed, JUUL products use nicotine  
24 formulas and delivery methods much stronger than combustible cigarettes, confirming that what  
25

---

26 <sup>914</sup> Gabriel Montoya, *Pax Labs: Origins with James Monsees*, SOCIAL UNDERGROUND,  
27 <https://socialunderground.com/2015/01/pax-ploom-origins-future-james-monsees/>.

28 <sup>915</sup> *How JUUL Made Nicotine Go Viral*, VOX (Aug. 10, 2018),  
<https://www.youtube.com/watch?v=AF0poKBUyok>.

<sup>916</sup> *Id.*

1 Bowen created an initiation product, not a cessation or cigarette replacement product. Bowen  
2 also innovated by making an e-cigarette that was smooth and easy to inhale, practically  
3 eliminating the harsh “throat hit,” which otherwise deters nicotine consumption, especially  
4 among nicotine “learners,” as R.J. Reynolds’ chemist Claude Teague called new addicts,  
5 primarily young people.

6 875. Bowen worked to minimize “throat hit” and maximize “buzz” of the JUUL e-  
7 cigarette. Dramatically reducing the throat hit is not necessary for a product that is aimed at  
8 smokers, who are accustomed to the harshness of cigarette smoke, but it very effectively  
9 appeals to nonsmokers, especially youth.

10 876. The “buzz” testing results demonstrate that Bowen’s goal was not to match the  
11 nicotine delivery profile of a cigarette, but to surpass it by designing a maximally addictive  
12 product, which could only be marketed as a cigarette substitute through a sophisticated fraud  
13 campaign.

14 877. Bowen designed the JUUL product to deliver nicotine in larger amounts and at a  
15 faster rate than traditional cigarettes. This feature made the product more likely to capture users  
16 with the first hit.

17 878. Bowen was also heavily involved with JLI’s marketing strategy, which primarily  
18 targeted youth users.

19 879. Bowen personally developed JLI’s strategy to market to youth and make JLI as  
20 profitable as possible, so that it would be an attractive investment for a major manufacturer of  
21 traditional cigarettes. In a 2016 e-mail exchange with JLI employees regarding potential  
22 partnerships with e-cigarette juice manufacturers, Bowen reminded the employees that “big  
23 tobacco is used to paying high multiples for brands and market share.”<sup>917</sup> Bowen knew that to  
24 achieve the ultimate goal of acquisition, JLI would have to grow the market share of nicotine-  
25 addicted e-cigarette users, regardless of the human cost.

26 880. Bowen’s role in marketing included changing the name of “Crisp Mint” to “Cool  
27  
28

---

<sup>917</sup> INREJUUL\_00294198.

Mint” in 2015. Bowen also oversaw JLI’s formation of a commercial relationship with Avail Vapor, LLC, an Altria subsidiary, which Altria and JLI used to coordinate the flavor preservation schemes described below.<sup>918</sup>

881. Like Bowen, Monsees was instrumental to founding JLI with the aim of expanding the market of nicotine addicted e-cigarette users to include those “who aren’t perfectly aligned with traditional tobacco products.”<sup>919</sup>

882. Monsees personally helped to market JLI to the “cool kids,” using a sophisticated viral marketing campaign that strategically laced social media with false and misleading messages, to ensure their uptake and distribution among young consumers. Then, he subsequently and personally denied to the public and regulators that JLI had done just that.

883. With help from their early investors and board members, who include Nicholas Pritzker, Huyoung Huh, and Riaz Valani, Bowen and Monsees succeeded in hooking millions of youth, intercepting millions of adults trying to overcome their nicotine addictions, delaying regulation that would have stopped their unlawful activities, and, of course, earning billions of dollars in profits.

**Pritzker, Huh, and Valani exercised control and direction over the JLI Enterprise**

884. Plaintiffs incorporate by reference, as if fully set forth herein, the factual allegations stated against Pritzker, Huh, and Valani above. As described above, Pritzker, Huh, and Valani were early investors in JLI who worked closely with Monsees and Bowen, and took control of the JLI Board of Directors in 2015. Working in close collaboration with Monsees and Bowen, Pritzker, Huh, and Valani directed JLI’s affairs and used the corporation to effectuate and continue fraudulent schemes for their own personal profits and financial benefits. Pritzker, Huh, and Valani were “more active than most” board members and, unlike most corporate board members, had active involvement in directing the company’s actions week-to-week, including JLI’s marketing efforts.

885. Pritzker, Huh, and Valani exercised an intimate level of control over JLI during

---

<sup>918</sup> JLI10678578.

<sup>919</sup> *Id.*

1 a key period—from October 2015 through at least May 2016—when the three Defendants  
 2 (Pritzker, Huh, and Valani) served as the Executive Committee of the JLI Board of Directors.

3 886. As detailed above, in 2015, there was a power struggle within JLI about whether  
 4 to grow JLI’s consumer base by targeting young people. Pritzker, Huh, and Valani favored  
 5 aggressive marketing of JUUL products to young people. By October 2015, the power struggle  
 6 was over, with the debate resolved in favor of selling to teens. At that time, Monsees stepped  
 7 down as CEO to be replaced by the three-member “Executive Committee” comprised of  
 8 Pritzker, Huh, and Valani. Huh served as the Executive Committee Chairman, and Pritzker  
 9 served as Co-Chairman. The Executive Committee had the final say over all day-to-day  
 10 operations of the JLI business. Huh, as Chairman, and Pritzker, as Co-Chairman of JLI, were  
 11 involved in the management of the company on a weekly basis. By December 2015, for  
 12 example, the Executive Committee gave Pritzker and Huh supervisory responsibility for JLI  
 13 employees. Valani, for his part, was also an active Board member, involved in the management  
 14 of the company on a weekly basis. Dating back to 2011, Valani was a regular presence in JLI’s  
 15 offices, appearing in person at JLI’s offices “a couple times a week.”<sup>920</sup>

16 Bowen, Monsees, Pritzker, Huh and Valani Exercised a Firm Grip over JLI

17 887. By the summer of 2015, and at all times prior to Altria’s investment in JLI, JLI  
 18 was controlled by a Board of Directors with a maximum of seven seats. JLI co-founder Bowen  
 19 has occupied a seat on JLI’s Board from its inception. Likewise, Defendant Monsees was a  
 20 member of the Board of Directors of JLI until he stepped down in March 2020. Defendant  
 21 Pritzker has been on the Board of Directors of JLI since at least August 2013. He controlled two  
 22 of JLI’s seven maximum Board seats. Defendant Valani has been on JLI’s Board of Directors  
 23 since at least 2007. He also controlled two of JLI’s maximum seven Board seats. Beginning  
 24 around March 2015, Hank Handelsman occupied Valani’s second seat. Notably, Handelsman  
 25 has a close relationship with Pritzker, as he serves as general counsel for the Pritzker  
 26 Organization. He also was a senior executive officer and general counsel for the Pritzkers’ Hyatt  
 27

28 <sup>920</sup> <https://www.vice.com/en/article/43kmwm/juul-founders-first-marketing-boss-told-us-the-vape-giants-strange-messy-origins>.



1 Corporation for several decades.

2 888. Collectively, and prior to Altria's investment, Pritzker, Valani, Huh, Bowen, and  
3 Monsees controlled at least six of the seven seats on the JLI Board of Directors, which in turn  
4 allowed them to appoint the seventh member of the JLI Board of Directors. Thus, the  
5 Management Defendants had total control of the decisions of the Board of Directors. Pritzker  
6 and Valani, each holding two Board seats (and thus a majority of the seven-seat Board), had the  
7 ability to control the outcome of all decisions of the Board of Directors, as Board decisions were  
8 decided by a majority vote. It also follows that, by controlling the majority of the JLI Board of  
9 Directors at all relevant times, Pritzker and Valani had an effective "veto" over any decisions  
10 made by the JLI Board of Directors. And, Pritzker, Huh, and Valani exercised even more close  
11 control during the time period in which they served on the Executive Committee.

12 889. Through the Board of Directors' control over all aspects of JLI's business,  
13 Bowen, Monsees, Pritzker, Huh, and Valani used JLI as a vehicle to further fraudulent schemes  
14 of targeting youth, misrepresenting and omitting to consumers of all ages what JLI was really  
15 selling and to whom, and seeking to delay or prevent regulation that would impede the  
16 exponential growth of JUUL's massive youth marketshare. They achieved their ultimate goal of  
17 self enrichment through fraud when Altria made an equity investment in JLI in December 2018.  
18 In 2017, Altria Conspired with Pritzker and Valani to Influence and Indirectly Exercise Control  
19 Over JLI.

20 890. Plaintiffs incorporate by reference, as if fully set forth herein, the factual  
21 allegations stated against the Altria Defendants above. As set forth above, Altria (through its  
22 subsidiary, Defendant Philip Morris) has been manufacturing and selling "combustible"  
23 cigarettes for more than a century, but, recognizing that regulation and litigation had resulted in  
24 declining cigarette sales, Altria was looking to enter the e-cigarette space. It formed a  
25 subsidiary, Nu Mark LLC, to develop and market an e-cigarette product, the Mark Ten. The  
26 Mark Ten was not a success, so Altria began eyeing an acquisition of the biggest player in the  
27 youth addiction game, JLI.

28 891. Altria's pursuit led to eighteen months of negotiations with Altria and Altria

Client Services on the one hand, and Defendants Pritzker and Valani on the other, regarding a potential acquisition or equity investment in JLI. They conspired to achieve the best outcome for Pritzker and Valani personally, and for Altria as an entity. During these eighteen months, Altria, and Altria Client Services specifically, enticed Pritzker and Valani with a potential multi-billion dollar payout. During that time, Pritzker, Valani, and the other Management Defendants committed numerous acts of fraud to grow the business of JLI to satisfy Altria's expectations. Meanwhile, Altria and Altria Client Services actively conspired with Pritzker and Valani to continue growing JLI's youth market by continuing JLI's fraudulent activities, their compliance ensured by that promised payout. Altria was gathering information on JLI to confirm Altria would be purchasing a company with a proven track record of sales to youths.

**Altria directly exercises control and participates in of the JLI Enterprise**

892. By October 2018, Altria was directly transmitting statements over the mail and wires to support the JLI enterprise's efforts to fraudulently market JUUL products and to prevent or delay regulation.

893. In December 2018, Altria publicly announced its ties to the JLI enterprise by making a \$12.8 billion equity investment in JLI, the largest private equity investment in United States history. This investment led to massive personal financial benefit for each of the Management Defendants and gave Altria three seats on the JLI Board of Directors, allowing it to assert greater management and control over the JLI Enterprise, which used the instrumentalities of JLI to effectuate many of its fraudulent schemes.

894. Following the investment, Altria also directly distributed fraudulent statements that JLI was a cessation device, that JLI did not target youth, and that the nicotine in a single JUUL pod was equivalent to a pack of cigarettes.

895. Moreover, to further bolster its influence and control of JLI, Altria worked with Pritzker and Valani to install two key Altria executives into leadership positions at JLI: K.C. Crosthwaite and Joe Murillo.

**The fraudulent schemes**

896. As detailed above, the operation of the JLI Enterprise, as directed by the five

individual Defendants and Altria, included several schemes to defraud that helped to further the goals of the RICO Defendants—i.e., to expand the e-cigarette market, particularly among youth, for the five individual Defendants to reap huge personal profits, and for Altria to regain the market share that it was losing in the traditional cigarette arena and could no longer openly pursue through the same tactics used by JLI and the five individual Defendants.

#### **Fraudulent marketing scheme**

897. As described above and in Sections IV.D, IV.E, JLI, and Defendants Bowen, Monsees, Pritzker, Huh, and Valani directed and caused JLI to make false and misleading advertisements that omitted references to JUUL’s nicotine content and potency to be transmitted via the mail and wires, including the Vaporized campaign.

898. As early as 2014, Pritzker participated in planning discussions with Monsees and Valani about how to expand JUUL’s market share through marketing.

899. In 2015, Bowen helped to finalize the messaging framework for JUUL’s launch plan, including sponsored content on social media. This messaging was patently youth oriented and intentionally targeted children.

900. Monsees studied the marketing techniques of the traditional cigarette industry, and he personally reviewed the photographs that were used in the youth-oriented advertisements that accompanied JUUL’s launch. The “Vaporized” campaign featured bright colors and young models who were in “poses were often evocative of behaviors more characteristic of underage teen than mature adults.”<sup>921</sup>

901. Monsees also provided specific direction as to the content of the JUUL website to JLI employees, and that content include false, misleading, and deceptive statements designed to induce consumers, and particularly young people, to purchase the JUUL product.

902. Pritzker, Valani, Monsees, and Bowen—individually and collectively—approved

---

<sup>921</sup> *Examining Juul’s Role in the Youth Nicotine Epidemic, Hearing Before the H. Comm. on Oversight and Reform, Subcomm. on Econ. and Consumer Policy, 116th Cong. (2019)* (statement of Robert K. Jackler, Professor, Stanford University).  
<https://docs.house.gov/meetings/GO/GO05/20190724/109844/HHRG-116-GO05-Wstate-JacklerR-20190724.pdf>.

1 images from the JUUL “Vaporized” ad campaign in 2015. While they noted the youthfulness  
2 of the models, they expressed no concerns about the direction of the campaign, which was  
3 clearly directed to young users, they all supported launching the campaign—which then proved  
4 to be a great “success” in expanding vaping among underage users. And even though Pritzker,  
5 Huh, and Valani knew—and explicitly stated—that what they were doing was wrong, JLI  
6 pressed ahead with its youth-oriented marketing through early 2016.

7 903. Before the launch of new JUUL advertising campaigns in 2015, Pritzker, Valani,  
8 and Bowen advised the JLI marketing team to allay their concerns about the messaging  
9 regarding the nicotine content of the JUUL product.

10 904. Along with Valani, Pritzker was so directly involved in the “Vaporized”  
11 advertising campaign—which, as described above, marketed the JUUL product to teens—that  
12 JLI’s COO in 2015 remarked that he was concerned that the Board would try to write copy for  
13 future branding changes.

14 905. Huh was also instrumental in these early marketing campaigns, which were  
15 targeted to youth and omitted references to JUUL’s nicotine content. In debates about whether  
16 to continue marketing JUUL aggressively to youth, Huh supported that action and asserted that  
17 the company could not be blamed for youth nicotine addiction.

18 906. During his stint as Executive Committee chairman, which lasted at least until  
19 May 2016, Huh approved specific branding changes in 2015 and 2016, as JLI developed and  
20 implemented its plans for marketing to youth.

21 907. Various communications post-October 2015 demonstrate that Monsees deferred  
22 to Huh with regard to the direction of the company.

23 908. Pritzker also personally controlled several aspects of JLI’s branding. For  
24 instance, Pritzker was directly involved in creating JLI’s corporate website in May 2017. JLI  
25 used this website as another means to market its products to youth.

26 909. Through the allegations above, Plaintiffs have shown a direct connection  
27 between the RICO Defendants and this fraudulent scheme, including personal involvement in  
28 directing, in some part, the affairs of the JLI Enterprise.

**Youth access scheme**

910. As described above and in Section IV.E, the five Management Defendants who controlled JLI acted individually and in concert to expand youth access to JUUL products through schemes to mislead customers about the products.

911. As reflected in Section IV.E.11, JLI worked with Veratad to expand youth access while giving the appearance the JLI was combating youth access to its products.

912. Through the allegations above, Plaintiffs have shown a direct connection between the RICO Defendants and this fraudulent scheme, including personal involvement in directing, in some part, the affairs of the JLI Enterprise.

**Nicotine content misrepresentation scheme**

913. As described above and in Section IV.D, IV.G, the five Management Defendants and Altria caused thousands, if not millions, of JUULpod packages to be distributed to consumers with false and misleading information regarding the JUUL pods' nicotine content. The five individual Defendants who controlled JLI also caused the same false and misleading information to be distributed via JLI's website.

914. Defendant Bowen participated in studies regarding the nicotine content of JUUL pods, including by altering or re-engineering his own studies concerning nicotine content to mask the true content and impact in the products he developed. He discussed his engineering test results (the Phase 1 results), and how they differed from the Phase 0 results, with Monsees, Pritzker and Valani. He helped to select the 4% benzonate formulation that served as a model for all formulations used with the JUUL product. As formulated, JUUL pods were foreseeably exceptionally addictive, particularly when used by persons without prior exposure to nicotine.

915. As alleged above, Defendants Monsees, Pritzker, and Valani had personal knowledge about JUUL product nicotine content through direct communications with Bowen discussing engineered test results (the Phase 1 results), and how they differed from the Phase 0 results.

916. Defendants Bowen, Monsees, Pritzker and Valani thus caused the distribution of numerous JUUL pod packages, and statements on the JLI website and elsewhere, that

1 fraudulently equated the nicotine content of one JUUL pod as equivalent to one pack of  
2 cigarettes. These statements were false, as a JUUL pod had substantially more nicotine than a  
3 standard pack of combustible cigarettes.

4 917. Defendant Bowen also directed, on May 4, 2018, that Ashley Gould convey to  
5 the Washington Post that JLI's studies "support that nic strength and pack equivalence holds  
6 true," even though he knew this statement was false. On May 10, 2018, the Washington Post  
7 published an article, quoting a JUUL spokesperson extensively and stating that JUUL "contains  
8 about the same amount of nicotine as a pack of cigarettes"—the exact false statement Bowen  
9 instructed Gould to convey to the Post.<sup>922</sup>

10 918. The following year, Monsees conveyed this same misinformation in deposition  
11 testimony in a proceeding before the United States International Trade Commission.

12 919. Defendant Monsees also required, by no later than July 2018, that JLI employees  
13 obtain his personal approval for the artwork on all JUUL pod packaging.

14 920. Several Altria Defendants were involved in this scheme as well. With the  
15 approval and consent of Altria Group and under the management of Altria Client Services (the  
16 "Provider Manager" for the contracts), Altria Group Distribution Company distributed millions  
17 of JUULpod packages to stores across the country. These packages included the false and  
18 misleading information regarding JUUL pods' nicotine content.

19 921. Through the allegations above, Plaintiffs have shown a direct connection  
20 between the RICO Defendants and this fraudulent scheme, including personal involvement in  
21 directing, in some part, the affairs of the JLI Enterprise.

22 **Flavor preservation scheme**

23 922. As described above and in Section IV.I, the RICO Defendants worked in concert  
24 to defraud the public and deceive regulators to prevent regulation that would have impeded their  
25 plan to keep selling to children. Specifically, they worked to ensure that the FDA allowed  
26 JUUL's mint flavor to remain on the market.

27  
28  

---

<sup>922</sup> JLI10499253.

923. Altria and JLI had been working together on flavor strategy as early as September 2017, when Tyler Goldman and Gal Cohen (Valani’s inside man within JLI) met with representatives of Altria Client Services to plan a strategy for responding to the FDA’s proposed regulation of flavors in e-cigarettes. This plan would be coordinated through Avail Vapor, LLC, a company partially owned by Altria. Through Avail, the RICO Defendants obtained evidence that confirmed that mint was so popular with non-smoking teenagers that even with mint as its sole flavor option, JLI would remain a multi-billion dollar enterprise.<sup>923</sup>

924. Weeks before Altria’s equity investment in December 2018, the regulatory pressure ramped up significantly, and Altria and JLI engaged in active fraud to lull the FDA that mint was simply a traditional cigarette flavor designed to help adult smokers switch, rather than a flavor that appealed primarily to youth. With the scheme in place, Altria and JLI finalized their deal.

925. In September 25, 2018, then-FDA Commissioner Scott Gottlieb sent letters to Altria, JLI and other e-cigarette manufacturers, requesting a “detailed plan, including specific timeframes, to address and mitigate widespread use by minors.”<sup>924</sup>

926. Altria and JLI’s responses to the FDA reflect a coordinated effort to mislead the FDA with the intention that regulators, in reliance on their statements, would allow JLI to continue marketing mint JUUL pods.<sup>925</sup>

927. On October 25, 2018, Altria Group sent a letter to the FDA portaying mint as a traditional tobacco flavor. Altria shared this letter with Pritzker and Valani. JLI, at the direction of the five Management Defendants, subsequently sent a similar letter and false youth study, fraudulently claiming that mint was a traditional tobacco flavor and was not attractive to kids.<sup>926</sup>

928. Altria Group Distribution Company and Altria Group (through K.C.

---

<sup>923</sup> JLI10678580.

<sup>924</sup> Letter from Scott Gottlieb, M.D. to JUUL Labs, Inc. (Sept. 12, 2018); Letter from Scott Gottlieb, M.D. to Altria Group Inc. (Sept. 12, 2018).

<sup>925</sup> See *United States v. Jones*, 712 F.2d 1316, 1320-21 (9th Cir. 1983) (“It is enough that the mails be used as part of a ‘lulling’ scheme by reassuring the victim that all is well and discouraging him from investigating and uncovering the fraud.”).

<sup>926</sup> JLIFTC00653389.



1 Crosthwaite) then distributed hundreds of thousands of mint pods in 2019. They focused on  
2 selling this flavor in particular to take advantage of delayed regulation.

3 929. Through the allegations above, Plaintiffs have shown a direct connection  
4 between the RICO Defendants and this fraudulent scheme, including personal involvement in  
5 directing, in some part, the affairs of the JLI Enterprise.

6 **Cover-up scheme**

7 930. The RICO Defendants were not only concerned with protecting flavors,  
8 however. In light of growing public scrutiny of JLI's role in the youth vaping crisis, these  
9 Defendants continued their scheme to prevent a complete ban on JLI's product by portraying  
10 JUUL as a smoking cessation device and denying that the company ever marketed to youth.

11 931. As described above and in Sections IV.D, IV.E, JLI maintained website pages  
12 that provided false information about the addictive potential of its products and denied that JLI  
13 marketed to youth. Defendants Bowen, Monsees, Pritzker, Huh, and Valani directed the content  
14 of the JLI website and had "final say" over JLI's marketing messaging.

15 932. Bowen understood that children were using the JUUL product and intentionally  
16 continued the youth-appealing marketing strategy. For instance, in 2016, upon seeing social  
17 media posts of teenagers using JUUL products, he remarked that he was "astounded by this 'ad  
18 campaign' that apparently some rich east coast boarding school kids are putting on," and he  
19 added that Valani was plotting how JUUL could "leverage user generated content" to increase  
20 sales.

21 933. Monsees knew before the JUUL launch that JUUL would be attractive to youth.  
22 In October 2014, Monsees received results from a JUUL prototype, including comments that  
23 while JUUL was "too much" for smokers, the "younger group" liked JUUL, and JUUL "might  
24 manage to make smoking cool again." Monsees saw this information as an opportunity, not as a  
25 warning.

26 934. Bowen and Monsees were well aware that JUUL branding was oriented toward  
27 teens, and they mimicked the previous efforts of the tobacco industry to hook children on  
28 nicotine, to increase JUUL sales.

1           935. In 2015, JLI’s Board—controlled by Bowen, Monsees, Pritzker, Huh, and  
2 Valani—met frequently, and the appeal of JUUL to underage users was a constant topic of  
3 discussion, as detailed above. Individually and collectively, Pritzker, Huh, and Valani affirmed  
4 this course of action, taking steps to continue marketing efforts to youth and rejecting efforts by  
5 other Board members to curtail them.

6           936. Also in 2018, when concern grew about youth vaping, Valani directed JLI’s  
7 strategy in responding to such concerns. As directed by Valani, the goal was to debunk studies  
8 linking the company with the youth vaping crisis and to try to focus attention on youth smokers  
9 who allegedly had switched to JUUL—a misinformation campaign designed to stave off  
10 regulation or the ban of JUUL products.

11           937. Likewise, in 2018, Pritzker and Valani were heavily involved in planning sham  
12 “youth prevention” activities, whereby JLI would put on seminars for school children that  
13 ostensibly were designed to prevent youth vaping, but which actually told school children that  
14 vaping was safe and even taught children how to use the product.

15           938. Pritzker was heavily involved in JLI’s public relations activities, including  
16 granular detail such as directing responses to particular inquiries from teachers. Along with  
17 Valani, Pritzker also approved a press release in response to an inquiry by U.S. Senators, falsely  
18 detailing JLI’s alleged youth vaping prevention efforts.

19           939. Pritzker and Valani each edited and revised press releases about JLI’s youth  
20 prevention activities and steps it claimed to be taking to prevent youth sales, and they approved  
21 CEO Kevin Burn’s op-ed to the Washington Post claiming that the company did not want to sell  
22 to youth and was only targetting adult smokers.

23           940. The five individual Defendants caused false and misleading advertising to be  
24 distributed over television and the internet, to give the impression that JLI’s product was a  
25 smoking cessation device and that JLI never marketed to youth.

26           941. Valani and Pritzker routinely approved the copy for JUUL advertising spots. For  
27 example, Kevin Burns sought Pritzker and Valani’s approval of the fraudulent “*Make the*  
28 *Switch*” advertising campaign, which was distributed over the mail and wires.

1           942. The *Make the Switch* campaign featured former smokers aged 37 to 54  
2 discussing how JUUL helped them quit smoking. According to JLI's Vice President of  
3 Marketing, the "*Make the Switch*" campaign was "an honest, straight down the middle of the  
4 fairway, very clear communication about what we're trying to do as a company." But these  
5 statements were false, as JUUL was not intended to be a smoking cessation device.

6           943. Defendant Altria Group's subsidiaries Philip Morris USA and AGDC continued  
7 this scheme by transmitting the fraudulent "*Make the Switch*" advertisements in packs of its  
8 combustible cigarettes. These advertisements falsely portrayed the JUUL product as a smoking  
9 cessation device for adults. Defendant Altria Client Services did the same by e-mailing and  
10 mailing out hundreds of thousands of "Make the Switch" advertisements, with the approval and  
11 consent of Altria Group.

12           944. Monsees perpetuated the myth that JUUL was designed as a smoking cessation  
13 device, even though it was designed to appeal to young nonsmokers. Monsees testified before  
14 congress that JUUL was an "alternative" to traditional "cessation products" that "have  
15 extremely low efficacy."

16           945. In response to a direct question about whether people buy JUUL to stop  
17 smoking, Defendant Monsees responded: "Yes. I would say nearly everyone uses our product as  
18 an alternative to traditional tobacco products."<sup>927</sup>

19           946. These statements were false, and Monsees knew that they were false, as JUUL  
20 was not intended as a smoking cessation device.

21           947. Monsees also committed mail or wire fraud by giving the following written  
22 testimony to Congress, which was false: "We never wanted any non-nicotine user, and certainly  
23 nobody under the legal age of purchase, to ever use JLI products. ... That is a serious problem.  
24 Our company has no higher priority than combatting underage use."

25           948. Monsees further committed mail or wire fraud with a false statement, through  
26 JLI's website, that: "We have no higher priority than to prevent youth usage of our products  
27  
28

---

<sup>927</sup> *Id.*

1 which is why we have taken aggressive, industry leading actions to combat youth usage.” In  
2 reality, the RICO Defendants, through JLI, knowingly and intentionally marketed its product to  
3 youth users.

4 949. Beginning in October 2018, both Altria and JLI transmitted false and misleading  
5 communications to the public and the federal government, including Congress and the FDA, in  
6 an attempt to stave off regulation of the JUUL product.

7 950. As detailed above, each RICO Defendant directed and participated in these  
8 fraudulent schemes, either directly or indirectly, with specific intent to defraud, and used JLI as  
9 a vehicle to carry out this pattern of racketeering activity.

10 **c. “Pattern of Racketeering Activity”**

11 951. The RICO Defendants did willfully or knowingly conduct or participate in,  
12 directly or indirectly, the affairs of the Enterprise through a pattern of racketeering activity  
13 within the meaning of 18 U.S.C. §§ 1961(1), 1961(5) and 1962(c), and employed the use of the  
14 mail and wire facilities, in violation of 18 U.S.C. § 1341 (mail fraud) and § 1343 (wire fraud).

15 952. Specifically, the RICO Defendants—individually and collectively—have  
16 committed, conspired to commit, and/or aided and abetted in the commission of, at least two  
17 predicate acts of racketeering activity (i.e., violations of 18 U.S.C. §§ 1341 and 1343), within  
18 the past ten years, as described herein.

19 953. The multiple acts of racketeering activity that the RICO Defendants committed,  
20 or aided or abetted in the commission of, were related to each other, pose a threat of continued  
21 racketeering activity, and therefore constitute a “pattern of racketeering activity.”

22 954. The RICO Defendants used, directed the use of, and/or caused to be used,  
23 thousands of interstate mail and wire communications in service of the Enterprise’s objectives  
24 through common misrepresentations, concealments, and material omissions.

25 955. As described above, the RICO Defendants devised and knowingly carried out  
26 material schemes and/or artifices to defraud the public and deceive regulators by (1)  
27 transmitting advertisements that fraudulently and deceptively omitted any reference to JUUL’s  
28 nicotine content or potency (or any meaningful reference, where one was made); (2) causing

1 false and misleading statements regarding the nicotine content of JUUL pods to be posted on the  
2 JLI website; (3) causing thousands, if not millions, of JUUL pod packages containing false and  
3 misleading statements regarding the nicotine content of JUUL pods to be transmitted via U.S.  
4 mail; (4) representing to consumers and the public at-large that JUUL was created and designed  
5 as a smoking cessation device; (5) misrepresenting the nicotine content and addictive potential  
6 of its products; (6) making fraudulent statements to the FDA to persuade the FDA to allow mint  
7 flavored JUUL pods to remain on the market; and (7) making fraudulent statements to the  
8 public (including through advertising), the FDA, and Congress to prevent prohibition of JUUL  
9 cigarettes, as was being contemplated in light of JLI's role in the youth vaping epidemic.

10 956. The RICO Defendants committed these racketeering acts intentionally and  
11 knowingly, with the specific intent to defraud and to personally or directly profit from these  
12 actions.

13 957. The RICO Defendants' predicate acts of racketeering (18 U.S.C. § 1961(1))  
14 include, but are not limited to:

15 A. Mail Fraud: the Enterprise violated 18 U.S.C. § 1341 by sending or receiving,  
16 or by causing to be sent and/or received, fraudulent materials via U.S. mail or  
17 commercial interstate carriers for the purpose of deceiving the public,  
regulators, and Congress.

18 B. Wire Fraud: the Enterprise violated 18 U.S.C. § 1343 by transmitting and/or  
19 receiving, or by causing to be transmitted and/or received, fraudulent  
20 materials by wire for the purpose of deceiving the public, regulators, and  
Congress.

21 958. As explained above, the RICO Defendants conducted the affairs of the Enterprise  
22 through a pattern of racketeering activity by falsely and misleadingly using the mails and wires  
23 in violation of 18 U.S.C. § 1341 and § 1343. To the extent that JLI itself or a JLI officer other  
24 than one or more of the RICO Defendants made a particular statement listed below, the five  
25 individual Defendants who controlled JLI and Altria caused those statements to be made  
26 through their control of JLI and through their control of the communications that JLI was  
27 disseminating to the FDA, to Congress, and to the general public in connection with directing  
28 the affairs of JLI. As detailed above, these statements are alleged to be part of the fraudulent

schemes masterminded by the RICO Defendants who conducted the affairs of JLI.

959. Illustrative and non-exhaustive examples include the following:

From	To	Date	Description
<b><i>Statements Omitting Reference to JUUL's Nicotine Content (see Section IV.E)</i></b>			
JLI	Public (via television, internet, and mail)	2015	"Vaporized" Campaign, and other advertising campaigns transmitted via the mails and wires which targeted under-age vapers and omitted any reference to JUUL's nicotine content.
<b><i>Statements that JUUL is a Cessation Device (see Section IV.D.4)</i></b>			
JLI	Public (via internet – JLI Website)	April 25, 2018 (or earlier) to Present	"JUUL Labs was founded by former smokers, James and Adam, with the goal of improving the lives of the world's one billion adult smokers by eliminating cigarettes. We envision a world where fewer adults use cigarettes, and where adults who smoke cigarettes have the tools to reduce or eliminate their consumption entirely, should they so desire."
Kevin Burns (former JLI CEO)	Public (via internet – JLI Website)	November 13, 2018	"To paraphrase Commissioner Gottlieb, we want to be the offramp for adult smokers to switch from cigarettes, not an on-ramp for America's youth to initiate on nicotine."
JLI	Public (via internet – JLI Website)	September 19, 2019	"JUUL Labs, which exists to help adult smokers switch off of combustible cigarettes."
Howard Willard (Altria CEO)	Public (via internet – Altria website)	December 20, 2018	"We are taking significant action to prepare for a future where adult smokers overwhelmingly choose non-combustible products over cigarettes by investing \$12.8 billion in JUUL, a world leader in switching adult smokers. ... We have long said that providing adult smokers with superior, satisfying products with the potential to reduce harm is the best way to achieve tobacco harm reduction."

From	To	Date	Description
Howard Willard	FDA (via U.S. mail or electronic transmission of letter to Commissioner Gottlieb)	October 25, 2018	"We believe e-vapor products present an important opportunity to adult smokers to switch from combustible cigarettes."
<b>Statements Regarding Nicotine Content in JUUL pods (see Section IV.D)</b>			
JLI	Public (via internet – JLI website)	July 2, 2019 (or earlier) to Present	"Each 5% JUUL pod is roughly equivalent to one pack of cigarettes in nicotine delivery."
JLI	Public (via internet – JLI website)	April 21, 2017	"JUUL pod is designed to contain approximately 0.7mL with 5% nicotine by weight at time of manufacture which is approximately equivalent to 1 pack of cigarettes or 200 puffs."
JLI; AGDC; Altria Client Services	Public (via U.S. mail distribution of JUUL pod packaging)	2015 to Present	JUUL pod packages (1) claiming a 5% nicotine strength; (2) stating that a JUUL pod is "approximately equivalent to about 1 pack of cigarettes."
<b>Statements to Prevent Regulation of mint Flavor (see Sections IV.C.6 and IV.I.2)</b>			
JLI	FDA (via U.S. mail or electronic transmission); Public (via internet – JLI website)	October 16, 2018 (FDA) November 12, 2018 (Public)	JLI's Action Plan that fraudulently characterizes mint as a non-flavored tobacco and menthol product, suggesting that it was a product for adult smokers.
Howard Willard (Altria CEO)	FDA (via U.S. mail or electronic transmission of letter to Commissioner Gottlieb)	October 25, 2018	Letter from H. Willard to FDA fraudulently representing mint as a non-flavored tobacco and menthol product, suggesting that it was a product for adult smokers.



From	To	Date	Description
JLI	FDA (via U.S. mail or electronic transmission)	November 5, 2018	Fraudulent youth prevalence study transmitted by JLI to the FDA.
<b><i>Statements to Prevent Ban on JUUL Products (see Sections IV.D.4 and IV.E.14)</i></b>			
JLI	Public (via Television)	January 2019	\$10 million “Make the Switch” advertising campaign, which was designed to deceive the public and regulators into believing that JLI was only targeting adult smokers with its advertising and product, and that JUUL was a smoking cessation product.
AGDC; Philip Morris; JLI	Public (via inserts in combustible cigarette packs)	December 2018 - Present	“Make the Switch” advertising campaign, for the purpose of deceiving smokers into believing that JUUL was a cessation product.
Altria Client Services; JLI	Public (via direct mail and email campaigns)	December 2018 – Present	“Make the Switch” advertising campaign, for the purpose of deceiving smokers into believing that JUUL was a cessation product.
JLI Chief Administrative Officer	Public (via interview with CNBC, later posted on internet)	December 14, 2017	“It’s a really, really important issue. We don’t want kids using our products.”
JLI	Public (via internet - social media)	March 14, 2018	“We market our products responsibly, following strict guidelines to have material directly exclusively toward adult smokers and never to youth audiences.”

From	To	Date	Description
JLI	FDA (via U.S. mail or electronic transmission); Public (via internet – JLI website)	October 16, 2018 (FDA) November 12, 2018 (Public)	“We don’t want anyone who doesn’t smoke, or already use nicotine, to use JUUL products. We certainly don’t want youth using the product. It is bad for public health, and it is bad for our mission. JUUL Labs and FDA share a common goal – preventing youth from initiating on nicotine. ... Our intent was never to have youth use JUUL products.”
Then-CEO of JLI (Kevin Burns)	Public (via interview with CNBC – later posted on internet)	July 13, 2019	“First of all, I’d tell them that I’m sorry that their child’s using the product. It’s not intended for them. I hope there was nothing that we did that made it appealing to them. As a parent of a 16-year-old, I’m sorry for them, and I have empathy for them, in terms of what the challenges they’re going through.”
JLI	Public (via internet - JLI website)	August 29, 2019	“We have no higher priority than to prevent youth usage of our products which is why we have taken aggressive, industry leading actions to combat youth usage.”
James Monsees	Public (via statement to New York Times – later posted on internet)	August 27, 2019	Monsees said selling JUUL products to youth was “antithetical to the company’s mission.”
JLI	Public (via statement to Los Angeles Times – later posted on internet)	September 24, 2019	“We have never marketed to youth and we never will.”

From	To	Date	Description
JLI (via counsel)	FDA (via U.S. mail or electronic transmission to Dr. Matthew Holman)	June 15, 2018	Letter from JLI's Counsel at Sidley Austin to Dr. Matthew Holman, FDA, stating: "JUUL was not designed for youth, nor has any marketing or research effort since the product's inception been targeted to youth." and "With this response, the Company hopes FDA comes to appreciate why the product was developed and how JUUL has been marketed — to provide a viable alternative to cigarettes for adult smokers."
James Monsees	Congress (via U.S. mail or electronic transmission of written testimony)	July 25, 2019	Written Testimony of J. Monsees provided to Congress, stating: "We never wanted any non-nicotine user, and certainly nobody under the legal age of purchase, to ever use JLI products. ... That is a serious problem. Our company has no higher priority than combatting underage use."
Howard Willard	FDA (via U.S. mail or electronic transmission of letter to Commissioner Gottlieb)	October 25, 2018	"[W]e do not believe we have a current issue with youth access to or use of our pod-based products, we do not want to risk contributing to the issue."
Howard Willard	Congress (via U.S. mail or electronic transmission of letter to Senator Durbin)	October 14, 2019	"In late 2017 and into early 2018, we saw that the previously flat e-vapor category had begun to grow rapidly. JUUL was responsible for much of the category growth and had quickly become a very compelling product among adult vapers. We decided to pursue an economic interest in JUUL, believing that an investment would significantly improve our ability to bring adult smokers a leading portfolio of non-combustible products and strengthen our competitive position with regards to potentially reduced risk products."

1           960. The mail and wire transmissions described herein were made in furtherance of  
2 the RICO Defendants' schemes and common course of conduct, thereby increasing or  
3 maintaining JLI's market share. The sections cross-referenced in the chart detail how the RICO  
4 Defendants caused such mailings or transmissions to be made. As described in those detailed  
5 factual allegations, the RICO Defendants did so either by directly approving certain fraudulent  
6 statements or by setting in motion a scheme to defraud that would reasonably lead to such  
7 fraudulent statements being transmitted via the mail and wires.

8           961. As described above, the RICO Defendants used JLI to further schemes to defraud  
9 the public and deceive regulators, to continue selling nicotine products to youth, and to protect  
10 their market share by denying that JLI marketed to youth and claiming that JUUL was created  
11 and designed as a smoking cessation device (or a mitigated risk product).

12           962. The RICO Defendants used these mail and wire transmissions, directly or  
13 indirectly, in furtherance of this scheme by transmitting deliberately false and misleading  
14 statements to the public and to government regulators.

15           963. The RICO Defendants had a specific intent to deceive regulators and defraud the  
16 public. For example, as alleged above, JLI made repeated and unequivocal statements through  
17 the wires and mails that it was not marketing to children and that its products were designed for  
18 adult smokers. These statements were false. Each of the RICO Defendants knew these  
19 statements were false but caused these statements to be made anyway. Similarly, the RICO  
20 Defendants caused to be transmitted through the wires and mails false and misleading  
21 statements regarding the nicotine content in JUUL pods, which JLI's own internal data, and  
22 Altria's own pharmacokinetic studies, showed were false. Moreover, each of the Enterprise  
23 Defendants had direct involvement in marketing statements by JLI and thus caused such  
24 statements to be made, notwithstanding that they knew they were false for the reasons detailed  
25 above.

26           964. The RICO Defendants intended the public and regulators to rely on these false  
27 transmissions, and this scheme was thereforereasonably calculated to deceive persons of  
28 ordinary prudence and comprehension.

1           965. The public and government regulators relied on the Enterprise's mail and wire  
2 fraud. For example, the regulators, including the FDA, relied on the Enterprise's statements that  
3 mint was not an appealing flavor for nonsmokers in allowing mint JUUL pods to remain on the  
4 market. Regulators also relied on the Enterprise's statements that it did not market to youth in  
5 allowing the RICO Defendants to continue marketing and selling JUUL. Congress likewise  
6 relied on the Enterprise's statements in not bringing legislation to recall or ban e-cigarettes,  
7 despite the calls of members of both parties to do just that. And, the public relied on statements  
8 (or the absence thereof) that were transmitted by the RICO Defendants regarding the nicotine  
9 content in and potency of JUUL pods in deciding to purchase JUUL products.

10           966. Many of the precise dates of the fraudulent uses of the U.S. mail and interstate  
11 wire facilities have been deliberately hidden and cannot be alleged without access to the RICO  
12 Defendants' books and records. Plaintiffs have, however, described the types of predicate acts  
13 of mail and/or wire fraud, including the specific types of fraudulent statements upon which,  
14 through the mail and wires, the RICO Defendants engaged in fraudulent activity in furtherance  
15 of their overlapping schemes.

16           967. These were not isolated incidents. Instead, the RICO Defendants engaged in a  
17 pattern of racketeering activity by committing thousands of related predicate acts in a five-year  
18 period, in the form of mail and wire fraud, and there remains a threat that such conduct will  
19 continue or recur in the future. That each RICO Defendant participated in a variety of schemes  
20 involving thousands of predicate acts of mail and wire fraud establishes that such fraudulent  
21 acts are part of the Enterprise's regular way of doing business. Moreover, Plaintiffs expect to  
22 uncover even more coordinated, predicate acts of fraud as discovery in this case continues.

23                   **d. Harm to Plaintiffs**

24           968. For a pattern of racketeering activity to be a cognizable cause of civil RICO  
25 injury to a private plaintiff, one or more of the predicate acts must not only be the "but for"  
26 cause of the injury, but the proximate cause as well. A wrongful act is a proximate cause if it is  
27 a substantial factor in the sequence of responsible causation. Plaintiffs must show a direct  
28 relation between the injury asserted and the injurious conduct alleged. What matters, though, is

1 not whether there is a direct relationship between the plaintiff and defendant, but whether there  
2 is a sufficiently direct relationship between the defendant's wrongful conduct and the plaintiff's  
3 injury .

4 969. Each Plaintiff and all members of the RICO Class were directly injured by the  
5 RICO Defendants' conduct, and such injury would not have occurred but for the predicate acts  
6 of the RICO Defendants. The combined effect of the RICO Defendants' fraudulent acts were:  
7 (1) inducing Plaintiffs and the RICO Class members to purchase JUUL products that they  
8 would not have purchased or, in the alternative, to pay more for JUUL products than they would  
9 have otherwise paid had they known that JUUL products were not cessation products or had  
10 they known about the intentional addictiveness of the nicotine levels in JUUL products; (2)  
11 persuading the FDA to allow the continued sale of JLI's mint pods, which allowed Plaintiffs  
12 and the RICO Class Members to purchase mint pods they would not have otherwise purchased;  
13 and (3) persuading Congress and the FDA to allow JUUL products to remain on the market,  
14 which allowed Plaintiffs and the RICO Class Members to purchase JUUL products they would  
15 not have purchased absent the RICO Defendants' schemes to preserve JLI's ill-gotten market  
16 share.

17 970. There are no intervening acts or parties that could interrupt the causal chain  
18 between the RICO Defendants' mail and wire fraud, and the Plaintiffs' and the RICO Class  
19 Members' injuries. The RICO Defendants made false and misleading statements directly to the  
20 public. And in the case of fraud on third parties (i.e., FDA and Congress), the RICO  
21 Defendants' misrepresentations to those parties were intended to cause, and did directly cause,  
22 the FDA's and Congress's failure to regulate the JUUL product and/or remove the JUUL  
23 product from the market, thereby allowing Plaintiffs and the RICO Class Members to purchase  
24 products that should not have been on the market.

25 971. As to predicate acts occurring prior to March 10, 2016, Plaintiffs did not  
26 discover, and could not have been aware despite the exercise of reasonable diligence, until  
27 shortly before the initiation of the instant litigation, that the RICO Defendants transmitted  
28 fraudulent statements via the mails and wires regarding the topics described above including,

1 *inter alia*, the true nicotine content in and delivered by JUUL products. The RICO Defendants  
2 concealed and failed to truthfully disclose this information.

3 **2. Violations of 18 U.S.C. § 1962(d)**

4 972. Plaintiffs hereby incorporate by reference the allegations contained in the  
5 preceding paragraphs of this complaint.

6 973. Section 1962(d) makes it unlawful for “any person to conspire to violate”  
7 Section 1962(c), among other provisions. *See* 18 U.S.C. § 1962(d).

8 974. The RICO Defendants have not undertaken the practices described herein in  
9 isolation, but as part of a common scheme and conspiracy. In violation of 18 U.S.C. § 1962(d),  
10 the RICO Defendants agreed to facilitate the operation of the Enterprise through a pattern of  
11 racketeering in violation of 18 U.S.C. § 1962(c), as described herein. The conspiracy is  
12 coterminous with the time period in which the Enterprise has existed, beginning before JLI was  
13 officially formed in 2015 and continuing to this day (with Defendant Altria joining the  
14 conspiracy by at least Spring 2017).

15 975. The RICO Defendants’ agreement is evidenced by their predicate acts and direct  
16 participation in the control and operation of the Enterprise, as detailed above in relation to the  
17 RICO Defendants’ substantive violation of Section 1962(c). In particular, as described above,  
18 Altria’s agreement is shown by the fact that it was well aware of JLI’s fraudulent activities in  
19 marketing its products to youth but claiming that it would not do so, yet Altria nonetheless  
20 secretly collaborated with JLI to continue those unlawful activities, and it eventually made a  
21 multi-billion dollar investment in JLI and continued the deception by directing the affairs of JLI.

22 976. The acts in furtherance of the conspiracy attributable to the RICO Defendants  
23 include each of the predicate acts underlying the RICO Defendants’ use of the JLI Enterprise to,  
24 directly or indirectly, engage in a pattern of racketeering activity in violation of Section 1962(c),  
25 as described above. Various other persons, firms, and corporations, including third-party entities  
26 and individuals not named as Defendants in this Complaint, have participated as co-conspirators  
27 with the members of the Enterprise in these offenses and have performed acts in furtherance of  
28 the conspiracy to increase or maintain revenue, maintain or increase market share, and/or



1 minimize losses for the Defendants and their named and unnamed co-conspirators throughout  
2 the illegal scheme and common course of conduct. Where a RICO Defendant did not commit a  
3 predicate act itself, it agreed to the commission of the predicate act.

4 977. Each Plaintiff and all members of the RICO Class were directly injured by  
5 reason of the RICO violations, and such injury would not have occurred but for the predicate  
6 acts of the RICO Defendants, which also constitute the acts taken by the RICO Defendants in  
7 furtherance of their conspiracy pursuant to Section 1962(d). The combined effect of the RICO  
8 Defendants' acts of mail and wire fraud in furtherance of their conspiracy were: (1) inducing  
9 Plaintiffs and the RICO Class members to purchase JUUL products that they would not have  
10 purchased, or—in the alternative—to pay more for JUUL products than they would have  
11 otherwise paid, had they known that JUUL products were not cessation products or if they had  
12 known about the intentional addictiveness of the nicotine levels in said products; (2) persuading  
13 the FDA to allow the continued sale of JLI's mint pods, which allowed Plaintiffs and the RICO  
14 Class Members to purchase mint pods they would not have purchased; and (3) persuading  
15 Congress and the FDA to allow JUUL products to remain on the market, which allowed  
16 Plaintiffs and the RICO Class Members to purchase JUUL products that they would not have  
17 purchased absent the RICO Defendants' conspiracy—which used JLI to expand the e-cigarette  
18 market and increase sales of the JUUL product, as described herein.

19 978. There are no intervening acts or parties that could interrupt the causal chain  
20 between the RICO Act violations in furtherance of their RICO conspiracy and Plaintiffs' and  
21 the RICO Class Members' injuries. The RICO Defendants, in furtherance of their conspiracy to  
22 operate and manage the JLI Enterprise made false and misleading statements directly to the  
23 public. And in the case of fraud on third parties (i.e., FDA and Congress), causation is not  
24 defeated merely because the RICO Act violations deceived a third party into not taking action  
25 where the FDA's and Congress's failure to regulate directly allowed Plaintiffs and the RICO  
26 Class Members to purchase products that should not have been on the market.

27 979. As to acts undertaken in furtherance of the conspiracy which occurred prior to  
28 March 10, 2016, Plaintiffs did not discover, and could not have been aware despite the exercise

1 of reasonable diligence, until shortly before the initiation of the instant litigation that the RICO  
 2 Defendants through the JLI Enterprise transmitted fraudulent statements via the mails and wires  
 3 regarding the topics described above including, inter alia, the true nicotine content in and  
 4 delivered by JUUL products, such information the Enterprise concealed and failed to truthfully  
 5 disclose.

6 **3. Violation of the Magnuson-Moss Warranty Act (15 U.S.C. §§ 2301, *et***  
 7 ***seq.*)**

8 980. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

9 981. This claim is brought against JLI on behalf of the members of the state  
 10 subclasses in Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, the  
 11 District of Columbia, Florida, Hawaii, Idaho, Indiana, Iowa, Kansas, Louisiana, Maine,  
 12 Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska,  
 13 Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Oklahoma, Pennsylvania,  
 14 Rhode Island, South Carolina, South Dakota, Texas, Utah, Virginia, West Virginia, and  
 15 Wyoming, and the state direct purchaser subclasses in Alabama, Georgia, Illinois, Kentucky,  
 16 New York, Ohio, Oregon, Tennessee, Vermont, Washington, and Wisconsin.

17 982. Plaintiffs and members of the class are “consumers” within the meaning of 15  
 18 U.S.C. § 2301(3).

19 983. JLI is a “supplier” and “warrantor” within the meaning of 15 U.S.C. § 2301(4)  
 20 and (5), respectively.

21 984. JUUL products are “consumer products” within the meaning of 15 U.S.C.  
 22 § 2301(1).

23 985. Plaintiffs have met all requirements for pre-suit notice.

24 986. 15 U.S.C. § 2310(d)(1) provides a cause of action for any consumer who is  
 25 damaged by the failure of a warrantor to comply with an implied warranty. The amount in  
 26 controversy of Plaintiffs’ individual claims meets or exceeds \$25.00 in value. In addition, the  
 27 amount in controversy meets or exceeds \$50,000 in value (exclusive of interest and costs).

28 987. JLI provided Plaintiffs and each member of the class with “implied warranties,”  
 including the implied warranty of merchantability, which is covered under 15 U.S.C. § 2301(7).

1           988. Each JUUL product sold by JLI comes with an implied warranty that it will  
2 merchantable and fit for the ordinary purpose for which it would be used. JLI has breached its  
3 implied warranty of merchantability because its products were not in merchantable condition  
4 when sold, were defective when sold, did not conform to the promises and affirmations of fact  
5 made on the products' containers or labels, and/or do not possess even the most basic degree of  
6 fitness for ordinary use.

7           989. The terms of these warranties became part of the basis of the bargain when  
8 Plaintiffs and each member of the class purchased JUUL products.

9           990. Plaintiffs and each member of the class have had sufficient direct dealings with  
10 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
11 by JUUL) to establish privity of contract between JLI, on the one hand, and Plaintiffs and each  
12 member of the class, on the other hand.

13           991. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
14 JLI's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale  
15 of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended  
16 beneficiaries of JLI's implied warranties. JUUL's products are manufactured with the express  
17 purpose an intent of being sold to consumers.

18           992. Affording JLI a reasonable opportunity to cure its breach of written warranties  
19 would be unnecessary and futile. At the time of sale of each JUUL product, JLI knew, or should  
20 have known that the products were not merchantable, but nonetheless failed to rectify the  
21 situation and/or disclose the defects. In addition, after over a year of litigation, JLI has not made  
22 any offer to cure. Under the circumstances, the remedies available under any informal  
23 settlement procedure would be inadequate and any requirement that Plaintiffs or members of the  
24 class resort to an informal dispute resolution procedure and/or afford JLI a reasonable  
25 opportunity to cure its breach of warranties is excused and thereby deemed satisfied.

26           993. In addition, given the conduct described herein, any attempts by JLI, in its  
27 capacity as a warrantor, to limit the implied warranties in a manner that would exclude coverage  
28 of the defects in JUUL products is unconscionable and any such effort to disclaim, or otherwise

limit, liability for the defects is null and void.

994. As a direct and proximate result of JLI's breach of the written and implied warranties, Plaintiffs and each member of the class have suffered damages. Plaintiffs, individually and on behalf of the class, seek all damages permitted by law, including compensation for the cost of purchasing JUUL products, along with all other incidental and consequential damages, statutory attorney fees, and all other relief allowed by law.

### **C. Causes of Action Brought on Behalf of the State Classes**

#### **1. Alabama**

995. Plaintiffs bring each of the following claims on behalf of the Alabama Subclass under Alabama law.

#### **a. Violation of the Alabama Deceptive Trade Practices Act (Ala. Code § 8-19-1, *et seq.*)**

996. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

997. This claim is brought against JLI, and for certain unconscionable conduct claims, all Defendants.

998. Defendants are "persons" and Plaintiffs and class members are "consumers" under the statute. Ala. Code § 8-19-3.

999. Plaintiffs and class members are consumers who purchased JUUL products for personal purposes.

1000. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1001. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible

1 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
2 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
3 decades, JLI used third parties and word of mouth to spread false and misleading information  
4 about JUUL products.

5 1002. Advertisements and representations for JUUL products concealed and failed to  
6 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed significant risks of substantial physical injury resulting from the use of the  
9 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
10 consumed through a pack of combustible cigarettes.

11 1003. The labels on JUUL products failed to disclose that the products posed  
12 significant risks of substantial physical injury resulting from the use of the products. The labels  
13 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

14 1004. The omissions were misleading and deceptive standing alone and were  
15 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
16 cigarettes and other representations.

17 1005. JLI's conduct was unfair and unconscionable in that it included (i) the  
18 manufacture and sale of products with a heightened propensity to cause addiction and physical  
19 injuries and (ii) misrepresentations and omissions of material facts concerning the  
20 characteristics and safety of JUUL products that offended public policy; were immoral,  
21 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
22 substantial harm that greatly outweighs any possible utility from the conduct. In addition, Ala.  
23 Code § 28-11-16 makes it unlawful for a retailer or manufacturer to advertise electronic nicotine  
24 delivery systems as tobacco cessation products and/or a healthier alternative to smoking.

25 1006. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
26 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
27 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
28 products are of a particular standard, quality, or grade, or that goods are of a particular style or

1 model, when they are not; (c) advertising goods or services with intent not to sell them as  
2 advertised; and (d) engaging in any other unconscionable, false, misleading, or deceptive act or  
3 practice in the conduct of trade or commerce.

4 1007. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
5 omissions had the capacity to deceive, and in fact did, deceive reasonable consumers, including  
6 the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to  
7 their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii)  
8 were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-  
9 delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of  
10 substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
11 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
12 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
13 Plaintiffs' and class members' decisions to purchase JUUL products.

14 1008. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
15 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
16 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
17 facts; because the facts would be material to reasonable consumers; because JLI actively  
18 concealed them; because JLI intended for consumers to rely on the omissions in question;  
19 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
20 made partial representations concerning the same subject matter as the omitted facts.

21 1009. JLI and the Management Defendants engaged in fraudulent and deceptive  
22 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
23 products were appropriate for minors, when in fact the products never should have been  
24 marketed to minors and are especially harmful to minors due to the potent and addictive  
25 nicotine doses, addictive qualities, and health risks.

26 1010. In addition, all Defendants engaged in conduct that is conduct is unfair and  
27 unconscionable because the targeting of minors offends public policy (Ala. Code § 28-11-1 and  
28 Ala. Code § 28-11-4); is immoral, unethical, oppressive, outrageous, unscrupulous, and

1 substantially injurious; and has caused substantial harm that greatly outweighs any possible  
2 utility from the conduct.

3 1011. As alleged above, all Defendants participated and/or facilitated the marketing of  
4 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
5 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
6 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
7 use of JUUL products by minors continues to rise.

8 1012. Defendants' conduct actually and proximately caused actual monetary damages  
9 to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs  
10 and class members would have behaved differently and would not have purchased JUUL  
11 products or would have paid less for them. Defendants' misrepresentations and omissions  
12 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
13 purchased and enter into purchase contracts they would not otherwise have entered into. In  
14 addition, class members who are minors are entitled to full repayment of the amounts they spent  
15 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
16 injunctive relief (except as to the Management Defendants), reasonable attorneys' fees, up to  
17 three times actual damages sustained by each such person, or any applicable statutory damages,  
18 whichever is greater, as well as any other relief the Court may deem just or proper.

19 1013. Plaintiffs have complied or substantially complied with all applicable notice  
20 requirements, or are otherwise excused from compliance because they do not maintain a place  
21 of business in and/ or does not keep assets within the state of Alabama.

22 **b. Common Law Fraud**

23 1014. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

24 1015. This claim is brought against JLI.

25 1016. JUUL created and implemented a scheme to create a market for e-cigarettes and  
26 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
27 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
28 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while



misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1017. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

1018. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

1019. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

1020. The omissions were misleading and deceptive standing alone and were particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to cigarettes and other representations.

1021. JLI's conduct was fraudulent and deceptive because its misrepresentations and omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine

1 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
2 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
3 Plaintiffs' and class members' decisions to purchase JUUL products.

4 1022. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
5 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
6 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
7 facts; because the facts would be material to reasonable consumers; because JUUL products  
8 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
9 representations concerning the same subject matter as the omitted facts.

10 1023. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
11 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
12 and/or omissions. Reasonable consumers would have been expected to have relied on the  
13 misrepresentations and omissions.

14 1024. JLI knew or should have known that its misrepresentations and/or omissions  
15 were false and misleading, and intended for consumers to rely on such misrepresentations and  
16 omissions.

17 1025. JLI knew that JUUL products were not safe or reasonable alternatives to  
18 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
19 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
20 products.

21 1026. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
22 class members. Absent JLI's conduct, Plaintiffs and class members would have behaved  
23 differently and would not have purchased JUUL products or would have paid less for them.  
24 JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
25 products they would not otherwise have purchased and enter into purchase contracts they would  
26 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
27 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
28 deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

1027. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1028. This claim is brought against JLI.

1029. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1030. Each JUUL product sold by JUUL comes with an implied warranty that it will merchantable and fit for the ordinary purpose for which it would be used. Ala. Code § 7-2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1031. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

1032. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

1033. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

1           1034. Plaintiffs and the members of the class were injured as a direct and proximate  
2 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
3 the Alabama Direct Purchaser Subclass were damaged as a result of JUUL's breach of its  
4 implied warranty of merchantability because, had they been aware of the unmerchantable  
5 condition of JUUL products, they would not have purchased JUUL products, or would have  
6 paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any  
7 other relief the Court may deem just or proper.

8           1035. JUUL was provided notice of these issues by numerous complaints filed against  
9 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
10 individual letters and communications sent by consumers before or within a reasonable amount  
11 of time after they discovered or should have discovered that's JUUL product were defective and  
12 unmerchantable.

13                           **d.       Unjust Enrichment**

14           1036. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

15           1037. This claim is brought against JLI and the Management Defendants.

16           1038. Defendants created and implemented a scheme to create a market for e-cigarettes  
17 and substantially increase sales of JUUL products through a pervasive pattern of false and  
18 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
19 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
20 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
21 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
22 products.

23           1039. Defendants were unjustly enriched as a result of their wrongful conduct,  
24 including through the false and misleading advertisements and omissions regarding (i) whether  
25 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
26 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
27 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
28 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the

1 nicotine consumed through a pack of combustible cigarettes. Ala. Code § 28-11-16 makes it  
 2 unlawful for a retailer or manufacturer to advertise electronic nicotine delivery systems as  
 3 tobacco cessation products and/or a healthier alternative to smoking. Defendants were also  
 4 unjustly enriched through their scheme of marketing their products to minors. Ala. Code § 28-  
 5 11-1 sets forth the intent of the Alabama legislature to “prohibit access to tobacco and tobacco  
 6 products by minors.” Ala. Code § 28-11-4 expresses the intent of Alabama legislature to  
 7 “prevent[] the distribution of . . . alternative nicotine products to minors.”

8 1040. Defendants requested and received a measurable benefit at the expense of  
 9 Plaintiffs and class members in the form of payment for JUUL products.

10 1041. Defendants appreciated, recognized, and chose to accept the monetary benefits  
 11 Plaintiffs conferred onto Defendants at the Plaintiffs’ detriment. These benefits were the  
 12 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

13 1042. There is no justification for Defendants’ enrichment. It would be inequitable,  
 14 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
 15 benefits were procured as a result of their wrongful conduct.

16 1043. Defendants wrongfully obfuscated the harm caused by their conduct. Thus,  
 17 Plaintiffs and class members, who relied on Defendants’ fraudulent representations, could not  
 18 and did not know the effect that using JUUL products would have on their health.

19 1044. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
 20 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
 21 with Defendant.

22 1045. Plaintiffs plead this claim separately as well as in the alternative to their other  
 23 claims, as without such claims they would have no adequate legal remedy.

## 24 **2. Alaska**

25 1046. Plaintiffs bring each of the following claims on behalf of the Alaska Subclass  
 26 under Alaska law.

### 27 **a. Violation of the Alaska Unfair Trade Practices and Consumer** 28 **Protection Act (Alaska Stat. § 45.50.471, et seq.)**

1047. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           1048. This claim is brought against JLI and, for certain unfair and/or unconscionable  
2 conduct claims as noted below, all Defendants.

3           1049. Plaintiffs and class members are consumers who sought or acquired goods from  
4 JUUL by purchase.

5           1050. Plaintiffs and class members purchased JUUL products for personal purposes.

6           1051. Defendants created and implemented a scheme to create a market for e-cigarettes  
7 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
8 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
9 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
10 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
11 addictiveness, and significant risks of substantial physical injury from using JUUL products.

12           1052. Advertisements and representations for JUUL products contained deceptive  
13 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
14 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
15 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
16 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
17 decades, JLI used third parties and word of mouth to spread false and misleading information  
18 about JUUL products.

19           1053. Advertisements and representations for JUUL products concealed and failed to  
20 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
21 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
22 addictive, posed significant risks of substantial physical injury resulting from the use of the  
23 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
24 consumed through a pack of combustible cigarettes.

25           1054. The labels on JUUL products failed to disclose that the products posed  
26 significant risks of substantial physical injury resulting from the use of the products. The labels  
27 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

28           1055. The omissions were misleading and deceptive standing alone and were

1 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
2 cigarettes and other representations.

3 1056. JLI's conduct was unfair and unconscionable in that it included (i) the  
4 manufacture and sale of products with a heightened propensity to cause addiction and physical  
5 injuries and (ii) misrepresentations and omissions of material facts concerning the  
6 characteristics and safety of JUUL products that offended public policy; were immoral,  
7 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
8 substantial harm that greatly outweighs any possible utility from the conduct.

9 1057. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
10 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
11 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
12 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
13 model, when they are not; (c) advertising goods or services with intent not to sell them as  
14 advertised; (d) engaging in other conduct creating a likelihood of confusion or of  
15 misunderstanding and that misled, deceived, and/ or damaged a buyer in connection with the  
16 sale or advertisement of goods or services; and (e) using or employing deception, fraud, false  
17 pretense, false promise, misrepresentation, or knowingly concealing, suppressing, or omitting a  
18 material fact with intent that others rely upon the concealment, suppression, or omission in  
19 connection with the sale or advertisement of goods.

20 1058. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
21 omissions had the capacity to deceive, and in fact did, deceive reasonable consumers, including  
22 the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to  
23 their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii)  
24 were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-  
25 delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of  
26 substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
27 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
28 combustible cigarettes. Knowledge of these facts would have been a substantial factor in



1 Plaintiffs' and class members' decisions to purchase JUUL products.

2 1059. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
3 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
4 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
5 facts; because the facts would be material to reasonable consumers; because JLI actively  
6 concealed them; because JLI intended for consumers to rely on the omissions in question;  
7 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
8 made partial representations concerning the same subject matter as the omitted facts.

9 1060. JLI and the Management Defendants engaged in fraudulent and deceptive  
10 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
11 products were appropriate for minors, when in fact the products never should have been  
12 marketed to minors and are especially harmful to minors due to the potent and addictive  
13 nicotine doses, addictive qualities, and health risks.

14 1061. In addition, all Defendants engaged in unfair and unconscionable conduct  
15 because the targeting of minors offends public policy (in particular Alaska Stat. § 11.76.109); is  
16 immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has  
17 caused substantial harm that greatly outweighs any possible utility from the conduct.

18 1062. As alleged above, all Defendants participated and/or facilitated the marketing of  
19 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
20 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
21 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
22 use of JUUL products by minors continues to rise.

23 1063. Defendants' conduct actually and proximately caused an ascertainable loss of  
24 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent  
25 conduct, Plaintiffs and class members would have behaved differently and would not have  
26 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
27 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
28 otherwise have purchased and enter into purchase contracts they would not otherwise have

1 entered into. In addition, class members who are minors are entitled to full repayment of the  
2 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
3 member of the class—injunctive relief (except as to the Management Defendants), reasonable  
4 attorneys’ fees, three times actual damages or \$500, whichever is greater, as well as any other  
5 relief the Court may deem just or proper.

6 1064. Plaintiffs have complied or substantially complied with all applicable notice  
7 requirements, or are otherwise excused from compliance for this proceeding.

8 **b. Common Law Fraud**

9 1065. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 1066. This claim is brought against JLI.

11 1067. JUUL created and implemented a scheme to create a market for e-cigarettes and  
12 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
13 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
14 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
15 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
16 addictiveness, and significant risks of substantial physical injury from using JUUL products.

17 1068. Advertisements and representations for JUUL products contained deceptive  
18 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
19 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
20 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
21 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
22 decades, JLI used third parties and word of mouth to spread false and misleading information  
23 about JUUL products.

24 1069. Advertisements and representations for JUUL products concealed and failed to  
25 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed significant risks of substantial physical injury resulting from the use of the  
28 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine

1 consumed through a pack of combustible cigarettes.

2 1070. The labels on JUUL products failed to disclose that the products posed  
3 significant risks of substantial physical injury resulting from the use of the products. The labels  
4 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

5 1071. The omissions were misleading and deceptive standing alone and were  
6 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
7 cigarettes and other representations.

8 1072. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
9 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
10 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
11 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
12 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
13 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
14 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
15 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
16 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
17 Plaintiffs' and class members' decisions to purchase JUUL products.

18 1073. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
19 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
20 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
21 facts; because the facts would be material to reasonable consumers; because JUUL products  
22 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
23 representations concerning the same subject matter as the omitted facts.

24 1074. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
25 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
26 and/or omissions. Reasonable consumers would have been expected to have relied on the  
27 misrepresentations and omissions.

28 1075. JLI knew or should have known that its misrepresentations and/or omissions

1 were false and misleading, and intended for consumers to rely on such misrepresentations and  
2 omissions.

3 1076. JLI knew that JUUL products were not safe or reasonable alternatives to  
4 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
5 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
6 products.

7 1077. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
8 class members. Absent JLI's conduct, Plaintiffs and class members would have behaved  
9 differently and would not have purchased JUUL products or would have paid less for them.  
10 JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
11 products they would not otherwise have purchased and enter into purchase contracts they would  
12 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
13 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
14 deem just or proper.

15 **c. Breach of the Implied Warranty of Merchantability**

16 1078. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

17 1079. This claim is brought against JLI.

18 1080. JUUL has at all times been a merchant with respect to the products which were  
19 sold to Plaintiff and the class and was in the business of selling such products.

20 1081. Each JUUL product sold by JUUL comes with an implied warranty that it will  
21 merchantable and fit for the ordinary purpose for which it would be used. Alaska Stat.  
22 § 45.02.314. JUUL has breached its implied warranty of merchantability because its products  
23 were not in merchantable condition when sold, were defective when sold, did not conform to the  
24 promises and affirmations of fact made on the products' containers or labels, and/or do not  
25 possess even the most basic degree of fitness for ordinary use.

26 1082. The ordinary intended purpose of JUUL's products—and the purpose for which  
27 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
28 products are not fit for that use—or any other use—because they (i) were not smoking cessation

1 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
2 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
3 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
4 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
5 recreation smoking devices.

6 1083. Plaintiffs and each member of the class have had sufficient direct dealings with  
7 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
8 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
9 each member of the class, on the other hand.

10 1084. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
11 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
12 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
13 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
14 the express purpose an intent of being sold to consumers.

15 1085. Plaintiffs and the members of the class were injured as a direct and proximate  
16 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
17 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
18 because, had they been aware of the unmerchantable condition of JUUL products, they would  
19 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
20 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

21 1086. JUUL was provided notice of these issues by numerous complaints filed against  
22 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
23 individual letters and communications sent by consumers before or within a reasonable amount  
24 of time after they discovered or should have discovered that's JUUL product were defective and  
25 unmerchantable.

26 **d. Unjust Enrichment**

27 1087. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

28 1088. This claim is brought against JLI and the Management Defendants.

1           1089. Defendants created and implemented a scheme to create a market for e-cigarettes  
2 and substantially increase sales of JUUL products through a pervasive pattern of false and  
3 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
4 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
5 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
6 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
7 products.

8           1090. Defendants were unjustly enriched as a result of their wrongful conduct,  
9 including through the false and misleading advertisements and omissions regarding (i) whether  
10 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
11 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
12 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
13 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
14 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
15 enriched through their scheme of marketing their products to minors. Alaska Stat. § 11.76.109  
16 prohibits the marketing and sale of JUUL products to minors.

17           1091. Defendants requested and received a measurable benefit at the expense of  
18 Plaintiffs and class members in the form of payment for JUUL products.

19           1092. Defendants appreciated, recognized, and chose to accept the monetary benefits  
20 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
21 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

22           1093. There is no justification for Defendants' enrichment. It would be inequitable,  
23 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
24 benefits were procured as a result of their wrongful conduct.

25           1094. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
26 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
27 with Defendant.

28           1095. Plaintiffs plead this claim separately as well as in the alternative to their other

1 claims, as without such claims they would have no adequate legal remedy.

2 **3. Arizona**

3 1096. Plaintiffs bring each of the following claims on behalf of the Arizona Subclass  
4 under Arizona law.

5 **a. Violation of the Arizona Consumer Fraud Act (Ariz. Rev.  
6 Stat. § 44-1521, *et seq.*)**

7 1097. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 1098. This claim is brought against JLI and, for certain unfair and/or unconscionable  
9 conduct claims as noted below, all Defendants.

10 1099. Plaintiffs and class members purchased JUUL products for personal purposes.

11 1100. Defendants created and implemented a scheme to create a market for e-cigarettes  
12 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
13 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
14 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
15 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
16 addictiveness, and significant risks of substantial physical injury from using JUUL products.

17 1101. Advertisements and representations for JUUL products contained deceptive  
18 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
19 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
20 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
21 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
22 decades, JLI used third parties and word of mouth to spread false and misleading information  
23 about JUUL products.

24 1102. Advertisements and representations for JUUL products concealed and failed to  
25 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed significant risks of substantial physical injury resulting from the use of the  
28 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
consumed through a pack of combustible cigarettes.



1           1103. The labels on JUUL products failed to disclose that the products posed  
2 significant risks of substantial physical injury resulting from the use of the products. The labels  
3 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

4           1104. The omissions were misleading and deceptive standing alone and were  
5 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
6 cigarettes and other representations.

7           1105. JLI's conduct was unfair and unconscionable in that it included (i) the  
8 manufacture and sale of products with a heightened propensity to cause addiction and physical  
9 injuries and (ii) misrepresentations and omissions of material facts concerning the  
10 characteristics and safety of JUUL products that offended public policy; were immoral,  
11 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
12 substantial harm that greatly outweighs any possible utility from the conduct.

13           1106. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
14 omissions had the tendency and capacity to convey misleading impressions to consumers, and  
15 in fact did, mislead reasonable consumers, including the Plaintiffs. Reasonable consumers,  
16 including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's  
17 products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to  
18 combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
19 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
20 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
21 nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would  
22 have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL  
23 products.

24           1107. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
25 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
26 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
27 facts; because the facts would be material to reasonable consumers; because JLI actively  
28 concealed them; because JLI intended for consumers to rely on the omissions in question;

1 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
2 made partial representations concerning the same subject matter as the omitted facts.

3 1108. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
4 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
5 Reasonable consumers would have been expected to have relied on the misrepresentations and  
6 omissions.

7 1109. Defendants knew or should have known that their misrepresentations and/or  
8 omissions were false and misleading, and intended for consumers to rely on such  
9 misrepresentations and omissions.

10 1110. JLI and the Management Defendants engaged in fraudulent and deceptive  
11 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
12 products were appropriate for minors, when in fact the products never should have been  
13 marketed to minors and are especially harmful to minors due to the potent and addictive  
14 nicotine doses, addictive qualities, and health risks.

15 1111. In addition, all Defendants engaged in unfair and unconscionable conduct  
16 because the targeting of minors offends public policy (in particular Ariz. Rev. Stat. § 13-  
17 3622(A)); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
18 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
19 conduct.

20 1112. As alleged above, all Defendants participated and/or facilitated the marketing of  
21 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
22 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
23 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
24 use of JUUL products by minors continues to rise.

25 1113. Defendants' conduct actually and proximately caused actual damages to  
26 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
27 class members would have behaved differently and would not have purchased JUUL products  
28 or would have paid less for them. Defendants' misrepresentations and omissions induced

1 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
2 purchased and enter into purchase contracts they would not otherwise have entered into. In  
3 addition, class members who are minors are entitled to full repayment of the amounts they spent  
4 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
5 injunctive relief (except as to the Management Defendants), reasonable attorneys’ fees, punitive  
6 damages, and actual damages, as well as any other relief the Court may deem just or proper.

7 **b. Common Law Fraud**

8 1114. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

9 1115. This claim is brought against JLI.

10 1116. JUUL created and implemented a scheme to create a market for e-cigarettes and  
11 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
12 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
13 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
14 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
15 addictiveness, and significant risks of substantial physical injury from using JUUL products.

16 1117. Advertisements and representations for JUUL products contained deceptive  
17 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
18 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
19 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
20 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
21 decades, JLI used third parties and word of mouth to spread false and misleading information  
22 about JUUL products.

23 1118. Advertisements and representations for JUUL products concealed and failed to  
24 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
25 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
26 addictive, posed significant risks of substantial physical injury resulting from the use of the  
27 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
28 consumed through a pack of combustible cigarettes.

1           1119. The labels on JUUL products failed to disclose that the products posed  
2 significant risks of substantial physical injury resulting from the use of the products. The labels  
3 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

4           1120. The omissions were misleading and deceptive standing alone and were  
5 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
6 cigarettes and other representations.

7           1121. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
8 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
9 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
10 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
11 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
12 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
13 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
14 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
15 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
16 Plaintiffs' and class members' decisions to purchase JUUL products.

17           1122. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
18 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
19 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
20 facts; because the facts would be material to reasonable consumers; because JUUL products  
21 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
22 representations concerning the same subject matter as the omitted facts.

23           1123. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
24 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
25 and/or omissions. Reasonable consumers would have been expected to have relied on the  
26 misrepresentations and omissions.

27           1124. JLI knew or should have known that its misrepresentations and/or omissions  
28 were false and misleading, and intended for consumers to rely on such misrepresentations and

omissions.

1125. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

1126. JLI's conduct actually and proximately caused damage to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

1127. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1128. This claim is brought against JLI.

1129. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1130. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. Ariz. Rev. Stat. § 47-2314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1131. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely

1 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
2 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
3 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
4 recreation smoking devices.

5 1132. Plaintiffs and each member of the class have had sufficient direct dealings with  
6 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
7 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
8 each member of the class, on the other hand.

9 1133. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
10 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
11 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
12 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
13 the express purpose an intent of being sold to consumers.

14 1134. Plaintiffs and the members of the class were injured as a direct and proximate  
15 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
16 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
17 because, had they been aware of the unmerchantable condition of JUUL products, they would  
18 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
19 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

20 1135. JUUL was provided notice of these issues by numerous complaints filed against  
21 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
22 individual letters and communications sent by consumers before or within a reasonable amount  
23 of time after they discovered or should have discovered that's JUUL product were defective and  
24 unmerchantable.

25 **d. Unjust Enrichment**

26 1136. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

27 1137. This claim is brought against JLI and the Management Defendants.

28 1138. Defendants created and implemented a scheme to create a market for e-cigarettes

1 and substantially increase sales of JUUL products through a pervasive pattern of false and  
2 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
3 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
4 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
5 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
6 products.

7 1139. Defendants were unjustly enriched as a result of their wrongful conduct,  
8 including through the false and misleading advertisements and omissions regarding (i) whether  
9 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
10 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
11 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
12 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
13 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
14 enriched through their scheme of marketing their products to minors. Ariz. Rev. Stat. § 13-  
15 3622(A) prohibits the marketing and sale of JUUL products to minors.

16 1140. Defendants requested and received a measurable benefit at the expense of  
17 Plaintiffs and class members in the form of payment for JUUL products.

18 1141. Defendants appreciated, recognized, and chose to accept the monetary benefits  
19 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
20 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

21 1142. There is no justification for Defendants' enrichment. It would be inequitable,  
22 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
23 benefits were procured as a result of their wrongful conduct.

24 1143. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
25 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
26 with Defendant.

27 1144. Plaintiffs plead this claim separately as well as in the alternative to their other  
28 claims, as without such claims they would have no adequate legal remedy.



1                   **4.       Arkansas**

2           1145. Plaintiffs bring each of the following claims on behalf of the Arkansas Subclass  
3 under Arkansas law.

4                   **a.       Violation of the Arkansas Deceptive Trade Practices Act (Ark.  
5                   Code § 4-88-101, *et seq.*)**

6           1146. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

7           1147. This claim is brought against JLI and, for certain unfairness or unconscionable  
8 conduct claims, all Defendants.

9           1148. Plaintiffs and class members purchased JUUL products for personal purposes.

10          1149. Defendants created and implemented a scheme to create a market for e-cigarettes  
11 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
12 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
13 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
14 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
15 addictiveness, and significant risks of substantial physical injury from using JUUL products.

16          1150. Advertisements and representations for JUUL products contained deceptive  
17 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
18 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
19 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
20 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
21 decades, JLI used third parties and word of mouth to spread false and misleading information  
22 about JUUL products.

23          1151. Advertisements and representations for JUUL products concealed and failed to  
24 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
25 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
26 addictive, posed significant risks of substantial physical injury resulting from the use of the  
27 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
28 consumed through a pack of combustible cigarettes.

1152. The labels on JUUL products failed to disclose that the products posed

1 significant risks of substantial physical injury resulting from the use of the products. The labels  
2 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

3 1153. The omissions were misleading and deceptive standing alone and were  
4 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
5 cigarettes and other representations.

6 1154. JLI's conduct was unfair and unconscionable in that it included (i) the  
7 manufacture and sale of products with a heightened propensity to cause addiction and physical  
8 injuries and (ii) misrepresentations and omissions of material facts concerning the  
9 characteristics and safety of JUUL products violated public policy and affronted the sense of  
10 justice, decency, or reasonableness.

11 1155. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
12 unfair business practices: (a) knowingly misrepresenting that JUUL products have  
13 characteristics, ingredients, uses, or benefits which they do not have; (b) knowingly  
14 misrepresenting that JUUL products are of a particular standard, quality, or grade, or that goods  
15 are of a particular style or model, when they are not; (c) advertising goods or services with  
16 intent not to sell them as advertised; (d) using or employing deception, fraud, or false pretense;  
17 (e) concealing, suppressing, or omitting material facts with the intent that other rely upon the  
18 concealment, suppression, or omission; and (f) engaging in other unconscionable, false or  
19 deceptive acts or practices in business commerce, or trade.

20 1156. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
21 omissions at issue were likely to and had the capacity to, and in fact did, deceive reasonable  
22 consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have  
23 found it material to their purchasing decisions that JUUL's products (i) were not smoking  
24 cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were  
25 extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
26 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
27 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
28 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor

1 in Plaintiffs' and class members' decisions to purchase JUUL products.

2 1157. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
3 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
4 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
5 facts; because the facts would be material to reasonable consumers; because JLI actively  
6 concealed them; because JLI intended for consumers to rely on the omissions in question;  
7 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
8 made partial representations concerning the same subject matter as the omitted facts.

9 1158. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
10 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
11 Reasonable consumers would have been expected to have relied on the misrepresentations and  
12 omissions.

13 1159. Defendants knew or should have known that their misrepresentations and/or  
14 omissions were false and misleading, and intended for consumers to rely on such  
15 misrepresentations and omissions.

16 1160. JLI and the Management Defendants engaged in fraudulent and deceptive  
17 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
18 products were appropriate for minors, when in fact the products never should have been  
19 marketed to minors and are especially harmful to minors due to the potent and addictive  
20 nicotine doses, addictive qualities, and health risks.

21 1161. In addition, all Defendants engaged in unfair and unconscionable conduct  
22 because the targeting of minors offends public policy (in particular Ark. Code § 5-27-227(a)(1))  
23 and affronted the sense of justice, decency, or reasonableness.

24 1162. As alleged above, all Defendants participated and/or facilitated the marketing of  
25 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
26 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
27 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
28 use of JUUL products by minors continues to rise.

1163. Defendants' conduct actually and proximately caused actual financial loss to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—to recover their actual financial loss, reasonable attorneys' fees, and punitive damages, as well as any other relief the Court may deem just or proper.

**b. Common Law Fraud**

1164. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1165. This claim is brought against JLI.

1166. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1167. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

1168. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to

1 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
2 addictive, posed significant risks of substantial physical injury resulting from the use of the  
3 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
4 consumed through a pack of combustible cigarettes.

5 1169. The labels on JUUL products failed to disclose that the products posed  
6 significant risks of substantial physical injury resulting from the use of the products. The labels  
7 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

8 1170. The omissions were misleading and deceptive standing alone and were  
9 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
10 cigarettes and other representations.

11 1171. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
12 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
13 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
14 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
15 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
16 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
17 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
18 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
19 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
20 Plaintiffs' and class members' decisions to purchase JUUL products.

21 1172. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
22 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
23 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
24 facts; because the facts would be material to reasonable consumers; because JUUL products  
25 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
26 representations concerning the same subject matter as the omitted facts.

27 1173. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
28 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations

1 and/or omissions. Reasonable consumers would have been expected to have relied on the  
2 misrepresentations and omissions.

3 1174. Defendants knew or should have known that their misrepresentations and/or  
4 omissions were false and misleading, and intended for consumers to rely on such  
5 misrepresentations and omissions.

6 1175. JLI knew that JUUL products were not safe or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
9 products.

10 1176. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
11 class members. Absent JLI's conduct, Plaintiffs and class members would have behaved  
12 differently and would not have purchased JUUL products or would have paid less for them.  
13 JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
14 products they would not otherwise have purchased and enter into purchase contracts they would  
15 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
16 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
17 deem just or proper.

18 **c. Breach of the Implied Warranty of Merchantability**

19 1177. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

20 1178. This claim is brought against JLI.

21 1179. JUUL has at all times been a merchant with respect to the products which were  
22 sold to Plaintiff and the class and was in the business of selling such products.

23 1180. Each JUUL product sold by JUUL comes with an implied warranty that it will  
24 merchantable and fit for the ordinary purpose for which it would be used. Ark. Code § 4-2-  
25 314. JUUL has breached its implied warranty of merchantability because its products were not  
26 in merchantable condition when sold, were defective when sold, did not conform to the  
27 promises and affirmations of fact made on the products' containers or labels, and/or do not  
28 possess even the most basic degree of fitness for ordinary use.

1           1181. The ordinary intended purpose of JUUL’s products—and the purpose for which  
2 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
3 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
4 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
5 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
6 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
7 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
8 recreation smoking devices.

9           1182. Plaintiffs and each member of the class have had sufficient direct dealings with  
10 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
11 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
12 each member of the class, on the other hand.

13           1183. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
14 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
15 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
16 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
17 the express purpose an intent of being sold to consumers.

18           1184. Plaintiffs and the members of the class were injured as a direct and proximate  
19 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
20 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
21 because, had they been aware of the unmerchantable condition of JUUL products, they would  
22 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
23 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

24           1185. JUUL was provided notice of these issues by numerous complaints filed against  
25 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
26 individual letters and communications sent by consumers before or within a reasonable amount  
27 of time after they discovered or should have discovered that’s JUUL product were defective and  
28 unmerchantable.



**d. Unjust Enrichment**

1186. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1187. This claim is brought against JLI and the Management Defendants.

1188. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1189. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Ark. Code § 5-27-227(a)(1) prohibits the marketing and sale of JUUL products to minors.

1190. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1191. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1192. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1193. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained

1 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
2 with Defendant.

3 1194. Plaintiffs plead this claim separately as well as in the alternative to their other  
4 claims, as without such claims they would have no adequate legal remedy.

5 **5. Colorado**

6 1195. Plaintiffs bring each of the following claims on behalf of the Colorado Subclass  
7 under Colorado law.

8 **a. Violation of the Colorado Consumer Protection Act (Colo.  
9 Rev. Stat. § 6-1-101, *et seq.*)**

10 1196. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 1197. This claim is brought against JLI and, for certain unfair and/or unconscionable  
12 conduct claims as noted below, all Defendants.

13 1198. Plaintiffs and class members purchased JUUL products for personal purposes.

14 1199. Defendants created and implemented a scheme to create a market for e-cigarettes  
15 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
16 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
17 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
18 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
19 addictiveness, and significant risks of substantial physical injury from using JUUL products.

20 1200. Advertisements and representations for JUUL products contained deceptive  
21 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
22 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
23 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
24 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
25 decades, JLI used third parties and word of mouth to spread false and misleading information  
26 about JUUL products.

27 1201. Advertisements and representations for JUUL products concealed and failed to  
28 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to

1 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
2 addictive, posed significant risks of substantial physical injury resulting from the use of the  
3 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
4 consumed through a pack of combustible cigarettes.

5 1202. The labels on JUUL products failed to disclose that the products posed  
6 significant risks of substantial physical injury resulting from the use of the products. The labels  
7 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

8 1203. The omissions were misleading and deceptive standing alone and were  
9 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
10 cigarettes and other representations.

11 1204. JLI's conduct was unfair and unconscionable in that it included (i) the  
12 manufacture and sale of products with a heightened propensity to cause addiction and physical  
13 injuries and (ii) misrepresentations and omissions of material facts concerning the  
14 characteristics and safety of JUUL products that offended public policy; were immoral,  
15 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
16 substantial harm that greatly outweighs any possible utility from the conduct.

17 1205. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
18 unfair business practices: (a) knowingly or recklessly misrepresenting that JUUL products have  
19 characteristics, ingredients, uses, benefits, or quantities, which they do not have; (b)  
20 misrepresenting that JUUL products are of a particular standard, quality, or grade, or that goods  
21 are of a particular style or model, while knowing or having should known that they are not; (c)  
22 advertising goods or services with intent not to sell them as advertised; (d) failing to disclose  
23 material information concerning goods or services which was known at the time of an  
24 advertisement or sale and intended to induce a consumer to enter into a transaction; and (e)  
25 knowingly or recklessly engaging in other unfair, unconscionable, deceptive, deliberately  
26 misleading, false, or fraudulent act or practices.

27 1206. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
28 omissions had the capacity or tendency to deceive, and in fact did, deceive reasonable

1 consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have  
2 found it material to their purchasing decisions that JUUL's products (i) were not smoking  
3 cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were  
4 extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
5 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
6 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
7 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
8 in Plaintiffs' and class members' decisions to purchase JUUL products.

9 1207. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JLI actively  
13 concealed them; because JLI intended for consumers to rely on the omissions in question;  
14 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
15 made partial representations concerning the same subject matter as the omitted facts.

16 1208. Defendants knew or should have known that their misrepresentations and/or  
17 omissions were false and misleading or otherwise exhibited reckless disregard for the truth, and  
18 intended for consumers to rely on such misrepresentations and omissions.

19 1209. JLI and the Management Defendants engaged in fraudulent and deceptive  
20 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
21 products were appropriate for minors, when in fact the products never should have been  
22 marketed to minors and are especially harmful to minors due to the potent and addictive  
23 nicotine doses, addictive qualities, and health risks.

24 1210. In addition, all Defendants engaged in unfair and unconscionable conduct  
25 because the targeting of minors offends public policy (in particular Colo. Rev. Stat. §§ 18-13-  
26 121(1)(a) and 44-7-103); is immoral, unethical, oppressive, outrageous, unscrupulous, and  
27 substantially injurious; and has caused substantial harm that greatly outweighs any possible  
28 utility from the conduct.

1211. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI and others have continued the deceptive, misleading, unfair, and unconscionable practices that Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by minors continues to rise.

1212. Defendants' conduct significantly impacts the public as actual or potential consumers of Defendant's goods.

1213. Defendants' conduct actually and proximately caused injury and actual damage to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—three times actual damages or \$500, whichever is greater, and reasonable attorneys' fees, as well as any other relief the Court may deem just or proper.

**b. Common Law Fraud**

1214. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1215. This claim is brought against JLI.

1216. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1217. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives

1 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
2 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
3 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
4 decades, JLI used third parties and word of mouth to spread false and misleading information  
5 about JUUL products.

6 1218. Advertisements and representations for JUUL products concealed and failed to  
7 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
8 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
9 addictive, posed significant risks of substantial physical injury resulting from the use of the  
10 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
11 consumed through a pack of combustible cigarettes.

12 1219. The labels on JUUL products failed to disclose that the products posed  
13 significant risks of substantial physical injury resulting from the use of the products. The labels  
14 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

15 1220. The omissions were misleading and deceptive standing alone and were  
16 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
17 cigarettes and other representations.

18 1221. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
19 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
20 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
21 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
22 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
23 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
24 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
25 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
26 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
27 Plaintiffs' and class members' decisions to purchase JUUL products.

28 1222. JLI owed Plaintiffs and class members a duty to disclose these facts because they

were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

1223. As set forth in the allegations concerning each Plaintiff in Appendix A, in purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations and/or omissions. Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

1224. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

1225. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

1226. JLI's conduct actually and proximately caused actual damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

1227. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1228. This claim is brought against JLI.

1229. JUUL has at all times been a merchant with respect to the products which were



1 sold to Plaintiff and the class and was in the business of selling such products.

2       1230. Each JUUL product sold by JUUL comes with an implied warranty that it will  
3 merchantable and fit for the ordinary purpose for which it would be used. Colo. Rev. Stat. § 4-  
4 2-314. JUUL has breached its implied warranty of merchantability because its products were  
5 not in merchantable condition when sold, were defective when sold, did not conform to the  
6 promises and affirmations of fact made on the products' containers or labels, and/or do not  
7 possess even the most basic degree of fitness for ordinary use.

8       1231. The ordinary intended purpose of JUUL's products—and the purpose for which  
9 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
10 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
11 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
12 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
13 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
14 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
15 recreation smoking devices.

16       1232. Plaintiffs and each member of the class have had sufficient direct dealings with  
17 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
18 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
19 each member of the class, on the other hand.

20       1233. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
21 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
22 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
23 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
24 the express purpose an intent of being sold to consumers.

25       1234. Plaintiffs and the members of the class were injured as a direct and proximate  
26 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
27 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
28 because, had they been aware of the unmerchantable condition of JUUL products, they would

1 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
2 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

3 1235. JUUL was provided notice of these issues by numerous complaints filed against  
4 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
5 individual letters and communications sent by consumers before or within a reasonable amount  
6 of time after they discovered or should have discovered that's JUUL product were defective and  
7 unmerchtable.

8 **d. Unjust Enrichment**

9 1236. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 1237. This claim is brought against JLI and the Management Defendants.

11 1238. Defendants created and implemented a scheme to create a market for e-cigarettes  
12 and substantially increase sales of JUUL products through a pervasive pattern of false and  
13 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
14 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
15 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
16 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
17 products.

18 1239. Defendants were unjustly enriched as a result of their wrongful conduct,  
19 including through the false and misleading advertisements and omissions regarding (i) whether  
20 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
21 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
22 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
23 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
24 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
25 enriched through their scheme of marketing their products to minors. Colo. Rev. Stat. §§ 18-13-  
26 121(1)(a) and 44-7-103 prohibits the marketing and sale of JUUL products to minors.

27 1240. Defendants requested and received a measurable benefit at the expense of  
28 Plaintiffs and class members in the form of payment for JUUL products.

1241. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1242. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1243. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1244. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## 6. Connecticut

1245. Plaintiffs bring each of the following claims on behalf of the Connecticut Subclass under Connecticut law.

### a. Violation of the Connecticut Unfair Trade Practices Act (Conn. Gen. Stat. § 42-110a, *et seq.*)

1246. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1247. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

1248. Defendants are "persons" as defined by Conn. Gen. Stat. Ann. § 42-110a.

1249. Plaintiffs and class members purchased JUUL products for personal purposes.

1250. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1251. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives

1 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
2 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
3 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
4 decades, JLI used third parties and word of mouth to spread false and misleading information  
5 about JUUL products.

6 1252. Advertisements and representations for JUUL products concealed and failed to  
7 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
8 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
9 addictive, posed significant risks of substantial physical injury resulting from the use of the  
10 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
11 consumed through a pack of combustible cigarettes.

12 1253. The labels on JUUL products failed to disclose that the products posed  
13 significant risks of substantial physical injury resulting from the use of the products. The labels  
14 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

15 1254. The omissions were misleading and deceptive standing alone and were  
16 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
17 cigarettes and other representations.

18 1255. JLI's conduct was unfair and unconscionable in that it included (i) the  
19 manufacture and sale of products with a heightened propensity to cause addiction and physical  
20 injuries and (ii) misrepresentations and omissions of material facts concerning the  
21 characteristics and safety of JUUL products that offended public policy; were immoral,  
22 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
23 substantial harm that greatly outweighs any possible utility from the conduct.

24 1256. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
25 omissions had the capacity to deceive, and in fact did, deceive reasonable consumers including  
26 the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to  
27 their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii)  
28 were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-

1 delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of  
2 substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
3 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
4 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
5 Plaintiffs' and class members' decisions to purchase JUUL products.

6 1257. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
7 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
8 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
9 facts; because the facts would be material to reasonable consumers; because JLI actively  
10 concealed them; because JLI intended for consumers to rely on the omissions in question;  
11 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
12 made partial representations concerning the same subject matter as the omitted facts.

13 1258. JLI and the Management Defendants engaged in fraudulent and deceptive  
14 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
15 products were appropriate for minors, when in fact the products never should have been  
16 marketed to minors and are especially harmful to minors due to the potent and addictive  
17 nicotine doses, addictive qualities, and health risks.

18 1259. In addition, all Defendants engaged in unfair and unconscionable conduct  
19 because the targeting of minors offends public policy (in particular Conn. Gen. Stat. § 53-  
20 344b(b)); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
21 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
22 conduct.

23 1260. As alleged above, all Defendants participated and/or facilitated the marketing of  
24 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
25 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
26 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
27 use of JUUL products by minors continues to rise.

28 1261. Defendants' conduct actually and proximately caused an ascertainable loss of

1 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent  
2 conduct, Plaintiffs and class members would have behaved differently and would not have  
3 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
4 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
5 otherwise have purchased and enter into purchase contracts they would not otherwise have  
6 entered into. In addition, class members who are minors are entitled to full repayment of the  
7 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
8 member of the class—injunctive relief (except as to the Management Defendants), attorney's  
9 fees, actual damages, and punitive damages, as well as any other relief the Court may deem just  
10 or proper.

11 **b. Common Law Fraud**

12 1262. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

13 1263. This claim is brought against JLI.

14 1264. JUUL created and implemented a scheme to create a market for e-cigarettes and  
15 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
16 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
17 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
18 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
19 addictiveness, and significant risks of substantial physical injury from using JUUL products.

20 1265. Advertisements and representations for JUUL products contained deceptive  
21 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
22 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
23 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
24 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
25 decades, JLI used third parties and word of mouth to spread false and misleading information  
26 about JUUL products.

27 1266. Advertisements and representations for JUUL products concealed and failed to  
28 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to

1 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
2 addictive, posed significant risks of substantial physical injury resulting from the use of the  
3 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
4 consumed through a pack of combustible cigarettes.

5 1267. The labels on JUUL products failed to disclose that the products posed  
6 significant risks of substantial physical injury resulting from the use of the products. The labels  
7 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

8 1268. The omissions were misleading and deceptive standing alone and were  
9 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
10 cigarettes and other representations.

11 1269. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
12 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
13 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
14 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
15 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
16 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
17 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
18 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
19 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
20 Plaintiffs' and class members' decisions to purchase JUUL products.

21 1270. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
22 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
23 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
24 facts; because the facts would be material to reasonable consumers; because JUUL products  
25 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
26 representations concerning the same subject matter as the omitted facts.

27 1271. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
28 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations



1 and/or omissions. Reasonable consumers would have been expected to have relied on the  
2 misrepresentations and omissions.

3 1272. Defendants knew or should have known that their misrepresentations and/or  
4 omissions were false and misleading, and intended for consumers to rely on such  
5 misrepresentations and omissions.

6 1273. JLI knew that JUUL products were not safe or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
9 products.

10 1274. JLI's conduct actually and proximately caused injury and harm to Plaintiffs and  
11 class members. Absent JLI's conduct, Plaintiffs and class members would have behaved  
12 differently and would not have purchased JUUL products or would have paid less for them.  
13 JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
14 products they would not otherwise have purchased and enter into purchase contracts they would  
15 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
16 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
17 deem just or proper.

18 **c. Breach of the Implied Warranty of Merchantability**

19 1275. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

20 1276. This claim is brought against JLI.

21 1277. JUUL has at all times been a merchant with respect to the products which were  
22 sold to Plaintiff and the class and was in the business of selling such products.

23 1278. Each JUUL product sold by JUUL comes with an implied warranty that it will  
24 merchantable and fit for the ordinary purpose for which it would be used. Conn. Gen. Stat.  
25 § 42a-2-314. JUUL has breached its implied warranty of merchantability because its products  
26 were not in merchantable condition when sold, were defective when sold, did not conform to the  
27 promises and affirmations of fact made on the products' containers or labels, and/or do not  
28 possess even the most basic degree of fitness for ordinary use.

1           1279. The ordinary intended purpose of JUUL’s products—and the purpose for which  
2 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
3 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
4 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
5 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
6 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
7 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
8 recreation smoking devices.

9           1280. Plaintiffs and each member of the class have had sufficient direct dealings with  
10 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
11 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
12 each member of the class, on the other hand.

13           1281. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
14 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
15 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
16 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
17 the express purpose an intent of being sold to consumers.

18           1282. Plaintiffs and the members of the class were injured as a direct and proximate  
19 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
20 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
21 because, had they been aware of the unmerchantable condition of JUUL products, they would  
22 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
23 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

24           1283. JUUL was provided notice of these issues by numerous complaints filed against  
25 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
26 individual letters and communications sent by consumers before or within a reasonable amount  
27 of time after they discovered or should have discovered that’s JUUL product were defective and  
28 unmerchantable.

**d. Unjust Enrichment**

1284. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1285. This claim is brought against JLI and the Management Defendants.

1286. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1287. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Conn. Gen. Stat. § 53-344b(b) prohibits the marketing and sale of JUUL products to minors.

1288. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1289. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1290. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1291. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained

and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1292. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **7. Delaware**

1293. Plaintiffs bring each of the following claims on behalf of the Delaware Subclass under Delaware law.

### **a. Violation of the Delaware Consumer Fraud Act (Del. Code tit. 6 § 2511, *et seq.*)**

1294. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1295. This claim is brought against JLI and, for certain claims as noted below, the Management Defendants.

1296. Plaintiffs and class members purchased JUUL products for personal purposes.

1297. JLI is a “person” as defined by Del. Code Ann. tit. 6, § 2511.

1298. JUUL products are “merchandise” as defined by Del. Code Ann. tit. 6, § 2511.

1299. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1300. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

1301. Advertisements and representations for JUUL products concealed and failed to

1 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
2 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
3 addictive, posed significant risks of substantial physical injury resulting from the use of the  
4 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
5 consumed through a pack of combustible cigarettes.

6 1302. The labels on JUUL products failed to disclose that the products posed  
7 significant risks of substantial physical injury resulting from the use of the products. The labels  
8 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

9 1303. The omissions were misleading and deceptive standing alone and were  
10 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
11 cigarettes and other representations.

12 1304. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
13 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the  
14 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
15 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
16 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
17 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
18 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
19 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
20 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
21 decisions to purchase JUUL products.

22 1305. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
23 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
24 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
25 facts; because the facts would be material to reasonable consumers; because JLI actively  
26 concealed them; because JLI intended for consumers to rely on the omissions in question;  
27 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
28 made partial representations concerning the same subject matter as the omitted facts.

1 1306. JLI and the Management Defendants engaged in fraudulent and deceptive  
2 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
3 products were appropriate for minors, when in fact the products never should have been  
4 marketed to minors and are especially harmful to minors due to the potent and addictive  
5 nicotine doses, addictive qualities, and health risks.

6 1307. As alleged above, all Defendants participated and/or facilitated the marketing of  
7 JUUL products to minors and took no action to curb the use of JUUL products by minors.  
8 JUUL has continued the deceptive and misleading practices that Defendants implemented,  
9 facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by  
10 minors continues to rise.

11 1308. Defendants' conduct actually and proximately caused an ascertainable loss and  
12 damages to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct,  
13 Plaintiffs and class members would have behaved differently and would not have purchased  
14 JUUL products or would have paid less for them. Defendants' misrepresentations and omissions  
15 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
16 purchased and enter into purchase contracts they would not otherwise have entered into. In  
17 addition, class members who are minors are entitled to full repayment of the amounts they spent  
18 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
19 injunctive relief (except as to the Management Defendants), actual damages, and punitive  
20 damages, as well as any other relief the Court may deem just or proper.

21 **b. Common Law Fraud**

22 1309. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

23 1310. This claim is brought against JLI.

24 1311. JUUL created and implemented a scheme to create a market for e-cigarettes and  
25 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
26 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
27 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
28 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,

1     addictiveness, and significant risks of substantial physical injury from using JUUL products.

2             1312. Advertisements and representations for JUUL products contained deceptive  
3     statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
4     to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
5     cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
6     not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
7     decades, JLI used third parties and word of mouth to spread false and misleading information  
8     about JUUL products.

9             1313. Advertisements and representations for JUUL products concealed and failed to  
10    disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
11    combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
12    addictive, posed significant risks of substantial physical injury resulting from the use of the  
13    products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
14    consumed through a pack of combustible cigarettes.

15            1314. The labels on JUUL products failed to disclose that the products posed  
16    significant risks of substantial physical injury resulting from the use of the products. The labels  
17    also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

18            1315. The omissions were misleading and deceptive standing alone and were  
19    particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
20    cigarettes and other representations.

21            1316. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
22    omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
23    including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
24    material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
25    devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
26    potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
27    risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
28    consumed through one JUUL pod exceeded the nicotine consumed through a pack of



1 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
2 Plaintiffs' and class members' decisions to purchase JUUL products.

3 1317. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
4 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
5 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
6 facts; because the facts would be material to reasonable consumers; because JUUL products  
7 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
8 representations concerning the same subject matter as the omitted facts.

9 1318. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
10 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
11 and/or omissions. Reasonable consumers would have been expected to have relied on the  
12 misrepresentations and omissions.

13 1319. Defendants knew or should have known that their misrepresentations and/or  
14 omissions were false and misleading, and intended for consumers to rely on such  
15 misrepresentations and omissions.

16 1320. JLI knew that JUUL products were not safe or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
19 products.

20 1321. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
21 class members. Absent JLI's conduct, Plaintiffs and class members would have behaved  
22 differently and would not have purchased JUUL products or would have paid less for them.  
23 JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
24 products they would not otherwise have purchased and enter into purchase contracts they would  
25 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
26 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
27 deem just or proper.  
28

**c. Breach of the Implied Warranty of Merchantability**

1322. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1323. This claim is brought against JLI.

1324. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1325. Each JUUL product sold by JUUL comes with an implied warranty that it will merchantable and fit for the ordinary purpose for which it would be used. Del. Code tit. 6, § 2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1326. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

1327. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

1328. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

1329. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

1330. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

1331. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1332. This claim is brought against JLI and the Management Defendants.

1333. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1334. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly

1 enriched through their scheme of marketing their products to minors. Del. Code tit. 11,  
2 §§ 1116(a) and 1118(a) prohibits the marketing and sale of JUUL products to minors.

3 1335. Defendants requested and received a measurable benefit at the expense of  
4 Plaintiffs and class members in the form of payment for JUUL products.

5 1336. Defendants appreciated, recognized, and chose to accept the monetary benefits  
6 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
7 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

8 1337. There is no justification for Defendants' enrichment. It would be inequitable,  
9 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
10 benefits were procured as a result of their wrongful conduct.

11 1338. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
12 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
13 with Defendant.

14 1339. Plaintiffs plead this claim separately as well as in the alternative to their other  
15 claims, as without such claims they would have no adequate legal remedy.

16 **8. District of Columbia**

17 1340. Plaintiffs bring each of the following claims on behalf of the District of  
18 Columbia Subclass under District of Columbia law.

19 **a. Violation of the D.C. Consumer Protection Procedures Act**  
20 **(D.C. Code § 28-3901, *et seq.*)**

21 1341. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

22 1342. This claim is brought against JLI and, for certain unfair and/or unconscionable  
23 conduct claims as noted below, all Defendants.

24 1343. Defendants are merchants under the statute who furnishes, makes available,  
25 provides information about, or, directly or indirectly, solicits or offers for or effectuates, a lease,  
26 lease or transfer of consumer goods or services.

27 1344. Plaintiffs and class members are consumers who purchased JUUL products for  
28 personal purposes.

1345. Defendants created and implemented a scheme to create a market for e-cigarettes

1 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
2 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
3 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
4 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
5 addictiveness, and significant risks of substantial physical injury from using JUUL products.

6 1346. Advertisements and representations for JUUL products contained deceptive  
7 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
8 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
9 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
10 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
11 decades, JLI used third parties and word of mouth to spread false and misleading information  
12 about JUUL products.

13 1347. Advertisements and representations for JUUL products concealed and failed to  
14 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
15 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
16 addictive, posed significant risks of substantial physical injury resulting from the use of the  
17 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
18 consumed through a pack of combustible cigarettes.

19 1348. The labels on JUUL products failed to disclose that the products posed  
20 significant risks of substantial physical injury resulting from the use of the products. The labels  
21 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

22 1349. The omissions were misleading and deceptive standing alone and were  
23 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
24 cigarettes and other representations.

25 1350. JLI's conduct was unfair trade practice because (i) the manufacture and sale of  
26 products with a heightened propensity to cause addiction and physical injuries and (ii)  
27 misrepresentations and omissions of material facts concerning the characteristics and safety of  
28 JUUL products that offended public policy; were immoral, unethical, oppressive, outrageous,

1 unscrupulous, and substantially injurious; and caused substantial harm that greatly outweighs  
2 any possible utility from the conduct.

3 1351. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
4 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
5 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
6 products are of a particular standard, quality, grade, style, or model, when they are not; (c)  
7 advertising or offering goods or services with intent not to sell them as advertised or offered; (d)  
8 misrepresenting a material fact which has a tendency to mislead; (e) failing to state a material  
9 fact when such failure tends to mislead; and (f) representing that the subject of a transaction has  
10 been supplied in accordance with a previous representation when it has not.

11 1352. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
12 omissions had a tendency to mislead, and in fact did, mislead reasonable consumers including  
13 the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to  
14 their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii)  
15 were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-  
16 delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of  
17 substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
18 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
19 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
20 Plaintiffs' and class members' decisions to purchase JUUL products.

21 1353. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
22 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
23 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
24 facts; because the facts would be material to reasonable consumers; because JLI actively  
25 concealed them; because JLI intended for consumers to rely on the omissions in question;  
26 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
27 made partial representations concerning the same subject matter as the omitted facts.

28 1354. As set forth in the allegations concerning each Plaintiff in Appendix A, in

1 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
2 Reasonable consumers would have been expected to have relied on the misrepresentations and  
3 omissions.

4 1355. Defendants knew or should have known that their misrepresentations and/or  
5 omissions were false and misleading, and intended for consumers to rely on such  
6 misrepresentations and omissions.

7 1356. In addition, all Defendants engaged in unfair and unconscionable conduct  
8 because the targeting of minors offends public policy (in particular D.C. Code § 7-1721.02); is  
9 immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has  
10 caused substantial harm that greatly outweighs any possible utility from the conduct.

11 1357. As alleged above, all Defendants participated and/or facilitated the marketing of  
12 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
13 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
14 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
15 use of JUUL products by minors continues to rise.

16 1358. Defendants' conduct actually and proximately caused actual damages to  
17 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
18 class members would have behaved differently and would not have purchased JUUL products  
19 or would have paid less for them. Defendants' misrepresentations and omissions induced  
20 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
21 purchased and enter into purchase contracts they would not otherwise have entered into. In  
22 addition, class members who are minors are entitled to full repayment of the amounts they spent  
23 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
24 injunctive relief (except as to the Management Defendants), reasonable attorneys' fees,  
25 restitution, \$1,500 per violation, and/ or statutory treble damages, whichever is greater, and  
26 punitive damages, as well as any other relief the Court may deem just or proper.

27 **b. Common Law Fraud**

28 1359. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.



1           1360. This claim is brought against JLI.

2           1361. JUUL created and implemented a scheme to create a market for e-cigarettes and  
3 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8           1362. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15           1363. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21           1364. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24           1365. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27           1366. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
28 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers

1 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
2 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
5 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
6 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
7 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
8 Plaintiffs' and class members' decisions to purchase JUUL products.

9 1367. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JUUL products  
13 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
14 representations concerning the same subject matter as the omitted facts.

15 1368. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
16 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
17 and/or omissions. Reasonable consumers would have been expected to have relied on the  
18 misrepresentations and omissions.

19 1369. Defendants knew or should have known that their misrepresentations and/or  
20 omissions were false and misleading, and intended for consumers to rely on such  
21 misrepresentations and omissions.

22 1370. JLI knew that JUUL products were not safe or reasonable alternatives to  
23 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
24 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
25 products.

26 1371. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
27 class members. Absent JLI's conduct, Plaintiffs and class members would have behaved  
28 differently and would not have purchased JUUL products or would have paid less for them.

JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

1372. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1373. This claim is brought against JLI.

1374. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1375. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. D.C. Code § 28:2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1376. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

1377. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

1378. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

1379. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

1380. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

1381. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1382. This claim is brought against JLI and the Management Defendants.

1383. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1384. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether

JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. D.C. Code § 7-1721.02 prohibits the marketing and sale of JUUL products to minors.

1385. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1386. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1387. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1388. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1389. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **9. Florida**

1390. Plaintiffs bring each of the following claims on behalf of the Florida Subclass under Florida law.

### **a. Violation of the Florida Deceptive and Unfair Trade Practices Act (Fla. Stat. § 501.201, *et seq.*)**

1391. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1392. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

1           1393. Plaintiffs and class members are individuals who purchased JUUL products for  
2 personal purposes.

3           1394. Defendants created and implemented a scheme to create a market for e-cigarettes  
4 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
5 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
6 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
7 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
8 addictiveness, and significant risks of substantial physical injury from using JUUL products.  
9 JUUL made or disseminated misleading advertisements to the general public or to a portion of  
10 the general public.

11           1395. Advertisements and representations for JUUL products contained deceptive  
12 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
13 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
14 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
15 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
16 decades, JLI used third parties and word of mouth to spread false and misleading information  
17 about JUUL products.

18           1396. Advertisements and representations for JUUL products concealed and failed to  
19 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
20 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
21 addictive, posed significant risks of substantial physical injury resulting from the use of the  
22 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
23 consumed through a pack of combustible cigarettes.

24           1397. The labels on JUUL products failed to disclose that the products posed  
25 significant risks of substantial physical injury resulting from the use of the products. The labels  
26 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

27           1398. The omissions were misleading and deceptive standing alone and were  
28 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to

1 cigarettes and other representations.

2 1399. JLI's conduct was unfair and unconscionable in that it included (i) the  
3 manufacture and sale of products with a heightened propensity to cause addiction and physical  
4 injuries and (ii) misrepresentations and omissions of material facts concerning the  
5 characteristics and safety of JUUL products that offended public policy; were immoral,  
6 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
7 substantial harm that greatly outweighs any possible utility from the conduct.

8 1400. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
9 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the  
10 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
11 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
12 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
13 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
14 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
15 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
16 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
17 decisions to purchase JUUL products.

18 1401. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
19 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
20 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
21 facts; because the facts would be material to reasonable consumers; because JLI actively  
22 concealed them; because JLI intended for consumers to rely on the omissions in question;  
23 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
24 made partial representations concerning the same subject matter as the omitted facts.

25 1402. Defendants knew or should have known that their misrepresentations and/or  
26 omissions were false and misleading, and intended for consumers to rely on such  
27 misrepresentations and omissions.

28 1403. JLI and the Management Defendants engaged in fraudulent and deceptive



1 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
2 products were appropriate for minors, when in fact the products never should have been  
3 marketed to minors and are especially harmful to minors due to the potent and addictive  
4 nicotine doses, addictive qualities, and health risks.

5 1404. In addition, all Defendants engaged in unfair and unconscionable conduct  
6 because the targeting of minors offends public policy (in particular Fla. Stat. § 877.112(2)-(3));  
7 is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has  
8 caused substantial harm that greatly outweighs any possible utility from the conduct.

9 1405. As alleged above, all Defendants participated and/or facilitated the marketing of  
10 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
11 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
12 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
13 use of JUUL products by minors continues to rise.

14 1406. Defendants' conduct actually and proximately caused actual damages to  
15 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
16 class members would have behaved differently and would not have purchased JUUL products  
17 or would have paid less for them. Defendants' misrepresentations and omissions induced  
18 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
19 purchased and enter into purchase contracts they would not otherwise have entered into. In  
20 addition, class members who are minors are entitled to full repayment of the amounts they spent  
21 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
22 injunctive relief (except as to the Management Defendants), reasonable attorneys' fees, and  
23 actual damages, as well as any other relief the Court may deem just or proper.

24 **b. Violation of the Florida False Advertising Law (Fla. Stat.**  
25 **§§ 817.06 and 817.41, *et seq.*)**

26 1407. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

27 1408. This claim is brought against JLI and, for certain claims as noted below, the  
28 Management Defendants.

1 1409. Plaintiffs and class members purchased JUUL products for personal purposes.

2 1410. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8 1411. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15 1412. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21 1413. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24 1414. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27 1415. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
28 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the

1 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
2 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
3 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
4 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
5 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
6 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
7 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
8 decisions to purchase JUUL products.

9 1416. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JLI actively  
13 concealed them; because JLI intended for consumers to rely on the omissions in question;  
14 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
15 made partial representations concerning the same subject matter as the omitted facts.

16 1417. JLI and the Management Defendants engaged in fraudulent and deceptive  
17 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
18 products were appropriate for minors, when in fact the products never should have been  
19 marketed to minors and are especially harmful to minors due to the potent and addictive  
20 nicotine doses, addictive qualities, and health risks.

21 1418. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
22 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
23 Reasonable consumers would have been expected to have relied on the misrepresentations and  
24 omissions.

25 1419. Defendants knew or should have known that their misrepresentations and/or  
26 omissions were false and misleading, and intended for consumers to rely on such  
27 misrepresentations and omissions.

28 1420. Defendants' conduct actually and proximately caused actual damages to

1 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
2 class members would have behaved differently and would not have purchased JUUL products  
3 or would have paid less for them. Defendants' misrepresentations and omissions induced  
4 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
5 purchased and enter into purchase contracts they would not otherwise have entered into. In  
6 addition, class members who are minors are entitled to full repayment of the amounts they spent  
7 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
8 actual damages, reasonable attorneys' fees, and punitive damages, as well as any other relief the  
9 Court may deem just or proper.

10 **c. Common Law Fraud**

11 1421. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

12 1422. This claim is brought against JLI.

13 1423. JUUL created and implemented a scheme to create a market for e-cigarettes and  
14 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
15 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
16 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
17 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
18 addictiveness, and significant risks of substantial physical injury from using JUUL products.

19 1424. Advertisements and representations for JUUL products contained deceptive  
20 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
21 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
22 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
23 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
24 decades, JLI used third parties and word of mouth to spread false and misleading information  
25 about JUUL products.

26 1425. Advertisements and representations for JUUL products concealed and failed to  
27 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 1426. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 1427. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes and other representations.

10 1428. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
11 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
12 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
13 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
14 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
15 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
16 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
17 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
18 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
19 Plaintiffs' and class members' decisions to purchase JUUL products.

20 1429. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
21 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
22 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
23 facts; because the facts would be material to reasonable consumers; because JUUL products  
24 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
25 representations concerning the same subject matter as the omitted facts.

26 1430. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
27 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
28 and/or omissions. Reasonable consumers would have been expected to have relied on the

misrepresentations and omissions.

1431. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

1432. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

1433. JLI's conduct actually and proximately caused detriment to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**d. Breach of the Implied Warranty of Merchantability**

1434. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1435. This claim is brought against JLI.

1436. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1437. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. Fla. Stat. § 672.314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1438. The ordinary intended purpose of JUUL's products—and the purpose for which

1 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
2 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
5 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
6 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
7 recreation smoking devices.

8 1439. Plaintiffs and each member of the class have had sufficient direct dealings with  
9 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
10 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
11 each member of the class, on the other hand.

12 1440. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
13 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
14 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
15 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
16 the express purpose an intent of being sold to consumers.

17 1441. Plaintiffs and the members of the class were injured as a direct and proximate  
18 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
19 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
20 because, had they been aware of the unmerchantable condition of JUUL products, they would  
21 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
22 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

23 1442. JUUL was provided notice of these issues by numerous complaints filed against  
24 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
25 individual letters and communications sent by consumers before or within a reasonable amount  
26 of time after they discovered or should have discovered that’s JUUL product were defective and  
27 unmerchantable.  
28



**e. Unjust Enrichment**

1443. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1444. This claim is brought against JLI and the Management Defendants.

1445. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1446. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Fla. Stat. § 877.112(2)-(3) prohibits the marketing and sale of JUUL products to minors.

1447. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1448. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1449. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1450. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained

1 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
2 with Defendant.

3 1451. Plaintiffs plead this claim separately as well as in the alternative to their other  
4 claims, as without such claims they would have no adequate legal remedy.

5 **10. Georgia**

6 1452. Plaintiffs bring each of the following claims on behalf of the Georgia Subclass  
7 under Georgia law.

8 **a. Violation of the Georgia Uniform Deceptive Trade Practices**  
9 **Act (Ga. Code § 10-1-370, et seq.)**

10 1453. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 1454. This claim is brought against JLI and, for certain claims as noted below, the  
12 Management Defendants.

13 1455. Plaintiffs and class members purchased JUUL products for personal purposes.

14 1456. JLI is a “person” as defined by Ga. Code Ann. § 10-1-371.

15 1457. Defendants created and implemented a scheme to create a market for e-cigarettes  
16 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
17 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
18 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
19 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
20 addictiveness, and significant risks of substantial physical injury from using JUUL products.

21 1458. Advertisements and representations for JUUL products contained deceptive  
22 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
23 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
24 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
25 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
26 decades, JLI used third parties and word of mouth to spread false and misleading information  
27 about JUUL products.

28 1459. Advertisements and representations for JUUL products concealed and failed to

1 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
2 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
3 addictive, posed significant risks of substantial physical injury resulting from the use of the  
4 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
5 consumed through a pack of combustible cigarettes.

6 1460. The labels on JUUL products failed to disclose that the products posed  
7 significant risks of substantial physical injury resulting from the use of the products. The labels  
8 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

9 1461. The omissions were misleading and deceptive standing alone and were  
10 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
11 cigarettes and other representations.

12 1462. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
13 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
14 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
15 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
16 model, when they are not; (c) advertising goods or services with intent not to sell them as  
17 advertised; and (d) engaging in other conduct which similarly creates a likelihood of confusion  
18 or of misunderstanding.

19 1463. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
20 omissions at issue were likely to, and in fact did, confuse and mislead reasonable consumers  
21 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
22 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
23 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
24 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
25 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
26 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
27 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
28 Plaintiffs' and class members' decisions to purchase JUUL products.

1           1464. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
2 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
3 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
4 facts; because the facts would be material to reasonable consumers; because JLI actively  
5 concealed them; because JLI intended for consumers to rely on the omissions in question;  
6 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
7 made partial representations concerning the same subject matter as the omitted facts.

8           1465. JLI and the Management Defendants engaged in fraudulent and deceptive  
9 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
10 products were appropriate for minors, when in fact the products never should have been  
11 marketed to minors and are especially harmful to minors due to the potent and addictive  
12 nicotine doses, addictive qualities, and health risks.

13           1466. Defendants' conduct actually and proximately caused actual damages to  
14 Plaintiffs and class members, who are also likely to be damaged in the future on an ongoing  
15 basis in the future. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class  
16 members would have behaved differently and would not have purchased JUUL products or  
17 would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs  
18 and class members to purchase JUUL products they would not otherwise have purchased and  
19 enter into purchase contracts they would not otherwise have entered into. In addition, class  
20 members who are minors are entitled to full repayment of the amounts they spent on JUUL  
21 products. Plaintiffs seek—on behalf of themselves and each member of the class—injunctive  
22 relief (except as to the Management Defendants) and reasonable attorneys' fees, as well as any  
23 other relief the Court may deem just or proper.

24                           **b.       Violation of the Georgia Fair Business Practices Act (Ga.**  
25                           **Code § 10-1-390, *et seq.*)**

26           1467. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

27           1468. This claim is brought against JLI and, for certain unfair and/or unconscionable  
28 conduct claims as noted below, all Defendants.

1 1469. Plaintiffs and class members purchased JUUL products for personal purposes.

2 1470. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8 1471. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15 1472. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21 1473. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24 1474. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27 1475. JLI's conduct was unfair and unconscionable in that it included (i) the  
28 manufacture and sale of products with a heightened propensity to cause addiction and physical

injuries and (ii) misrepresentations and omissions of material facts concerning the characteristics and safety of JUUL products that offended public policy; were immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused substantial harm that greatly outweighs any possible utility from the conduct.

1476. JLI's conduct constituted the following prohibited fraudulent, deceptive, and unfair business practices: (a) misrepresenting that JUUL products have characteristics, ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL products are of a particular standard, quality, or grade, or that goods are of a particular style or model, when they are not; and (c) advertising goods or services with intent not to sell them as advertised.

1477. JLI's conduct was fraudulent and deceptive because the misrepresentations and omissions had the tendency or capacity to deceive, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

1478. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

1479. As set forth in the allegations concerning each Plaintiff in Appendix A, in

1 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
2 Reasonable consumers would have been expected to have relied on the misrepresentations and  
3 omissions.

4 1480. Defendants knew or should have known that their misrepresentations and/or  
5 omissions were false and misleading, and intended for consumers to rely on such  
6 misrepresentations and omissions.

7 1481. JLI and the Management Defendants engaged in fraudulent and deceptive  
8 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
9 products were appropriate for minors, when in fact the products never should have been  
10 marketed to minors and are especially harmful to minors due to the potent and addictive  
11 nicotine doses, addictive qualities, and health risks.

12 1482. In addition, all Defendants engaged in unfair and unconscionable conduct  
13 because the targeting of minors offends public policy (in particular Ga. Code § 16-12-  
14 171(a)(1)(A)); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
15 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
16 conduct.

17 1483. As alleged above, all Defendants participated and/or facilitated the marketing of  
18 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
19 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
20 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
21 use of JUUL products by minors continues to rise.

22 1484. Defendants' conduct actually and proximately caused injury or damages to  
23 Plaintiffs and class members as a result of consumer acts or practices in violation of the statute.  
24 Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have  
25 behaved differently and would not have purchased JUUL products or would have paid less for  
26 them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to  
27 purchase JUUL products they would not otherwise have purchased and enter into purchase  
28 contracts they would not otherwise have entered into. In addition, class members who are



1 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
2 seek—on behalf of themselves and each member of the class—injunctive relief (except as to the  
3 Management Defendants), reasonable attorneys’ fees, general damages and/ or statutory  
4 damages in the amount of three times actual damages, whichever is greater, and punitive  
5 damages, as well as any other relief the Court may deem just or proper.

6 1485. Plaintiffs have complied or substantially complied with all applicable notice  
7 requirements, or are otherwise excused from compliance because Defendants do not maintain a  
8 place of business in and/ or does not keep assets within the state of Georgia.

9 **c. Common Law Fraud**

10 1486. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 1487. This claim is brought against JLI.

12 1488. JUUL created and implemented a scheme to create a market for e-cigarettes and  
13 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
14 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
15 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
16 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
17 addictiveness, and significant risks of substantial physical injury from using JUUL products.

18 1489. Advertisements and representations for JUUL products contained deceptive  
19 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
20 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
21 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
22 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
23 decades, JLI used third parties and word of mouth to spread false and misleading information  
24 about JUUL products.

25 1490. Advertisements and representations for JUUL products concealed and failed to  
26 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
27 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
28 addictive, posed significant risks of substantial physical injury resulting from the use of the

1 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
2 consumed through a pack of combustible cigarettes.

3 1491. The labels on JUUL products failed to disclose that the products posed  
4 significant risks of substantial physical injury resulting from the use of the products. The labels  
5 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

6 1492. The omissions were misleading and deceptive standing alone and were  
7 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
8 cigarettes and other representations.

9 1493. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
10 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
11 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
12 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
13 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
14 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
15 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
16 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
17 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
18 Plaintiffs' and class members' decisions to purchase JUUL products.

19 1494. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
20 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
21 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
22 facts; because the facts would be material to reasonable consumers; because JUUL products  
23 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
24 representations concerning the same subject matter as the omitted facts.

25 1495. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
26 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
27 and/or omissions. Reasonable consumers would have been expected to have relied on the  
28 misrepresentations and omissions.

1 1496. Defendants knew or should have known that their misrepresentations and/or  
 2 omissions were false and misleading, and intended for consumers to rely on such  
 3 misrepresentations and omissions.

4 1497. JLI knew that JUUL products were not safe or reasonable alternatives to  
 5 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
 6 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
 7 products.

8 1498. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
 9 class members. Absent JLI's conduct, Plaintiffs and class members would have behaved  
 10 differently and would not have purchased JUUL products or would have paid less for them.  
 11 JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
 12 products they would not otherwise have purchased and enter into purchase contracts they would  
 13 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
 14 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
 15 deem just or proper.

16 **d. Breach of the Implied Warranty of Merchantability**

17 1499. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

18 1500. This claim is brought against JLI.

19 1501. JUUL has at all times been a merchant with respect to the products which were  
 20 sold to Plaintiff and the class and was in the business of selling such products.

21 1502. Each JUUL product sold by JUUL comes with an implied warranty that it will  
 22 merchantable and fit for the ordinary purpose for which it would be used. Ga. Code § 11-2-314.  
 23 JUUL has breached its implied warranty of merchantability because its products were not in  
 24 merchantable condition when sold, were defective when sold, did not conform to the promises  
 25 and affirmations of fact made on the products' containers or labels, and/or do not possess even  
 26 the most basic degree of fitness for ordinary use.

27 1503. The ordinary intended purpose of JUUL's products—and the purpose for which  
 28 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's

1 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
2 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
3 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
4 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
5 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
6 recreation smoking devices.

7 1504. Plaintiffs and each member of the class have had sufficient direct dealings with  
8 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
9 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
10 each member of the class, on the other hand.

11 1505. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
12 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
13 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
14 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
15 the express purpose an intent of being sold to consumers.

16 1506. Plaintiffs and the members of the class were injured as a direct and proximate  
17 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
18 the Georgia Direct Purchaser Subclass were damaged as a result of JUUL’s breach of its  
19 implied warranty of merchantability because, had they been aware of the unmerchantable  
20 condition of JUUL products, they would not have purchased JUUL products, or would have  
21 paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any  
22 other relief the Court may deem just or proper.

23 1507. JUUL was provided notice of these issues by numerous complaints filed against  
24 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
25 individual letters and communications sent by consumers before or within a reasonable amount  
26 of time after they discovered or should have discovered that’s JUUL product were defective and  
27 unmerchantable.  
28

**e. Unjust Enrichment**

1508. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1509. This claim is brought against JLI and the Management Defendants.

1510. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1511. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Ga. Code § 16-12-171(a)(1)(A) prohibits the marketing and sale of JUUL products to minors.

1512. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1513. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1514. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1515. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained

1 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
2 with Defendant.

3 1516. Plaintiffs plead this claim separately as well as in the alternative to their other  
4 claims, as without such claims they would have no adequate legal remedy.

5 **11. Hawaii**

6 1517. Plaintiffs bring each of the following claims on behalf of the Hawaii Subclass  
7 under Hawaii law.

8 **a. Violation of the Hawaii Unfair and Deceptive Trade Practices**  
9 **Act (Haw. Rev. Stat. § 480-1, et seq.)**

10 1518. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 1519. This claim is brought against JLI and, for certain unfair and/or unconscionable  
12 conduct claims as noted below, all Defendants.

13 1520. Plaintiffs and class members are consumers who purchased JUUL products for  
14 personal purposes.

15 1521. Defendants created and implemented a scheme to create a market for e-cigarettes  
16 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
17 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
18 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
19 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
20 addictiveness, and significant risks of substantial physical injury from using JUUL products.

21 1522. Advertisements and representations for JUUL products contained deceptive  
22 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
23 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
24 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
25 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
26 decades, JLI used third parties and word of mouth to spread false and misleading information  
27 about JUUL products.

28 1523. Advertisements and representations for JUUL products concealed and failed to

1 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
2 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
3 addictive, posed significant risks of substantial physical injury resulting from the use of the  
4 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
5 consumed through a pack of combustible cigarettes.

6 1524. The labels on JUUL products failed to disclose that the products posed  
7 significant risks of substantial physical injury resulting from the use of the products. The labels  
8 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

9 1525. The omissions were misleading and deceptive standing alone and were  
10 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
11 cigarettes and other representations.

12 1526. JLI's conduct was unfair and unconscionable in that it included (i) the  
13 manufacture and sale of products with a heightened propensity to cause addiction and physical  
14 injuries and (ii) misrepresentations and omissions of material facts concerning the  
15 characteristics and safety of JUUL products that offended public policy; were immoral,  
16 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
17 substantial harm that greatly outweighs any possible utility from the conduct.

18 1527. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
19 omissions had the capacity or tendency to mislead or deceive, and in fact did, mislead or  
20 deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the  
21 Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i)  
22 were not smoking cessation devices, (ii) were not reasonable alternatives to combustible  
23 cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully  
24 addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the  
25 products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine  
26 consumed through a pack of combustible cigarettes. Knowledge of these facts would have been  
27 a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

28 1528. JLI owed Plaintiffs and class members a duty to disclose these facts because they



1 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
2 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
3 facts; because the facts would be material to reasonable consumers; because JLI actively  
4 concealed them; because JLI intended for consumers to rely on the omissions in question;  
5 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
6 made partial representations concerning the same subject matter as the omitted facts.

7 1529. Defendants knew or should have known that their misrepresentations and/or  
8 omissions were false and misleading, and intended for consumers to rely on such  
9 misrepresentations and omissions.

10 1530. In addition, all Defendants engaged in unfair and unconscionable conduct  
11 because the targeting of minors offends public policy (in particular Haw. Rev. Stat. §§ 712-  
12 1258(1) and 245-17(a)); is immoral, unethical, oppressive, outrageous, unscrupulous, and  
13 substantially injurious; and has caused substantial harm that greatly outweighs any possible  
14 utility from the conduct.

15 1531. As alleged above, all Defendants participated and/or facilitated the marketing of  
16 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
17 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
18 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
19 use of JUUL products by minors continues to rise.

20 1532. Defendants' conduct actually and proximately caused actual damages to  
21 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
22 class members would have behaved differently and would not have purchased JUUL products  
23 or would have paid less for them. Defendants' misrepresentations and omissions induced  
24 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
25 purchased and enter into purchase contracts they would not otherwise have entered into. In  
26 addition, class members who are minors are entitled to full repayment of the amounts they spent  
27 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
28 injunctive relief (except as to the Management Defendants), reasonable attorneys' fees, actual

1 damages not less than \$1,000 as provided by the statute and/ or statutory damages in the amount  
 2 of threefold the damages sustained, whichever is greater, and punitive damages, as well as any  
 3 other relief the Court may deem just or proper.

4 **b. Violation of the Hawaii Uniform Deceptive Trade Practice Act**  
 5 **(Haw. Rev. Stat. § 481A-1, *et seq.*)**

6 1533. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

7 1534. This claim is brought against JLI and, for certain claims as noted below, the  
 8 Management Defendants.

9 1535. Plaintiffs and class members purchased JUUL products for personal purposes.

10 1536. JLI is a “person” as defined in Haw. Rev. Stat. § 481A-2.

11 1537. Defendants created and implemented a scheme to create a market for e-cigarettes  
 12 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
 13 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
 14 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
 15 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
 16 addictiveness, and significant risks of substantial physical injury from using JUUL products.

17 1538. Advertisements and representations for JUUL products contained deceptive  
 18 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
 19 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
 20 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
 21 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
 22 decades, JLI used third parties and word of mouth to spread false and misleading information  
 23 about JUUL products.

24 1539. Advertisements and representations for JUUL products concealed and failed to  
 25 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
 26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
 27 addictive, posed significant risks of substantial physical injury resulting from the use of the  
 28 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine

1 consumed through a pack of combustible cigarettes.

2 1540. The labels on JUUL products failed to disclose that the products posed  
3 significant risks of substantial physical injury resulting from the use of the products. The labels  
4 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

5 1541. The omissions were misleading and deceptive standing alone and were  
6 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
7 cigarettes and other representations.

8 1542. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
9 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
10 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
11 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
12 model, when they are not; (c) advertising goods or services with intent not to sell them as  
13 advertised; and (d) engaging in other conduct which similarly creates a likelihood of confusion  
14 or of misunderstanding.

15 1543. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
16 omissions at issue were likely to, and in fact did, confuse and mislead reasonable consumers  
17 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
18 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
19 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
20 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
21 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
22 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
23 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
24 Plaintiffs' and class members' decisions to purchase JUUL products.

25 1544. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
26 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
27 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
28 facts; because the facts would be material to reasonable consumers; because JLI actively

1 concealed them; because JLI intended for consumers to rely on the omissions in question;  
2 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
3 made partial representations concerning the same subject matter as the omitted facts.

4 1545. JLI and the Management Defendants engaged in fraudulent and deceptive  
5 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
6 products were appropriate for minors, when in fact the products never should have been  
7 marketed to minors and are especially harmful to minors due to the potent and addictive  
8 nicotine doses, addictive qualities, and health risks.

9 1546. Defendants' conduct actually and proximately caused actual damages to  
10 Plaintiffs and class members, and Plaintiffs and class members are likely to be damaged on an  
11 ongoing basis and in the future. Absent Defendants' unfair and fraudulent conduct, Plaintiffs  
12 and class members would have behaved differently and would not have purchased JUUL  
13 products or would have paid less for them. Defendants' misrepresentations and omissions  
14 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
15 purchased and enter into purchase contracts they would not otherwise have entered into. In  
16 addition, class members who are minors are entitled to full repayment of the amounts they spent  
17 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
18 injunctive relief (except as to the Management Defendants) and reasonable attorneys' fees, as  
19 well as any other relief the Court may deem just or proper.

20 **c. Common Law Fraud**

21 1547. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

22 1548. This claim is brought against JLI.

23 1549. JUUL created and implemented a scheme to create a market for e-cigarettes and  
24 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
25 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
26 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
27 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
28 addictiveness, and significant risks of substantial physical injury from using JUUL products.

1           1550. Advertisements and representations for JUUL products contained deceptive  
2 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
3 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
4 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
5 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
6 decades, JLI used third parties and word of mouth to spread false and misleading information  
7 about JUUL products.

8           1551. Advertisements and representations for JUUL products concealed and failed to  
9 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
10 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
11 addictive, posed significant risks of substantial physical injury resulting from the use of the  
12 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
13 consumed through a pack of combustible cigarettes.

14           1552. The labels on JUUL products failed to disclose that the products posed  
15 significant risks of substantial physical injury resulting from the use of the products. The labels  
16 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

17           1553. The omissions were misleading and deceptive standing alone and were  
18 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
19 cigarettes and other representations.

20           1554. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
21 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
22 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
23 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
24 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
25 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
26 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
27 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
28 combustible cigarettes. Knowledge of these facts would have been a substantial factor in

1 Plaintiffs' and class members' decisions to purchase JUUL products.

2 1555. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
3 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
4 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
5 facts; because the facts would be material to reasonable consumers; because JUUL products  
6 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
7 representations concerning the same subject matter as the omitted facts.

8 1556. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
9 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
10 and/or omissions. Reasonable consumers would have been expected to have relied on the  
11 misrepresentations and omissions.

12 1557. Defendants knew or should have known that their misrepresentations and/or  
13 omissions were false and misleading, and intended for consumers to rely on such  
14 misrepresentations and omissions.

15 1558. JLI knew that JUUL products were not safe or reasonable alternatives to  
16 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
17 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
18 products.

19 1559. JLI's conduct actually and proximately caused detriment to Plaintiffs and class  
20 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
21 and would not have purchased JUUL products or would have paid less for them. JLI's  
22 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
23 products they would not otherwise have purchased and enter into purchase contracts they would  
24 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
25 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
26 deem just or proper.

27 **d. Breach of the Implied Warranty of Merchantability**

28 1560. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           1561. This claim is brought against JLI.

2           1562. JUUL has at all times been a merchant with respect to the products which were  
3 sold to Plaintiff and the class and was in the business of selling such products.

4           1563. Each JUUL product sold by JUUL comes with an implied warranty that it will  
5 merchantable and fit for the ordinary purpose for which it would be used. Haw. Rev. Stat.  
6 § 490:2-314. JUUL has breached its implied warranty of merchantability because its products  
7 were not in merchantable condition when sold, were defective when sold, did not conform to the  
8 promises and affirmations of fact made on the products' containers or labels, and/or do not  
9 possess even the most basic degree of fitness for ordinary use.

10           1564. The ordinary intended purpose of JUUL's products—and the purpose for which  
11 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
12 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
13 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
14 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
15 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
16 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
17 recreation smoking devices.

18           1565. Plaintiffs and each member of the class have had sufficient direct dealings with  
19 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
20 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
21 each member of the class, on the other hand.

22           1566. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
23 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
24 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
25 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
26 the express purpose an intent of being sold to consumers.

27           1567. Plaintiffs and the members of the class were injured as a direct and proximate  
28 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of



1 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
2 because, had they been aware of the unmerchantable condition of JUUL products, they would  
3 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
4 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

5 1568. JUUL was provided notice of these issues by numerous complaints filed against  
6 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
7 individual letters and communications sent by consumers before or within a reasonable amount  
8 of time after they discovered or should have discovered that's JUUL product were defective and  
9 unmerchantable.

10 **e. Unjust Enrichment**

11 1569. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

12 1570. This claim is brought against JLI and the Management Defendants.

13 1571. Defendants created and implemented a scheme to create a market for e-cigarettes  
14 and substantially increase sales of JUUL products through a pervasive pattern of false and  
15 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
16 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
17 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
18 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
19 products.

20 1572. Defendants were unjustly enriched as a result of their wrongful conduct,  
21 including through the false and misleading advertisements and omissions regarding (i) whether  
22 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
23 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
24 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
25 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
26 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
27 enriched through their scheme of marketing their products to minors. Haw. Rev. Stat. §§ 712-  
28 1258(1) and 245-17(a) prohibits the marketing and sale of JUUL products to minors.

1573. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1574. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1575. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1576. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1577. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **12. Idaho**

1578. Plaintiffs bring each of the following claims on behalf of the Idaho Subclass under Idaho law.

### **a. Violation of the Idaho Consumer Protection Act (Idaho Code § 48-601, *et seq.*)**

1579. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1580. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

1581. Plaintiffs and class members are persons who purchased JUUL products for personal purposes.

1582. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,

1     addictiveness, and significant risks of substantial physical injury from using JUUL products.

2             1583. Advertisements and representations for JUUL products contained deceptive  
3     statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
4     to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
5     cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
6     not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
7     decades, JLI used third parties and word of mouth to spread false and misleading information  
8     about JUUL products.

9             1584. Advertisements and representations for JUUL products concealed and failed to  
10    disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
11    combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
12    addictive, posed significant risks of substantial physical injury resulting from the use of the  
13    products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
14    consumed through a pack of combustible cigarettes.

15            1585. The labels on JUUL products failed to disclose that the products posed  
16    significant risks of substantial physical injury resulting from the use of the products. The labels  
17    also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

18            1586. The omissions were misleading and deceptive standing alone and were  
19    particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
20    cigarettes and other representations.

21            1587. JLI's conduct was unfair and unconscionable in that it included (i) the  
22    manufacture and sale of products with a heightened propensity to cause addiction and physical  
23    injuries and (ii) misrepresentations and omissions of material facts concerning the  
24    characteristics and safety of JUUL products offended public policy; was immoral, unethical,  
25    oppressive, and unscrupulous; was part of a pattern of sales conduct that would outrage and  
26    offend the public conscience; and caused substantial harm that greatly outweighs any benefits  
27    associated with the conduct.

28            1588. JLI's conduct constituted the following prohibited fraudulent, deceptive, and

1 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
2 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
3 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
4 model, when they are not; (c) advertising goods or services with intent not to sell them as  
5 advertised; (d) engaging in acts or practices which are otherwise misleading, false, or deceptive  
6 to a consumer; and (e) engaging in unconscionable methods, acts, or practices in the conduct of  
7 trade or commerce.

8 1589. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
9 omissions had the tendency or capacity to deceive, and in fact did, deceive reasonable  
10 consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have  
11 found it material to their purchasing decisions that JUUL's products (i) were not smoking  
12 cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were  
13 extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
14 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
15 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
16 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
17 in Plaintiffs' and class members' decisions to purchase JUUL products.

18 1590. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
19 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
20 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
21 facts; because the facts would be material to reasonable consumers; because JLI actively  
22 concealed them; because JLI intended for consumers to rely on the omissions in question;  
23 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
24 made partial representations concerning the same subject matter as the omitted facts.

25 1591. Defendants knew or should have known that their misrepresentations and/or  
26 omissions were false and misleading, and intended for consumers to rely on such  
27 misrepresentations and omissions.

28 1592. JLI and the Management Defendants engaged in fraudulent and deceptive

1 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
2 products were appropriate for minors, when in fact the products never should have been  
3 marketed to minors and are especially harmful to minors due to the potent and addictive  
4 nicotine doses, addictive qualities, and health risks.

5 1593. In addition, all Defendants engaged in unfair and unconscionable conduct  
6 because the targeting of minors offends public policy (in particular Idaho Code §§ 39-5705(1)  
7 and 39-5714(1)); is immoral, unethical, oppressive, and unscrupulous; was part of a pattern of  
8 sales conduct that would outrage and offend the public conscience; took advantage of minor  
9 consumers that are not reasonably able to protect their interests; and has caused substantial harm  
10 that greatly outweighs any benefits associated with the conduct.

11 1594. As alleged above, all Defendants participated and/or facilitated the marketing of  
12 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
13 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
14 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
15 use of JUUL products by minors continues to rise.

16 1595. Defendants' conduct actually and proximately caused an ascertainable loss of  
17 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent  
18 conduct, Plaintiffs and class members would have behaved differently and would not have  
19 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
20 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
21 otherwise have purchased and enter into purchase contracts they would not otherwise have  
22 entered into. In addition, class members who are minors are entitled to full repayment of the  
23 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
24 member of the class—injunctive relief (except as to the Management Defendants), reasonable  
25 attorneys' fees, actual damages, disgorgement, restitution, and/ or statutory damages in the  
26 amount of \$1,000, whichever is greater, and punitive damages, as well as any other relief the  
27 Court may deem just or proper.  
28

**b. Common Law Fraud**

1596. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1597. This claim is brought against JLI.

1598. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1599. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

1600. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

1601. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

1602. The omissions were misleading and deceptive standing alone and were particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to cigarettes and other representations.

1           1603. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
2 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
3 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
4 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
5 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
6 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
7 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
8 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
9 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
10 Plaintiffs' and class members' decisions to purchase JUUL products.

11           1604. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
12 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
13 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
14 facts; because the facts would be material to reasonable consumers; because JUUL products  
15 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
16 representations concerning the same subject matter as the omitted facts.

17           1605. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
18 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
19 and/or omissions. Reasonable consumers would have been expected to have relied on the  
20 misrepresentations and omissions.

21           1606. Defendants knew or should have known that their misrepresentations and/or  
22 omissions were false and misleading, and intended for consumers to rely on such  
23 misrepresentations and omissions.

24           1607. JLI knew that JUUL products were not safe or reasonable alternatives to  
25 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
26 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
27 products.

28           1608. JLI's conduct actually and proximately caused injury to Plaintiffs and class



1 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
2 and would not have purchased JUUL products or would have paid less for them. JLI's  
3 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
4 products they would not otherwise have purchased and enter into purchase contracts they would  
5 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
6 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
7 deem just or proper.

8 **c. Breach of the Implied Warranty of Merchantability**

9 1609. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 1610. This claim is brought against JLI.

11 1611. JUUL has at all times been a merchant with respect to the products which were  
12 sold to Plaintiff and the class and was in the business of selling such products.

13 1612. Each JUUL product sold by JUUL comes with an implied warranty that it will  
14 merchantable and fit for the ordinary purpose for which it would be used. Idaho Code § 28-2-  
15 314. JUUL has breached its implied warranty of merchantability because its products were not  
16 in merchantable condition when sold, were defective when sold, did not conform to the  
17 promises and affirmations of fact made on the products' containers or labels, and/or do not  
18 possess even the most basic degree of fitness for ordinary use.

19 1613. The ordinary intended purpose of JUUL's products—and the purpose for which  
20 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
21 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
22 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
23 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
24 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
25 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
26 recreation smoking devices.

27 1614. Plaintiffs and each member of the class have had sufficient direct dealings with  
28 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized

1 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
2 each member of the class, on the other hand.

3 1615. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
4 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
5 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
6 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
7 the express purpose an intent of being sold to consumers.

8 1616. Plaintiffs and the members of the class were injured as a direct and proximate  
9 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
10 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
11 because, had they been aware of the unmerchantable condition of JUUL products, they would  
12 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
13 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

14 1617. JUUL was provided notice of these issues by numerous complaints filed against  
15 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
16 individual letters and communications sent by consumers before or within a reasonable amount  
17 of time after they discovered or should have discovered that's JUUL product were defective and  
18 unmerchantable.

19 **d. Unjust Enrichment**

20 1618. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

21 1619. This claim is brought against JLI and the Management Defendants.

22 1620. Defendants created and implemented a scheme to create a market for e-cigarettes  
23 and substantially increase sales of JUUL products through a pervasive pattern of false and  
24 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
25 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
26 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
27 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
28 products.

1621. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Idaho Code §§ 39-5705(1) and 39-5714(1) prohibits the marketing and sale of JUUL products to minors.

1622. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1623. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1624. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1625. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1626. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

### **13. Illinois**

1627. Plaintiffs bring each of the following claims on behalf of the Illinois Subclass under Illinois law.

#### **a. Violation of the Illinois Consumer Fraud and Deceptive Business Practices Act (815 Ill. Comp. Stat. § 505/1, *et seq.*)**

1628. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           1629. This claim is brought against JLI and, for certain unfair and/or unconscionable  
2 conduct claims as noted below, all Defendants.

3           1630. Plaintiffs and class members are persons who purchased JUUL products for  
4 personal purposes.

5           1631. Defendants, Plaintiffs, and class members are “persons” under the statute.

6           1632. Defendants created and implemented a scheme to create a market for e-cigarettes  
7 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
8 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
9 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
10 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
11 addictiveness, and significant risks of substantial physical injury from using JUUL products.

12           1633. Advertisements and representations for JUUL products contained deceptive  
13 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
14 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
15 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
16 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
17 decades, JLI used third parties and word of mouth to spread false and misleading information  
18 about JUUL products.

19           1634. Advertisements and representations for JUUL products concealed and failed to  
20 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
21 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
22 addictive, posed significant risks of substantial physical injury resulting from the use of the  
23 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
24 consumed through a pack of combustible cigarettes.

25           1635. The labels on JUUL products failed to disclose that the products posed  
26 significant risks of substantial physical injury resulting from the use of the products. The labels  
27 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

28           1636. The omissions were misleading and deceptive standing alone and were

1 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
2 cigarettes and other representations.

3 1637. JLI's conduct was unfair and unconscionable in that it included (i) the  
4 manufacture and sale of products with a heightened propensity to cause addiction and physical  
5 injuries and (ii) misrepresentations and omissions of material facts concerning the  
6 characteristics and safety of JUUL products that offended public policy; were immoral,  
7 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
8 substantial harm that greatly outweighs any possible utility from the conduct.

9 1638. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
10 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
11 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
12 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
13 model, when they are not; (c) advertising goods or services with intent not to sell them as  
14 advertised; and (d) engaging in other conduct which similarly creates a likelihood of confusion  
15 or misunderstanding.

16 1639. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
17 omissions at issue were likely to, and in fact did, cause confusion or misunderstanding to  
18 reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
19 would have found it material to their purchasing decisions that JUUL's products (i) were not  
20 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
21 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
22 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
23 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
24 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
25 in Plaintiffs' and class members' decisions to purchase JUUL products.

26 1640. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
27 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
28 other than Plaintiffs and class members), who had exclusive and superior knowledge of the

1 facts; because the facts would be material to reasonable consumers; because JLI actively  
2 concealed them; because JLI intended for consumers to rely on the omissions in question;  
3 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
4 made partial representations concerning the same subject matter as the omitted facts.

5 1641. Defendants knew or should have known that their misrepresentations and/or  
6 omissions were false and misleading, and intended for consumers to rely on such  
7 misrepresentations and omissions.

8 1642. JLI and the Management Defendants engaged in fraudulent and deceptive  
9 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
10 products were appropriate for minors, when in fact the products never should have been  
11 marketed to minors and are especially harmful to minors due to the potent and addictive  
12 nicotine doses, addictive qualities, and health risks.

13 1643. In addition, all Defendants engaged in unfair and unconscionable conduct  
14 because the targeting of minors offends public policy (in particular 720 Ill. Comp. Stat.  
15 § 675/1.5(b) and 675/1.5(b)(c)(2)); is immoral, unethical, oppressive, outrageous, unscrupulous,  
16 and substantially injurious; and has caused substantial harm that greatly outweighs any possible  
17 utility from the conduct.

18 1644. As alleged above, all Defendants participated and/or facilitated the marketing of  
19 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
20 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
21 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
22 use of JUUL products by minors continues to rise.

23 1645. Defendants' conduct actually and proximately caused actual damages to  
24 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
25 class members would have behaved differently and would not have purchased JUUL products  
26 or would have paid less for them. Defendants' misrepresentations and omissions induced  
27 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
28 purchased and enter into purchase contracts they would not otherwise have entered into. In

1 addition, class members who are minors are entitled to full repayment of the amounts they spent  
2 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
3 injunctive relief (except as to the Management Defendants), reasonable attorneys’ fees, actual  
4 economic damages, and punitive damages, as well as any other relief the Court may deem just  
5 or proper.

6 **b. Common Law Fraud**

7 1646. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 1647. This claim is brought against JLI.

9 1648. JUUL created and implemented a scheme to create a market for e-cigarettes and  
10 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
11 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
12 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
13 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
14 addictiveness, and significant risks of substantial physical injury from using JUUL products.

15 1649. Advertisements and representations for JUUL products contained deceptive  
16 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
17 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
18 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
19 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
20 decades, JLI used third parties and word of mouth to spread false and misleading information  
21 about JUUL products.

22 1650. Advertisements and representations for JUUL products concealed and failed to  
23 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
24 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
25 addictive, posed significant risks of substantial physical injury resulting from the use of the  
26 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
27 consumed through a pack of combustible cigarettes.

28 1651. The labels on JUUL products failed to disclose that the products posed



1 significant risks of substantial physical injury resulting from the use of the products. The labels  
2 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

3 1652. The omissions were misleading and deceptive standing alone and were  
4 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
5 cigarettes and other representations.

6 1653. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
7 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
8 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
9 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
10 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
11 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
12 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
13 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
14 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
15 Plaintiffs' and class members' decisions to purchase JUUL products.

16 1654. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
17 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
18 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
19 facts; because the facts would be material to reasonable consumers; because JUUL products  
20 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
21 representations concerning the same subject matter as the omitted facts.

22 1655. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
23 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
24 and/or omissions. Reasonable consumers would have been expected to have relied on the  
25 misrepresentations and omissions.

26 1656. Defendants knew or should have known that their misrepresentations and/or  
27 omissions were false and misleading, and intended for consumers to rely on such  
28 misrepresentations and omissions.

1 1657. JLI knew that JUUL products were not safe or reasonable alternatives to  
2 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
3 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
4 products.

5 1658. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
6 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
7 and would not have purchased JUUL products or would have paid less for them. JLI's  
8 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
9 products they would not otherwise have purchased and enter into purchase contracts they would  
10 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
11 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
12 deem just or proper.

13 **c. Breach of the Implied Warranty of Merchantability**

14 1659. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

15 1660. This claim is brought against JLI.

16 1661. JUUL has at all times been a merchant with respect to the products which were  
17 sold to Plaintiff and the class and was in the business of selling such products.

18 1662. Each JUUL product sold by JUUL comes with an implied warranty that it will  
19 merchantable and fit for the ordinary purpose for which it would be used. 810 Ill. Comp. Stat.  
20 § 5/2-314. JUUL has breached its implied warranty of merchantability because its products  
21 were not in merchantable condition when sold, were defective when sold, did not conform to the  
22 promises and affirmations of fact made on the products' containers or labels, and/or do not  
23 possess even the most basic degree of fitness for ordinary use.

24 1663. The ordinary intended purpose of JUUL's products—and the purpose for which  
25 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
26 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
27 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
28 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed

1 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
2 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
3 recreation smoking devices.

4 1664. Plaintiffs and each member of the class have had sufficient direct dealings with  
5 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
6 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
7 each member of the class, on the other hand.

8 1665. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
9 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
10 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
11 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
12 the express purpose an intent of being sold to consumers.

13 1666. Plaintiffs and the members of the class were injured as a direct and proximate  
14 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
15 the Illinois Direct Purchaser Subclass were damaged as a result of JUUL's breach of its implied  
16 warranty of merchantability because, had they been aware of the unmerchantable condition of  
17 JUUL products, they would not have purchased JUUL products, or would have paid less for  
18 them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the  
19 Court may deem just or proper.

20 1667. JUUL was provided notice of these issues by numerous complaints filed against  
21 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
22 individual letters and communications sent by consumers before or within a reasonable amount  
23 of time after they discovered or should have discovered that's JUUL product were defective and  
24 unmerchantable.

25 **d. Unjust Enrichment**

26 1668. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

27 1669. This claim is brought against JLI and the Management Defendants.

28 1670. Defendants created and implemented a scheme to create a market for e-cigarettes

1 and substantially increase sales of JUUL products through a pervasive pattern of false and  
2 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
3 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
4 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
5 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
6 products.

7 1671. Defendants were unjustly enriched as a result of their wrongful conduct,  
8 including through the false and misleading advertisements and omissions regarding (i) whether  
9 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
10 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
11 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
12 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
13 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
14 enriched through their scheme of marketing their products to minors. 720 Ill. Comp. Stat.  
15 § 675/1(a) and 675/1(b)(2) prohibits the marketing and sale of JUUL products to minors.

16 1672. Defendants requested and received a measurable benefit at the expense of  
17 Plaintiffs and class members in the form of payment for JUUL products.

18 1673. Defendants appreciated, recognized, and chose to accept the monetary benefits  
19 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
20 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

21 1674. There is no justification for Defendants' enrichment. It would be inequitable,  
22 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
23 benefits were procured as a result of their wrongful conduct.

24 1675. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
25 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
26 with Defendant.

27 1676. Plaintiffs plead this claim separately as well as in the alternative to their other  
28 claims, as without such claims they would have no adequate legal remedy.

1                   **14.     Indiana**

2                   1677. Plaintiffs bring each of the following claims on behalf of the Indiana Subclass  
3 under Indiana law.

4                               **a.     Violation of Indiana’s Deceptive Consumer Sales Act (Ind.  
5                               Code §§ 24-5-0.5-1, *et seq.*).**

6                   1678. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

7                   1679. This claim is brought against JLI and, for certain unfair and/or unconscionable  
8 conduct claims as noted below, all Defendants.

9                   1680. Defendants are “suppliers” as that term is defined in Indiana’s Deceptive  
10 Consumer Sales Act. Defendants engaged in incurable deceptive acts as set forth herein.

11                  1681. Plaintiffs and class members are individual consumers who purchased JUUL  
12 products for personal purposes.

13                  1682. Defendants created and implemented a scheme to create a market for e-cigarettes  
14 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
15 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
16 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
17 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
18 addictiveness, and significant risks of substantial physical injury from using JUUL products.

19                  1683. Advertisements and representations for JUUL products contained deceptive  
20 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
21 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
22 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
23 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
24 decades, JLI used third parties and word of mouth to spread false and misleading information  
25 about JUUL products.

26                  1684. Advertisements and representations for JUUL products concealed and failed to  
27 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 1685. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 1686. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes and other representations.

10 1687. JLI's conduct was unfair and unconscionable in that it included (i) the  
11 manufacture and sale of products with a heightened propensity to cause addiction and physical  
12 injuries and (ii) misrepresentations and omissions of material facts concerning the  
13 characteristics and safety of JUUL products that offended public policy; were immoral,  
14 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
15 substantial harm that greatly outweighs any possible utility from the conduct.

16 1688. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
17 unfair business practices: (a) misrepresenting that JUUL products have characteristics, uses, or  
18 benefits they do not have, which JUUL knows or reasonably should know they do not have; (b)  
19 misrepresenting that JUUL products are of a particular standard, quality, or grade, or that goods  
20 are of a particular style or model, when they are not, and JUUL knows or reasonably should  
21 know they are not; and (c) advertising goods or services with intent not to sell them as  
22 advertised.

23 1689. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
24 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the  
25 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
26 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
27 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
28 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily

1 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
2 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
3 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
4 decisions to purchase JUUL products.

5 1690. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
6 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
7 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
8 facts; because the facts would be material to reasonable consumers; because JLI actively  
9 concealed them; because JLI intended for consumers to rely on the omissions in question;  
10 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
11 made partial representations concerning the same subject matter as the omitted facts.

12 1691. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
13 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
14 Reasonable consumers would have been expected to have relied on the misrepresentations and  
15 omissions.

16 1692. Defendants knew or should have known that their misrepresentations and/or  
17 omissions were false and misleading, and intended for consumers to rely on such  
18 misrepresentations and omissions.

19 1693. JLI and the Management Defendants engaged in fraudulent and deceptive  
20 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
21 products were appropriate for minors, when in fact the products never should have been  
22 marketed to minors and are especially harmful to minors due to the potent and addictive  
23 nicotine doses, addictive qualities, and health risks.

24 1694. In addition, all Defendants engaged in unfair and unconscionable conduct  
25 because the targeting of minors offends public policy (*see, e.g.*, Ind. Code §§ 35-46-1-10(a); 35-  
26 46-1-10.2(a); 7.1-7-5.5-1; 7.1-7-5.5-2); is immoral, unethical, oppressive, outrageous,  
27 unscrupulous, and substantially injurious; and has caused substantial harm that greatly  
28 outweighs any possible utility from the conduct.



1 1695. As alleged above, all Defendants participated and/or facilitated the marketing of  
2 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
3 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
4 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
5 use of JUUL products by minors continues to rise.

6 1696. Defendants' conduct was incurable because it was done as part of a scheme with  
7 the intent to defraud, mislead, and engage in unfair business practices.

8 1697. Defendants' conduct actually and proximately caused actual damages to  
9 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
10 class members would have behaved differently and would not have purchased JUUL products  
11 or would have paid less for them. Defendants' misrepresentations and omissions induced  
12 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
13 purchased and enter into purchase contracts they would not otherwise have entered into. In  
14 addition, class members who are minors are entitled to full repayment of the amounts they spent  
15 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
16 actual damages and/or statutory damages in the amount of \$500, whichever is greater; punitive  
17 damages because Defendants' deceptive acts were willful; restitution; and attorney's fees; as  
18 well as any other relief the Court may deem just or proper.

19 1698. Plaintiffs have complied or substantially complied with all applicable notice  
20 requirements.

21 **b. Common Law Fraud**

22 1699. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

23 1700. This claim is brought against JLI.

24 1701. JUUL created and implemented a scheme to create a market for e-cigarettes and  
25 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
26 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
27 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
28 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,

1 addictiveness, and significant risks of substantial physical injury from using JUUL products.

2 1702. Advertisements and representations for JUUL products contained deceptive  
3 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
4 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
5 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
6 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
7 decades, JLI used third parties and word of mouth to spread false and misleading information  
8 about JUUL products.

9 1703. Advertisements and representations for JUUL products concealed and failed to  
10 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
11 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
12 addictive, posed significant risks of substantial physical injury resulting from the use of the  
13 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
14 consumed through a pack of combustible cigarettes.

15 1704. The labels on JUUL products failed to disclose that the products posed  
16 significant risks of substantial physical injury resulting from the use of the products. The labels  
17 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

18 1705. The omissions were misleading and deceptive standing alone and were  
19 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
20 cigarettes and other representations.

21 1706. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
22 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
23 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
24 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
25 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
26 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
27 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
28 consumed through one JUUL pod exceeded the nicotine consumed through a pack of

1 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
2 Plaintiffs' and class members' decisions to purchase JUUL products.

3 1707. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
4 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
5 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
6 facts; because the facts would be material to reasonable consumers; because JUUL products  
7 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
8 representations concerning the same subject matter as the omitted facts.

9 1708. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
10 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
11 and/or omissions. Reasonable consumers would have been expected to have relied on the  
12 misrepresentations and omissions.

13 1709. Defendants knew or should have known that their misrepresentations and/or  
14 omissions were false and misleading, and intended for consumers to rely on such  
15 misrepresentations and omissions.

16 1710. JLI knew that JUUL products were not safe or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
19 products.

20 1711. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
21 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
22 and would not have purchased JUUL products or would have paid less for them. JLI's  
23 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
24 products they would not otherwise have purchased and enter into purchase contracts they would  
25 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
26 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
27 relief the Court may deem just or proper.  
28

**c. Breach of the Implied Warranty of Merchantability**

1712. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1713. This claim is brought against JLI.

1714. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1715. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. *See* Ind. Code § 26-1-2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1716. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

1717. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

1718. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose and intent of being sold to consumers.

1719. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

1720. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

1721. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1722. This claim is brought against JLI and the Management Defendants.

1723. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1724. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly

enriched through their scheme of marketing their products to minors. Indiana law (*see* Ind. Code §§ 35-46-1-10(a); 35-46-1-10.2(a); 7.1-7-5.5-1; 7.1-7-5.5-2) prohibits the marketing and sale of JUUL products to minors.

1725. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1726. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1727. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1728. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1729. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **15. Iowa**

1730. Plaintiffs bring each of the following claims on behalf of the Iowa Subclass under Iowa law.

### **a. Violation of the Iowa Consumer Fraud Act (Iowa Code § 714H.1, *et seq.*)**

1731. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1732. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

1733. Plaintiffs and class members purchased JUUL products for personal purposes.

1734. Defendants are "persons" under the statute.

1735. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading

1 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
2 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
3 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
4 addictiveness, and significant risks of substantial physical injury from using JUUL products.

5 1736. Advertisements and representations for JUUL products contained deceptive  
6 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
7 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
8 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
9 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
10 decades, JLI used third parties and word of mouth to spread false and misleading information  
11 about JUUL products.

12 1737. Advertisements and representations for JUUL products concealed and failed to  
13 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
14 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
15 addictive, posed significant risks of substantial physical injury resulting from the use of the  
16 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
17 consumed through a pack of combustible cigarettes.

18 1738. The labels on JUUL products failed to disclose that the products posed  
19 significant risks of substantial physical injury resulting from the use of the products. The labels  
20 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

21 1739. The omissions were misleading and deceptive standing alone and were  
22 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
23 cigarettes and other representations.

24 1740. JLI's conduct was unfair and unconscionable in that it included (i) the  
25 manufacture and sale of products with a heightened propensity to cause addiction and physical  
26 injuries and (ii) misrepresentations and omissions of material facts concerning the  
27 characteristics and safety of JUUL products that offended public policy; were immoral,  
28 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused



1 substantial harm that greatly outweighs any possible utility from the conduct.

2 1741. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
3 omissions at issue were likely to, and in fact did, deceive ordinary and/or reasonable consumers  
4 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
5 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
6 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
7 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
8 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
9 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
10 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
11 Plaintiffs' and class members' decisions to purchase JUUL products.

12 1742. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
13 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
14 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
15 facts; because the facts would be material to reasonable consumers; because JLI actively  
16 concealed them; because JLI intended for consumers to rely on the omissions in question;  
17 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
18 made partial representations concerning the same subject matter as the omitted facts.

19 1743. JUUL knew or reasonably should have known that its misrepresentations and/or  
20 omissions were false and misleading, and intended for consumers to rely on such  
21 misrepresentations and omissions.

22 1744. JLI and the Management Defendants engaged in fraudulent and deceptive  
23 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
24 products were appropriate for minors, when in fact the products never should have been  
25 marketed to minors and are especially harmful to minors due to the potent and addictive  
26 nicotine doses, addictive qualities, and health risks.

27 1745. In addition, all Defendants engaged in unfair and unconscionable conduct  
28 because the targeting of minors offends public policy (*see, e.g.*, Iowa Code Ann. § 453A.2) is

1 immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has  
2 caused substantial harm that greatly outweighs any possible utility from the conduct.

3 1746. As alleged above, all Defendants participated and/or facilitated the marketing of  
4 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
5 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
6 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
7 use of JUUL products by minors continues to rise.

8 1747. Defendants' conduct actually and proximately caused an ascertainable loss of  
9 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent  
10 conduct, Plaintiffs and class members would have behaved differently and would not have  
11 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
12 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
13 otherwise have purchased and enter into purchase contracts they would not otherwise have  
14 entered into. In addition, class members who are minors are entitled to full repayment of the  
15 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
16 member of the class—actual damages, statutory damages up to three times actual damages  
17 because Defendants' conduct represented a willful and wanton disregard for the safety of  
18 Plaintiffs, attorney's fees, and equitable relief, as well as any other relief the Court may deem  
19 just or proper.

20 **b. Common Law Fraud**

21 1748. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

22 1749. This claim is brought against JLI.

23 1750. JUUL created and implemented a scheme to create a market for e-cigarettes and  
24 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
25 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
26 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
27 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
28 addictiveness, and significant risks of substantial physical injury from using JUUL products.

1 1751. Advertisements and representations for JUUL products contained deceptive  
2 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
3 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
4 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
5 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
6 decades, JLI used third parties and word of mouth to spread false and misleading information  
7 about JUUL products.

8 1752. Advertisements and representations for JUUL products concealed and failed to  
9 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
10 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
11 addictive, posed significant risks of substantial physical injury resulting from the use of the  
12 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
13 consumed through a pack of combustible cigarettes.

14 1753. The labels on JUUL products failed to disclose that the products posed  
15 significant risks of substantial physical injury resulting from the use of the products. The labels  
16 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

17 1754. The omissions were misleading and deceptive standing alone and were  
18 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
19 cigarettes and other representations.

20 1755. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
21 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
22 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
23 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
24 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
25 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
26 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
27 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
28 combustible cigarettes. Knowledge of these facts would have been a substantial factor in

1 Plaintiffs' and class members' decisions to purchase JUUL products.

2 1756. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
3 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
4 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
5 facts; because the facts would be material to reasonable consumers; because JUUL products  
6 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
7 representations concerning the same subject matter as the omitted facts.

8 1757. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
9 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
10 and/or omissions. Reasonable consumers would have been expected to have relied on the  
11 misrepresentations and omissions.

12 1758. Defendants knew or should have known that their misrepresentations and/or  
13 omissions were false and misleading, and intended for consumers to rely on such  
14 misrepresentations and omissions.

15 1759. JLI knew that JUUL products were not safe or reasonable alternatives to  
16 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
17 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
18 products.

19 1760. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
20 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
21 and would not have purchased JUUL products or would have paid less for them. JLI's  
22 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
23 products they would not otherwise have purchased and enter into purchase contracts they would  
24 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
25 class, compensatory damages in an amount to be proven at trial and punitive damages, as well  
26 as any other relief the Court may deem just or proper.

27 **c. Breach of the Implied Warranty of Merchantability**

28 1761. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1762. This claim is brought against JLI.

1763. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1764. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. *See* Iowa Code Ann. § 554.2314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

1765. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

1766. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

1767. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose and intent of being sold to consumers.

1768. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of

the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

1769. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

1770. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1771. This claim is brought against JLI and the Management Defendants.

1772. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1773. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Iowa law (Iowa Code Ann. § 453A.2) prohibits the marketing and sale of JUUL products to minors.

1774. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1775. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1776. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1777. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1778. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

#### **16. Kansas**

1779. Plaintiffs bring each of the following claims on behalf of the Kansas Subclass under Kansas law.

##### **a. Violation of Kansas Consumer Protection Act (Kan. Stat. Ann. § 50-623, *et seq.*)**

1780. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1781. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

1782. Defendants are "suppliers" as that term is defined in Kansas's Consumer Protection Act.

1783. Plaintiffs and class members are individuals who purchased JUUL products for personal purposes.

1784. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe



1 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
2 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
3 addictiveness, and significant risks of substantial physical injury from using JUUL products.

4 1785. Advertisements and representations for JUUL products contained deceptive  
5 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
6 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
7 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
8 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
9 decades, JLI used third parties and word of mouth to spread false and misleading information  
10 about JUUL products.

11 1786. Advertisements and representations for JUUL products concealed and failed to  
12 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
13 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
14 addictive, posed significant risks of substantial physical injury resulting from the use of the  
15 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
16 consumed through a pack of combustible cigarettes.

17 1787. The labels on JUUL products failed to disclose that the products posed  
18 significant risks of substantial physical injury resulting from the use of the products. The labels  
19 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

20 1788. The omissions were misleading and deceptive standing alone and were  
21 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
22 cigarettes and other representations.

23 1789. JLI's conduct was unfair and unconscionable in that it included (i) the  
24 manufacture and sale of products with a heightened propensity to cause addiction and physical  
25 injuries and (ii) misrepresentations and omissions of material facts concerning the  
26 characteristics and safety of JUUL products that offended public policy; were immoral,  
27 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
28 substantial harm that greatly outweighs any possible utility from the conduct.

1790. JLI's conduct constituted the following prohibited fraudulent, deceptive, and unfair business practices: (a) misrepresenting that JUUL products have characteristics, ingredients, uses, benefits, or quantities, which they do not have and (b) misrepresenting that JUUL products are of a particular standard, quality, or grade, or that goods are of a particular style or model, when they are not; (c) the willful use, in any oral or written representation, of exaggeration, falsehood, innuendo or ambiguity as to a material fact; and (d) the willful failure to state a material fact, or the willful concealment, suppression or omission of a material fact.

1791. JLI's conduct was fraudulent and deceptive because the misrepresentations and omissions had the capacity to deceive, were likely to deceive, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

1792. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

1793. As set forth in the allegations concerning each Plaintiff in Appendix A, in purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions. Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

1 1794. Defendants knew or should have known that their misrepresentations and/or  
2 omissions were false and misleading, and intended for consumers to rely on such  
3 misrepresentations and omissions.

4 1795. JLI and the Management Defendants engaged in fraudulent and deceptive  
5 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
6 products were appropriate for minors, when in fact the products never should have been  
7 marketed to minors and are especially harmful to minors due to the potent and addictive  
8 nicotine doses, addictive qualities, and health risks.

9 1796. In addition, all Defendants engaged in unfair and unconscionable conduct  
10 because the targeting of minors offends public policy (*see, e.g.*, Kan. Stat. Ann. § 79-3321); is  
11 immoral, unethical, oppressive, and unscrupulous; took advantage of minors' inability to  
12 reasonably protect their interests; and has caused substantial harm that greatly outweighs any  
13 benefits associated with the conduct.

14 1797. As alleged above, all Defendants participated and/or facilitated the marketing of  
15 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
16 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
17 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
18 use of JUUL products by minors continues to rise.

19 1798. Defendants' conduct actually and proximately caused damage to Plaintiffs and  
20 class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members  
21 would have behaved differently and would not have purchased JUUL products or would have  
22 paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class  
23 members to purchase JUUL products they would not otherwise have purchased and enter into  
24 purchase contracts they would not otherwise have entered into. In addition, class members who  
25 are minors are entitled to full repayment of the amounts they spent on JUUL products.  
26 Plaintiffs seek—on behalf of themselves and each member of the class—actual damages,  
27 attorney's fees, and equitable relief, as well as any other relief the Court may deem just or  
28 proper.

**b. Common Law Fraud**

1799. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1800. This claim is brought against JLI.

1801. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1802. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

1803. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

1804. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

1805. The omissions were misleading and deceptive standing alone and were particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to cigarettes and other representations.

1806. JLI's conduct was fraudulent and deceptive because its misrepresentations and omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

1807. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

1808. As set forth in the allegations concerning each Plaintiff in Appendix A, in purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations and/or omissions. Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

1809. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

1810. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

1811. JLI's conduct actually and proximately caused damage to Plaintiffs and class

1 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
2 and would not have purchased JUUL products or would have paid less for them. JLI's  
3 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
4 products they would not otherwise have purchased and enter into purchase contracts they would  
5 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
6 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
7 relief the Court may deem just or proper.

8 **c. Breach of the Implied Warranty of Merchantability**

9 1812. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 1813. This claim is brought against JLI.

11 1814. JUUL has at all times been a merchant with respect to the products which were  
12 sold to Plaintiff and the class and was in the business of selling such products.

13 1815. Each JUUL product sold by JUUL comes with an implied warranty that it will  
14 merchantable and fit for the ordinary purpose for which it would be used. *See* Kan. Stat. Ann.  
15 § 84-2-314. JUUL has breached its implied warranty of merchantability because its products  
16 were not in merchantable condition when sold, were defective when sold, did not conform to the  
17 promises and affirmations of fact made on the products' containers or labels, and/or do not  
18 possess even the most basic degree of fitness for ordinary use.

19 1816. The ordinary intended purpose of JUUL's products—and the purpose for which  
20 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
21 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
22 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
23 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
24 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
25 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
26 recreation smoking devices.

27 1817. Plaintiffs and each member of the class have had sufficient direct dealings with  
28 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized

1 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
2 each member of the class, on the other hand.

3 1818. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
4 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
5 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
6 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
7 the express purpose an intent of being sold to consumers.

8 1819. Plaintiffs and the members of the class were injured as a direct and proximate  
9 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
10 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
11 because, had they been aware of the unmerchantable condition of JUUL products, they would  
12 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
13 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

14 1820. JUUL was provided notice of these issues by numerous complaints filed against  
15 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
16 individual letters and communications sent by consumers before or within a reasonable amount  
17 of time after they discovered or should have discovered that's JUUL product were defective and  
18 unmerchantable.

19 **d. Unjust Enrichment**

20 1821. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

21 1822. This claim is brought against JLI and the Management Defendants.

22 1823. Defendants created and implemented a scheme to create a market for e-cigarettes  
23 and substantially increase sales of JUUL products through a pervasive pattern of false and  
24 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
25 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
26 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
27 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
28 products.



1824. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Kansas law (*see* Kan. Stat. Ann. § 79-3321(l)) prohibits the marketing and sale of JUUL products to minors

1825. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

1826. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

1827. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1828. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

1829. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **17. Kentucky**

1830. Plaintiffs bring each of the following claims on behalf of the Kentucky Subclass under Kentucky law.

### **a. Violation of Kentucky Consumer Protection Act (Ky. Rev. Stat. Ann. § 367.110, *et seq.*)**

1831. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1 1832. This claim is brought against JLI and, for certain unfair and/or unconscionable  
2 conduct claims as noted below, all Defendants.

3 1833. Defendants are sellers of JUUL products.

4 1834. Plaintiffs and class member are “persons” under the statute.

5 1835. Plaintiffs and class members are individuals who purchased JUUL products for  
6 personal purposes.

7 1836. Plaintiffs and each member of the class have had direct dealings with either  
8 JUUL via its website or its agents (including distributors, dealers, and sellers authorized by  
9 JUUL). Further, Plaintiffs and each member of the class were third-party beneficiaries of  
10 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
11 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
12 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
13 the express purpose an intent of being sold to consumers.

14 1837. Defendants created and implemented a scheme to create a market for e-cigarettes  
15 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
16 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
17 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
18 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
19 addictiveness, and significant risks of substantial physical injury from using JUUL products.

20 1838. Advertisements and representations for JUUL products contained deceptive  
21 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
22 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
23 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
24 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
25 decades, JLI used third parties and word of mouth to spread false and misleading information  
26 about JUUL products.

27 1839. Advertisements and representations for JUUL products concealed and failed to  
28 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to

1 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
2 addictive, posed significant risks of substantial physical injury resulting from the use of the  
3 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
4 consumed through a pack of combustible cigarettes.

5 1840. The labels on JUUL products failed to disclose that the products posed  
6 significant risks of substantial physical injury resulting from the use of the products. The labels  
7 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

8 1841. The omissions were misleading and deceptive standing alone and were  
9 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
10 cigarettes and other representations.

11 1842. JLI's conduct was unfair and unconscionable in that it included (i) the  
12 manufacture and sale of products with a heightened propensity to cause addiction and physical  
13 injuries and (ii) misrepresentations and omissions of material facts concerning the  
14 characteristics and safety of JUUL products that offended public policy; were immoral,  
15 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
16 substantial harm that greatly outweighs any possible utility from the conduct.

17 1843. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
18 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
19 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
20 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
21 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
22 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
23 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
24 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
25 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
26 Plaintiffs' and class members' decisions to purchase JUUL products.

27 1844. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
28 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties

1 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
2 facts; because the facts would be material to reasonable consumers; because JLI actively  
3 concealed them; because JLI intended for consumers to rely on the omissions in question;  
4 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
5 made partial representations concerning the same subject matter as the omitted facts.

6 1845. JLI and the Management Defendants engaged in fraudulent and deceptive  
7 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
8 products were appropriate for minors, when in fact the products never should have been  
9 marketed to minors and are especially harmful to minors due to the potent and addictive  
10 nicotine doses, addictive qualities, and health risks.

11 1846. In addition, all Defendants engaged in unfair and unconscionable conduct  
12 because the targeting of minors offends public policy (*see, e.g.*, Ky. Rev. Stat. Ann. §§ 438.310,  
13 438.313); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
14 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
15 conduct.

16 1847. As alleged above, all Defendants participated and/or facilitated the marketing of  
17 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
18 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
19 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
20 use of JUUL products by minors continues to rise.

21 1848. Defendants' conduct actually and proximately caused an ascertainable loss of  
22 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent  
23 conduct, Plaintiffs and class members would have behaved differently and would not have  
24 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
25 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
26 otherwise have purchased and enter into purchase contracts they would not otherwise have  
27 entered into. In addition, class members who are minors are entitled to full repayment of the  
28 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each

1 member of the class—actual damages, punitive damages, attorney’s fees and costs, and  
2 equitable relief, as well as any other relief the Court may deem just or proper.

3 **b. Common Law Fraud**

4 1849. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

5 1850. This claim is brought against JLI.

6 1851. JUUL created and implemented a scheme to create a market for e-cigarettes and  
7 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
8 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
9 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
10 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
11 addictiveness, and significant risks of substantial physical injury from using JUUL products.

12 1852. Advertisements and representations for JUUL products contained deceptive  
13 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
14 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
15 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
16 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
17 decades, JLI used third parties and word of mouth to spread false and misleading information  
18 about JUUL products.

19 1853. Advertisements and representations for JUUL products concealed and failed to  
20 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
21 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
22 addictive, posed significant risks of substantial physical injury resulting from the use of the  
23 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
24 consumed through a pack of combustible cigarettes.

25 1854. The labels on JUUL products failed to disclose that the products posed  
26 significant risks of substantial physical injury resulting from the use of the products. The labels  
27 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

28 1855. The omissions were misleading and deceptive standing alone and were

1 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
2 cigarettes and other representations.

3 1856. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
4 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
5 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
6 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
7 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
8 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
9 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
10 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
11 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
12 Plaintiffs' and class members' decisions to purchase JUUL products.

13 1857. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
14 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
15 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
16 facts; because the facts would be material to reasonable consumers; because JUUL products  
17 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
18 representations concerning the same subject matter as the omitted facts.

19 1858. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
20 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
21 and/or omissions. Reasonable consumers would have been expected to have relied on the  
22 misrepresentations and omissions.

23 1859. Defendants knew or should have known that their misrepresentations and/or  
24 omissions were false and misleading, and intended for consumers to rely on such  
25 misrepresentations and omissions.

26 1860. JLI knew that JUUL products were not safe or reasonable alternatives to  
27 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
28 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the

1 products.

2 1861. JLI's conduct actually and proximately caused damage including an  
3 ascertainable loss of money or property to Plaintiffs and class members. Absent JLI's conduct,  
4 Plaintiffs and class members would have behaved differently and would not have purchased  
5 JUUL products or would have paid less for them. JLI's misrepresentations and omissions  
6 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
7 purchased and enter into purchase contracts they would not otherwise have entered into.  
8 Plaintiffs seek, on behalf of themselves and each member of the class, damages in an amount to  
9 be proven at trial and punitive damages, as well as any other relief the Court may deem just or  
10 proper.

11 **c. Breach of the Implied Warranty of Merchantability**

12 1862. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

13 1863. This claim is brought against JLI.

14 1864. JUUL has at all times been a merchant with respect to the products which were  
15 sold to Plaintiff and the class and was in the business of selling such products.

16 1865. Each JUUL product sold by JUUL comes with an implied warranty that it will  
17 merchantable and fit for the ordinary purpose for which it would be used. *See Ky. Rev. Stat.*  
18 *Ann. § 355.2-314.* JUUL has breached its implied warranty of merchantability because its  
19 products were not in merchantable condition when sold, were defective when sold, did not  
20 conform to the promises and affirmations of fact made on the products' containers or labels,  
21 and/or do not possess even the most basic degree of fitness for ordinary use.

22 1866. The ordinary intended purpose of JUUL's products—and the purpose for which  
23 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
24 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
25 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
26 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
27 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
28 products are not fit for their ordinary, intended use as either cigarette replacement devices or



1 recreation smoking devices.

2 1867. Plaintiffs and each member of the class have had sufficient direct dealings with  
3 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
4 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
5 each member of the class, on the other hand.

6 1868. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
7 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
8 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
9 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
10 the express purpose an intent of being sold to consumers.

11 1869. Plaintiffs and the members of the class were injured as a direct and proximate  
12 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
13 the Kentucky Direct Purchase Subclass were damaged as a result of JUUL's breach of its  
14 implied warranty of merchantability because, had they been aware of the unmerchantable  
15 condition of JUUL products, they would not have purchased JUUL products, or would have  
16 paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any  
17 other relief the Court may deem just or proper.

18 1870. JUUL was provided notice of these issues by numerous complaints filed against  
19 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
20 individual letters and communications sent by consumers before or within a reasonable amount  
21 of time after they discovered or should have discovered that's JUUL product were defective and  
22 unmerchantable.

23 **d. Unjust Enrichment**

24 1871. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

25 1872. This claim is brought against JLI and the Management Defendants.

26 1873. Defendants created and implemented a scheme to create a market for e-cigarettes  
27 and substantially increase sales of JUUL products through a pervasive pattern of false and  
28 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and

1 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
2 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
3 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
4 products.

5 1874. Defendants were unjustly enriched as a result of their wrongful conduct,  
6 including through the false and misleading advertisements and omissions regarding (i) whether  
7 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
8 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
9 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
10 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
11 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
12 enriched through their scheme of marketing their products to minors. Kentucky law (*see* Ky.  
13 Rev. Stat. Ann. §§ 438.310, 438.313) prohibits the marketing and sale of JUUL products to  
14 minors.

15 1875. Defendants requested and received a measurable benefit at the expense of  
16 Plaintiffs and class members in the form of payment for JUUL products.

17 1876. Defendants appreciated, recognized, and chose to accept the monetary benefits  
18 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
19 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

20 1877. There is no justification for Defendants' enrichment. It would be inequitable,  
21 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
22 benefits were procured as a result of their wrongful conduct.

23 1878. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
24 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
25 with Defendant.

26 1879. Plaintiffs plead this claim separately as well as in the alternative to their other  
27 claims, as without such claims they would have no adequate legal remedy.  
28

1                   **18. Louisiana**

2           1880. Plaintiffs bring each of the following claims on behalf of the Louisiana Subclass  
3 under Louisiana law.

4                   **a. Violation of Louisiana Unfair Trade Practices and Consumer**  
5                   **Protection Law (La. Rev. Stat. Ann. § 51:1401, et seq.)**

6           1881. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

7           1882. This claim is brought against JLI and, for certain unfair and/or unconscionable  
8 conduct claims as noted below, all Defendants.

9           1883. Plaintiffs and class members are persons who purchased JUUL products for  
10 personal purposes.

11           1884. Defendants created and implemented a scheme to create a market for e-cigarettes  
12 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
13 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
14 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
15 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
16 addictiveness, and significant risks of substantial physical injury from using JUUL products.

17           1885. Advertisements and representations for JUUL products contained deceptive  
18 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
19 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
20 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
21 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
22 decades, JLI used third parties and word of mouth to spread false and misleading information  
23 about JUUL products.

24           1886. Advertisements and representations for JUUL products concealed and failed to  
25 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed significant risks of substantial physical injury resulting from the use of the  
28 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine

1 consumed through a pack of combustible cigarettes.

2 1887. The labels on JUUL products failed to disclose that the products posed  
3 significant risks of substantial physical injury resulting from the use of the products. The labels  
4 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

5 1888. The omissions were misleading and deceptive standing alone and were  
6 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
7 cigarettes and other representations.

8 1889. JLI's conduct was unfair and unconscionable in that it included (i) the  
9 manufacture and sale of products with a heightened propensity to cause addiction and physical  
10 injuries and (ii) misrepresentations and omissions of material facts concerning the  
11 characteristics and safety of JUUL products that offended public policy; were immoral,  
12 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
13 substantial harm that greatly outweighs any possible utility from the conduct.

14 1890. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
15 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
16 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
17 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
18 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
19 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
20 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
21 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
22 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
23 Plaintiffs' and class members' decisions to purchase JUUL products.

24 1891. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
25 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
26 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
27 facts; because the facts would be material to reasonable consumers; because JLI actively  
28 concealed them; because JLI intended for consumers to rely on the omissions in question;

1 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
2 made partial representations concerning the same subject matter as the omitted facts.

3 1892. Defendants knew or should have known that their misrepresentations and/or  
4 omissions were false and misleading, and intended for consumers to rely on such  
5 misrepresentations and omissions.

6 1893. JLI and the Management Defendants engaged in fraudulent and deceptive  
7 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
8 products were appropriate for minors, when in fact the products never should have been  
9 marketed to minors and are especially harmful to minors due to the potent and addictive  
10 nicotine doses, addictive qualities, and health risks.

11 1894. In addition, all Defendants engaged in unfair and unconscionable conduct  
12 because the targeting of minors offends public policy (*see, e.g.*, La. Rev. Stat. Ann. §§ 14:91.8,  
13 14:91.6(A)); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
14 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
15 conduct.

16 1895. As alleged above, all Defendants participated and/or facilitated the marketing of  
17 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
18 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
19 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
20 use of JUUL products by minors continues to rise.

21 1896. Defendants' conduct actually and proximately caused an ascertainable loss of  
22 money or movable property to Plaintiffs and class members. Absent Defendants' unfair and  
23 fraudulent conduct, Plaintiffs and class members would have behaved differently and would not  
24 have purchased JUUL products or would have paid less for them. Defendants'  
25 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
26 products they would not otherwise have purchased and enter into purchase contracts they would  
27 not otherwise have entered into. In addition, class members who are minors are entitled to full  
28 repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of

1 themselves and each member of the class—three times damages because Defendants deceptive  
2 and fraudulent conduct was done knowingly, and reasonable attorneys’ fees and costs, as well  
3 as any other relief the Court may deem just or proper.

4 **b. Common Law Fraud**

5 1897. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

6 1898. This claim is brought against JLI.

7 1899. JUUL created and implemented a scheme to create a market for e-cigarettes and  
8 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
9 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
10 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
11 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
12 addictiveness, and significant risks of substantial physical injury from using JUUL products.

13 1900. Advertisements and representations for JUUL products contained deceptive  
14 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
15 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
16 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
17 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
18 decades, JLI used third parties and word of mouth to spread false and misleading information  
19 about JUUL products.

20 1901. Advertisements and representations for JUUL products concealed and failed to  
21 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
22 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
23 addictive, posed significant risks of substantial physical injury resulting from the use of the  
24 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
25 consumed through a pack of combustible cigarettes.

26 1902. The labels on JUUL products failed to disclose that the products posed  
27 significant risks of substantial physical injury resulting from the use of the products. The labels  
28 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

1           1903. The omissions were misleading and deceptive standing alone and were  
2 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
3 cigarettes and other representations.

4           1904. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
5 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
6 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
7 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
8 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
9 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
10 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
11 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
12 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
13 Plaintiffs' and class members' decisions to purchase JUUL products.

14           1905. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
15 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
16 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
17 facts; because the facts would be material to reasonable consumers; because JUUL products  
18 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
19 representations concerning the same subject matter as the omitted facts.

20           1906. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
21 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
22 and/or omissions. Reasonable consumers would have been expected to have relied on the  
23 misrepresentations and omissions.

24           1907. Defendants knew or should have known that their misrepresentations and/or  
25 omissions were false and misleading, and intended for consumers to rely on such  
26 misrepresentations and omissions.

27           1908. JLI knew that JUUL products were not safe or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully



1 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
2 products.

3 1909. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
4 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
5 and would not have purchased JUUL products or would have paid less for them. JLI's  
6 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
7 products they would not otherwise have purchased and enter into purchase contracts they would  
8 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
9 class, compensatory damages in an amount to be proven at trial and punitive damages, as well  
10 as any other relief the Court may deem just or proper.

11 **c. Breach of the Implied Warranty of Merchantability**

12 1910. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

13 1911. This claim is brought against JLI.

14 1912. JUUL has at all times been a merchant with respect to the products which were  
15 sold to Plaintiff and the class and was in the business of selling such products.

16 1913. Each JUUL product sold by JUUL comes with an implied warranty that it will  
17 merchantable and fit for the ordinary purpose for which it would be used. *See* LSA-C.C. Art.  
18 2475. JUUL has breached its implied warranty of merchantability because its products were not  
19 in merchantable condition when sold, were defective when sold, did not conform to the  
20 promises and affirmations of fact made on the products' containers or labels, and/or do not  
21 possess even the most basic degree of fitness for ordinary use.

22 1914. The ordinary intended purpose of JUUL's products—and the purpose for which  
23 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
24 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
25 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
26 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
27 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
28 products are not fit for their ordinary, intended use as either cigarette replacement devices or

1 recreation smoking devices.

2 1915. Plaintiffs and each member of the class have had sufficient direct dealings with  
3 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
4 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
5 each member of the class, on the other hand.

6 1916. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
7 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
8 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
9 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
10 the express purpose an intent of being sold to consumers.

11 1917. Plaintiffs and the members of the class were injured as a direct and proximate  
12 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
13 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
14 because, had they been aware of the unmerchantable condition of JUUL products, they would  
15 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
16 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

17 1918. JUUL was provided notice of these issues by numerous complaints filed against  
18 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
19 individual letters and communications sent by consumers before or within a reasonable amount  
20 of time after they discovered or should have discovered that's JUUL product were defective and  
21 unmerchantable.

22 **d. Unjust Enrichment**

23 1919. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

24 1920. This claim is brought against JLI and the Management Defendants.

25 1921. Defendants created and implemented a scheme to create a market for e-cigarettes  
26 and substantially increase sales of JUUL products through a pervasive pattern of false and  
27 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
28 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,

1 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
2 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
3 products.

4 1922. Defendants were unjustly enriched as a result of their wrongful conduct,  
5 including through the false and misleading advertisements and omissions regarding (i) whether  
6 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
7 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
8 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
9 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
10 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
11 enriched through their scheme of marketing their products to minors. The Louisiana Prevention  
12 of Youth Access to Tobacco Law and other statutes (*see* La. Rev. Stat. Ann. §§ 14:91.8 and  
13 14:91.6) prohibit the marketing and sale of JUUL products to minors.

14 1923. Defendants requested and received a measurable benefit at the expense of  
15 Plaintiffs and class members in the form of payment for JUUL products.

16 1924. Defendants appreciated, recognized, and chose to accept the monetary benefits  
17 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
18 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

19 1925. There is no justification for Defendants' enrichment. It would be inequitable,  
20 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
21 benefits were procured as a result of their wrongful conduct.

22 1926. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
23 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
24 with Defendant.

25 1927. Plaintiffs plead this claim separately as well as in the alternative to their other  
26 claims, as without such claims they would have no adequate legal remedy.

27 **19. Maine**

28 1928. Plaintiffs bring each of the following claims on behalf of the Maine Subclass

1 under Maine law.

2 **a. Violation of Maine Unfair Trade Practices Act (5 M.R.S.A.**  
3 **§ 205-A, *et seq.*)**

4 1929. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

5 1930. This claim is brought against JLI and, for certain unfair and/or unconscionable  
6 conduct claims as noted below, all Defendants.

7 1931. Plaintiffs and class members are persons who purchased JUUL products for  
8 personal purposes.

9 1932. Defendants created and implemented a scheme to create a market for e-cigarettes  
10 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
11 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
12 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
13 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
14 addictiveness, and significant risks of substantial physical injury from using JUUL products.

15 1933. Advertisements and representations for JUUL products contained deceptive  
16 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
17 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
18 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
19 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
20 decades, JLI used third parties and word of mouth to spread false and misleading information  
21 about JUUL products.

22 1934. Advertisements and representations for JUUL products concealed and failed to  
23 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
24 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
25 addictive, posed significant risks of substantial physical injury resulting from the use of the  
26 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
27 consumed through a pack of combustible cigarettes.

28 1935. The labels on JUUL products failed to disclose that the products posed

1 significant risks of substantial physical injury resulting from the use of the products. The labels  
2 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

3 1936. The omissions were misleading and deceptive standing alone and were  
4 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
5 cigarettes and other representations.

6 1937. JLI's conduct was unfair and unconscionable in that it included (i) the  
7 manufacture and sale of products with a heightened propensity to cause addiction and physical  
8 injuries and (ii) misrepresentations and omissions of material facts concerning the  
9 characteristics and safety of JUUL products that offended public policy; were immoral,  
10 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
11 substantial harm that greatly outweighs any possible utility from the conduct.

12 1938. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
13 omissions at issue were likely to, and in fact did, mislead reasonable consumers including the  
14 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
15 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
16 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
17 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
18 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
19 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
20 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
21 decisions to purchase JUUL products.

22 1939. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
23 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
24 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
25 facts; because the facts would be material to reasonable consumers; because JLI actively  
26 concealed them; because JLI intended for consumers to rely on the omissions in question;  
27 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
28 made partial representations concerning the same subject matter as the omitted facts.

1           1940. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
2 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
3 Reasonable consumers would have been expected to have relied on the misrepresentations and  
4 omissions.

5           1941. JLI and the Management Defendants engaged in fraudulent and deceptive  
6 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
7 products were appropriate for minors, when in fact the products never should have been  
8 marketed to minors and are especially harmful to minors due to the potent and addictive  
9 nicotine doses, addictive qualities, and health risks.

10           1942. In addition, all Defendants engaged in unfair and unconscionable conduct  
11 because the targeting of minors offends public policy (*see, e.g.*, 22 M.R.S.A. § 1555-B (2)); is  
12 immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has  
13 caused substantial harm that greatly outweighs any possible utility from the conduct.

14           1943. As alleged above, all Defendants participated and/or facilitated the marketing of  
15 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
16 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
17 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
18 use of JUUL products by minors continues to rise.

19           1944. Defendants' conduct actually and proximately caused the loss of money or  
20 property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct,  
21 Plaintiffs and class members would have behaved differently and would not have purchased  
22 JUUL products or would have paid less for them. Defendants' misrepresentations and omissions  
23 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
24 purchased and enter into purchase contracts they would not otherwise have entered into. In  
25 addition, class members who are minors are entitled to full repayment of the amounts they spent  
26 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
27 actual damages, restitution, attorney's fees and costs, and injunctive relief (except as to the  
28 Management Defendants), as well as any other relief the Court may deem just or proper.

1           1945. Plaintiffs have complied or substantially complied with all applicable notice  
2 requirements.

3                           **b.       Violation of Maine Uniform Deceptive Trade Practices Act**  
4                           **(10 M.R.S.A. § 1211, *et seq.*)**

5           1946. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

6           1947. This claim is brought against JLI and, for certain claims as noted below, the  
7 Management Defendants.

8           1948. Plaintiffs and class members are persons who purchased JUUL products for  
9 personal purposes.

10          1949. Defendants created and implemented a scheme to create a market for e-cigarettes  
11 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
12 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
13 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
14 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
15 addictiveness, and significant risks of substantial physical injury from using JUUL products.

16          1950. Advertisements and representations for JUUL products contained deceptive  
17 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
18 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
19 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
20 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
21 decades, JLI used third parties and word of mouth to spread false and misleading information  
22 about JUUL products.

23          1951. Advertisements and representations for JUUL products concealed and failed to  
24 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
25 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
26 addictive, posed significant risks of substantial physical injury resulting from the use of the  
27 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
28 consumed through a pack of combustible cigarettes.



1           1952. The labels on JUUL products failed to disclose that the products posed  
2 significant risks of substantial physical injury resulting from the use of the products. The labels  
3 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

4           1953. The omissions were misleading and deceptive standing alone and were  
5 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
6 cigarettes and other representations.

7           1954. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
8 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
9 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
10 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
11 model, when they are not; (c) advertising goods or services with intent not to sell them as  
12 advertised; and (d) engaging in conduct which creates a likelihood of confusion or of  
13 misunderstanding.

14           1955. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
15 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the  
16 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
17 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
18 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
19 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
20 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
21 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
22 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
23 decisions to purchase JUUL products.

24           1956. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
25 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
26 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
27 facts; because the facts would be material to reasonable consumers; because JLI actively  
28 concealed them; because JLI intended for consumers to rely on the omissions in question;

1 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
2 made partial representations concerning the same subject matter as the omitted facts.

3 1957. JLI and the Management Defendants engaged in fraudulent and deceptive  
4 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
5 products were appropriate for minors, when in fact the products never should have been  
6 marketed to minors and are especially harmful to minors due to the potent and addictive  
7 nicotine doses, addictive qualities, and health risks.

8 1958. Defendants' conduct actually and proximately caused damage to Plaintiffs and  
9 class members and is likely to cause damage in the future. Absent Defendants' deceptive and  
10 fraudulent conduct, Plaintiffs and class members would have behaved differently and would not  
11 have purchased JUUL products or would have paid less for them. Defendants'  
12 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
13 products they would not otherwise have purchased and enter into purchase contracts they would  
14 not otherwise have entered into. In addition, class members who are minors are entitled to full  
15 repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of  
16 themselves and each member of the class—injunctive relief (except as to the Management  
17 Defendants), attorney's fees, and equitable relief, as well as any other relief the Court may deem  
18 just or proper.

19 **c. Common Law Fraud**

20 1959. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

21 1960. This claim is brought against JLI.

22 1961. JUUL created and implemented a scheme to create a market for e-cigarettes and  
23 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
24 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
25 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
26 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
27 addictiveness, and significant risks of substantial physical injury from using JUUL products.

28 1962. Advertisements and representations for JUUL products contained deceptive

1 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
2 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
3 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
4 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
5 decades, JLI used third parties and word of mouth to spread false and misleading information  
6 about JUUL products.

7 1963. Advertisements and representations for JUUL products concealed and failed to  
8 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
9 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
10 addictive, posed significant risks of substantial physical injury resulting from the use of the  
11 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
12 consumed through a pack of combustible cigarettes.

13 1964. The labels on JUUL products failed to disclose that the products posed  
14 significant risks of substantial physical injury resulting from the use of the products. The labels  
15 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

16 1965. The omissions were misleading and deceptive standing alone and were  
17 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
18 cigarettes and other representations.

19 1966. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
20 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
21 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
22 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
23 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
24 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
25 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
26 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
27 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
28 Plaintiffs' and class members' decisions to purchase JUUL products.

1           1967. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
2 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
3 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
4 facts; because the facts would be material to reasonable consumers; because JUUL products  
5 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
6 representations concerning the same subject matter as the omitted facts.

7           1968. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
8 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
9 and/or omissions. Reasonable consumers would have been expected to have relied on the  
10 misrepresentations and omissions.

11           1969. Defendants knew or should have known that their misrepresentations and/or  
12 omissions were false and misleading, and intended for consumers to rely on such  
13 misrepresentations and omissions.

14           1970. JLI knew that JUUL products were not safe or reasonable alternatives to  
15 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
16 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
17 products.

18           1971. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
19 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
20 and would not have purchased JUUL products or would have paid less for them. JLI's  
21 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
22 products they would not otherwise have purchased and enter into purchase contracts they would  
23 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
24 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
25 relief the Court may deem just or proper.

26                           **d. Breach of the Implied Warranty of Merchantability**

27           1972. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

28           1973. This claim is brought against JLI.

1           1974. JUUL has at all times been a merchant with respect to the products which were  
2 sold to Plaintiff and the class and was in the business of selling such products.

3           1975. Each JUUL product sold by JUUL comes with an implied warranty that it will  
4 merchantable and fit for the ordinary purpose for which it would be used. *See* 11 M.R.S.A. § 2-  
5 314. JUUL has breached its implied warranty of merchantability because its products were not  
6 in merchantable condition when sold, were defective when sold, did not conform to the  
7 promises and affirmations of fact made on the products' containers or labels, and/or do not  
8 possess even the most basic degree of fitness for ordinary use.

9           1976. The ordinary intended purpose of JUUL's products—and the purpose for which  
10 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
11 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
12 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
13 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
14 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
15 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
16 recreation smoking devices.

17           1977. Plaintiffs and each member of the class have had sufficient direct dealings with  
18 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
19 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
20 each member of the class, on the other hand.

21           1978. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
22 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
23 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
24 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
25 the express purpose an intent of being sold to consumers.

26           1979. Plaintiffs and the members of the class were injured as a direct and proximate  
27 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
28 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability

1 because, had they been aware of the unmerchantable condition of JUUL products, they would  
2 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
3 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

4 1980. JUUL was provided notice of these issues by numerous complaints filed against  
5 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
6 individual letters and communications sent by consumers before or within a reasonable amount  
7 of time after they discovered or should have discovered that's JUUL product were defective and  
8 unmerchantable.

9 **e. Unjust Enrichment**

10 1981. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 1982. This claim is brought against JLI and the Management Defendants.

12 1983. Defendants created and implemented a scheme to create a market for e-cigarettes  
13 and substantially increase sales of JUUL products through a pervasive pattern of false and  
14 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
15 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
16 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
17 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
18 products.

19 1984. Defendants were unjustly enriched as a result of their wrongful conduct,  
20 including through the false and misleading advertisements and omissions regarding (i) whether  
21 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
22 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
23 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
24 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
25 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
26 enriched through their scheme of marketing their products to minors. Maine law (*see* 22  
27 M.R.S.A. § 1555-B) prohibits the marketing and sale of JUUL products to minors.

28 1985. Defendants requested and received a measurable benefit at the expense of

1 Plaintiffs and class members in the form of payment for JUUL products.

2 1986. Defendants appreciated, recognized, and chose to accept the monetary benefits  
3 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
4 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

5 1987. There is no justification for Defendants' enrichment. It would be inequitable,  
6 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
7 benefits were procured as a result of their wrongful conduct.

8 1988. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
9 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
10 with Defendant.

11 1989. Plaintiffs plead this claim separately as well as in the alternative to their other  
12 claims, as without such claims they would have no adequate legal remedy.

13 **20. Maryland**

14 1990. Plaintiffs bring each of the following claims on behalf of the Maryland Subclass  
15 under Maryland law.

16 **a. Violation of Maryland Consumer Protection Act (Md. Code**  
17 **Ann. Com. Law § 13-101, et seq.)**

18 1991. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

19 1992. This claim is brought against JLI and, for certain unfair and/or unconscionable  
20 conduct claims as noted below, all Defendants.

21 1993. Plaintiffs and class members are individuals who purchased JUUL products for  
22 personal purposes.

23 1994. Defendants created and implemented a scheme to create a market for e-cigarettes  
24 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
25 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
26 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
27 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
28 addictiveness, and significant risks of substantial physical injury from using JUUL products.



1           1995. Advertisements and representations for JUUL products contained deceptive  
2 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
3 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
4 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
5 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
6 decades, JLI used third parties and word of mouth to spread false and misleading information  
7 about JUUL products.

8           1996. Advertisements and representations for JUUL products concealed and failed to  
9 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
10 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
11 addictive, posed significant risks of substantial physical injury resulting from the use of the  
12 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
13 consumed through a pack of combustible cigarettes.

14           1997. The labels on JUUL products failed to disclose that the products posed  
15 significant risks of substantial physical injury resulting from the use of the products. The labels  
16 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

17           1998. The omissions were misleading and deceptive standing alone and were  
18 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
19 cigarettes and other representations.

20           1999. JLI's conduct was unfair and unconscionable in that it included (i) the  
21 manufacture and sale of products with a heightened propensity to cause addiction and physical  
22 injuries and (ii) misrepresentations and omissions of material facts concerning the  
23 characteristics and safety of JUUL products that offended public policy; were immoral,  
24 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
25 substantial harm that greatly outweighs any possible utility from the conduct.

26           2000. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
27 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
28 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL

1 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
2 model, when they are not; (c) advertising goods or services with intent not to sell them as  
3 advertised; (d) stating a material fact that deceives or tends to deceive; and (e) engaging in  
4 deception, fraud, false pretense, false premise, misrepresentation, or knowing concealment,  
5 suppression, or omission of any material fact with the intent that a consumer rely on the same.

6 2001. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
7 omissions had the capacity, tendency and effect of deceiving or misleading reasonable  
8 consumers; and in fact did, deceive and mislead reasonable consumers including the Plaintiffs.  
9 Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing  
10 decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable  
11 alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms,  
12 (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury  
13 resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL  
14 pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of  
15 these facts would have been a substantial factor in Plaintiffs' and class members' decisions to  
16 purchase JUUL products.

17 2002. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
18 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
19 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
20 facts; because the facts would be material to reasonable consumers; because JLI actively  
21 concealed them; because JLI intended for consumers to rely on the omissions in question;  
22 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
23 made partial representations concerning the same subject matter as the omitted facts.

24 2003. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
25 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
26 Reasonable consumers would have been expected to have relied on the misrepresentations and  
27 omissions.

28 2004. Defendants knew or should have known that their misrepresentations and/or

omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2005. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL products were appropriate for minors, when in fact the products never should have been marketed to minors and are especially harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health risks.

2006. In addition, all Defendants engaged in unfair and unconscionable conduct because the targeting of minors offends public policy (*see, e.g.*, Md. Code Ann. Health Gen. § 24- 305(b); Md. Code Ann. Crim. Law §§ 10-107(b)(2), (c)(1)); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has caused substantial harm that greatly outweighs any possible utility from the conduct.

2007. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI and others have continued the deceptive, misleading, unfair, and unconscionable practices that Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by minors continues to rise.

2008. Defendants' conduct actually and proximately caused injury and loss to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—damages and attorney's fees, as well as any other relief the Court may deem just or proper.

**b. Common Law Fraud**

2009. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           2010. This claim is brought against JLI.

2           2011. JUUL created and implemented a scheme to create a market for e-cigarettes and  
3 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8           2012. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15           2013. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21           2014. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24           2015. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27           2016. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
28 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers

1 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
2 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
5 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
6 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
7 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
8 Plaintiffs' and class members' decisions to purchase JUUL products.

9         2017. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JUUL products  
13 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
14 representations concerning the same subject matter as the omitted facts.

15         2018. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
16 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
17 and/or omissions. Reasonable consumers would have been expected to have relied on the  
18 misrepresentations and omissions.

19         2019. Defendants knew or should have known that their misrepresentations and/or  
20 omissions were false and misleading, and intended for consumers to rely on such  
21 misrepresentations and omissions.

22         2020. JLI knew that JUUL products were not safe or reasonable alternatives to  
23 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
24 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
25 products.

26         2021. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
27 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
28 and would not have purchased JUUL products or would have paid less for them. JLI's

1 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
2 products they would not otherwise have purchased and enter into purchase contracts they would  
3 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
4 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
5 relief the Court may deem just or proper.

6 **c. Breach of the Implied Warranty of Merchantability**

7 2022. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 2023. This claim is brought against JLI.

9 2024. JUUL has at all times been a merchant with respect to the products which were  
10 sold to Plaintiff and the class and was in the business of selling such products.

11 2025. Each JUUL product sold by JUUL comes with an implied warranty that it will  
12 merchantable and fit for the ordinary purpose for which it would be used. *See* Md. Code Ann.  
13 Com. Law § 2-314. JUUL has breached its implied warranty of merchantability because its  
14 products were not in merchantable condition when sold, were defective when sold, did not  
15 conform to the promises and affirmations of fact made on the products' containers or labels,  
16 and/or do not possess even the most basic degree of fitness for ordinary use.

17 2026. The ordinary intended purpose of JUUL's products—and the purpose for which  
18 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
19 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
20 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
21 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
22 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
23 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
24 recreation smoking devices.

25 2027. Plaintiffs and each member of the class have had sufficient direct dealings with  
26 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
27 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
28 each member of the class, on the other hand.

2028. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

2029. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2030. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

2031. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2032. This claim is brought against JLI and the Management Defendants.

2033. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2034. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether



JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Maryland law (*see* Md. Code Ann. Health Gen. § 24- 305(b); Md. Code Ann. Crim. Law §§ 10-107(b)(2), (c)(1)) prohibits the marketing and sale of JUUL products to minors.

2035. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

2036. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

2037. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

2038. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

2039. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **21. Massachusetts**

2040. Plaintiffs bring each of the following claims on behalf of the Massachusetts Subclass under Massachusetts law.

### **a. Violation of Massachusetts Regulation of Business Practice and Consumer Protection Act (M.G.L.A. 93A, § 1, *et seq.*)**

2041. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2042. This claim is brought against JLI and, for certain unfair and/or unconscionable

1 conduct claims as noted below, all Defendants.

2 2043. Plaintiffs and class members are persons who purchased JUUL products for  
3 personal purposes.

4 2044. Defendants created and implemented a scheme to create a market for e-cigarettes  
5 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
6 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
7 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
8 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
9 addictiveness, and significant risks of substantial physical injury from using JUUL products.

10 2045. Advertisements and representations for JUUL products contained deceptive  
11 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
12 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
13 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
14 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
15 decades, JLI used third parties and word of mouth to spread false and misleading information  
16 about JUUL products.

17 2046. Advertisements and representations for JUUL products concealed and failed to  
18 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
19 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
20 addictive, posed significant risks of substantial physical injury resulting from the use of the  
21 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
22 consumed through a pack of combustible cigarettes.

23 2047. The labels on JUUL products failed to disclose that the products posed  
24 significant risks of substantial physical injury resulting from the use of the products. The labels  
25 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

26 2048. The omissions were misleading and deceptive standing alone and were  
27 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
28 cigarettes and other representations.

2049. JLI's conduct was unfair and unconscionable in that it included (i) the manufacture and sale of products with a heightened propensity to cause addiction and physical injuries and (ii) misrepresentations and omissions of material facts concerning the characteristics and safety of JUUL products that offended public policy; were immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused substantial harm that greatly outweighs any possible utility from the conduct.

2050. JLI's conduct was fraudulent and deceptive because the misrepresentations and omissions had the capacity to, tendency to, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

2051. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

2052. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2053. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL

1 products were appropriate for minors, when in fact the products never should have been  
2 marketed to minors and are especially harmful to minors due to the potent and addictive  
3 nicotine doses, addictive qualities, and health risks.

4 2054. In addition, all Defendants engaged in unfair and unconscionable conduct  
5 because the targeting of minors offends public policy (*see, e.g.*, M.G.L.A. 270 § 6(b)); is  
6 immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has  
7 caused substantial harm that greatly outweighs any possible utility from the conduct.

8 2055. As alleged above, all Defendants participated and/or facilitated the marketing of  
9 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
10 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
11 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
12 use of JUUL products by minors continues to rise.

13 2056. Defendants' conduct actually and proximately caused injury to Plaintiffs and  
14 class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members  
15 would have behaved differently and would not have purchased JUUL products or would have  
16 paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class  
17 members to purchase JUUL products they would not otherwise have purchased and enter into  
18 purchase contracts they would not otherwise have entered into. In addition, class members who  
19 are minors are entitled to full repayment of the amounts they spent on JUUL products.  
20 Plaintiffs seek—on behalf of themselves and each member of the class—actual damages;  
21 injunctive relief (except as to the Management Defendants); attorney's fees and costs; and  
22 because Defendants' conduct was a willful and knowing violation, punitive damages; as well as  
23 any other relief the Court may deem just or proper.

24 2057. Plaintiffs have complied or substantially complied with all applicable notice  
25 requirements, or are otherwise excused from compliance because Defendants do not maintain a  
26 place of business in and/ or do not keep assets within the state of Massachusetts.

27 **b. Common Law Fraud**

28 2058. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           2059. This claim is brought against JLI.

2           2060. JUUL created and implemented a scheme to create a market for e-cigarettes and  
3 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8           2061. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15           2062. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21           2063. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24           2064. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27           2065. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
28 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers

1 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
2 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
5 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
6 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
7 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
8 Plaintiffs' and class members' decisions to purchase JUUL products.

9       2066. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JUUL products  
13 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
14 representations concerning the same subject matter as the omitted facts.

15       2067. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
16 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
17 and/or omissions. Reasonable consumers would have been expected to have relied on the  
18 misrepresentations and omissions.

19       2068. Defendants knew or should have known that their misrepresentations and/or  
20 omissions were false and misleading, and intended for consumers to rely on such  
21 misrepresentations and omissions.

22       2069. JLI knew that JUUL products were not safe or reasonable alternatives to  
23 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
24 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
25 products.

26       2070. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
27 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
28 and would not have purchased JUUL products or would have paid less for them. JLI's

1 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
2 products they would not otherwise have purchased and enter into purchase contracts they would  
3 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
4 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
5 relief the Court may deem just or proper.

6 **c. Breach of the Implied Warranty of Merchantability**

7 2071. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 2072. This claim is brought against JLI.

9 2073. JUUL has at all times been a merchant with respect to the products which were  
10 sold to Plaintiff and the class and was in the business of selling such products.

11 2074. Each JUUL product sold by JUUL comes with an implied warranty that it will  
12 merchantable and fit for the ordinary purpose for which it would be used. *See* M.G.L.A. 106  
13 § 2-314. JUUL has breached its implied warranty of merchantability because its products were  
14 not in merchantable condition when sold, were defective when sold, did not conform to the  
15 promises and affirmations of fact made on the products' containers or labels, and/or do not  
16 possess even the most basic degree of fitness for ordinary use.

17 2075. The ordinary intended purpose of JUUL's products—and the purpose for which  
18 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
19 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
20 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
21 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
22 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
23 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
24 recreation smoking devices.

25 2076. Plaintiffs and each member of the class have had sufficient direct dealings with  
26 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
27 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
28 each member of the class, on the other hand.



2077. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

2078. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2079. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

2080. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2081. This claim is brought against JLI and the Management Defendants.

2082. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2083. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether

JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Massachusetts law (*see* M.G.L.A. 270 § 6(b)) prohibits the marketing and sale of JUUL products to minors.

2084. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

2085. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

2086. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

2087. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

2088. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **22. Michigan**

2089. Plaintiffs bring each of the following claims on behalf of the Michigan Subclass under Michigan law.

### **a. Violation of Michigan Consumer Protection Act (M.C.L.A. § 445.901, *et seq.*)**

2090. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2091. This claim is brought against JLI.

2092. Plaintiffs and class members are individuals who purchased JUUL products for

1 personal purposes.

2 2093. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8 2094. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15 2095. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21 2096. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24 2097. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27 2098. JUUL's prohibited fraudulent, deceptive, and unfair business practices conduct  
28 includes, but is not limited to the following: (a) representing that the goods or services have

1 characteristics, ingredients, uses, benefits, or quantities that they do not have ; (b)  
2 misrepresenting that JUUL products are of a particular standard, quality, or grade, or that goods  
3 are of a particular style or model, when they are not; (c) advertising goods or services with  
4 intent not to sell them as advertised; (d) failing to reveal a material fact, the omission of which  
5 tends to mislead or deceive the consumer, and which fact could not reasonably be known by the  
6 consumer; (e) making a representation of fact or statement of fact material to the transaction  
7 such that a person reasonably believes the represented or suggested state of affairs to be other  
8 than it actually is; and (f) failing to reveal facts that are material to the transaction in light of  
9 representations of fact made in a positive manner.

10 2099. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
11 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the  
12 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
13 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
14 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
15 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
16 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
17 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
18 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
19 decisions to purchase JUUL products.

20 2100. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
21 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
22 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
23 facts; because the facts would be material to reasonable consumers; because JLI actively  
24 concealed them; because JLI intended for consumers to rely on the omissions in question;  
25 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
26 made partial representations concerning the same subject matter as the omitted facts.

27 2101. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
28 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.

Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

2102. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2103. Defendants' conduct actually and proximately caused Plaintiffs and class members to be injured and to sustain losses. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—actual damages and equitable relief, as well as any other relief the Court may deem just or proper.

**b. Common Law Fraud**

2104. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2105. This claim is brought against JLI.

2106. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2107. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or

1 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
2 decades, JLI used third parties and word of mouth to spread false and misleading information  
3 about JUUL products.

4 2108. Advertisements and representations for JUUL products concealed and failed to  
5 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
6 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
7 addictive, posed significant risks of substantial physical injury resulting from the use of the  
8 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
9 consumed through a pack of combustible cigarettes.

10 2109. The labels on JUUL products failed to disclose that the products posed  
11 significant risks of substantial physical injury resulting from the use of the products. The labels  
12 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

13 2110. The omissions were misleading and deceptive standing alone and were  
14 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
15 cigarettes and other representations.

16 2111. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
17 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
18 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
19 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
20 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
21 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
22 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
23 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
24 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
25 Plaintiffs' and class members' decisions to purchase JUUL products.

26 2112. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
27 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
28 other than Plaintiffs and class members), who had exclusive and superior knowledge of the

1 facts; because the facts would be material to reasonable consumers; because JUUL products  
2 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
3 representations concerning the same subject matter as the omitted facts.

4 2113. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
5 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
6 and/or omissions. Reasonable consumers would have been expected to have relied on the  
7 misrepresentations and omissions.

8 2114. Defendants knew or should have known that their misrepresentations and/or  
9 omissions were false and misleading, and intended for consumers to rely on such  
10 misrepresentations and omissions.

11 2115. JLI knew that JUUL products were not safe or reasonable alternatives to  
12 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
13 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
14 products.

15 2116. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
16 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
17 and would not have purchased JUUL products or would have paid less for them. JLI's  
18 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
19 products they would not otherwise have purchased and enter into purchase contracts they would  
20 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
21 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
22 relief the Court may deem just or proper.

23 **c. Breach of the Implied Warranty of Merchantability**

24 2117. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

25 2118. This claim is brought against JLI.

26 2119. JUUL has at all times been a merchant with respect to the products which were  
27 sold to Plaintiff and the class and was in the business of selling such products.

28 2120. Each JUUL product sold by JUUL comes with an implied warranty that it will



1 merchantable and fit for the ordinary purpose for which it would be used. *See* M.C.L.A.  
2 § 440.2314. JUUL has breached its implied warranty of merchantability because its products  
3 were not in merchantable condition when sold, were defective when sold, did not conform to the  
4 promises and affirmations of fact made on the products' containers or labels, and/or do not  
5 possess even the most basic degree of fitness for ordinary use.

6 2121. The ordinary intended purpose of JUUL's products—and the purpose for which  
7 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
8 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
9 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
10 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
11 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
12 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
13 recreation smoking devices.

14 2122. Plaintiffs and each member of the class have had sufficient direct dealings with  
15 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
16 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
17 each member of the class, on the other hand.

18 2123. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
19 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
20 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
21 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
22 the express purpose an intent of being sold to consumers.

23 2124. Plaintiffs and the members of the class were injured as a direct and proximate  
24 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
25 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
26 because, had they been aware of the unmerchantable condition of JUUL products, they would  
27 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
28 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2125. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

2126. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2127. This claim is brought against JLI and the Management Defendants.

2128. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2129. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Michigan law (*see* M.C.L.A. § 722.641) prohibits the marketing and sale of JUUL products to minors.

2130. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

2131. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the

1 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

2 2132. There is no justification for Defendants' enrichment. It would be inequitable,  
3 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
4 benefits were procured as a result of their wrongful conduct.

5 2133. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
6 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
7 with Defendant.

8 2134. Plaintiffs plead this claim separately as well as in the alternative to their other  
9 claims, as without such claims they would have no adequate legal remedy.

10 **23. Minnesota**

11 2135. Plaintiffs bring each of the following claims on behalf of the Minnesota Subclass  
12 under Minnesota law.

13 **a. Violation of Minnesota Prevention of Consumer Fraud Act**  
14 **(Minn. Stat. § 325F.69)**

15 2136. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

16 2137. This claim is brought against JLI and, for certain claims below, the Management  
17 Defendants.

18 2138. Plaintiffs and class members are individuals who purchased JUUL products for  
19 personal purposes.

20 2139. Defendants created and implemented a scheme to create a market for e-cigarettes  
21 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
22 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
23 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
24 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
25 addictiveness, and significant risks of substantial physical injury from using JUUL products.

26 2140. Advertisements and representations for JUUL products contained deceptive  
27 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
28 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible

1 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
2 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
3 decades, JLI used third parties and word of mouth to spread false and misleading information  
4 about JUUL products.

5 2141. Advertisements and representations for JUUL products concealed and failed to  
6 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed significant risks of substantial physical injury resulting from the use of the  
9 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
10 consumed through a pack of combustible cigarettes.

11 2142. The labels on JUUL products failed to disclose that the products posed  
12 significant risks of substantial physical injury resulting from the use of the products. The labels  
13 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

14 2143. The omissions were misleading and deceptive standing alone and were  
15 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
16 cigarettes and other representations.

17 2144. JUUL engaged in acts, used, and employed, fraud, false pretenses, false  
18 promises, misrepresentations, misleading statements and deceptive practices. JLI's conduct had  
19 the capacity to, tendency to, and in fact did, deceive reasonable consumers including the  
20 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
21 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
22 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
23 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
24 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
25 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
26 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
27 decisions to purchase JUUL products.

28 2145. JLI owed Plaintiffs and class members a duty to disclose these facts because they

1 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
2 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
3 facts; because the facts would be material to reasonable consumers; because JLI actively  
4 concealed them; because JLI intended for consumers to rely on the omissions in question;  
5 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
6 made partial representations concerning the same subject matter as the omitted facts.

7 2146. Defendants knew or should have known that their misrepresentations and/or  
8 omissions were false and misleading, and intended for consumers to rely on such  
9 misrepresentations and omissions.

10 2147. JLI and the Management Defendants engaged in fraudulent and deceptive  
11 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
12 products were appropriate for minors, when in fact the products never should have been  
13 marketed to minors and are especially harmful to minors due to the potent and addictive  
14 nicotine doses, addictive qualities, and health risks.

15 2148. Defendants' conduct actually and proximately caused injury to Plaintiffs and  
16 class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members  
17 would have behaved differently and would not have purchased JUUL products or would have  
18 paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class  
19 members to purchase JUUL products they would not otherwise have purchased and enter into  
20 purchase contracts they would not otherwise have entered into. In addition, class members who  
21 are minors are entitled to full repayment of the amounts they spent on JUUL products.  
22 Plaintiffs seek—on behalf of themselves and each member of the class—damages, attorney's  
23 fees and costs, and injunctive relief (except as to the Management Defendants); as well as any  
24 other relief the Court may deem just or proper. *See* M.S.A. § 8.31. This cause of action will  
25 benefit the public by requiring JUUL to permanently cease the deceptive sale and marketing of  
26 dangerous products to consumers in Minnesota and throughout the country, and to require  
27 JUUL to cease, and take steps to prevent, the marketing and sale of JUUL products to minors.  
28

**b. Violation of Minnesota False Statement in Advertising Law  
(Minn. Stat. § 325F.67)**

2149. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2150. This claim is brought against JLI and, for certain claims below, the Management Defendants.

2151. Plaintiffs and class members are individuals who purchased JUUL products for personal purposes.

2152. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2153. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2154. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2155. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels

1 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

2 2156. The omissions were misleading and deceptive standing alone and were  
3 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
4 cigarettes and other representations.

5 2157. JUUL has made, published, disseminated, circulated and placed before the  
6 public, and caused to be made, published, disseminated, circulated and placed before the public  
7 advertisements of merchandise for use, consumption, purchase, and sale that contain material  
8 assertions, representations, and statements of fact that are untrue, deceptive, and misleading.

9 2158. JLI's conduct had the capacity to, tendency to, and in fact did, deceive  
10 reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
11 would have found it material to their purchasing decisions that JUUL's products (i) were not  
12 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
13 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
14 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
15 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
16 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
17 in Plaintiffs' and class members' decisions to purchase JUUL products.

18 2159. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
19 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
20 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
21 facts; because the facts would be material to reasonable consumers; because JLI actively  
22 concealed them; because JLI intended for consumers to rely on the omissions in question;  
23 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
24 made partial representations concerning the same subject matter as the omitted facts.

25 2160. JLI knew or should have known that its misrepresentations and/or omissions  
26 were false and misleading, and intended for consumers to rely on such misrepresentations and  
27 omissions.

28 2161. JLI and the Management Defendants engaged in fraudulent and deceptive



1 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
2 products were appropriate for minors, when in fact the products never should have been  
3 marketed to minors and are especially harmful to minors due to the potent and addictive  
4 nicotine doses, addictive qualities, and health risks.

5 2162. Defendants' conduct actually and proximately caused injury to Plaintiffs and  
6 class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members  
7 would have behaved differently and would not have purchased JUUL products or would have  
8 paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class  
9 members to purchase JUUL products they would not otherwise have purchased and enter into  
10 purchase contracts they would not otherwise have entered into. In addition, class members who  
11 are minors are entitled to full repayment of the amounts they spent on JUUL products.  
12 Plaintiffs seek—on behalf of themselves and each member of the class—damages, attorney's  
13 fees and costs, and injunctive relief (except as to the Management Defendants); as well as any  
14 other relief the Court may deem just or proper. *See* M.S.A. § 8.31. This cause of action will  
15 benefit the public by requiring JUUL to permanently cease the deceptive sale and marketing of  
16 dangerous products to consumers in Minnesota and throughout the country, and to require  
17 JUUL to cease, and take steps to prevent, the marketing and sale of JUUL products to minors.

18 **c. Violation of Minnesota Deceptive Trade Practices Act (Minn.**  
19 **Stat. § 325D.43, *et seq.*)**

20 2163. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

21 2164. This claim is brought against JLI.

22 2165. Plaintiffs and class members are individuals who purchased JUUL products for  
23 personal purposes.

24 2166. Defendants created and implemented a scheme to create a market for e-cigarettes  
25 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
26 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
27 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
28 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,

1 addictiveness, and significant risks of substantial physical injury from using JUUL products.

2       2167. Advertisements and representations for JUUL products contained deceptive  
3 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
4 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
5 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
6 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
7 decades, JLI used third parties and word of mouth to spread false and misleading information  
8 about JUUL products.

9       2168. Advertisements and representations for JUUL products concealed and failed to  
10 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
11 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
12 addictive, posed significant risks of substantial physical injury resulting from the use of the  
13 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
14 consumed through a pack of combustible cigarettes.

15       2169. The labels on JUUL products failed to disclose that the products posed  
16 significant risks of substantial physical injury resulting from the use of the products. The labels  
17 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

18       2170. The omissions were misleading and deceptive standing alone and were  
19 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
20 cigarettes and other representations.

21       2171. JLI's conduct constituted the following prohibited fraudulent and deceptive  
22 business practices: (a) misrepresenting that JUUL products have characteristics, ingredients,  
23 uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL products are  
24 of a particular standard, quality, or grade, or that goods are of a particular style or model, when  
25 they are not; (c) advertising goods or services with intent not to sell them as advertised; and (d)  
26 engaging in conduct that creates a likelihood of confusion or misunderstanding.

27       2172. JLI's conduct had the capacity to, tendency to, and in fact did, deceive  
28 reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs,

1 would have found it material to their purchasing decisions that JUUL's products (i) were not  
2 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
3 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
4 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
5 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
6 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
7 in Plaintiffs' and class members' decisions to purchase JUUL products.

8         2173. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
9 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
10 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
11 facts; because the facts would be material to reasonable consumers; because JLI actively  
12 concealed them; because JLI intended for consumers to rely on the omissions in question;  
13 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
14 made partial representations concerning the same subject matter as the omitted facts.

15         2174. JLI's conduct actually and proximately caused injury to Plaintiffs and class  
16 members and is likely to cause injury in the future. Absent Defendants' unfair and fraudulent  
17 conduct, Plaintiffs and class members would have behaved differently and would not have  
18 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
19 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
20 otherwise have purchased and enter into purchase contracts they would not otherwise have  
21 entered into. In addition, class members who are minors are entitled to full repayment of the  
22 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
23 member of the class—injunctive relief, attorney's fees and costs, and equitable relief; as well as  
24 any other relief the Court may deem just or proper.

25                     **d. Common Law Fraud**

26         2175. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

27         2176. This claim is brought against JLI.

28         2177. JUUL created and implemented a scheme to create a market for e-cigarettes and

1 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
2 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
3 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
4 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
5 addictiveness, and significant risks of substantial physical injury from using JUUL products.

6 2178. Advertisements and representations for JUUL products contained deceptive  
7 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
8 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
9 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
10 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
11 decades, JLI used third parties and word of mouth to spread false and misleading information  
12 about JUUL products.

13 2179. Advertisements and representations for JUUL products concealed and failed to  
14 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
15 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
16 addictive, posed significant risks of substantial physical injury resulting from the use of the  
17 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
18 consumed through a pack of combustible cigarettes.

19 2180. The labels on JUUL products failed to disclose that the products posed  
20 significant risks of substantial physical injury resulting from the use of the products. The labels  
21 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

22 2181. The omissions were misleading and deceptive standing alone and were  
23 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
24 cigarettes and other representations.

25 2182. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
26 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
27 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
28 material to their purchasing decisions that JUUL's products (i) were not smoking cessation

1 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
2 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
3 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
4 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
5 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
6 Plaintiffs' and class members' decisions to purchase JUUL products.

7 2183. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
8 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
9 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
10 facts; because the facts would be material to reasonable consumers; because JUUL products  
11 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
12 representations concerning the same subject matter as the omitted facts.

13 2184. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
14 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
15 and/or omissions. Reasonable consumers would have been expected to have relied on the  
16 misrepresentations and omissions.

17 2185. Defendants knew or should have known that their misrepresentations and/or  
18 omissions were false and misleading, and intended for consumers to rely on such  
19 misrepresentations and omissions.

20 2186. JLI knew that JUUL products were not safe or reasonable alternatives to  
21 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
22 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
23 products.

24 2187. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
25 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
26 and would not have purchased JUUL products or would have paid less for them. JLI's  
27 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
28 products they would not otherwise have purchased and enter into purchase contracts they would

1 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
2 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
3 relief the Court may deem just or proper.

4 **e. Breach of the Implied Warranty of Merchantability**

5 2188. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

6 2189. This claim is brought against JLI.

7 2190. JUUL has at all times been a merchant with respect to the products which were  
8 sold to Plaintiff and the class and was in the business of selling such products.

9 2191. Each JUUL product sold by JUUL comes with an implied warranty that it will  
10 merchantable and fit for the ordinary purpose for which it would be used. *See* Minn. Stat.  
11 § 336.2-314. JUUL has breached its implied warranty of merchantability because its products  
12 were not in merchantable condition when sold, were defective when sold, did not conform to the  
13 promises and affirmations of fact made on the products' containers or labels, and/or do not  
14 possess even the most basic degree of fitness for ordinary use.

15 2192. The ordinary intended purpose of JUUL's products—and the purpose for which  
16 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
17 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
18 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
19 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
20 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
21 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
22 recreation smoking devices.

23 2193. Plaintiffs and each member of the class have had sufficient direct dealings with  
24 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
25 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
26 each member of the class, on the other hand.

27 2194. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
28 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and

1 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
2 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
3 the express purpose an intent of being sold to consumers.

4 2195. Plaintiffs and the members of the class were injured as a direct and proximate  
5 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
6 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
7 because, had they been aware of the unmerchantable condition of JUUL products, they would  
8 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
9 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

10 2196. JUUL was provided notice of these issues by numerous complaints filed against  
11 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
12 individual letters and communications sent by consumers before or within a reasonable amount  
13 of time after they discovered or should have discovered that's JUUL product were defective and  
14 unmerchantable.

15 **f. Unjust Enrichment**

16 2197. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

17 2198. This claim is brought against JLI and the Management Defendants.

18 2199. Defendants created and implemented a scheme to create a market for e-cigarettes  
19 and substantially increase sales of JUUL products through a pervasive pattern of false and  
20 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
21 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
22 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
23 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
24 products.

25 2200. Defendants were unjustly enriched as a result of their wrongful conduct,  
26 including through the false and misleading advertisements and omissions regarding (i) whether  
27 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
28 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were



1 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
2 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
3 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
4 enriched through their scheme of marketing their products to minors. Minnesota law (*see* Minn.  
5 Stat. §§ 609.685) prohibits the marketing and sale of JUUL products to minors.

6 2201. Defendants requested and received a measurable benefit at the expense of  
7 Plaintiffs and class members in the form of payment for JUUL products.

8 2202. Defendants appreciated, recognized, and chose to accept the monetary benefits  
9 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
10 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

11 2203. There is no justification for Defendants' enrichment. It would be inequitable,  
12 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
13 benefits were procured as a result of their wrongful conduct.

14 2204. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
15 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
16 with Defendant.

17 2205. Plaintiffs plead this claim separately as well as in the alternative to their other  
18 claims, as without such claims they would have no adequate legal remedy.

19 **24. Mississippi**

20 2206. Plaintiffs bring each of the following claims on behalf of the Mississippi  
21 Subclass under Mississippi law.

22 **a. Violation of Mississippi Consumer Protection Act (Miss. Code**  
23 **Ann. § 75-24-1, et seq.)**

24 2207. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

25 2208. This claim is brought against JLI.

26 2209. Plaintiffs and class members are individuals who purchased JUUL products for  
27 personal purposes.

28 2210. Defendants created and implemented a scheme to create a market for e-cigarettes

1 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
2 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
3 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
4 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
5 addictiveness, and significant risks of substantial physical injury from using JUUL products.

6 2211. Advertisements and representations for JUUL products contained deceptive  
7 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
8 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
9 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
10 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
11 decades, JLI used third parties and word of mouth to spread false and misleading information  
12 about JUUL products.

13 2212. Advertisements and representations for JUUL products concealed and failed to  
14 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
15 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
16 addictive, posed significant risks of substantial physical injury resulting from the use of the  
17 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
18 consumed through a pack of combustible cigarettes.

19 2213. The labels on JUUL products failed to disclose that the products posed  
20 significant risks of substantial physical injury resulting from the use of the products. The labels  
21 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

22 2214. The omissions were misleading and deceptive standing alone and were  
23 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
24 cigarettes and other representations.

25 2215. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
26 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
27 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
28 products are of a particular standard, quality, or grade, or that goods are of a particular style or

1 model, when they are not; and (c) advertising goods or services with intent not to sell them as  
2 advertised.

3 2216. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
4 omissions had the capacity to, had the tendency to, were likely to, and in fact did, deceive  
5 reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
6 would have found it material to their purchasing decisions that JUUL's products (i) were not  
7 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
8 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
9 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
10 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
11 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
12 in Plaintiffs' and class members' decisions to purchase JUUL products.

13 2217. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
14 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
15 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
16 facts; because the facts would be material to reasonable consumers; because JLI actively  
17 concealed them; because JLI intended for consumers to rely on the omissions in question;  
18 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
19 made partial representations concerning the same subject matter as the omitted facts.

20 2218. Defendants knew or should have known that their misrepresentations and/or  
21 omissions were false and misleading, and intended for consumers to rely on such  
22 misrepresentations and omissions.

23 2219. Defendants' conduct actually and proximately caused an ascertainable loss of  
24 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent  
25 conduct, Plaintiffs and class members would have behaved differently and would not have  
26 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
27 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
28 otherwise have purchased and enter into purchase contracts they would not otherwise have

1 entered into. In addition, class members who are minors are entitled to full repayment of the  
2 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
3 member of the class—damages, as well as any other relief the Court may deem just or proper.

4 **b. Common Law Fraud**

5 2220. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

6 2221. This claim is brought against JLI.

7 2222. JUUL created and implemented a scheme to create a market for e-cigarettes and  
8 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
9 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
10 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
11 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
12 addictiveness, and significant risks of substantial physical injury from using JUUL products.

13 2223. Advertisements and representations for JUUL products contained deceptive  
14 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
15 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
16 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
17 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
18 decades, JLI used third parties and word of mouth to spread false and misleading information  
19 about JUUL products.

20 2224. Advertisements and representations for JUUL products concealed and failed to  
21 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
22 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
23 addictive, posed significant risks of substantial physical injury resulting from the use of the  
24 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
25 consumed through a pack of combustible cigarettes.

26 2225. The labels on JUUL products failed to disclose that the products posed  
27 significant risks of substantial physical injury resulting from the use of the products. The labels  
28 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

1           2226. The omissions were misleading and deceptive standing alone and were  
2 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
3 cigarettes and other representations.

4           2227. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
5 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
6 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
7 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
8 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
9 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
10 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
11 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
12 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
13 Plaintiffs' and class members' decisions to purchase JUUL products.

14           2228. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
15 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
16 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
17 facts; because the facts would be material to reasonable consumers; because JUUL products  
18 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
19 representations concerning the same subject matter as the omitted facts.

20           2229. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
21 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
22 and/or omissions. Reasonable consumers would have been expected to have relied on the  
23 misrepresentations and omissions.

24           2230. Defendants knew or should have known that their misrepresentations and/or  
25 omissions were false and misleading, and intended for consumers to rely on such  
26 misrepresentations and omissions.

27           2231. JLI knew that JUUL products were not safe or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
2 products.

3 2232. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
4 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
5 and would not have purchased JUUL products or would have paid less for them. JLI's  
6 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
7 products they would not otherwise have purchased and enter into purchase contracts they would  
8 not otherwise have entered into. Plaintiffs seek, on behalf of themselves and each member of the  
9 class, damages in an amount to be proven at trial and punitive damages, as well as any other  
10 relief the Court may deem just or proper.

11 **c. Breach of the Implied Warranty of Merchantability**

12 2233. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

13 2234. This claim is brought against JLI.

14 2235. JUUL has at all times been a merchant with respect to the products which were  
15 sold to Plaintiff and the class and was in the business of selling such products.

16 2236. Each JUUL product sold by JUUL comes with an implied warranty that it will  
17 merchantable and fit for the ordinary purpose for which it would be used. *See* Miss. Code Ann.  
18 § 75-2-314. JUUL has breached its implied warranty of merchantability because its products  
19 were not in merchantable condition when sold, were defective when sold, did not conform to the  
20 promises and affirmations of fact made on the products' containers or labels, and/or do not  
21 possess even the most basic degree of fitness for ordinary use.

22 2237. The ordinary intended purpose of JUUL's products—and the purpose for which  
23 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
24 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
25 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
26 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
27 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
28 products are not fit for their ordinary, intended use as either cigarette replacement devices or

1 recreation smoking devices.

2 2238. Plaintiffs and each member of the class have had sufficient direct dealings with  
3 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
4 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
5 each member of the class, on the other hand.

6 2239. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
7 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
8 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
9 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
10 the express purpose an intent of being sold to consumers.

11 2240. Plaintiffs and the members of the class were injured as a direct and proximate  
12 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
13 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
14 because, had they been aware of the unmerchantable condition of JUUL products, they would  
15 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
16 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

17 2241. JUUL was provided notice of these issues by numerous complaints filed against  
18 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
19 individual letters and communications sent by consumers before or within a reasonable amount  
20 of time after they discovered or should have discovered that's JUUL product were defective and  
21 unmerchantable.

22 **d. Unjust Enrichment**

23 2242. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

24 2243. This claim is brought against JLI and the Management Defendants.

25 2244. Defendants created and implemented a scheme to create a market for e-cigarettes  
26 and substantially increase sales of JUUL products through a pervasive pattern of false and  
27 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
28 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,



1 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
2 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
3 products.

4 2245. Defendants were unjustly enriched as a result of their wrongful conduct,  
5 including through the false and misleading advertisements and omissions regarding (i) whether  
6 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
7 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
8 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
9 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
10 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
11 enriched through their scheme of marketing their products to minors. Mississippi law (*see* Miss.  
12 Code Ann. § 97-32-51(2)) prohibits the marketing and sale of JUUL products to minors.

13 2246. Defendants requested and received a measurable benefit at the expense of  
14 Plaintiffs and class members in the form of payment for JUUL products.

15 2247. Defendants appreciated, recognized, and chose to accept the monetary benefits  
16 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
17 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

18 2248. There is no justification for Defendants' enrichment. It would be inequitable,  
19 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
20 benefits were procured as a result of their wrongful conduct.

21 2249. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
22 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
23 with Defendant.

24 2250. Plaintiffs plead this claim separately as well as in the alternative to their other  
25 claims, as without such claims they would have no adequate legal remedy.

26 **25. Missouri**

27 2251. Plaintiffs bring each of the following claims on behalf of the Missouri Subclass  
28 under Missouri law.

**a. Violation of the Missouri Merchandising Practices Act (Mo. Rev. Stat. § 407.010, *et seq.*)**

2252. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2253. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

2254. Plaintiffs and class members are persons who purchased JUUL products for personal purposes.

2255. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2256. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2257. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2258. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels

1 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

2 2259. The omissions were misleading and deceptive standing alone and were  
3 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
4 cigarettes and other representations.

5 2260. JLI's conduct was unfair and unconscionable in that it included (i) the  
6 manufacture and sale of products with a heightened propensity to cause addiction and physical  
7 injuries and (ii) misrepresentations and omissions of material facts concerning the  
8 characteristics and safety of JUUL products that offended public policy; were immoral,  
9 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
10 substantial harm that greatly outweighs any possible utility from the conduct.

11 2261. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
12 omissions had the capacity or tendency to mislead, deceive or cheat, and in fact did, mislead,  
13 deceive, and/or cheat reasonable consumers including the Plaintiffs. In addition, the  
14 misrepresentations and omissions were the type that tend to create a false impression.  
15 Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing  
16 decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable  
17 alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms,  
18 (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury  
19 resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL  
20 pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of  
21 these facts would have been a substantial factor in Plaintiffs' and class members' decisions to  
22 purchase JUUL products.

23 2262. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
24 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
25 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
26 facts; because the facts would be material to reasonable consumers; because JLI actively  
27 concealed them; because JLI intended for consumers to rely on the omissions in question;  
28 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI

made partial representations concerning the same subject matter as the omitted facts.

2263. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL products were appropriate for minors, when in fact the products never should have been marketed to minors and are especially harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health risks.

2264. In addition, all Defendants engaged in unfair and unconscionable conduct because the targeting of minors offends public policy (*see* Mo. Rev. Stat. §§ 407.926 and 407.931); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has caused substantial harm that greatly outweighs any possible utility from the conduct.

2265. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI and others have continued the deceptive, misleading, unfair, and unconscionable practices that Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by minors continues to rise.

2266. Defendants' conduct actually and proximately caused an ascertainable loss of money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—actual damages, punitive damages, attorney's fees, and equitable relief; as well as any other relief the Court may deem just or proper.

**b. Common Law Fraud**

2267. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           2268. This claim is brought against JLI.

2           2269. JUUL created and implemented a scheme to create a market for e-cigarettes and  
3 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8           2270. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15           2271. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21           2272. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24           2273. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27           2274. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
28 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers

1 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
2 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
5 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
6 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
7 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
8 Plaintiffs' and class members' decisions to purchase JUUL products.

9       2275. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JUUL products  
13 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
14 representations concerning the same subject matter as the omitted facts.

15       2276. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
16 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
17 and/or omissions. Reasonable consumers would have been expected to have relied on the  
18 misrepresentations and omissions.

19       2277. Defendants knew or should have known that their misrepresentations and/or  
20 omissions were false and misleading, and intended for consumers to rely on such  
21 misrepresentations and omissions.

22       2278. JLI knew that JUUL products were not safe or reasonable alternatives to  
23 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
24 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
25 products.

26       2279. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
27 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
28 and would not have purchased JUUL products or would have paid less for them. JLI's

1 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
2 products they would not otherwise have purchased and enter into purchase contracts they would  
3 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
4 the class, damages in an amount to be proven at trial and punitive damages, as well as any other  
5 relief the Court may deem just or proper.

6 **c. Breach of the Implied Warranty of Merchantability**

7 2280. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 2281. This claim is brought against JLI.

9 2282. JUUL has at all times been a merchant with respect to the products which were  
10 sold to Plaintiff and the class and was in the business of selling such products.

11 2283. Each JUUL product sold by JUUL comes with an implied warranty that it will  
12 merchantable and fit for the ordinary purpose for which it would be used. *See* Mo. Rev. Stat.  
13 § 400.2-314. JUUL has breached its implied warranty of merchantability because its products  
14 were not in merchantable condition when sold, were defective when sold, did not conform to the  
15 promises and affirmations of fact made on the products' containers or labels, and/or do not  
16 possess even the most basic degree of fitness for ordinary use.

17 2284. The ordinary intended purpose of JUUL's products—and the purpose for which  
18 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
19 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
20 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
21 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
22 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
23 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
24 recreation smoking devices.

25 2285. Plaintiffs and each member of the class have had sufficient direct dealings with  
26 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
27 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
28 each member of the class, on the other hand.



2286. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

2287. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2288. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

2289. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2290. This claim is brought against JLI and the Management Defendants.

2291. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2292. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether

JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Missouri law (*see* Mo. Rev. Stat. §§ 407.926 and 407.931) prohibits the marketing and sale of JUUL products to minors.

2293. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

2294. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

2295. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

2296. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

2297. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **26. Montana**

2298. Plaintiffs bring each of the following claims on behalf of the Montana Subclass under Montana law.

### **a. Violation of the Montana Unfair Trade Practices and Consumer Protection Act (Mont. Code Ann. § 30-14-101, *et seq.*)**

2299. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2300. This claim is brought against JLI and, for certain unfair and/or unconscionable

1 conduct claims as noted below, all Defendants.

2 2301. Plaintiffs and class members are persons who purchased JUUL products for  
3 personal purposes.

4 2302. Defendants created and implemented a scheme to create a market for e-cigarettes  
5 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
6 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
7 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
8 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
9 addictiveness, and significant risks of substantial physical injury from using JUUL products.

10 2303. Advertisements and representations for JUUL products contained deceptive  
11 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
12 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
13 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
14 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
15 decades, JLI used third parties and word of mouth to spread false and misleading information  
16 about JUUL products.

17 2304. Advertisements and representations for JUUL products concealed and failed to  
18 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
19 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
20 addictive, posed significant risks of substantial physical injury resulting from the use of the  
21 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
22 consumed through a pack of combustible cigarettes.

23 2305. The labels on JUUL products failed to disclose that the products posed  
24 significant risks of substantial physical injury resulting from the use of the products. The labels  
25 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

26 2306. The omissions were misleading and deceptive standing alone and were  
27 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
28 cigarettes and other representations.

2307. JLI's conduct was unfair and unconscionable in that it included (i) the manufacture and sale of products with a heightened propensity to cause addiction and physical injuries and (ii) misrepresentations and omissions of material facts concerning the characteristics and safety of JUUL products that offended public policy; were immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused substantial harm that greatly outweighs any possible utility from the conduct.

2308. JLI's conduct was fraudulent and deceptive because the misrepresentations and omissions at issue were likely to, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

2309. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

2310. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL products were appropriate for minors, when in fact the products never should have been marketed to minors and are especially harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health risks.

2311. In addition, all Defendants engaged in unfair and unconscionable conduct because the targeting of minors offends public policy (*see, e.g.*, Mont. Code Ann. § 16-11-305); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has caused substantial harm that greatly outweighs any possible utility from the conduct.

2312. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI and others have continued the deceptive, misleading, unfair, and unconscionable practices that Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by minors continues to rise.

2313. Defendants' conduct actually and proximately caused an ascertainable loss of money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—actual damages, treble damages, and attorney's fees, as well as any other relief the Court may deem just or proper.

**b. Common Law Fraud**

2314. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2315. This claim is brought against JLI.

2316. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2317. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2318. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2319. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

2320. The omissions were misleading and deceptive standing alone and were particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to cigarettes and other representations.

2321. JLI's conduct was fraudulent and deceptive because its misrepresentations and omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in

1 Plaintiffs' and class members' decisions to purchase JUUL products.

2 2322. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
3 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
4 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
5 facts; because the facts would be material to reasonable consumers; because JUUL products  
6 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
7 representations concerning the same subject matter as the omitted facts.

8 2323. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
9 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
10 and/or omissions. Reasonable consumers would have been expected to have relied on the  
11 misrepresentations and omissions.

12 2324. Defendants knew or should have known that their misrepresentations and/or  
13 omissions were false and misleading, and intended for consumers to rely on such  
14 misrepresentations and omissions.

15 2325. JLI knew that JUUL products were not safe or reasonable alternatives to  
16 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
17 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
18 products.

19 2326. JLI's conduct actually and proximately caused damage to Plaintiffs and class  
20 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
21 and would not have purchased JUUL products or would have paid less for them. JLI's  
22 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
23 products they would not otherwise have purchased and enter into purchase contracts they would  
24 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
25 the class, damages in an amount to be proven at trial and punitive damages, as well as any other  
26 relief the Court may deem just or proper.

27 **c. Breach of the Implied Warranty of Merchantability**

28 2327. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.



2328. This claim is brought against JLI.

2329. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

2330. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. *See* Mont. Code Ann. § 30-2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

2331. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

2332. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

2333. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose and intent of being sold to consumers.

2334. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of

the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2335. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

2336. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2337. This claim is brought against JLI and the Management Defendants.

2338. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2339. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Montana law (*see* Mont. Code Ann. § 16-11-305) prohibits the marketing and sale of JUUL products to minors.

2340. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

2341. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

2342. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

2343. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

2344. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

## **27. Nebraska**

2345. Plaintiffs bring each of the following claims on behalf of the Nebraska Subclass under Nebraska law.

### **a. Violation of the Nebraska Consumer Protection Act (Neb. Rev. Stat. §§ 59-1601, *et seq.*)**

2346. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2347. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

2348. Plaintiffs and class members and are persons who purchased JUUL products for personal purposes.

2349. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,

1     addictiveness, and significant risks of substantial physical injury from using JUUL products.

2             2350. Advertisements and representations for JUUL products contained deceptive  
3     statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
4     to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
5     cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
6     not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
7     decades, JLI used third parties and word of mouth to spread false and misleading information  
8     about JUUL products.

9             2351. Advertisements and representations for JUUL products concealed and failed to  
10    disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
11    combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
12    addictive, posed significant risks of substantial physical injury resulting from the use of the  
13    products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
14    consumed through a pack of combustible cigarettes.

15            2352. The labels on JUUL products failed to disclose that the products posed  
16    significant risks of substantial physical injury resulting from the use of the products. The labels  
17    also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

18            2353. The omissions were misleading and deceptive standing alone and were  
19    particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
20    cigarettes and other representations.

21            2354. JLI's conduct was unfair and unconscionable in that it included (i) the  
22    manufacture and sale of products with a heightened propensity to cause addiction and physical  
23    injuries and (ii) misrepresentations and omissions of material facts concerning the  
24    characteristics and safety of JUUL products that offended public policy; were immoral,  
25    unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
26    substantial harm that greatly outweighs any possible utility from the conduct.

27            2355. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
28    omissions at issue were likely to, and in fact did, deceive reasonable consumers and had the

tendency or capacity to mislead reasonable consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

2356. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

2357. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2358. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL products were appropriate for minors, when in fact the products never should have been marketed to minors and are especially harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health risks.

2359. In addition, all Defendants engaged in unfair and unconscionable conduct because the targeting of minors offends public policy (in particular Neb. Rev. Stat. §§ 28-1419; 28-1425); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has caused substantial harm that greatly outweighs any possible utility from the

1 conduct.

2 2360. As alleged above, all Defendants participated and/or facilitated the marketing of  
3 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
4 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
5 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
6 use of JUUL products by minors continues to rise.

7 2361. Defendants' deceptive and unfair conduct has had a detrimental impact on the  
8 public interest.

9 2362. Defendants' conduct actually and proximately caused loss of money or property  
10 to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs  
11 and class members would have behaved differently and would not have purchased JUUL  
12 products or would have paid less for them. Defendants' misrepresentations and omissions  
13 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
14 purchased and enter into purchase contracts they would not otherwise have entered into. In  
15 addition, class members who are minors are entitled to full repayment of the amounts they spent  
16 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
17 actual damages (as increased as the Court may deem fit), injunctive relief (except as to the  
18 Management Defendants), and reasonable attorneys' fees, as well as any other relief the Court  
19 may deem just or proper.

20 **b. Violation of the Nebraska Uniform Deceptive Trade Practices**  
21 **Act (Neb. Rev. Stat. §§ 87-301, *et seq.*)**

22 2363. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

23 2364. This claim is brought against JLI.

24 2365. Plaintiffs and class members are persons who purchased JUUL products for  
25 personal purposes.

26 2366. Defendants created and implemented a scheme to create a market for e-cigarettes  
27 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
28 statements and omissions. Defendants aimed to portray JUUL products as cool and safe

alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2367. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2368. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2369. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

2370. The omissions were misleading and deceptive standing alone and were particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to cigarettes and other representations.

2371. JLI's conduct constituted the following prohibited fraudulent, deceptive, and unfair business practices: (a) misrepresenting that JUUL products have characteristics, ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL products are of a particular standard, quality, or grade, or that goods are of a particular style or model, when they are not; (c) advertising goods or services with intent not to sell them as advertised; (d) causing confusion or misunderstanding as to the effects a substance causes when



1 ingested, inhaled, or otherwise introduced into the human body; and (e) making a deceptive  
2 and misleading representations, and omitting material information, about a substance and failing  
3 to identify the contents of the package or the nature of the substance contained inside the  
4 package.

5 2372. JLI's conduct had the capacity to and was likely to, and in fact did, deceive  
6 reasonable consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
7 would have found it material to their purchasing decisions that JUUL's products (i) were not  
8 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
9 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
10 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
11 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
12 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
13 in Plaintiffs' and class members' decisions to purchase JUUL products.

14 2373. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
15 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
16 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
17 facts; because the facts would be material to reasonable consumers; because JLI actively  
18 concealed them; because JLI intended for consumers to rely on the omissions in question;  
19 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
20 made partial representations concerning the same subject matter as the omitted facts.

21 2374. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
22 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
23 Reasonable consumers would have been expected to have relied on the misrepresentations and  
24 omissions.

25 2375. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
26 class members, and is likely to cause damage in the future. Absent JLI's conduct, Plaintiffs and  
27 class members would have behaved differently and would not have purchased JUUL products  
28 or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and

1 class members to purchase JUUL products they would not otherwise have purchased and enter  
2 into purchase contracts they would not otherwise have entered into. In addition, class members  
3 who are minors are entitled to full repayment of the amounts they spent on JUUL products.  
4 Plaintiffs seek—on behalf of themselves and each member of the class—injunctive relief, as  
5 well as any other relief the Court may deem just or proper. Plaintiffs are also entitled to  
6 reasonable attorneys’ fees because JUUL willfully engaged in trade practices that are known to  
7 be deceptive.

8 **c. Common Law Fraud**

9 2376. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 2377. This claim is brought against JLI.

11 2378. JUUL created and implemented a scheme to create a market for e-cigarettes and  
12 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
13 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
14 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
15 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
16 addictiveness, and significant risks of substantial physical injury from using JUUL products.

17 2379. Advertisements and representations for JUUL products contained deceptive  
18 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
19 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
20 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
21 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
22 decades, JLI used third parties and word of mouth to spread false and misleading information  
23 about JUUL products.

24 2380. Advertisements and representations for JUUL products concealed and failed to  
25 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed significant risks of substantial physical injury resulting from the use of the  
28 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine

1 consumed through a pack of combustible cigarettes.

2 2381. The labels on JUUL products failed to disclose that the products posed  
3 significant risks of substantial physical injury resulting from the use of the products. The labels  
4 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

5 2382. The omissions were misleading and deceptive standing alone and were  
6 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
7 cigarettes and other representations.

8 2383. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
9 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
10 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
11 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
12 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
13 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
14 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
15 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
16 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
17 Plaintiffs' and class members' decisions to purchase JUUL products.

18 2384. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
19 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
20 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
21 facts; because the facts would be material to reasonable consumers; because JUUL products  
22 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
23 representations concerning the same subject matter as the omitted facts.

24 2385. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
25 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
26 and/or omissions. Reasonable consumers would have been expected to have relied on the  
27 misrepresentations and omissions.

28 2386. Defendants knew or should have known that their misrepresentations and/or

omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2387. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

2388. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**d. Breach of the Implied Warranty of Merchantability**

2389. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2390. This claim is brought against JLI.

2391. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

2392. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. Neb. U.C.C. § 2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

2393. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation

1 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
2 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
3 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
4 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
5 recreation smoking devices.

6 2394. Plaintiffs and each member of the class have had sufficient direct dealings with  
7 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
8 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
9 each member of the class, on the other hand.

10 2395. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
11 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
12 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
13 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
14 the express purpose an intent of being sold to consumers.

15 2396. Plaintiffs and the members of the class were injured as a direct and proximate  
16 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
17 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
18 because, had they been aware of the unmerchantable condition of JUUL products, they would  
19 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
20 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

21 2397. JUUL was provided notice of these issues by numerous complaints filed against  
22 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
23 individual letters and communications sent by consumers before or within a reasonable amount  
24 of time after they discovered or should have discovered that's JUUL product were defective and  
25 unmerchantable.

26 **e. Unjust Enrichment**

27 2398. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

28 2399. This claim is brought against JLI and the Management Defendants.

1           2400. Defendants created and implemented a scheme to create a market for e-cigarettes  
2 and substantially increase sales of JUUL products through a pervasive pattern of false and  
3 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
4 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
5 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
6 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
7 products.

8           2401. Defendants were unjustly enriched as a result of their wrongful conduct,  
9 including through the false and misleading advertisements and omissions regarding (i) whether  
10 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
11 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
12 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
13 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
14 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
15 enriched through their scheme of marketing their products to minors. Neb. Rev. Stat. §§ 28-  
16 1419 and 28-1425 prohibit the marketing and sale of JUUL products to minors.

17           2402. Defendants requested and received a measurable benefit at the expense of  
18 Plaintiffs and class members in the form of payment for JUUL products.

19           2403. Defendants appreciated, recognized, and chose to accept the monetary benefits  
20 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
21 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

22           2404. There is no justification for Defendants' enrichment. It would be inequitable,  
23 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
24 benefits were procured as a result of their wrongful conduct.

25           2405. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
26 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
27 with Defendant.

28           2406. Plaintiffs plead this claim separately as well as in the alternative to their other

claims, as without such claims they would have no adequate legal remedy.

**28. Nevada**

2407. Plaintiffs bring each of the following claims on behalf of the Nevada Subclass under Nevada law.

**a. Violation of the Nevada Deceptive Trade Practices Act (Nev. Rev. Stat. §§ 598.0903, *et seq.*)**

2408. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2409. This claim is brought against JLI, and for certain claims below, the Management Defendants.

2410. Plaintiffs and class members purchased JUUL products for personal purposes.

2411. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2412. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2413. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine



1 consumed through a pack of combustible cigarettes.

2 2414. The labels on JUUL products failed to disclose that the products posed  
3 significant risks of substantial physical injury resulting from the use of the products. The labels  
4 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

5 2415. The omissions were misleading and deceptive standing alone and were  
6 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
7 cigarettes and other representations.

8 2416. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
9 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
10 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
11 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
12 model, when they are not; (c) advertising goods or services with intent not to sell them as  
13 advertised; (d) knowingly making other false representations in a transaction; and (e) failing to  
14 disclose a material fact in connection with the sale of goods or services.

15 2417. JLI's conduct was likely to, and in fact did, deceive reasonable consumers  
16 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
17 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
18 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
19 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
20 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
21 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
22 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
23 Plaintiffs' and class members' decisions to purchase JUUL products.

24 2418. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
25 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
26 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
27 facts; because the facts would be material to reasonable consumers; because JLI actively  
28 concealed them; because JLI intended for consumers to rely on the omissions in question;

1 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
2 made partial representations concerning the same subject matter as the omitted facts.

3 2419. JLI's conduct was unlawful because it violated state and federal statutes and  
4 regulations relating to the sale of e-cigarettes, including the Racketeer Influenced and Corrupt  
5 Organizations Act, 18 U.S.C. § 1961, *et seq.*; the Magnuson-Moss Warranty Act, 15 U.S.C.  
6 §§ 2301, *et seq.*; and Nev. Rev. Stat. § 202.24935.

7 2420. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
8 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
9 Reasonable consumers would have been expected to have relied on the misrepresentations and  
10 omissions.

11 2421. Defendants knew or should have known that their misrepresentations and/or  
12 omissions were false and misleading, and intended for consumers to rely on such  
13 misrepresentations and omissions.

14 2422. JLI and the Management Defendants engaged in fraudulent and deceptive  
15 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
16 products were appropriate for minors, when in fact the products never should have been  
17 marketed to minors and are especially harmful to minors due to the potent and addictive  
18 nicotine doses, addictive qualities, and health risks.

19 2423. Defendants' conduct actually and proximately caused actual damages to  
20 Plaintiffs and class members, who were victims of Defendants' unfair and fraudulent conduct.  
21 Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have  
22 behaved differently and would not have purchased JUUL products or would have paid less for  
23 them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to  
24 purchase JUUL products they would not otherwise have purchased and enter into purchase  
25 contracts they would not otherwise have entered into. In addition, class members who are  
26 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
27 seek—on behalf of themselves and each member of the class—actual damages, injunctive relief  
28 (except as to the Management Defendants), and reasonable attorneys' fees, as well as any other

relief the Court may deem just or proper. Nev. Rev. Stat. § 41.600(1), (2)(e).

**b. Common Law Fraud**

2424. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2425. This claim is brought against JLI.

2426. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2427. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2428. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2429. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

2430. The omissions were misleading and deceptive standing alone and were particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to

1 cigarettes and other representations.

2       2431. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
3 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
4 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
5 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
6 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
7 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
8 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
9 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
10 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
11 Plaintiffs' and class members' decisions to purchase JUUL products.

12       2432. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
13 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
14 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
15 facts; because the facts would be material to reasonable consumers; because JUUL products  
16 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
17 representations concerning the same subject matter as the omitted facts.

18       2433. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
19 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
20 and/or omissions. Reasonable consumers would have been expected to have relied on the  
21 misrepresentations and omissions.

22       2434. Defendants knew or should have known that their misrepresentations and/or  
23 omissions were false and misleading, and intended for consumers to rely on such  
24 misrepresentations and omissions.

25       2435. JLI knew that JUUL products were not safe or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
28 products.

2436. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

2437. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2438. This claim is brought against JLI.

2439. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

2440. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. Nev. Rev. Stat. Ann. § 104. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

2441. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

2442. Plaintiffs and each member of the class have had sufficient direct dealings with

1 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
2 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
3 each member of the class, on the other hand.

4 2443. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
5 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
6 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
7 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
8 the express purpose an intent of being sold to consumers.

9 2444. Plaintiffs and the members of the class were injured as a direct and proximate  
10 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
11 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
12 because, had they been aware of the unmerchantable condition of JUUL products, they would  
13 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
14 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

15 2445. JUUL was provided notice of these issues by numerous complaints filed against  
16 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
17 individual letters and communications sent by consumers before or within a reasonable amount  
18 of time after they discovered or should have discovered that's JUUL product were defective and  
19 unmerchantable.

20 **d. Unjust Enrichment**

21 2446. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

22 2447. This claim is brought against JLI and the Management Defendants.

23 2448. Defendants created and implemented a scheme to create a market for e-cigarettes  
24 and substantially increase sales of JUUL products through a pervasive pattern of false and  
25 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
26 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
27 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
28 doses, addictiveness, and significant risks of substantial physical injury from using JUUL

1 products.

2 2449. Defendants were unjustly enriched as a result of their wrongful conduct,  
3 including through the false and misleading advertisements and omissions regarding (i) whether  
4 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
5 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
6 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
7 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
8 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
9 enriched through their scheme of marketing their products to minors. Nev. Rev. Stat.  
10 § 202.24935 prohibits the marketing and sale of JUUL products to minors.

11 2450. Defendants requested and received a measurable benefit at the expense of  
12 Plaintiffs and class members in the form of payment for JUUL products.

13 2451. Defendants appreciated, recognized, and chose to accept the monetary benefits  
14 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
15 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

16 2452. There is no justification for Defendants' enrichment. It would be inequitable,  
17 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
18 benefits were procured as a result of their wrongful conduct.

19 2453. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
20 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
21 with Defendant.

22 2454. Plaintiffs plead this claim separately as well as in the alternative to their other  
23 claims, as without such claims they would have no adequate legal remedy.

24 **29. New Hampshire**

25 2455. Plaintiffs bring each of the following claims on behalf of the New Hampshire  
26 Subclass under New Hampshire law.  
27  
28



**a. Violation of the New Hampshire Regulation of Business Practices for Consumer Protection (N.H. Rev. Stat. §§ 358-A:1, *et seq.*)**

2456. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2457. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

2458. The marketing and sale of JUUL products constitutes “trade” and “commerce” as defined by statute. Defendants are “persons” as defined by the statute.

2459. Plaintiffs and class members purchased JUUL products for personal purposes.

2460. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2461. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2462. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2463. The labels on JUUL products failed to disclose that the products posed

1 significant risks of substantial physical injury resulting from the use of the products. The labels  
2 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

3 2464. The omissions were misleading and deceptive standing alone and were  
4 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
5 cigarettes and other representations.

6 2465. JLI's conduct was unfair and unconscionable in that it included (i) the  
7 manufacture and sale of products with a heightened propensity to cause addiction and physical  
8 injuries and (ii) misrepresentations and omissions of material facts concerning the  
9 characteristics and safety of JUUL products that offended public policy; were immoral,  
10 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
11 substantial harm that greatly outweighs any possible utility from the conduct.

12 2466. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
13 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
14 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
15 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
16 model, when they are not; or (c) advertising goods or services with intent not to sell them as  
17 advertised.

18 2467. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
19 omissions created a likelihood of confusion or misunderstanding reasonable consumers,  
20 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
21 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
22 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
23 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
24 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
25 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
26 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
27 Plaintiffs' and class members' decisions to purchase JUUL products. In addition, JUUL's  
28 fraudulent and deceptive conduct was of a level of rascality that would raise an eyebrow of

1 someone inured to the rough and tumble of the world of commerce.

2       2468. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
3 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
4 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
5 facts; because the facts would be material to reasonable consumers; because JLI actively  
6 concealed them; because JLI intended for consumers to rely on the omissions in question;  
7 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
8 made partial representations concerning the same subject matter as the omitted facts.

9       2469. JLI and the Management Defendants engaged in fraudulent and deceptive  
10 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
11 products were appropriate for minors, when in fact the products never should have been  
12 marketed to minors and are especially harmful to minors due to the potent and addictive  
13 nicotine doses, addictive qualities, and health risks.

14       2470. Defendants knew or should have known that its misrepresentations and/or  
15 omissions were false and misleading, and intended for consumers to rely on such  
16 misrepresentations and omissions.

17       2471. In addition, all Defendants engaged in unfair and unconscionable conduct  
18 because the targeting of minors offends public policy (in particular N.H. Rev. Stat. Ann.  
19 §§ 126-K:4); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
20 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
21 conduct.

22       2472. As alleged above, all Defendants participated and/or facilitated the marketing of  
23 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
24 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
25 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
26 use of JUUL products by minors continues to rise.

27       2473. Defendants' conduct actually and proximately caused loss of money or property  
28 to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs

1 and class members would have behaved differently and would not have purchased JUUL  
2 products or would have paid less for them. Defendants' misrepresentations and omissions  
3 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
4 purchased and enter into purchase contracts they would not otherwise have entered into. In  
5 addition, class members who are minors are entitled to full repayment of the amounts they spent  
6 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
7 threefold their actual damages and statutory damages in the amount of \$1,000, whichever is  
8 greater, injunctive relief (except as to the Management Defendants), and reasonable attorneys'  
9 fees, as well as any other relief the Court may deem just or proper.

10 **b. Common Law Fraud**

11 2474. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

12 2475. This claim is brought against JLI.

13 2476. JUUL created and implemented a scheme to create a market for e-cigarettes and  
14 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
15 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
16 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
17 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
18 addictiveness, and significant risks of substantial physical injury from using JUUL products.

19 2477. Advertisements and representations for JUUL products contained deceptive  
20 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
21 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
22 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
23 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
24 decades, JLI used third parties and word of mouth to spread false and misleading information  
25 about JUUL products.

26 2478. Advertisements and representations for JUUL products concealed and failed to  
27 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 2479. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 2480. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes and other representations.

10 2481. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
11 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
12 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
13 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
14 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
15 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
16 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
17 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
18 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
19 Plaintiffs' and class members' decisions to purchase JUUL products.

20 2482. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
21 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
22 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
23 facts; because the facts would be material to reasonable consumers; because JUUL products  
24 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
25 representations concerning the same subject matter as the omitted facts.

26 2483. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
27 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
28 and/or omissions. Reasonable consumers would have been expected to have relied on the

misrepresentations and omissions.

2484. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2485. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

2486. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

2487. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2488. This claim is brought against JLI.

2489. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

2490. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. N.H. Rev. Stat. § 382—A:2A-212. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

2491. The ordinary intended purpose of JUUL's products—and the purpose for which

1 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
2 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
5 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
6 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
7 recreation smoking devices.

8 2492. Plaintiffs and each member of the class have had sufficient direct dealings with  
9 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
10 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
11 each member of the class, on the other hand.

12 2493. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
13 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
14 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
15 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
16 the express purpose an intent of being sold to consumers.

17 2494. Plaintiffs and the members of the class were injured as a direct and proximate  
18 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
19 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
20 because, had they been aware of the unmerchantable condition of JUUL products, they would  
21 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
22 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

23 2495. JUUL was provided notice of these issues by numerous complaints filed against  
24 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
25 individual letters and communications sent by consumers before or within a reasonable amount  
26 of time after they discovered or should have discovered that’s JUUL product were defective and  
27 unmerchantable.  
28



**d. Unjust Enrichment**

2496. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2497. This claim is brought against JLI and the Management Defendants.

2498. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2499. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. N.H. Rev. Stat. Ann. § 126-K:4 prohibits the sale of JUUL products to minors.

2500. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

2501. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

2502. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

2503. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained

1 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
2 with Defendant.

3 2504. Plaintiffs plead this claim separately as well as in the alternative to their other  
4 claims, as without such claims they would have no adequate legal remedy.

5 **30. New Jersey**

6 2505. Plaintiffs bring each of the following claims on behalf of the New Jersey  
7 Subclass under New Jersey law.

8 **a. Common Law Fraud**

9 2506. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 2507. This claim is brought against JLI.

11 2508. JUUL created and implemented a scheme to create a market for e-cigarettes and  
12 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
13 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
14 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
15 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
16 addictiveness, and significant risks of substantial physical injury from using JUUL products.

17 2509. Advertisements and representations for JUUL products contained deceptive  
18 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
19 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
20 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
21 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
22 decades, JLI used third parties and word of mouth to spread false and misleading information  
23 about JUUL products.

24 2510. Advertisements and representations for JUUL products concealed and failed to  
25 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed significant risks of substantial physical injury resulting from the use of the  
28 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine

1 consumed through a pack of combustible cigarettes.

2 2511. The labels on JUUL products failed to disclose that the products posed  
3 significant risks of substantial physical injury resulting from the use of the products. The labels  
4 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

5 2512. The omissions were misleading and deceptive standing alone and were  
6 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
7 cigarettes and other representations.

8 2513. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
9 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
10 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
11 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
12 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
13 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
14 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
15 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
16 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
17 Plaintiffs' and class members' decisions to purchase JUUL products.

18 2514. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
19 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
20 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
21 facts; because the facts would be material to reasonable consumers; because JUUL products  
22 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
23 representations concerning the same subject matter as the omitted facts.

24 2515. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
25 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
26 and/or omissions. Reasonable consumers would have been expected to have relied on the  
27 misrepresentations and omissions.

28 2516. Defendants knew or should have known that their misrepresentations and/or

omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2517. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

2518. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**b. Breach of the Implied Warranty of Merchantability**

2519. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2520. This claim is brought against JLI.

2521. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

2522. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. N.J. Stat. Ann. § 12A:2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

2523. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation

1 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
2 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
3 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
4 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
5 recreation smoking devices.

6 2524. Plaintiffs and each member of the class have had sufficient direct dealings with  
7 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
8 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
9 each member of the class, on the other hand.

10 2525. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
11 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
12 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
13 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
14 the express purpose an intent of being sold to consumers.

15 2526. Plaintiffs and the members of the class were injured as a direct and proximate  
16 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
17 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
18 because, had they been aware of the unmerchantable condition of JUUL products, they would  
19 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
20 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

21 2527. JUUL was provided notice of these issues by numerous complaints filed against  
22 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
23 individual letters and communications sent by consumers before or within a reasonable amount  
24 of time after they discovered or should have discovered that's JUUL product were defective and  
25 unmerchantable.

26 **c. Unjust Enrichment**

27 2528. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

28 2529. This claim is brought against JLI and the Management Defendants.

1           2530. Defendants created and implemented a scheme to create a market for e-cigarettes  
2 and substantially increase sales of JUUL products through a pervasive pattern of false and  
3 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
4 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
5 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
6 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
7 products.

8           2531. Defendants were unjustly enriched as a result of their wrongful conduct,  
9 including through the false and misleading advertisements and omissions regarding (i) whether  
10 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
11 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
12 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
13 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
14 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
15 enriched through their scheme of marketing their products to minors. N.J. Stat. §§ 2A:170-  
16 51.4(a)(2) and 2C:33-13.1(a) prohibit the marketing and sale of JUUL products to minors.

17           2532. Defendants requested and received a measurable benefit at the expense of  
18 Plaintiffs and class members in the form of payment for JUUL products.

19           2533. Defendants appreciated, recognized, and chose to accept the monetary benefits  
20 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
21 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

22           2534. There is no justification for Defendants' enrichment. It would be inequitable,  
23 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
24 benefits were procured as a result of their wrongful conduct.

25           2535. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
26 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
27 with Defendant.

28           2536. Plaintiffs plead this claim separately as well as in the alternative to their other

claims, as without such claims they would have no adequate legal remedy.

**31. New Mexico**

2537. Plaintiffs bring each of the following claims on behalf of the New Mexico Subclass under New Mexico law.

**a. Violation of the New Mexico Unfair Trade Practices Act (N.M. Stat. § 57-12-1)**

2538. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2539. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

2540. Defendants are “persons” under the statute and the sale and marketing of JUUL products is “trade” and “commerce.”

2541. Plaintiffs and class members purchased JUUL products for personal purposes.

2542. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2543. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2544. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully



1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 2545. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 2546. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes and other representations.

10 2547. JLI's conduct was unfair and unconscionable in that it included (i) the  
11 manufacture and sale of products with a heightened propensity to cause addiction and physical  
12 injuries and (ii) misrepresentations and omissions of material facts concerning the  
13 characteristics and safety of JUUL products offended public policy; was immoral, unethical,  
14 oppressive, and unscrupulous; resulted in a gross disparity between the value received by the  
15 person and the price paid; and caused substantial harm that greatly outweighs any benefits  
16 associated with the conduct. JUUL's acts took advantage of the lack of knowledge, ability,  
17 experience, or capacity of Plaintiffs and class members to a grossly unfair degree and to the  
18 detriment of Plaintiffs and class members.

19 2548. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
20 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
21 ingredients, uses, benefits, or quantities, which they do not have; or (b) misrepresenting that  
22 JUUL products are of a particular standard, quality, or grade, or that goods are of a particular  
23 style or model, when they are not.

24 2549. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
25 omissions may, tends to, or does deceive or mislead reasonable consumers including the  
26 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
27 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
28 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery

mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

2550. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

2551. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2552. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL products were appropriate for minors, when in fact the products never should have been marketed to minors and are especially harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health risks.

2553. In addition, all Defendants engaged in unfair and unconscionable conduct because the targeting of minors offends public policy (in particular N.M. Stat. Ann. §§ 30-49-3(A), (E)); is immoral, unethical, oppressive, and unscrupulous; resulted in a gross disparity between the value received by the person and the price paid; takes advantage of the lack of knowledge, ability, experience, or capacity of minors to a grossly unfair degree; and has caused substantial harm that greatly outweighs any benefits associated with the conduct.

2554. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI

1 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
2 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
3 use of JUUL products by minors continues to rise. Defendants' acts took advantage of the lack  
4 of knowledge, ability, experience, or capacity of Plaintiffs and class members to a grossly unfair  
5 degree and to the detriment of Plaintiffs and class members

6 2555. Defendants' conduct actually and proximately caused loss of money or property  
7 to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs  
8 and class members would have behaved differently and would not have purchased JUUL  
9 products or would have paid less for them. Defendants' misrepresentations and omissions  
10 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
11 purchased and enter into purchase contracts they would not otherwise have entered into. In  
12 addition, class members who are minors are entitled to full repayment of the amounts they spent  
13 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
14 three times actual damages and/or statutory damages in the amount of \$300, whichever is  
15 greater, injunctive relief (except as to the Management Defendants), and reasonable attorneys'  
16 fees, as well as any other relief the Court may deem just or proper.

17 **b. Common Law Fraud**

18 2556. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

19 2557. This claim is brought against JLI.

20 2558. JUUL created and implemented a scheme to create a market for e-cigarettes and  
21 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
22 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
23 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
24 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
25 addictiveness, and significant risks of substantial physical injury from using JUUL products.

26 2559. Advertisements and representations for JUUL products contained deceptive  
27 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
28 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible

1 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
2 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
3 decades, JLI used third parties and word of mouth to spread false and misleading information  
4 about JUUL products.

5 2560. Advertisements and representations for JUUL products concealed and failed to  
6 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed significant risks of substantial physical injury resulting from the use of the  
9 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
10 consumed through a pack of combustible cigarettes.

11 2561. The labels on JUUL products failed to disclose that the products posed  
12 significant risks of substantial physical injury resulting from the use of the products. The labels  
13 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

14 2562. The omissions were misleading and deceptive standing alone and were  
15 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
16 cigarettes and other representations.

17 2563. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
18 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
19 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
20 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
21 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
22 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
23 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
24 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
25 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
26 Plaintiffs' and class members' decisions to purchase JUUL products.

27 2564. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
28 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties

other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

2565. As set forth in the allegations concerning each Plaintiff in Appendix A, in purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations and/or omissions. Reasonable consumers would have been expected to have relied on the misrepresentations and omissions.

2566. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

2567. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

2568. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

2569. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2570. This claim is brought against JLI.

2571. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

1           2572. Each JUUL product sold by JUUL comes with an implied warranty that it will  
2 merchantable and fit for the ordinary purpose for which it would be used. N.M. Stat. Ann. § 55-  
3 2-314. JUUL has breached its implied warranty of merchantability because its products were  
4 not in merchantable condition when sold, were defective when sold, did not conform to the  
5 promises and affirmations of fact made on the products' containers or labels, and/or do not  
6 possess even the most basic degree of fitness for ordinary use.

7           2573. The ordinary intended purpose of JUUL's products—and the purpose for which  
8 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
9 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
10 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
11 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
12 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
13 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
14 recreation smoking devices.

15           2574. Plaintiffs and each member of the class have had sufficient direct dealings with  
16 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
17 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
18 each member of the class, on the other hand.

19           2575. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
20 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
21 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
22 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
23 the express purpose an intent of being sold to consumers.

24           2576. Plaintiffs and the members of the class were injured as a direct and proximate  
25 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
26 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
27 because, had they been aware of the unmerchantable condition of JUUL products, they would  
28 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages

1 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2 2577. JUUL was provided notice of these issues by numerous complaints filed against  
3 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
4 individual letters and communications sent by consumers before or within a reasonable amount  
5 of time after they discovered or should have discovered that's JUUL product were defective and  
6 unmerchtable.

7 **d. Unjust Enrichment**

8 2578. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

9 2579. This claim is brought against JLI and the Management Defendants.

10 2580. Defendants created and implemented a scheme to create a market for e-cigarettes  
11 and substantially increase sales of JUUL products through a pervasive pattern of false and  
12 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
13 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
14 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
15 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
16 products.

17 2581. Defendants were unjustly enriched as a result of their wrongful conduct,  
18 including through the false and misleading advertisements and omissions regarding (i) whether  
19 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
20 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
21 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
22 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
23 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
24 enriched through their scheme of marketing their products to minors. N.M. Stat. Ann. §§ 30-  
25 493(A), (E); 30-49-8(A) prohibit the marketing and sale of JUUL products to minors.

26 2582. Defendants requested and received a measurable benefit at the expense of  
27 Plaintiffs and class members in the form of payment for JUUL products.

28 2583. Defendants appreciated, recognized, and chose to accept the monetary benefits



1 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
2 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3 2584. There is no justification for Defendants' enrichment. It would be inequitable,  
4 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
5 benefits were procured as a result of their wrongful conduct.

6 2585. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
7 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
8 with Defendant.

9 2586. Plaintiffs plead this claim separately as well as in the alternative to their other  
10 claims, as without such claims they would have no adequate legal remedy.

11 **32. New York**

12 2587. Plaintiffs bring each of the following claims on behalf of the New York Subclass  
13 under New York law.

14 **a. Violation of New York General Business Law § 349**

15 2588. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

16 2589. This claim is brought against JLI and, for certain claims below, the Management  
17 Defendants.

18 2590. Plaintiffs and class members purchased JUUL products for personal purposes.

19 2591. Defendants created and implemented a scheme to create a market for e-cigarettes  
20 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
21 statements and omissions directed to consumers. Defendants aimed to portray JUUL products as  
22 cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to  
23 minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine  
24 content and doses, addictiveness, and significant risks of substantial physical injury from using  
25 JUUL products.

26 2592. Advertisements and representations for JUUL products contained deceptive  
27 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
28 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible

1 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
2 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
3 decades, JLI used third parties and word of mouth to spread false and misleading information  
4 about JUUL products.

5 2593. Advertisements and representations for JUUL products concealed and failed to  
6 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed significant risks of substantial physical injury resulting from the use of the  
9 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
10 consumed through a pack of combustible cigarettes.

11 2594. The labels on JUUL products failed to disclose that the products posed  
12 significant risks of substantial physical injury resulting from the use of the products. The labels  
13 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

14 2595. The omissions were misleading and deceptive standing alone and were  
15 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
16 cigarettes and other representations.

17 2596. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
18 omissions at issue were likely to, and in fact did, mislead reasonable consumers including the  
19 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
20 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
21 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
22 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
23 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
24 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
25 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
26 decisions to purchase JUUL products.

27 2597. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
28 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties

1 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
2 facts; because the facts would be material to reasonable consumers; because JLI actively  
3 concealed them; because JLI intended for consumers to rely on the omissions in question;  
4 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
5 made partial representations concerning the same subject matter as the omitted facts.

6 2598. Defendants knew or should have known that their misrepresentations and/or  
7 omissions were false and misleading, and intended for consumers to rely on such  
8 misrepresentations and omissions.

9 2599. JLI and the Management Defendants engaged in fraudulent and deceptive  
10 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
11 products were appropriate for minors, when in fact the products never should have been  
12 marketed to minors and are especially harmful to minors due to the potent and addictive  
13 nicotine doses, addictive qualities, and health risks.

14 2600. Defendants' conduct actually and proximately caused actual damages to  
15 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
16 class members would have behaved differently and would not have purchased JUUL products  
17 or would have paid less for them. Defendants' misrepresentations and omissions induced  
18 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
19 purchased and enter into purchase contracts they would not otherwise have entered into. In  
20 addition, class members who are minors are entitled to full repayment of the amounts they spent  
21 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
22 three times actual damages or statutory damages in the amount of \$50, whichever is greater,  
23 injunctive relief (except as to the Management Defendants), and reasonable attorneys' fees, as  
24 well as any other relief the Court may deem just or proper.

25 **b. Violation of New York General Business Law § 350**

26 2601. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

27 2602. This claim is brought against JLI and, for certain claims below, the Management  
28 Defendants.

1           2603. Plaintiffs and class members purchased JUUL products for personal purposes.

2           2604. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8           2605. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15           2606. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21           2607. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24           2608. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27           2609. JUUL's advertising in the conduct of its business was fraudulent and deceptive  
28 because the misrepresentations and omissions had the capacity, tendency, or effect of deceiving

1 reasonable consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
2 would have found it material to their purchasing decisions that JUUL's products (i) were not  
3 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
4 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
5 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
6 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
7 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
8 in Plaintiffs' and class members' decisions to purchase JUUL products.

9       2610. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JLI actively  
13 concealed them; because JLI intended for consumers to rely on the omissions in question;  
14 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
15 made partial representations concerning the same subject matter as the omitted facts.

16       2611. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
17 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
18 Reasonable consumers would have been expected to have relied on the misrepresentations and  
19 omissions.

20       2612. JLI and the Management Defendants engaged in fraudulent and deceptive  
21 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
22 products were appropriate for minors, when in fact the products never should have been  
23 marketed to minors and are especially harmful to minors due to the potent and addictive  
24 nicotine doses, addictive qualities, and health risks.

25       2613. Defendants' conduct actually and proximately caused actual damages to  
26 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
27 class members would have behaved differently and would not have purchased JUUL products  
28 or would have paid less for them. Defendants' misrepresentations and omissions induced

1 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
2 purchased and enter into purchase contracts they would not otherwise have entered into. In  
3 addition, class members who are minors are entitled to full repayment of the amounts they spent  
4 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
5 actual damages or \$500, whichever is greater; treble damages; injunctive relief (except as to the  
6 Management Defendants); and reasonable attorneys’ fees, as well as any other relief the Court  
7 may deem just or proper.

8 **c. Common Law Fraud**

9 2614. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 2615. This claim is brought against JLI.

11 2616. JUUL created and implemented a scheme to create a market for e-cigarettes and  
12 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
13 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
14 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
15 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
16 addictiveness, and significant risks of substantial physical injury from using JUUL products.

17 2617. Advertisements and representations for JUUL products contained deceptive  
18 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
19 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
20 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
21 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
22 decades, JLI used third parties and word of mouth to spread false and misleading information  
23 about JUUL products.

24 2618. Advertisements and representations for JUUL products concealed and failed to  
25 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed significant risks of substantial physical injury resulting from the use of the  
28 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine

1 consumed through a pack of combustible cigarettes.

2 2619. The labels on JUUL products failed to disclose that the products posed  
3 significant risks of substantial physical injury resulting from the use of the products. The labels  
4 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

5 2620. The omissions were misleading and deceptive standing alone and were  
6 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
7 cigarettes and other representations.

8 2621. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
9 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
10 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
11 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
12 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
13 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
14 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
15 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
16 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
17 Plaintiffs' and class members' decisions to purchase JUUL products.

18 2622. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
19 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
20 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
21 facts; because the facts would be material to reasonable consumers; because JUUL products  
22 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
23 representations concerning the same subject matter as the omitted facts.

24 2623. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
25 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
26 and/or omissions. Reasonable consumers would have been expected to have relied on the  
27 misrepresentations and omissions.

28 2624. Defendants knew or should have known that their misrepresentations and/or



1 omissions were false and misleading, and intended for consumers to rely on such  
2 misrepresentations and omissions.

3 2625. JLI knew that JUUL products were not safe or reasonable alternatives to  
4 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
5 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
6 products.

7 2626. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
8 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
9 and would not have purchased JUUL products or would have paid less for them. JLI's  
10 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
11 products they would not otherwise have purchased and enter into purchase contracts they would  
12 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
13 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
14 deem just or proper.

15 **d. Breach of the Implied Warranty of Merchantability**

16 2627. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

17 2628. This claim is brought against JLI.

18 2629. JUUL has at all times been a merchant with respect to the products which were  
19 sold to Plaintiff and the class and was in the business of selling such products.

20 2630. Each JUUL product sold by JUUL comes with an implied warranty that it will  
21 merchantable and fit for the ordinary purpose for which it would be used. N.Y. U.C.C. Law  
22 § 2-314. JUUL has breached its implied warranty of merchantability because its products were  
23 not in merchantable condition when sold, were defective when sold, did not conform to the  
24 promises and affirmations of fact made on the products' containers or labels, and/or do not  
25 possess even the most basic degree of fitness for ordinary use.

26 2631. The ordinary intended purpose of JUUL's products—and the purpose for which  
27 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
28 products are not fit for that use—or any other use—because they (i) were not smoking cessation

1 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
2 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
3 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
4 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
5 recreation smoking devices.

6 2632. Plaintiffs and each member of the class have had sufficient direct dealings with  
7 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
8 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
9 each member of the class, on the other hand.

10 2633. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
11 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
12 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
13 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
14 the express purpose an intent of being sold to consumers.

15 2634. Plaintiffs and the members of the class were injured as a direct and proximate  
16 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
17 the New York Direct Purchaser Subclass were damaged as a result of JUUL's breach of its  
18 implied warranty of merchantability because, had they been aware of the unmerchantable  
19 condition of JUUL products, they would not have purchased JUUL products, or would have  
20 paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any  
21 other relief the Court may deem just or proper.

22 2635. JUUL was provided notice of these issues by numerous complaints filed against  
23 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
24 individual letters and communications sent by consumers before or within a reasonable amount  
25 of time after they discovered or should have discovered that's JUUL product were defective and  
26 unmerchantable.

27 **e. Unjust Enrichment**

28 2636. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           2637. This claim is brought against JLI and the Management Defendants.

2           2638. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL products through a pervasive pattern of false and  
4 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
5 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
6 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
7 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
8 products.

9           2639. Defendants were unjustly enriched as a result of their wrongful conduct,  
10 including through the false and misleading advertisements and omissions regarding (i) whether  
11 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
12 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
13 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
14 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
15 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
16 enriched through their scheme of marketing their products to minors. N.Y. Pub. Health Law  
17 §§ 1399-cc(2), 1399-bb(4), and 1399-bb(5) prohibit the marketing and sale of JUUL products to  
18 minors.

19           2640. Defendants requested and received a measurable benefit at the expense of  
20 Plaintiffs and class members in the form of payment for JUUL products.

21           2641. Defendants appreciated, recognized, and chose to accept the monetary benefits  
22 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
23 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

24           2642. There is no justification for Defendants' enrichment. It would be inequitable,  
25 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
26 benefits were procured as a result of their wrongful conduct.

27           2643. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
28 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing

1 with Defendant.

2 2644. Plaintiffs plead this claim separately as well as in the alternative to their other  
3 claims, as without such claims they would have no adequate legal remedy.

4 **33. North Carolina**

5 2645. Plaintiffs bring each of the following claims on behalf of the North Carolina  
6 Subclass under North Carolina law.

7 **a. Violation of the North Carolina Unfair & Deceptive Trade**  
8 **Practices Act (N.C. Gen. Stat. §§ 75-1.1, et seq.)**

9 2646. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 2647. This claim is brought against JLI and, for certain unfair and/or unconscionable  
11 conduct claims as noted below, all Defendants.

12 2648. Plaintiffs and class members purchased JUUL products for personal purposes.

13 2649. Defendants created and implemented a scheme to create a market for e-cigarettes  
14 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
15 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
16 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
17 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
18 addictiveness, and significant risks of substantial physical injury from using JUUL products.

19 2650. Advertisements and representations for JUUL products contained deceptive  
20 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
21 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
22 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
23 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
24 decades, JLI used third parties and word of mouth to spread false and misleading information  
25 about JUUL products.

26 2651. Advertisements and representations for JUUL products concealed and failed to  
27 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 2652. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 2653. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes and other representations.

10 2654. JLI's conduct was unfair and unconscionable in that it included (i) the  
11 manufacture and sale of products with a heightened propensity to cause addiction and physical  
12 injuries and (ii) misrepresentations and omissions of material facts concerning the  
13 characteristics and safety of JUUL products that offended public policy; were immoral,  
14 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
15 substantial harm that greatly outweighs any possible utility from the conduct.

16 2655. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
17 omissions had the tendency or capacity to mislead or created the likelihood of deception of  
18 average consumers such as including the Plaintiffs. Reasonable consumers, including the  
19 Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i)  
20 were not smoking cessation devices, (ii) were not reasonable alternatives to combustible  
21 cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully  
22 addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the  
23 products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine  
24 consumed through a pack of combustible cigarettes. Knowledge of these facts would have been  
25 a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

26 2656. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
27 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
28 other than Plaintiffs and class members), who had exclusive and superior knowledge of the

1 facts; because the facts would be material to reasonable consumers; because JLI actively  
2 concealed them; because JLI intended for consumers to rely on the omissions in question;  
3 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
4 made partial representations concerning the same subject matter as the omitted facts.

5 2657. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
6 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
7 Reasonable consumers would have been expected to have relied on the misrepresentations and  
8 omissions.

9 2658. JLI and the Management Defendants engaged in fraudulent and deceptive  
10 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
11 products were appropriate for minors, when in fact the products never should have been  
12 marketed to minors and are especially harmful to minors due to the potent and addictive  
13 nicotine doses, addictive qualities, and health risks.

14 2659. In addition, all Defendants engaged in unfair and unconscionable conduct  
15 because the targeting of minors offends public policy (in particular N.C. Gen. Stat. § 14-313(b)  
16 and N.C. Gen. Stat. § 14-313(b2); is immoral, unethical, oppressive, outrageous, unscrupulous,  
17 and substantially injurious; and has caused substantial harm that greatly outweighs any possible  
18 utility from the conduct.

19 2660. As alleged above, all Defendants participated and/or facilitated the marketing of  
20 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
21 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
22 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
23 use of JUUL products by minors continues to rise.

24 2661. Defendants' conduct, alleged herein, was in and affected commerce since the  
25 conduct was part and parcel of Defendants' business activities related to the sale of JUUL  
26 products.

27 2662. Defendants' conduct actually and proximately caused actual damages to  
28 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and

1 class members would have behaved differently and would not have purchased JUUL products  
2 or would have paid less for them. Defendants' misrepresentations and omissions induced  
3 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
4 purchased and enter into purchase contracts they would not otherwise have entered into. In  
5 addition, class members who are minors are entitled to full repayment of the amounts they spent  
6 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
7 three times damages, injunctive relief (except as to the Management Defendants), and  
8 reasonable attorneys' fees, as well as any other relief the Court may deem just or proper.

9 **b. Common Law Fraud**

10 2663. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 2664. This claim is brought against JLI.

12 2665. JUUL created and implemented a scheme to create a market for e-cigarettes and  
13 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
14 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
15 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
16 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
17 addictiveness, and significant risks of substantial physical injury from using JUUL products.

18 2666. Advertisements and representations for JUUL products contained deceptive  
19 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
20 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
21 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
22 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
23 decades, JLI used third parties and word of mouth to spread false and misleading information  
24 about JUUL products.

25 2667. Advertisements and representations for JUUL products concealed and failed to  
26 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
27 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
28 addictive, posed significant risks of substantial physical injury resulting from the use of the



1 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
2 consumed through a pack of combustible cigarettes.

3 2668. The labels on JUUL products failed to disclose that the products posed  
4 significant risks of substantial physical injury resulting from the use of the products. The labels  
5 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

6 2669. The omissions were misleading and deceptive standing alone and were  
7 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
8 cigarettes and other representations.

9 2670. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
10 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
11 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
12 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
13 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
14 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
15 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
16 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
17 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
18 Plaintiffs' and class members' decisions to purchase JUUL products.

19 2671. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
20 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
21 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
22 facts; because the facts would be material to reasonable consumers; because JUUL products  
23 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
24 representations concerning the same subject matter as the omitted facts.

25 2672. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
26 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
27 and/or omissions. Reasonable consumers would have been expected to have relied on the  
28 misrepresentations and omissions.

1           2673. Defendants knew or should have known that their misrepresentations and/or  
2 omissions were false and misleading, and intended for consumers to rely on such  
3 misrepresentations and omissions.

4           2674. JLI knew that JUUL products were not safe or reasonable alternatives to  
5 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
6 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
7 products.

8           2675. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
9 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
10 and would not have purchased JUUL products or would have paid less for them. JLI's  
11 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
12 products they would not otherwise have purchased and enter into purchase contracts they would  
13 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
14 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
15 deem just or proper.

16                           **c. Breach of the Implied Warranty of Merchantability**

17           2676. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

18           2677. This claim is brought against JLI.

19           2678. JUUL has at all times been a merchant with respect to the products which were  
20 sold to Plaintiff and the class and was in the business of selling such products.

21           2679. Each JUUL product sold by JUUL comes with an implied warranty that it will  
22 merchantable and fit for the ordinary purpose for which it would be used. N.C. GEN. STAT.  
23 § 25-2-314. JUUL has breached its implied warranty of merchantability because its products  
24 were not in merchantable condition when sold, were defective when sold, did not conform to the  
25 promises and affirmations of fact made on the products' containers or labels, and/or do not  
26 possess even the most basic degree of fitness for ordinary use.

27           2680. The ordinary intended purpose of JUUL's products—and the purpose for which  
28 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's

1 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
2 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
3 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
4 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
5 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
6 recreation smoking devices.

7 2681. Plaintiffs and each member of the class have had sufficient direct dealings with  
8 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
9 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
10 each member of the class, on the other hand.

11 2682. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
12 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
13 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
14 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
15 the express purpose an intent of being sold to consumers.

16 2683. Plaintiffs and the members of the class were injured as a direct and proximate  
17 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
18 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
19 because, had they been aware of the unmerchantable condition of JUUL products, they would  
20 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
21 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

22 2684. JUUL was provided notice of these issues by numerous complaints filed against  
23 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
24 individual letters and communications sent by consumers before or within a reasonable amount  
25 of time after they discovered or should have discovered that’s JUUL product were defective and  
26 unmerchantable.

27 **d. Unjust Enrichment**

28 2685. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           2686. This claim is brought against JLI and the Management Defendants.

2           2687. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL products through a pervasive pattern of false and  
4 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
5 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
6 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
7 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
8 products.

9           2688. Defendants were unjustly enriched as a result of their wrongful conduct,  
10 including through the false and misleading advertisements and omissions regarding (i) whether  
11 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
12 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
13 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
14 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
15 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
16 enriched through their scheme of marketing their products to minors. N.C. Gen. Stat. § 14-  
17 313(b) and N.C. Gen. Stat. § 14-313(b2) prohibit the marketing and sale of JUUL products to  
18 minors.

19           2689. Defendants requested and received a measurable benefit at the expense of  
20 Plaintiffs and class members in the form of payment for JUUL products.

21           2690. Defendants appreciated, recognized, and chose to accept the monetary benefits  
22 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
23 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

24           2691. There is no justification for Defendants' enrichment. It would be inequitable,  
25 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
26 benefits were procured as a result of their wrongful conduct.

27           2692. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
28 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing

1 with Defendant.

2 2693. Plaintiffs plead this claim separately as well as in the alternative to their other  
3 claims, as without such claims they would have no adequate legal remedy.

4 **34. North Dakota**

5 2694. Plaintiffs bring each of the following claims on behalf of the North Dakota  
6 Subclass under North Dakota law.

7 **a. Violation of North Dakota Consumer Fraud Act (N.D. Cent.  
8 Code § 51-15-01, *et seq.*)**

9 2695. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

10 2696. This claim is brought against JLI, and for certain unfair and unconscionable  
11 conduct claims, all Defendants.

12 2697. Plaintiffs and class members purchased JUUL products for personal purposes.

13 2698. Defendants created and implemented a scheme to create a market for e-cigarettes  
14 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
15 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
16 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
17 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
18 addictiveness, and significant risks of substantial physical injury from using JUUL products.

19 2699. Advertisements and representations for JUUL products contained deceptive  
20 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
21 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
22 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
23 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
24 decades, JLI used third parties and word of mouth to spread false and misleading information  
25 about JUUL products.

26 2700. Advertisements and representations for JUUL products concealed and failed to  
27 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 2701. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 2702. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes and other representations.

10 2703. JLI's conduct was unfair and unconscionable in that it included (i) the  
11 manufacture and sale of products with a heightened propensity to cause addiction and physical  
12 injuries and (ii) misrepresentations and omissions of material facts concerning the  
13 characteristics and safety of JUUL products that offended public policy; were immoral,  
14 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
15 substantial harm that greatly outweighs any possible utility from the conduct.

16 2704. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
17 omissions at issue were likely to, and in fact did, deceive reasonable consumers, including the  
18 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
19 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
20 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
21 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
22 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
23 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
24 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
25 decisions to purchase JUUL products.

26 2705. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
27 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
28 other than Plaintiffs and class members), who had exclusive and superior knowledge of the

1 facts; because the facts would be material to reasonable consumers; because JLI actively  
2 concealed them; because JLI intended for consumers to rely on the omissions in question;  
3 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
4 made partial representations concerning the same subject matter as the omitted facts.

5 2706. JLI and the Management Defendants engaged in fraudulent and deceptive  
6 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
7 products were appropriate for minors, when in fact the products never should have been  
8 marketed to minors and are especially harmful to minors due to the potent and addictive  
9 nicotine doses, addictive qualities, and health risks.

10 2707. In addition, all Defendants engaged in unfair and unconscionable conduct  
11 because the targeting of minors offends public policy (in particular N.D. Cent. Code § 12.1-31-  
12 03(1)(a)) is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
13 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
14 conduct.

15 2708. As alleged above, all Defendants participated and/or facilitated the marketing of  
16 JUUL products to minors and took no action to curb the use of JUUL products by minors.  
17 JUUL has continued the unconscionable practices that Defendants implemented, facilitated,  
18 and/or did not take adequate steps to end. As a result, the use of JUUL products by minors  
19 continues to rise.

20 2709. Defendants knew or should have known that their misrepresentations and/or  
21 omissions were false and misleading, and intended for consumers to rely on such  
22 misrepresentations and omissions.

23 2710. Defendants' conduct actually and proximately caused actual damages to  
24 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
25 class members would have behaved differently and would not have purchased JUUL products  
26 or would have paid less for them. Defendants' misrepresentations and omissions induced  
27 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
28 purchased and enter into purchase contracts they would not otherwise have entered into. In



1 addition, class members who are minors are entitled to full repayment of the amounts they spent  
 2 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
 3 three times actual damages, injunctive relief (except as to the Management Defendants), and  
 4 reasonable attorneys’ fees, as well as any other relief the Court may deem just or proper.

5 **b. Violation of North Dakota False Advertising Law (N.D. Cent.**  
 6 **Code § 51-12-08)**

7 2711. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 2712. This claim is brought against JLI.

9 2713. Plaintiffs and class members purchased JUUL products for personal purposes.

10 2714. Defendants created and implemented a scheme to create a market for e-cigarettes  
 11 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
 12 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
 13 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
 14 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
 15 addictiveness, and significant risks of substantial physical injury from using JUUL products.

16 2715. Advertisements and representations for JUUL products contained deceptive  
 17 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
 18 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
 19 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
 20 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
 21 decades, JLI used third parties and word of mouth to spread false and misleading information  
 22 about JUUL products.

23 2716. Advertisements and representations for JUUL products concealed and failed to  
 24 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
 25 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
 26 addictive, posed significant risks of substantial physical injury resulting from the use of the  
 27 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
 28 consumed through a pack of combustible cigarettes.

1           2717. The labels on JUUL products failed to disclose that the products posed  
2 significant risks of substantial physical injury resulting from the use of the products. The labels  
3 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

4           2718. The omissions were misleading and deceptive standing alone and were  
5 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
6 cigarettes and other representations.

7           2719. JLI's conduct constituted the following prohibited practices: making or  
8 disseminating or causing to be made or disseminated before the public in North Dakota, in any  
9 newspaper or other publication, or any advertising device, or by public outcry or proclamation,  
10 or in any other manner or means whatever, statements, concerning such real or personal  
11 property or services, professional or otherwise or concerning any circumstance or matter of fact  
12 connected with the proposed performance or disposition thereof, which is untrue or misleading.

13           2720. JLI's conduct was likely to, and in fact did, deceive reasonable consumers  
14 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
15 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
16 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
17 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
18 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
19 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
20 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
21 Plaintiffs' and class members' decisions to purchase JUUL products.

22           2721. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
23 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
24 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
25 facts; because the facts would be material to reasonable consumers; because JLI actively  
26 concealed them; because JLI intended for consumers to rely on the omissions in question;  
27 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
28 made partial representations concerning the same subject matter as the omitted facts.

1           2722. Defendants knew or should have known that their misrepresentations and/or  
2 omissions were false and misleading, and intended for consumers to rely on such  
3 misrepresentations and omissions.

4           2723. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
5 class members. Absent JLI's unfair and fraudulent conduct, Plaintiffs and class members would  
6 have behaved differently and would not have purchased JUUL products or would have paid less  
7 for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to  
8 purchase JUUL products they would not otherwise have purchased and enter into purchase  
9 contracts they would not otherwise have entered into. In addition, class members who are  
10 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
11 seek—on behalf of themselves and each member of the class—injunctive relief and reasonable  
12 attorneys' fees, as well as any other relief the Court may deem just or proper.

13                           **c.       Common Law Fraud**

14           2724. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

15           2725. This claim is brought against JLI.

16           2726. JUUL created and implemented a scheme to create a market for e-cigarettes and  
17 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
18 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
19 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
20 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
21 addictiveness, and significant risks of substantial physical injury from using JUUL products.

22           2727. Advertisements and representations for JUUL products contained deceptive  
23 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
24 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
25 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
26 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
27 decades, JLI used third parties and word of mouth to spread false and misleading information  
28 about JUUL products.

1           2728. Advertisements and representations for JUUL products concealed and failed to  
2 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
3 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
4 addictive, posed significant risks of substantial physical injury resulting from the use of the  
5 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
6 consumed through a pack of combustible cigarettes.

7           2729. The labels on JUUL products failed to disclose that the products posed  
8 significant risks of substantial physical injury resulting from the use of the products. The labels  
9 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

10          2730. The omissions were misleading and deceptive standing alone and were  
11 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
12 cigarettes and other representations.

13          2731. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
14 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
15 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
16 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
17 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
18 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
19 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
20 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
21 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
22 Plaintiffs' and class members' decisions to purchase JUUL products.

23          2732. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
24 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
25 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
26 facts; because the facts would be material to reasonable consumers; because JUUL products  
27 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
28 representations concerning the same subject matter as the omitted facts.

1           2733. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
2 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
3 and/or omissions. Reasonable consumers would have been expected to have relied on the  
4 misrepresentations and omissions.

5           2734. Defendants knew or should have known that their misrepresentations and/or  
6 omissions were false and misleading, and intended for consumers to rely on such  
7 misrepresentations and omissions.

8           2735. JLI knew that JUUL products were not safe or reasonable alternatives to  
9 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
10 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
11 products.

12           2736. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
13 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
14 and would not have purchased JUUL products or would have paid less for them. JLI's  
15 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
16 products they would not otherwise have purchased and enter into purchase contracts they would  
17 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
18 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
19 deem just or proper.

20                           **d. Breach of the Implied Warranty of Merchantability**

21           2737. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

22           2738. This claim is brought against JLI.

23           2739. JUUL has at all times been a merchant with respect to the products which were  
24 sold to Plaintiff and the class and was in the business of selling such products.

25           2740. Each JUUL product sold by JUUL comes with an implied warranty that it will  
26 merchantable and fit for the ordinary purpose for which it would be used. N.D. Cent. Code  
27 § 41-02-32. JUUL has breached its implied warranty of merchantability because its products  
28 were not in merchantable condition when sold, were defective when sold, did not conform to the

1 promises and affirmations of fact made on the products' containers or labels, and/or do not  
2 possess even the most basic degree of fitness for ordinary use.

3 2741. The ordinary intended purpose of JUUL's products—and the purpose for which  
4 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
5 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
6 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
7 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
8 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
9 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
10 recreation smoking devices.

11 2742. Plaintiffs and each member of the class have had sufficient direct dealings with  
12 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
13 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
14 each member of the class, on the other hand.

15 2743. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
16 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
17 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
18 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
19 the express purpose an intent of being sold to consumers.

20 2744. Plaintiffs and the members of the class were injured as a direct and proximate  
21 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
22 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
23 because, had they been aware of the unmerchantable condition of JUUL products, they would  
24 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
25 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

26 2745. JUUL was provided notice of these issues by numerous complaints filed against  
27 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
28 individual letters and communications sent by consumers before or within a reasonable amount

1 of time after they discovered or should have discovered that's JUUL product were defective and  
2 unmerchtable.

3 **e. Unjust Enrichment**

4 2746. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

5 2747. This claim is brought against JLI and the Management Defendants.

6 2748. Defendants created and implemented a scheme to create a market for e-cigarettes  
7 and substantially increase sales of JUUL products through a pervasive pattern of false and  
8 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
9 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
10 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
11 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
12 products.

13 2749. Defendants were unjustly enriched as a result of their wrongful conduct,  
14 including through the false and misleading advertisements and omissions regarding (i) whether  
15 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
16 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
17 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
18 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
19 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
20 enriched through their scheme of marketing their products to minors. N.D. Cent. Code § 12.1-  
21 31-03(1)(a) prohibits the marketing and sale of JUUL products to minors.

22 2750. Defendants requested and received a measurable benefit at the expense of  
23 Plaintiffs and class members in the form of payment for JUUL products.

24 2751. Defendants appreciated, recognized, and chose to accept the monetary benefits  
25 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
26 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

27 2752. There is no justification for Defendants' enrichment. It would be inequitable,  
28 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the



benefits were procured as a result of their wrongful conduct.

2753. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

2754. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

### **35. Ohio**

2755. Plaintiffs bring each of the following claims on behalf of the Ohio Subclass under Ohio law.

#### **a. Violation of the Ohio Consumer Sales Practices Act (Ohio Rev. Code Ann. §§ 1345.01, *et seq.*)**

2756. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2757. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

2758. Plaintiffs and class members purchased JUUL products for personal purposes.

2759. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2760. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

1           2761. Advertisements and representations for JUUL products concealed and failed to  
2 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
3 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
4 addictive, posed significant risks of substantial physical injury resulting from the use of the  
5 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
6 consumed through a pack of combustible cigarettes.

7           2762. The labels on JUUL products failed to disclose that the products posed  
8 significant risks of substantial physical injury resulting from the use of the products. The labels  
9 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

10          2763. The omissions were misleading and deceptive standing alone and were  
11 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
12 cigarettes and other representations.

13          2764. JLI's conduct was unfair and unconscionable in that it included (i) the  
14 manufacture and sale of products with a heightened propensity to cause addiction and physical  
15 injuries; (ii) misrepresentations and omissions of material facts concerning the characteristics  
16 and safety of JUUL products; (iii) knowingly making a misleading statement of opinion on  
17 which Plaintiffs and class members were likely to rely to their detriment; and (iv) knowingly  
18 taking advantage of Plaintiffs' and class members' inability to protect their interests, due to their  
19 ignorance regarding the actual characteristics of JUUL products, offended public policy; was  
20 immoral, unethical, oppressive, and unscrupulous; caused substantial harm that greatly  
21 outweighs any benefits associated with the conduct; and is marked by injustice.

22          2765. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
23 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
24 ingredients, uses, benefits, or quantities, which they do not have; or (b) misrepresenting that  
25 JUUL products are of a particular standard, quality, or grade, or that goods are of a particular  
26 style or model, when they are not.

27          2766. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
28 omissions had the tendency or capacity to mislead reasonable consumers including the

1 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
2 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
3 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
4 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
5 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
6 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
7 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
8 decisions to purchase JUUL products.

9       2767. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JLI actively  
13 concealed them; because JLI intended for consumers to rely on the omissions in question;  
14 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
15 made partial representations concerning the same subject matter as the omitted facts.

16       2768. Defendants knew or should have known that their misrepresentations and/or  
17 omissions were false and misleading, and intended for consumers to rely on such  
18 misrepresentations and omissions.

19       2769. JLI and the Management Defendants engaged in fraudulent and deceptive  
20 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
21 products were appropriate for minors, when in fact the products never should have been  
22 marketed to minors and are especially harmful to minors due to the potent and addictive  
23 nicotine doses, addictive qualities, and health risks.

24       2770. In addition, all Defendants engaged in unfair and unconscionable conduct  
25 because the targeting of minors offends public policy (in particular Ohio Rev. Code Ann.  
26 § 2927.02(B)(1)) is immoral, unethical, oppressive, and unscrupulous; has caused substantial  
27 harm that greatly outweighs any benefits associated with the conduct; is marked by injustice;  
28 and takes advantage of minors' inability to protect their own interests.

2771. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI and others have continued the deceptive, misleading, unfair, and unconscionable practices that Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by minors continues to rise.

2772. Defendants' conduct actually and proximately caused actual damages to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—actual economic damages and/or statutory damages, injunctive relief (except as to the Management Defendants), and reasonable attorneys' fees, as well as any other relief the Court may deem just or proper.

2773. Defendants had notice that their conduct was in violation based on prior rules and/or case decisions, including litigation related to combustible cigarettes and subsequent settlement agreements, and Ohio Rev. Code Ann. § 2927.02(B)(1) and Ohio Administrative Code § 109:4-3-10, which prohibit much of the conduct Defendants' engaged in with respect to JUUL products.

**b. Violation of the Ohio Deceptive Trade Practices Act (Ohio Rev. Code §§ 4165.01 - .04)**

2774. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2775. This claim is brought against JLI.

2776. Plaintiffs and class members purchased JUUL products for personal purposes.

2777. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading

1 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
2 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
3 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
4 addictiveness, and significant risks of substantial physical injury from using JUUL products.

5 2778. Advertisements and representations for JUUL products contained deceptive  
6 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
7 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
8 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
9 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
10 decades, JLI used third parties and word of mouth to spread false and misleading information  
11 about JUUL products.

12 2779. Advertisements and representations for JUUL products concealed and failed to  
13 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
14 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
15 addictive, posed significant risks of substantial physical injury resulting from the use of the  
16 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
17 consumed through a pack of combustible cigarettes.

18 2780. The labels on JUUL products failed to disclose that the products posed  
19 significant risks of substantial physical injury resulting from the use of the products. The labels  
20 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

21 2781. The omissions were misleading and deceptive standing alone and were  
22 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
23 cigarettes and other representations.

24 2782. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
25 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
26 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
27 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
28 model, when they are not; and (c) advertising goods or services with intent not to sell them as

1 advertised.

2 2783. JLI's conduct had the tendency to, were likely to, and in fact did, deceive  
3 reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
4 would have found it material to their purchasing decisions that JUUL's products (i) were not  
5 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
6 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
7 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
8 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
9 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
10 in Plaintiffs' and class members' decisions to purchase JUUL products.

11 2784. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
12 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
13 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
14 facts; because the facts would be material to reasonable consumers; because JLI actively  
15 concealed them; because JLI intended for consumers to rely on the omissions in question;  
16 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
17 made partial representations concerning the same subject matter as the omitted facts.

18 2785. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
19 class members. Absent JLI's unfair and fraudulent conduct, Plaintiffs and class members would  
20 have behaved differently and would not have purchased JUUL products or would have paid less  
21 for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to  
22 purchase JUUL products they would not otherwise have purchased and enter into purchase  
23 contracts they would not otherwise have entered into. In addition, class members who are  
24 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
25 seek—on behalf of themselves and each member of the class—actual damages, injunctive relief,  
26 and reasonable attorneys' fees, as well as any other relief the Court may deem just or proper.

27 **c. Common Law Fraud**

28 2786. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1 2787. This claim is brought against JLI.

2 2788. JUUL created and implemented a scheme to create a market for e-cigarettes and  
3 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8 2789. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15 2790. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21 2791. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24 2792. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27 2793. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
28 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers



1 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
2 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
5 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
6 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
7 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
8 Plaintiffs' and class members' decisions to purchase JUUL products.

9       2794. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JUUL products  
13 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
14 representations concerning the same subject matter as the omitted facts.

15       2795. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
16 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
17 and/or omissions. Reasonable consumers would have been expected to have relied on the  
18 misrepresentations and omissions.

19       2796. Defendants knew or should have known that their misrepresentations and/or  
20 omissions were false and misleading, and intended for consumers to rely on such  
21 misrepresentations and omissions.

22       2797. JLI knew that JUUL products were not safe or reasonable alternatives to  
23 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
24 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
25 products.

26       2798. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
27 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
28 and would not have purchased JUUL products or would have paid less for them. JLI's

1 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
2 products they would not otherwise have purchased and enter into purchase contracts they would  
3 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
4 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
5 deem just or proper.

6 **d. Breach of the Implied Warranty of Merchantability**

7 2799. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 2800. This claim is brought against JLI.

9 2801. JUUL has at all times been a merchant with respect to the products which were  
10 sold to Plaintiff and the class and was in the business of selling such products.

11 2802. Each JUUL product sold by JUUL comes with an implied warranty that it will  
12 merchantable and fit for the ordinary purpose for which it would be used. Ohio Rev. Code Ann.  
13 § 1302.27. JUUL has breached its implied warranty of merchantability because its products  
14 were not in merchantable condition when sold, were defective when sold, did not conform to the  
15 promises and affirmations of fact made on the products' containers or labels, and/or do not  
16 possess even the most basic degree of fitness for ordinary use.

17 2803. The ordinary intended purpose of JUUL's products—and the purpose for which  
18 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
19 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
20 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
21 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
22 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
23 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
24 recreation smoking devices.

25 2804. Plaintiffs and each member of the class have had sufficient direct dealings with  
26 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
27 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
28 each member of the class, on the other hand.

2805. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

2806. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the Ohio Direct Purchaser Subclass were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2807. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**e. Unjust Enrichment**

2808. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2809. This claim is brought against JLI and the Management Defendants.

2810. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2811. Defendants were unjustly enriched as a result of their wrongful conduct,

including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Ohio Rev. Code Ann. § 2927.02(B)(1) prohibits the marketing and sale of JUUL products to minors.

2812. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

2813. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

2814. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

2815. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

2816. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

### **36. Oklahoma**

2817. Plaintiffs bring each of the following claims on behalf of the Oklahoma Subclass under Oklahoma law.

#### **a. Violation of the Oklahoma Consumer Protection Act (Okla. Stat. tit. 15, §§ 751, *et seq.*)**

2818. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2819. This claim is brought against JLI and, for certain unfair and/or unconscionable

1 conduct claims as noted below, all Defendants.

2 2820. Plaintiffs and class members purchased JUUL products for purposes that are  
3 personal, household, or business oriented.

4 2821. Defendants created and implemented a scheme to create a market for e-cigarettes  
5 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
6 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
7 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
8 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
9 addictiveness, and significant risks of substantial physical injury from using JUUL products.

10 2822. Advertisements and representations for JUUL products contained deceptive  
11 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
12 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
13 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
14 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
15 decades, JLI used third parties and word of mouth to spread false and misleading information  
16 about JUUL products.

17 2823. Advertisements and representations for JUUL products concealed and failed to  
18 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
19 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
20 addictive, posed significant risks of substantial physical injury resulting from the use of the  
21 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
22 consumed through a pack of combustible cigarettes.

23 2824. The labels on JUUL products failed to disclose that the products posed  
24 significant risks of substantial physical injury resulting from the use of the products. The labels  
25 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

26 2825. The omissions were misleading and deceptive standing alone and were  
27 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
28 cigarettes and other representations.

1           2826. JLI's conduct was unfair and unconscionable in that it included (i) the  
2 manufacture and sale of products with a heightened propensity to cause addiction and physical  
3 injuries and (ii) misrepresentations and omissions of material facts concerning the  
4 characteristics and safety of JUUL products that offended public policy; were immoral,  
5 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
6 substantial harm that greatly outweighs any possible utility from the conduct.

7           2827. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
8 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
9 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
10 products are of a particular standard, or that goods are of a particular style or model, when they  
11 are not; and (c) advertising goods or services with intent not to sell them as advertised.

12           2828. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
13 omissions have deceived or could reasonably be expected to deceive or mislead a person to the  
14 detriment of that person, including the Plaintiffs. Reasonable consumers, including the  
15 Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i)  
16 were not smoking cessation devices, (ii) were not reasonable alternatives to combustible  
17 cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully  
18 addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the  
19 products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes. Knowledge of these facts would have been  
21 a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

22           2829. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
23 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
24 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
25 facts; because the facts would be material to reasonable consumers; because JLI actively  
26 concealed them; because JLI intended for consumers to rely on the omissions in question;  
27 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
28 made partial representations concerning the same subject matter as the omitted facts.

1 2830. JLI and the Management Defendants engaged in fraudulent and deceptive  
2 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
3 products were appropriate for minors, when in fact the products never should have been  
4 marketed to minors and are especially harmful to minors due to the potent and addictive  
5 nicotine doses, addictive qualities, and health risks.

6 2831. In addition, all Defendants engaged in unfair and unconscionable conduct  
7 because the targeting of minors offends public policy (in particular 63 Okl. St. §§ 1-229.13, 1-  
8 229.26); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
9 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
10 conduct.

11 2832. As alleged above, all Defendants participated and/or facilitated the marketing of  
12 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
13 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
14 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
15 use of JUUL products by minors continues to rise.

16 2833. Defendants' conduct actually and proximately caused actual damages to  
17 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
18 class members would have behaved differently and would not have purchased JUUL products  
19 or would have paid less for them. Defendants' misrepresentations and omissions induced  
20 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
21 purchased and enter into purchase contracts they would not otherwise have entered into. In  
22 addition, class members who are minors are entitled to full repayment of the amounts they spent  
23 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
24 actual damages, injunctive relief (except as to the Management Defendants), and reasonable  
25 attorneys' fees, as well as any other relief the Court may deem just or proper.

26 **b. Violation of the Oklahoma Deceptive Trade Practices Act**  
27 **(Okla. Stat. tit. 78, §§ 51, *et seq.*)**

28 2834. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.



1           2835. This claim is brought against JLI.

2           2836. Plaintiffs and class members purchased JUUL products for purposes that are  
3 personal, household, or business oriented.

4           2837. Defendants created and implemented a scheme to create a market for e-cigarettes  
5 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
6 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
7 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
8 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
9 addictiveness, and significant risks of substantial physical injury from using JUUL products.

10          2838. Advertisements and representations for JUUL products contained deceptive  
11 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
12 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
13 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
14 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
15 decades, JLI used third parties and word of mouth to spread false and misleading information  
16 about JUUL products.

17          2839. Advertisements and representations for JUUL products concealed and failed to  
18 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
19 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
20 addictive, posed significant risks of substantial physical injury resulting from the use of the  
21 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
22 consumed through a pack of combustible cigarettes.

23          2840. The labels on JUUL products failed to disclose that the products posed  
24 significant risks of substantial physical injury resulting from the use of the products. The labels  
25 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

26          2841. The omissions were misleading and deceptive standing alone and were  
27 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
28 cigarettes and other representations.

1           2842. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
2 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
3 ingredients, uses, benefits, or quantities, which they do not have and (b) misrepresenting that  
4 JUUL products are of a particular standard, or that goods are of a particular style or model,  
5 when they are not.

6           2843. JLI's conduct has deceived or could reasonably be expected to deceive or  
7 mislead a person to the detriment of that person, including the Plaintiffs. Reasonable  
8 consumers, including the Plaintiffs, would have found it material to their purchasing decisions  
9 that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable  
10 alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms,  
11 (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury  
12 resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL  
13 pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of  
14 these facts would have been a substantial factor in Plaintiffs' and class members' decisions to  
15 purchase JUUL products.

16           2844. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
17 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
18 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
19 facts; because the facts would be material to reasonable consumers; because JLI actively  
20 concealed them; because JLI intended for consumers to rely on the omissions in question;  
21 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
22 made partial representations concerning the same subject matter as the omitted facts.

23           2845. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
24 class members. Absent JLI's unfair and fraudulent conduct, Plaintiffs and class members would  
25 have behaved differently and would not have purchased JUUL products or would have paid less  
26 for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to  
27 purchase JUUL products they would not otherwise have purchased and enter into purchase  
28 contracts they would not otherwise have entered into. In addition, class members who are

1 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
2 seek—on behalf of themselves and each member of the class—actual damages, injunctive relief,  
3 and reasonable attorneys’ fees, as well as any other relief the Court may deem just or proper.

4 **c. Common Law Fraud**

5 2846. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

6 2847. This claim is brought against JLI.

7 2848. JUUL created and implemented a scheme to create a market for e-cigarettes and  
8 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
9 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
10 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
11 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
12 addictiveness, and significant risks of substantial physical injury from using JUUL products.

13 2849. Advertisements and representations for JUUL products contained deceptive  
14 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
15 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
16 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
17 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
18 decades, JLI used third parties and word of mouth to spread false and misleading information  
19 about JUUL products.

20 2850. Advertisements and representations for JUUL products concealed and failed to  
21 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
22 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
23 addictive, posed significant risks of substantial physical injury resulting from the use of the  
24 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
25 consumed through a pack of combustible cigarettes.

26 2851. The labels on JUUL products failed to disclose that the products posed  
27 significant risks of substantial physical injury resulting from the use of the products. The labels  
28 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

1           2852. The omissions were misleading and deceptive standing alone and were  
2 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
3 cigarettes and other representations.

4           2853. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
5 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
6 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
7 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
8 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
9 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
10 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
11 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
12 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
13 Plaintiffs' and class members' decisions to purchase JUUL products.

14           2854. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
15 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
16 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
17 facts; because the facts would be material to reasonable consumers; because JUUL products  
18 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
19 representations concerning the same subject matter as the omitted facts.

20           2855. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
21 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
22 and/or omissions. Reasonable consumers would have been expected to have relied on the  
23 misrepresentations and omissions.

24           2856. Defendants knew or should have known that their misrepresentations and/or  
25 omissions were false and misleading, and intended for consumers to rely on such  
26 misrepresentations and omissions.

27           2857. JLI knew that JUUL products were not safe or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
2 products.

3 2858. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
4 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
5 and would not have purchased JUUL products or would have paid less for them. JLI's  
6 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
7 products they would not otherwise have purchased and enter into purchase contracts they would  
8 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
9 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
10 deem just or proper.

11 **d. Breach of the Implied Warranty of Merchantability**

12 2859. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

13 2860. This claim is brought against JLI.

14 2861. JUUL has at all times been a merchant with respect to the products which were  
15 sold to Plaintiff and the class and was in the business of selling such products.

16 2862. Each JUUL product sold by JUUL comes with an implied warranty that it will  
17 merchantable and fit for the ordinary purpose for which it would be used. Okla. Stat. tit. 12A  
18 §§ 2A-212. JUUL has breached its implied warranty of merchantability because its products  
19 were not in merchantable condition when sold, were defective when sold, did not conform to the  
20 promises and affirmations of fact made on the products' containers or labels, and/or do not  
21 possess even the most basic degree of fitness for ordinary use.

22 2863. The ordinary intended purpose of JUUL's products—and the purpose for which  
23 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
24 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
25 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
26 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
27 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
28 products are not fit for their ordinary, intended use as either cigarette replacement devices or

1 recreation smoking devices.

2 2864. Plaintiffs and each member of the class have had sufficient direct dealings with  
3 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
4 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
5 each member of the class, on the other hand.

6 2865. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
7 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
8 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
9 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
10 the express purpose an intent of being sold to consumers.

11 2866. Plaintiffs and the members of the class were injured as a direct and proximate  
12 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
13 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
14 because, had they been aware of the unmerchantable condition of JUUL products, they would  
15 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
16 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

17 2867. JUUL was provided notice of these issues by numerous complaints filed against  
18 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
19 individual letters and communications sent by consumers before or within a reasonable amount  
20 of time after they discovered or should have discovered that's JUUL product were defective and  
21 unmerchantable.

22 **e. Unjust Enrichment**

23 2868. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

24 2869. This claim is brought against JLI and the Management Defendants.

25 2870. Defendants created and implemented a scheme to create a market for e-cigarettes  
26 and substantially increase sales of JUUL products through a pervasive pattern of false and  
27 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
28 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,

1 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
2 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
3 products.

4 2871. Defendants were unjustly enriched as a result of their wrongful conduct,  
5 including through the false and misleading advertisements and omissions regarding (i) whether  
6 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
7 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
8 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
9 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
10 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
11 enriched through their scheme of marketing their products to minors. 63 Okl. St. §§ 1-229.13, 1-  
12 229.26 prohibit the marketing, sale, and transfer of JUUL products to minors.

13 2872. Defendants requested and received a measurable benefit at the expense of  
14 Plaintiffs and class members in the form of payment for JUUL products.

15 2873. Defendants appreciated, recognized, and chose to accept the monetary benefits  
16 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
17 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

18 2874. There is no justification for Defendants' enrichment. It would be inequitable,  
19 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
20 benefits were procured as a result of their wrongful conduct.

21 2875. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
22 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
23 with Defendant.

24 2876. Plaintiffs plead this claim separately as well as in the alternative to their other  
25 claims, as without such claims they would have no adequate legal remedy.

26 **37. Oregon**

27 2877. Plaintiffs bring each of the following claims on behalf of the Oregon Subclass  
28 under Oregon law.



**a. Violation of the Oregon Unfair Trade Practices Act (Or. Rev. Stat. §§ 646.605, *et seq.*)**

2878. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2879. This claim is brought against JLI.

2880. Plaintiffs and class members purchased JUUL products for personal purposes.

2881. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2882. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2883. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2884. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

2885. The omissions were misleading and deceptive standing alone and were

1 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
2 cigarettes and other representations.

3 2886. JLI's conduct was unfair and unconscionable in that it included (i) the  
4 manufacture and sale of products with a heightened propensity to cause addiction and physical  
5 injuries and (ii) misrepresentations and omissions of material facts concerning the  
6 characteristics and safety of JUUL products that offended public policy; were immoral,  
7 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
8 substantial harm that greatly outweighs any possible utility from the conduct.

9 2887. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
10 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
11 ingredients, uses, benefits, or quantities, which they do not have; and (b) misrepresenting that  
12 JUUL products are of a particular standard, quality, or grade, or that goods are of a particular  
13 style or model, when they are not.

14 2888. JLI's conduct had a tendency to, was likely to, and in fact did, deceive  
15 reasonable consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
16 would have found it material to their purchasing decisions that JUUL's products (i) were not  
17 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
18 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
19 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
20 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
21 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
22 in Plaintiffs' and class members' decisions to purchase JUUL products.

23 2889. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
24 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
25 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
26 facts; because the facts would be material to reasonable consumers; because JLI actively  
27 concealed them; because JLI intended for consumers to rely on the omissions in question;  
28 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI

1 made partial representations concerning the same subject matter as the omitted facts.

2 2890. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
3 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
4 Reasonable consumers would have been expected to have relied on the misrepresentations and  
5 omissions.

6 2891. Defendants knew or should have known that their misrepresentations and/or  
7 omissions were false and misleading, and intended for consumers to rely on such  
8 misrepresentations and omissions.

9 2892. In addition, all Defendants engaged in unfair and unconscionable conduct  
10 because the targeting of minors offends public policy (in particular Or. Rev. Stat. Ann.  
11 § 167.755(1)); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
12 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
13 conduct.

14 2893. As alleged above, all Defendants participated and/or facilitated the marketing of  
15 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
16 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
17 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
18 use of JUUL products by minors continues to rise.

19 2894. Defendants' conduct actually and proximately caused loss of money or property  
20 to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs  
21 and class members would have behaved differently and would not have purchased JUUL  
22 products or would have paid less for them. Defendants' misrepresentations and omissions  
23 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
24 purchased and enter into purchase contracts they would not otherwise have entered into. In  
25 addition, class members who are minors are entitled to full repayment of the amounts they spent  
26 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
27 actual damages or statutory damages of \$200, whichever is greater, injunctive relief (except as  
28 to the Management Defendants), restitution, and reasonable attorneys' fees, as well as any other

1 relief the Court may deem just or proper.

2 **b. Common Law Fraud**

3 2895. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

4 2896. This claim is brought against JLI.

5 2897. JUUL created and implemented a scheme to create a market for e-cigarettes and  
6 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
7 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
8 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
9 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
10 addictiveness, and significant risks of substantial physical injury from using JUUL products.

11 2898. Advertisements and representations for JUUL products contained deceptive  
12 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
13 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
14 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
15 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
16 decades, JLI used third parties and word of mouth to spread false and misleading information  
17 about JUUL products.

18 2899. Advertisements and representations for JUUL products concealed and failed to  
19 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
20 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
21 addictive, posed significant risks of substantial physical injury resulting from the use of the  
22 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
23 consumed through a pack of combustible cigarettes.

24 2900. The labels on JUUL products failed to disclose that the products posed  
25 significant risks of substantial physical injury resulting from the use of the products. The labels  
26 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

27 2901. The omissions were misleading and deceptive standing alone and were  
28 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to

1 cigarettes and other representations.

2       2902. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
3 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
4 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
5 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
6 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
7 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
8 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
9 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
10 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
11 Plaintiffs' and class members' decisions to purchase JUUL products.

12       2903. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
13 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
14 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
15 facts; because the facts would be material to reasonable consumers; because JUUL products  
16 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
17 representations concerning the same subject matter as the omitted facts.

18       2904. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
19 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
20 and/or omissions. Reasonable consumers would have been expected to have relied on the  
21 misrepresentations and omissions.

22       2905. Defendants knew or should have known that their misrepresentations and/or  
23 omissions were false and misleading, and intended for consumers to rely on such  
24 misrepresentations and omissions.

25       2906. JLI knew that JUUL products were not safe or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
28 products.

2907. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

2908. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2909. This claim is brought against JLI.

2910. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

2911. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. OR. Rev. Stat. Ann. § 72.3140. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

2912. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

2913. Plaintiffs and each member of the class have had sufficient direct dealings with

1 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
2 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
3 each member of the class, on the other hand.

4 2914. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
5 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
6 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
7 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
8 the express purpose an intent of being sold to consumers.

9 2915. Plaintiffs and the members of the class were injured as a direct and proximate  
10 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
11 the Oregon Direct Purchaser Subclass were damaged as a result of JUUL's breach of its implied  
12 warranty of merchantability because, had they been aware of the unmerchantable condition of  
13 JUUL products, they would not have purchased JUUL products, or would have paid less for  
14 them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the  
15 Court may deem just or proper.

16 2916. JUUL was provided notice of these issues by numerous complaints filed against  
17 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
18 individual letters and communications sent by consumers before or within a reasonable amount  
19 of time after they discovered or should have discovered that's JUUL product were defective and  
20 unmerchantable.

21 **d. Unjust Enrichment**

22 2917. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

23 2918. This claim is brought against JLI and the Management Defendants.

24 2919. Defendants created and implemented a scheme to create a market for e-cigarettes  
25 and substantially increase sales of JUUL products through a pervasive pattern of false and  
26 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
27 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
28 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and



1 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
2 products.

3 2920. Defendants were unjustly enriched as a result of their wrongful conduct,  
4 including through the false and misleading advertisements and omissions regarding (i) whether  
5 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
6 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
7 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
8 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
9 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
10 enriched through their scheme of marketing their products to minors. OR. Rev. Stat. Ann.  
11 §§ 167.755(1) prohibits the marketing and sale of JUUL products to minors.

12 2921. Defendants requested and received a measurable benefit at the expense of  
13 Plaintiffs and class members in the form of payment for JUUL products.

14 2922. Defendants appreciated, recognized, and chose to accept the monetary benefits  
15 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
16 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

17 2923. There is no justification for Defendants' enrichment. It would be inequitable,  
18 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
19 benefits were procured as a result of their wrongful conduct.

20 2924. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
21 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
22 with Defendant.

23 2925. Plaintiffs plead this claim separately as well as in the alternative to their other  
24 claims, as without such claims they would have no adequate legal remedy.

25 **38. Pennsylvania**

26 2926. Plaintiffs bring each of the following claims on behalf of the Pennsylvania  
27 Subclass under Pennsylvania law.  
28

**a. Violation of the Pennsylvania Unfair Trade Practices and Consumer Protection Law (73 Pa. Stat. Ann. §§ 201-1, *et seq.*)**

2927. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2928. This claim is brought against JLI.

2929. Plaintiffs and class members purchased JUUL products for personal purposes.

2930. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2931. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

2932. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

2933. The labels on JUUL products failed to disclose that the products posed significant risks of substantial physical injury resulting from the use of the products. The labels also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

2934. The omissions were misleading and deceptive standing alone and were

1 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
2 cigarettes and other representations.

3 2935. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
4 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
5 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
6 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
7 model, when they are not; (c) advertising goods or services with intent not to sell them as  
8 advertised; and (d) engaging in fraudulent and deceptive conduct that creates a likelihood of  
9 confusion and misunderstanding.

10 2936. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
11 omissions created a likelihood of confusion and misunderstanding and had the capacity or  
12 tendency to deceive and in fact did deceive, ordinary consumers, including the Plaintiffs.  
13 Ordinary consumers, including the Plaintiffs, would have found it material to their purchasing  
14 decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable  
15 alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms,  
16 (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury  
17 resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL  
18 pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of  
19 these facts would have been a substantial factor in Plaintiffs' and class members' decisions to  
20 purchase JUUL products.

21 2937. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
22 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
23 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
24 facts; because the facts would be material to reasonable consumers; because JLI actively  
25 concealed them; because JLI intended for consumers to rely on the omissions in question;  
26 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
27 made partial representations concerning the same subject matter as the omitted facts.

28 2938. As set forth in the allegations concerning each Plaintiff in Appendix A, in

1 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
2 Reasonable consumers would have been expected to have relied on the misrepresentations and  
3 omissions.

4 2939. JLI and the Management Defendants engaged in fraudulent and deceptive  
5 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
6 products were appropriate for minors, when in fact the products never should have been  
7 marketed to minors and are especially harmful to minors due to the potent and addictive  
8 nicotine doses, addictive qualities, and health risks.

9 2940. Defendants' conduct actually and proximately caused loss of money or property  
10 to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs  
11 and class members would have behaved differently and would not have purchased JUUL  
12 products or would have paid less for them. Defendants' misrepresentations and omissions  
13 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
14 purchased and enter into purchase contracts they would not otherwise have entered into. In  
15 addition, class members who are minors are entitled to full repayment of the amounts they spent  
16 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
17 three times actual damages and/or statutory damages in the amount of \$100, whichever is  
18 greater, injunctive relief (except as to the Management Defendants), and reasonable attorneys'  
19 fees, as well as any other relief the Court may deem just or proper.

20 **b. Common Law Fraud**

21 2941. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

22 2942. This claim is brought against JLI.

23 2943. JUUL created and implemented a scheme to create a market for e-cigarettes and  
24 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
25 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
26 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
27 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
28 addictiveness, and significant risks of substantial physical injury from using JUUL products.

1           2944. Advertisements and representations for JUUL products contained deceptive  
2 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
3 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
4 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
5 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
6 decades, JLI used third parties and word of mouth to spread false and misleading information  
7 about JUUL products.

8           2945. Advertisements and representations for JUUL products concealed and failed to  
9 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
10 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
11 addictive, posed significant risks of substantial physical injury resulting from the use of the  
12 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
13 consumed through a pack of combustible cigarettes.

14           2946. The labels on JUUL products failed to disclose that the products posed  
15 significant risks of substantial physical injury resulting from the use of the products. The labels  
16 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

17           2947. The omissions were misleading and deceptive standing alone and were  
18 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
19 cigarettes and other representations.

20           2948. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
21 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
22 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
23 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
24 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
25 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
26 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
27 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
28 combustible cigarettes. Knowledge of these facts would have been a substantial factor in

1 Plaintiffs' and class members' decisions to purchase JUUL products.

2 2949. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
3 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
4 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
5 facts; because the facts would be material to reasonable consumers; because JUUL products  
6 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
7 representations concerning the same subject matter as the omitted facts.

8 2950. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
9 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
10 and/or omissions. Reasonable consumers would have been expected to have relied on the  
11 misrepresentations and omissions.

12 2951. Defendants knew or should have known that their misrepresentations and/or  
13 omissions were false and misleading, and intended for consumers to rely on such  
14 misrepresentations and omissions.

15 2952. JLI knew that JUUL products were not safe or reasonable alternatives to  
16 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
17 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
18 products.

19 2953. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
20 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
21 and would not have purchased JUUL products or would have paid less for them. JLI's  
22 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
23 products they would not otherwise have purchased and enter into purchase contracts they would  
24 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
25 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
26 deem just or proper.

27 **c. Breach of the Implied Warranty of Merchantability**

28 2954. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           2955. This claim is brought against JLI.

2           2956. JUUL has at all times been a merchant with respect to the products which were  
3 sold to Plaintiff and the class and was in the business of selling such products.

4           2957. Each JUUL product sold by JUUL comes with an implied warranty that it will  
5 merchantable and fit for the ordinary purpose for which it would be used. 13 Pa. C.S.A. § 2314.  
6 JUUL has breached its implied warranty of merchantability because its products were not in  
7 merchantable condition when sold, were defective when sold, did not conform to the promises  
8 and affirmations of fact made on the products' containers or labels, and/or do not possess even  
9 the most basic degree of fitness for ordinary use.

10           2958. The ordinary intended purpose of JUUL's products—and the purpose for which  
11 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
12 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
13 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
14 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
15 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
16 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
17 recreation smoking devices.

18           2959. Plaintiffs and each member of the class have had sufficient direct dealings with  
19 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
20 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
21 each member of the class, on the other hand.

22           2960. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
23 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
24 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
25 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
26 the express purpose an intent of being sold to consumers.

27           2961. Plaintiffs and the members of the class were injured as a direct and proximate  
28 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of



the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

2962. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

2963. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

2964. This claim is brought against JLI and the Management Defendants.

2965. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

2966. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors.

2967. Defendants requested and received a measurable benefit at the expense of

1 Plaintiffs and class members in the form of payment for JUUL products.

2 2968. Defendants appreciated, recognized, and chose to accept the monetary benefits  
3 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
4 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

5 2969. There is no justification for Defendants' enrichment. It would be inequitable,  
6 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
7 benefits were procured as a result of their wrongful conduct.

8 2970. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
9 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
10 with Defendant.

11 2971. Plaintiffs plead this claim separately as well as in the alternative to their other  
12 claims, as without such claims they would have no adequate legal remedy.

13 **39. Rhode Island**

14 2972. Plaintiffs bring each of the following claims on behalf of the Rhode Island  
15 Subclass under Rhode Island law.

16 **a. Violation of the Rhode Island Unfair Trade Practice and**  
17 **Consumer Protection Act (6 R.I. Gen. Laws §§ 13.1-1, et seq.)**

18 2973. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

19 2974. This claim is brought against JLI and, for certain unfair and/or unconscionable  
20 conduct claims as noted below, all Defendants.

21 2975. Plaintiffs, class members, and Defendants are persons under Rhode Island's  
22 Unfair Trade Practice and Consumer Protection Act.

23 2976. Plaintiffs and class members purchased JUUL products for personal purposes.

24 2977. Defendants created and implemented a scheme to create a market for e-cigarettes  
25 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
26 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
27 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
28 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,

1     addictiveness, and significant risks of substantial physical injury from using JUUL products.

2             2978. Advertisements and representations for JUUL products contained deceptive  
3     statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
4     to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
5     cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
6     not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
7     decades, JLI used third parties and word of mouth to spread false and misleading information  
8     about JUUL products.

9             2979. Advertisements and representations for JUUL products concealed and failed to  
10    disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
11    combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
12    addictive, posed significant risks of substantial physical injury resulting from the use of the  
13    products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
14    consumed through a pack of combustible cigarettes.

15            2980. The labels on JUUL products failed to disclose that the products posed  
16    significant risks of substantial physical injury resulting from the use of the products. The labels  
17    also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

18            2981. The omissions were misleading and deceptive standing alone and were  
19    particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
20    cigarettes and other representations.

21            2982. JLI's conduct was unfair and unconscionable in that it included (i) the  
22    manufacture and sale of products with a heightened propensity to cause addiction and physical  
23    injuries and (ii) misrepresentations and omissions of material facts concerning the  
24    characteristics and safety of JUUL products that offended public policy; were immoral,  
25    unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
26    substantial harm that greatly outweighs any possible utility from the conduct.

27            2983. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
28    unfair business practices: (a) misrepresenting that JUUL products have characteristics,

1 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
2 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
3 model, when they are not; and (c) advertising goods or services with intent not to sell them as  
4 advertised.

5 2984. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
6 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the  
7 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
8 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
9 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
10 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
11 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
12 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
13 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
14 decisions to purchase JUUL products.

15 2985. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
16 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
17 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
18 facts; because the facts would be material to reasonable consumers; because JLI actively  
19 concealed them; because JLI intended for consumers to rely on the omissions in question;  
20 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
21 made partial representations concerning the same subject matter as the omitted facts.

22 2986. JLI and the Management Defendants engaged in fraudulent and deceptive  
23 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
24 products were appropriate for minors, when in fact the products never should have been  
25 marketed to minors and are especially harmful to minors due to the potent and addictive  
26 nicotine doses, addictive qualities, and health risks.

27 2987. In addition, all Defendants engaged in unfair and unconscionable conduct  
28 because the targeting of minors offends public policy (in particular R.I. Gen. Laws §§ 11-9-13,

1 *et seq.*); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially  
2 injurious; and has caused substantial harm that greatly outweighs any possible utility from the  
3 conduct.

4 2988. As alleged above, all Defendants participated and/or facilitated the marketing of  
5 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
6 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
7 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
8 use of JUUL products by minors continues to rise.

9 2989. Defendants' conduct actually and proximately caused actual damages to  
10 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
11 class members would have behaved differently and would not have purchased JUUL products  
12 or would have paid less for them. Defendants' misrepresentations and omissions induced  
13 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
14 purchased and enter into purchase contracts they would not otherwise have entered into. In  
15 addition, class members who are minors are entitled to full repayment of the amounts they spent  
16 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
17 actual damages, restitution, and/ or statutory damages in the amount of \$200 per claim,  
18 whichever is greater, as well as punitive damages, injunctive relief (except as to the  
19 Management Defendants), attorney's fees, and any other relief the Court may deem just or  
20 proper.

21 **b. Common Law Fraud**

22 2990. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

23 2991. This claim is brought against JLI.

24 2992. JUUL created and implemented a scheme to create a market for e-cigarettes and  
25 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
26 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
27 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
28 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,

1     addictiveness, and significant risks of substantial physical injury from using JUUL products.

2             2993. Advertisements and representations for JUUL products contained deceptive  
3     statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
4     to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
5     cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
6     not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
7     decades, JLI used third parties and word of mouth to spread false and misleading information  
8     about JUUL products.

9             2994. Advertisements and representations for JUUL products concealed and failed to  
10    disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
11    combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
12    addictive, posed significant risks of substantial physical injury resulting from the use of the  
13    products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
14    consumed through a pack of combustible cigarettes.

15            2995. The labels on JUUL products failed to disclose that the products posed  
16    significant risks of substantial physical injury resulting from the use of the products. The labels  
17    also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

18            2996. The omissions were misleading and deceptive standing alone and were  
19    particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
20    cigarettes and other representations.

21            2997. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
22    omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
23    including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
24    material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
25    devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
26    potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
27    risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
28    consumed through one JUUL pod exceeded the nicotine consumed through a pack of

1 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
2 Plaintiffs' and class members' decisions to purchase JUUL products.

3 2998. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
4 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
5 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
6 facts; because the facts would be material to reasonable consumers; because JUUL products  
7 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
8 representations concerning the same subject matter as the omitted facts.

9 2999. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
10 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
11 and/or omissions. Reasonable consumers would have been expected to have relied on the  
12 misrepresentations and omissions.

13 3000. Defendants knew or should have known that their misrepresentations and/or  
14 omissions were false and misleading, and intended for consumers to rely on such  
15 misrepresentations and omissions.

16 3001. JLI knew that JUUL products were not safe or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
19 products.

20 3002. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
21 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
22 and would not have purchased JUUL products or would have paid less for them. JLI's  
23 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
24 products they would not otherwise have purchased and enter into purchase contracts they would  
25 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
26 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
27 deem just or proper.  
28



**c. Breach of the Implied Warranty of Merchantability**

3003. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3004. This claim is brought against JLI.

3005. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

3006. Each JUUL product sold by JUUL comes with an implied warranty that it will merchantable and fit for the ordinary purpose for which it would be used. *See* 6A R.I. Gen. Laws § 2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

3007. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

3008. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

3009. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

1           3010. Plaintiffs and the members of the class were injured as a direct and proximate  
2 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
3 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
4 because, had they been aware of the unmerchantable condition of JUUL products, they would  
5 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
6 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

7           3011. JUUL was provided notice of these issues by numerous complaints filed against  
8 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
9 individual letters and communications sent by consumers before or within a reasonable amount  
10 of time after they discovered or should have discovered that's JUUL product were defective and  
11 unmerchantable.

12                           **d.       Unjust Enrichment**

13           3012. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

14           3013. This claim is brought against JLI and the Management Defendants.

15           3014. Defendants created and implemented a scheme to create a market for e-cigarettes  
16 and substantially increase sales of JUUL products through a pervasive pattern of false and  
17 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
18 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
19 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
20 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
21 products.

22           3015. Defendants were unjustly enriched as a result of their wrongful conduct,  
23 including through the false and misleading advertisements and omissions regarding (i) whether  
24 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
25 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
26 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
27 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
28 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly

enriched through their scheme of marketing their products to minors. The General Laws of Rhode Island sections 11-9-13 prohibits the marketing and sale of JUUL products to minors.

3016. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

3017. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3018. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

3019. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

3020. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

#### **40. South Carolina**

3021. Plaintiffs bring each of the following claims on behalf of the South Carolina Subclass under South Carolina law.

##### **a. Violation of the South Carolina Unfair Trade Practices Act (S.C. Code Ann. §§ 39-5-10, *et seq.*)**

3022. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3023. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

3024. Plaintiffs, class members, and Defendants are persons under South Carolina's Unfair Trade Practices Act.

3025. Defendants engaged in trade or commerce directly or indirectly affecting the people of South Carolina by participating and furthering the advertising, offering for sale, selling, or distributing JUUL products.

1           3026. Plaintiffs and class members purchased JUUL products for personal purposes.

2           3027. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8           3028. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15           3029. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21           3030. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24           3031. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27           3032. JLI's conduct was unfair and unconscionable in that it included (i) the  
28 manufacture and sale of products with a heightened propensity to cause addiction and physical

injuries and (ii) misrepresentations and omissions of material facts concerning the characteristics and safety of JUUL products that offended public policy; were immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused substantial harm that greatly outweighs any possible utility from the conduct.

3033. JLI's conduct was fraudulent and deceptive because the misrepresentations and omissions had the capacity to deceive, and in fact did, deceive reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members' decisions to purchase JUUL products.

3034. JLI owed Plaintiffs and class members a duty to disclose these facts because they were known and/or accessible exclusively to Defendants (and potentially other unnamed parties other than Plaintiffs and class members), who had exclusive and superior knowledge of the facts; because the facts would be material to reasonable consumers; because JLI actively concealed them; because JLI intended for consumers to rely on the omissions in question; because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI made partial representations concerning the same subject matter as the omitted facts.

3035. JLI and the Management Defendants engaged in fraudulent and deceptive conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL products were appropriate for minors, when in fact the products never should have been marketed to minors and are especially harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health risks.

3036. In addition, all Defendants engaged in unfair and unconscionable conduct because the targeting of minors offends public policy (in particular S.C. Code Ann. §§ 16-17-

500, *et seq.*); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has caused substantial harm that greatly outweighs any possible utility from the conduct.

3037. As alleged above, all Defendants participated and/or facilitated the marketing of JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI and others have continued the deceptive, misleading, unfair, and unconscionable practices that Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the use of JUUL products by minors continues to rise.

3038. Defendants' conduct actually and proximately caused actual damages and loss of money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—actual damages and treble damages, as well as restitution, attorney's fees and any other relief the Court may deem just or proper.

**b. Common Law Fraud**

3039. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3040. This claim is brought against JLI.

3041. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3042. Advertisements and representations for JUUL products contained deceptive

1 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
2 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
3 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
4 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
5 decades, JLI used third parties and word of mouth to spread false and misleading information  
6 about JUUL products.

7 3043. Advertisements and representations for JUUL products concealed and failed to  
8 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
9 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
10 addictive, posed significant risks of substantial physical injury resulting from the use of the  
11 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
12 consumed through a pack of combustible cigarettes.

13 3044. The labels on JUUL products failed to disclose that the products posed  
14 significant risks of substantial physical injury resulting from the use of the products. The labels  
15 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

16 3045. The omissions were misleading and deceptive standing alone and were  
17 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
18 cigarettes and other representations.

19 3046. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
20 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
21 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
22 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
23 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
24 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
25 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
26 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
27 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
28 Plaintiffs' and class members' decisions to purchase JUUL products.



1           3047. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
2 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
3 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
4 facts; because the facts would be material to reasonable consumers; because JUUL products  
5 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
6 representations concerning the same subject matter as the omitted facts.

7           3048. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
8 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
9 and/or omissions. Reasonable consumers would have been expected to have relied on the  
10 misrepresentations and omissions.

11           3049. Defendants knew or should have known that their misrepresentations and/or  
12 omissions were false and misleading, and intended for consumers to rely on such  
13 misrepresentations and omissions.

14           3050. JLI knew that JUUL products were not safe or reasonable alternatives to  
15 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
16 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
17 products.

18           3051. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
19 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
20 and would not have purchased JUUL products or would have paid less for them. JLI's  
21 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
22 products they would not otherwise have purchased and enter into purchase contracts they would  
23 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
24 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
25 deem just or proper.

26                           **c. Breach of the Implied Warranty of Merchantability**

27           3052. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

28           3053. This claim is brought against JLI.

1           3054. JUUL has at all times been a merchant with respect to the products which were  
2 sold to Plaintiff and the class and was in the business of selling such products.

3           3055. Each JUUL product sold by JUUL comes with an implied warranty that it will  
4 merchantable and fit for the ordinary purpose for which it would be used. *See* S.C. Code Ann.  
5 § 36-2-314. JUUL has breached its implied warranty of merchantability because its products  
6 were not in merchantable condition when sold, were defective when sold, did not conform to the  
7 promises and affirmations of fact made on the products' containers or labels, and/or do not  
8 possess even the most basic degree of fitness for ordinary use.

9           3056. The ordinary intended purpose of JUUL's products—and the purpose for which  
10 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
11 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
12 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
13 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
14 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
15 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
16 recreation smoking devices.

17           3057. Plaintiffs and each member of the class have had sufficient direct dealings with  
18 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
19 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
20 each member of the class, on the other hand.

21           3058. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
22 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
23 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
24 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
25 the express purpose an intent of being sold to consumers.

26           3059. Plaintiffs and the members of the class were injured as a direct and proximate  
27 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
28 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability

1 because, had they been aware of the unmerchantable condition of JUUL products, they would  
2 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
3 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

4 3060. JUUL was provided notice of these issues by numerous complaints filed against  
5 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
6 individual letters and communications sent by consumers before or within a reasonable amount  
7 of time after they discovered or should have discovered that's JUUL product were defective and  
8 unmerchantable.

9 **d. Unjust Enrichment**

10 3061. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 3062. This claim is brought against JLI and the Management Defendants.

12 3063. Defendants created and implemented a scheme to create a market for e-cigarettes  
13 and substantially increase sales of JUUL products through a pervasive pattern of false and  
14 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
15 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
16 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
17 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
18 products.

19 3064. Defendants were unjustly enriched as a result of their wrongful conduct,  
20 including through the false and misleading advertisements and omissions regarding (i) whether  
21 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
22 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
23 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
24 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
25 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
26 enriched through their scheme of marketing their products to minors. S.C. Code Ann. §§ 16-17-  
27 500 & 16-17-502(A) prohibit the marketing and sale of JUUL products to minors.

28 3065. Defendants requested and received a measurable benefit at the expense of

1 Plaintiffs and class members in the form of payment for JUUL products.

2 3066. Defendants appreciated, recognized, and chose to accept the monetary benefits  
3 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
4 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

5 3067. There is no justification for Defendants' enrichment. It would be inequitable,  
6 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
7 benefits were procured as a result of their wrongful conduct.

8 3068. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
9 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
10 with Defendant.

11 3069. Plaintiffs plead this claim separately as well as in the alternative to their other  
12 claims, as without such claims they would have no adequate legal remedy.

13 3070. [Intentionally Omitted]

14 **41. South Dakota**

15 3071. Plaintiffs bring each of the following claims on behalf of the South Dakota  
16 Subclass under South Dakota law.

17 **a. Violation of the South Dakota Deceptive Trade Practices and**  
18 **Consumer Protection Act (S.D. Codified Laws §§ 37-24-1, *et***  
***seq.*)**

19 3072. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

20 3073. This claim is brought against JLI and, for certain claims below, the Management  
21 Defendants.

22 3074. Plaintiffs, class members, and JUUL are persons under South Dakota's  
23 Deceptive Trade Practices and Consumer Protection Act.

24 3075. JUUL engaged in trade or commerce directly or indirectly affecting the people of  
25 South Dakota by advertising, offering for sale, attempting to sell, selling, or distributing JUUL  
26 products.

27 3076. Plaintiffs and class members purchased JUUL products for personal purposes.

28 3077. Defendants created and implemented a scheme to create a market for e-cigarettes

1 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
2 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
3 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
4 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
5 addictiveness, and significant risks of substantial physical injury from using JUUL products.

6 3078. Advertisements and representations for JUUL products contained deceptive  
7 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
8 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
9 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
10 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
11 decades, JLI used third parties and word of mouth to spread false and misleading information  
12 about JUUL products.

13 3079. Advertisements and representations for JUUL products concealed and failed to  
14 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
15 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
16 addictive, posed significant risks of substantial physical injury resulting from the use of the  
17 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
18 consumed through a pack of combustible cigarettes.

19 3080. The labels on JUUL products failed to disclose that the products posed  
20 significant risks of substantial physical injury resulting from the use of the products. The labels  
21 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

22 3081. The omissions were misleading and deceptive standing alone and were  
23 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
24 cigarettes and other representations.

25 3082. JUUL engaged in, used, and employed deceptive acts and practices, fraud, false  
26 pretense, false promises, and misrepresentations and concealed, suppressed, and omitted  
27 material information in connection with the sale of JUUL products.

28 3083. JLI's conduct had the capacity to, were likely to, and in fact did, deceive

1 reasonable consumers, including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
2 would have found it material to their purchasing decisions that JUUL's products (i) were not  
3 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
4 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
5 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
6 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
7 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
8 in Plaintiffs' and class members' decisions to purchase JUUL products.

9 3084. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JLI actively  
13 concealed them; because JLI intended for consumers to rely on the omissions in question;  
14 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
15 made partial representations concerning the same subject matter as the omitted facts.

16 3085. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
17 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
18 Reasonable consumers would have been expected to have relied on the misrepresentations and  
19 omissions.

20 3086. Defendants knew or should have known that their misrepresentations and/or  
21 omissions were false and misleading, and intended for consumers to rely on such  
22 misrepresentations and omissions.

23 3087. JLI and the Management Defendants engaged in fraudulent and deceptive  
24 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
25 products were appropriate for minors, when in fact the products never should have been  
26 marketed to minors and are especially harmful to minors due to the potent and addictive  
27 nicotine doses, addictive qualities, and health risks.

28 3088. JLI's conduct actually and proximately caused actual damages and loss of money

1 or property to Plaintiffs and class members. Absent JUUL's deceptive and fraudulent conduct,  
2 Plaintiffs and class members would have behaved differently and would not have purchased  
3 JUUL products or would have paid less for them. JLI's misrepresentations and omissions  
4 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
5 purchased and enter into purchase contracts they would not otherwise have entered into. In  
6 addition, class members who are minors are entitled to full repayment of the amounts they spent  
7 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
8 actual damages, as well as any other relief the Court may deem just or proper.

9 **b. Common Law Fraud**

10 3089. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 3090. This claim is brought against JLI.

12 3091. JUUL created and implemented a scheme to create a market for e-cigarettes and  
13 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
14 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
15 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
16 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
17 addictiveness, and significant risks of substantial physical injury from using JUUL products.

18 3092. Advertisements and representations for JUUL products contained deceptive  
19 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
20 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
21 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
22 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
23 decades, JLI used third parties and word of mouth to spread false and misleading information  
24 about JUUL products.

25 3093. Advertisements and representations for JUUL products concealed and failed to  
26 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
27 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
28 addictive, posed significant risks of substantial physical injury resulting from the use of the



1 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
2 consumed through a pack of combustible cigarettes.

3 3094. The labels on JUUL products failed to disclose that the products posed  
4 significant risks of substantial physical injury resulting from the use of the products. The labels  
5 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

6 3095. The omissions were misleading and deceptive standing alone and were  
7 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
8 cigarettes and other representations.

9 3096. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
10 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
11 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
12 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
13 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
14 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
15 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
16 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
17 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
18 Plaintiffs' and class members' decisions to purchase JUUL products.

19 3097. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
20 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
21 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
22 facts; because the facts would be material to reasonable consumers; because JUUL products  
23 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
24 representations concerning the same subject matter as the omitted facts.

25 3098. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
26 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
27 and/or omissions. Reasonable consumers would have been expected to have relied on the  
28 misrepresentations and omissions.

1           3099. Defendants knew or should have known that their misrepresentations and/or  
2 omissions were false and misleading, and intended for consumers to rely on such  
3 misrepresentations and omissions.

4           3100. JLI knew that JUUL products were not safe or reasonable alternatives to  
5 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
6 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
7 products.

8           3101. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
9 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
10 and would not have purchased JUUL products or would have paid less for them. JLI's  
11 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
12 products they would not otherwise have purchased and enter into purchase contracts they would  
13 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
14 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
15 deem just or proper.

16                           **c. Breach of the Implied Warranty of Merchantability**

17           3102. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

18           3103. This claim is brought against JLI.

19           3104. JUUL has at all times been a merchant with respect to the products which were  
20 sold to Plaintiff and the class and was in the business of selling such products.

21           3105. Each JUUL product sold by JUUL comes with an implied warranty that it will  
22 merchantable and fit for the ordinary purpose for which it would be used. *See* S.D. Codified  
23 Laws § 57A-2-314. JUUL has breached its implied warranty of merchantability because its  
24 products were not in merchantable condition when sold, were defective when sold, did not  
25 conform to the promises and affirmations of fact made on the products' containers or labels,  
26 and/or do not possess even the most basic degree of fitness for ordinary use.

27           3106. The ordinary intended purpose of JUUL's products—and the purpose for which  
28 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's

1 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
2 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
3 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
4 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
5 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
6 recreation smoking devices.

7 3107. Plaintiffs and each member of the class have had sufficient direct dealings with  
8 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
9 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
10 each member of the class, on the other hand.

11 3108. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
12 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
13 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
14 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
15 the express purpose an intent of being sold to consumers.

16 3109. Plaintiffs and the members of the class were injured as a direct and proximate  
17 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
18 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
19 because, had they been aware of the unmerchantable condition of JUUL products, they would  
20 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
21 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

22 3110. JUUL was provided notice of these issues by numerous complaints filed against  
23 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
24 individual letters and communications sent by consumers before or within a reasonable amount  
25 of time after they discovered or should have discovered that’s JUUL product were defective and  
26 unmerchantable.

27 **d. Unjust Enrichment**

28 3111. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1 3112. This claim is brought against JLI and the Management Defendants.

2 3113. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL products through a pervasive pattern of false and  
4 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
5 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
6 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
7 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
8 products.

9 3114. Defendants were unjustly enriched as a result of their wrongful conduct,  
10 including through the false and misleading advertisements and omissions regarding (i) whether  
11 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
12 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
13 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
14 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
15 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
16 enriched through their scheme of marketing their products to minors. South Dakota Codified  
17 Laws § 34-46-2 prohibits the marketing and sale of JUUL products to minors.

18 3115. Defendants requested and received a measurable benefit at the expense of  
19 Plaintiffs and class members in the form of payment for JUUL products.

20 3116. Defendants appreciated, recognized, and chose to accept the monetary benefits  
21 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
22 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

23 3117. There is no justification for Defendants' enrichment. It would be inequitable,  
24 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
25 benefits were procured as a result of their wrongful conduct.

26 3118. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
27 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
28 with Defendant.

3119. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

**42. Tennessee**

3120. Plaintiffs bring each of the following claims on behalf of the Tennessee Subclass under Tennessee law.

**a. Violation of the Tennessee Consumer Protection Act (Tenn. Code Ann. §§ 47-18-101, *et seq.*)**

3121. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3122. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

3123. Plaintiffs, class members, and Defendants are persons under Tennessee's Consumer Protection Act.

3124. Plaintiffs and class members are natural persons who purchased JUUL products for personal purposes.

3125. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3126. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

3127. Advertisements and representations for JUUL products concealed and failed to

1 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
2 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
3 addictive, posed significant risks of substantial physical injury resulting from the use of the  
4 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
5 consumed through a pack of combustible cigarettes.

6 3128. The labels on JUUL products failed to disclose that the products posed  
7 significant risks of substantial physical injury resulting from the use of the products. The labels  
8 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

9 3129. The omissions were misleading and deceptive standing alone and were  
10 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
11 cigarettes and other representations.

12 3130. JLI's conduct was unfair and unconscionable in that it included (i) the  
13 manufacture and sale of products with a heightened propensity to cause addiction and physical  
14 injuries and (ii) misrepresentations and omissions of material facts concerning the  
15 characteristics and safety of JUUL products that offended public policy; were immoral,  
16 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
17 substantial harm that greatly outweighs any possible utility from the conduct.

18 3131. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
19 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
20 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
21 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
22 model, when they are not; (c) advertising goods or services with intent not to sell them as  
23 advertised; and (d) using statements or illustrations in advertisements that create a false  
24 impression of the grade, quality, quantity, value, or usability of the goods or services offered.

25 3132. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
26 omissions at issue were likely to or tend to, and in fact did, deceive reasonable consumers  
27 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
28 material to their purchasing decisions that JUUL's products (i) were not smoking cessation

1 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
2 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
3 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
4 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
5 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
6 Plaintiffs' and class members' decisions to purchase JUUL products.

7 3133. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
8 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
9 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
10 facts; because the facts would be material to reasonable consumers; because JLI actively  
11 concealed them; because JLI intended for consumers to rely on the omissions in question;  
12 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
13 made partial representations concerning the same subject matter as the omitted facts.

14 3134. JLI and the Management Defendants engaged in fraudulent and deceptive  
15 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
16 products were appropriate for minors, when in fact the products never should have been  
17 marketed to minors and are especially harmful to minors due to the potent and addictive  
18 nicotine doses, addictive qualities, and health risks.

19 3135. In addition, all Defendants engaged in unfair and unconscionable conduct  
20 because the targeting of minors offends public policy (in particular Tenn. Code Ann. § 39-17-  
21 1504); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious;  
22 and has caused substantial harm that greatly outweighs any possible utility from the conduct.

23 3136. As alleged above, all Defendants participated and/or facilitated the marketing of  
24 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
25 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
26 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
27 use of JUUL products by minors continues to rise.

28 3137. Defendants' conduct actually and proximately caused ascertainable loss of



1 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent  
2 conduct, Plaintiffs and class members would have behaved differently and would not have  
3 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
4 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
5 otherwise have purchased and enter into purchase contracts they would not otherwise have  
6 entered into. In addition, class members who are minors are entitled to full repayment of the  
7 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
8 member of the class—actual damages and statutory treble damages, as well as injunctive relief  
9 (except as to the Management Defendants), attorney's fees, and any other relief the Court may  
10 deem just or proper.

11 **b. Common Law Intentional Misrepresentation**

12 3138. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

13 3139. This claim is brought against JLI.

14 3140. JUUL created and implemented a scheme to create a market for e-cigarettes and  
15 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
16 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
17 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
18 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
19 addictiveness, and significant risks of substantial physical injury from using JUUL products.

20 3141. Advertisements and representations for JUUL products contained deceptive  
21 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
22 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
23 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
24 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
25 decades, JLI used third parties and word of mouth to spread false and misleading information  
26 about JUUL products.

27 3142. Advertisements and representations for JUUL products concealed and failed to  
28 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to

1 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
2 addictive, posed significant risks of substantial physical injury resulting from the use of the  
3 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
4 consumed through a pack of combustible cigarettes.

5 3143. The labels on JUUL products failed to disclose that the products posed  
6 significant risks of substantial physical injury resulting from the use of the products. The labels  
7 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

8 3144. The omissions were misleading and deceptive standing alone and were  
9 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
10 cigarettes and other representations.

11 3145. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
12 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
13 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
14 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
15 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
16 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
17 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
18 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
19 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
20 Plaintiffs' and class members' decisions to purchase JUUL products.

21 3146. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
22 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
23 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
24 facts; because the facts would be material to reasonable consumers; because JUUL products  
25 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
26 representations concerning the same subject matter as the omitted facts.

27 3147. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
28 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations

1 and/or omissions. Reasonable consumers would have been expected to have relied on the  
2 misrepresentations and omissions.

3 3148. Defendants knew or should have known that their misrepresentations and/or  
4 omissions were false and misleading, and intended for consumers to rely on such  
5 misrepresentations and omissions.

6 3149. JLI knew that JUUL products were not safe or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
9 products.

10 3150. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
11 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
12 and would not have purchased JUUL products or would have paid less for them. JLI's  
13 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
14 products they would not otherwise have purchased and enter into purchase contracts they would  
15 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
16 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
17 deem just or proper.

18 **c. Breach of the Implied Warranty of Merchantability**

19 3151. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

20 3152. This claim is brought against JLI.

21 3153. JUUL has at all times been a merchant with respect to the products which were  
22 sold to Plaintiff and the class and was in the business of selling such products.

23 3154. Each JUUL product sold by JUUL comes with an implied warranty that it will  
24 merchantable and fit for the ordinary purpose for which it would be used. *See* Tenn. Code Ann.  
25 § 47-2-314. JUUL has breached its implied warranty of merchantability because its products  
26 were not in merchantable condition when sold, were defective when sold, did not conform to the  
27 promises and affirmations of fact made on the products' containers or labels, and/or do not  
28 possess even the most basic degree of fitness for ordinary use.

1           3155. The ordinary intended purpose of JUUL’s products—and the purpose for which  
2 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
3 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
4 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
5 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
6 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
7 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
8 recreation smoking devices.

9           3156. Plaintiffs and each member of the class have had sufficient direct dealings with  
10 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
11 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
12 each member of the class, on the other hand.

13           3157. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
14 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
15 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
16 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
17 the express purpose an intent of being sold to consumers.

18           3158. Plaintiffs and the members of the class were injured as a direct and proximate  
19 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
20 the Tennessee Direct Purchaser Subclass were damaged as a result of JUUL’s breach of its  
21 implied warranty of merchantability because, had they been aware of the unmerchantable  
22 condition of JUUL products, they would not have purchased JUUL products, or would have  
23 paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any  
24 other relief the Court may deem just or proper.

25           3159. JUUL was provided notice of these issues by numerous complaints filed against  
26 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
27 individual letters and communications sent by consumers before or within a reasonable amount  
28 of time after they discovered or should have discovered that’s JUUL product were defective and

unmerchtable.

**d. Unjust Enrichment**

3160. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3161. This claim is brought against JLI and the Management Defendants.

3162. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3163. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Tennessee Code Annotated §§ 39-17-1504(a) and 39-17-1504(d) prohibit the marketing and sale of JUUL products to minors.

3164. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

3165. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3166. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the

benefits were procured as a result of their wrongful conduct.

3167. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

3168. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

**43. Texas**

3169. Plaintiffs bring each of the following claims on behalf of the Texas Subclass under Texas law.

**a. Violation of the Texas Deceptive Trade Practices-Consumer Protection Act (Tex. Bus. & Com. Code §§ 17.41, et seq.)**

3170. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3171. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

3172. Plaintiffs, class members, and Defendants are persons under Texas's Deceptive Trade Practices-Consumer Protection Act.

3173. Plaintiffs and class members are individuals who purchased JUUL products.

3174. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3175. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous

1 decades, JLI used third parties and word of mouth to spread false and misleading information  
2 about JUUL products.

3 3176. Advertisements and representations for JUUL products concealed and failed to  
4 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
5 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
6 addictive, posed significant risks of substantial physical injury resulting from the use of the  
7 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
8 consumed through a pack of combustible cigarettes.

9 3177. The labels on JUUL products failed to disclose that the products posed  
10 significant risks of substantial physical injury resulting from the use of the products. The labels  
11 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

12 3178. The omissions were misleading and deceptive standing alone and were  
13 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
14 cigarettes and other representations.

15 3179. JLI's conduct was unfair and unconscionable in that it included (i) the  
16 manufacture and sale of products with a heightened propensity to cause addiction and physical  
17 injuries and (ii) misrepresentations and omissions of material facts concerning the  
18 characteristics and safety of JUUL products that offended public policy; were immoral,  
19 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
20 substantial harm that greatly outweighs any possible utility from the conduct. JUUL's acts took  
21 advantage of the lack of knowledge, ability, experience, or capacity of Plaintiffs and class  
22 members to a grossly unfair degree and to the detriment of Plaintiffs and class members.

23 3180. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
24 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
25 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
26 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
27 model, when they are not; (c) advertising goods or services with intent not to sell them as  
28 advertised; and (d) failing to disclose information concerning JUUL products which was known



1 at the time of the JUUL's sale of the products, with the intention to induce the consumers into  
2 transactions into which consumers would not have entered had the information been disclosed.

3 3181. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
4 omissions had the capacity and tendency to deceive, and in fact did, deceive reasonable  
5 consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have  
6 found it material to their purchasing decisions that JUUL's products (i) were not smoking  
7 cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were  
8 extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
9 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
10 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
11 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
12 in Plaintiffs' and class members' decisions to purchase JUUL products.

13 3182. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
14 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
15 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
16 facts; because the facts would be material to reasonable consumers; because JLI actively  
17 concealed them; because JLI intended for consumers to rely on the omissions in question;  
18 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
19 made partial representations concerning the same subject matter as the omitted facts.

20 3183. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
21 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
22 Reasonable consumers would have been expected to have relied on the misrepresentations and  
23 omissions.

24 3184. Defendants knew or should have known that their misrepresentations and/or  
25 omissions were false and misleading, and intended for consumers to rely on such  
26 misrepresentations and omissions.

27 3185. In addition, all Defendants engaged in unconscionable conduct because the  
28 targeting of minors took advantage of the lack of knowledge, ability, experience, or capacity of

1 Plaintiffs and class members to a grossly unfair degree and to the detriment of Plaintiffs and  
2 class members. In particular, Texas law seeks to protect minors from being the target of sales  
3 and marketing practices concerning JUUL products. Texas Health & Safety Code § 161.082,  
4 161.087 and 161.452(c).

5 3186. Defendants' conduct actually and proximately caused actual damages to  
6 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
7 class members would have behaved differently and would not have purchased JUUL products  
8 or would have paid less for them. Defendants' misrepresentations and omissions induced  
9 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
10 purchased and enter into purchase contracts they would not otherwise have entered into. In  
11 addition, class members who are minors are entitled to full repayment of the amounts they spent  
12 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
13 economic damages, treble damages, and restitution, as well as injunctive relief (except as to the  
14 Management Defendants), attorney's fees, and any other relief the Court may deem just or  
15 proper.

16 **b. Common Law Fraud**

17 3187. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

18 3188. This claim is brought against JLI.

19 3189. JUUL created and implemented a scheme to create a market for e-cigarettes and  
20 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
21 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
22 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
23 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
24 addictiveness, and significant risks of substantial physical injury from using JUUL products.

25 3190. Advertisements and representations for JUUL products contained deceptive  
26 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
27 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
28 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or

1 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
2 decades, JLI used third parties and word of mouth to spread false and misleading information  
3 about JUUL products.

4 3191. Advertisements and representations for JUUL products concealed and failed to  
5 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
6 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
7 addictive, posed significant risks of substantial physical injury resulting from the use of the  
8 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
9 consumed through a pack of combustible cigarettes.

10 3192. The labels on JUUL products failed to disclose that the products posed  
11 significant risks of substantial physical injury resulting from the use of the products. The labels  
12 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

13 3193. The omissions were misleading and deceptive standing alone and were  
14 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
15 cigarettes and other representations.

16 3194. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
17 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
18 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
19 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
20 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
21 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
22 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
23 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
24 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
25 Plaintiffs' and class members' decisions to purchase JUUL products.

26 3195. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
27 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
28 other than Plaintiffs and class members), who had exclusive and superior knowledge of the

1 facts; because the facts would be material to reasonable consumers; because JUUL products  
2 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
3 representations concerning the same subject matter as the omitted facts.

4 3196. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
5 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
6 and/or omissions. Reasonable consumers would have been expected to have relied on the  
7 misrepresentations and omissions.

8 3197. Defendants knew or should have known that their misrepresentations and/or  
9 omissions were false and misleading, and intended for consumers to rely on such  
10 misrepresentations and omissions.

11 3198. JLI knew that JUUL products were not safe or reasonable alternatives to  
12 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
13 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
14 products.

15 3199. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
16 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
17 and would not have purchased JUUL products or would have paid less for them. JLI's  
18 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
19 products they would not otherwise have purchased and enter into purchase contracts they would  
20 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
21 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
22 deem just or proper.

23 **c. Breach of the Implied Warranty of Merchantability**

24 3200. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

25 3201. This claim is brought against JLI.

26 3202. JUUL has at all times been a merchant with respect to the products which were  
27 sold to Plaintiff and the class and was in the business of selling such products.

28 3203. Each JUUL product sold by JUUL comes with an implied warranty that it will

1 merchantable and fit for the ordinary purpose for which it would be used. *See* Tex. Bus. & Com.  
2 Code § 2.314. JUUL has breached its implied warranty of merchantability because its products  
3 were not in merchantable condition when sold, were defective when sold, did not conform to the  
4 promises and affirmations of fact made on the products' containers or labels, and/or do not  
5 possess even the most basic degree of fitness for ordinary use.

6 3204. The ordinary intended purpose of JUUL's products—and the purpose for which  
7 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
8 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
9 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
10 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
11 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
12 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
13 recreation smoking devices.

14 3205. Plaintiffs and each member of the class have had sufficient direct dealings with  
15 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
16 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
17 each member of the class, on the other hand.

18 3206. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
19 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
20 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
21 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
22 the express purpose an intent of being sold to consumers.

23 3207. Plaintiffs and the members of the class were injured as a direct and proximate  
24 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
25 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
26 because, had they been aware of the unmerchantable condition of JUUL products, they would  
27 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
28 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

3208. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

3209. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3210. This claim is brought against JLI and the Management Defendants.

3211. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3212. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Texas Health & Safety Code § 161.082, 161.087 and 161.452(c) prohibit the marketing and sale of JUUL products to minors.

3213. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

3214. Defendants appreciated, recognized, and chose to accept the monetary benefits

1 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
2 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3 3215. There is no justification for Defendants' enrichment. It would be inequitable,  
4 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
5 benefits were procured as a result of their wrongful conduct.

6 3216. Plaintiffs plead this claim separately as well as in the alternative to their other  
7 claims, as without such claims they would have no adequate legal remedy.

8 **44. Utah**

9 3217. Plaintiffs bring each of the following claims on behalf of the Utah Subclass  
10 under Utah law.

11 **a. Violation of the Utah Consumer Sales Practices Act (Utah**  
12 **Code Ann. §§ 13-11-1, et seq.)**

13 3218. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

14 3219. This claim is brought against JLI.

15 3220. Plaintiffs, class members, and Defendants are persons under Utah's Consumer  
16 Sales Practices Act.

17 3221. Plaintiffs and class members purchased JUUL products in consumer transactions  
18 primarily for personal purposes.

19 3222. Defendants created and implemented a scheme to create a market for e-cigarettes  
20 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
21 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
22 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
23 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
24 addictiveness, and significant risks of substantial physical injury from using JUUL products.

25 3223. Advertisements and representations for JUUL products contained deceptive  
26 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
27 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
28 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or



1 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
2 decades, JLI used third parties and word of mouth to spread false and misleading information  
3 about JUUL products.

4 3224. Advertisements and representations for JUUL products concealed and failed to  
5 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
6 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
7 addictive, posed significant risks of substantial physical injury resulting from the use of the  
8 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
9 consumed through a pack of combustible cigarettes.

10 3225. The labels on JUUL products failed to disclose that the products posed  
11 significant risks of substantial physical injury resulting from the use of the products. The labels  
12 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

13 3226. The omissions were misleading and deceptive standing alone and were  
14 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
15 cigarettes and other representations.

16 3227. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
17 unfair business practices: (a) misrepresenting that JUUL products have performance  
18 characteristics, uses, or benefits, which they do not have; (b) misrepresenting that JUUL  
19 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
20 model, when they are not; and (c) misrepresenting that the subject of a transaction has been  
21 supplied in accordance with a previous representation when it has not.

22 3228. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
23 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers,  
24 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
25 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
26 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
27 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
28 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine

1 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
2 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
3 Plaintiffs' and class members' decisions to purchase JUUL products.

4 3229. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
5 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
6 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
7 facts; because the facts would be material to reasonable consumers; because JLI actively  
8 concealed them; because JLI intended for consumers to rely on the omissions in question;  
9 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
10 made partial representations concerning the same subject matter as the omitted facts.

11 3230. JLI knew or should have known that their misrepresentations and/or omissions  
12 were false and misleading, and intended for consumers to rely on such misrepresentations and  
13 omissions.

14 3231. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
15 class members. Absent JLI's unfair and fraudulent conduct, Plaintiffs and class members would  
16 have behaved differently and would not have purchased JUUL products or would have paid less  
17 for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to  
18 purchase JUUL products they would not otherwise have purchased and enter into purchase  
19 contracts they would not otherwise have entered into. In addition, class members who are  
20 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
21 seek—on behalf of themselves and each member of the class—actual damages as well as  
22 restitution, injunctive relief, attorney's fees, and any other relief the Court may deem just or  
23 proper.

24 3232. Defendants had notice that its conduct was in violation of the law based on prior  
25 rulings in sprawling, decades-long tobacco litigation and other notice they have received as a  
26 result of lawsuits filed against them, and regulations promulgated under Utah Code §§ 13-11-1,  
27 *et seq.*, including, but not limited to, Utah Administrative Code R152-11-3(B)(1).  
28

**b. Violation of the Utah Truth in Advertising Law (Utah Code Ann. §§ 13-11a-1, *et seq.*)**

3233. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3234. This claim is brought against JLI.

3235. Plaintiffs, class members, and Defendants are persons under Utah's Truth in Advertising Law.

3236. JLI is a supplier of JUUL products because it sells, assigns, offers, brokers, or regularly solicits, engages in, or enforces sales of JUUL products.

3237. Plaintiffs and class members purchased JUUL products for personal purposes.

3238. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3239. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

3240. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.

1           3241. The labels on JUUL products failed to disclose that the products posed  
2 significant risks of substantial physical injury resulting from the use of the products. The labels  
3 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

4           3242. The omissions were misleading and deceptive standing alone and were  
5 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
6 cigarettes and other representations.

7           3243. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
8 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
9 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
10 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
11 model, when they are not; and (c) advertising goods or services with intent not to sell them as  
12 advertised.

13           3244. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
14 omissions at issue were likely to cause, and in fact did cause, a likelihood of confusion or  
15 misunderstanding. Reasonable consumers, including the Plaintiffs, would have found it  
16 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
17 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
18 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
19 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
20 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
21 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
22 Plaintiffs' and class members' decisions to purchase JUUL products.

23           3245. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
24 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
25 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
26 facts; because the facts would be material to reasonable consumers; because JLI actively  
27 concealed them; because JLI intended for consumers to rely on the omissions in question;  
28 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI

1 made partial representations concerning the same subject matter as the omitted facts.

2 3246. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
3 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
4 Reasonable consumers would have been expected to have relied on the misrepresentations and  
5 omissions.

6 3247. JLI knew or should have known that their misrepresentations and/or omissions  
7 were false and misleading, and intended for consumers to rely on such misrepresentations and  
8 omissions.

9 3248. JLI's conduct actually and proximately caused actual damages to Plaintiffs and  
10 class members. Absent JLI's deceptive and fraudulent conduct, Plaintiffs and class members  
11 would have behaved differently and would not have purchased JUUL products or would have  
12 paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members  
13 to purchase JUUL products they would not otherwise have purchased and enter into purchase  
14 contracts they would not otherwise have entered into. In addition, class members who are  
15 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
16 seek—on behalf of themselves and each member of the class—actual damages or \$2,000,  
17 whichever is greater, and statutory damages, as well as restitution, injunctive relief, attorney's  
18 fees, and any other relief the Court may deem just or proper.

19 **c. Common Law Fraud**

20 3249. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

21 3250. This claim is brought against JLI.

22 3251. JUUL created and implemented a scheme to create a market for e-cigarettes and  
23 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
24 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
25 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
26 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
27 addictiveness, and significant risks of substantial physical injury from using JUUL products.

28 3252. Advertisements and representations for JUUL products contained deceptive

1 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
2 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
3 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
4 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
5 decades, JLI used third parties and word of mouth to spread false and misleading information  
6 about JUUL products.

7 3253. Advertisements and representations for JUUL products concealed and failed to  
8 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
9 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
10 addictive, posed significant risks of substantial physical injury resulting from the use of the  
11 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
12 consumed through a pack of combustible cigarettes.

13 3254. The labels on JUUL products failed to disclose that the products posed  
14 significant risks of substantial physical injury resulting from the use of the products. The labels  
15 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

16 3255. The omissions were misleading and deceptive standing alone and were  
17 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
18 cigarettes and other representations.

19 3256. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
20 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
21 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
22 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
23 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
24 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
25 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
26 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
27 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
28 Plaintiffs' and class members' decisions to purchase JUUL products.

1           3257. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
2 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
3 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
4 facts; because the facts would be material to reasonable consumers; because JUUL products  
5 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
6 representations concerning the same subject matter as the omitted facts.

7           3258. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
8 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
9 and/or omissions. Reasonable consumers would have been expected to have relied on the  
10 misrepresentations and omissions.

11           3259. Defendants knew or should have known that their misrepresentations and/or  
12 omissions were false and misleading, and intended for consumers to rely on such  
13 misrepresentations and omissions.

14           3260. JLI knew that JUUL products were not safe or reasonable alternatives to  
15 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
16 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
17 products.

18           3261. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
19 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
20 and would not have purchased JUUL products or would have paid less for them. JLI's  
21 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
22 products they would not otherwise have purchased and enter into purchase contracts they would  
23 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
24 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
25 deem just or proper.

26                           **d. Breach of the Implied Warranty of Merchantability**

27           3262. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

28           3263. This claim is brought against JLI.



1           3264. JUUL has at all times been a merchant with respect to the products which were  
2 sold to Plaintiff and the class and was in the business of selling such products.

3           3265. Each JUUL product sold by JUUL comes with an implied warranty that it will  
4 merchantable and fit for the ordinary purpose for which it would be used. *See* Utah Code Ann.  
5 § 70A-2-314. JUUL has breached its implied warranty of merchantability because its products  
6 were not in merchantable condition when sold, were defective when sold, did not conform to the  
7 promises and affirmations of fact made on the products' containers or labels, and/or do not  
8 possess even the most basic degree of fitness for ordinary use.

9           3266. The ordinary intended purpose of JUUL's products—and the purpose for which  
10 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
11 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
12 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
13 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
14 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
15 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
16 recreation smoking devices.

17           3267. Plaintiffs and each member of the class have had sufficient direct dealings with  
18 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
19 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
20 each member of the class, on the other hand.

21           3268. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
22 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
23 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
24 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
25 the express purpose an intent of being sold to consumers.

26           3269. Plaintiffs and the members of the class were injured as a direct and proximate  
27 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
28 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability

1 because, had they been aware of the unmerchantable condition of JUUL products, they would  
2 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
3 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

4 3270. JUUL was provided notice of these issues by numerous complaints filed against  
5 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
6 individual letters and communications sent by consumers before or within a reasonable amount  
7 of time after they discovered or should have discovered that's JUUL product were defective and  
8 unmerchantable.

9 **e. Unjust Enrichment**

10 3271. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

11 3272. This claim is brought against JLI and the Management Defendants.

12 3273. Defendants created and implemented a scheme to create a market for e-cigarettes  
13 and substantially increase sales of JUUL products through a pervasive pattern of false and  
14 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
15 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
16 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
17 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
18 products.

19 3274. Defendants were unjustly enriched as a result of their wrongful conduct,  
20 including through the false and misleading advertisements and omissions regarding (i) whether  
21 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
22 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
23 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
24 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
25 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
26 enriched through their scheme of marketing their products to minors. Utah Code Annotated  
27 section 76-10-104 prohibits the marketing and sale of JUUL products to minors.

28 3275. Defendants requested and received a measurable benefit at the expense of

1 Plaintiffs and class members in the form of payment for JUUL products.

2 3276. Defendants appreciated, recognized, and chose to accept the monetary benefits  
3 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
4 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

5 3277. There is no justification for Defendants' enrichment. It would be inequitable,  
6 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
7 benefits were procured as a result of their wrongful conduct.

8 3278. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
9 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
10 with Defendant.

11 3279. Plaintiffs plead this claim separately as well as in the alternative to their other  
12 claims, as without such claims they would have no adequate legal remedy.

13 **45. Vermont**

14 3280. Plaintiffs bring each of the following claims on behalf of the Vermont Subclass  
15 under Vermont law.

16 **a. Violation of the Vermont Consumer Protection Act (Vt. Stat.**  
17 **Ann. tit. 9 §§ 2451, et seq.)**

18 3281. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

19 3282. This claim is brought against JLI and, for certain unfair and/or unconscionable  
20 conduct claims as noted below, all Defendants.

21 3283. Plaintiffs and class members purchased JUUL products not for resale in the  
22 ordinary course of their trade or business but for personal purposes.

23 3284. Defendants created and implemented a scheme to create a market for e-cigarettes  
24 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
25 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
26 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
27 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
28 addictiveness, and significant risks of substantial physical injury from using JUUL products.

1           3285. Advertisements and representations for JUUL products contained deceptive  
2 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
3 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
4 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
5 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
6 decades, JLI used third parties and word of mouth to spread false and misleading information  
7 about JUUL products.

8           3286. Advertisements and representations for JUUL products concealed and failed to  
9 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
10 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
11 addictive, posed significant risks of substantial physical injury resulting from the use of the  
12 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
13 consumed through a pack of combustible cigarettes.

14           3287. The labels on JUUL products failed to disclose that the products posed  
15 significant risks of substantial physical injury resulting from the use of the products. The labels  
16 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

17           3288. The omissions were misleading and deceptive standing alone and were  
18 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
19 cigarettes and other representations.

20           3289. JLI's conduct was unfair and unconscionable in that it included (i) the  
21 manufacture and sale of products with a heightened propensity to cause addiction and physical  
22 injuries and (ii) misrepresentations and omissions of material facts concerning the  
23 characteristics and safety of JUUL products that offended public policy; were immoral,  
24 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
25 substantial harm that greatly outweighs any possible utility from the conduct.

26           3290. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
27 omissions had the tendency or capacity to deceive, and in fact did, deceive reasonable  
28 consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have

1 found it material to their purchasing decisions that JUUL's products (i) were not smoking  
2 cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were  
3 extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
4 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)  
5 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
6 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
7 in Plaintiffs' and class members' decisions to purchase JUUL products.

8 3291. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
9 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
10 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
11 facts; because the facts would be material to reasonable consumers; because JLI actively  
12 concealed them; because JLI intended for consumers to rely on the omissions in question;  
13 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
14 made partial representations concerning the same subject matter as the omitted facts.

15 3292. JLI and the Management Defendants engaged in fraudulent and deceptive  
16 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
17 products were appropriate for minors, when in fact the products never should have been  
18 marketed to minors and are especially harmful to minors due to the potent and addictive  
19 nicotine doses, addictive qualities, and health risks.

20 3293. In addition, all Defendants engaged in unfair and unconscionable conduct  
21 because the targeting of minors offends public policy (in particular Vt. Stat. Ann. tit. 7  
22 §§ 1003(a) & 1007(a)); is immoral, unethical, oppressive, outrageous, unscrupulous, and  
23 substantially injurious; and has caused substantial harm that greatly outweighs any possible  
24 utility from the conduct.

25 3294. As alleged above, all Defendants participated and/or facilitated the marketing of  
26 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
27 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
28 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the

1 use of JUUL products by minors continues to rise.

2 3295. Defendants' conduct actually and proximately caused actual damages to  
3 Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and  
4 class members would have behaved differently and would not have purchased JUUL products  
5 or would have paid less for them. Defendants' misrepresentations and omissions induced  
6 Plaintiffs and class members to purchase JUUL products they would not otherwise have  
7 purchased and enter into purchase contracts they would not otherwise have entered into. In  
8 addition, class members who are minors are entitled to full repayment of the amounts they spent  
9 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
10 actual, treble, and punitive damages and restitution, as well as injunctive relief (except as to the  
11 Management Defendants), attorney's fees, and any other relief the Court may deem just or  
12 proper.

13 **b. Common Law Fraud**

14 3296. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

15 3297. This claim is brought against JLI.

16 3298. JUUL created and implemented a scheme to create a market for e-cigarettes and  
17 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
18 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
19 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
20 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
21 addictiveness, and significant risks of substantial physical injury from using JUUL products.

22 3299. Advertisements and representations for JUUL products contained deceptive  
23 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
24 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
25 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
26 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
27 decades, JLI used third parties and word of mouth to spread false and misleading information  
28 about JUUL products.

1           3300. Advertisements and representations for JUUL products concealed and failed to  
2 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
3 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
4 addictive, posed significant risks of substantial physical injury resulting from the use of the  
5 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
6 consumed through a pack of combustible cigarettes.

7           3301. The labels on JUUL products failed to disclose that the products posed  
8 significant risks of substantial physical injury resulting from the use of the products. The labels  
9 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

10          3302. The omissions were misleading and deceptive standing alone and were  
11 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
12 cigarettes and other representations.

13          3303. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
14 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
15 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
16 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
17 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
18 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
19 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
20 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
21 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
22 Plaintiffs' and class members' decisions to purchase JUUL products.

23          3304. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
24 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
25 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
26 facts; because the facts would be material to reasonable consumers; because JUUL products  
27 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
28 representations concerning the same subject matter as the omitted facts.



1 3305. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
2 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
3 and/or omissions. Reasonable consumers would have been expected to have relied on the  
4 misrepresentations and omissions.

5 3306. Defendants knew or should have known that their misrepresentations and/or  
6 omissions were false and misleading, and intended for consumers to rely on such  
7 misrepresentations and omissions.

8 3307. JLI knew that JUUL products were not safe or reasonable alternatives to  
9 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
10 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
11 products.

12 3308. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
13 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
14 and would not have purchased JUUL products or would have paid less for them. JLI's  
15 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
16 products they would not otherwise have purchased and enter into purchase contracts they would  
17 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
18 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
19 deem just or proper.

20 **c. Breach of the Implied Warranty of Merchantability**

21 3309. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

22 3310. This claim is brought against JLI.

23 3311. JUUL has at all times been a merchant with respect to the products which were  
24 sold to Plaintiff and the class and was in the business of selling such products.

25 3312. Each JUUL product sold by JUUL comes with an implied warranty that it will  
26 merchantable and fit for the ordinary purpose for which it would be used. *See* Vt. Stat. Ann. tit.  
27 9A § 2-314. JUUL has breached its implied warranty of merchantability because its products  
28 were not in merchantable condition when sold, were defective when sold, did not conform to the

promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

3313. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

3314. Plaintiffs and each member of the class have had sufficient direct dealings with either JUUL via its website or its agents (including distributors, dealers, and sellers authorized by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and each member of the class, on the other hand.

3315. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

3316. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the Vermont Direct Purchaser Subclass were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

3317. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous

individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

3318. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3319. This claim is brought against JLI and the Management Defendants.

3320. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3321. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Vermont Statutes Annotated title 7 §§ 1003(a) and 1007(a) prohibit the marketing and sale of JUUL products to minors.

3322. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

3323. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3324. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

3325. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

3326. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

**46. Virginia**

3327. Plaintiffs bring each of the following claims on behalf of the Virginia Subclass under Virginia law.

**a. Violation of the Virginia Consumer Protection Act (Va. Code Ann. § 59.1-196, *et seq.*)**

3328. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3329. This claim is brought against JLI.

3330. Plaintiffs, class members, and JUUL are persons under Virginia's Consumer Protection Act.

3331. Plaintiffs and class members purchased JUUL products in consumer transactions, *i.e.*, for personal purposes.

3332. JLI advertised, solicited, or engaged in consumer transactions to sell JUUL products, or is a manufacturer, distributor, or licensor that advertised, sold, or licensed JUUL products to be resold, leased, or sublicensed by other persons in consumer transactions.

3333. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

1           3334. Advertisements and representations for JUUL products contained deceptive  
2 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
3 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
4 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
5 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
6 decades, JLI used third parties and word of mouth to spread false and misleading information  
7 about JUUL products.

8           3335. Advertisements and representations for JUUL products concealed and failed to  
9 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
10 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
11 addictive, posed significant risks of substantial physical injury resulting from the use of the  
12 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
13 consumed through a pack of combustible cigarettes.

14           3336. The labels on JUUL products failed to disclose that the products posed  
15 significant risks of substantial physical injury resulting from the use of the products. The labels  
16 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

17           3337. The omissions were misleading and deceptive standing alone and were  
18 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
19 cigarettes and other representations.

20           3338. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
21 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
22 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
23 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
24 model, when they are not; and (c) advertising goods or services with intent not to sell them as  
25 advertised.

26           3339. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
27 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers,  
28 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it

1 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
2 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
3 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
4 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
5 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
6 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
7 Plaintiffs' and class members' decisions to purchase JUUL products.

8 3340. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
9 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
10 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
11 facts; because the facts would be material to reasonable consumers; because JLI actively  
12 concealed them; because JLI intended for consumers to rely on the omissions in question;  
13 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
14 made partial representations concerning the same subject matter as the omitted facts.

15 3341. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
16 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
17 Reasonable consumers would have been expected to have relied on the misrepresentations and  
18 omissions.

19 3342. JLI engaged in fraudulent and deceptive conduct by devising and executing a  
20 scheme to deceptively and misleadingly convey that JUUL products were appropriate for  
21 minors, when in fact the products never should have been marketed to minors and are especially  
22 harmful to minors due to the potent and addictive nicotine doses, addictive qualities, and health  
23 risks.

24 3343. JLI's conduct actually and proximately caused actual damages and loss to  
25 Plaintiffs and class members. Absent JLI's fraudulent conduct, Plaintiffs and class members  
26 would have behaved differently and would not have purchased JUUL products or would have  
27 paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members  
28 to purchase JUUL products they would not otherwise have purchased and enter into purchase

1 contracts they would not otherwise have entered into. In addition, class members who are  
2 minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs  
3 seek—on behalf of themselves and each member of the class—actual damages or \$500 per  
4 violation, whichever is greater, and statutory damages for each willful violation in the amount  
5 of treble damages or \$1,000, whichever is greater, as well as attorney’s fees and any other relief  
6 the Court may deem just or proper.

7 **b. Common Law Fraud**

8 3344. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

9 3345. This claim is brought against JLI.

10 3346. JUUL created and implemented a scheme to create a market for e-cigarettes and  
11 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
12 statements and omissions. JUUL’s plan was to portray JUUL products as cool and safe  
13 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
14 misrepresenting or omitting key facts concerning JUUL products’ nicotine content and doses,  
15 addictiveness, and significant risks of substantial physical injury from using JUUL products.

16 3347. Advertisements and representations for JUUL products contained deceptive  
17 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
18 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
19 cigarettes. The advertisements and JLI’s public statements portrayed JUUL products as safe or  
20 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
21 decades, JLI used third parties and word of mouth to spread false and misleading information  
22 about JUUL products.

23 3348. Advertisements and representations for JUUL products concealed and failed to  
24 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
25 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
26 addictive, posed significant risks of substantial physical injury resulting from the use of the  
27 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
28 consumed through a pack of combustible cigarettes.



1           3349. The labels on JUUL products failed to disclose that the products posed  
2 significant risks of substantial physical injury resulting from the use of the products. The labels  
3 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

4           3350. The omissions were misleading and deceptive standing alone and were  
5 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
6 cigarettes and other representations.

7           3351. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
8 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
9 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
10 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
11 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
12 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
13 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
14 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
15 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
16 Plaintiffs' and class members' decisions to purchase JUUL products.

17           3352. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
18 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
19 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
20 facts; because the facts would be material to reasonable consumers; because JUUL products  
21 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
22 representations concerning the same subject matter as the omitted facts.

23           3353. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
24 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
25 and/or omissions. Reasonable consumers would have been expected to have relied on the  
26 misrepresentations and omissions.

27           3354. Defendants knew or should have known that their misrepresentations and/or  
28 omissions were false and misleading, and intended for consumers to rely on such

misrepresentations and omissions.

3355. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

3356. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

3357. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3358. This claim is brought against JLI.

3359. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

3360. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. *See* Va. Code Ann. § 8.2-314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

3361. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely

1 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
2 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
3 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
4 recreation smoking devices.

5 3362. Plaintiffs and each member of the class have had sufficient direct dealings with  
6 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
7 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
8 each member of the class, on the other hand.

9 3363. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
10 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
11 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
12 intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with  
13 the express purpose an intent of being sold to consumers.

14 3364. Plaintiffs and the members of the class were injured as a direct and proximate  
15 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
16 the class were damaged as a result of JUUL's breach of its implied warranty of merchantability  
17 because, had they been aware of the unmerchantable condition of JUUL products, they would  
18 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
19 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

20 3365. JUUL was provided notice of these issues by numerous complaints filed against  
21 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
22 individual letters and communications sent by consumers before or within a reasonable amount  
23 of time after they discovered or should have discovered that's JUUL product were defective and  
24 unmerchantable.

25 **d. Unjust Enrichment**

26 3366. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

27 3367. This claim is brought against JLI and the Management Defendants.

28 3368. Defendants created and implemented a scheme to create a market for e-cigarettes

1 and substantially increase sales of JUUL products through a pervasive pattern of false and  
2 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
3 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
4 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and  
5 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
6 products.

7 3369. Defendants were unjustly enriched as a result of their wrongful conduct,  
8 including through the false and misleading advertisements and omissions regarding (i) whether  
9 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
10 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
11 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
12 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
13 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
14 enriched through their scheme of marketing their products to minors. Code of Virginia  
15 Annotated section 18.2-371.2 prohibits the marketing and sale of JUUL products to minors, or  
16 knowingly permitting the purchase of JUUL products by minors.

17 3370. Defendants requested and received a measurable benefit at the expense of  
18 Plaintiffs and class members in the form of payment for JUUL products.

19 3371. Defendants appreciated, recognized, and chose to accept the monetary benefits  
20 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
21 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

22 3372. There is no justification for Defendants' enrichment. It would be inequitable,  
23 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
24 benefits were procured as a result of their wrongful conduct.

25 3373. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
26 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
27 with Defendant.

28 3374. Plaintiffs plead this claim separately as well as in the alternative to their other

claims, as without such claims they would have no adequate legal remedy.

**47. Washington**

3375. Plaintiffs bring each of the following claims on behalf of the Washington Subclass under Washington law.

**a. Violation of the Washington Consumer Protection Act (Wash. Rev. Code §§ 19.86.010, *et seq.*)**

3376. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3377. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

3378. Plaintiffs, class members, and Defendants are each natural persons, corporations, trusts, unincorporated associations or partnerships, and are thus persons under Washington's Consumer Sales Practices Act.

3379. Plaintiffs and class members purchased JUUL products for personal purposes.

3380. Defendants engaged in trade or commerce directly or indirectly affecting the people of Washington by advertising, offering for sale, selling, or distributing JUUL products.

3381. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3382. Defendants' unlawful acts and practices occurred in connection with their sales of JUUL products, in commerce directly or indirectly affecting the people of the state of Washington.

3383. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or

1 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
2 decades, JLI used third parties and word of mouth to spread false and misleading information  
3 about JUUL products.

4 3384. Advertisements and representations for JUUL products concealed and failed to  
5 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
6 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
7 addictive, posed significant risks of substantial physical injury resulting from the use of the  
8 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
9 consumed through a pack of combustible cigarettes.

10 3385. The labels on JUUL products failed to disclose that the products posed  
11 significant risks of substantial physical injury resulting from the use of the products. The labels  
12 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

13 3386. The omissions were misleading and deceptive standing alone and were  
14 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
15 cigarettes and other representations.

16 3387. JLI's conduct was unfair and unconscionable in that it included (i) the  
17 manufacture and sale of products with a heightened propensity to cause addiction and physical  
18 injuries and (ii) misrepresentations and omissions of material facts concerning the  
19 characteristics and safety of JUUL products that offended public policy; were immoral,  
20 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
21 substantial harm that greatly outweighs any possible utility from the conduct.

22 3388. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
23 omissions had the capacity to deceive, and in fact did, deceive reasonable consumers including  
24 the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to  
25 their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii)  
26 were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-  
27 delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of  
28 substantial bodily injury resulting from the use of the products, and (vi) that the nicotine

1 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
2 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
3 Plaintiffs' and class members' decisions to purchase JUUL products. JLI's conduct thus had the  
4 capacity to injure not just Plaintiffs but also other members of the public.

5 3389. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
6 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
7 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
8 facts; because the facts would be material to reasonable consumers; because JLI actively  
9 concealed them; because JLI intended for consumers to rely on the omissions in question;  
10 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
11 made partial representations concerning the same subject matter as the omitted facts.

12 3390. JLI and the Management Defendants engaged in fraudulent and deceptive  
13 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
14 products were appropriate for minors, when in fact the products never should have been  
15 marketed to minors and are especially harmful to minors due to the potent and addictive  
16 nicotine doses, addictive qualities, and health risks.

17 3391. In addition, all Defendants engaged in unfair and unconscionable conduct that  
18 affects the public interest because the targeting of minors offends public policy (in particular  
19 Wash. Rev. Code Ann. §§ 70.155.005, *et seq.*, § 26.28.080 and § 70.345.090.); is immoral,  
20 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and has caused  
21 substantial harm that greatly outweighs any possible utility from the conduct.

22 3392. As alleged above, all Defendants participated and/or facilitated the marketing of  
23 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
24 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
25 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
26 use of JUUL products by minors continues to rise.

27 3393. Defendants' conduct actually and proximately caused actual damages and loss of  
28 money or property to Plaintiffs and class members. Absent Defendants' unfair and fraudulent



1 conduct, Plaintiffs and class members would have behaved differently and would not have  
2 purchased JUUL products or would have paid less for them. Defendants' misrepresentations and  
3 omissions induced Plaintiffs and class members to purchase JUUL products they would not  
4 otherwise have purchased and enter into purchase contracts they would not otherwise have  
5 entered into. In addition, class members who are minors are entitled to full repayment of the  
6 amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each  
7 member of the class—actual damages and statutory treble damages up to \$25,000 for each  
8 violation, as well as injunctive relief (except as to the Management Defendants), attorney's fees,  
9 and any other relief the Court may deem just or proper.

10 **b. Common Law Fraud**

11 3394. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

12 3395. This claim is brought against JLI.

13 3396. JUUL created and implemented a scheme to create a market for e-cigarettes and  
14 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
15 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
16 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
17 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
18 addictiveness, and significant risks of substantial physical injury from using JUUL products.

19 3397. Advertisements and representations for JUUL products contained deceptive  
20 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
21 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
22 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
23 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
24 decades, JLI used third parties and word of mouth to spread false and misleading information  
25 about JUUL products.

26 3398. Advertisements and representations for JUUL products concealed and failed to  
27 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
28 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully

1 addictive, posed significant risks of substantial physical injury resulting from the use of the  
2 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
3 consumed through a pack of combustible cigarettes.

4 3399. The labels on JUUL products failed to disclose that the products posed  
5 significant risks of substantial physical injury resulting from the use of the products. The labels  
6 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

7 3400. The omissions were misleading and deceptive standing alone and were  
8 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
9 cigarettes and other representations.

10 3401. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
11 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
12 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
13 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
14 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
15 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
16 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
17 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
18 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
19 Plaintiffs' and class members' decisions to purchase JUUL products.

20 3402. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
21 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
22 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
23 facts; because the facts would be material to reasonable consumers; because JUUL products  
24 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
25 representations concerning the same subject matter as the omitted facts.

26 3403. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
27 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
28 and/or omissions. Reasonable consumers would have been expected to have relied on the

misrepresentations and omissions.

3404. Defendants knew or should have known that their misrepresentations and/or omissions were false and misleading, and intended for consumers to rely on such misrepresentations and omissions.

3405. JLI knew that JUUL products were not safe or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the products.

3406. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper.

**c. Breach of the Implied Warranty of Merchantability**

3407. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3408. This claim is brought against JLI.

3409. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

3410. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. *See* Wash. Rev. Code § 62A-2.314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

3411. The ordinary intended purpose of JUUL's products—and the purpose for which

1 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
2 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
5 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
6 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
7 recreation smoking devices.

8 3412. Plaintiffs and each member of the class have had sufficient direct dealings with  
9 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
10 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
11 each member of the class, on the other hand.

12 3413. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
13 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
14 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the  
15 intended beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with  
16 the express purpose an intent of being sold to consumers.

17 3414. Plaintiffs and the members of the class were injured as a direct and proximate  
18 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
19 the Washington Direct Purchaser Subclass were damaged as a result of JUUL’s breach of its  
20 implied warranty of merchantability because, had they been aware of the unmerchantable  
21 condition of JUUL products, they would not have purchased JUUL products, or would have  
22 paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any  
23 other relief the Court may deem just or proper.

24 3415. JUUL was provided notice of these issues by numerous complaints filed against  
25 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
26 individual letters and communications sent by consumers before or within a reasonable amount  
27 of time after they discovered or should have discovered that’s JUUL product were defective and  
28 unmerchantable.

**d. Unjust Enrichment**

3416. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3417. This claim is brought against JLI and the Management Defendants.

3418. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3419. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Revised Code of Washington § 26.28.080, § 70.345.090 and §§ 70.155.005, *et seq.*, prohibit the marketing and sale of JUUL products to minors.

3420. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

3421. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3422. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

1 3423. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
2 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
3 with Defendant.

4 3424. Plaintiffs plead this claim separately as well as in the alternative to their other  
5 claims, as without such claims they would have no adequate legal remedy.

6 **48. West Virginia**

7 3425. Plaintiffs bring each of the following claims on behalf of the West Virginia  
8 Subclass under West Virginia law.

9 **a. Violation of the West Virginia Consumer Credit and**  
10 **Protection Act (W. Va. Code §§ 46A-6-101, et seq.)**

11 3426. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

12 3427. This claim is brought against JLI and, for certain claims, the Management  
13 Defendants.

14 3428. JUUL engaged in trade or commerce directly or indirectly affecting the people  
15 of West Virginia by advertising, offering for sale, selling, or distributing JUUL products.

16 3429. Plaintiffs and class members are natural persons who purchased JUUL products  
17 for personal purposes.

18 3430. [Intentionally Omitted]

19 3431. Defendants created and implemented a scheme to create a market for e-cigarettes  
20 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
21 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
22 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
23 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
24 addictiveness, and significant risks of substantial physical injury from using JUUL products.

25 3432. Advertisements and representations for JUUL products contained deceptive  
26 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
27 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
28 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or

1 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
2 decades, JLI used third parties and word of mouth to spread false and misleading information  
3 about JUUL products.

4 3433. Advertisements and representations for JUUL products concealed and failed to  
5 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
6 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
7 addictive, posed significant risks of substantial physical injury resulting from the use of the  
8 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
9 consumed through a pack of combustible cigarettes.

10 3434. The labels on JUUL products failed to disclose that the products posed  
11 significant risks of substantial physical injury resulting from the use of the products. The labels  
12 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

13 3435. The omissions were misleading and deceptive standing alone and were  
14 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
15 cigarettes and other representations.

16 3436. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
17 unfair business practices: (a) misrepresenting that JUUL products have characteristics,  
18 ingredients, uses, benefits, or quantities, which they do not have; (b) misrepresenting that JUUL  
19 products are of a particular standard, quality, or grade, or that goods are of a particular style or  
20 model, when they are not; and (c) advertising goods or services with intent not to sell them as  
21 advertised.

22 3437. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
23 omissions caused a likelihood of confusion or misunderstanding, and in fact did, deceive  
24 reasonable consumers including the Plaintiffs. Reasonable consumers, including the Plaintiffs,  
25 would have found it material to their purchasing decisions that JUUL's products (i) were not  
26 smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii)  
27 were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed  
28 unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi)



1 that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a  
2 pack of combustible cigarettes. Knowledge of these facts would have been a substantial factor  
3 in Plaintiffs' and class members' decisions to purchase JUUL products.

4 3438. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
5 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
6 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
7 facts; because the facts would be material to reasonable consumers; because JLI actively  
8 concealed them; because JLI intended for consumers to rely on the omissions in question;  
9 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
10 made partial representations concerning the same subject matter as the omitted facts.

11 3439. JLI and the Management Defendants engaged in fraudulent and deceptive  
12 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
13 products were appropriate for minors, when in fact the products never should have been  
14 marketed to minors and are especially harmful to minors due to the potent and addictive  
15 nicotine doses, addictive qualities, and health risks.

16 3440. JLI's conduct actually and proximately caused ascertainable loss of money or  
17 property to Plaintiffs and class members. Absent JUUL's unfair and fraudulent conduct,  
18 Plaintiffs and class members would have behaved differently and would not have purchased  
19 JUUL products or would have paid less for them. JLI's misrepresentations and omissions  
20 induced Plaintiffs and class members to purchase JUUL products they would not otherwise have  
21 purchased and enter into purchase contracts they would not otherwise have entered into. In  
22 addition, class members who are minors are entitled to full repayment of the amounts they spent  
23 on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—  
24 actual damages or \$200, whichever is greater, as well as restitution, injunctive relief (except as  
25 to the Management Defendants), attorney's fees, and any other relief the Court may deem just  
26 or proper.

27 **b. Common Law Fraud**

28 3441. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

1           3442. This claim is brought against JLI.

2           3443. JUUL created and implemented a scheme to create a market for e-cigarettes and  
3 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8           3444. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15           3445. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21           3446. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24           3447. The omissions were misleading and deceptive standing alone and were  
25 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
26 cigarettes and other representations.

27           3448. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
28 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers

1 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
2 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
3 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
4 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
5 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
6 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
7 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
8 Plaintiffs' and class members' decisions to purchase JUUL products.

9 3449. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
10 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
11 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
12 facts; because the facts would be material to reasonable consumers; because JUUL products  
13 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
14 representations concerning the same subject matter as the omitted facts.

15 3450. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
16 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
17 and/or omissions. Reasonable consumers would have been expected to have relied on the  
18 misrepresentations and omissions.

19 3451. Defendants knew or should have known that their misrepresentations and/or  
20 omissions were false and misleading, and intended for consumers to rely on such  
21 misrepresentations and omissions.

22 3452. JLI knew that JUUL products were not safe or reasonable alternatives to  
23 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
24 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
25 products.

26 3453. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
27 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
28 and would not have purchased JUUL products or would have paid less for them. JLI's

1 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
2 products they would not otherwise have purchased and enter into purchase contracts they would  
3 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
4 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
5 deem just or proper

6 **c. Breach of the Implied Warranty of Merchantability**

7 3454. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

8 3455. This claim is brought against JLI.

9 3456. JUUL has at all times been a merchant with respect to the products which were  
10 sold to Plaintiff and the class and was in the business of selling such products.

11 3457. Each JUUL product sold by JUUL comes with an implied warranty that it will  
12 merchantable and fit for the ordinary purpose for which it would be used. *See* W. Va. Code  
13 § 46-2-314. JUUL has breached its implied warranty of merchantability because its products  
14 were not in merchantable condition when sold, were defective when sold, did not conform to the  
15 promises and affirmations of fact made on the products' containers or labels, and/or do not  
16 possess even the most basic degree of fitness for ordinary use.

17 3458. The ordinary intended purpose of JUUL's products—and the purpose for which  
18 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's  
19 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
20 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
21 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
22 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's  
23 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
24 recreation smoking devices.

25 3459. Plaintiffs and each member of the class have had sufficient direct dealings with  
26 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
27 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
28 each member of the class, on the other hand.

3460. Further, Plaintiffs and each member of the class were third-party beneficiaries of JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the express purpose an intent of being sold to consumers.

3461. Plaintiffs and the members of the class were injured as a direct and proximate result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of the class were damaged as a result of JUUL's breach of its implied warranty of merchantability because, had they been aware of the unmerchantable condition of JUUL products, they would not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper

3462. JUUL was provided notice of these issues by numerous complaints filed against it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous individual letters and communications sent by consumers before or within a reasonable amount of time after they discovered or should have discovered that's JUUL product were defective and unmerchantable.

**d. Unjust Enrichment**

3463. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3464. This claim is brought against JLI and the Management Defendants.

3465. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3466. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether

JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. West Virginia Code section 16-9A-2 prohibits the marketing and sale of JUUL products to minors.

3467. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

3468. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3469. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

3470. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing with Defendant.

3471. Plaintiffs plead this claim separately as well as in the alternative to their other claims, as without such claims they would have no adequate legal remedy.

#### **49. Wisconsin**

3472. Plaintiffs bring each of the following claims on behalf of the Wisconsin Subclass under Wisconsin law.

##### **a. Violation of the Wisconsin Deceptive Trade Practices Act (Wis. Stat. § 100.18)**

3473. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3474. This claim is brought against JLI and, for certain claims below, the Management Defendants.

1 3475. Plaintiffs and class members purchased JUUL products for personal purposes.

2 3476. Defendants created and implemented a scheme to create a market for e-cigarettes  
3 and substantially increase sales of JUUL through a pervasive pattern of false and misleading  
4 statements and omissions. Defendants aimed to portray JUUL products as cool and safe  
5 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
6 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
7 addictiveness, and significant risks of substantial physical injury from using JUUL products.

8 3477. Advertisements and representations for JUUL products contained deceptive  
9 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
10 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
11 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
12 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
13 decades, JLI used third parties and word of mouth to spread false and misleading information  
14 about JUUL products.

15 3478. Advertisements and representations for JUUL products concealed and failed to  
16 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
17 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
18 addictive, posed significant risks of substantial physical injury resulting from the use of the  
19 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
20 consumed through a pack of combustible cigarettes.

21 3479. The labels on JUUL products failed to disclose that the products posed  
22 significant risks of substantial physical injury resulting from the use of the products. The labels  
23 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

24 3480. The omissions were misleading and deceptive standing in light of JLI's  
25 advertising of its products as reasonable alternatives to cigarettes and other representations.

26 3481. JLI's conduct was misleading and deceptive because the misrepresentations and  
27 omissions had the capacity to deceive, and in fact did, deceive reasonable consumers including  
28 the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to



1 their purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii)  
2 were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-  
3 delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of  
4 substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
5 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
6 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
7 Plaintiffs' and class members' decisions to purchase JUUL products.

8 3482. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
9 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
10 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
11 facts; because the facts would be material to reasonable consumers; because JLI actively  
12 concealed them; because JLI intended for consumers to rely on the omissions in question;  
13 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
14 made partial representations concerning the same subject matter as the omitted facts.

15 3483. JLI and the Management Defendants engaged in fraudulent and deceptive  
16 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
17 products were appropriate for minors, when in fact the products never should have been  
18 marketed to minors and are especially harmful to minors due to the potent and addictive  
19 nicotine doses, addictive qualities, and health risks.

20 3484. JLI's conduct actually and proximately caused pecuniary loss to Plaintiffs and  
21 class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members  
22 would have behaved differently and would not have purchased JUUL products or would have  
23 paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class  
24 members to purchase JUUL products they would not otherwise have purchased and enter into  
25 purchase contracts they would not otherwise have entered into. In addition, class members who  
26 are minors are entitled to full repayment of the amounts they spent on JUUL products.  
27 Plaintiffs seek—on behalf of themselves and each member of the class—actual damages for  
28 pecuniary loss as well as restitution, attorney's fees, and any other relief the Court may deem

1 just or proper.

2 **b. Common Law Fraud**

3 3485. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

4 3486. This claim is brought against JLI.

5 3487. JUUL created and implemented a scheme to create a market for e-cigarettes and  
6 substantially increase sales of JUUL through a pervasive pattern of false and misleading  
7 statements and omissions. JUUL's plan was to portray JUUL products as cool and safe  
8 alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while  
9 misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses,  
10 addictiveness, and significant risks of substantial physical injury from using JUUL products.

11 3488. Advertisements and representations for JUUL products contained deceptive  
12 statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives  
13 to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible  
14 cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or  
15 not harmful. Like the tobacco companies that marketed combustible cigarettes in previous  
16 decades, JLI used third parties and word of mouth to spread false and misleading information  
17 about JUUL products.

18 3489. Advertisements and representations for JUUL products concealed and failed to  
19 disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to  
20 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
21 addictive, posed significant risks of substantial physical injury resulting from the use of the  
22 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
23 consumed through a pack of combustible cigarettes.

24 3490. The labels on JUUL products failed to disclose that the products posed  
25 significant risks of substantial physical injury resulting from the use of the products. The labels  
26 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

27 3491. The omissions were misleading and deceptive standing alone and were  
28 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to

1 cigarettes and other representations.

2 3492. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
3 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
4 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
5 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
6 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
7 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
8 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
9 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
10 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
11 Plaintiffs' and class members' decisions to purchase JUUL products.

12 3493. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
13 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
14 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
15 facts; because the facts would be material to reasonable consumers; because JUUL products  
16 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
17 representations concerning the same subject matter as the omitted facts.

18 3494. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
19 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations  
20 and/or omissions. Reasonable consumers would have been expected to have relied on the  
21 misrepresentations and omissions.

22 3495. Defendants knew or should have known that their misrepresentations and/or  
23 omissions were false and misleading, and intended for consumers to rely on such  
24 misrepresentations and omissions.

25 3496. JLI knew that JUUL products were not safe or reasonable alternatives to  
26 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
27 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
28 products.

3497. JLI's conduct actually and proximately caused damages to Plaintiffs and class members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. JLI's misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of the class damages in an amount to be proven at trial, as well as any other relief the Court may deem just or proper

**c. Breach of the Implied Warranty of Merchantability**

3498. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3499. This claim is brought against JLI.

3500. JUUL has at all times been a merchant with respect to the products which were sold to Plaintiff and the class and was in the business of selling such products.

3501. Each JUUL product sold by JUUL comes with an implied warranty that it will be merchantable and fit for the ordinary purpose for which it would be used. *See* Wisc. Stat. § 402.314. JUUL has breached its implied warranty of merchantability because its products were not in merchantable condition when sold, were defective when sold, did not conform to the promises and affirmations of fact made on the products' containers or labels, and/or do not possess even the most basic degree of fitness for ordinary use.

3502. The ordinary intended purpose of JUUL's products—and the purpose for which they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL's products are not fit for that use—or any other use—because they (i) were not smoking cessation devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed unreasonable risks of substantial bodily injury. Due to these and other features, JUUL's products are not fit for their ordinary, intended use as either cigarette replacement devices or recreation smoking devices.

3503. Plaintiffs and each member of the class have had sufficient direct dealings with

1 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
2 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
3 each member of the class, on the other hand.

4 3504. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
5 JUUL's agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
6 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended  
7 beneficiaries of JUUL's implied warranties. JUUL's products are manufactured with the  
8 express purpose an intent of being sold to consumers.

9 3505. Plaintiffs and the members of the class were injured as a direct and proximate  
10 result of JUUL's breach of its implied warranties of merchantability. Plaintiffs and members of  
11 the Wisconsin Direct Purchaser Subclass were damaged as a result of JUUL's breach of its  
12 implied warranty of merchantability because, had they been aware of the unmerchantable  
13 condition of JUUL products, they would not have purchased JUUL products, or would have  
14 paid less for them. Plaintiffs seek damages in an amount to be proven at trial, as well as any  
15 other relief the Court may deem just or proper.

16 3506. JUUL was provided notice of these issues by numerous complaints filed against  
17 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
18 individual letters and communications sent by consumers before or within a reasonable amount  
19 of time after they discovered or should have discovered that's JUUL product were defective and  
20 unmerchantable.

21 **d. Unjust Enrichment**

22 3507. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

23 3508. This claim is brought against JLI and the Management Defendants.

24 3509. Defendants created and implemented a scheme to create a market for e-cigarettes  
25 and substantially increase sales of JUUL products through a pervasive pattern of false and  
26 misleading statements and omissions. Defendants aimed to portray JUUL products as cool and  
27 safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors,  
28 while misrepresenting or omitting key facts concerning JUUL products' nicotine content and

1 doses, addictiveness, and significant risks of substantial physical injury from using JUUL  
2 products.

3 3510. Defendants were unjustly enriched as a result of their wrongful conduct,  
4 including through the false and misleading advertisements and omissions regarding (i) whether  
5 JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable  
6 alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were  
7 powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from  
8 the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the  
9 nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly  
10 enriched through their scheme of marketing their products to minors. Wisconsin Statutes section  
11 134.66 prohibits the marketing and sale of JUUL products to minors.

12 3511. Defendants requested and received a measurable benefit at the expense of  
13 Plaintiffs and class members in the form of payment for JUUL products.

14 3512. Defendants appreciated, recognized, and chose to accept the monetary benefits  
15 Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the  
16 expected result of Defendant acting in its pecuniary interest at the expense of its customers.

17 3513. There is no justification for Defendants' enrichment. It would be inequitable,  
18 unconscionable, and unjust for Defendants to be permitted to retain these benefits because the  
19 benefits were procured as a result of their wrongful conduct.

20 3514. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained  
21 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
22 with Defendant.

23 3515. Plaintiffs plead this claim separately as well as in the alternative to their other  
24 claims, as without such claims they would have no adequate legal remedy.

25 **50. Wyoming**

26 3516. Plaintiffs bring each of the following claims on behalf of the Wyoming Subclass  
27 under Wyoming law.  
28

**a. Violation of the Wyoming Consumer Protection Act (Wyo. Stat. Ann. §§ 40-12-101, *et seq.*)**

3517. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3518. This claim is brought against JLI and, for certain unfair and/or unconscionable conduct claims as noted below, all Defendants.

3519. Plaintiffs, class members, and Defendants are each natural persons, corporations, trusts, partnerships, incorporated or unincorporated associations, or other legal entities and are thus persons under Wyoming's Consumer Protection Act.

3520. Plaintiffs and class members purchased JUUL products for personal purposes.

3521. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3522. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

3523. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully addictive, posed significant risks of substantial physical injury resulting from the use of the products, and that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.



1           3524. The labels on JUUL products failed to disclose that the products posed  
2 significant risks of substantial physical injury resulting from the use of the products. The labels  
3 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

4           3525. The omissions were misleading and deceptive standing alone and were  
5 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
6 cigarettes and other representations.

7           3526. JLI's conduct was unfair and unconscionable in that it included (i) the  
8 manufacture and sale of products with a heightened propensity to cause addiction and physical  
9 injuries and (ii) misrepresentations and omissions of material facts concerning the  
10 characteristics and safety of JUUL products that offended public policy; were immoral,  
11 unethical, oppressive, outrageous, unscrupulous, and substantially injurious; and caused  
12 substantial harm that greatly outweighs any possible utility from the conduct.

13           3527. JLI's conduct constituted the following prohibited fraudulent, deceptive, and  
14 unfair business practices: (a) misrepresenting that JUUL products have uses which they do not  
15 have; (b) misrepresenting that JUUL products are of a particular standard or grade, or that goods  
16 are of a particular style or model, when they are not; (c) advertising goods or services with  
17 intent not to sell them as advertised; and (d) misrepresenting that the subject of a transaction has  
18 been supplied in accordance with a previous representation when it has not.

19           3528. JLI's conduct was fraudulent and deceptive because the misrepresentations and  
20 omissions at issue were likely to, and in fact did, deceive reasonable consumers including the  
21 Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it material to their  
22 purchasing decisions that JUUL's products (i) were not smoking cessation devices, (ii) were not  
23 reasonable alternatives to combustible cigarettes, (iii) were extremely potent nicotine-delivery  
24 mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily  
25 injury resulting from the use of the products, and (vi) that the nicotine consumed through one  
26 JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes.  
27 Knowledge of these facts would have been a substantial factor in Plaintiffs' and class members'  
28 decisions to purchase JUUL products.

1           3529. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
2 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
3 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
4 facts; because the facts would be material to reasonable consumers; because JLI actively  
5 concealed them; because JLI intended for consumers to rely on the omissions in question;  
6 because JUUL products pose an unreasonable risk of substantial bodily injury; and because JLI  
7 made partial representations concerning the same subject matter as the omitted facts.

8           3530. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
9 purchasing JUUL products, the Plaintiffs relied on the misrepresentations and/or omissions.  
10 Reasonable consumers would have been expected to have relied on the misrepresentations and  
11 omissions.

12           3531. Defendants knew or should have known that their misrepresentations and/or  
13 omissions were false and misleading, and intended for consumers to rely on such  
14 misrepresentations and omissions.

15           3532. JLI and the Management Defendants engaged in fraudulent and deceptive  
16 conduct by devising and executing a scheme to deceptively and misleadingly convey that JUUL  
17 products were appropriate for minors, when in fact the products never should have been  
18 marketed to minors and are especially harmful to minors due to the potent and addictive  
19 nicotine doses, addictive qualities, and health risks.

20           3533. In addition, all Defendants engaged in unfair and unconscionable conduct  
21 because the targeting of minors offends public policy (in particular Wyo. Stat. Ann. § 14-3-  
22 302); is immoral, unethical, oppressive, outrageous, unscrupulous, and substantially injurious;  
23 and has caused substantial harm that greatly outweighs any possible utility from the conduct.

24           3534. As alleged above, all Defendants participated and/or facilitated the marketing of  
25 JUUL products to minors and took no action to curb the use of JUUL products by minors. JLI  
26 and others have continued the deceptive, misleading, unfair, and unconscionable practices that  
27 Defendants implemented, facilitated, and/or did not take adequate steps to end. As a result, the  
28 use of JUUL products by minors continues to rise.

3535. Defendants' conduct actually and proximately caused actual damages to Plaintiffs and class members. Absent Defendants' unfair and fraudulent conduct, Plaintiffs and class members would have behaved differently and would not have purchased JUUL products or would have paid less for them. Defendants' misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL products they would not otherwise have purchased and enter into purchase contracts they would not otherwise have entered into. In addition, class members who are minors are entitled to full repayment of the amounts they spent on JUUL products. Plaintiffs seek—on behalf of themselves and each member of the class—actual damages as well as restitution, attorney's fees, and any other relief the Court may deem just or proper.

**b. Common Law Fraud**

3536. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3537. This claim is brought against JLI.

3538. JUUL created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL through a pervasive pattern of false and misleading statements and omissions. JUUL's plan was to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3539. Advertisements and representations for JUUL products contained deceptive statements that JUUL e-cigarettes were smoking cessation devices and reasonable alternatives to combustible cigarettes, and that a pod of JUUL was equivalent to one pack of combustible cigarettes. The advertisements and JLI's public statements portrayed JUUL products as safe or not harmful. Like the tobacco companies that marketed combustible cigarettes in previous decades, JLI used third parties and word of mouth to spread false and misleading information about JUUL products.

3540. Advertisements and representations for JUUL products concealed and failed to disclose that JUUL e-cigarettes were not smoking cessation devices or reasonable alternatives to

1 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
2 addictive, posed significant risks of substantial physical injury resulting from the use of the  
3 products, and that the nicotine consumed through one JUUL pod exceeded the nicotine  
4 consumed through a pack of combustible cigarettes.

5 3541. The labels on JUUL products failed to disclose that the products posed  
6 significant risks of substantial physical injury resulting from the use of the products. The labels  
7 also falsely stated that JUUL products were reasonable alternatives to combustible cigarettes.

8 3542. The omissions were misleading and deceptive standing alone and were  
9 particularly deceptive in light of JLI's advertising of its products as reasonable alternatives to  
10 cigarettes and other representations.

11 3543. JLI's conduct was fraudulent and deceptive because its misrepresentations and  
12 omissions had the capacity to, were likely to, and in fact did, deceive reasonable consumers  
13 including the Plaintiffs. Reasonable consumers, including the Plaintiffs, would have found it  
14 material to their purchasing decisions that JUUL's products (i) were not smoking cessation  
15 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
16 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable  
17 risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine  
18 consumed through one JUUL pod exceeded the nicotine consumed through a pack of  
19 combustible cigarettes. Knowledge of these facts would have been a substantial factor in  
20 Plaintiffs' and class members' decisions to purchase JUUL products.

21 3544. JLI owed Plaintiffs and class members a duty to disclose these facts because they  
22 were known and/or accessible exclusively to Defendants (and potentially other unnamed parties  
23 other than Plaintiffs and class members), who had exclusive and superior knowledge of the  
24 facts; because the facts would be material to reasonable consumers; because JUUL products  
25 pose an unreasonable risk of substantial bodily injury; and because JLI made partial  
26 representations concerning the same subject matter as the omitted facts.

27 3545. As set forth in the allegations concerning each Plaintiff in Appendix A, in  
28 purchasing JUUL products, Plaintiffs reasonably and justifiably relied on the misrepresentations

1 and/or omissions. Reasonable consumers would have been expected to have relied on the  
2 misrepresentations and omissions.

3 3546. Defendants knew or should have known that their misrepresentations and/or  
4 omissions were false and misleading, and intended for consumers to rely on such  
5 misrepresentations and omissions.

6 3547. JLI knew that JUUL products were not safe or reasonable alternatives to  
7 combustible cigarettes, were extremely potent nicotine-delivery mechanisms, were powerfully  
8 addictive, posed unreasonable risks of substantial bodily injury resulting from the use of the  
9 products.

10 3548. JLI's conduct actually and proximately caused damages to Plaintiffs and class  
11 members. Absent JLI's conduct, Plaintiffs and class members would have behaved differently  
12 and would not have purchased JUUL products or would have paid less for them. JLI's  
13 misrepresentations and omissions induced Plaintiffs and class members to purchase JUUL  
14 products they would not otherwise have purchased and enter into purchase contracts they would  
15 not otherwise have entered into. Plaintiffs seek—on behalf of themselves and each member of  
16 the class damages in an amount to be proven at trial, as well as any other relief the Court may  
17 deem just or proper.

18 **c. Breach of the Implied Warranty of Merchantability**

19 3549. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

20 3550. This claim is brought against JLI.

21 3551. JUUL has at all times been a merchant with respect to the products which were  
22 sold to Plaintiff and the class and was in the business of selling such products.

23 3552. Each JUUL product sold by JUUL comes with an implied warranty that it will  
24 merchantable and fit for the ordinary purpose for which it would be used. *See* Wyo. Stat. Ann.  
25 § 34.1-2-314. JUUL has breached its implied warranty of merchantability because its products  
26 were not in merchantable condition when sold, were defective when sold, did not conform to the  
27 promises and affirmations of fact made on the products' containers or labels, and/or do not  
28 possess even the most basic degree of fitness for ordinary use.

1           3553. The ordinary intended purpose of JUUL’s products—and the purpose for which  
2 they are marketed, promoted, and sold—is to serve as a safe alternative to cigarettes. JUUL’s  
3 products are not fit for that use—or any other use—because they (i) were not smoking cessation  
4 devices, (ii) were not reasonable alternatives to combustible cigarettes, (iii) were extremely  
5 potent nicotine-delivery mechanisms, (iv) were powerfully addictive, and (v) posed  
6 unreasonable risks of substantial bodily injury. Due to these and other features, JUUL’s  
7 products are not fit for their ordinary, intended use as either cigarette replacement devices or  
8 recreation smoking devices.

9           3554. Plaintiffs and each member of the class have had sufficient direct dealings with  
10 either JUUL via its website or its agents (including distributors, dealers, and sellers authorized  
11 by JUUL) to establish privity of contract between JUUL, on the one hand, and Plaintiffs and  
12 each member of the class, on the other hand.

13           3555. Further, Plaintiffs and each member of the class were third-party beneficiaries of  
14 JUUL’s agreements with its distributors, dealers, and sellers for the distribution, dealing, and  
15 sale of JUUL products to consumers. Specifically, Plaintiffs and class members are the intended  
16 beneficiaries of JUUL’s implied warranties. JUUL’s products are manufactured with the  
17 express purpose an intent of being sold to consumers.

18           3556. Plaintiffs and the members of the class were injured as a direct and proximate  
19 result of JUUL’s breach of its implied warranties of merchantability. Plaintiffs and members of  
20 the class were damaged as a result of JUUL’s breach of its implied warranty of merchantability  
21 because, had they been aware of the unmerchantable condition of JUUL products, they would  
22 not have purchased JUUL products, or would have paid less for them. Plaintiffs seek damages  
23 in an amount to be proven at trial, as well as any other relief the Court may deem just or proper

24           3557. JUUL was provided notice of these issues by numerous complaints filed against  
25 it, including the complaints in *In re: JUUL Labs, Inc. Product Litigation*, and by numerous  
26 individual letters and communications sent by consumers before or within a reasonable amount  
27 of time after they discovered or should have discovered that’s JUUL product were defective and  
28 unmerchantable.

**d. Unjust Enrichment**

3558. Plaintiffs incorporate the allegations set forth above as if fully set forth herein.

3559. This claim is brought against JLI and the Management Defendants.

3560. Defendants created and implemented a scheme to create a market for e-cigarettes and substantially increase sales of JUUL products through a pervasive pattern of false and misleading statements and omissions. Defendants aimed to portray JUUL products as cool and safe alternatives to combustible cigarettes, with a particular emphasis on appealing to minors, while misrepresenting or omitting key facts concerning JUUL products' nicotine content and doses, addictiveness, and significant risks of substantial physical injury from using JUUL products.

3561. Defendants were unjustly enriched as a result of their wrongful conduct, including through the false and misleading advertisements and omissions regarding (i) whether JUUL products were smoking cessation devices, (ii) whether JUUL products are reasonable alternatives to cigarettes, (iii) were extremely potent nicotine-delivery mechanisms, (iv) were powerfully addictive, (v) posed unreasonable risks of substantial bodily injury resulting from the use of the products, and (vi) that the nicotine consumed through one JUUL pod exceeded the nicotine consumed through a pack of combustible cigarettes. Defendants were also unjustly enriched through their scheme of marketing their products to minors. Wyoming Statutes Annotated section 14-3-302 prohibits the marketing and sale of JUUL products to minors.

3562. Defendants requested and received a measurable benefit at the expense of Plaintiffs and class members in the form of payment for JUUL products.

3563. Defendants appreciated, recognized, and chose to accept the monetary benefits Plaintiffs conferred onto Defendants at the Plaintiffs' detriment. These benefits were the expected result of Defendant acting in its pecuniary interest at the expense of its customers.

3564. There is no justification for Defendants' enrichment. It would be inequitable, unconscionable, and unjust for Defendants to be permitted to retain these benefits because the benefits were procured as a result of their wrongful conduct.

3565. Plaintiffs are entitled to restitution of the benefits Defendant unjustly retained



1 and/or any amounts necessary to return Plaintiffs to the position they occupied prior to dealing  
2 with Defendant. Due to the sprawling, decades-long tobacco litigations and other notice they  
3 have received as a result of lawsuits filed against them, Defendants are reasonably notified that  
4 Plaintiffs and class members would expect compensation from Defendants' unjust enrichment  
5 stemming from their wrongful actions.

6 3566. Plaintiffs plead this claim separately as well as in the alternative to their other  
7 claims, as without such claims they would have no adequate legal remedy.

#### 8 **VIII. PRAYER FOR RELIEF**

9 Plaintiff, on behalf of themselves and the proposed classes, respectfully demand that the  
10 Court:

11 A. Determine that this action may be maintained as a class action pursuant to Fed.  
12 R. Civ. P. Rule 23(a) and (b)(3), direct that reasonable notice of this action be given to the  
13 classes, declare Plaintiffs as a named representatives of the classes, and declare that Plaintiffs'  
14 counsel be appointed as class counsel;

15 B. Enter judgment against Defendants and in favor of Plaintiffs and the classes;

16 C. Award damages (including statutory, punitive, and multiple damages as  
17 provided by law) and restitution to the classes in an amount to be determined at trial, plus  
18 interest in accordance with law;

19 D. Order disgorgement from the Defendants;

20 E. Award Plaintiffs and the classes their costs of suit, including reasonable  
21 attorneys' fees as provided by law; and

22 F. Award such further and additional relief as is necessary to redress the harm  
23 caused by Defendants' unlawful conduct and as the Court may deem just and proper under the  
24 circumstances.

#### 25 **IX. LACK OF ADEQUATE REMEDIES AT LAW**

26 3567. To the extent that equitable relief is sought under any of the above claims,  
27 plaintiffs plead such claims in the alternative to any legal claims and further plead that their  
28 legal claims do not provide adequate remedies at law. Until discovery and other pretrial matters

1 are complete, the extent to which the legal claims above may provide the same relief for the  
2 same harms as could be available under claims providing equitable relief is unknown.  
3 Restitution may, for example, be measured differently than legal damages and provide for a  
4 different amount of relief. The difference between the value of restitutionary and legal relief will  
5 therefore be unknown until, at the earliest, the completion of expert reports and discovery.

6 3568. In states where only equitable remedies are available for claims of unfair or  
7 unconscionable conduct (such as claims under the California Unfair Competition Law), legal  
8 claims that prohibit fraudulent conduct or provide for implied warranties would not be adequate  
9 to provide relief for such unfair or unconscionable conduct. In other instances, equitable  
10 claims (again, such as the California Unfair Competition Law) broadly prohibit fraudulent  
11 conduct whereas legal claims only prohibit specifically enumerated types of conduct. In  
12 addition, claims alleging unfair or unconscionable conduct or unjust enrichment are brought  
13 against numerous defendants in addition to JLI, and thus seek relief that is different and broader  
14 than the relief sought by way of plaintiffs' legal claims. The legal claims thus do not inherently  
15 provide the same relief for the same harms as the equitable claims.

#### 16 **X. RELIEF NOT REQUESTED AND RESERVATION OF RIGHTS**

17 3569. None of the causes of action asserted herein seeks damages or other relief as a  
18 result of personal injuries allegedly attributable to Plaintiffs' and class members' use of JUUL  
19 products. Such claims are governed by the personal injury Master Complaint and any additional  
20 Short Form complaints that may be filed (or as otherwise agreed by the parties). The named  
21 Plaintiffs in this complaint expressly reserve their right to seek damages or other relief for  
22 personal injuries they may have suffered, regardless of whether those damages are sought  
23 through causes of action alleged herein or otherwise.

#### 24 **XI. DEMAND FOR JURY TRIAL**

25 3570. Pursuant to Federal Rule of Civil Procedure 38, Plaintiffs, on behalf of  
26 themselves and the classes, demand a trial by jury on all issues to triable.  
27  
28

1 DATED: February 2, 2021

Respectfully Submitted,

2 By: Dena C. Sharp

3 Dena C. Sharp  
4 **GIRARD SHARP LLP**  
5 601 California St., Suite 1400  
6 San Francisco, CA 94108  
7 Telephone: (415) 981-4800

8 By: Sarah R. London

9 Sarah R. London  
10 **LIEFF CABRASER HEIMANN &**  
11 **BERNSTEIN**  
12 275 Battery Street, Fl. 29  
13 San Francisco, CA 94111  
14 Telephone: (415) 956-1000

15 By: Dean Kawamoto

16 Dean Kawamoto  
17 **KELLER ROHRBACK L.L.P.**  
18 1201 Third Ave., Ste. 3200  
19 Seattle, WA 98101  
20 Telephone: (206) 623-1900

21 By: Ellen Relkin

22 Ellen Relkin  
23 **WEITZ & LUXENBERG**  
24 700 Broadway  
25 New York, NY 10003  
26 Telephone: (212) 558-5500

27 *Co-Lead Counsel for the Plaintiffs*  
28

**CERTIFICATE OF SERVICE**

I hereby certify that on February 2, 2021, I electronically filed the foregoing document using the CM/ECF system, which will send notification of such filing to all counsel of record registered in the CM/ECF system.

/s/ Sarah R. London